Patient ID	Donor Age	Sex	Race	Diagnosis	Tumor type	Survival Status	Missense Mutation - KRAS	Missense Mutation - TP53	Missense Mutation - CDKN2A	Missense Mutation - SMAD4	hidden	hidden	hidden
CHOP-C2829369	<18	Female	White	Solid pseudopapillary tumor	Metastasis	Alive	No	No	No	No	No	No	17.0
CHOP-C3977205	<18	Female	White	Pancreatoblastoma	Primary	Alive	No	No	No	No	No	No	17.0
CHOP-C4045716	<18	Male	Asian	Pancreatoblastoma	Primary	Alive	No	No	No	No	No	No	17.0
COLU-00001	50	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	50.0
COLU-00004	58	Male	White	PDAC	Primary	Alive	G12D	R175H	D84G	No	G12	Yes	58.0
COLU-00005	86	Male	White	PDAC	Metastasis	Deceased	No	R175H	No	D404N	No	Yes	86.0
COLU-00021	69	Female	White	PDAC	Primary	Alive	G12V	R273H	No	No	G12	Yes	69.0
COLU-00024	85	Male	Asian	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	85.0
COLU-00031	77	Female	White	PDAC	Primary	Alive	G12V	L130V	No	No	G12	Yes	77.0
COLU-00034	80	Female	White	PDAC	Primary	Alive	G12R	M237I	No	No	G12	Yes	80.0
COLU-00037	49	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	49.0
COLU-00039	71	Female	NA	PDAC	Primary	Alive	G12D	I162F	No	No	G12	Yes	71.0
COLU-00040	65	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	65.0
COLU-00056	68	Female	White	PDAC	Primary	Alive	Q61K	R248G	No	No	Q61	Yes	68.0
COLU-00063	50	Female	White	PDAC	Metastasis	Alive	A146T	No	No	K340T,R361H,S411N	Other	No	50.0
COLU-00066	71	Male	NA	PDAC	Primary	Deceased	G12V	R248W	No	No	G12	Yes	71.0
COLU-00071	65	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	65.0
COLU-00074	61	Male	NA	PDAC	Primary	Alive	G12C	No	No	No	G12	No	61.0
COLU-00076	71	Female	White	PDAC	Metastasis	Deceased	Q61H	P278R	No	No	Q61	Yes	71.0
COLU-00080	55	Female	Black/African-American	PDAC	Primary	Alive	G12V	A138V	No	No	G12	Yes	55.0
COLU-00089	57	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	57.0
COLU-00090	70	Male	White	PDAC	Primary	Alive	G12R	Q38E	No	No	G12	Yes	70.0
COLU-00091	46	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	46.0
COLU-00092	84	Female	NA	PDAC	Primary	Alive	No	No	No	No	No	No	84.0
COLU-00102	71	Female	White	PDAC	Metastasis	Alive	No	C176G	No	No	No	Yes	71.0
COLU-00106	80	Female	White	PDAC	Primary	Deceased	G12R	D259V	No	No	G12	Yes	80.0
COLU-00107	75	Female	White	PDAC	Primary	Deceased	No	R282W	No	No	No	Yes	75.0
COLU-00114	43	Male	White	PDAC	Primary	Alive	G12D	R273C	No	No	G12	Yes	43.0
COLU-00115	76	Male	White	PDAC	Metastasis	Alive	G12V	L114V	No	No	G12	Yes	76.0
COLU-00116	59	Female	NA	PDAC	Metastasis	Alive	G12R	R175H	No	T521P	G12	Yes	59.0
COLU-00117	65	Female	White	PDAC	Primary	Alive	G12D	No	No	R361H	G12	No	65.0
COLU-00118	67	Male	White	PDAC	Primary	Alive	G12D	R156C	No	No	G12	Yes	67.0
COLU-00121	54	Female	NA	PDAC	Primary	Alive	G12D	No	No	No	G12	No	54.0
COLU-00124	69	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	69.0
COLU-00126	68	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	68.0
COLU-00132	60	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	60.0
COLU-00135	72	Male	White	PDAC	Primary	Alive	G12D	No	L97P	No	G12	No	72.0
COLU-00139	79	Male	NA	PDAC	Primary	Alive	G12D	S366A,P151S	No	No	G12	Yes	79.0
COLU-00146	72	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	72.0
COLU-00149	55	Female	NA	PDAC	Metastasis	Alive	G12R	No	H83Y	No	G12	No	55.0
COLU-00160	66	Female	Black/African-American	PDAC	Metastasis	Alive	G12D	M246V	No	R361H	G12	Yes	66.0
COLU-00162	79	Female	NA	PDAC	Metastasis	Alive	G12R	K132M	No	No	G12	Yes	79.0
COLU-00164	63	Female	NA	PDAC	Primary	Alive	G12D	No	No	No	G12	No	63.0
COLU-00174	60	Male	White	PDAC	Unknown	Alive	G12D	Q144P	No	No	G12	Yes	60.0
COLU-00177	74	Male	White	Carcinoma, NOS	Primary	Alive	G12D	No	No	No	G12	No	74.0
COLU-00182	74	Male	White	PDAC	Metastasis	Alive	G12D	R273C	No	No	G12	Yes	74.0
COLU-00184	88	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12D	Y220C	No	No	G12	Yes	88.0
COLU-00185	71	Female	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	71.0
COLU-00193	72	Female	White	PDAC	Metastasis	Alive	G12V	H214R	No	No	G12	Yes	72.0
COLU-00200	75	Male	White	PDAC	Primary	Alive	G12R	R249S	No	No	G12	Yes	75.0
COLU-00231	69	Male	White	PDAC	Primary	Alive	G12D	R273H	H83Y	R361H	G12	Yes	69.0
COLU-00290	87	Male	White	PDAC	Metastasis	Deceased	No	M133K	No	No	No	Yes	87.0
COLU-00294	70	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	70.0
COLU-00349	81	Female	NA	Carcinoma, NOS	Primary	Deceased	No	No	No	No	No	No	81.0
COLU-00351	51	Male	NA	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	51.0
COLU-00352	76	Female	Black/African-American	PDAC	Metastasis	Alive	G12D	S215I	No	No	G12	Yes	76.0
COLU-00356	61	Male	Black/African-American	PDAC	Metastasis	Alive	No	No	No	No	No	No	61.0
COLU-00357	51	Male	White	PDAC	Primary	Deceased	G12V	C135Y	No	No	G12	Yes	51.0
COLU-00359	51	Female	White	PDAC	Unknown	Alive	G12D	No	No	No	G12	No	51.0
COLU-00361	87	Female	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	87.0
COLU-00363	54	Male	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	54.0
COLU-00369	72	Male	White	Carcinoma, NOS	Metastasis	Alive	G12R	No	G101W	No	G12	No	72.0
COLU-00377	72	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	72.0
COLU-00379	63	Female	NA	PDAC	Metastasis	Alive	No	No	No	No	No	No	63.0
COLU-00380	64	Male	NA	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	64.0
COLU-00386	61	Female	White	PDAC	Primary	Alive	G12R	R273H	R24G	No	G12	Yes	61.0
COLU-00399	69	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	69.0
COLU-1036	80	Male	NA	PNET	Primary	Alive	G12V	No	No	No	G12	No	80.0
COLU-1075	55	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	55.0
COLU-1076	68	Female	Black/African-American	PDAC	Metastasis	Alive	No	No	No	No	No	No	68.0
COLU-1080	64	Female	NA	PDAC	Primary	Alive	No	No	No	No	No	No	64.0
COLU-1116	55	Male	Other	PDAC	Metastasis	Alive	G12D	No	L97V	No	G12	No	55.0
COLU-1162	77	Male	White	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	77.0
COLU-1170	82	Male	Black/African-American	PDAC	Primary	Alive	No	No	No	No	No	No	82.0
COLU-1222	44	Female	White	PDAC	Metastasis	Alive	G12D	H179R	No	No	G12	Yes	44.0
COLU-1238	68	Male	Black/African-American	PDAC	Primary	Alive	G12R	G266E	No	No	G12	Yes	68.0
COLU-1263	28	Female	NA	PDAC	Metastasis	Alive	No	No	No	No	No	No	28.0
COLU-1269	75	Female	NA	PDAC	Metastasis	Alive	No	No	No	No	No	No	75.0
COLU-1277	60	Female	White	PDAC	Primary	Alive	G12A	No	No	No	G12	No	60.0
COLU-1296	73	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	73.0
COLU-1311	69	Female	White	PDAC	Primary	Alive	No	Y220C	No	No	No	Yes	69.0
COLU-1327	65	Male	White	PDAC	Primary	Alive	G12D	R273C	No	No	G12	Yes	65.0
COLU-1328	50	Male	NA	PDAC	Primary	Alive	G12D	R273S	A86D	No	G12	Yes	50.0
COLU-1332	55	Female	Black/African-American	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	55.0
COLU-1336	61	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	61.0
COLU-1376	69	Male	White	PDAC	Metastasis	Deceased	G12R	R337L	No	No	G12	Yes	69.0
COLU-1388	70	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	70.0
COLU-1399	61	Male	White	PDAC	Primary	Alive	G12R	V172D	No	C71F	G12	Yes	61.0
COLU-1480	71	Female	Black/African-American	PDAC	Primary	Alive	No	No	No	No	No	No	71.0
COLU-1488	72	Female	NA	PDAC	Primary	Alive	No	No	No	No	No	No	72.0
COLU-1495	61	Male	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	61.0
COLU-1501	71	Female	Black/African-American	PDAC	Primary	Alive	G12D	R248Q	No	No	G12	Yes	71.0
COLU-1527	67	Male	NA	PDAC	Primary	Alive	G12D	H179Y	No	No	G12	Yes	67.0
COLU-1539	59	Female	Other	PDAC	Primary	Alive	G12V	G245S	No	No	G12	Yes	59.0
COLU-1615	82	Female	White	PDAC	Primary	Alive	G12V	R175H	H83P	No	G12	Yes	82.0
COLU-1624	44	Male	White	PDAC	Metastasis	Alive	G12V	L130P	No	No	G12	Yes	44.0
COLU-1638	79	Female	Asian	PDAC	Primary	Deceased	G12D	R249S	No	No	G12	Yes	79.0
COLU-1708	67	Male	Asian	Adenosquamous carcinoma	Primary	Alive	Q61H	K132R	No	No	Q61	Yes	67.0
COLU-1778	69	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	69.0
COLU-1805	64	Male	Asian	PNET	Primary	Alive	No	No	No	No	No	No	64.0
COLU-1836	39	Male	NA	Carcinoma, NOS	Primary	Alive	No	No	No	No	No	No	39.0
COLU-1879	70	Female	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	70.0
COLU-1885	77	Male	NA	PDAC	Primary	Alive	G12R	C135R	No	G352R	G12	Yes	77.0
COLU-1892	69	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	69.0
COLU-1922	86	Female	White	PDAC	Metastasis	Alive	G12D	No	No	A118V	G12	No	86.0
COLU-1924	59	Female	NA	PNET	Primary	Alive	No	No	No	No	No	No	59.0
COLU-1929	66	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	66.0
COLU-2007	50	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	50.0
COLU-2016	67	Female	Asian	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	67.0
COLU-2020	66	Female	White	PDAC	Metastasis	Alive	H27R,G12V	Y220C	No	D142G	G12\|Other	Yes	66.0
COLU-2031	83	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	83.0
COLU-2037	75	Female	White	PDAC	Primary	Alive	G12D	R248W	No	No	G12	Yes	75.0
COLU-2046	62	Male	White	PDAC	Primary	Alive	No	No	L63R	No	No	No	62.0
COLU-2090	65	Female	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	65.0
COLU-2099	71	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	71.0
COLU-2144	55	Female	Other	PDAC	Primary	Alive	G12D	Y234N	No	No	G12	Yes	55.0
COLU-2187	77	Female	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	77.0
COLU-2278	>89	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	90.0
COLU-2297	>89	Female	Asian	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	90.0
COLU-2301	59	Male	White	PDAC	Primary	Alive	G12V	T211I	No	No	G12	Yes	59.0
COLU-2307	65	Male	NA	PDAC	Metastasis	Alive	No	No	No	No	No	No	65.0
COLU-2339	72	Female	White	PDAC	Metastasis	Alive	G12D	F134L	No	No	G12	Yes	72.0
COLU-2350	63	Male	White	PDAC	Primary	Alive	No	R282W	No	No	No	Yes	63.0
COLU-2438	59	Male	NA	PDAC	Primary	Alive	No	No	No	No	No	No	59.0
COLU-2494	57	Female	White	PDAC	Metastasis	Alive	G12A	No	No	No	G12	No	57.0
COLU-2504	56	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	56.0
COLU-2523	64	Male	White	PDAC	Primary	Alive	G12V	K132R	No	D355E	G12	Yes	64.0
COLU-2527	73	Male	White	PDAC	Metastasis	Deceased	No	No	G67R	No	No	No	73.0
COLU-2529	62	Male	NA	PDAC	Primary	Alive	G12D	No	No	No	G12	No	62.0
COLU-2539	67	Male	White	IPMN	Metastasis	Alive	No	No	No	No	No	No	67.0
COLU-2550	68	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	68.0
COLU-2608	46	Female	NA	PNET	Metastasis	Alive	No	No	No	No	No	No	46.0
COLU-2614	75	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	75.0
COLU-2639	70	Male	Other	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	70.0
COLU-2667	72	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	72.0
COLU-2677	65	Male	White	PDAC	Primary	Alive	G12D	L194R	No	No	G12	Yes	65.0
COLU-2678	79	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	79.0
COLU-2734	76	Male	White	PDAC	Primary	Deceased	Q61H	R175H	No	No	Q61	Yes	76.0
COLU-2743	78	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	78.0
COLU-2774	72	Female	Other	PDAC	Metastasis	Alive	No	R282Q	No	No	No	Yes	72.0
COLU-2798	76	Female	White	PDAC	Metastasis	Alive	G12D	R156P	No	No	G12	Yes	76.0
COLU-2849	81	Male	White	PDAC	Primary	Deceased	G12V	R248W	No	No	G12	Yes	81.0
COLU-2869	68	Male	White	PDAC	Metastasis	Alive	G12C	No	No	No	G12	No	68.0
COLU-2894	58	Female	White	PDAC	Metastasis	Alive	G12V	I195S	No	N151S	G12	Yes	58.0
COLU-2923	85	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	M447L	G12	No	85.0
COLU-2927	72	Male	Black/African-American	PDAC	Primary	Alive	No	C176Y	No	No	No	Yes	72.0
COLU-2928	70	Male	White	PDAC	Primary	Alive	G12V	R110H	No	No	G12	Yes	70.0
COLU-2931	63	Male	White	PDAC	Metastasis	Alive	G12D	R110H	No	No	G12	Yes	63.0
COLU-2932	55	Male	White	PDAC	Metastasis	Deceased	G12D	F113C	P114R	No	G12	Yes	55.0
COLU-2985	58	Male	NA	PDAC	Metastasis	Alive	No	No	No	No	No	No	58.0
COLU-2995	73	Male	White	PDAC	Metastasis	Alive	G12V	Y220C	No	No	G12	Yes	73.0
COLU-3028	56	Male	Other	PDAC	Metastasis	Alive	G12D	C135Y	No	No	G12	Yes	56.0
COLU-3077	73	Female	Asian	PDAC	Primary	Alive	G12V	No	No	No	G12	No	73.0
COLU-3105	69	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	69.0
COLU-3107	67	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	67.0
COLU-3108	50	Female	White	Solid pseudopapillary tumor	Primary	Alive	No	No	No	No	No	No	50.0
COLU-3112	69	Female	White	PDAC	Primary	Alive	G12C	R273H	No	R361C	G12	Yes	69.0
COLU-3149	73	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	73.0
COLU-3255	77	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	77.0
COLU-3257	71	Female	White	PNET	Primary	Alive	No	K132R	No	No	No	Yes	71.0
COLU-3260	85	Male	NA	PDAC	Metastasis	Alive	G12V	M237I	No	No	G12	Yes	85.0
COLU-3265	55	Male	Other	PDAC	Metastasis	Alive	G13D	G266V	No	No	G13	Yes	55.0
COLU-3266	69	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	69.0
COLU-3273	68	Female	Black/African-American	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	68.0
COLU-573	70	Male	NA	PDAC	Primary	Alive	Q61R	No	No	No	Q61	No	70.0
COLU-594	53	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	53.0
COLU-633	65	Male	NA	PDAC	Metastasis	Alive	F90V,G12D	V274F	No	No	G12\|Other	Yes	65.0
COLU-652	70	Male	NA	PDAC	Metastasis	Alive	Q61H	No	No	No	Q61	No	70.0
COLU-680	39	Male	NA	PDAC	Primary	Alive	G12D	R110L	No	No	G12	Yes	39.0
COLU-705	65	Male	White	PDAC	Primary	Alive	G12V	G266E	No	No	G12	Yes	65.0
COLU-708	54	Female	White	PDAC	Metastasis	Alive	G12V	G245S	No	No	G12	Yes	54.0
COLU-709	60	Female	NA	PDAC	Metastasis	Alive	G13H	No	No	No	G13	No	60.0
COLU-733	86	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	86.0
COLU-748	77	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	77.0
COLU-763	67	Male	NA	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	67.0
COLU-769	77	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	77.0
COLU-789	63	Male	White	PDAC	Metastasis	Alive	G12V	Y220C	No	No	G12	Yes	63.0
COLU-791	87	Female	NA	PDAC	Primary	Alive	No	No	No	No	No	No	87.0
COLU-802	69	Male	NA	PDAC	Metastasis	Alive	Q61H	S127F	No	No	Q61	Yes	69.0
COLU-816	70	Male	NA	PDAC	Metastasis	Alive	Q61L	L257R	No	No	Q61	Yes	70.0
COLU-853	75	Male	White	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	75.0
COLU-895	72	Female	NA	PDAC	Primary	Alive	G12V	R248Q	No	No	G12	Yes	72.0
COLU-904	68	Female	White	Adenosquamous carcinoma	Primary	Alive	G12D	E286K	No	No	G12	Yes	68.0
COLU-932	60	Female	NA	PDAC	Primary	Alive	G12V	R282G	No	No	G12	Yes	60.0
COLU-945	54	Male	White	PDAC	Primary	Deceased	No	R273C	No	T521P	No	Yes	54.0
COLU-982	74	Male	NA	Adenosquamous carcinoma	Primary	Alive	G12V	No	No	No	G12	No	74.0
COLU-989	47	Male	Black/African-American	PDAC	Primary	Alive	G12D	A159V	No	No	G12	Yes	47.0
DFCI-000162	65	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	65.0
DFCI-000165	50	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	50.0
DFCI-000345	82	Male	White	PDAC	Unknown	Deceased	G12V	No	No	No	G12	No	82.0
DFCI-000431	45	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	45.0
DFCI-000434	75	Female	White	PDAC	Metastasis	Deceased	G12D	V274F	No	No	G12	Yes	75.0
DFCI-000444	68	Male	White	PDAC	Metastasis	Deceased	G12D	R248W	No	No	G12	Yes	68.0
DFCI-000481	65	Male	White	IPMN	Primary	Alive	G13D	No	No	No	G13	No	65.0
DFCI-000496	58	Female	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	58.0
DFCI-000501	61	Male	Asian	PDAC	Primary	Deceased	G12D	L194R	No	No	G12	Yes	61.0
DFCI-000589	64	Female	White	IPMN	Primary	Alive	G12V	No	No	No	G12	No	64.0
DFCI-000628	58	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	58.0
DFCI-000740	65	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	65.0
DFCI-000805	60	Female	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	60.0
DFCI-000994	67	Male	White	PDAC	Metastasis	Deceased	G12D	V272L,R158C	No	R361H	G12	Yes	67.0
DFCI-001005	59	Male	White	PDAC	Metastasis	Deceased	Q61R	E271K	No	No	Q61	Yes	59.0
DFCI-001267	>89	Male	White	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	90.0
DFCI-001283	64	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	64.0
DFCI-001332	83	Female	White	PDAC	NA or Heme	Deceased	G12D	G105V	No	No	G12	Yes	83.0
DFCI-001374	49	Female	Other	PDAC	Primary	Deceased	E63D,Q61H	No	No	No	Q61\|Other	No	49.0
DFCI-001437	67	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	67.0
DFCI-001448	63	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	63.0
DFCI-001556	56	Female	White	PDAC	Primary	Deceased	G12R	No	No	Q248L	G12	No	56.0
DFCI-001709	83	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	83.0
DFCI-001730	80	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	80.0
DFCI-001742	61	Male	White	PDAC	Primary	Deceased	G12V	No	L31P	No	G12	No	61.0
DFCI-001797	74	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	74.0
DFCI-001868	65	Female	White	PDAC	Primary	Deceased	G12R	A138V	No	R361H	G12	Yes	65.0
DFCI-002030	60	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	60.0
DFCI-002034	68	Female	White	PDAC	Primary	Alive	G12D	No	No	R361H	G12	No	68.0
DFCI-002077	67	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	67.0
DFCI-002190	73	Female	White	IPMN	Primary	Deceased	G12V	R248W	No	No	G12	Yes	73.0
DFCI-002273	58	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	58.0
DFCI-002395	46	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	46.0
DFCI-002418	85	Male	White	PDAC	Metastasis	Deceased	G12D	G266R	No	No	G12	Yes	85.0
DFCI-002420	74	Female	White	Adenosquamous carcinoma	Primary	Deceased	G12D	R175H	No	No	G12	Yes	74.0
DFCI-002426	53	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	53.0
DFCI-002492	57	Female	Black/African-American	PNET	Primary	Deceased	No	No	No	No	No	No	57.0
DFCI-002544	70	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	70.0
DFCI-002847	59	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	59.0
DFCI-002862	56	Female	Other	PDAC	Primary	Deceased	G12R	H193D	No	No	G12	Yes	56.0
DFCI-002915	62	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	62.0
DFCI-003011	68	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	68.0
DFCI-003144	52	Male	Other	IPMN	Primary	Deceased	No	V157G	No	No	No	Yes	52.0
DFCI-003202	74	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	74.0
DFCI-003227	58	Male	White	PDAC	Primary	Deceased	G12D	C242Y	No	No	G12	Yes	58.0
DFCI-003238	59	Male	NA	Acinar cell carcinoma	Primary	Deceased	No	No	No	C363F	No	No	59.0
DFCI-003268	69	Male	White	PDAC	Metastasis	Deceased	G12R	R282W	No	No	G12	Yes	69.0
DFCI-003291	67	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	67.0
DFCI-003311	77	Male	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	77.0
DFCI-003364	74	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	74.0
DFCI-003374	72	Male	White	PDAC	Primary	Deceased	G12R	C176Y	No	No	G12	Yes	72.0
DFCI-003413	66	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	D355G	G12	No	66.0
DFCI-003480	72	Male	White	PDAC	Primary	Alive	Q61R	V274G	No	No	Q61	Yes	72.0
DFCI-003572	41	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	41.0
DFCI-003637	69	Male	White	PDAC	Primary	Deceased	G12R	R333C	No	R361H	G12	Yes	69.0
DFCI-003719	60	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	60.0
DFCI-003722	64	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	64.0
DFCI-003758	55	Female	White	Pancreatoblastoma	Primary	Deceased	No	No	No	No	No	No	55.0
DFCI-003860	79	Male	White	PDAC	Primary	Alive	G12D	No	No	C363W	G12	No	79.0
DFCI-003864	40	Female	White	PNET	Primary	Alive	No	No	A57V	No	No	No	40.0
DFCI-004069	58	Female	White	Solid pseudopapillary tumor	Primary	Alive	No	No	No	No	No	No	58.0
DFCI-004102	61	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	61.0
DFCI-004153	72	Male	White	PDAC	Primary	Deceased	G12V	V157D	R22P	No	G12	Yes	72.0
DFCI-004204	73	Male	White	PNET	Metastasis	Alive	No	D281N	G45D	No	No	Yes	73.0
DFCI-004326	66	Male	White	PDAC	Primary	Deceased	G12R	No	D108Y	No	G12	No	66.0
DFCI-004381	69	Female	White	Adenosquamous carcinoma	Primary	Deceased	G12V	No	No	No	G12	No	69.0
DFCI-004546	65	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	65.0
DFCI-004571	58	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	58.0
DFCI-004616	59	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	59.0
DFCI-004698	56	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	56.0
DFCI-004706	70	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	70.0
DFCI-004712	39	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	39.0
DFCI-004850	59	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	59.0
DFCI-004917	46	Male	NA	PNET	Primary	Alive	No	No	No	No	No	No	46.0
DFCI-004939	63	Female	White	PNET	Primary	Deceased	No	Y107S	No	No	No	Yes	63.0
DFCI-005030	55	Female	White	PDAC	Primary	Deceased	G12R	Y205D	No	I94K	G12	Yes	55.0
DFCI-005182	75	Female	White	PDAC	Primary	Deceased	G12R	M237K	No	No	G12	Yes	75.0
DFCI-005212	82	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	82.0
DFCI-005240	72	Male	White	PDAC	Primary	Deceased	G12V	E258D	H83Y	No	G12	Yes	72.0
DFCI-005261	73	Male	White	PDAC	Primary	Deceased	G12R	P278S	No	No	G12	Yes	73.0
DFCI-005323	64	Male	White	PDAC	Primary	Deceased	G12R	S241F	No	G352E	G12	Yes	64.0
DFCI-005409	75	Male	White	PDAC	Primary	Deceased	G12C	No	No	No	G12	No	75.0
DFCI-005480	63	Male	White	PNET	Primary	Deceased	No	Y163C	No	No	No	Yes	63.0
DFCI-005512	73	Male	White	PDAC	Primary	Deceased	Q61H	R156H	No	No	Q61	Yes	73.0
DFCI-005677	79	Female	White	PDAC	Metastasis	Deceased	Q61H	R273H	No	No	Q61	Yes	79.0
DFCI-005804	47	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	47.0
DFCI-005805	71	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	71.0
DFCI-005856	53	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	53.0
DFCI-005860	28	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	28.0
DFCI-005916	54	Male	White	PDAC	Primary	Alive	No	A161F	No	No	No	Yes	54.0
DFCI-005937	68	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	68.0
DFCI-005958	46	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	46.0
DFCI-005980	64	Female	White	PDAC	Primary	Deceased	No	R282W	No	No	No	Yes	64.0
DFCI-006038	58	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	58.0
DFCI-006062	63	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	63.0
DFCI-006142	80	Female	White	PDAC	Primary	Deceased	G12D	No	H83Y	No	G12	No	80.0
DFCI-006173	64	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	64.0
DFCI-006177	52	Male	Black/African-American	PNET	Metastasis	Deceased	No	No	No	No	No	No	52.0
DFCI-006203	84	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	84.0
DFCI-006221	63	Female	White	PDAC	Primary	Deceased	G12D	No	No	D537V	G12	No	63.0
DFCI-006287	65	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	65.0
DFCI-006322	72	Male	White	PDAC	Primary	Deceased	G12D	H179Y	No	No	G12	Yes	72.0
DFCI-006344	78	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	78.0
DFCI-006387	77	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	77.0
DFCI-006477	64	Female	White	PDAC	Metastasis	Deceased	Q61H	R273L	No	No	Q61	Yes	64.0
DFCI-006555	68	Male	White	PDAC	Primary	Deceased	G12D	Y220C	No	No	G12	Yes	68.0
DFCI-006667	70	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	70.0
DFCI-006708	35	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	35.0
DFCI-006837	69	Female	White	IPMN	Primary	Alive	G12V	No	No	No	G12	No	69.0
DFCI-006867	58	Male	White	PDAC	Primary	Deceased	G12D	E286K	No	No	G12	Yes	58.0
DFCI-006899	63	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	63.0
DFCI-006905	51	Male	White	PDAC	Primary	Deceased	G12V	C275Y	No	No	G12	Yes	51.0
DFCI-006992	86	Female	White	PDAC	Primary	Deceased	G12D	M237I	No	No	G12	Yes	86.0
DFCI-006998	40	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	40.0
DFCI-007107	71	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	71.0
DFCI-007333	76	Male	White	IPMN	Primary	Alive	G13V	No	No	V348I	G13	No	76.0
DFCI-007348	73	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	73.0
DFCI-007358	58	Male	White	PDAC	Metastasis	Deceased	G12V	H179R	No	No	G12	Yes	58.0
DFCI-007365	65	Female	Other	PDAC	Primary	Deceased	G12D	R248W	No	D351H	G12	Yes	65.0
DFCI-007366	66	Female	White	PDAC	Primary	Deceased	G12D	R282W	No	G352E	G12	Yes	66.0
DFCI-007639	65	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	65.0
DFCI-007680	74	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	74.0
DFCI-007776	80	Male	White	PDAC	Primary	Deceased	Q61H	C141W	No	R361H	Q61	Yes	80.0
DFCI-007810	59	Male	White	Adenosquamous carcinoma	Metastasis	Deceased	G12D	E258G	No	No	G12	Yes	59.0
DFCI-007884	59	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	59.0
DFCI-007956	63	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
DFCI-008074	50	Male	White	PNET	Metastasis	Alive	No	R248L	No	No	No	Yes	50.0
DFCI-008093	58	Male	White	PDAC	Primary	Deceased	G12V	N235D	No	No	G12	Yes	58.0
DFCI-008188	61	Female	White	PNET	Primary	Deceased	G12D	No	No	No	G12	No	61.0
DFCI-008242	66	Female	White	PDAC	Primary	Deceased	G12D	Y220C	No	No	G12	Yes	66.0
DFCI-008245	70	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	70.0
DFCI-008297	61	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	61.0
DFCI-008314	80	Male	White	PDAC	Primary	Deceased	G12D	N239D	L31P	No	G12	Yes	80.0
DFCI-008407	79	Female	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	79.0
DFCI-008456	85	Male	White	PDAC	Primary	Deceased	G12D	L194R	No	No	G12	Yes	85.0
DFCI-008573	54	Male	White	PDAC	Primary	Deceased	G12D	No	H83N	No	G12	No	54.0
DFCI-008708	69	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	69.0
DFCI-008783	65	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	65.0
DFCI-008852	83	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	83.0
DFCI-008937	71	Male	White	PDAC	Primary	Deceased	G12A	R273H	No	R361H	G12	Yes	71.0
DFCI-009035	64	Male	White	PNET	Metastasis	Deceased	No	R273H	No	D351G	No	Yes	64.0
DFCI-009043	49	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	49.0
DFCI-009050	56	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	56.0
DFCI-009150	71	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	R361H	G12	No	71.0
DFCI-009170	75	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	75.0
DFCI-009198	63	Female	White	PDAC	NA or Heme	Deceased	G12D	No	No	No	G12	No	63.0
DFCI-009234	77	Female	Asian	PDAC	Metastasis	Deceased	G12R	V216G	No	No	G12	Yes	77.0
DFCI-009246	55	Female	Black/African-American	PNET	Primary	Deceased	No	No	No	No	No	No	55.0
DFCI-009257	53	Male	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	53.0
DFCI-009267	80	Female	White	PDAC	Primary	Deceased	G12V	R282W	No	A118V	G12	Yes	80.0
DFCI-009365	84	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	84.0
DFCI-009453	78	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	78.0
DFCI-009477	67	Female	White	PDAC	Metastasis	Deceased	G12D	C242S	No	No	G12	Yes	67.0
DFCI-009510	73	Male	White	PDAC	Metastasis	Deceased	G12D	P190L	No	No	G12	Yes	73.0
DFCI-009515	58	Female	White	Adenosquamous carcinoma	Primary	Alive	No	No	No	No	No	No	58.0
DFCI-009520	74	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	W524C	G12	No	74.0
DFCI-009637	63	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	63.0
DFCI-009644	62	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	62.0
DFCI-009684	74	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	74.0
DFCI-009709	77	Female	White	PDAC	Metastasis	Deceased	Q61L	No	No	No	Q61	No	77.0
DFCI-009736	55	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	55.0
DFCI-009767	59	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	59.0
DFCI-009781	71	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	71.0
DFCI-009832	68	Female	White	PNET	Primary	Alive	No	C135Y	No	No	No	Yes	68.0
DFCI-009875	78	Male	White	PDAC	Primary	Deceased	G12D	I232N	No	No	G12	Yes	78.0
DFCI-009888	>89	Male	White	PDAC	Primary	Deceased	G12D	D208V,R248Q	No	No	G12	Yes	90.0
DFCI-009897	54	Male	White	PDAC	Metastasis	Deceased	G12D	L130H	No	No	G12	Yes	54.0
DFCI-009916	56	Male	White	PDAC	Metastasis	Deceased	G12D	L257P	No	No	G12	Yes	56.0
DFCI-009946	53	Male	Black/African-American	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	53.0
DFCI-009999	73	Female	White	PDAC	Primary	Alive	G12D	No	No	G352R	G12	No	73.0
DFCI-010005	65	Male	White	PDAC	Primary	Deceased	G12D	K132R	No	No	G12	Yes	65.0
DFCI-010008	75	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	V350D	G12	No	75.0
DFCI-010014	72	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	72.0
DFCI-010055	65	Male	White	PDAC	Primary	Alive	G12D	H179D	No	No	G12	Yes	65.0
DFCI-010159	68	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	68.0
DFCI-010162	76	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	76.0
DFCI-010166	52	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	52.0
DFCI-010220	57	Female	White	PDAC	Primary	Alive	G12D	H179D	No	No	G12	Yes	57.0
DFCI-010250	72	Female	White	PDAC	Primary	Deceased	Q61R	C135R	No	No	Q61	Yes	72.0
DFCI-010275	67	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	67.0
DFCI-010297	50	Male	White	PDAC	Primary	Deceased	G12D	C242F	No	No	G12	Yes	50.0
DFCI-010300	60	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	60.0
DFCI-010306	47	Male	White	PDAC	Primary	Deceased	G12V	R273H	No	No	G12	Yes	47.0
DFCI-010315	76	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	76.0
DFCI-010343	67	Male	White	Adenosquamous carcinoma	Metastasis	Deceased	A66S,Q61H	F109V	No	No	Q61\|Other	Yes	67.0
DFCI-010352	41	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	41.0
DFCI-010428	63	Female	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	63.0
DFCI-010442	65	Male	White	PDAC	Metastasis	Deceased	Q61H	N239S	No	No	Q61	Yes	65.0
DFCI-010451	60	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	60.0
DFCI-010453	26	Female	White	Solid pseudopapillary tumor	Primary	Alive	No	No	No	No	No	No	26.0
DFCI-010566	77	Male	White	PDAC	Primary	Alive	G13D	No	No	No	G13	No	77.0
DFCI-010635	44	Male	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	44.0
DFCI-010698	80	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	80.0
DFCI-010715	69	Male	White	PDAC	Primary	Deceased	G12R	V203E	No	No	G12	Yes	69.0
DFCI-010728	51	Female	White	PDAC	Primary	Deceased	G12D	No	D84G	No	G12	No	51.0
DFCI-010760	61	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	61.0
DFCI-010767	53	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	53.0
DFCI-010784	69	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	69.0
DFCI-010790	63	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
DFCI-010818	63	Male	White	PDAC	Primary	Deceased	G12A	V272M	No	No	G12	Yes	63.0
DFCI-010821	53	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	53.0
DFCI-010870	62	Female	White	PDAC	Primary	Deceased	G12D	R248W	No	No	G12	Yes	62.0
DFCI-010882	77	Male	White	PDAC	Primary	Deceased	G12V	A161T	No	No	G12	Yes	77.0
DFCI-010913	50	Female	White	PDAC	Primary	Deceased	G12D	R248W	No	No	G12	Yes	50.0
DFCI-010919	73	Male	White	PDAC	Primary	Alive	G12V	No	V51D	Y513C	G12	No	73.0
DFCI-010926	63	Female	White	PDAC	Primary	Deceased	G12D	No	No	R100G	G12	No	63.0
DFCI-011021	64	Male	White	PDAC	Metastasis	Deceased	G12R	E224D	No	No	G12	Yes	64.0
DFCI-011079	57	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	57.0
DFCI-011136	50	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	50.0
DFCI-011154	76	Female	White	PDAC	Primary	Alive	G12F	No	No	No	G12	No	76.0
DFCI-011191	66	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	66.0
DFCI-011200	36	Male	White	PDAC	Metastasis	Deceased	G12D	Y236C	No	No	G12	Yes	36.0
DFCI-011278	65	Female	White	PDAC	Primary	Alive	G12D	L257Q	No	No	G12	Yes	65.0
DFCI-011295	50	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	50.0
DFCI-011298	61	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	61.0
DFCI-011314	56	Female	White	PNET	Metastasis	Deceased	G12V	No	No	No	G12	No	56.0
DFCI-011329	60	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	60.0
DFCI-011338	72	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	72.0
DFCI-011398	65	Female	White	PDAC	Primary	Deceased	G12D	No	No	G386D	G12	No	65.0
DFCI-011407	66	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	66.0
DFCI-011417	67	Male	White	PDAC	Primary	Deceased	G12R	A159V	No	No	G12	Yes	67.0
DFCI-011450	49	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	49.0
DFCI-011451	64	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	64.0
DFCI-011488	69	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	69.0
DFCI-011491	75	Female	Black/African-American	PDAC	Metastasis	Deceased	Q61R	No	No	No	Q61	No	75.0
DFCI-011506	57	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	57.0
DFCI-011518	38	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	38.0
DFCI-011547	65	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	65.0
DFCI-011558	63	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	63.0
DFCI-011574	69	Male	Black/African-American	PDAC	Metastasis	Deceased	G12R	H193L	No	No	G12	Yes	69.0
DFCI-011575	48	Male	White	PDAC	Metastasis	Deceased	G12V	R175H	No	W99R	G12	Yes	48.0
DFCI-011582	58	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	58.0
DFCI-011631	75	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	75.0
DFCI-011635	59	Female	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	59.0
DFCI-011694	55	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	55.0
DFCI-011707	67	Female	White	PDAC	Primary	Deceased	G12V	V172F	No	No	G12	Yes	67.0
DFCI-012001	65	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	65.0
DFCI-021951	34	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	34.0
DFCI-022962	67	Female	White	PDAC	Primary	Alive	G12R	V173G	No	R361H	G12	Yes	67.0
DFCI-023025	68	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	68.0
DFCI-023503	58	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	58.0
DFCI-023565	67	Female	White	PDAC	Metastasis	Deceased	Q61R	No	No	No	Q61	No	67.0
DFCI-023628	39	Male	White	PDAC	Primary	Deceased	G12D	Y220C	No	No	G12	Yes	39.0
DFCI-023638	59	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	59.0
DFCI-023679	54	Male	Asian	PNET	Metastasis	Deceased	G12D	No	No	R361H	G12	No	54.0
DFCI-023705	59	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	59.0
DFCI-023725	65	Male	White	PDAC	Metastasis	Deceased	G12A	No	No	No	G12	No	65.0
DFCI-023729	65	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	65.0
DFCI-023949	70	Female	White	PDAC	Metastasis	Deceased	Q61R	No	No	No	Q61	No	70.0
DFCI-024168	57	Male	White	PDAC	Metastasis	Deceased	No	L145P	No	No	No	Yes	57.0
DFCI-024191	73	Female	White	IPMN	Primary	Alive	No	No	No	No	No	No	73.0
DFCI-024268	84	Male	White	IPMN	Primary	Deceased	No	No	No	No	No	No	84.0
DFCI-024525	54	Male	Black/African-American	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	54.0
DFCI-024954	78	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	78.0
DFCI-024997	65	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	65.0
DFCI-025512	75	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	75.0
DFCI-025583	66	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	66.0
DFCI-025646	53	Female	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	53.0
DFCI-025682	63	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	63.0
DFCI-025846	79	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	79.0
DFCI-026058	78	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	78.0
DFCI-026142	61	Male	White	PDAC	Primary	Deceased	G12D	R175G	No	No	G12	Yes	61.0
DFCI-026472	61	Male	White	PDAC	Primary	Deceased	Q61H	V173M	No	No	Q61	Yes	61.0
DFCI-026507	63	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
DFCI-026535	68	Female	White	PDAC	Metastasis	Deceased	G12R	E258K	V126D	L533R	G12	Yes	68.0
DFCI-027072	76	Female	White	Solid pseudopapillary tumor	Primary	Deceased	No	No	No	No	No	No	76.0
DFCI-027178	76	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	76.0
DFCI-027846	53	Male	White	Carcinoma, NOS	Primary	Deceased	G12D	No	No	No	G12	No	53.0
DFCI-027931	69	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	69.0
DFCI-028112	65	Male	White	PDAC	Primary	Deceased	Q61H	R175H	No	No	Q61	Yes	65.0
DFCI-031086	59	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	59.0
DFCI-033243	57	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	57.0
DFCI-034732	66	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	66.0
DFCI-035237	64	Male	White	PDAC	Metastasis	Deceased	G12V	R248Q	No	A406V	G12	Yes	64.0
DFCI-035278	70	Male	White	PDAC	Metastasis	Deceased	G12V	R273C	No	No	G12	Yes	70.0
DFCI-035593	63	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	63.0
DFCI-035797	55	Male	White	PDAC	Primary	Deceased	G12D	V157F	No	No	G12	Yes	55.0
DFCI-035891	67	Male	Black/African-American	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	67.0
DFCI-035984	65	Male	White	PDAC	Primary	Deceased	G12V	R248W	H83Y	No	G12	Yes	65.0
DFCI-036068	60	Male	White	PDAC	Primary	Deceased	G12D	P278S	No	No	G12	Yes	60.0
DFCI-036457	53	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	53.0
DFCI-036472	68	Female	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	68.0
DFCI-036504	65	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	65.0
DFCI-036515	63	Male	White	PDAC	Metastasis	Deceased	G12V	V173L	No	No	G12	Yes	63.0
DFCI-036520	68	Male	White	PDAC	Primary	Deceased	G12D	R273L	No	No	G12	Yes	68.0
DFCI-036592	57	Male	White	PDAC	Primary	Alive	No	No	No	L364S	No	No	57.0
DFCI-036705	78	Female	White	PDAC	Primary	Deceased	G12V	G245V	No	No	G12	Yes	78.0
DFCI-036796	67	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	67.0
DFCI-036809	66	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	66.0
DFCI-036813	52	Male	White	PDAC	Metastasis	Deceased	G12V	R273H	N71K	No	G12	Yes	52.0
DFCI-036825	60	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	60.0
DFCI-036839	67	Female	White	PDAC	Metastasis	Alive	G12V	E285K	No	No	G12	Yes	67.0
DFCI-036870	55	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	55.0
DFCI-036888	81	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	81.0
DFCI-036936	63	Male	White	PDAC	Primary	Deceased	G12R	R175H	L97Q	No	G12	Yes	63.0
DFCI-037032	54	Female	White	PDAC	Metastasis	Deceased	G12D	V216M	No	No	G12	Yes	54.0
DFCI-037033	58	Male	White	PDAC	Metastasis	Deceased	G12D	S215G	No	No	G12	Yes	58.0
DFCI-037069	48	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	48.0
DFCI-037130	69	Male	White	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	69.0
DFCI-037139	75	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	G365D	G12	No	75.0
DFCI-037166	49	Female	White	PDAC	Primary	Alive	G12V	V272M	No	No	G12	Yes	49.0
DFCI-037281	61	Male	White	PNET	Metastasis	Deceased	No	C242Y	No	No	No	Yes	61.0
DFCI-037289	63	Male	White	PDAC	Metastasis	Deceased	No	G244D	No	No	No	Yes	63.0
DFCI-037303	65	Male	White	PDAC	Primary	Deceased	G12D	A138V	No	No	G12	Yes	65.0
DFCI-037319	54	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	54.0
DFCI-037350	67	Male	White	PDAC	Metastasis	Deceased	G12D	P152L	No	No	G12	Yes	67.0
DFCI-037388	55	Female	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	55.0
DFCI-037420	64	Male	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	64.0
DFCI-037421	87	Female	White	PDAC	Metastasis	Deceased	No	No	No	R361H	No	No	87.0
DFCI-037455	60	Male	White	PDAC	Primary	Deceased	G12R	C135Y	H83Y	No	G12	Yes	60.0
DFCI-037463	71	Male	White	PDAC	Primary	Deceased	G12D	G245D	No	No	G12	Yes	71.0
DFCI-037478	63	Male	White	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	63.0
DFCI-037512	68	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	68.0
DFCI-037516	77	Male	White	PDAC	Metastasis	Deceased	Q61R	S241C	No	No	Q61	Yes	77.0
DFCI-037567	64	Female	White	PDAC	Primary	Deceased	G12D	P250S	No	No	G12	Yes	64.0
DFCI-037587	66	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	66.0
DFCI-037677	64	Male	Black/African-American	PDAC	Primary	Deceased	Q61H	E286K	No	No	Q61	Yes	64.0
DFCI-037690	72	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	72.0
DFCI-037692	62	Female	White	PDAC	Primary	Deceased	G12D	No	No	D360V	G12	No	62.0
DFCI-037780	68	Male	White	PNET	NA or Heme	Alive	No	No	No	No	No	No	68.0
DFCI-037809	68	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	68.0
DFCI-037824	70	Male	White	PDAC	Primary	Alive	No	E258K	No	No	No	Yes	70.0
DFCI-037853	69	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	69.0
DFCI-037884	75	Female	White	PDAC	Primary	Deceased	G12D	No	No	D351V	G12	No	75.0
DFCI-037888	47	Male	White	PDAC	Primary	Deceased	G12R	R273P	No	No	G12	Yes	47.0
DFCI-037907	71	Female	White	PDAC	Primary	Deceased	No	R273H	No	No	No	Yes	71.0
DFCI-037929	78	Female	White	PDAC	Primary	Deceased	G12V	No	M52K	No	G12	No	78.0
DFCI-037933	70	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	70.0
DFCI-037950	60	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	60.0
DFCI-037970	66	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	66.0
DFCI-037983	38	Female	White	PDAC	Primary	Deceased	G12D	D259V	No	No	G12	Yes	38.0
DFCI-038005	77	Male	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	77.0
DFCI-038006	79	Female	White	PDAC	Metastasis	Deceased	G12D	E286K	G89V	No	G12	Yes	79.0
DFCI-038010	67	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	67.0
DFCI-038013	78	Female	White	PDAC	Primary	Alive	G12V	S127T	No	No	G12	Yes	78.0
DFCI-038016	59	Male	Asian	PDAC	Metastasis	Deceased	G12V	R273H	No	No	G12	Yes	59.0
DFCI-038018	76	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
DFCI-038062	62	Female	Black/African-American	PDAC	Metastasis	Deceased	G12D	V216M	No	No	G12	Yes	62.0
DFCI-038161	79	Male	White	PDAC	Primary	Deceased	G12V	G245S	No	No	G12	Yes	79.0
DFCI-038509	49	Female	Black/African-American	PNET	Primary	Alive	No	No	No	No	No	No	49.0
DFCI-038713	61	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	61.0
DFCI-039534	66	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	66.0
DFCI-039950	50	Female	Black/African-American	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	50.0
DFCI-040217	74	Male	White	PDAC	Primary	Deceased	G12C	No	No	No	G12	No	74.0
DFCI-040391	69	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	69.0
DFCI-041741	62	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	62.0
DFCI-042425	53	Female	White	PNET	Metastasis	Deceased	No	No	No	P320S,T73I	No	No	53.0
DFCI-042589	63	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	63.0
DFCI-044643	84	Male	NA	PDAC	Primary	Alive	No	No	P81L	No	No	No	84.0
DFCI-047682	62	Male	White	PDAC	Primary	Deceased	No	R267W	No	R531W	No	Yes	62.0
DFCI-049981	68	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	68.0
DFCI-050253	64	Female	White	PDAC	Metastasis	Deceased	G12V	C242G	No	No	G12	Yes	64.0
DFCI-050713	70	Male	White	PDAC	Primary	Deceased	G12D	L265P	No	No	G12	Yes	70.0
DFCI-050728	72	Male	White	PDAC	Metastasis	Deceased	G12V	M237I	No	No	G12	Yes	72.0
DFCI-050729	69	Female	White	PNET	Primary	Deceased	No	No	No	G386D	No	No	69.0
DFCI-050733	28	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	28.0
DFCI-050778	63	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	63.0
DFCI-050779	73	Female	White	PDAC	Metastasis	Deceased	G12R	Y126D	No	No	G12	Yes	73.0
DFCI-050783	52	Male	White	PDAC	Primary	Deceased	G12R	V173L	No	No	G12	Yes	52.0
DFCI-050790	62	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	62.0
DFCI-050791	65	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	65.0
DFCI-050804	60	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	C71S	G12	No	60.0
DFCI-050805	51	Female	White	PDAC	Primary	Deceased	G12D	V274A	No	No	G12	Yes	51.0
DFCI-050806	47	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	47.0
DFCI-050921	66	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	66.0
DFCI-050923	64	Male	White	PDAC	Metastasis	Alive	G12D	R175H	D84V	No	G12	Yes	64.0
DFCI-050977	67	Male	White	PDAC	Primary	Alive	G12V	R175H	No	No	G12	Yes	67.0
DFCI-050980	69	Female	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	69.0
DFCI-050989	85	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	85.0
DFCI-051024	59	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	59.0
DFCI-051027	60	Male	White	PDAC	Metastasis	Deceased	G12R	V272M	D108G	R97S	G12	Yes	60.0
DFCI-051164	55	Female	White	PDAC	Metastasis	Deceased	Q61L	No	No	No	Q61	No	55.0
DFCI-051165	56	Female	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	56.0
DFCI-051188	66	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	66.0
DFCI-051212	60	Female	White	PDAC	Metastasis	Deceased	G12D	A159P	No	No	G12	Yes	60.0
DFCI-051232	65	Male	White	PDAC	Primary	Deceased	G12R	P151H	No	No	G12	Yes	65.0
DFCI-051246	65	Female	White	PDAC	Metastasis	Deceased	G12D,R68S	No	No	P356L	G12\|Other	No	65.0
DFCI-051254	62	Male	White	PDAC	Primary	Deceased	G12V	No	No	Y95H	G12	No	62.0
DFCI-051400	52	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	52.0
DFCI-052086	69	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	69.0
DFCI-052104	19	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	19.0
DFCI-052127	57	Female	White	PDAC	Metastasis	Deceased	No	Y234C	No	No	No	Yes	57.0
DFCI-052242	61	Male	White	PDAC	Primary	Deceased	G12D	G245S	No	No	G12	Yes	61.0
DFCI-052355	69	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	69.0
DFCI-052948	85	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	85.0
DFCI-053054	75	Male	NA	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	75.0
DFCI-053187	79	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	79.0
DFCI-053207	54	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	54.0
DFCI-053252	81	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	81.0
DFCI-053384	66	Female	White	PDAC	Primary	Deceased	G12V	R282W	No	No	G12	Yes	66.0
DFCI-053393	48	Male	White	PNET	Metastasis	Deceased	No	C238R	No	No	No	Yes	48.0
DFCI-053456	76	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	76.0
DFCI-053458	57	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	57.0
DFCI-053474	73	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	73.0
DFCI-075788	71	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	71.0
DFCI-075979	44	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	44.0
DFCI-076085	73	Female	White	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	73.0
DFCI-076396	81	Male	NA	PDAC	Primary	Deceased	G12C	No	No	No	G12	No	81.0
DFCI-076446	62	Female	White	PDAC	Primary	Deceased	G12D	No	No	R361C	G12	No	62.0
DFCI-077266	78	Female	White	PDAC	Primary	Deceased	G12D	E271V	No	No	G12	Yes	78.0
DFCI-077409	54	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	54.0
DFCI-077479	82	Male	White	PDAC	Primary	Deceased	G12R	M133K	No	No	G12	Yes	82.0
DFCI-077748	68	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	68.0
DFCI-077791	>89	Male	White	Adenosquamous carcinoma	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	90.0
DFCI-077941	81	Female	White	PDAC	Primary	Deceased	G12D	Y205F	No	No	G12	Yes	81.0
DFCI-077951	47	Male	White	PNET	Metastasis	Deceased	G12R	No	No	No	G12	No	47.0
DFCI-078477	69	Male	White	PDAC	Primary	Deceased	G12R	V272L	No	D351H	G12	Yes	69.0
DFCI-079170	56	Female	White	PDAC	Primary	Deceased	G12R	R282W	No	No	G12	Yes	56.0
DFCI-079194	64	Female	NA	PDAC	Primary	Deceased	No	No	No	No	No	No	64.0
DFCI-079715	54	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	54.0
DFCI-080526	75	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	75.0
DFCI-081115	53	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	53.0
DFCI-082356	69	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	69.0
DFCI-084096	69	Female	White	PDAC	Primary	Deceased	G12V	R273H	No	No	G12	Yes	69.0
DFCI-084705	74	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	74.0
DFCI-085643	81	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	81.0
DFCI-086403	58	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	58.0
DFCI-086621	82	Male	White	PDAC	Primary	Deceased	G12C	H193R	No	No	G12	Yes	82.0
DFCI-086776	61	Female	White	PDAC	Primary	Alive	G12V	H193N	No	No	G12	Yes	61.0
DFCI-086921	79	Male	White	PDAC	Primary	Deceased	G13E	Y220C	No	No	G13	Yes	79.0
DFCI-087435	52	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	52.0
DFCI-088509	66	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	66.0
DFCI-088578	50	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	50.0
DFCI-088585	60	Male	White	Adenosquamous carcinoma	Primary	Deceased	G13D	No	No	No	G13	No	60.0
DFCI-088835	64	Female	Black/African-American	PDAC	Metastasis	Deceased	Q61H	R175H	No	No	Q61	Yes	64.0
DFCI-088862	81	Female	White	PDAC	Primary	Deceased	G12D	No	No	A118V	G12	No	81.0
DFCI-088875	57	Male	White	PDAC	Metastasis	Alive	Q61R	S241F	No	No	Q61	Yes	57.0
DFCI-088891	70	Male	White	PDAC	Metastasis	Deceased	G12D	G245D	No	No	G12	Yes	70.0
DFCI-088900	58	Female	White	PNET	Primary	Deceased	No	F109V	No	No	No	Yes	58.0
DFCI-088906	64	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
DFCI-089143	41	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	41.0
DFCI-089178	33	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	33.0
DFCI-089253	57	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	57.0
DFCI-089882	57	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	57.0
DFCI-089883	54	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	54.0
DFCI-089892	61	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	61.0
DFCI-089908	69	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	69.0
DFCI-090147	78	Female	White	PDAC	Metastasis	Deceased	G12D	R273C	No	G386S	G12	Yes	78.0
DFCI-090197	73	Female	White	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	73.0
DFCI-090199	79	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	79.0
DFCI-090200	64	Female	White	Adenosquamous carcinoma	Primary	Deceased	G12D	I195T	No	No	G12	Yes	64.0
DFCI-090221	46	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	46.0
DFCI-090223	66	Male	White	PDAC	Metastasis	Deceased	G12R	R337L	No	G510V	G12	Yes	66.0
DFCI-090288	74	Male	Asian	PDAC	Metastasis	Deceased	G12R	R282W	No	No	G12	Yes	74.0
DFCI-090558	65	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	65.0
DFCI-090562	74	Male	White	PDAC	Primary	Deceased	G12R	No	No	T63I	G12	No	74.0
DFCI-090564	73	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	73.0
DFCI-090569	57	Male	White	PDAC	Metastasis	Deceased	G12V	No	R87P	No	G12	No	57.0
DFCI-090575	81	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	81.0
DFCI-090723	57	Male	White	PDAC	Primary	Deceased	G12D	S127F	No	No	G12	Yes	57.0
DFCI-090879	49	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	49.0
DFCI-091139	66	Male	White	PDAC	Primary	Deceased	G12D	No	D153H	No	G12	No	66.0
DFCI-091150	62	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	62.0
DFCI-091185	64	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	64.0
DFCI-091200	60	Male	White	PDAC	Primary	Deceased	G12V	No	H83Y	No	G12	No	60.0
DFCI-091204	65	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	65.0
DFCI-091216	67	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	67.0
DFCI-091221	67	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	67.0
DFCI-091225	76	Female	White	PDAC	Primary	Deceased	G12R	C238F	H83Y	R497H	G12	Yes	76.0
DFCI-091233	60	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	60.0
DFCI-091238	76	Male	White	PDAC	Primary	Deceased	G12D	S127F	No	P356L	G12	Yes	76.0
DFCI-091479	84	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	84.0
DFCI-091509	62	Male	NA	PDAC	Metastasis	Deceased	G12V	T155N	No	No	G12	Yes	62.0
DFCI-091518	79	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	79.0
DFCI-091701	66	Male	White	PDAC	Primary	Deceased	G12R	I251F	No	No	G12	Yes	66.0
DFCI-091801	63	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	E53K	G12	No	63.0
DFCI-091804	66	Female	NA	PDAC	Primary	Alive	No	No	No	No	No	No	66.0
DFCI-091837	60	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	60.0
DFCI-091869	68	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	68.0
DFCI-091892	63	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
DFCI-091894	33	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	33.0
DFCI-092129	71	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	71.0
DFCI-092131	84	Male	White	PDAC	Primary	Deceased	G12V	R249W	L130Q	No	G12	Yes	84.0
DFCI-092147	59	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	59.0
DFCI-092190	76	Male	White	PDAC	Primary	Deceased	Q61R	No	No	No	Q61	No	76.0
DFCI-092428	72	Male	White	PDAC	Primary	Deceased	G12V	H178P,R175H	No	No	G12	Yes	72.0
DFCI-093079	77	Female	White	PDAC	Primary	Deceased	G12D	No	No	R380G	G12	No	77.0
DFCI-093087	66	Female	White	PDAC	Primary	Deceased	G12R	No	Q50P	No	G12	No	66.0
DFCI-093358	71	Male	White	PDAC	Primary	Deceased	G12V	C275R	No	No	G12	Yes	71.0
DFCI-093449	74	Female	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	74.0
DFCI-093772	67	Female	White	PDAC	Primary	Alive	G12R	R175G	No	No	G12	Yes	67.0
DFCI-093907	67	Female	White	PDAC	Metastasis	Deceased	Q61L	No	No	No	Q61	No	67.0
DFCI-093980	86	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	86.0
DFCI-094975	74	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	74.0
DFCI-095090	69	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	69.0
DFCI-095212	63	Male	White	PDAC	Metastasis	Deceased	G12R	R248W	No	No	G12	Yes	63.0
DFCI-095543	77	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	77.0
DFCI-095670	49	Female	White	PDAC	Metastasis	Deceased	G12D	A161T	No	D351Y	G12	Yes	49.0
DFCI-095732	63	Female	White	PDAC	Metastasis	Deceased	G12V	N131S,R248W	No	No	G12	Yes	63.0
DFCI-096020	72	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	72.0
DFCI-096269	64	Female	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	64.0
DFCI-096915	62	Female	White	PDAC	Primary	Alive	No	S127F	No	No	No	Yes	62.0
DFCI-097135	73	Male	White	PDAC	Primary	Deceased	G12R	Q144P	No	No	G12	Yes	73.0
DFCI-098087	56	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	56.0
DFCI-099011	70	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	70.0
DFCI-106620	85	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	85.0
DFCI-107071	50	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	50.0
DFCI-107073	75	Male	White	PDAC	Primary	Deceased	G12D	L130V	No	No	G12	Yes	75.0
DFCI-107083	72	Male	White	PDAC	Primary	Deceased	G12R	M133K	No	No	G12	Yes	72.0
DFCI-107087	72	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	72.0
DFCI-107584	62	Female	White	PNET	Primary	Alive	No	No	V59G	No	No	No	62.0
DFCI-108007	71	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	71.0
DFCI-108017	64	Female	Black/African-American	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	64.0
DFCI-108105	56	Female	White	PDAC	NA or Heme	Deceased	G12D	No	No	No	G12	No	56.0
DFCI-108410	63	Male	White	PDAC	Metastasis	Deceased	G12D	V272Q	No	No	G12	Yes	63.0
DFCI-108425	62	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	62.0
DFCI-108439	55	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	55.0
DFCI-108478	62	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	62.0
DFCI-108871	56	Male	White	PDAC	Metastasis	Deceased	G12V	No	H83Y	No	G12	No	56.0
DFCI-108911	64	Male	White	PDAC	Metastasis	Deceased	G12D	E285K	P48R	L57S	G12	Yes	64.0
DFCI-109231	57	Male	White	PDAC	Metastasis	Deceased	G12V	R273C	No	No	G12	Yes	57.0
DFCI-109272	53	Male	Black/African-American	PNET	Primary	Alive	No	No	No	R100S	No	No	53.0
DFCI-109291	52	Male	White	PDAC	Metastasis	Deceased	G12D	H179Y	No	No	G12	Yes	52.0
DFCI-109307	39	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	39.0
DFCI-109308	84	Male	White	PDAC	Primary	Deceased	Q61H	V272M	No	No	Q61	Yes	84.0
DFCI-109323	60	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	60.0
DFCI-109641	54	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	54.0
DFCI-109719	61	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	61.0
DFCI-109725	37	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	37.0
DFCI-109750	<18	Female	White	Solid pseudopapillary tumor	Primary	Alive	No	No	No	No	No	No	17.0
DFCI-109775	75	Male	White	PDAC	Primary	Deceased	G12D	G245S	No	A406V	G12	Yes	75.0
DFCI-109795	73	Male	White	PDAC	Primary	Deceased	G12D	R248Q	No	No	G12	Yes	73.0
DFCI-109931	45	Female	White	PDAC	Primary	Deceased	Q61R	R282W	No	No	Q61	Yes	45.0
DFCI-110146	51	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	51.0
DFCI-110154	32	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	32.0
DFCI-110155	71	Male	White	PDAC	Primary	Deceased	G12V	R282W	No	No	G12	Yes	71.0
DFCI-110558	63	Male	White	PDAC	Metastasis	Deceased	G12D	C141W	V51D	No	G12	Yes	63.0
DFCI-110583	59	Female	White	PDAC	Primary	Deceased	G12V	No	No	Q116E	G12	No	59.0
DFCI-110600	63	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	63.0
DFCI-110604	>89	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	90.0
DFCI-110687	69	Male	White	PDAC	Metastasis	Deceased	G12D	C135W	No	No	G12	Yes	69.0
DFCI-111056	69	Male	White	PDAC	Primary	Deceased	G12C	R248Q	No	No	G12	Yes	69.0
DFCI-111087	75	Female	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	75.0
DFCI-111106	61	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	61.0
DFCI-111466	75	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	75.0
DFCI-111484	53	Male	White	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	53.0
DFCI-111487	78	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	78.0
DFCI-111568	70	Male	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	70.0
DFCI-112204	69	Female	NA	PDAC	Metastasis	Deceased	No	No	No	No	No	No	69.0
DFCI-113096	78	Male	White	PDAC	Primary	Alive	S65G,Q61R	No	No	No	Q61\|Other	No	78.0
DFCI-113191	54	Female	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	54.0
DFCI-113194	71	Male	White	PDAC	Primary	Deceased	G12R	M237I	No	No	G12	Yes	71.0
DFCI-113197	68	Male	White	PNET	NA or Heme	Alive	No	No	No	No	No	No	68.0
DFCI-113228	58	Male	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	58.0
DFCI-113298	73	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	73.0
DFCI-115874	54	Male	White	PDAC	Primary	Deceased	G12D	R175H	H83Y	No	G12	Yes	54.0
DFCI-116532	66	Female	White	PDAC	Metastasis	Alive	Q61H	No	No	No	Q61	No	66.0
DFCI-116895	68	Female	White	PDAC	Metastasis	Deceased	G12V	V157F	No	No	G12	Yes	68.0
DFCI-117945	84	Male	White	PDAC	Metastasis	Deceased	G12V	G266E	No	No	G12	Yes	84.0
DFCI-117946	66	Male	White	PDAC	Metastasis	Deceased	G12D	A138D	No	No	G12	Yes	66.0
DFCI-117959	72	Male	White	PDAC	Primary	Deceased	G12D	R273L	No	No	G12	Yes	72.0
DFCI-117968	60	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	60.0
DFCI-118360	53	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	53.0
DFCI-118375	75	Male	White	PDAC	Metastasis	Deceased	No	F134S	No	No	No	Yes	75.0
DFCI-118380	62	Male	White	PDAC	Primary	Deceased	G12D	Y236N	No	No	G12	Yes	62.0
DFCI-118430	71	Female	White	PDAC	Metastasis	Alive	G12R	L130R	No	No	G12	Yes	71.0
DFCI-118433	39	Female	Asian	PNET	Metastasis	Deceased	No	No	No	No	No	No	39.0
DFCI-118450	54	Female	White	PDAC	Metastasis	Deceased	G12D	G266V	No	No	G12	Yes	54.0
DFCI-118461	74	Female	White	PDAC	Primary	Deceased	G12D	No	M53I	No	G12	No	74.0
DFCI-119383	40	Female	Asian	PNET	Metastasis	Alive	No	No	No	No	No	No	40.0
DFCI-120186	67	Male	Black/African-American	PDAC	Primary	Deceased	G12V	No	No	L109P	G12	No	67.0
DFCI-120305	67	Male	White	PDAC	Primary	Deceased	G12V	C135R	No	No	G12	Yes	67.0
DFCI-120380	74	Male	White	PDAC	NA or Heme	Deceased	G12D	No	No	No	G12	No	74.0
DFCI-120439	54	Female	White	PDAC	NA or Heme	Deceased	G12R	P151H	No	R361H	G12	Yes	54.0
DFCI-120520	53	Male	White	PDAC	Metastasis	Deceased	G12V	R280T	No	No	G12	Yes	53.0
DFCI-120578	66	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	66.0
DFCI-120853	70	Female	White	PDAC	NA or Heme	Deceased	G12V	R248W	No	No	G12	Yes	70.0
DFCI-121075	76	Male	White	PDAC	Metastasis	Deceased	G12D	No	H83Y	No	G12	No	76.0
DFCI-121417	77	Male	White	PDAC	NA or Heme	Deceased	Q61H	No	No	No	Q61	No	77.0
DFCI-121874	62	Male	Asian	PDAC	NA or Heme	Deceased	G12V	R248W	No	P356L	G12	Yes	62.0
DFCI-122041	80	Male	Other	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	80.0
DFCI-122936	75	Male	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	75.0
DFCI-124085	73	Male	White	PDAC	NA or Heme	Deceased	G12D	No	No	No	G12	No	73.0
DFCI-129634	63	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	63.0
DFCI-131026	68	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	68.0
DFCI-132145	80	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	80.0
DFCI-132163	66	Female	White	PDAC	Primary	Deceased	G12V	R273C	No	C363F	G12	Yes	66.0
DFCI-132167	59	Female	White	PDAC	Metastasis	Deceased	G12D	No	H83D	No	G12	No	59.0
DFCI-132179	67	Female	White	PDAC	Metastasis	Deceased	Q61L	No	No	No	Q61	No	67.0
DFCI-132182	77	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	77.0
DFCI-132205	50	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	50.0
DFCI-132209	66	Female	White	PDAC	Metastasis	Deceased	G12V	I195T	No	No	G12	Yes	66.0
DFCI-132228	77	Male	White	PDAC	Metastasis	Deceased	G12D	G244D	No	No	G12	Yes	77.0
DFCI-132244	40	Male	Other	PNET	NA or Heme	Alive	No	No	No	No	No	No	40.0
DFCI-132245	70	Male	White	PDAC	Primary	Deceased	G12D	G245S	No	No	G12	Yes	70.0
DFCI-132250	68	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	68.0
DFCI-132508	76	Male	White	PDAC	Primary	Deceased	G12D	G245S	No	No	G12	Yes	76.0
DFCI-132604	72	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	72.0
DFCI-132612	71	Female	White	PDAC	Metastasis	Deceased	G12D	Y220S	No	No	G12	Yes	71.0
DFCI-132922	70	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	70.0
DFCI-134339	69	Female	White	PDAC	Primary	Deceased	G12V	A159P	No	No	G12	Yes	69.0
DFCI-134720	<18	Female	Black/African-American	PNET	Primary	Alive	No	No	No	No	No	No	17.0
DFCI-135162	32	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	32.0
DFCI-135178	58	Male	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	58.0
DFCI-135179	66	Female	White	PDAC	NA or Heme	Deceased	Q61H	I251F	No	No	Q61	Yes	66.0
DFCI-135180	70	Female	White	PDAC	NA or Heme	Alive	G12C	No	No	No	G12	No	70.0
DFCI-135219	64	Female	White	PDAC	Primary	Alive	G12D	V272L	No	No	G12	Yes	64.0
DFCI-135579	61	Female	White	PDAC	NA or Heme	Deceased	G12V	No	No	No	G12	No	61.0
DFCI-135583	66	Male	White	PDAC	NA or Heme	Deceased	G12V	V173L	No	No	G12	Yes	66.0
DFCI-135591	57	Female	White	PDAC	Metastasis	Deceased	G13D	S241F	No	No	G13	Yes	57.0
DFCI-135603	82	Female	White	PDAC	Primary	Deceased	G12D	F134V	No	No	G12	Yes	82.0
DFCI-135619	51	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	51.0
DFCI-135630	59	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	59.0
DFCI-135646	68	Male	White	PDAC	Primary	Deceased	G12D	P278L	No	E53K	G12	Yes	68.0
DFCI-136008	33	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	33.0
DFCI-136045	62	Male	Black/African-American	PDAC	Metastasis	Deceased	G12V	R273H	No	No	G12	Yes	62.0
DFCI-136050	69	Male	NA	PDAC	NA or Heme	Deceased	G12V	P152L	No	No	G12	Yes	69.0
DFCI-136071	65	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	65.0
DFCI-136079	69	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	69.0
DFCI-136092	53	Female	White	PDAC	Metastasis	Deceased	G12D	S127F	No	No	G12	Yes	53.0
DFCI-136097	71	Male	White	Acinar cell carcinoma	NA or Heme	Alive	No	No	No	No	No	No	71.0
DFCI-136098	79	Female	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	79.0
DFCI-136109	70	Male	White	PDAC	NA or Heme	Deceased	G12D	No	No	No	G12	No	70.0
DFCI-136455	50	Male	White	PDAC	Metastasis	Deceased	G12R	R248Q	No	No	G12	Yes	50.0
DFCI-136464	59	Male	White	PDAC	Metastasis	Deceased	G12D	Y220C	R22P	No	G12	Yes	59.0
DFCI-136491	46	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	46.0
DFCI-136889	53	Male	White	PDAC	Primary	Deceased	Q61H	Y126C	No	G510V	Q61	Yes	53.0
DFCI-136906	82	Female	White	Carcinoma, NOS	NA or Heme	Deceased	G12R	No	No	No	G12	No	82.0
DFCI-136934	55	Male	White	PDAC	NA or Heme	Deceased	G12D	R175H	No	No	G12	Yes	55.0
DFCI-136935	58	Male	White	PDAC	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	58.0
DFCI-136937	67	Male	White	PDAC	Primary	Deceased	G12D	H193L	No	No	G12	Yes	67.0
DFCI-136950	34	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	34.0
DFCI-136963	70	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	70.0
DFCI-136978	73	Female	Asian	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	73.0
DFCI-136995	80	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	80.0
DFCI-137246	53	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	53.0
DFCI-137247	53	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	53.0
DFCI-137335	51	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	51.0
DFCI-137345	77	Male	White	PDAC	Primary	Deceased	G12D	No	No	D493N	G12	No	77.0
DFCI-137360	69	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	69.0
DFCI-137386	63	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	63.0
DFCI-137404	65	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	65.0
DFCI-137406	>89	Female	White	PDAC	NA or Heme	Deceased	G12R	R282W	No	No	G12	Yes	90.0
DFCI-137419	58	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	58.0
DFCI-137423	59	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	59.0
DFCI-137425	67	Male	Asian	PDAC	Metastasis	Deceased	G12C	C242F	No	No	G12	Yes	67.0
DFCI-137693	70	Male	White	PDAC	Primary	Deceased	G12V	G266V	No	No	G12	Yes	70.0
DFCI-137768	60	Female	White	PDAC	NA or Heme	Deceased	G12D	No	No	No	G12	No	60.0
DFCI-137773	64	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	R361H	G12	No	64.0
DFCI-137780	62	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	62.0
DFCI-137785	86	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	86.0
DFCI-137786	69	Male	White	PDAC	Primary	Deceased	G12D	M133K	No	No	G12	Yes	69.0
DFCI-137797	57	Female	White	PDAC	Metastasis	Deceased	G12R	E285K	No	No	G12	Yes	57.0
DFCI-137799	71	Female	White	PDAC	NA or Heme	Alive	No	No	No	No	No	No	71.0
DFCI-137817	76	Female	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	76.0
DFCI-137821	53	Female	White	PDAC	Primary	Deceased	G12I	No	No	No	G12	No	53.0
DFCI-137839	59	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	59.0
DFCI-138250	62	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	62.0
DFCI-138257	66	Male	White	PDAC	NA or Heme	Deceased	G12V	No	No	R361H	G12	No	66.0
DFCI-138281	42	Male	White	PDAC	Metastasis	Deceased	G12R	R248G	No	Y353C	G12	Yes	42.0
DFCI-138298	50	Female	White	PDAC	Metastasis	Deceased	G12V	M246R	No	No	G12	Yes	50.0
DFCI-138314	81	Male	White	PDAC	Metastasis	Deceased	G12V	A138V	No	No	G12	Yes	81.0
DFCI-138599	67	Male	White	PDAC	Metastasis	Deceased	Q61R	V172D	No	K428E	Q61	Yes	67.0
DFCI-138809	69	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	69.0
DFCI-140340	64	Male	White	PDAC	Metastasis	Deceased	G12V	G266R	No	No	G12	Yes	64.0
DFCI-140451	64	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
DFCI-141703	71	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	R361C	G12	No	71.0
DFCI-144266	76	Male	White	PDAC	NA or Heme	Alive	G12D	No	No	No	G12	No	76.0
DFCI-144392	65	Female	White	PDAC	Metastasis	Deceased	Q61R	No	No	No	Q61	No	65.0
DFCI-145095	72	Male	White	PDAC	NA or Heme	Deceased	G12D	G245D	No	No	G12	Yes	72.0
DFCI-147955	60	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	60.0
DFCI-147967	65	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	Y234C	No	No	G12	Yes	65.0
DFCI-148025	44	Female	White	PDAC	Primary	Deceased	G12C	No	No	No	G12	No	44.0
DFCI-148183	75	Female	NA	PDAC	Primary	Alive	No	No	No	No	No	No	75.0
DFCI-148264	64	Female	White	PDAC	Primary	Deceased	G12V	G245S	No	L533R	G12	Yes	64.0
DFCI-148353	48	Female	Black/African-American	PNET	Metastasis	Deceased	No	No	No	G89E	No	No	48.0
DFCI-148792	64	Female	White	PDAC	Metastasis	Deceased	G12D	G245S	No	No	G12	Yes	64.0
DFCI-148892	76	Male	White	PDAC	Primary	Deceased	G12D	H179R	No	No	G12	Yes	76.0
DFCI-148928	77	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	77.0
DFCI-150093	65	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	65.0
DFCI-150942	62	Female	Black/African-American	PDAC	Primary	Deceased	G12D	I195T	No	No	G12	Yes	62.0
DFCI-151321	80	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	80.0
DFCI-151558	52	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	52.0
DFCI-151567	72	Female	NA	PDAC	Metastasis	Deceased	G12V	R273L	No	No	G12	Yes	72.0
DFCI-151798	80	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	80.0
DFCI-154059	77	Male	White	PDAC	Primary	Deceased	G12C	R273H	No	R497H	G12	Yes	77.0
DFCI-155214	71	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	71.0
DFCI-155955	39	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	39.0
DFCI-158457	67	Female	White	PDAC	NA or Heme	Deceased	G12V	E271K	No	No	G12	Yes	67.0
DFCI-158611	66	Female	White	PDAC	Metastasis	Deceased	G12V	G245S	No	No	G12	Yes	66.0
DFCI-159282	51	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	51.0
DFCI-159596	75	Male	White	PDAC	Metastasis	Deceased	G12D	R273C	No	No	G12	Yes	75.0
DFCI-161895	54	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	54.0
DFCI-163265	76	Female	White	PDAC	Metastasis	Deceased	G12R	C176F	No	No	G12	Yes	76.0
DFCI-165907	55	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	55.0
DFCI-165952	68	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	68.0
DFCI-166257	71	Female	White	PDAC	Metastasis	Deceased	G12D	Y163C	No	No	G12	Yes	71.0
DFCI-167311	57	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	57.0
DFCI-167536	81	Female	White	Adenosquamous carcinoma	Primary	Deceased	G12V	V217G	No	No	G12	Yes	81.0
DFCI-167545	64	Female	White	PDAC	Metastasis	Deceased	G12D	R248G	No	No	G12	Yes	64.0
DFCI-167552	47	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	47.0
DFCI-167554	69	Male	White	Adenosquamous carcinoma	NA or Heme	Deceased	G12V	R175H	Q50H	No	G12	Yes	69.0
DFCI-167559	62	Male	White	PDAC	Metastasis	Deceased	G12V	C238Y	No	No	G12	Yes	62.0
DFCI-167583	60	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	60.0
DFCI-167605	60	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	60.0
DFCI-167615	80	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	80.0
DFCI-167616	64	Female	White	PDAC	Primary	Deceased	G12D	C275R	No	No	G12	Yes	64.0
DFCI-167629	55	Female	White	PDAC	Metastasis	Deceased	No	R273H	No	No	No	Yes	55.0
DFCI-167971	63	Male	White	PDAC	Metastasis	Deceased	G12D	E258Q	No	No	G12	Yes	63.0
DFCI-167973	68	Male	White	PDAC	Metastasis	Deceased	G12V	N239D	No	No	G12	Yes	68.0
DFCI-168005	77	Male	White	PDAC	Primary	Deceased	G12R	T125M	No	No	G12	Yes	77.0
DFCI-168007	74	Male	White	Adenosquamous carcinoma	Primary	Deceased	No	H214R	No	No	No	Yes	74.0
DFCI-168019	71	Male	White	PDAC	Metastasis	Deceased	G12V	R175H	H83Y	No	G12	Yes	71.0
DFCI-168030	60	Female	White	PDAC	Metastasis	Deceased	Q61L	C141Y,P250L	No	No	Q61	Yes	60.0
DFCI-168032	84	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	84.0
DFCI-168041	<18	Female	Other	Solid pseudopapillary tumor	Primary	Alive	No	No	No	No	No	No	17.0
DFCI-168340	57	Female	White	PDAC	Primary	Deceased	G12D	No	H83Y	No	G12	No	57.0
DFCI-168407	65	Female	White	PDAC	NA or Heme	Deceased	G12V	T256P	No	G365D	G12	Yes	65.0
DFCI-168423	75	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	75.0
DFCI-168428	53	Female	Asian	PDAC	Primary	Alive	G12D	No	No	No	G12	No	53.0
DFCI-168436	80	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	80.0
DFCI-168438	69	Male	White	PDAC	Primary	Deceased	G12D	R175H	No	Y95S	G12	Yes	69.0
DFCI-168444	75	Male	NA	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	75.0
DFCI-168452	42	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	42.0
DFCI-168453	57	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	57.0
DFCI-168475	74	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	74.0
DFCI-168501	73	Male	White	PDAC	NA or Heme	Alive	G12C	No	No	No	G12	No	73.0
DFCI-168841	50	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	50.0
DFCI-168850	67	Male	White	PDAC	Primary	Deceased	G12R	H179R	No	No	G12	Yes	67.0
DFCI-168852	47	Male	White	PNET	NA or Heme	Alive	No	No	No	No	No	No	47.0
DFCI-168853	73	Male	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	73.0
DFCI-168889	67	Female	White	PDAC	Unknown	Deceased	G12D	R248W	H83Y	No	G12	Yes	67.0
DFCI-168917	64	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	R273C	No	No	G12	Yes	64.0
DFCI-168922	64	Male	White	PDAC	Metastasis	Deceased	G12V	V272L	No	No	G12	Yes	64.0
DFCI-168926	37	Female	White	Mucinous Cystic Neoplasm	NA or Heme	Deceased	G12R	No	No	No	G12	No	37.0
DFCI-168940	75	Male	White	PDAC	Metastasis	Deceased	G12V	E286G	No	No	G12	Yes	75.0
DFCI-168941	53	Male	Asian	PDAC	Primary	Alive	G12V	No	No	No	G12	No	53.0
DFCI-169284	74	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	74.0
DFCI-169296	59	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	59.0
DFCI-169312	66	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	66.0
DFCI-169313	56	Female	White	PDAC	Metastasis	Deceased	G12D	R110L	No	No	G12	Yes	56.0
DFCI-169324	64	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	64.0
DFCI-169328	67	Male	White	PDAC	Primary	Alive	G12D	R248Q	V82L	No	G12	Yes	67.0
DFCI-169335	67	Male	White	PDAC	Metastasis	Deceased	G12V	H214R	D108V	No	G12	Yes	67.0
DFCI-169350	52	Male	White	PDAC	Metastasis	Alive	G12D	G245C	No	No	G12	Yes	52.0
DFCI-169354	66	Male	White	PDAC	Metastasis	Deceased	G12V	R248W	P81L	No	G12	Yes	66.0
DFCI-169355	54	Male	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	54.0
DFCI-169363	70	Female	White	PDAC	Metastasis	Deceased	G12V	R248W	No	No	G12	Yes	70.0
DFCI-169388	51	Male	White	PDAC	Primary	Alive	G12D	G245S	No	No	G12	Yes	51.0
DFCI-169650	83	Male	White	PDAC	NA or Heme	Deceased	No	R213L	No	No	No	Yes	83.0
DFCI-169725	72	Male	White	PDAC	Metastasis	Deceased	G12V	R175H	No	H132Y	G12	Yes	72.0
DFCI-169744	68	Female	White	PDAC	Primary	Deceased	G12L	Y126N	No	R361H	G12	Yes	68.0
DFCI-169749	68	Female	White	PDAC	NA or Heme	Deceased	G12D	No	No	No	G12	No	68.0
DFCI-169753	61	Female	White	PDAC	Metastasis	Deceased	G12R	No	H83Y	No	G12	No	61.0
DFCI-169760	63	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
DFCI-169776	64	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	64.0
DFCI-169786	48	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	48.0
DFCI-169791	56	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	56.0
DFCI-170160	61	Male	White	PDAC	Primary	Deceased	G12V	R249S	No	No	G12	Yes	61.0
DFCI-170162	70	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	70.0
DFCI-170167	65	Male	White	PDAC	Metastasis	Deceased	G12C	I251N	No	No	G12	Yes	65.0
DFCI-170180	57	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	57.0
DFCI-170181	61	Male	White	PDAC	Metastasis	Deceased	G12D	R282W	No	No	G12	Yes	61.0
DFCI-170208	75	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	75.0
DFCI-170217	67	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	67.0
DFCI-170220	72	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	72.0
DFCI-170229	<18	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	17.0
DFCI-170239	77	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	C523R	G12	No	77.0
DFCI-170256	<18	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	17.0
DFCI-170268	60	Female	White	PDAC	Primary	Deceased	G12R	No	H83D	No	G12	No	60.0
DFCI-170515	83	Male	White	PDAC	Metastasis	Deceased	Q61H	R273H	No	No	Q61	Yes	83.0
DFCI-170611	61	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	61.0
DFCI-170632	69	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	69.0
DFCI-170637	64	Male	White	PDAC	Metastasis	Deceased	G12V	R273C	No	No	G12	Yes	64.0
DFCI-170645	72	Male	White	PDAC	Primary	Deceased	G12D	P278R	No	No	G12	Yes	72.0
DFCI-170674	53	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	53.0
DFCI-170678	66	Male	White	PDAC	Metastasis	Alive	G12I	H179R	No	No	G12	Yes	66.0
DFCI-170680	75	Male	White	PDAC	Primary	Deceased	L19F	No	A20P	No	Other	No	75.0
DFCI-170693	81	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	81.0
DFCI-170960	70	Female	White	PDAC	NA or Heme	Deceased	G12R	No	No	No	G12	No	70.0
DFCI-171034	64	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	64.0
DFCI-171038	80	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	80.0
DFCI-171051	74	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	74.0
DFCI-171052	46	Female	Other	PDAC	Primary	Deceased	G12D	C238Y	No	No	G12	Yes	46.0
DFCI-171097	63	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
DFCI-171104	78	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	78.0
DFCI-171108	73	Female	White	PDAC	Metastasis	Deceased	G12V	R248Q	No	No	G12	Yes	73.0
DFCI-171117	79	Female	Asian	PDAC	Metastasis	Deceased	G12D	C135Y	No	No	G12	Yes	79.0
DFCI-171127	56	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	56.0
DFCI-171140	78	Male	White	PDAC	Primary	Deceased	G12D	G266E	No	No	G12	Yes	78.0
DFCI-171284	54	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	54.0
DFCI-171456	53	Female	White	PDAC	Metastasis	Deceased	No	R175H	H83Y	No	No	Yes	53.0
DFCI-171486	74	Female	White	PDAC	Primary	Deceased	G12V	E286G	No	No	G12	Yes	74.0
DFCI-171496	66	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	66.0
DFCI-171499	68	Female	White	PDAC	Metastasis	Deceased	G12V	E224D	No	No	G12	Yes	68.0
DFCI-171512	65	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	65.0
DFCI-171516	78	Female	White	PDAC	Metastasis	Deceased	G12V	K132R	No	No	G12	Yes	78.0
DFCI-171517	63	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	63.0
DFCI-171523	73	Female	White	Adenosquamous carcinoma	Primary	Deceased	G12V	No	No	No	G12	No	73.0
DFCI-171525	56	Male	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	56.0
DFCI-171531	33	Female	Black/African-American	PNET	Primary	Alive	No	No	No	No	No	No	33.0
DFCI-171544	63	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
DFCI-171558	76	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	D351Y	G12	No	76.0
DFCI-171574	66	Female	White	PDAC	Metastasis	Deceased	G12V	R273H	No	No	G12	Yes	66.0
DFCI-171582	62	Male	White	PDAC	Metastasis	Deceased	G12V	R273C	No	No	G12	Yes	62.0
DFCI-171585	63	Male	White	PDAC	Primary	Alive	G12V	Y236C	No	No	G12	Yes	63.0
DFCI-171883	67	Male	White	PDAC	Metastasis	Deceased	G12V	Y220C	H83Y	No	G12	Yes	67.0
DFCI-171897	72	Female	White	PDAC	Primary	Alive	G12V	R267W	No	No	G12	Yes	72.0
DFCI-172263	51	Female	White	PDAC	Metastasis	Deceased	G12R	R175H	No	No	G12	Yes	51.0
DFCI-172291	61	Male	NA	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	61.0
DFCI-172587	77	Female	White	PDAC	Primary	Deceased	G12C	No	No	No	G12	No	77.0
DFCI-173204	79	Female	White	PDAC	Primary	Deceased	G12V	G245S	No	No	G12	Yes	79.0
DFCI-173532	70	Female	White	PDAC	Metastasis	Deceased	G12D	L130V	No	R361C	G12	Yes	70.0
DFCI-173617	78	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	78.0
DFCI-173977	57	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	57.0
DFCI-174018	68	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	68.0
DFCI-174027	52	Female	White	PDAC	Primary	Deceased	G12D	H179R	No	No	G12	Yes	52.0
DFCI-174040	60	Female	White	PDAC	Primary	Deceased	G12V	No	H83Y	L104R	G12	No	60.0
DFCI-174081	55	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	55.0
DFCI-174094	68	Male	Asian	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	68.0
DFCI-174391	56	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	56.0
DFCI-174493	52	Male	White	PDAC	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	52.0
DFCI-174515	60	Female	White	PDAC	Metastasis	Deceased	G12R	C135W	No	R416K	G12	Yes	60.0
DFCI-174530	50	Male	Other	PDAC	Primary	Alive	G12C	No	No	No	G12	No	50.0
DFCI-174536	69	Male	White	PDAC	Metastasis	Deceased	G13D	R175H	No	No	G13	Yes	69.0
DFCI-180067	77	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	77.0
DFCI-180393	81	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	81.0
DFCI-180628	79	Female	White	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	79.0
DFCI-181157	57	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	57.0
DFCI-182692	74	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	74.0
DFCI-182773	56	Male	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	56.0
DFCI-184657	72	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	72.0
DFCI-191201	66	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	G245S	No	No	G12	Yes	66.0
DFCI-193154	71	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	71.0
DFCI-199744	79	Male	White	PDAC	Primary	Deceased	G12R	C135Y	No	R496H	G12	Yes	79.0
DFCI-199763	75	Male	White	PDAC	Primary	Deceased	G12D	R156P	No	No	G12	Yes	75.0
DFCI-199788	52	Female	White	PNET	Primary	Alive	No	G356R	No	No	No	Yes	52.0
DFCI-199797	68	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	68.0
DFCI-199835	71	Female	White	Carcinoma, NOS	Primary	Deceased	G12D	R248W	No	No	G12	Yes	71.0
DFCI-200194	70	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	70.0
DFCI-200198	57	Male	White	PDAC	Primary	Alive	G12D	G245F	No	R361H	G12	Yes	57.0
DFCI-200204	79	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	79.0
DFCI-200236	50	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	50.0
DFCI-200238	64	Male	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	64.0
DFCI-200249	66	Male	White	PDAC	Metastasis	Alive	G12D	R249S	No	No	G12	Yes	66.0
DFCI-200254	55	Male	White	PDAC	Primary	Alive	G12D	R175H	No	G352R	G12	Yes	55.0
DFCI-200257	67	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	67.0
DFCI-200518	69	Female	White	PDAC	Metastasis	Deceased	G12V	V173L	No	No	G12	Yes	69.0
DFCI-200632	70	Female	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	70.0
DFCI-200637	64	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	64.0
DFCI-200648	74	Male	White	PDAC	Metastasis	Deceased	No	R248W	No	No	No	Yes	74.0
DFCI-200666	51	Female	White	PDAC	Metastasis	Alive	G12R	V272M	No	No	G12	Yes	51.0
DFCI-200681	75	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	75.0
DFCI-200683	80	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	80.0
DFCI-200688	84	Female	White	PDAC	Metastasis	Deceased	G12V	G105V	No	No	G12	Yes	84.0
DFCI-200701	61	Male	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	61.0
DFCI-200709	63	Male	Black/African-American	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	63.0
DFCI-200720	48	Male	White	PDAC	Primary	Deceased	G12C	C176F	No	No	G12	Yes	48.0
DFCI-201061	72	Male	White	PDAC	Primary	Deceased	G12D	Y236C	No	No	G12	Yes	72.0
DFCI-201070	67	Female	White	PDAC	Primary	Deceased	No	R248Q	No	No	No	Yes	67.0
DFCI-201085	72	Female	White	PDAC	Primary	Deceased	G12V	No	H83Y	No	G12	No	72.0
DFCI-201099	75	Male	White	PDAC	Metastasis	Deceased	G12L	No	No	No	G12	No	75.0
DFCI-201111	77	Male	White	PDAC	Primary	Alive	G12V	G245S	No	No	G12	Yes	77.0
DFCI-201116	61	Male	Asian	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	61.0
DFCI-201133	69	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	69.0
DFCI-201145	66	Female	Other	PNET	Metastasis	Deceased	Q61R	No	No	No	Q61	No	66.0
DFCI-201494	54	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	54.0
DFCI-201498	86	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	86.0
DFCI-201511	67	Male	White	PDAC	Primary	Deceased	G12D	Y205S	No	No	G12	Yes	67.0
DFCI-201557	59	Female	White	PDAC	Primary	Deceased	G12V	No	M53I	No	G12	No	59.0
DFCI-201563	53	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	53.0
DFCI-201567	64	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	64.0
DFCI-201576	53	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	53.0
DFCI-201589	50	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	50.0
DFCI-201599	78	Female	White	PDAC	Primary	Alive	G12D	R248W	No	No	G12	Yes	78.0
DFCI-201846	86	Female	White	PDAC	Primary	Deceased	G12V	P151H	No	No	G12	Yes	86.0
DFCI-201941	74	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	74.0
DFCI-201944	70	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	70.0
DFCI-201965	59	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	59.0
DFCI-201998	66	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	66.0
DFCI-201999	61	Female	Other	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	61.0
DFCI-202000	54	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	54.0
DFCI-202006	47	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	47.0
DFCI-202031	77	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	77.0
DFCI-202272	59	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	59.0
DFCI-202410	75	Female	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	75.0
DFCI-202412	74	Male	White	PDAC	Primary	Deceased	No	R273C	No	No	No	Yes	74.0
DFCI-202427	73	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	73.0
DFCI-202428	71	Male	White	PDAC	Primary	Deceased	G12D	R273C	Q50R	R361H	G12	Yes	71.0
DFCI-202478	54	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	54.0
DFCI-202822	66	Male	White	PDAC	Metastasis	Deceased	G12R	V173G	No	No	G12	Yes	66.0
DFCI-203604	37	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	37.0
DFCI-204415	69	Female	White	PDAC	Metastasis	Deceased	Q61H	R248W	No	No	Q61	Yes	69.0
DFCI-204561	77	Female	White	PDAC	Primary	Alive	G12R	R196P	No	No	G12	Yes	77.0
DFCI-205363	49	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	D351G	G12	No	49.0
DFCI-205897	74	Female	White	PDAC	Primary	Deceased	G12R	R213L	No	No	G12	Yes	74.0
DFCI-214354	79	Female	White	PDAC	Primary	Deceased	G12V	R175H	H83Y	No	G12	Yes	79.0
DFCI-214830	43	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	43.0
DFCI-214919	56	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	56.0
DFCI-215810	67	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	67.0
DFCI-216626	66	Female	White	PDAC	Primary	Alive	G12R	T125K	No	No	G12	Yes	66.0
DFCI-216645	67	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	67.0
DFCI-218040	56	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	56.0
DFCI-218685	71	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	71.0
DFCI-230781	78	Female	White	PDAC	Primary	Deceased	G12V	I232N	No	No	G12	Yes	78.0
DFCI-233982	64	Male	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	64.0
DFCI-234051	69	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	69.0
DFCI-234410	64	Male	White	PDAC	Metastasis	Deceased	G12V	V157I,C135F	No	No	G12	Yes	64.0
DFCI-234537	66	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	66.0
DFCI-234539	62	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	62.0
DFCI-234941	76	Female	White	PDAC	Primary	Alive	G12V	R267P	No	No	G12	Yes	76.0
DFCI-235406	52	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	52.0
DFCI-235578	64	Female	White	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	64.0
DFCI-235794	71	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	W524R	G12	No	71.0
DFCI-235827	74	Male	White	PDAC	Metastasis	Deceased	G12D	No	L62P,A36T	No	G12	No	74.0
DFCI-235844	72	Female	White	PDAC	Metastasis	Deceased	G12D	P190L	No	No	G12	Yes	72.0
DFCI-236209	59	Female	Asian	PDAC	Primary	Alive	Q61R	G245S	No	G352V	Q61	Yes	59.0
DFCI-236218	69	Female	White	PDAC	Primary	Deceased	A11_G12delinsVV	R175H	No	No	G12\|Other	Yes	69.0
DFCI-236244	62	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	62.0
DFCI-236248	69	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	69.0
DFCI-236270	51	Male	White	PDAC	Primary	Deceased	G12V	P278T	No	No	G12	Yes	51.0
DFCI-236272	66	Male	NA	PDAC	Primary	Deceased	G12D	No	A118P	M24V	G12	No	66.0
DFCI-236296	64	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
DFCI-236310	42	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	42.0
DFCI-236311	66	Male	White	PDAC	Primary	Alive	G12V	No	D84N	No	G12	No	66.0
DFCI-236557	60	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	60.0
DFCI-236651	72	Male	White	PNET	Metastasis	Deceased	G12V	No	No	No	G12	No	72.0
DFCI-236704	75	Male	White	PDAC	Metastasis	Deceased	G12D	Y205H	No	No	G12	Yes	75.0
DFCI-236714	66	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	66.0
DFCI-236725	60	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	60.0
DFCI-236737	67	Female	White	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	67.0
DFCI-236758	65	Female	White	PDAC	Metastasis	Deceased	G12D	R273C	L97P	No	G12	Yes	65.0
DFCI-236834	76	Female	White	PDAC	Metastasis	Alive	G12R	R282W	No	No	G12	Yes	76.0
DFCI-237105	>89	Female	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	90.0
DFCI-237169	46	Male	Black/African-American	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	46.0
DFCI-237183	66	Female	White	PDAC	Metastasis	Alive	G12V	R273C	No	No	G12	Yes	66.0
DFCI-237188	56	Male	White	PDAC	Metastasis	Deceased	G12V	M246V	No	No	G12	Yes	56.0
DFCI-237192	87	Male	White	PDAC	Primary	Deceased	G12R	No	No	A425D	G12	No	87.0
DFCI-237197	69	Female	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	69.0
DFCI-237528	66	Female	White	PDAC	Primary	Deceased	G12V	D281N	No	No	G12	Yes	66.0
DFCI-237596	77	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	77.0
DFCI-237597	63	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	63.0
DFCI-237634	49	Male	Other	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	49.0
DFCI-237993	69	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	69.0
DFCI-237999	57	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	57.0
DFCI-238005	51	Female	White	Solid pseudopapillary tumor	Metastasis	Alive	No	No	No	No	No	No	51.0
DFCI-238020	33	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	33.0
DFCI-238021	80	Female	White	PDAC	Primary	Deceased	G12D	No	No	W99C	G12	No	80.0
DFCI-238028	72	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	72.0
DFCI-238035	38	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	38.0
DFCI-238067	55	Male	White	PDAC	Metastasis	Deceased	G12R	R273H	No	No	G12	Yes	55.0
DFCI-238077	75	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	75.0
DFCI-238677	81	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	81.0
DFCI-238740	69	Male	Asian	PDAC	Primary	Alive	G12V	No	No	No	G12	No	69.0
DFCI-240083	41	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	41.0
DFCI-240847	71	Female	NA	PDAC	Primary	Alive	G12V	No	No	No	G12	No	71.0
DFCI-241035	69	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	69.0
DFCI-241059	61	Female	White	PDAC	Primary	Alive	G12D	M237I	No	No	G12	Yes	61.0
DFCI-241063	54	Female	Asian	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	54.0
DFCI-241090	61	Male	White	PDAC	Metastasis	Alive	G12D	C275Y	No	No	G12	Yes	61.0
DFCI-241253	59	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	59.0
DFCI-242515	70	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	70.0
DFCI-242798	66	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	66.0
DFCI-243436	62	Female	Other	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	62.0
DFCI-244853	68	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	68.0
DFCI-245092	45	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	45.0
DFCI-245129	69	Male	White	PDAC	Metastasis	Deceased	G12L	Y220C	No	No	G12	Yes	69.0
DFCI-245415	83	Male	White	PDAC	Primary	Deceased	G12D	V274F	No	No	G12	Yes	83.0
DFCI-245647	78	Female	Black/African-American	PDAC	Primary	Deceased	G12R	R248W	No	No	G12	Yes	78.0
DFCI-247216	57	Female	Black/African-American	Adenosquamous carcinoma	Primary	Alive	G12D	R175H	No	No	G12	Yes	57.0
DFCI-248150	67	Male	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	67.0
DFCI-252723	70	Female	Black/African-American	PDAC	Primary	Deceased	G12D	R248Q	No	No	G12	Yes	70.0
DFCI-256821	63	Female	White	PDAC	Primary	Deceased	G12D	No	No	G386S	G12	No	63.0
DFCI-258352	67	Male	White	PDAC	Primary	Deceased	G12D	C238Y	No	No	G12	Yes	67.0
DFCI-260060	71	Male	White	Acinar cell carcinoma	Primary	Deceased	No	No	No	No	No	No	71.0
DFCI-261815	58	Male	White	PDAC	Metastasis	Deceased	G12L	R282W	No	D537G	G12	Yes	58.0
DFCI-263090	68	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	68.0
DFCI-263582	66	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	66.0
DFCI-263969	68	Male	White	PDAC	Metastasis	Deceased	No	C176R	No	No	No	Yes	68.0
DFCI-264018	75	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	75.0
DFCI-264418	88	Male	White	PDAC	Primary	Deceased	G12V	V143A	No	No	G12	Yes	88.0
DFCI-264426	58	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	58.0
DFCI-264428	57	Male	White	PDAC	Metastasis	Alive	G12R	R282W	No	No	G12	Yes	57.0
DFCI-264441	72	Female	NA	PDAC	Primary	Deceased	G12R	R273H	No	No	G12	Yes	72.0
DFCI-266190	48	Male	White	PDAC	Metastasis	Deceased	G12C	No	No	No	G12	No	48.0
DFCI-266206	63	Female	White	PDAC	Primary	Deceased	G12V	P278L	D108Y	No	G12	Yes	63.0
DFCI-266358	77	Female	Asian	PNET	Metastasis	Alive	No	No	No	No	No	No	77.0
DFCI-266563	58	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	58.0
DFCI-266573	59	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	59.0
DFCI-268148	76	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	A159V	No	No	G12	Yes	76.0
DFCI-268232	74	Male	White	PDAC	NA or Heme	Deceased	No	No	No	No	No	No	74.0
DFCI-268410	40	Male	White	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	40.0
DFCI-268424	43	Male	White	PDAC	Metastasis	Deceased	G12C	No	No	No	G12	No	43.0
DFCI-268436	75	Female	White	PDAC	Primary	Deceased	G12D	R273C	No	No	G12	Yes	75.0
DFCI-268507	50	Female	White	PDAC	Primary	Alive	G12D	R248L	No	G386S	G12	Yes	50.0
DFCI-268516	69	Male	White	PDAC	Primary	Deceased	G12D	No	No	C499R	G12	No	69.0
DFCI-268555	73	Female	White	PDAC	Primary	Deceased	G12V	H193N	No	No	G12	Yes	73.0
DFCI-268573	68	Male	White	PDAC	Metastasis	Deceased	G12R	F270S	No	No	G12	Yes	68.0
DFCI-268580	67	Male	NA	PDAC	Metastasis	Deceased	Q61K	No	No	No	Q61	No	67.0
DFCI-268600	>89	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	90.0
DFCI-268641	62	Male	White	PDAC	Metastasis	Deceased	G12V	V272M	No	No	G12	Yes	62.0
DFCI-268655	74	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	74.0
DFCI-268685	72	Male	White	PDAC	Metastasis	Deceased	No	V274A	No	No	No	Yes	72.0
DFCI-268694	40	Male	Asian	PNET	Primary	Alive	No	No	No	No	No	No	40.0
DFCI-268700	82	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	82.0
DFCI-268705	85	Male	White	PDAC	Primary	Deceased	Q61R	No	A20P	No	Q61	No	85.0
DFCI-268717	69	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	69.0
DFCI-268718	64	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
DFCI-268736	60	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	60.0
DFCI-268742	46	Male	White	PDAC	Metastasis	Alive	G12D	S215I	No	No	G12	Yes	46.0
DFCI-268756	55	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	55.0
DFCI-268778	60	Female	White	PDAC	Primary	Deceased	G12D	P278L	No	No	G12	Yes	60.0
DFCI-268788	59	Female	White	PDAC	Primary	Alive	G12D	A159V	No	No	G12	Yes	59.0
DFCI-268790	71	Male	White	PDAC	Metastasis	Deceased	G12D	Y163N	No	No	G12	Yes	71.0
DFCI-268798	71	Male	White	PDAC	Primary	Deceased	G12R	P177R	No	No	G12	Yes	71.0
DFCI-268808	67	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	67.0
DFCI-268811	61	Male	White	PDAC	Primary	Alive	G12V	R249M	No	No	G12	Yes	61.0
DFCI-268817	81	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12V	D259Y	No	No	G12	Yes	81.0
DFCI-268823	57	Female	Asian	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	57.0
DFCI-268825	67	Female	White	PDAC	Primary	Alive	G12V	No	H83Y	No	G12	No	67.0
DFCI-268855	59	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	59.0
DFCI-268858	66	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	R273H	No	No	G12	Yes	66.0
DFCI-268868	71	Female	White	PDAC	Primary	Deceased	G12C	G244S	No	No	G12	Yes	71.0
DFCI-268885	73	Male	White	Adenosquamous carcinoma	Primary	Deceased	No	No	No	No	No	No	73.0
DFCI-268923	73	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	73.0
DFCI-268941	64	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	64.0
DFCI-269006	80	Male	White	PDAC	Primary	Deceased	G12R	M133K	No	No	G12	Yes	80.0
DFCI-269009	59	Male	White	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	59.0
DFCI-269020	59	Male	White	PDAC	Metastasis	Deceased	G12R	C141Y	No	No	G12	Yes	59.0
DFCI-269025	55	Male	White	PDAC	Primary	Alive	G12V	M133K	No	No	G12	Yes	55.0
DFCI-269043	62	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	62.0
DFCI-269058	61	Male	White	PDAC	Primary	Alive	G12V	R273H	No	No	G12	Yes	61.0
DFCI-269061	61	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	61.0
DFCI-269067	83	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	83.0
DFCI-269087	64	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	64.0
DFCI-269102	42	Female	White	PDAC	Primary	Alive	G12D	R273C	No	No	G12	Yes	42.0
DFCI-269129	66	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	66.0
DFCI-269151	52	Male	White	PDAC	Primary	Alive	G12D	C135G	No	No	G12	Yes	52.0
DFCI-269173	68	Female	White	PDAC	Primary	Alive	G12D	V203E	No	No	G12	Yes	68.0
DFCI-269179	75	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	75.0
DFCI-269185	73	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	G244A	No	No	G12	Yes	73.0
DFCI-269191	59	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	59.0
DFCI-269195	83	Female	White	PDAC	Metastasis	Deceased	G12D	P151R	No	No	G12	Yes	83.0
DFCI-269233	52	Male	White	PDAC	Metastasis	Alive	G12D	R273H	No	No	G12	Yes	52.0
DFCI-269261	57	Female	White	PDAC	Primary	Alive	G12V	No	No	C324R	G12	No	57.0
DFCI-269267	72	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	72.0
DFCI-269296	69	Male	White	PDAC	Primary	Deceased	Q61R	R175H	No	No	Q61	Yes	69.0
DFCI-269506	79	Female	White	PDAC	Primary	Alive	G12D	V172F	No	No	G12	Yes	79.0
DFCI-270027	76	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	76.0
DFCI-279308	79	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	79.0
DFCI-282211	55	Male	White	PDAC	Metastasis	Alive	Q61L	R248Q	No	No	Q61	Yes	55.0
DFCI-296370	61	Female	White	PDAC	Metastasis	Deceased	G12R	R175H	No	No	G12	Yes	61.0
DFCI-296373	68	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	68.0
DFCI-296406	67	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	67.0
DFCI-296430	68	Male	White	PDAC	Metastasis	Alive	G12R	No	No	R361C	G12	No	68.0
DFCI-296569	48	Male	White	PDAC	Metastasis	Deceased	G12V	I195N	No	No	G12	Yes	48.0
DFCI-296574	74	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	74.0
DFCI-297968	65	Male	Other	PDAC	Metastasis	Deceased	G12V	No	No	R361C	G12	No	65.0
DFCI-298009	59	Male	White	PDAC	Primary	Alive	G12D	I232F	No	No	G12	Yes	59.0
DFCI-303871	74	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	74.0
DFCI-325153	66	Male	White	PDAC	Metastasis	Deceased	Q61H	No	No	S171L	Q61	No	66.0
DFCI-325516	80	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	80.0
DFCI-325597	70	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	70.0
DFCI-325955	66	Female	White	PDAC	Metastasis	Alive	G12V	R248Q	No	No	G12	Yes	66.0
DFCI-325959	71	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	71.0
DFCI-326209	67	Male	White	PDAC	Metastasis	Deceased	G12D	V197G	No	No	G12	Yes	67.0
DFCI-326220	74	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	74.0
DFCI-326224	73	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	73.0
DFCI-326248	43	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	43.0
DFCI-326866	61	Male	White	PDAC	Primary	Deceased	G12R	R248Q	No	No	G12	Yes	61.0
DFCI-328128	64	Female	White	PDAC	Metastasis	Deceased	G12I	Y220C	Y129D	K507E	G12	Yes	64.0
DFCI-331105	74	Male	White	PDAC	Metastasis	Deceased	G12V	I195T	No	No	G12	Yes	74.0
DFCI-344719	77	Male	Black/African-American	PDAC	Primary	Alive	G12V	R175H	No	A118V	G12	Yes	77.0
DFCI-354341	61	Female	White	PDAC	Primary	Alive	G12D	No	No	P356R	G12	No	61.0
DFCI-354738	71	Female	White	PDAC	Primary	Deceased	G12D	R248Q	No	No	G12	Yes	71.0
DFCI-354740	59	Female	White	PNET	Primary	Alive	G12V	R273H	No	No	G12	Yes	59.0
DFCI-354748	48	Male	White	PDAC	Metastasis	Alive	No	R273H	No	No	No	Yes	48.0
DFCI-356034	26	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	26.0
DFCI-356880	60	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	60.0
DFCI-357981	75	Female	White	PDAC	Primary	Deceased	G12D	No	No	R380K	G12	No	75.0
DFCI-359064	55	Female	White	PDAC	Primary	Deceased	G12D	Y220C	D84Y	No	G12	Yes	55.0
DFCI-359144	65	Female	White	PDAC	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	65.0
DFCI-359227	76	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
DFCI-360119	58	Female	Black/African-American	PDAC	Primary	Alive	G12R	R273H	H83Y	R380G	G12	Yes	58.0
DFCI-361260	66	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	66.0
DFCI-361324	77	Female	White	PDAC	Metastasis	Alive	G12V	R282W	No	No	G12	Yes	77.0
DFCI-364402	38	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	38.0
DFCI-365663	61	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	61.0
DFCI-368703	73	Female	White	PDAC	Metastasis	Deceased	G12D	H179Y	No	No	G12	Yes	73.0
DFCI-369053	65	Male	Asian	PDAC	Primary	Alive	L52H,Q61L	R158L	No	No	Q61\|Other	Yes	65.0
DFCI-370190	60	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	60.0
DFCI-371313	65	Female	White	PDAC	Primary	Alive	G12V	R273H	No	No	G12	Yes	65.0
DFCI-377804	56	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	56.0
DFCI-377810	60	Male	White	PDAC	Metastasis	Deceased	G12R	H193R	No	No	G12	Yes	60.0
DFCI-378604	62	Male	White	PDAC	Primary	Deceased	G12D	G262V	No	No	G12	Yes	62.0
DFCI-378706	65	Female	White	PDAC	Primary	Alive	G12D	E286K	No	No	G12	Yes	65.0
DFCI-378773	42	Female	White	PDAC	Metastasis	Alive	G12D	No	H83D	No	G12	No	42.0
DFCI-378931	69	Male	Other	PDAC	Metastasis	Deceased	Q61H	C141Y	No	No	Q61	Yes	69.0
DFCI-379018	72	Female	Black/African-American	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	72.0
DFCI-379028	75	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	75.0
DFCI-379033	48	Male	White	PDAC	Metastasis	Alive	G12D	R273S	No	No	G12	Yes	48.0
DFCI-379043	71	Male	White	PDAC	Metastasis	Deceased	G12D	G245S	No	No	G12	Yes	71.0
DFCI-379292	63	Male	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	63.0
DFCI-379293	19	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	19.0
DFCI-379296	55	Male	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	55.0
DFCI-379309	76	Female	White	PDAC	Metastasis	Alive	G12V	P190L	No	No	G12	Yes	76.0
DFCI-379312	52	Female	White	PDAC	Metastasis	Alive	G12R	V173G	No	No	G12	Yes	52.0
DFCI-379320	64	Male	White	PDAC	Metastasis	Alive	G12D	No	No	R515S	G12	No	64.0
DFCI-379327	60	Female	White	PDAC	Primary	Alive	G12D	R273C	No	No	G12	Yes	60.0
DFCI-379339	75	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	75.0
DFCI-379344	51	Female	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	51.0
DFCI-379348	74	Male	White	PDAC	Metastasis	Alive	G12V	R282W	No	No	G12	Yes	74.0
DFCI-379357	59	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	59.0
DFCI-379628	73	Male	White	PDAC	Metastasis	Deceased	G12V	V157G	No	No	G12	Yes	73.0
DFCI-379661	53	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	53.0
DFCI-379867	62	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	62.0
DFCI-379875	78	Female	White	PDAC	Metastasis	Alive	Q61K	R273C	No	No	Q61	Yes	78.0
DFCI-379905	56	Female	White	PDAC	Metastasis	Alive	G12D	C238Y	No	No	G12	Yes	56.0
DFCI-379916	77	Male	White	PDAC	Primary	Alive	G12D	C141Y	No	No	G12	Yes	77.0
DFCI-379922	60	Male	White	PDAC	Primary	Alive	G12R	R273H	No	No	G12	Yes	60.0
DFCI-379997	59	Female	White	PDAC	Metastasis	Deceased	G12D	R282W	No	No	G12	Yes	59.0
DFCI-380155	60	Male	White	PDAC	Metastasis	Alive	No	S366A,R156H	No	No	No	Yes	60.0
DFCI-380183	68	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	68.0
DFCI-380324	63	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	63.0
DFCI-380464	53	Male	White	PDAC	Metastasis	Alive	G12V	H214R	No	No	G12	Yes	53.0
DFCI-380473	41	Male	White	PDAC	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	41.0
DFCI-380501	53	Male	Other	PDAC	Metastasis	Deceased	G12R	V218G	No	No	G12	Yes	53.0
DFCI-380508	49	Female	White	PDAC	Primary	Alive	Q61A	No	No	No	Q61	No	49.0
DFCI-380523	71	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	71.0
DFCI-380545	63	Male	White	PDAC	Primary	Alive	G12V	L194R	No	No	G12	Yes	63.0
DFCI-380989	76	Male	White	PDAC	Metastasis	Alive	G12D	No	No	H297L	G12	No	76.0
DFCI-381322	51	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	51.0
DFCI-382773	74	Male	White	PDAC	Primary	Deceased	G12D	R175H	No	I61K	G12	Yes	74.0
DFCI-383353	64	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	L533R	G12	No	64.0
DFCI-385364	61	Female	White	PDAC	Primary	Deceased	G12R	P151R	No	No	G12	Yes	61.0
DFCI-386591	69	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	69.0
DFCI-386596	66	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	66.0
DFCI-386617	64	Male	White	PDAC	Primary	Deceased	G12D	Y220N	No	No	G12	Yes	64.0
DFCI-386628	60	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	60.0
DFCI-386629	60	Female	White	PDAC	Metastasis	Alive	G12D	R273H	No	No	G12	Yes	60.0
DFCI-386630	71	Female	White	PDAC	Primary	Deceased	G12D	R175H	M53I	No	G12	Yes	71.0
DFCI-386634	74	Male	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	74.0
DFCI-386836	81	Male	White	PDAC	Primary	Deceased	G12V	Y126N	No	No	G12	Yes	81.0
DFCI-386961	74	Male	White	PDAC	Metastasis	Alive	G12R	G245V	No	C363Y	G12	Yes	74.0
DFCI-388067	59	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	59.0
DFCI-390803	48	Female	White	PDAC	Primary	Alive	Q61L	No	No	No	Q61	No	48.0
DFCI-391165	60	Female	White	PDAC	Metastasis	Deceased	G12D	R249S	No	P356L	G12	Yes	60.0
DFCI-391715	>89	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	90.0
DFCI-392713	73	Female	White	PDAC	Metastasis	Alive	G12R	G245S	No	No	G12	Yes	73.0
DFCI-392841	54	Male	White	PDAC	Primary	Alive	G12D	No	P81L	No	G12	No	54.0
DFCI-392889	75	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	75.0
DFCI-392983	59	Male	White	PDAC	Metastasis	Alive	G12V	R248Q	No	G386V	G12	Yes	59.0
DFCI-393849	69	Male	White	PDAC	Metastasis	Deceased	G12R	F113C	No	T62P	G12	Yes	69.0
DFCI-394195	76	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	76.0
DFCI-396043	66	Female	White	PDAC	Primary	Alive	G12D	R175H	D74Y	No	G12	Yes	66.0
DFCI-397903	62	Female	Asian	PDAC	Metastasis	Deceased	G12V	R248Q	No	No	G12	Yes	62.0
DFCI-398606	84	Female	White	PDAC	Primary	Deceased	G12A	R248Q	No	No	G12	Yes	84.0
DFCI-398614	61	Female	White	PDAC	Primary	Deceased	G12D	S127F	No	No	G12	Yes	61.0
DFCI-398930	78	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	78.0
DFCI-407092	63	Female	White	PDAC	Primary	Alive	G12V	F270L	No	No	G12	Yes	63.0
DFCI-409410	63	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	63.0
DFCI-412148	79	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	79.0
DFCI-412437	59	Female	White	PDAC	Metastasis	Deceased	G12D	G244D	No	No	G12	Yes	59.0
DFCI-412680	61	Male	White	PDAC	Primary	Alive	Q61K	L257Q	P70R	R97H	Q61	Yes	61.0
DFCI-413019	52	Male	Asian	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	52.0
DFCI-413430	62	Female	White	PDAC	Primary	Alive	G12V	P151S	No	No	G12	Yes	62.0
DFCI-413775	31	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	31.0
DFCI-413825	69	Male	Other	PDAC	Primary	Deceased	G12D	R342P	No	No	G12	Yes	69.0
DFCI-415596	83	Female	Black/African-American	PDAC	NA or Heme	Deceased	G12D	P151S	No	No	G12	Yes	83.0
DFCI-415854	66	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	66.0
DFCI-416160	65	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	65.0
DFCI-416808	65	Female	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	65.0
DFCI-416825	63	Female	Black/African-American	PDAC	Metastasis	Alive	G12V	H193L	No	No	G12	Yes	63.0
DFCI-416829	63	Male	White	PDAC	Primary	Alive	G12D	R282W	No	No	G12	Yes	63.0
DFCI-416832	80	Male	White	PDAC	Primary	Deceased	G12V	R273H	No	D351V	G12	Yes	80.0
DFCI-416845	62	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	62.0
DFCI-416852	65	Female	Other	PDAC	Primary	Alive	G12R	No	No	No	G12	No	65.0
DFCI-416862	58	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	58.0
DFCI-416870	63	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	63.0
DFCI-416890	79	Female	White	PDAC	Primary	Alive	Q61R	C176S	No	No	Q61	Yes	79.0
DFCI-416898	81	Male	White	PDAC	Primary	Deceased	G12V	V216M	No	No	G12	Yes	81.0
DFCI-416908	79	Male	White	PDAC	Metastasis	Alive	G12R	R273H	No	No	G12	Yes	79.0
DFCI-416920	77	Male	White	PDAC	Metastasis	Alive	Q61H	No	No	No	Q61	No	77.0
DFCI-416926	56	Male	White	PDAC	Primary	Alive	G12D	I195F	No	R361H	G12	Yes	56.0
DFCI-416936	49	Male	White	PDAC	Metastasis	Alive	G12D	R175C	No	No	G12	Yes	49.0
DFCI-416937	54	Male	White	PDAC	Metastasis	Alive	G12V	R273H	No	No	G12	Yes	54.0
DFCI-416939	84	Male	Asian	PDAC	Primary	Alive	G12V	R273H	No	G386S	G12	Yes	84.0
DFCI-416943	67	Male	White	PDAC	Primary	Alive	Q61H	V216E	No	No	Q61	Yes	67.0
DFCI-416956	66	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	66.0
DFCI-416957	56	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	56.0
DFCI-416960	46	Male	White	PDAC	Metastasis	Alive	G12V	R282W	No	I40N	G12	Yes	46.0
DFCI-416966	57	Female	White	PDAC	Metastasis	Deceased	G12D	I195T	No	No	G12	Yes	57.0
DFCI-416967	69	Male	White	PDAC	Primary	Alive	G12V	G244D	H83Y	No	G12	Yes	69.0
DFCI-416973	54	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	54.0
DFCI-416997	56	Male	Asian	PDAC	Primary	Deceased	G12D	No	No	R361G	G12	No	56.0
DFCI-417003	67	Male	White	PDAC	Metastasis	Alive	G12D	P250L	No	No	G12	Yes	67.0
DFCI-417010	74	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	74.0
DFCI-417028	66	Female	White	PDAC	Primary	Alive	G12D	C141Y	No	No	G12	Yes	66.0
DFCI-417046	77	Male	White	PDAC	Primary	Alive	G12V	R249T	No	No	G12	Yes	77.0
DFCI-417054	71	Male	White	PDAC	Primary	Alive	G12V	P151A	No	No	G12	Yes	71.0
DFCI-417060	63	Female	NA	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	63.0
DFCI-417085	68	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	68.0
DFCI-417093	79	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	79.0
DFCI-417095	71	Male	White	PDAC	Primary	Alive	Q61H	R175H	No	No	Q61	Yes	71.0
DFCI-417099	58	Male	White	Pancreatoblastoma	Primary	Alive	No	No	No	No	No	No	58.0
DFCI-417117	59	Male	White	PDAC	Metastasis	Alive	G12R	I195T	No	No	G12	Yes	59.0
DFCI-417120	72	Female	White	PDAC	Primary	Alive	Q61H	I195T	D108Y	No	Q61	Yes	72.0
DFCI-417134	73	Male	White	PDAC	Primary	Alive	G12V	V173G	No	No	G12	Yes	73.0
DFCI-417273	56	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	56.0
DFCI-417317	68	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	68.0
DFCI-417418	43	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	G336E,D351N	G12	No	43.0
DFCI-417506	64	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	C238Y	H83Y	No	G12	Yes	64.0
DFCI-417508	78	Female	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	78.0
DFCI-417517	72	Female	White	PDAC	Primary	Alive	G12V	No	No	R361H	G12	No	72.0
DFCI-417532	85	Male	White	PDAC	Metastasis	Alive	G12V	C242Y	No	No	G12	Yes	85.0
DFCI-417573	55	Female	Other	PDAC	Primary	Alive	G12D	G262V	No	No	G12	Yes	55.0
DFCI-417613	73	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	73.0
DFCI-417672	18	Male	NA	PNET	Metastasis	Alive	No	No	No	No	No	No	18.0
DFCI-417681	53	Male	White	PDAC	Primary	Deceased	G12D	R282_R283delinsQG	Q50R	No	G12	Yes	53.0
DFCI-417684	33	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	33.0
DFCI-417727	65	Male	White	PDAC	Metastasis	Deceased	G12D	S127F	No	No	G12	Yes	65.0
DFCI-417734	67	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	67.0
DFCI-417753	65	Male	White	PDAC	Metastasis	Deceased	G12D	C141Y	No	No	G12	Yes	65.0
DFCI-417755	70	Male	White	PDAC	Metastasis	Alive	G12R	R213G	No	No	G12	Yes	70.0
DFCI-417781	62	Female	White	PDAC	Primary	Deceased	G12V	S215G	No	No	G12	Yes	62.0
DFCI-417784	69	Male	White	PDAC	Primary	Alive	G12D	T125M	No	No	G12	Yes	69.0
DFCI-417839	61	Female	White	PDAC	Primary	Alive	G12R	I195T	No	R361C	G12	Yes	61.0
DFCI-418302	65	Female	White	PDAC	Primary	Alive	G12D	L257Q	No	No	G12	Yes	65.0
DFCI-418352	78	Female	White	PDAC	Primary	Alive	G12D	N239D	No	No	G12	Yes	78.0
DFCI-418447	70	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	70.0
DFCI-418458	69	Male	White	PDAC	Primary	Alive	G12V	P278S	No	No	G12	Yes	69.0
DFCI-418511	79	Female	White	PDAC	Primary	Deceased	G12V	L111Q	No	No	G12	Yes	79.0
DFCI-418706	72	Female	White	Adenosquamous carcinoma	Metastasis	Alive	G12V	R175H	No	No	G12	Yes	72.0
DFCI-418789	83	Female	White	PDAC	Metastasis	Deceased	Q61H	M246V	No	No	Q61	Yes	83.0
DFCI-418907	67	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	67.0
DFCI-418961	68	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	68.0
DFCI-419237	81	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	81.0
DFCI-419295	67	Male	White	PDAC	Primary	Alive	G12V	H179R	No	D351Y	G12	Yes	67.0
DFCI-420693	54	Female	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	54.0
DFCI-420754	62	Female	White	PDAC	Primary	Alive	Q61R	No	No	No	Q61	No	62.0
DFCI-420922	74	Female	White	PDAC	Primary	Alive	G12D	No	No	R361H	G12	No	74.0
DFCI-421291	62	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	62.0
DFCI-421516	69	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	69.0
DFCI-423097	83	Female	White	PDAC	Primary	Alive	G12V	R249S	No	No	G12	Yes	83.0
DFCI-423666	69	Male	NA	PDAC	Primary	Alive	No	No	No	No	No	No	69.0
DFCI-424078	63	Male	NA	PDAC	Metastasis	Deceased	G12D	G245S	Q50R	No	G12	Yes	63.0
DFCI-424144	57	Male	White	PDAC	Metastasis	Deceased	G12D	No	P114H	No	G12	No	57.0
DFCI-424274	39	Female	Black/African-American	PDAC	Primary	Alive	G12V	R175H	No	No	G12	Yes	39.0
DFCI-424631	64	Male	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	64.0
DFCI-425976	70	Female	White	PDAC	Primary	Alive	G12D	V197M	No	W101R	G12	Yes	70.0
DFCI-426244	79	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	79.0
DFCI-428361	84	Male	White	PDAC	Metastasis	Deceased	Q61R	C242S	No	No	Q61	Yes	84.0
DFCI-431174	67	Male	White	PDAC	Primary	Deceased	G12V	K132R	No	No	G12	Yes	67.0
DFCI-442685	67	Female	White	PDAC	Primary	Deceased	No	H179R	No	No	No	Yes	67.0
DFCI-444198	69	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	69.0
DFCI-444459	62	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	62.0
DFCI-446064	45	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	45.0
DFCI-446501	62	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	62.0
DFCI-447857	63	Male	White	PDAC	NA or Heme	Deceased	G12D	No	No	No	G12	No	63.0
DFCI-448184	78	Male	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	78.0
DFCI-448327	77	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	77.0
DFCI-448444	64	Female	White	PDAC	Metastasis	Deceased	G12D	G266E	No	H132D	G12	Yes	64.0
DFCI-448452	79	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	79.0
DFCI-448457	66	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	66.0
DFCI-448464	72	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	G386V,R272K	G12	No	72.0
DFCI-448473	68	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	68.0
DFCI-448488	70	Female	White	PDAC	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	70.0
DFCI-448489	70	Female	White	PDAC	Primary	Deceased	G12D	No	H83Y	No	G12	No	70.0
DFCI-448514	66	Male	White	PDAC	Primary	Alive	G12D	D281E	No	No	G12	Yes	66.0
DFCI-448588	75	Male	White	PDAC	Primary	Alive	G12D	E258G	No	No	G12	Yes	75.0
DFCI-448604	63	Female	Black/African-American	PDAC	Primary	Deceased	G12V	S215G	No	No	G12	Yes	63.0
DFCI-448633	84	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	84.0
DFCI-448646	79	Male	NA	PNET	Metastasis	Alive	No	No	No	No	No	No	79.0
DFCI-448650	57	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	57.0
DFCI-448661	66	Female	White	PDAC	NA or Heme	Alive	G12V	T125P	No	No	G12	Yes	66.0
DFCI-448671	67	Male	White	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	67.0
DFCI-448685	62	Female	White	PDAC	Metastasis	Alive	G12D	No	No	G386R	G12	No	62.0
DFCI-448750	67	Male	White	PDAC	NA or Heme	Alive	G12D	G244C	No	No	G12	Yes	67.0
DFCI-448770	60	Female	White	PDAC	Primary	Alive	Q61H	Y220C	No	No	Q61	Yes	60.0
DFCI-448779	81	Male	White	PDAC	Metastasis	Deceased	G13D	No	No	R361H	G13	No	81.0
DFCI-448782	64	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	64.0
DFCI-448787	67	Female	White	PDAC	Primary	Alive	G12V	H214R	No	No	G12	Yes	67.0
DFCI-448812	83	Male	White	PDAC	Metastasis	Alive	No	S241Y	V51D	No	No	Yes	83.0
DFCI-448848	64	Male	White	PDAC	Metastasis	Alive	G12D	V173M	No	No	G12	Yes	64.0
DFCI-448876	57	Male	White	PDAC	Metastasis	Deceased	Q61R	No	No	No	Q61	No	57.0
DFCI-448902	68	Male	Other	PDAC	Primary	Alive	G12D	R282W	No	No	G12	Yes	68.0
DFCI-448939	66	Male	White	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	66.0
DFCI-448941	79	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	79.0
DFCI-448950	50	Male	White	PDAC	Primary	Alive	G12R	V216M	No	R361H	G12	Yes	50.0
DFCI-449004	51	Female	Black/African-American	PDAC	Metastasis	Alive	G12D	Y220C	No	No	G12	Yes	51.0
DFCI-449043	56	Male	White	PDAC	Metastasis	Deceased	G12D	E224D	No	No	G12	Yes	56.0
DFCI-449052	71	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	71.0
DFCI-449070	67	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	67.0
DFCI-449075	41	Male	White	PDAC	Metastasis	Deceased	G12D	C242W	No	No	G12	Yes	41.0
DFCI-449090	62	Female	White	PDAC	Primary	Alive	Q61H	R248Q	No	No	Q61	Yes	62.0
DFCI-449175	62	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	62.0
DFCI-449180	80	Female	Asian	PDAC	Primary	Alive	G12D	R248W	No	No	G12	Yes	80.0
DFCI-449203	67	Female	White	PDAC	Metastasis	Alive	G12D	R283C	No	No	G12	Yes	67.0
DFCI-449204	58	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	58.0
DFCI-449210	62	Male	White	PDAC	Metastasis	Deceased	G12L	Y220C	No	No	G12	Yes	62.0
DFCI-449253	65	Female	Black/African-American	PDAC	Metastasis	Alive	Q61H	No	No	M156L	Q61	No	65.0
DFCI-449324	63	Male	White	PDAC	Metastasis	Alive	Q61H	No	No	No	Q61	No	63.0
DFCI-449345	60	Female	Other	PDAC	Primary	Alive	G12D	No	No	No	G12	No	60.0
DFCI-449346	49	Male	White	Adenosquamous carcinoma	Metastasis	Deceased	Q61H	A161D	No	No	Q61	Yes	49.0
DFCI-449356	78	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	78.0
DFCI-449405	56	Male	White	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	56.0
DFCI-449416	67	Male	White	PDAC	Primary	Alive	G12V	V157F	No	No	G12	Yes	67.0
DFCI-449422	70	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	70.0
DFCI-449444	72	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	R361S	G12	No	72.0
DFCI-449544	57	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	57.0
DFCI-449560	70	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	70.0
DFCI-449568	68	Female	White	PDAC	Metastasis	Alive	G12V	R273H	No	No	G12	Yes	68.0
DFCI-449604	68	Male	White	PDAC	NA or Heme	Deceased	No	No	No	No	No	No	68.0
DFCI-449613	65	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	65.0
DFCI-449644	52	Male	White	PDAC	Primary	Alive	G12R	R290H,R196P	No	No	G12	Yes	52.0
DFCI-449652	64	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
DFCI-449689	73	Female	White	PDAC	Metastasis	Alive	G12R	T125M,V203M	No	No	G12	Yes	73.0
DFCI-449701	74	Male	White	PDAC	Metastasis	Alive	Q61H	R175H	No	No	Q61	Yes	74.0
DFCI-449708	68	Female	White	PDAC	Primary	Alive	G12R	L257P	No	No	G12	Yes	68.0
DFCI-449721	68	Female	White	PDAC	Metastasis	Deceased	G12D	R282W	No	No	G12	Yes	68.0
DFCI-449727	52	Male	White	PDAC	Metastasis	Alive	G12V	V274G	No	No	G12	Yes	52.0
DFCI-449753	71	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	71.0
DFCI-449837	61	Female	Asian	PDAC	Primary	Deceased	Q61L	No	No	No	Q61	No	61.0
DFCI-449890	62	Male	White	PDAC	Primary	Alive	G12D	No	L78V,D84Y	No	G12	No	62.0
DFCI-449901	81	Female	Asian	PDAC	Primary	Alive	G12D	No	No	No	G12	No	81.0
DFCI-449902	59	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	59.0
DFCI-449929	62	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	62.0
DFCI-449953	62	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	62.0
DFCI-450088	80	Female	White	PDAC	Primary	Alive	G12D	S366A,G266V	D84N	L109P	G12	Yes	80.0
DFCI-450114	77	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	77.0
DFCI-450121	70	Male	White	PDAC	Metastasis	Deceased	G12D	C176R	No	No	G12	Yes	70.0
DFCI-450142	72	Male	White	PDAC	Metastasis	Deceased	G12D	R248W	No	No	G12	Yes	72.0
DFCI-450143	67	Female	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	67.0
DFCI-450170	68	Male	White	PDAC	Primary	Alive	G12R	R175H	No	No	G12	Yes	68.0
DFCI-450178	80	Male	Black/African-American	PDAC	Metastasis	Deceased	No	No	No	No	No	No	80.0
DFCI-450190	50	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	50.0
DFCI-450267	75	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	75.0
DFCI-450453	50	Female	White	PDAC	Primary	Alive	G12D	Y220N	No	No	G12	Yes	50.0
DFCI-450456	63	Female	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	63.0
DFCI-450466	63	Male	White	PDAC	Primary	Alive	G12V	Y163C	No	No	G12	Yes	63.0
DFCI-450470	63	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	63.0
DFCI-450473	56	Male	White	PDAC	Primary	Alive	No	G245S	No	R496H	No	Yes	56.0
DFCI-450594	75	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	75.0
DFCI-450620	78	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	78.0
DFCI-450628	51	Male	White	PDAC	Metastasis	Alive	G12V	Y234C	No	No	G12	Yes	51.0
DFCI-450707	63	Male	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	63.0
DFCI-480789	70	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	70.0
DFCI-480803	54	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	54.0
DUKE-P1142	68	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	68.0
DUKE-P1174	57	Female	White	PDAC	Metastasis	NA	G12D	No	No	No	G12	No	57.0
DUKE-P1176	80	Female	White	PDAC	Primary	Deceased	G12D	C176G	No	No	G12	Yes	80.0
DUKE-P1208	49	Male	White	PDAC	Primary	NA	G12V	E258D	No	No	G12	Yes	49.0
DUKE-P1235	59	Female	Black/African-American	PDAC	Metastasis	Deceased	G12R	P278S	No	No	G12	Yes	59.0
DUKE-P1239	58	Female	White	PDAC	Metastasis	NA	G12D	P151T	No	No	G12	Yes	58.0
DUKE-P1240	73	Female	White	PDAC	Metastasis	NA	G12R	R175H	No	No	G12	Yes	73.0
DUKE-P1246	60	Female	Black/African-American	PDAC	Primary	Deceased	G12V	C176Y	No	No	G12	Yes	60.0
DUKE-P1248	80	Male	White	Carcinoma, NOS	Primary	NA	G12V	R175H	No	No	G12	Yes	80.0
DUKE-P1255	72	Male	White	PDAC	Primary	Deceased	G12D	No	H83Y	No	G12	No	72.0
DUKE-P1257	64	Female	White	PDAC	Primary	Deceased	G12R	No	No	D493N	G12	No	64.0
DUKE-P1268	84	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	R361H	G12	No	84.0
DUKE-P1270	66	Female	White	PDAC	Metastasis	Deceased	G12R	V173M	No	No	G12	Yes	66.0
DUKE-P1277	61	Male	White	PDAC	Primary	Deceased	G12V	E171G	No	No	G12	Yes	61.0
DUKE-P1298	69	Male	NA	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	69.0
DUKE-P1313	56	Male	White	PDAC	Primary	Deceased	G12C	No	No	No	G12	No	56.0
DUKE-P1336	53	Male	Black/African-American	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	53.0
DUKE-P1362	63	Male	White	PDAC	Metastasis	Deceased	G12D	Y126C,H214R	No	D493H	G12	Yes	63.0
DUKE-P137	72	Male	White	PDAC	Metastasis	Deceased	G12D	E285K	No	No	G12	Yes	72.0
DUKE-P1378	41	Female	Asian	PNET	Metastasis	NA	No	No	No	No	No	No	41.0
DUKE-P1380	66	Male	White	PDAC	Primary	NA	G12D	H193Y	No	No	G12	Yes	66.0
DUKE-P1437	67	Female	White	PDAC	Primary	Deceased	G12R	S127F	No	No	G12	Yes	67.0
DUKE-P1449	72	Female	NA	PDAC	Metastasis	NA	G12R	No	No	No	G12	No	72.0
DUKE-P1453	69	Female	White	PDAC	Primary	NA	G12D	No	No	No	G12	No	69.0
DUKE-P1484	43	Female	White	PDAC	Unknown	Deceased	G12D	No	No	No	G12	No	43.0
DUKE-P1517	42	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	42.0
DUKE-P1544	67	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	67.0
DUKE-P1584	83	Male	White	PDAC	Primary	Deceased	G12R	V157D	No	No	G12	Yes	83.0
DUKE-P1605	68	Female	Asian	PDAC	Unknown	Deceased	G12V	T155I	No	No	G12	Yes	68.0
DUKE-P1653	60	Female	White	PDAC	Metastasis	Deceased	G12V	No	L63P	No	G12	No	60.0
DUKE-P1686	49	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	49.0
DUKE-P1711	67	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	67.0
DUKE-P1716	59	Male	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	59.0
DUKE-P1719	63	Male	NA	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	63.0
DUKE-P1723	77	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	77.0
DUKE-P1727	71	Female	Black/African-American	Adenosquamous carcinoma	Primary	Deceased	G12R	No	No	No	G12	No	71.0
DUKE-P1738	69	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	69.0
DUKE-P1741	78	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	78.0
DUKE-P1744	62	Female	White	PDAC	Primary	Deceased	G12D	T155N	T93K	No	G12	Yes	62.0
DUKE-P1773	60	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	60.0
DUKE-P1776	67	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	67.0
DUKE-P1781	76	Male	White	PDAC	Primary	Deceased	G12V	M237I	No	L229P	G12	Yes	76.0
DUKE-P1784	68	Female	White	PDAC	Unknown	Deceased	G12V	C242Y	H83Y	No	G12	Yes	68.0
DUKE-P1859	83	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	83.0
DUKE-P1868	66	Female	White	PDAC	Unknown	Deceased	G12V	No	No	No	G12	No	66.0
DUKE-P1871	69	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	69.0
DUKE-P1887	52	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	52.0
DUKE-P1889	70	Female	White	PDAC	Metastasis	Deceased	G12V	C242F	No	No	G12	Yes	70.0
DUKE-P1899	61	Male	White	PDAC	Primary	Deceased	G12V	K132R	No	No	G12	Yes	61.0
DUKE-P1912	67	Female	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	67.0
DUKE-P1930	70	Male	White	PDAC	Metastasis	Deceased	G12V	R248W	No	No	G12	Yes	70.0
DUKE-P1963	63	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	R248W	No	No	G12	Yes	63.0
DUKE-P2021	65	Male	Black/African-American	PDAC	Primary	Deceased	G12C	No	No	No	G12	No	65.0
DUKE-P2057	72	Female	White	PDAC	Primary	Deceased	G12V	R110P	No	No	G12	Yes	72.0
DUKE-P2061	67	Female	White	Adenosquamous carcinoma	Primary	Deceased	G12V	No	No	No	G12	No	67.0
DUKE-P2073	81	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	81.0
DUKE-P2111	73	Female	White	PDAC	Primary	Deceased	G12V	H193R	No	No	G12	Yes	73.0
DUKE-P2129	74	Male	White	PDAC	Primary	Deceased	Q61H	G245D	No	No	Q61	Yes	74.0
DUKE-P2158	77	Male	NA	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	77.0
DUKE-P2170	79	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	79.0
DUKE-P2177	60	Female	Black/African-American	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	60.0
DUKE-P2195	74	Male	White	PDAC	Primary	Deceased	G12V	G245S	No	No	G12	Yes	74.0
DUKE-P2224	64	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
DUKE-P2232	71	Female	NA	PDAC	Primary	Deceased	No	No	No	No	No	No	71.0
DUKE-P2259	50	Female	Black/African-American	PDAC	Primary	Deceased	G12D	K132E	No	No	G12	Yes	50.0
DUKE-P2273	60	Male	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	60.0
DUKE-P2277	57	Male	White	PDAC	Primary	Deceased	A146V	No	No	No	Other	No	57.0
DUKE-P2281	70	Male	White	PDAC	Primary	Deceased	G12R	R248W	No	No	G12	Yes	70.0
DUKE-P2287	61	Male	White	PDAC	Metastasis	Deceased	G12R	G105V	No	Q249P	G12	Yes	61.0
DUKE-P2298	62	Female	Black/African-American	PDAC	Primary	Deceased	G12R	V173G	No	No	G12	Yes	62.0
DUKE-P2304	65	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	65.0
DUKE-P2322	84	Female	White	PDAC	Primary	Deceased	G12V	No	No	R361H	G12	No	84.0
DUKE-P2324	63	Male	White	PDAC	Metastasis	Deceased	G12D	G245S	No	No	G12	Yes	63.0
DUKE-P2347	65	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	65.0
DUKE-P2348	66	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	66.0
DUKE-P2356	70	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	70.0
DUKE-P2374	79	Male	White	PDAC	Metastasis	Deceased	G12D	R110P	No	No	G12	Yes	79.0
DUKE-P2378	76	Male	White	Carcinoma, NOS	Primary	Deceased	G12D	R175H	No	No	G12	Yes	76.0
DUKE-P2419	49	Female	White	PDAC	Primary	Deceased	G12V	R282W	No	No	G12	Yes	49.0
DUKE-P2456	45	Male	White	PDAC	Primary	Deceased	G12V	A138V	No	No	G12	Yes	45.0
DUKE-P2461	68	Female	White	PDAC	Primary	Deceased	Q61L	R273L	No	No	Q61	Yes	68.0
DUKE-P2474	63	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	63.0
DUKE-P2506	65	Male	Black/African-American	PDAC	Primary	Deceased	G12R	R248W	No	No	G12	Yes	65.0
DUKE-P2518	77	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	77.0
DUKE-P2535	67	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	67.0
DUKE-P2566	75	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	75.0
DUKE-P2593	71	Male	White	PDAC	Primary	Deceased	G12D	No	No	A118V	G12	No	71.0
DUKE-P2634	54	Female	Black/African-American	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	54.0
DUKE-P2651	78	Female	White	PNET	Metastasis	Deceased	G12V	V272G	H83Y	D537V	G12	Yes	78.0
DUKE-P2675	77	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	77.0
DUKE-P2688	73	Female	Black/African-American	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	73.0
DUKE-P2693	65	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	65.0
DUKE-P2705	57	Male	White	PDAC	Primary	Deceased	G12V	R248Q	No	No	G12	Yes	57.0
DUKE-P2741	66	Female	White	Carcinoma, NOS	Primary	Deceased	G12V	L265P	D84N	No	G12	Yes	66.0
DUKE-P2745	58	Male	White	Carcinoma, NOS	Metastasis	NA	G12D	C176S	No	No	G12	Yes	58.0
DUKE-P2754	59	Male	Black/African-American	PDAC	Primary	Deceased	Q61L	R273H	No	No	Q61	Yes	59.0
DUKE-P2756	70	Male	Black/African-American	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	70.0
DUKE-P2758	69	Male	White	PDAC	Primary	Deceased	G12D	S241A	A102L	No	G12	Yes	69.0
DUKE-P2763	41	Female	Black/African-American	PDAC	Metastasis	Deceased	G12D	Y126C	No	No	G12	Yes	41.0
DUKE-P2770	73	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	73.0
DUKE-P2780	58	Male	White	PDAC	Metastasis	Deceased	Q61H	A159V	No	No	Q61	Yes	58.0
DUKE-P279	38	Male	Asian	PDAC	Primary	Deceased	G12D	L130V	No	No	G12	Yes	38.0
DUKE-P2791	66	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	No	H83Y	No	G12	No	66.0
DUKE-P2794	68	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	68.0
DUKE-P280	81	Male	White	PDAC	Primary	Deceased	G13D	R248W	No	No	G13	Yes	81.0
DUKE-P2813	45	Female	Asian	PDAC	Metastasis	Deceased	G12D	T125P	No	No	G12	Yes	45.0
DUKE-P2814	68	Female	White	Adenosquamous carcinoma	Primary	Deceased	G12D	R248W	No	No	G12	Yes	68.0
DUKE-P2842	75	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	75.0
DUKE-P2846	70	Female	White	PDAC	Primary	Deceased	G12V	R282W	No	No	G12	Yes	70.0
DUKE-P2853	70	Male	White	PDAC	Primary	Deceased	G12I	No	No	No	G12	No	70.0
DUKE-P2878	63	Male	White	PDAC	Primary	Deceased	G12D	T253A	No	W99R	G12	Yes	63.0
DUKE-P2891	51	Male	Black/African-American	PDAC	Primary	Deceased	G12R	No	No	C71Y	G12	No	51.0
DUKE-P2905	53	Male	Other	PDAC	Metastasis	Deceased	G12V	V173M	No	No	G12	Yes	53.0
DUKE-P2906	53	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	53.0
DUKE-P2909	59	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	59.0
DUKE-P2910	54	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	54.0
DUKE-P2931	60	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	60.0
DUKE-P2944	53	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	53.0
DUKE-P2973	44	Female	White	PDAC	Primary	Deceased	G12V	V216L	No	No	G12	Yes	44.0
DUKE-P2980	63	Male	White	PDAC	Metastasis	Deceased	G12D	P250L	No	No	G12	Yes	63.0
DUKE-P2984	69	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	69.0
DUKE-P2994	78	Female	White	Adenosquamous carcinoma	Primary	Deceased	G12D	No	No	R420C	G12	No	78.0
DUKE-P2995	59	Male	White	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	59.0
DUKE-P2996	60	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	60.0
DUKE-P2999	65	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	65.0
DUKE-P3008	74	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	E287Q,L194R	No	R361C	G12	Yes	74.0
DUKE-P3015	65	Female	White	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	65.0
DUKE-P3017	67	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	67.0
DUKE-P3022	64	Female	NA	PDAC	Primary	Deceased	G12D	L130F	No	No	G12	Yes	64.0
DUKE-P3025	74	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	74.0
DUKE-P3032	64	Male	White	PDAC	Primary	Deceased	G12R	No	No	R361H	G12	No	64.0
DUKE-P3045	52	Male	Other	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	52.0
DUKE-P3080	72	Female	White	PDAC	Primary	Deceased	G12A	E258Q	No	No	G12	Yes	72.0
DUKE-P3103	50	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	50.0
DUKE-P3105	67	Female	Black/African-American	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	67.0
DUKE-P3113	85	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	85.0
DUKE-P3120	64	Male	White	PDAC	Primary	Deceased	G12D	R248W	No	No	G12	Yes	64.0
DUKE-P3132	55	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	55.0
DUKE-P3148	71	Female	White	PDAC	Primary	Deceased	G12V	No	D108H	No	G12	No	71.0
DUKE-P3151	62	Female	White	PDAC	Metastasis	Deceased	G12D	R273C	No	No	G12	Yes	62.0
DUKE-P3167	66	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	66.0
DUKE-P3188	75	Female	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	75.0
DUKE-P319	40	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	40.0
DUKE-P3197	72	Female	White	PDAC	Metastasis	Deceased	G12V	No	L64P	No	G12	No	72.0
DUKE-P3199	65	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	65.0
DUKE-P3208	70	Male	White	PDAC	Metastasis	Deceased	G12V	Y234C	I49N	V128M	G12	Yes	70.0
DUKE-P337	70	Female	White	Carcinoma, NOS	Primary	Deceased	G12D	No	No	A118V	G12	No	70.0
DUKE-P38	70	Male	White	PDAC	Metastasis	Deceased	G12D	R158L	No	No	G12	Yes	70.0
DUKE-P442	54	Male	White	PDAC	Metastasis	Deceased	G12D	F113S	No	No	G12	Yes	54.0
DUKE-P47	63	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	63.0
DUKE-P486	58	Male	NA	Carcinoma, NOS	Primary	Deceased	G12V	C135Y	No	No	G12	Yes	58.0
DUKE-P55	48	Male	White	Acinar cell carcinoma	Primary	Deceased	No	No	No	No	No	No	48.0
DUKE-P577	76	Male	White	Carcinoma, NOS	Primary	Deceased	No	No	No	No	No	No	76.0
DUKE-P598	61	Male	White	PDAC	Primary	Deceased	G12V	No	No	D537N	G12	No	61.0
DUKE-P606	53	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	53.0
DUKE-P639	54	Male	White	PDAC	Primary	Deceased	G12D	R248Q	No	No	G12	Yes	54.0
DUKE-P641	50	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	50.0
DUKE-P655	78	Male	NA	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	78.0
DUKE-P668	74	Female	White	Carcinoma, NOS	Primary	Deceased	G12D	No	No	No	G12	No	74.0
DUKE-P676	51	Female	White	PDAC	Metastasis	Deceased	G12V	G245S	No	No	G12	Yes	51.0
DUKE-P713	53	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	H179Q	No	No	G12	Yes	53.0
DUKE-P764	64	Male	Other	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	64.0
DUKE-P77	58	Male	White	PDAC	Metastasis	NA	No	V218G	No	No	No	Yes	58.0
DUKE-P779	62	Male	White	Carcinoma, NOS	Primary	Deceased	G12V	M237I	No	G352V	G12	Yes	62.0
DUKE-P780	71	Male	White	PDAC	Primary	NA	G12V	No	No	No	G12	No	71.0
DUKE-P781	60	Female	White	PDAC	Primary	Deceased	G12V	G244C	No	No	G12	Yes	60.0
DUKE-P797	56	Male	White	Carcinoma, NOS	Primary	Deceased	G12V	No	No	No	G12	No	56.0
DUKE-P816	67	Female	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	67.0
DUKE-P819	52	Female	White	PDAC	Primary	Deceased	G12D	R280T	No	No	G12	Yes	52.0
DUKE-P831	47	Female	NA	PDAC	Primary	Deceased	G12D	Y220C	No	No	G12	Yes	47.0
DUKE-P854	71	Female	White	Carcinoma, NOS	Metastasis	Deceased	G12D	L130F	No	No	G12	Yes	71.0
DUKE-P878	58	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	58.0
DUKE-P887	60	Male	White	Carcinoma, NOS	Primary	NA	No	Y163C	No	No	No	Yes	60.0
DUKE-P917	68	Male	White	PDAC	Metastasis	Deceased	G12R	No	H83Y	No	G12	No	68.0
DUKE-P972	69	Female	White	PNET	Metastasis	NA	No	No	No	No	No	No	69.0
DUKE-P987	49	Male	Black/African-American	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	49.0
DUKE-P988	66	Male	White	PDAC	Metastasis	Deceased	No	R175H	No	No	No	Yes	66.0
GRCC-00a38510	NA	Male	NA	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	NA
GRCC-0677096c	45	Female	NA	PDAC	Metastasis	NA	No	No	No	No	No	No	45.0
GRCC-16b16e1e	68	Male	NA	PDAC	Metastasis	Deceased	G12D	F113V	No	No	G12	Yes	68.0
GRCC-4d0dp64a	58	Female	NA	PDAC	Unknown	NA	G12D	No	No	No	G12	No	58.0
GRCC-51ce3894	62	Female	NA	PDAC	Metastasis	NA	No	No	No	No	No	No	62.0
GRCC-52345d76	65	Male	NA	PNET	Metastasis	NA	G12D	No	No	No	G12	No	65.0
GRCC-5oj5vwds	39	Female	NA	PDAC	Unknown	NA	G12D	No	No	No	G12	No	39.0
GRCC-8008f5b2	43	Female	NA	PNET	Primary	Deceased	G12V	No	No	No	G12	No	43.0
GRCC-84b7f427	69	Male	NA	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	69.0
GRCC-85f57752	NA	Male	NA	Carcinoma, NOS	Metastasis	NA	No	No	No	No	No	No	NA
GRCC-a0120ad6	57	Female	NA	PDAC	Metastasis	Deceased	G12D	H193R	No	No	G12	Yes	57.0
GRCC-aefd025d	42	Female	NA	Carcinoma, NOS	Metastasis	NA	No	No	No	No	No	No	42.0
GRCC-b708f7d2	58	Female	NA	PDAC	Metastasis	NA	No	No	No	No	No	No	58.0
GRCC-b8whux5n	65	Male	NA	Adenosquamous carcinoma	Metastasis	NA	No	No	No	No	No	No	65.0
GRCC-c4228fb9	65	Male	NA	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	65.0
GRCC-c440d44a	60	Male	NA	PDAC	Metastasis	Deceased	G12V	G245S	No	No	G12	Yes	60.0
GRCC-c5tln120	61	Male	NA	PNET	Primary	NA	G12V	E285K	H83Y	No	G12	Yes	61.0
GRCC-d2ed496f	63	Female	NA	PDAC	Primary	NA	G12D	No	No	No	G12	No	63.0
GRCC-dmdeoadn	35	Female	NA	PNET	Metastasis	NA	No	No	No	No	No	No	35.0
GRCC-e897f3c7	46	Male	NA	PDAC	Metastasis	Deceased	No	No	No	No	No	No	46.0
GRCC-ebe6a6ba	40	Female	NA	PDAC	Primary	Deceased	G12D	Y163C	No	No	G12	Yes	40.0
GRCC-es91s2m2	50	Male	NA	PDAC	Metastasis	NA	A11G	No	No	No	Other	No	50.0
GRCC-f554f267	64	Male	NA	PDAC	NA or Heme	Deceased	G12R	G266R	No	No	G12	Yes	64.0
GRCC-f95862eb	59	Male	NA	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	59.0
GRCC-fc35b2a3	62	Female	NA	Carcinoma, NOS	Metastasis	Deceased	G12V	No	No	No	G12	No	62.0
GRCC-fe290a88	63	Male	NA	PDAC	Metastasis	NA	G12R	R202P	No	No	G12	Yes	63.0
GRCC-febd98b3	52	Female	NA	Carcinoma, NOS	Metastasis	Deceased	G12D	No	No	No	G12	No	52.0
GRCC-gyyetabf	49	Male	NA	Adenosquamous carcinoma	Metastasis	NA	G12S	No	No	No	G12	No	49.0
GRCC-hidtf11m	70	Male	NA	PDAC	Metastasis	NA	G12V	No	No	R361C	G12	No	70.0
GRCC-jvp0u1a7	45	Male	NA	PNET	Metastasis	NA	No	No	No	No	No	No	45.0
GRCC-moxuk4tk	49	Male	NA	PDAC	Metastasis	NA	Q61H	No	No	No	Q61	No	49.0
GRCC-qpv9ib08	41	Female	NA	PDAC	Metastasis	NA	G10_A11delinsAD	No	No	No	Other	No	41.0
GRCC-r0dd7exs	61	Female	NA	PDAC	Metastasis	NA	No	M237I	No	No	No	Yes	61.0
GRCC-wx2pajzp	65	Male	NA	PDAC	Metastasis	NA	No	H179R	No	No	No	Yes	65.0
JHU-00129	81	Female	White	PDAC	Metastasis	Alive	No	G244D	No	No	No	Yes	81.0
JHU-00173	70	Female	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	70.0
JHU-00572	46	Male	White	PDAC	Metastasis	Alive	G12V	No	No	A118V	G12	No	46.0
JHU-00675	59	Male	White	PDAC	Primary	Alive	G12R	S240G	No	No	G12	Yes	59.0
JHU-00737	57	Male	White	PDAC	Primary	Alive	G12V	R158L	No	E330K	G12	Yes	57.0
JHU-00935	52	Male	NA	PDAC	Metastasis	NA	No	No	No	No	No	No	52.0
JHU-01004	78	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	78.0
JHU-01638	59	Male	Asian	PDAC	Primary	Deceased	G12R	R175H	No	No	G12	Yes	59.0
JHU-02102	56	Male	White	IPMN	Primary	Alive	G12D	R282W	No	No	G12	Yes	56.0
JHU-02305	66	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	66.0
JHU-02314	29	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	29.0
JHU-02648	72	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	72.0
JHU-03327	68	Female	White	PDAC	Metastasis	Deceased	G12R	R249M	No	No	G12	Yes	68.0
JHU-03867	65	Female	White	PDAC	Metastasis	Deceased	G12V	G245S	No	No	G12	Yes	65.0
JHU-03901	52	Female	White	PDAC	Primary	Alive	G12R	R175H	No	No	G12	Yes	52.0
JHU-04143	61	Female	Black/African-American	PDAC	Metastasis	Alive	G12D	Y220C	No	No	G12	Yes	61.0
JHU-04190	63	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	63.0
JHU-04193	68	Male	White	PDAC	Metastasis	Deceased	G12V	R249S	No	No	G12	Yes	68.0
JHU-04253	76	Male	White	PDAC	Metastasis	Alive	G12V	G105R	No	R361G	G12	Yes	76.0
JHU-04414	60	Female	White	PDAC	Primary	Alive	G12V	P190L	R138K	V350I	G12	Yes	60.0
JHU-04417	61	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	61.0
JHU-04421	48	Female	White	PDAC	Metastasis	Alive	G12V	R175H	No	C363Y	G12	Yes	48.0
JHU-04442	57	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	57.0
JHU-04480	81	Male	Other	PDAC	Metastasis	Alive	G12E	R273C	No	No	G12	Yes	81.0
JHU-04503	77	Female	White	PDAC	Primary	Alive	G12V	E271V	No	No	G12	Yes	77.0
JHU-04517	82	Female	White	PDAC	Unknown	Alive	G12V	No	No	G510V	G12	No	82.0
JHU-04518	58	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	58.0
JHU-04527	67	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	67.0
JHU-04543	64	Male	White	PDAC	Primary	Alive	G12D	No	No	L104R	G12	No	64.0
JHU-04561	67	Male	White	PDAC	Unknown	Alive	G12V	No	No	No	G12	No	67.0
JHU-04570	NA	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	NA
JHU-04623	54	Female	Black/African-American	PDAC	Primary	Alive	G12R	No	No	No	G12	No	54.0
JHU-04624	NA	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	M447K	G12	No	NA
JHU-04639	58	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	58.0
JHU-04640	70	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	70.0
JHU-04641	72	Female	Other	PNET	Primary	Alive	No	No	No	No	No	No	72.0
JHU-04655	NA	Male	Asian	PDAC	Primary	Alive	G12V	Y126H	No	No	G12	Yes	NA
JHU-04666	55	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	55.0
JHU-04679	76	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	76.0
JHU-04690	NA	Male	White	PDAC	Primary	Alive	G12R	Y163C	No	H132Y	G12	Yes	NA
JHU-04712	68	Male	White	PDAC	Primary	Alive	G12V	No	H83Y	No	G12	No	68.0
JHU-04714	64	Male	Asian	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	64.0
JHU-04728	65	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	65.0
JHU-04731	53	Female	Black/African-American	PDAC	Primary	Alive	No	A76T	No	No	No	Yes	53.0
JHU-04732	36	Male	White	PDAC	Primary	Alive	G12D	R248W	No	R361H	G12	Yes	36.0
JHU-04752	68	Male	White	PDAC	Primary	Deceased	G12R	S127P	No	No	G12	Yes	68.0
JHU-04768	62	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	62.0
JHU-04787	60	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	60.0
JHU-04788	78	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	78.0
JHU-04793	55	Male	White	PDAC	Primary	Alive	G12D	S241F,V10I	No	No	G12	Yes	55.0
JHU-04821	75	Male	White	PDAC	Primary	Alive	G12D	R273C	No	No	G12	Yes	75.0
JHU-04834	69	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	69.0
JHU-04922	52	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	52.0
JHU-04943	56	Female	White	PDAC	NA or Heme	Alive	No	P72A,E271K	No	No	No	Yes	56.0
JHU-04956	76	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	76.0
JHU-04985	61	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	61.0
JHU-05000	62	Female	White	PDAC	Primary	Alive	G12D	G245S	No	No	G12	Yes	62.0
JHU-05025	65	Female	White	PDAC	Primary	Alive	G12D	R248Q	No	No	G12	Yes	65.0
JHU-05026	61	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	61.0
JHU-05040	72	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	72.0
JHU-05045	49	Female	Black/African-American	PDAC	Primary	Alive	G12R	Y163C,E287K	No	No	G12	Yes	49.0
JHU-05070	51	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	51.0
JHU-05076	78	Female	White	PDAC	Primary	Deceased	G12V	Y236N	No	No	G12	Yes	78.0
JHU-05081	76	Female	White	PDAC	Primary	Alive	Q61R	No	No	No	Q61	No	76.0
JHU-05082	60	Female	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	60.0
JHU-05094	75	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	75.0
JHU-05104	62	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	62.0
JHU-05108	70	Female	White	PDAC	Primary	Alive	G12R	Y220C	No	No	G12	Yes	70.0
JHU-05111	79	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	79.0
JHU-05112	76	Male	White	PDAC	Primary	Alive	G12C	No	No	No	G12	No	76.0
JHU-05114	67	Male	White	PDAC	Primary	Alive	G12D	P278H	No	No	G12	Yes	67.0
JHU-05116	66	Female	Black/African-American	PDAC	Primary	Alive	G12D	No	No	No	G12	No	66.0
JHU-05123	62	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	62.0
JHU-05124	70	Male	White	PDAC	Primary	Alive	G12R	No	No	D351N	G12	No	70.0
JHU-05126	79	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	79.0
JHU-05130	73	Male	White	PDAC	Primary	Alive	G12D	L194R,M243I	C72Y	No	G12	Yes	73.0
JHU-05139	72	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	72.0
JHU-05142	66	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	66.0
JHU-05148	54	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	54.0
JHU-05149	68	Male	White	PDAC	Primary	Deceased	G12D	V157F	No	No	G12	Yes	68.0
JHU-05150	57	Male	White	PDAC	Primary	Alive	G12D	R248G	D108Y	No	G12	Yes	57.0
JHU-05151	73	Female	White	PDAC	Primary	Alive	G12V	M133T	No	No	G12	Yes	73.0
JHU-05161	72	Male	Black/African-American	PDAC	Primary	Deceased	G12D	I232S	No	No	G12	Yes	72.0
JHU-05177	66	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	66.0
JHU-05185	58	Male	White	PDAC	Primary	Deceased	G12D	C176R	No	No	G12	Yes	58.0
JHU-05189	61	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	61.0
JHU-05190	74	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	74.0
JHU-05201	73	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	73.0
JHU-05203	72	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	72.0
JHU-05225	63	Male	White	PDAC	Primary	Alive	G12V	R273H	No	No	G12	Yes	63.0
JHU-05228	58	Female	White	PDAC	Primary	Alive	G12V	P82L,P82S	A57V	No	G12	Yes	58.0
JHU-05241	82	Male	White	PDAC	Primary	Alive	G12V	E339K	No	No	G12	Yes	82.0
JHU-05247	77	Male	White	PDAC	Primary	Alive	G12V	No	No	R361C	G12	No	77.0
JHU-05248	76	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	76.0
JHU-05249	51	Female	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	51.0
JHU-05259	61	Female	Black/African-American	PDAC	Primary	Alive	G12D	R248Q	No	No	G12	Yes	61.0
JHU-05291	69	Male	White	PDAC	Metastasis	Deceased	G12V	F270L	No	No	G12	Yes	69.0
JHU-05293	73	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	73.0
JHU-05299	57	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	57.0
JHU-05310	77	Male	Black/African-American	PDAC	Metastasis	Alive	G12V,A134T	P191S,A189T	No	No	G12\|Other	Yes	77.0
JHU-05337	71	Male	White	PDAC	Primary	Deceased	G12R	G245S	No	R361H	G12	Yes	71.0
JHU-05343	61	Female	White	PDAC	Primary	Deceased	G12D	R248W	No	No	G12	Yes	61.0
JHU-05347	NA	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	NA
JHU-05352	57	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	57.0
JHU-05662	57	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	57.0
JHU-05669	74	Female	White	PDAC	Primary	Alive	G12D	Y234C	No	No	G12	Yes	74.0
JHU-05670	70	Female	White	PDAC	Primary	Deceased	G12V	E285K	No	No	G12	Yes	70.0
JHU-05686	43	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	43.0
JHU-05709	70	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	70.0
JHU-05711	62	Female	Other	PDAC	Primary	Alive	No	No	No	No	No	No	62.0
JHU-05752	65	Female	White	PDAC	Primary	Alive	G12R	P151S	No	No	G12	Yes	65.0
JHU-05755	55	Female	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	55.0
JHU-05757	59	Female	White	PDAC	Primary	Alive	G12R	No	No	R416K	G12	No	59.0
JHU-05802	47	Female	Asian	PDAC	Primary	Alive	G12V	V272M	No	No	G12	Yes	47.0
JHU-05803	69	Male	White	PDAC	Primary	Alive	G12R	R175H	No	No	G12	Yes	69.0
JHU-05827	80	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	80.0
JHU-05839	71	Female	White	PDAC	Primary	Alive	G12R	Y220C	No	No	G12	Yes	71.0
JHU-05846	50	Male	Other	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	50.0
JHU-05850	63	Male	White	PDAC	Primary	Alive	G12D	R273C	No	No	G12	Yes	63.0
JHU-05859	67	Female	Asian	PDAC	Unknown	Alive	No	No	No	No	No	No	67.0
JHU-05882	64	Male	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	64.0
JHU-05889	75	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	75.0
JHU-05892	47	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	47.0
JHU-05895	64	Female	Asian	PDAC	Primary	Alive	G12V	C242Y	No	No	G12	Yes	64.0
JHU-05909	69	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	69.0
JHU-05912	62	Male	White	PDAC	Metastasis	Alive	G12D	No	G139S	No	G12	No	62.0
JHU-05917	76	Female	White	PDAC	NA or Heme	Alive	G12R	H179R	No	No	G12	Yes	76.0
JHU-05919	82	Male	Other	PDAC	Primary	Alive	G12D	No	No	No	G12	No	82.0
JHU-05934	62	Male	White	PDAC	Primary	Alive	Q61R	No	No	G508D	Q61	No	62.0
JHU-05937	62	Male	Black/African-American	PDAC	Primary	Alive	G12V	No	No	No	G12	No	62.0
JHU-05940	64	Male	White	PDAC	Primary	Alive	G12V	R213L	No	No	G12	Yes	64.0
JHU-05960	57	Male	Black/African-American	PDAC	Primary	Alive	No	No	H83Y	No	No	No	57.0
JHU-05961	75	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	75.0
JHU-05965	75	Male	White	PDAC	Unknown	Alive	G12V	No	No	No	G12	No	75.0
JHU-05966	84	Male	White	PDAC	Primary	Alive	G12V	V274D	No	No	G12	Yes	84.0
JHU-05986	71	Female	Other	PDAC	Primary	Alive	G12V	P278R	No	No	G12	Yes	71.0
JHU-05994	57	Female	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	57.0
JHU-05998	73	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	73.0
JHU-05999	75	Male	White	PDAC	Primary	Alive	G12D	E285K	No	No	G12	Yes	75.0
JHU-06016	77	Female	Asian	PDAC	Primary	Alive	G12V	No	No	No	G12	No	77.0
JHU-06025	75	Female	White	PDAC	Primary	Alive	G12V	Y220C	No	No	G12	Yes	75.0
JHU-06026	78	Male	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	78.0
JHU-06044	48	Male	Black/African-American	PDAC	Primary	Alive	No	No	No	No	No	No	48.0
JHU-06050	59	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	59.0
JHU-06054	64	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	64.0
JHU-06062	64	Male	Asian	PDAC	Primary	Deceased	No	No	No	No	No	No	64.0
JHU-06080	70	Male	White	PDAC	Primary	Deceased	G12R	R249W	No	No	G12	Yes	70.0
JHU-06147	59	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	59.0
JHU-06149	48	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	48.0
JHU-06152	72	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	72.0
JHU-06157	68	Male	White	PDAC	Primary	Alive	No	Y220C	No	No	No	Yes	68.0
JHU-06176	59	Male	White	PDAC	Unknown	Alive	G12R	No	No	No	G12	No	59.0
JHU-06177	70	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	70.0
JHU-06197	55	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	55.0
JHU-06206	82	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	82.0
JHU-06215	68	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	68.0
JHU-06223	73	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	73.0
JHU-06242	80	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	80.0
JHU-06244	74	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	74.0
JHU-06248	59	Female	Other	PDAC	Primary	Alive	G12D	G245V	H83Y	No	G12	Yes	59.0
JHU-06249	66	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	66.0
JHU-06254	72	Female	Black/African-American	PDAC	Primary	Alive	No	No	No	No	No	No	72.0
JHU-06256	61	Male	White	PDAC	Primary	Alive	G12R	P278H	No	No	G12	Yes	61.0
JHU-06262	47	Male	White	PDAC	Primary	Alive	G12R	I195T	No	No	G12	Yes	47.0
JHU-06286	67	Male	Other	PDAC	Primary	Alive	G12D	G245S	No	No	G12	Yes	67.0
JHU-06291	66	Female	White	Acinar cell carcinoma	Primary	Deceased	No	No	No	No	No	No	66.0
JHU-06305	70	Male	Black/African-American	PNET	Primary	Alive	No	No	No	No	No	No	70.0
JHU-06307	72	Female	Black/African-American	PDAC	Primary	Alive	G12R	No	No	No	G12	No	72.0
JHU-06338	71	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	71.0
JHU-06344	78	Male	White	PDAC	Primary	Alive	G12R,V14I	R175H	No	No	G12\|Other	Yes	78.0
JHU-06349	60	Female	White	PDAC	Metastasis	Alive	Q61R	R282W	No	E330Q	Q61	Yes	60.0
JHU-06350	72	Male	Black/African-American	PDAC	Primary	Alive	G12D	R273H	No	No	G12	Yes	72.0
JHU-06382	68	Male	White	PDAC	Primary	Deceased	G12D	No	No	G386V	G12	No	68.0
JHU-06384	65	Female	Asian	Adenosquamous carcinoma	Primary	Alive	G12D	Y126D	No	No	G12	Yes	65.0
JHU-06388	61	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	61.0
JHU-06389	72	Male	White	PDAC	Primary	Alive	G12V	R273H	No	No	G12	Yes	72.0
JHU-06397	62	Female	White	PDAC	Metastasis	Alive	Q61R	No	No	No	Q61	No	62.0
JHU-06401	76	Male	Other	PDAC	Primary	Alive	No	R248Q	No	No	No	Yes	76.0
JHU-06421	69	Female	White	PDAC	Primary	Alive	G12V	S241F	No	No	G12	Yes	69.0
JHU-06422	53	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	53.0
JHU-06423	75	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	75.0
JHU-06427	62	Female	White	PDAC	Primary	Alive	Q61R	No	No	No	Q61	No	62.0
JHU-06438	63	Male	White	PDAC	Primary	Alive	G12V	C176F	No	No	G12	Yes	63.0
JHU-06440	73	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	73.0
JHU-06446	80	Male	White	PDAC	Primary	Alive	G12V	V173M	No	No	G12	Yes	80.0
JHU-06453	83	Male	White	Adenosquamous carcinoma	Primary	Alive	G12D	No	No	No	G12	No	83.0
JHU-06454	68	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	68.0
JHU-06458	64	Male	White	Adenosquamous carcinoma	Primary	Alive	G12R	H193R	No	No	G12	Yes	64.0
JHU-06463	66	Male	White	PDAC	Primary	Alive	G12D	Y234H	No	No	G12	Yes	66.0
JHU-06470	86	Female	White	PDAC	Metastasis	Deceased	G12V	R248Q	No	No	G12	Yes	86.0
JHU-06472	78	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	78.0
JHU-06473	73	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	73.0
JHU-06474	86	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	86.0
JHU-06487	75	Female	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	75.0
JHU-06488	81	Female	Black/African-American	PDAC	Primary	Alive	Q61H	R175H	No	No	Q61	Yes	81.0
JHU-06489	48	Female	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	48.0
JHU-06490	69	Female	Other	PDAC	Primary	Alive	G12D	R249G	No	No	G12	Yes	69.0
JHU-06491	68	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	68.0
JHU-06505	78	Female	Asian	PDAC	Primary	Alive	G12D	No	No	No	G12	No	78.0
JHU-06529	64	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	64.0
JHU-06546	51	Female	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	51.0
JHU-06574	82	Male	White	PNET	Primary	Alive	G12V	No	No	No	G12	No	82.0
JHU-06591	62	Male	Black/African-American	PDAC	Primary	Alive	No	M237I	No	No	No	Yes	62.0
JHU-06604	50	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	50.0
JHU-06607	69	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	69.0
JHU-06621	70	Female	Black/African-American	PNET	Primary	Alive	No	No	No	No	No	No	70.0
JHU-06626	70	Male	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	70.0
JHU-06627	78	Female	Black/African-American	PDAC	Primary	Deceased	G12D	K132T	No	C499Y	G12	Yes	78.0
JHU-06638	70	Male	White	PDAC	Metastasis	Deceased	G12D	R158H	No	R361S	G12	Yes	70.0
JHU-06662	65	Female	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	65.0
JHU-06702	73	Male	White	PDAC	Primary	Alive	G12V	No	No	G386D	G12	No	73.0
JHU-06709	65	Female	White	PDAC	Primary	Alive	G12R	M237I	No	No	G12	Yes	65.0
JHU-06710	71	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	71.0
JHU-06744	80	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12V	V216L	No	No	G12	Yes	80.0
JHU-06745	67	Male	White	PDAC	Primary	Alive	G12D	No	L64P	No	G12	No	67.0
JHU-06750	74	Female	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	74.0
JHU-06751	85	Female	Black/African-American	PDAC	Primary	Alive	G12V	No	No	No	G12	No	85.0
JHU-06754	58	Female	Asian	PDAC	Primary	Alive	G12D	I195T	No	No	G12	Yes	58.0
JHU-06777	75	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	75.0
JHU-06778	76	Female	White	Adenosquamous carcinoma	Primary	Alive	G12D	P250L	No	No	G12	Yes	76.0
JHU-06781	74	Female	White	PDAC	NA or Heme	Alive	G12D	No	No	No	G12	No	74.0
JHU-06805	48	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	48.0
JHU-06817	62	Male	White	PDAC	Primary	Alive	G12D	No	H83Y	No	G12	No	62.0
JHU-06855	69	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	69.0
JHU-06856	72	Male	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	R361C	No	No	72.0
JHU-06861	72	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	72.0
JHU-06922	65	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	65.0
JHU-06927	70	Female	White	PDAC	Primary	Alive	G12D	V172F	No	No	G12	Yes	70.0
JHU-06931	56	Male	Black/African-American	PDAC	Primary	Alive	G12V	Y220H	No	No	G12	Yes	56.0
JHU-06932	77	Female	Asian	PDAC	Primary	Alive	G12V	R175H	No	R361C	G12	Yes	77.0
JHU-06936	76	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	76.0
JHU-06941	79	Female	White	PDAC	Metastasis	Alive	G12V	R248W	No	No	G12	Yes	79.0
JHU-06952	68	Male	White	PDAC	Primary	Alive	G12D	No	No	R361C	G12	No	68.0
JHU-06963	65	Male	White	PDAC	Primary	Alive	G12D	N239S	No	No	G12	Yes	65.0
JHU-06969	68	Male	White	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	68.0
JHU-06974	56	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	56.0
JHU-06990	63	Female	White	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	63.0
JHU-07004	71	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	71.0
JHU-07008	69	Male	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	69.0
JHU-07009	54	Female	Black/African-American	PDAC	Primary	Alive	Q61R	H179Y	No	No	Q61	Yes	54.0
JHU-07031	73	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	73.0
JHU-07032	80	Female	Asian	PDAC	Primary	Alive	Q61R	No	H83Y	No	Q61	No	80.0
JHU-07059	50	Female	White	PDAC	Primary	Alive	G12D	M237K	No	No	G12	Yes	50.0
JHU-07061	45	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	45.0
JHU-07096	68	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	68.0
JHU-07098	48	Male	White	PDAC	Primary	Alive	G12V	V173M	No	No	G12	Yes	48.0
JHU-07118	54	Female	Asian	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	54.0
JHU-07119	80	Female	Asian	PDAC	Primary	Alive	G12D	A161D	No	No	G12	Yes	80.0
JHU-07120	43	Male	White	PDAC	Primary	Alive	G12D	R248Q,R175H	No	No	G12	Yes	43.0
JHU-07131	70	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	70.0
JHU-07133	87	Female	White	PDAC	Primary	Alive	Q61H	S127F	No	No	Q61	Yes	87.0
JHU-07135	57	Male	White	Adenosquamous carcinoma	Primary	Alive	G12D	No	No	No	G12	No	57.0
JHU-07142	64	Female	Asian	PDAC	Primary	Alive	No	No	No	No	No	No	64.0
JHU-07170	75	Male	White	PDAC	Primary	Alive	G12V	G244C	No	No	G12	Yes	75.0
JHU-07173	52	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	52.0
JHU-07196	NA	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	NA
JHU-07237	NA	Female	White	Adenosquamous carcinoma	Primary	Alive	G12D	No	No	No	G12	No	NA
JHU-07255	71	Female	Black/African-American	PDAC	Primary	Alive	G12R	No	No	No	G12	No	71.0
JHU-07260	61	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	61.0
JHU-07261	85	Female	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	85.0
JHU-07277	52	Female	Black/African-American	PNET	Metastasis	Alive	No	C176F	No	No	No	Yes	52.0
JHU-07285	50	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	50.0
JHU-07287	NA	Female	White	PDAC	Primary	Alive	G12D	G245S	No	No	G12	Yes	NA
JHU-07309	66	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	66.0
JHU-07313	62	Female	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	62.0
JHU-07322	62	Male	White	PDAC	Primary	Deceased	G12R	G245D	No	No	G12	Yes	62.0
JHU-07336	74	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	74.0
JHU-07346	68	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	68.0
JHU-07348	73	Male	White	PDAC	Metastasis	Deceased	Q61H	No	No	A118V	Q61	No	73.0
JHU-07354	58	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	58.0
JHU-07359	73	Female	White	PDAC	Primary	Alive	G12D	K132R	No	No	G12	Yes	73.0
JHU-07380	72	Male	White	PDAC	Metastasis	Alive	G12R	N247I,T155N	No	No	G12	Yes	72.0
JHU-07388	49	Female	Asian	PNET	Metastasis	Deceased	No	No	No	No	No	No	49.0
JHU-07398	73	Male	White	PDAC	Primary	Alive	G12R	No	No	D351G	G12	No	73.0
JHU-07425	70	Male	White	PDAC	Primary	Deceased	G12D	D281E	No	No	G12	Yes	70.0
JHU-07430	61	Male	White	PDAC	Primary	Alive	G13D	No	No	No	G13	No	61.0
JHU-07441	78	Female	Asian	PDAC	Primary	Alive	G12R	R282W	No	No	G12	Yes	78.0
JHU-07442	63	Male	Other	PNET	Metastasis	Alive	No	No	No	No	No	No	63.0
JHU-07464	52	Female	White	PDAC	Primary	Alive	G12R	Y220C	No	No	G12	Yes	52.0
JHU-07470	55	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	55.0
JHU-07489	63	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	63.0
JHU-07492	62	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	62.0
JHU-07499	73	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	73.0
JHU-07506	85	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	85.0
JHU-07546	33	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	33.0
JHU-07552	67	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	67.0
JHU-07554	54	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	54.0
JHU-07590	68	Female	Asian	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	68.0
JHU-07592	74	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	74.0
JHU-07595	52	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	52.0
JHU-07609	73	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	73.0
JHU-07616	72	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	72.0
JHU-07627	78	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	78.0
JHU-07631	73	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	73.0
JHU-07633	72	Male	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	72.0
JHU-07639	73	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	73.0
JHU-07643	68	Female	White	PDAC	Primary	Alive	G12R	R175H,M246I,P190L	No	R361C	G12	Yes	68.0
JHU-07646	66	Male	White	PDAC	Primary	Deceased	G12R	S241F	No	No	G12	Yes	66.0
JHU-07647	69	Male	Other	PDAC	Primary	Deceased	G12D	H193R	No	No	G12	Yes	69.0
JHU-07652	66	Male	Black/African-American	PDAC	Primary	Alive	G12R	No	No	No	G12	No	66.0
JHU-07665	68	Female	White	PDAC	Primary	Alive	No	R175H	No	No	No	Yes	68.0
JHU-07666	49	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	49.0
JHU-07678	83	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	83.0
JHU-07679	72	Male	White	PDAC	Primary	Alive	No	I195T	No	No	No	Yes	72.0
JHU-07684	80	Female	White	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	80.0
JHU-07691	69	Male	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	69.0
JHU-07708	50	Female	White	PDAC	Metastasis	Alive	G12D	S241F	No	No	G12	Yes	50.0
JHU-07710	66	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	66.0
JHU-07713	68	Male	White	PDAC	Primary	Alive	G12R	R175H	No	No	G12	Yes	68.0
JHU-07720	60	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	60.0
JHU-07756	63	Male	White	PDAC	Primary	NA	G12V	G245D	No	No	G12	Yes	63.0
JHU-07762	63	Female	White	PDAC	Metastasis	Deceased	Q61R	No	No	No	Q61	No	63.0
JHU-07765	65	Male	White	PDAC	Primary	NA	G12D	H214R	H83R	No	G12	Yes	65.0
JHU-07781	73	Female	White	PDAC	Primary	NA	G12D	No	No	No	G12	No	73.0
JHU-07787	51	Male	Asian	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	51.0
JHU-07811	63	Male	White	PDAC	Metastasis	Alive	G12D	C275Y	No	No	G12	Yes	63.0
JHU-07817	77	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	77.0
JHU-07818	65	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	65.0
JHU-07820	55	Male	Other	PDAC	Primary	Alive	G12V	R110P	No	No	G12	Yes	55.0
JHU-07825	54	Female	White	PDAC	Primary	Alive	G12V	H193R	No	No	G12	Yes	54.0
JHU-07829	47	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	47.0
JHU-07832	83	Male	White	PDAC	Primary	NA	G12D	No	No	No	G12	No	83.0
JHU-07833	>89	Female	Black/African-American	PDAC	Primary	NA	No	No	No	No	No	No	90.0
JHU-07834	NA	Female	White	PDAC	Primary	Alive	G12D	R273C	No	No	G12	Yes	NA
JHU-07845	64	Male	Black/African-American	PDAC	Primary	Alive	G12D	C238F	No	No	G12	Yes	64.0
JHU-07849	60	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	60.0
JHU-07852	47	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	47.0
JHU-07865	61	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	61.0
JHU-07867	77	Female	White	PDAC	Primary	NA	G12D	R175H	No	No	G12	Yes	77.0
JHU-07874	63	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	63.0
JHU-07888	61	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	61.0
JHU-07890	57	Male	White	PDAC	Metastasis	Alive	G12V	P151H	No	No	G12	Yes	57.0
JHU-07891	80	Male	White	PDAC	Primary	Alive	G12D	H179L	H83Y	No	G12	Yes	80.0
JHU-07903	>89	Male	White	PDAC	Metastasis	Alive	G12D	G266R	No	No	G12	Yes	90.0
JHU-07906	70	Male	Black/African-American	Mucinous adenocarcinoma	Primary	Alive	G12D	No	No	No	G12	No	70.0
JHU-07909	80	Male	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	80.0
JHU-07910	72	Male	White	PDAC	Primary	Alive	G12D	H193R	No	R361H	G12	Yes	72.0
JHU-07911	65	Female	White	PDAC	Metastasis	Alive	G12R	G245S	No	R361C	G12	Yes	65.0
JHU-07913	68	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	68.0
JHU-07918	71	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	71.0
JHU-07922	73	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	73.0
JHU-07929	65	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	65.0
JHU-07933	58	Male	Black/African-American	PDAC	Primary	Alive	G12D	No	No	No	G12	No	58.0
JHU-07936	71	Female	Black/African-American	PDAC	Metastasis	Alive	G12D	R273H	No	No	G12	Yes	71.0
JHU-07943	79	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	79.0
JHU-07945	67	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	67.0
JHU-07950	62	Male	White	PDAC	Primary	Alive	G12D	F270C	No	No	G12	Yes	62.0
JHU-07951	70	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	70.0
JHU-07955	80	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	80.0
JHU-07962	52	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	52.0
JHU-07967	75	Female	Asian	PDAC	Primary	Deceased	No	No	No	No	No	No	75.0
JHU-07979	67	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	67.0
JHU-07982	49	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	49.0
JHU-07983	62	Male	Other	PDAC	Primary	Alive	No	R175H	D84N	No	No	Yes	62.0
JHU-07994	NA	Male	Black/African-American	PDAC	Metastasis	Alive	G12D	No	L78F	No	G12	No	NA
JHU-08014	70	Female	White	PDAC	Primary	Alive	Q61R	Y234C	No	No	Q61	Yes	70.0
JHU-08030	69	Female	White	PDAC	Primary	Alive	Q61H	V272M	No	No	Q61	Yes	69.0
JHU-08031	68	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	68.0
JHU-08040	72	Male	Black/African-American	PDAC	Primary	Alive	G12R	No	No	No	G12	No	72.0
JHU-08046	59	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	59.0
JHU-08055	73	Male	White	PDAC	Primary	Alive	G12R	A86T	No	No	G12	Yes	73.0
JHU-08060	68	Male	Black/African-American	PDAC	Primary	Deceased	G12C	No	No	No	G12	No	68.0
JHU-08069	70	Female	White	PDAC	Primary	Alive	G12V	Y220C	No	No	G12	Yes	70.0
JHU-08082	68	Male	White	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	68.0
JHU-08100	79	Male	White	PDAC	Primary	Alive	G12R	S127F	No	No	G12	Yes	79.0
JHU-08110	57	Female	White	PNET	Metastasis	NA	G12V	No	No	G510R	G12	No	57.0
JHU-08117	72	Male	White	PDAC	Primary	Alive	No	I195T	No	No	No	Yes	72.0
JHU-08119	59	Male	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	59.0
JHU-08124	76	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
JHU-08126	78	Male	White	PNET	Metastasis	Alive	G12D	No	No	No	G12	No	78.0
JHU-08133	72	Female	White	PDAC	Metastasis	Alive	G12V	I195T	No	No	G12	Yes	72.0
JHU-08138	77	Male	White	PDAC	Metastasis	Deceased	G12D	P250L	No	No	G12	Yes	77.0
JHU-08149	72	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	72.0
JHU-08152	54	Male	White	PDAC	Primary	Deceased	G12V	G245F	H83Y	No	G12	Yes	54.0
JHU-08157	56	Female	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	56.0
JHU-08186	66	Male	White	PDAC	Primary	Alive	G12C	V173M	No	No	G12	Yes	66.0
JHU-08209	70	Male	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	70.0
JHU-08213	74	Male	White	PDAC	Primary	NA	G12R	No	No	No	G12	No	74.0
JHU-08228	77	Male	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	77.0
JHU-08241	56	Female	Black/African-American	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	56.0
JHU-08254	49	Male	White	PDAC	Primary	Alive	G12D	R273H	No	No	G12	Yes	49.0
JHU-08257	66	Male	White	PDAC	Primary	Alive	No	R273C	No	No	No	Yes	66.0
JHU-08261	59	Female	Other	PDAC	Primary	Alive	G12D	No	No	No	G12	No	59.0
JHU-08264	62	Female	Black/African-American	PNET	Metastasis	NA	No	No	No	No	No	No	62.0
MDA-1103	71	Female	White	PDAC	Metastasis	NA	No	R273C	No	No	No	Yes	71.0
MDA-1112	54	Male	White	PDAC	Metastasis	NA	No	No	No	R361H	No	No	54.0
MDA-1115	65	Male	Asian	PDAC	Metastasis	NA	G12V	No	No	No	G12	No	65.0
MDA-1548	59	Female	White	PDAC	Metastasis	NA	G12D	No	No	No	G12	No	59.0
MDA-1561	82	Male	White	PDAC	Primary	NA	G12D	No	No	No	G12	No	82.0
MDA-1784	43	Male	White	PDAC	Metastasis	NA	G12V	V173L	No	No	G12	Yes	43.0
MDA-1860	70	Female	White	PDAC	Primary	NA	No	No	No	No	No	No	70.0
MDA-1899	60	Male	NA	PDAC	Metastasis	NA	G13D	No	No	No	G13	No	60.0
MDA-1968	49	Male	NA	PDAC	Metastasis	NA	G12D	No	No	No	G12	No	49.0
MDA-2106	61	Female	NA	PDAC	Primary	NA	R41G,G12D	No	No	No	G12\|Other	No	61.0
MDA-2179	49	Male	White	PDAC	Metastasis	NA	No	No	No	No	No	No	49.0
MDA-2202	61	Male	NA	PDAC	Metastasis	NA	G12V	No	No	K385R	G12	No	61.0
MDA-2229	71	Male	White	PDAC	Metastasis	NA	G12V	R273C	No	No	G12	Yes	71.0
MDA-2366	46	Male	NA	PDAC	Primary	NA	G12D	H193Y	No	No	G12	Yes	46.0
MDA-2510	52	Male	White	PDAC	Primary	NA	G12V	No	No	No	G12	No	52.0
MDA-2651	67	Male	White	PDAC	Primary	NA	G12D	No	No	No	G12	No	67.0
MDA-2706	63	Male	NA	PDAC	Primary	NA	G12D	No	No	No	G12	No	63.0
MDA-2960	66	Female	White	PDAC	Metastasis	NA	No	No	No	No	No	No	66.0
MDA-2964	30	Female	White	PDAC	Metastasis	NA	G12D	No	No	No	G12	No	30.0
MDA-2965	51	Female	White	PDAC	Metastasis	NA	No	No	No	No	No	No	51.0
MDA-2986	68	Female	White	PDAC	Primary	NA	G12V	R273H	No	No	G12	Yes	68.0
MDA-3022	43	Male	White	PDAC	Metastasis	NA	G12V	R273L	No	No	G12	Yes	43.0
MDA-3030	39	Male	White	PDAC	Primary	NA	G12R	Y220C	No	No	G12	Yes	39.0
MDA-3068	52	Male	White	PDAC	Metastasis	NA	No	No	No	G386R	No	No	52.0
MDA-3196	80	Male	White	PDAC	Primary	NA	G12R	No	No	No	G12	No	80.0
MDA-3292	69	Male	White	PDAC	Primary	NA	G12V	No	No	V126G	G12	No	69.0
MDA-3398	67	Female	White	PDAC	Primary	NA	Q61H	No	No	No	Q61	No	67.0
MDA-3564	55	Female	White	PDAC	Metastasis	NA	No	R248Q	No	No	No	Yes	55.0
MDA-3909	64	Male	White	PDAC	Metastasis	NA	G12D	V218A	No	No	G12	Yes	64.0
MDA-4469	58	Male	White	PDAC	Primary	NA	G12V	No	No	No	G12	No	58.0
MDA-4473	65	Female	Black/African-American	PDAC	Metastasis	NA	Q61H,N116S	G245S	No	No	Q61\|Other	Yes	65.0
MDA-4670	51	Male	White	PNET	Metastasis	NA	No	No	No	No	No	No	51.0
MDA-4699	57	Female	Black/African-American	PDAC	Metastasis	NA	G12V	No	No	No	G12	No	57.0
MDA-4836	65	Male	NA	PDAC	Primary	NA	G12D	No	No	No	G12	No	65.0
MDA-4902	37	Female	Asian	Solid pseudopapillary tumor	Primary	NA	No	No	No	No	No	No	37.0
MDA-4959	50	Male	NA	PDAC	Metastasis	NA	G12D	R175H	No	No	G12	Yes	50.0
MDA-4987	60	Female	White	PDAC	Metastasis	NA	G12D	V172D	No	No	G12	Yes	60.0
MDA-5018	78	Male	White	PDAC	Metastasis	NA	G12D	R282W	No	No	G12	Yes	78.0
MDA-5022	64	Male	White	PDAC	Primary	NA	G12D	L111P	No	No	G12	Yes	64.0
MDA-5058	58	Male	White	PDAC	Primary	NA	G12V	F270I	No	No	G12	Yes	58.0
MDA-5107	57	Female	White	PDAC	Primary	NA	G12V	R175H	No	No	G12	Yes	57.0
MDA-5110	60	Male	NA	PDAC	Metastasis	NA	G12D	No	No	No	G12	No	60.0
MDA-5182	48	Male	NA	PDAC	Metastasis	NA	G12V	G245S	No	No	G12	Yes	48.0
MDA-5300	17	Female	White	PDAC	Primary	NA	G12D	E271V	No	No	G12	Yes	17.0
MDA-55571	49	Female	White	PDAC	Metastasis	NA	No	No	No	No	No	No	49.0
MDA-5741	43	Female	White	PDAC	Metastasis	NA	G12D	No	H83Y	No	G12	No	43.0
MDA-5886	72	Male	NA	PDAC	Primary	NA	G12D	R282W	No	No	G12	Yes	72.0
MDA-5904	63	Male	White	PDAC	Metastasis	NA	G12R	No	No	No	G12	No	63.0
MDA-5915	48	Female	White	PDAC	Primary	NA	G12V	R273H	No	R361C	G12	Yes	48.0
MDA-5933	74	Female	White	PDAC	Metastasis	NA	G12R	No	No	No	G12	No	74.0
MDA-6031	56	Female	White	PDAC	Primary	NA	No	No	No	No	No	No	56.0
MDA-6110	43	Female	White	PDAC	Metastasis	NA	G12R	R248W	No	No	G12	Yes	43.0
MDA-6124	52	Female	NA	PDAC	Metastasis	NA	No	No	No	No	No	No	52.0
MDA-6149	55	Female	White	PDAC	Metastasis	NA	No	No	No	No	No	No	55.0
MDA-6230	64	Female	Black/African-American	PDAC	Primary	NA	G12V	No	No	No	G12	No	64.0
MDA-6706	33	Male	White	PDAC	Metastasis	NA	No	No	No	No	No	No	33.0
MDA-671	53	Female	White	PDAC	Metastasis	NA	G12D	No	No	No	G12	No	53.0
MDA-6725	56	Male	White	PDAC	Metastasis	NA	G12D	H179R	No	No	G12	Yes	56.0
MDA-8264	70	Male	White	PDAC	Metastasis	NA	G12R	No	No	No	G12	No	70.0
MDA-8282	56	Female	White	PDAC	Primary	NA	G12D	No	No	No	G12	No	56.0
MDA-8288	62	Male	White	PDAC	Metastasis	NA	G12R	V197M	No	No	G12	Yes	62.0
MDA-950	51	Male	White	PDAC	Metastasis	NA	Q61H	No	No	No	Q61	No	51.0
MSK-P-0000142	55	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	55.0
MSK-P-0000314	44	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	44.0
MSK-P-0000421	67	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	67.0
MSK-P-0000783	64	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	64.0
MSK-P-0000879	39	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	39.0
MSK-P-0001138	34	Female	Asian	PNET	Metastasis	Alive	No	No	No	No	No	No	34.0
MSK-P-0001304	62	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	62.0
MSK-P-0001313	73	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	73.0
MSK-P-0001509	58	Female	Black/African-American	PNET	Primary	Alive	No	No	No	No	No	No	58.0
MSK-P-0001518	58	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	58.0
MSK-P-0001526	55	Male	Asian	PNET	Primary	Deceased	No	No	No	No	No	No	55.0
MSK-P-0001548	68	Female	Asian	PDAC	Metastasis	Deceased	G12V	R280G	No	No	G12	Yes	68.0
MSK-P-0001776	64	Male	White	PDAC	Metastasis	Deceased	G12R	G245S	No	No	G12	Yes	64.0
MSK-P-0001886	67	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	67.0
MSK-P-0001943	54	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	54.0
MSK-P-0001993	43	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	43.0
MSK-P-0002021	43	Female	White	PDAC	Primary	Alive	No	R273C	No	No	No	Yes	43.0
MSK-P-0002071	44	Female	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	44.0
MSK-P-0002103	28	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	28.0
MSK-P-0002167	60	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	60.0
MSK-P-0002197	52	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	52.0
MSK-P-0002202	72	Female	White	PNET	Metastasis	Alive	No	No	No	D537V	No	No	72.0
MSK-P-0002230	76	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	76.0
MSK-P-0002253	77	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	77.0
MSK-P-0002290	56	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	56.0
MSK-P-0002369	51	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	51.0
MSK-P-0002391	73	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	73.0
MSK-P-0002419	64	Male	White	PDAC	Metastasis	Deceased	G12D	V216M	No	No	G12	Yes	64.0
MSK-P-0002433	51	Male	White	PDAC	Metastasis	Deceased	G12V	R248W	No	M447K	G12	Yes	51.0
MSK-P-0002441	63	Female	White	PDAC	Primary	Deceased	G12V	R248W	No	No	G12	Yes	63.0
MSK-P-0002458	56	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0002597	72	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	72.0
MSK-P-0002619	48	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	48.0
MSK-P-0002704	76	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	76.0
MSK-P-0002772	60	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	60.0
MSK-P-0002830	72	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	72.0
MSK-P-0002839	56	Female	White	PNET	Primary	Alive	No	R248Q	No	No	No	Yes	56.0
MSK-P-0002907	71	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	71.0
MSK-P-0002908	64	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	64.0
MSK-P-0002985	64	Female	NA	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	64.0
MSK-P-0003006	40	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	40.0
MSK-P-0003008	52	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	52.0
MSK-P-0003145	56	Female	White	PDAC	Primary	Alive	Q61R	No	No	No	Q61	No	56.0
MSK-P-0003259	67	Female	White	PDAC	Metastasis	Deceased	Q61H	R248W	No	No	Q61	Yes	67.0
MSK-P-0003346	76	Male	White	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	76.0
MSK-P-0003412	46	Female	NA	PDAC	Primary	Alive	G12D	E224D	No	No	G12	Yes	46.0
MSK-P-0003455	65	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	65.0
MSK-P-0003540	63	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
MSK-P-0003558	68	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0003864	63	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	63.0
MSK-P-0003870	71	Male	White	PDAC	Metastasis	Deceased	G12V	Q136E	No	R420C	G12	Yes	71.0
MSK-P-0003902	68	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	68.0
MSK-P-0003926	46	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	46.0
MSK-P-0004026	44	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	44.0
MSK-P-0004069	72	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	72.0
MSK-P-0004141	50	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	50.0
MSK-P-0004185	71	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	71.0
MSK-P-0004206	36	Female	White	PDAC	Metastasis	Deceased	G12D	L348W	No	No	G12	Yes	36.0
MSK-P-0004219	60	Female	White	PDAC	Primary	Deceased	G13D	No	No	D537Y	G13	No	60.0
MSK-P-0004223	52	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	52.0
MSK-P-0004227	80	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	80.0
MSK-P-0004307	58	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	58.0
MSK-P-0004364	55	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	55.0
MSK-P-0004387	85	Male	White	PDAC	Primary	Deceased	G12D	P152L	No	No	G12	Yes	85.0
MSK-P-0004399	59	Male	Asian	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	59.0
MSK-P-0004451	42	Female	NA	Acinar cell carcinoma	Primary	Alive	G12V	No	No	No	G12	No	42.0
MSK-P-0004460	68	Female	White	PDAC	Primary	Deceased	G12D	Y234N	No	No	G12	Yes	68.0
MSK-P-0004571	68	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	68.0
MSK-P-0004595	52	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	52.0
MSK-P-0004644	28	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	28.0
MSK-P-0004701	59	Female	Black/African-American	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	59.0
MSK-P-0004727	63	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	63.0
MSK-P-0004737	39	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	39.0
MSK-P-0004789	52	Female	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	52.0
MSK-P-0004796	60	Male	White	PDAC	Primary	Deceased	G12D	Y236D	No	G386D	G12	Yes	60.0
MSK-P-0004801	59	Female	White	PDAC	Primary	Alive	G12V	R280G	No	No	G12	Yes	59.0
MSK-P-0004806	56	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0004810	68	Female	Black/African-American	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	68.0
MSK-P-0004811	77	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	77.0
MSK-P-0004839	60	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	60.0
MSK-P-0004856	40	Male	White	PDAC	Metastasis	Deceased	Q61H	E258D	No	No	Q61	Yes	40.0
MSK-P-0004864	64	Male	White	PDAC	Primary	Deceased	G12D	P278H	No	No	G12	Yes	64.0
MSK-P-0004866	63	Female	White	PDAC	Primary	Deceased	G12R	Q375K	No	R361H	G12	Yes	63.0
MSK-P-0004874	75	Male	White	PDAC	Primary	Deceased	No	No	No	R361H	No	No	75.0
MSK-P-0004895	71	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	71.0
MSK-P-0004905	48	Male	Black/African-American	Adenosquamous carcinoma	Primary	Deceased	G12D	No	No	No	G12	No	48.0
MSK-P-0004906	60	Male	White	PDAC	Metastasis	Deceased	G12V	C238Y	No	No	G12	Yes	60.0
MSK-P-0004919	63	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	63.0
MSK-P-0004923	72	Female	White	PDAC	Primary	Deceased	G12R	I195T	No	No	G12	Yes	72.0
MSK-P-0004944	67	Female	White	PDAC	Metastasis	Deceased	G12D	C176F	No	No	G12	Yes	67.0
MSK-P-0004956	65	Male	Asian	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	65.0
MSK-P-0004970	76	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	76.0
MSK-P-0004972	72	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	72.0
MSK-P-0004985	64	Female	White	PDAC	Primary	Alive	G12V	Y236C	No	No	G12	Yes	64.0
MSK-P-0005035	52	Male	White	PDAC	Metastasis	Deceased	G12D	H179Y	No	No	G12	Yes	52.0
MSK-P-0005041	72	Male	White	PDAC	Primary	Alive	Q61H	S215I	No	No	Q61	Yes	72.0
MSK-P-0005043	79	Male	White	PDAC	Primary	Deceased	G12V	I195T	No	No	G12	Yes	79.0
MSK-P-0005075	73	Male	NA	PDAC	Metastasis	Alive	G12D	H179D	No	No	G12	Yes	73.0
MSK-P-0005084	38	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	38.0
MSK-P-0005130	<18	Male	White	Acinar cell carcinoma	Primary	Deceased	No	No	No	G386R	No	No	17.0
MSK-P-0005142	56	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0005185	60	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0005211	54	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	54.0
MSK-P-0005250	68	Male	White	PDAC	Metastasis	Alive	G12D	R273H	No	N129S	G12	Yes	68.0
MSK-P-0005257	58	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	58.0
MSK-P-0005275	54	Female	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	54.0
MSK-P-0005288	55	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	55.0
MSK-P-0005335	64	Female	NA	PDAC	Metastasis	Deceased	G12V	K132N	No	No	G12	Yes	64.0
MSK-P-0005349	64	Female	Other	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0005378	62	Female	Black/African-American	PDAC	Primary	Deceased	No	L130F	No	No	No	Yes	62.0
MSK-P-0005390	76	Male	White	PDAC	Primary	Deceased	G12D	Y234N	No	No	G12	Yes	76.0
MSK-P-0005391	43	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	43.0
MSK-P-0005434	76	Female	White	PNET	Metastasis	Deceased	No	H179Y	No	No	No	Yes	76.0
MSK-P-0005448	69	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12D	No	No	No	G12	No	69.0
MSK-P-0005468	51	Male	White	PDAC	Primary	Alive	G12V	Y205F	No	No	G12	Yes	51.0
MSK-P-0005479	84	Female	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	84.0
MSK-P-0005518	72	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	P190T	No	No	G12	Yes	72.0
MSK-P-0005519	52	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	52.0
MSK-P-0005558	63	Female	White	PDAC	Primary	Deceased	G12V	Y220H	No	No	G12	Yes	63.0
MSK-P-0005563	80	Male	Asian	PDAC	Metastasis	Deceased	G12V	Y220C	No	No	G12	Yes	80.0
MSK-P-0005568	65	Female	White	PDAC	Primary	Deceased	G12R	A161D	No	No	G12	Yes	65.0
MSK-P-0005575	54	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	54.0
MSK-P-0005642	69	Male	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	69.0
MSK-P-0005652	56	Male	White	PDAC	Metastasis	Deceased	G12D	P278S	No	No	G12	Yes	56.0
MSK-P-0005662	76	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	76.0
MSK-P-0005708	58	Male	White	PDAC	Primary	Deceased	G12D	I195T	No	No	G12	Yes	58.0
MSK-P-0005720	76	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0005741	75	Male	White	PDAC	Metastasis	Deceased	G12D	V173L	No	No	G12	Yes	75.0
MSK-P-0005758	56	Female	White	PDAC	Metastasis	Deceased	G12R	R175H	No	L57S	G12	Yes	56.0
MSK-P-0005793	68	Female	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	68.0
MSK-P-0005807	76	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0005815	68	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0005821	38	Male	Asian	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	38.0
MSK-P-0005836	40	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	40.0
MSK-P-0005922	39	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	39.0
MSK-P-0005937	72	Female	White	PDAC	Primary	Deceased	G12C	R248W	No	No	G12	Yes	72.0
MSK-P-0005980	67	Female	White	PNET	Metastasis	Alive	Q61H	No	No	No	Q61	No	67.0
MSK-P-0005997	59	Male	White	PDAC	Metastasis	Deceased	G12D	R248W	No	No	G12	Yes	59.0
MSK-P-0006009	59	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	59.0
MSK-P-0006013	60	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	60.0
MSK-P-0006018	81	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	81.0
MSK-P-0006027	48	Female	White	PDAC	Primary	Alive	G12D	V272L	No	G386V	G12	Yes	48.0
MSK-P-0006038	69	Male	White	PDAC	Primary	Deceased	G12D	R273H	No	G491V	G12	Yes	69.0
MSK-P-0006056	67	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	67.0
MSK-P-0006066	52	Female	White	PDAC	Primary	Deceased	G12V	L130V	No	G508V	G12	Yes	52.0
MSK-P-0006072	77	Female	White	PDAC	Primary	Deceased	G12D	H193R	No	No	G12	Yes	77.0
MSK-P-0006073	73	Male	White	PDAC	Primary	Deceased	G12C,G12D	R248W	No	No	G12	Yes	73.0
MSK-P-0006106	71	Male	White	PDAC	Primary	Deceased	G12V	R249S	No	No	G12	Yes	71.0
MSK-P-0006125	72	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0006141	76	Female	White	Adenosquamous carcinoma	Primary	Deceased	G12V	L194R	No	No	G12	Yes	76.0
MSK-P-0006143	75	Female	NA	PDAC	Primary	Deceased	G12V	M237I	H83Y	No	G12	Yes	75.0
MSK-P-0006144	65	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12V	Y205F	No	No	G12	Yes	65.0
MSK-P-0006147	64	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	64.0
MSK-P-0006165	71	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0006188	84	Female	White	Adenosquamous carcinoma	Primary	Deceased	No	No	No	No	No	No	84.0
MSK-P-0006236	79	Female	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	79.0
MSK-P-0006260	64	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	R361S	G12	No	64.0
MSK-P-0006266	55	Female	White	PDAC	Metastasis	Deceased	G12V	K132M	No	No	G12	Yes	55.0
MSK-P-0006322	67	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	67.0
MSK-P-0006326	75	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	75.0
MSK-P-0006332	60	Female	White	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	60.0
MSK-P-0006337	68	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0006358	56	Male	NA	PDAC	Primary	Deceased	No	No	No	No	No	No	56.0
MSK-P-0006362	72	Female	White	PDAC	Primary	Deceased	Q61R	No	No	No	Q61	No	72.0
MSK-P-0006371	59	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	59.0
MSK-P-0006374	56	Male	NA	PDAC	Primary	Deceased	Q61A	No	No	No	Q61	No	56.0
MSK-P-0006382	50	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	50.0
MSK-P-0006398	55	Female	White	PDAC	Primary	Alive	G12R	R282W	No	No	G12	Yes	55.0
MSK-P-0006399	72	Male	White	PDAC	Primary	Deceased	G12V	G266E	No	No	G12	Yes	72.0
MSK-P-0006401	29	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	29.0
MSK-P-0006409	64	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	64.0
MSK-P-0006412	69	Female	NA	PDAC	Metastasis	Deceased	No	V272L	No	No	No	Yes	69.0
MSK-P-0006417	71	Female	Asian	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0006433	77	Male	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	77.0
MSK-P-0006451	28	Female	Asian	PNET	Metastasis	Deceased	No	No	No	No	No	No	28.0
MSK-P-0006494	48	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	48.0
MSK-P-0006502	80	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	80.0
MSK-P-0006505	46	Male	White	Solid pseudopapillary tumor	Metastasis	Deceased	No	No	No	No	No	No	46.0
MSK-P-0006523	65	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	65.0
MSK-P-0006526	40	Male	White	PDAC	Metastasis	Alive	G13D	No	No	No	G13	No	40.0
MSK-P-0006562	56	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0006580	65	Male	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	65.0
MSK-P-0006593	60	Male	NA	PDAC	Primary	Deceased	G12V	R282W	No	No	G12	Yes	60.0
MSK-P-0006613	76	Male	NA	PDAC	Metastasis	Alive	Q61H	No	No	No	Q61	No	76.0
MSK-P-0006617	79	Male	White	PDAC	Metastasis	Deceased	G12V	G266R	No	No	G12	Yes	79.0
MSK-P-0006618	67	Female	White	PDAC	Primary	Deceased	G12R	P151S	No	No	G12	Yes	67.0
MSK-P-0006623	56	Female	White	PDAC	Metastasis	Deceased	G12V	R248W	No	No	G12	Yes	56.0
MSK-P-0006626	80	Female	White	PDAC	Primary	Deceased	G12V	H193L	No	No	G12	Yes	80.0
MSK-P-0006644	68	Male	White	PDAC	Metastasis	Deceased	No	R248W	No	No	No	Yes	68.0
MSK-P-0006661	68	Male	White	PDAC	Metastasis	Deceased	G12C	E258K	H83Y,P48L	No	G12	Yes	68.0
MSK-P-0006691	64	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	64.0
MSK-P-0006702	72	Female	White	PDAC	Metastasis	Deceased	G12V	Y220N	No	No	G12	Yes	72.0
MSK-P-0006709	72	Male	White	PDAC	Metastasis	Deceased	G12D	R282W	No	No	G12	Yes	72.0
MSK-P-0006710	51	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	51.0
MSK-P-0006716	72	Male	NA	PDAC	Primary	Deceased	G12C	No	No	K159N	G12	No	72.0
MSK-P-0006734	59	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	59.0
MSK-P-0006760	73	Male	White	PDAC	Primary	Deceased	G12D	L344Q	No	No	G12	Yes	73.0
MSK-P-0006790	62	Male	White	PDAC	Primary	Deceased	G13V	No	No	No	G13	No	62.0
MSK-P-0006798	79	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	79.0
MSK-P-0006828	81	Male	White	PDAC	Metastasis	Deceased	G12V	C238Y	No	No	G12	Yes	81.0
MSK-P-0006862	52	Female	White	PDAC	Metastasis	Deceased	Q61R	Y163C	No	No	Q61	Yes	52.0
MSK-P-0006881	73	Male	NA	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	73.0
MSK-P-0006907	83	Female	White	PDAC	Primary	Deceased	G12V	F134L	No	No	G12	Yes	83.0
MSK-P-0006930	85	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	85.0
MSK-P-0006940	73	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	73.0
MSK-P-0006953	48	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	48.0
MSK-P-0006987	68	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	68.0
MSK-P-0007022	30	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	30.0
MSK-P-0007046	71	Male	White	Acinar cell carcinoma	Primary	Alive	No	No	No	L533I	No	No	71.0
MSK-P-0007047	50	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	50.0
MSK-P-0007060	56	Male	White	PDAC	Metastasis	Deceased	G12D	E286K	No	No	G12	Yes	56.0
MSK-P-0007062	51	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	51.0
MSK-P-0007063	69	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	69.0
MSK-P-0007065	42	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	42.0
MSK-P-0007075	35	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	35.0
MSK-P-0007076	68	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	68.0
MSK-P-0007113	58	Male	White	PDAC	Metastasis	Deceased	G12R	I251F	No	No	G12	Yes	58.0
MSK-P-0007122	58	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	58.0
MSK-P-0007165	79	Male	White	PDAC	Primary	Deceased	G12R	P151T	No	No	G12	Yes	79.0
MSK-P-0007179	63	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	63.0
MSK-P-0007202	62	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	62.0
MSK-P-0007215	36	Male	White	PDAC	Metastasis	Alive	G12D	M237I	No	No	G12	Yes	36.0
MSK-P-0007241	67	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	67.0
MSK-P-0007276	52	Male	White	PDAC	Primary	Alive	G12R	R175H	No	No	G12	Yes	52.0
MSK-P-0007300	56	Female	White	Mucinous adenocarcinoma	Primary	Deceased	G12V	No	No	R361H	G12	No	56.0
MSK-P-0007302	79	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	79.0
MSK-P-0007330	56	Female	White	PDAC	Primary	Deceased	G12C	No	No	No	G12	No	56.0
MSK-P-0007333	73	Female	White	PDAC	Primary	Deceased	G12D	L194R	No	No	G12	Yes	73.0
MSK-P-0007336	42	Male	White	PDAC	Primary	Deceased	G12D	Y234C	No	No	G12	Yes	42.0
MSK-P-0007338	62	Female	White	PDAC	Primary	Alive	G12D	C238F	No	No	G12	Yes	62.0
MSK-P-0007355	68	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	68.0
MSK-P-0007408	79	Female	Asian	PDAC	Primary	Alive	G12D	No	No	No	G12	No	79.0
MSK-P-0007494	72	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	72.0
MSK-P-0007502	65	Male	White	PDAC	Primary	Deceased	G12V	M246T	No	No	G12	Yes	65.0
MSK-P-0007521	40	Female	White	PDAC	Primary	Deceased	G12V	H179Y	No	No	G12	Yes	40.0
MSK-P-0007565	46	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	46.0
MSK-P-0007604	32	Male	NA	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	32.0
MSK-P-0007607	72	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0007624	60	Male	White	PDAC	Metastasis	Deceased	G12R	C238Y	No	No	G12	Yes	60.0
MSK-P-0007635	72	Female	White	PDAC	Primary	Deceased	G12D	V272M	No	No	G12	Yes	72.0
MSK-P-0007670	63	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
MSK-P-0007678	75	Female	White	PDAC	Primary	Deceased	G12V	G245D	No	No	G12	Yes	75.0
MSK-P-0007791	84	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	84.0
MSK-P-0007838	79	Male	White	PDAC	Metastasis	Deceased	G12V	V157F	No	No	G12	Yes	79.0
MSK-P-0007865	54	Female	White	PDAC	Metastasis	Deceased	G12D	R248W	No	V126A	G12	Yes	54.0
MSK-P-0007894	56	Female	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	56.0
MSK-P-0007898	72	Female	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	72.0
MSK-P-0007906	55	Male	White	PDAC	Metastasis	Deceased	G12D	V173G	No	No	G12	Yes	55.0
MSK-P-0007972	72	Female	NA	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0008013	76	Male	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	76.0
MSK-P-0008014	67	Male	White	PDAC	Primary	Deceased	Q61H	A161_I162delinsPS	No	D537G	Q61	Yes	67.0
MSK-P-0008021	58	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	58.0
MSK-P-0008041	69	Female	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	69.0
MSK-P-0008043	64	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	64.0
MSK-P-0008056	73	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	73.0
MSK-P-0008099	71	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	71.0
MSK-P-0008136	65	Female	White	PDAC	Primary	Deceased	G12D	No	No	A118V	G12	No	65.0
MSK-P-0008140	46	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	46.0
MSK-P-0008154	59	Female	White	PDAC	Primary	Alive	G12V	P152L	No	No	G12	Yes	59.0
MSK-P-0008157	40	Male	White	PDAC	Metastasis	Deceased	G12D	R249M	No	No	G12	Yes	40.0
MSK-P-0008162	55	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	55.0
MSK-P-0008164	48	Male	White	PDAC	Metastasis	Deceased	G12R	R175H	No	No	G12	Yes	48.0
MSK-P-0008165	68	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0008172	52	Female	White	PDAC	Primary	Deceased	G12V	R273H	No	No	G12	Yes	52.0
MSK-P-0008175	64	Male	White	PDAC	Primary	Deceased	G12R	R175H	No	No	G12	Yes	64.0
MSK-P-0008181	48	Female	White	PDAC	Primary	Alive	G12L	I254S	No	No	G12	Yes	48.0
MSK-P-0008224	59	Male	White	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	59.0
MSK-P-0008243	75	Male	White	PDAC	Primary	Deceased	Q61H	S241Y	H83Y	No	Q61	Yes	75.0
MSK-P-0008245	77	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	77.0
MSK-P-0008260	34	Female	NA	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	34.0
MSK-P-0008370	76	Female	White	Carcinoma, NOS	Primary	Deceased	G12A	No	No	No	G12	No	76.0
MSK-P-0008371	46	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	46.0
MSK-P-0008372	62	Female	White	Solid pseudopapillary tumor	Primary	Alive	No	No	No	No	No	No	62.0
MSK-P-0008374	67	Female	White	PDAC	Primary	Deceased	Q61H	I195F	No	No	Q61	Yes	67.0
MSK-P-0008405	68	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0008430	55	Female	White	PDAC	Primary	Deceased	No	F270V	No	No	No	Yes	55.0
MSK-P-0008436	60	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	60.0
MSK-P-0008458	72	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	72.0
MSK-P-0008464	69	Female	White	PDAC	Primary	Deceased	G12V,G12R	No	No	No	G12	No	69.0
MSK-P-0008527	48	Male	White	PDAC	Primary	Deceased	G12D	R248W	No	No	G12	Yes	48.0
MSK-P-0008552	60	Female	White	PNET	Metastasis	Deceased	No	L257R	No	No	No	Yes	60.0
MSK-P-0008644	68	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	68.0
MSK-P-0008673	62	Female	Black/African-American	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	62.0
MSK-P-0008674	72	Male	White	PDAC	Primary	Deceased	Q61R	S241C	No	R361C	Q61	Yes	72.0
MSK-P-0008706	43	Male	White	PDAC	Primary	Alive	G12R	R273H	No	No	G12	Yes	43.0
MSK-P-0008707	58	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	58.0
MSK-P-0008719	69	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	69.0
MSK-P-0008736	52	Female	White	PDAC	Metastasis	Deceased	G12R	Y220C	No	No	G12	Yes	52.0
MSK-P-0008748	64	Female	White	Carcinoma, NOS	Primary	Deceased	G12R	E286Q	No	No	G12	Yes	64.0
MSK-P-0008754	56	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	R361H	G12	No	56.0
MSK-P-0008761	73	Male	White	PDAC	Metastasis	Deceased	Q61R	G245S	No	No	Q61	Yes	73.0
MSK-P-0008780	64	Male	White	PDAC	Primary	Deceased	G12D	No	H83Y	No	G12	No	64.0
MSK-P-0008790	60	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0008799	36	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	36.0
MSK-P-0008818	68	Male	White	PDAC	Primary	Deceased	G12D	C135Y	No	No	G12	Yes	68.0
MSK-P-0008838	76	Female	White	PDAC	Primary	Alive	G12V	No	P81R	No	G12	No	76.0
MSK-P-0008862	55	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	55.0
MSK-P-0008872	58	Female	NA	Serous cystadenoma	Primary	Alive	No	No	No	No	No	No	58.0
MSK-P-0008906	44	Female	White	PDAC	Primary	Deceased	G12C	P278A	No	A118V	G12	Yes	44.0
MSK-P-0008909	52	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	52.0
MSK-P-0008911	72	Female	NA	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	72.0
MSK-P-0008919	72	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0008950	65	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	65.0
MSK-P-0008953	65	Male	White	PDAC	Metastasis	Deceased	G12V	C176G	No	No	G12	Yes	65.0
MSK-P-0008967	55	Female	White	PDAC	Primary	Alive	G12D	No	No	R361C	G12	No	55.0
MSK-P-0009045	80	Female	White	PDAC	Metastasis	Deceased	G12D	R282W	No	No	G12	Yes	80.0
MSK-P-0009047	65	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	65.0
MSK-P-0009063	68	Male	White	PDAC	Primary	Deceased	G12R	R282W	No	No	G12	Yes	68.0
MSK-P-0009091	73	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	73.0
MSK-P-0009093	80	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	80.0
MSK-P-0009098	67	Female	White	PDAC	Primary	Deceased	G12D	R248W	No	No	G12	Yes	67.0
MSK-P-0009109	68	Male	NA	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0009111	72	Male	White	PDAC	Primary	Deceased	Q61H	K132R	No	R496H	Q61	Yes	72.0
MSK-P-0009117	76	Male	White	PDAC	Primary	Deceased	G12R	R175H	No	No	G12	Yes	76.0
MSK-P-0009141	48	Female	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	48.0
MSK-P-0009146	60	Male	White	PDAC	Metastasis	Alive	G12R	R282W	No	No	G12	Yes	60.0
MSK-P-0009153	60	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	60.0
MSK-P-0009186	55	Female	NA	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	55.0
MSK-P-0009203	56	Male	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	56.0
MSK-P-0009225	40	Female	White	Mucinous adenocarcinoma	Primary	Deceased	G12D	No	No	No	G12	No	40.0
MSK-P-0009228	56	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	56.0
MSK-P-0009242	47	Female	Black/African-American	Solid pseudopapillary tumor	Primary	Alive	No	No	No	No	No	No	47.0
MSK-P-0009251	60	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	60.0
MSK-P-0009254	63	Male	White	PDAC	Primary	Deceased	G12D	R175H	H83Y	No	G12	Yes	63.0
MSK-P-0009268	58	Female	Black/African-American	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	58.0
MSK-P-0009270	52	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	52.0
MSK-P-0009271	50	Male	Asian	PDAC	Metastasis	Deceased	Q61K	No	No	No	Q61	No	50.0
MSK-P-0009288	65	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	65.0
MSK-P-0009299	48	Male	White	PDAC	Primary	Deceased	G12D	No	No	R81G	G12	No	48.0
MSK-P-0009310	71	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0009335	55	Female	White	PDAC	Metastasis	Alive	G12V	H193R	No	No	G12	Yes	55.0
MSK-P-0009351	79	Female	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	79.0
MSK-P-0009354	71	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	71.0
MSK-P-0009395	60	Male	White	PDAC	Primary	Alive	G12V	H214R	No	No	G12	Yes	60.0
MSK-P-0009396	55	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	55.0
MSK-P-0009404	>89	Female	White	PDAC	Primary	Deceased	G12R	G245V	H83Y	No	G12	Yes	90.0
MSK-P-0009413	51	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	51.0
MSK-P-0009421	72	Female	White	Adenosquamous carcinoma	Primary	Deceased	Q61H	No	No	No	Q61	No	72.0
MSK-P-0009425	60	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	60.0
MSK-P-0009443	67	Female	White	PDAC	Metastasis	Deceased	Q61R	No	No	No	Q61	No	67.0
MSK-P-0009446	81	Male	White	PDAC	Primary	Deceased	G12D	R248Q	No	No	G12	Yes	81.0
MSK-P-0009465	62	Male	White	PDAC	Primary	Deceased	Q61H	S215R	No	No	Q61	Yes	62.0
MSK-P-0009492	75	Female	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	75.0
MSK-P-0009515	64	Female	White	PNET	Primary	Deceased	G12R	R248W	No	No	G12	Yes	64.0
MSK-P-0009530	59	Male	White	PDAC	Metastasis	Alive	G12D	N131I	No	No	G12	Yes	59.0
MSK-P-0009597	56	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	56.0
MSK-P-0009609	64	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0009619	59	Female	White	PDAC	Primary	Deceased	No	C141Y	No	No	No	Yes	59.0
MSK-P-0009635	<18	Female	NA	Pancreatoblastoma	Primary	Alive	No	No	No	No	No	No	17.0
MSK-P-0009647	55	Male	Black/African-American	PDAC	Metastasis	Deceased	G12V	C176Y	No	V426F	G12	Yes	55.0
MSK-P-0009758	50	Female	White	PDAC	Primary	Alive	G12D	G245V	No	No	G12	Yes	50.0
MSK-P-0009765	65	Male	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	65.0
MSK-P-0009793	58	Female	White	PDAC	Primary	Alive	G12V	D259Y	No	No	G12	Yes	58.0
MSK-P-0009813	50	Male	White	PDAC	Primary	Alive	Q61H	R175H	No	No	Q61	Yes	50.0
MSK-P-0009827	58	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	58.0
MSK-P-0009836	72	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0009845	62	Female	White	PDAC	Metastasis	Deceased	Q61R	No	No	No	Q61	No	62.0
MSK-P-0009848	80	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	80.0
MSK-P-0009854	72	Male	White	PDAC	Primary	Deceased	Q61R	No	No	No	Q61	No	72.0
MSK-P-0009858	67	Male	Asian	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	67.0
MSK-P-0009860	68	Male	White	PDAC	Primary	Deceased	G12V	K132R	No	D351N	G12	Yes	68.0
MSK-P-0009870	65	Male	White	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	65.0
MSK-P-0009909	42	Female	White	Adenosquamous carcinoma	Primary	Deceased	G12V	No	No	No	G12	No	42.0
MSK-P-0009911	64	Female	NA	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0009943	60	Male	White	PDAC	Primary	Deceased	Q61R	No	No	No	Q61	No	60.0
MSK-P-0009953	60	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	60.0
MSK-P-0009965	77	Female	White	PDAC	Primary	Deceased	G12V	G245V	No	No	G12	Yes	77.0
MSK-P-0009974	68	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	68.0
MSK-P-0009981	64	Male	White	PDAC	Metastasis	Deceased	G12R	P152R	No	No	G12	Yes	64.0
MSK-P-0010000	50	Male	White	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	50.0
MSK-P-0010012	85	Male	White	IPMN	Primary	Deceased	G12D	No	No	No	G12	No	85.0
MSK-P-0010067	67	Male	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	67.0
MSK-P-0010086	63	Female	Black/African-American	PDAC	Metastasis	Deceased	No	No	No	No	No	No	63.0
MSK-P-0010090	50	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	50.0
MSK-P-0010091	75	Female	White	PDAC	Primary	Deceased	G12D	Y234C	No	No	G12	Yes	75.0
MSK-P-0010092	46	Male	NA	PDAC	Metastasis	Deceased	No	No	No	No	No	No	46.0
MSK-P-0010093	73	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	73.0
MSK-P-0010105	44	Female	White	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	44.0
MSK-P-0010132	56	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0010135	55	Female	White	Adenosquamous carcinoma	Primary	Deceased	G12D	T155P,R156L	No	No	G12	Yes	55.0
MSK-P-0010162	60	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	60.0
MSK-P-0010163	69	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	69.0
MSK-P-0010166	72	Male	White	PDAC	Metastasis	Deceased	G12V	H193R	No	W101C	G12	Yes	72.0
MSK-P-0010176	59	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	59.0
MSK-P-0010195	>89	Female	White	PDAC	Primary	Deceased	G12D	S241P	No	No	G12	Yes	90.0
MSK-P-0010208	68	Female	White	PDAC	Primary	Deceased	G12D	R248W	No	No	G12	Yes	68.0
MSK-P-0010223	73	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	73.0
MSK-P-0010228	64	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	64.0
MSK-P-0010229	NA	NA	NA	IPMN	Primary	NA	G12C	No	No	No	G12	No	NA
MSK-P-0010246	64	Male	White	PDAC	Primary	Deceased	G12V	R273H	No	No	G12	Yes	64.0
MSK-P-0010255	72	Female	White	PDAC	Metastasis	Deceased	G12D	I195T	No	No	G12	Yes	72.0
MSK-P-0010262	48	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	48.0
MSK-P-0010264	72	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	72.0
MSK-P-0010274	65	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	65.0
MSK-P-0010298	55	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	55.0
MSK-P-0010303	44	Male	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	44.0
MSK-P-0010372	48	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	H179R	No	No	G12	Yes	48.0
MSK-P-0010373	60	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0010383	68	Male	Asian	PDAC	Metastasis	Deceased	G12V	I251F	No	S150I	G12	Yes	68.0
MSK-P-0010387	71	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0010394	62	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	62.0
MSK-P-0010445	54	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	54.0
MSK-P-0010452	55	Male	White	PDAC	Primary	Deceased	G12V	V274D	No	No	G12	Yes	55.0
MSK-P-0010490	69	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	69.0
MSK-P-0010494	68	Male	White	Acinar cell carcinoma	Primary	Deceased	No	No	No	No	No	No	68.0
MSK-P-0010496	68	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0010650	68	Male	White	IPMN	Primary	Alive	Q61H	R248Q	No	No	Q61	Yes	68.0
MSK-P-0010652	65	Male	NA	PNET	Primary	Alive	No	No	No	No	No	No	65.0
MSK-P-0010653	60	Female	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	60.0
MSK-P-0010661	60	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	60.0
MSK-P-0010662	83	Male	White	Carcinoma, NOS	Primary	Alive	G12V	No	No	No	G12	No	83.0
MSK-P-0010689	59	Female	White	PDAC	Metastasis	Deceased	G12D	L188Q	No	No	G12	Yes	59.0
MSK-P-0010691	65	Male	Black/African-American	PDAC	Metastasis	Deceased	G12V	R248Q	No	No	G12	Yes	65.0
MSK-P-0010692	68	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0010716	63	Female	White	PDAC	Primary	Deceased	G12V	R248W	No	No	G12	Yes	63.0
MSK-P-0010720	52	Male	Black/African-American	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	52.0
MSK-P-0010756	72	Female	Black/African-American	IPMN	Primary	Alive	No	No	No	No	No	No	72.0
MSK-P-0010785	79	Male	White	PDAC	Metastasis	Deceased	G12V	Y236H	No	No	G12	Yes	79.0
MSK-P-0010788	72	Male	White	PDAC	Primary	Deceased	G12V	H179Y	No	P130S	G12	Yes	72.0
MSK-P-0010790	68	Male	White	PDAC	Primary	Deceased	G12V	R282W	No	No	G12	Yes	68.0
MSK-P-0010804	64	Male	White	PDAC	Primary	Deceased	G12D	R248W	No	No	G12	Yes	64.0
MSK-P-0010806	81	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	81.0
MSK-P-0010814	63	Male	White	PDAC	Metastasis	Deceased	G12D	V216G	No	G510E	G12	Yes	63.0
MSK-P-0010824	52	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	52.0
MSK-P-0010830	56	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	56.0
MSK-P-0010837	73	Female	White	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	73.0
MSK-P-0010839	56	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0010852	50	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	50.0
MSK-P-0010854	62	Male	White	PDAC	Primary	Deceased	S65N,Q61R	R213L	No	No	Q61\|Other	Yes	62.0
MSK-P-0010866	51	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	51.0
MSK-P-0010867	40	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	40.0
MSK-P-0010899	28	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	28.0
MSK-P-0010914	56	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	56.0
MSK-P-0010926	47	Female	White	Solid pseudopapillary tumor	Primary	Deceased	No	No	No	No	No	No	47.0
MSK-P-0010948	68	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	68.0
MSK-P-0010984	52	Male	NA	PDAC	Metastasis	Alive	No	No	H83Y	No	No	No	52.0
MSK-P-0010988	58	Male	White	PDAC	Primary	Deceased	G12R	I255F	No	R361H	G12	Yes	58.0
MSK-P-0011037	<18	Male	White	Carcinoma, NOS	Metastasis	Deceased	No	No	No	No	No	No	17.0
MSK-P-0011043	76	Male	NA	PDAC	Metastasis	Deceased	G12R,F28L	H214R	No	No	G12\|Other	Yes	76.0
MSK-P-0011044	71	Male	White	PDAC	Metastasis	Deceased	G12D	V272L	No	No	G12	Yes	71.0
MSK-P-0011062	69	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	69.0
MSK-P-0011066	62	Female	White	PDAC	Metastasis	Alive	G12D	L130V	No	No	G12	Yes	62.0
MSK-P-0011082	48	Female	White	IPMN	Primary	Alive	No	No	No	No	No	No	48.0
MSK-P-0011111	85	Male	White	PDAC	Primary	Deceased	No	E286K	No	R361H	No	Yes	85.0
MSK-P-0011115	72	Female	Asian	PDAC	Primary	Alive	Q61L	L130R	No	No	Q61	Yes	72.0
MSK-P-0011135	64	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	64.0
MSK-P-0011163	38	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	38.0
MSK-P-0011191	76	Female	White	PDAC	Metastasis	Deceased	G12D	H193Y	No	No	G12	Yes	76.0
MSK-P-0011208	59	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	59.0
MSK-P-0011217	64	Male	White	IPMN	Primary	Alive	No	No	No	No	No	No	64.0
MSK-P-0011239	80	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	80.0
MSK-P-0011249	76	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0011251	72	Female	NA	PDAC	Metastasis	Deceased	No	No	No	No	No	No	72.0
MSK-P-0011253	71	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	71.0
MSK-P-0011265	58	Male	White	PDAC	Primary	Deceased	G12R	R248Q	No	No	G12	Yes	58.0
MSK-P-0011285	73	Female	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	73.0
MSK-P-0011339	76	Male	White	PDAC	Metastasis	Deceased	G12D	A161T	P114L	No	G12	Yes	76.0
MSK-P-0011341	85	Female	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	85.0
MSK-P-0011361	65	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	65.0
MSK-P-0011371	69	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	69.0
MSK-P-0011379	67	Female	White	PDAC	Primary	Deceased	G12D	S127F	No	L501R	G12	Yes	67.0
MSK-P-0011405	44	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	44.0
MSK-P-0011435	75	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	75.0
MSK-P-0011464	73	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	73.0
MSK-P-0011469	39	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	39.0
MSK-P-0011479	44	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	44.0
MSK-P-0011481	68	Male	White	PDAC	Primary	Alive	G12V	L194F	No	No	G12	Yes	68.0
MSK-P-0011513	54	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	54.0
MSK-P-0011527	68	Male	White	PDAC	Metastasis	Deceased	G12D	P151H	No	No	G12	Yes	68.0
MSK-P-0011554	79	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	79.0
MSK-P-0011555	72	Female	White	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	72.0
MSK-P-0012010	56	Female	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	56.0
MSK-P-0012041	64	Female	White	PDAC	Metastasis	Deceased	Q61R	C238Y	No	No	Q61	Yes	64.0
MSK-P-0012066	42	Female	White	PDAC	Metastasis	Deceased	No	C135Y	No	No	No	Yes	42.0
MSK-P-0012075	64	Male	White	IPMN	Primary	Alive	G12V	No	No	No	G12	No	64.0
MSK-P-0012078	51	Female	Black/African-American	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	51.0
MSK-P-0012095	65	Male	White	PDAC	Metastasis	Deceased	No	C124L	No	No	No	Yes	65.0
MSK-P-0012106	73	Male	White	PDAC	Metastasis	Deceased	G12R	R249W	No	No	G12	Yes	73.0
MSK-P-0012112	81	Male	White	PDAC	Primary	Deceased	G12V	E258Q	No	No	G12	Yes	81.0
MSK-P-0012117	62	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	62.0
MSK-P-0012118	58	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	L54S	G12	No	58.0
MSK-P-0012139	71	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	71.0
MSK-P-0012143	60	Female	White	PDAC	Primary	Deceased	G12V	V274L	No	No	G12	Yes	60.0
MSK-P-0012208	68	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	68.0
MSK-P-0012210	64	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0012215	NA	NA	NA	PDAC	Primary	NA	G12D	No	No	No	G12	No	NA
MSK-P-0012224	68	Male	NA	PDAC	Primary	Deceased	G12D	R273C	No	No	G12	Yes	68.0
MSK-P-0012231	50	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	50.0
MSK-P-0012246	27	Female	Asian	PNET	Metastasis	Alive	No	E258K	No	No	No	Yes	27.0
MSK-P-0012252	56	Male	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	56.0
MSK-P-0012272	64	Male	White	Adenosquamous carcinoma	Metastasis	Deceased	G12C	No	No	No	G12	No	64.0
MSK-P-0012283	76	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0012289	64	Male	White	PDAC	Metastasis	Deceased	Q61L	No	No	No	Q61	No	64.0
MSK-P-0012329	60	Female	White	PDAC	Metastasis	Deceased	G12V	G245V	No	No	G12	Yes	60.0
MSK-P-0012336	76	Female	White	PDAC	Metastasis	Deceased	G12D	L265P	No	No	G12	Yes	76.0
MSK-P-0012365	67	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	67.0
MSK-P-0012371	63	Male	White	PDAC	Metastasis	Deceased	G12V	V172D	No	No	G12	Yes	63.0
MSK-P-0012380	72	Female	White	IPMN	Primary	Alive	G12R	No	No	No	G12	No	72.0
MSK-P-0012382	51	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	51.0
MSK-P-0012395	52	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	52.0
MSK-P-0012405	81	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	81.0
MSK-P-0012409	72	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	72.0
MSK-P-0012413	54	Male	White	PDAC	Primary	Deceased	G12D	R273C	No	No	G12	Yes	54.0
MSK-P-0012442	75	Female	White	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	75.0
MSK-P-0012504	68	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	68.0
MSK-P-0012505	47	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	47.0
MSK-P-0012510	67	Male	White	Adenosquamous carcinoma	Primary	Alive	G12A,V8L	No	No	No	G12\|Other	No	67.0
MSK-P-0012523	71	Female	NA	PDAC	Primary	Alive	G12D	No	No	No	G12	No	71.0
MSK-P-0012533	51	Male	White	PDAC	Primary	Deceased	G12V	E285K	No	No	G12	Yes	51.0
MSK-P-0012535	68	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0012556	72	Male	White	PDAC	Primary	Deceased	G12D	K132R	No	No	G12	Yes	72.0
MSK-P-0012579	88	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	88.0
MSK-P-0012586	64	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	64.0
MSK-P-0012641	69	Female	White	PDAC	Primary	Deceased	G12V	V216L	No	No	G12	Yes	69.0
MSK-P-0012645	77	Female	White	PDAC	Primary	Deceased	G12D	E286K	No	No	G12	Yes	77.0
MSK-P-0012661	80	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	80.0
MSK-P-0012673	69	Female	White	PDAC	Metastasis	Deceased	G12D	Y234C	No	No	G12	Yes	69.0
MSK-P-0012688	60	Female	Asian	PDAC	Primary	Deceased	G12R	P278L	No	D493H	G12	Yes	60.0
MSK-P-0012710	77	Male	White	Acinar cell carcinoma	Primary	Deceased	No	No	No	No	No	No	77.0
MSK-P-0012716	72	Male	NA	Adenosquamous carcinoma	Metastasis	Alive	G12V	No	No	No	G12	No	72.0
MSK-P-0012733	67	Female	NA	PDAC	Primary	Deceased	G12D	E271V	No	No	G12	Yes	67.0
MSK-P-0012735	72	Male	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	72.0
MSK-P-0012751	73	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	73.0
MSK-P-0012786	43	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	43.0
MSK-P-0012787	58	Female	White	PDAC	Primary	Deceased	G12I	R175H	No	No	G12	Yes	58.0
MSK-P-0012792	65	Female	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	65.0
MSK-P-0012814	76	Male	White	PDAC	Primary	Deceased	G12V	No	H83Y	No	G12	No	76.0
MSK-P-0012827	68	Female	White	PDAC	Primary	Deceased	G12D	Y163C	No	No	G12	Yes	68.0
MSK-P-0012844	80	Female	White	PDAC	Primary	Deceased	G12D	Y220H	No	No	G12	Yes	80.0
MSK-P-0012891	68	Male	Asian	PDAC	Primary	Alive	No	No	No	L109P	No	No	68.0
MSK-P-0012920	44	Female	Asian	PDAC	Metastasis	Deceased	No	H193R	No	No	No	Yes	44.0
MSK-P-0012921	62	Male	White	PDAC	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	62.0
MSK-P-0012926	72	Female	White	PDAC	Metastasis	Deceased	Q61L	No	H83Y	No	Q61	No	72.0
MSK-P-0012942	60	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	60.0
MSK-P-0012972	68	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	68.0
MSK-P-0012973	79	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	79.0
MSK-P-0012978	72	Male	White	PDAC	Primary	Deceased	G12D	G245D	No	No	G12	Yes	72.0
MSK-P-0013009	87	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	87.0
MSK-P-0013019	64	Male	White	PDAC	Primary	Deceased	G12D	R273C	No	No	G12	Yes	64.0
MSK-P-0013021	76	Male	White	PDAC	Primary	Deceased	G12V	H193Y	No	No	G12	Yes	76.0
MSK-P-0013038	64	Male	White	PDAC	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	64.0
MSK-P-0013053	55	Male	Asian	PDAC	Metastasis	Alive	G12D	C141G	No	No	G12	Yes	55.0
MSK-P-0013083	80	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	80.0
MSK-P-0013086	73	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	73.0
MSK-P-0013153	80	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	80.0
MSK-P-0013220	56	Male	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	56.0
MSK-P-0013221	35	Male	NA	PNET	Metastasis	Alive	No	No	No	No	No	No	35.0
MSK-P-0013222	73	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	73.0
MSK-P-0013225	40	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	40.0
MSK-P-0013226	58	Male	White	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	58.0
MSK-P-0013266	56	Female	White	PDAC	Metastasis	Deceased	G13D	No	No	No	G13	No	56.0
MSK-P-0013286	59	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	59.0
MSK-P-0013307	62	Male	White	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	62.0
MSK-P-0013317	71	Male	Asian	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0013319	76	Male	White	PDAC	Primary	Alive	G12D	P151T	No	No	G12	Yes	76.0
MSK-P-0013328	73	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	73.0
MSK-P-0013337	73	Female	White	PDAC	Primary	Deceased	G12R	H168R	No	No	G12	Yes	73.0
MSK-P-0013346	63	Female	NA	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	63.0
MSK-P-0013367	48	Female	White	Solid pseudopapillary tumor	Primary	Alive	No	No	No	No	No	No	48.0
MSK-P-0013391	65	Male	White	PDAC	Primary	Deceased	G12D	S215G	No	No	G12	Yes	65.0
MSK-P-0013416	64	Male	White	PDAC	Metastasis	Deceased	G12R	M133R	No	No	G12	Yes	64.0
MSK-P-0013450	68	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0013456	75	Male	White	PDAC	Metastasis	Deceased	G12R	D281N	No	No	G12	Yes	75.0
MSK-P-0013487	60	Male	White	PDAC	Metastasis	Deceased	Q61L	R337C	No	G423V	Q61	Yes	60.0
MSK-P-0013496	83	Male	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	83.0
MSK-P-0013499	63	Female	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	63.0
MSK-P-0013504	64	Female	White	PDAC	Primary	Deceased	G12R	R175H	No	No	G12	Yes	64.0
MSK-P-0013528	76	Male	Asian	PDAC	Primary	Deceased	G12V	No	P48L	No	G12	No	76.0
MSK-P-0013532	75	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	75.0
MSK-P-0013555	39	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	39.0
MSK-P-0013564	76	Female	White	PDAC	Primary	Deceased	G12D	R248W	No	No	G12	Yes	76.0
MSK-P-0013571	87	Male	Asian	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	87.0
MSK-P-0013651	85	Female	White	PDAC	Metastasis	Deceased	G12V	R273H	H83Y	No	G12	Yes	85.0
MSK-P-0013655	48	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	48.0
MSK-P-0013709	68	Female	White	PDAC	Metastasis	Deceased	Q61R	R273C	No	No	Q61	Yes	68.0
MSK-P-0013714	63	Female	White	PDAC	Metastasis	Deceased	G12R	F113V	No	No	G12	Yes	63.0
MSK-P-0013749	47	Female	Other	PNET	Primary	Alive	No	R175H	No	No	No	Yes	47.0
MSK-P-0013766	68	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	68.0
MSK-P-0013792	63	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	63.0
MSK-P-0013821	54	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	54.0
MSK-P-0013822	73	Female	White	Adenosquamous carcinoma	Primary	Deceased	Q61H	No	No	No	Q61	No	73.0
MSK-P-0013824	55	Male	White	PDAC	Primary	Deceased	G12D	H193R	No	No	G12	Yes	55.0
MSK-P-0013829	64	Male	White	PDAC	Primary	Deceased	G12R,G12V	No	No	No	G12	No	64.0
MSK-P-0013830	68	Male	NA	PDAC	Primary	Deceased	G12D	I255F	No	No	G12	Yes	68.0
MSK-P-0013839	60	Female	NA	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0013866	79	Female	White	PDAC	Primary	Deceased	G12D	C176S	No	No	G12	Yes	79.0
MSK-P-0013870	52	Female	White	PDAC	Metastasis	Deceased	G12R	V147G	No	No	G12	Yes	52.0
MSK-P-0013899	65	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	65.0
MSK-P-0013921	67	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	67.0
MSK-P-0013924	68	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	68.0
MSK-P-0013953	44	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	44.0
MSK-P-0013974	71	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	71.0
MSK-P-0013979	64	Male	White	IPMN	Primary	Alive	No	No	No	No	No	No	64.0
MSK-P-0013996	79	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	79.0
MSK-P-0014024	77	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	77.0
MSK-P-0014036	60	Female	White	PNET	Metastasis	Deceased	L19F	No	No	No	Other	No	60.0
MSK-P-0014039	54	Male	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	54.0
MSK-P-0014070	55	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	R361H	G12	No	55.0
MSK-P-0014098	51	Male	NA	PNET	Metastasis	Alive	No	No	No	No	No	No	51.0
MSK-P-0014115	60	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0014123	48	Female	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	48.0
MSK-P-0014140	64	Female	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	64.0
MSK-P-0014141	60	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	60.0
MSK-P-0014144	65	Female	NA	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	65.0
MSK-P-0014158	60	Male	White	PDAC	Metastasis	Deceased	G12V	N131I	No	No	G12	Yes	60.0
MSK-P-0014160	64	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	I383K	G12	No	64.0
MSK-P-0014197	72	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0014228	65	Male	White	PDAC	Primary	Deceased	G12R	P250L	No	No	G12	Yes	65.0
MSK-P-0014246	56	Male	White	PDAC	Metastasis	Deceased	No	C176Y	No	No	No	Yes	56.0
MSK-P-0014275	60	Female	Asian	PDAC	Primary	Deceased	G12V	R273H	No	Q366V	G12	Yes	60.0
MSK-P-0014300	48	Female	White	PDAC	Primary	Alive	G12D	I195T	No	No	G12	Yes	48.0
MSK-P-0014312	58	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	58.0
MSK-P-0014329	58	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	58.0
MSK-P-0014339	65	Female	White	PDAC	Primary	Deceased	G12D	I232S	No	No	G12	Yes	65.0
MSK-P-0014365	40	Male	Other	PDAC	Primary	Deceased	No	R248Q	No	No	No	Yes	40.0
MSK-P-0014383	80	Female	White	PDAC	Primary	Deceased	G12V	L194R	No	No	G12	Yes	80.0
MSK-P-0014423	76	Male	White	PDAC	Metastasis	Deceased	G12R	I195T	No	D355V	G12	Yes	76.0
MSK-P-0014438	68	Male	White	Carcinoma, NOS	Primary	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0014457	48	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	48.0
MSK-P-0014459	55	Female	White	PDAC	Metastasis	Alive	G12L	No	No	No	G12	No	55.0
MSK-P-0014462	69	Female	Black/African-American	PDAC	Metastasis	Alive	G12V	R282W	No	No	G12	Yes	69.0
MSK-P-0014475	60	Female	Asian	PNET	Metastasis	Alive	No	No	No	No	No	No	60.0
MSK-P-0014512	67	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	67.0
MSK-P-0014549	59	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	59.0
MSK-P-0014552	56	Male	Asian	PDAC	Metastasis	Deceased	No	No	No	No	No	No	56.0
MSK-P-0014564	48	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	48.0
MSK-P-0014610	55	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	55.0
MSK-P-0014621	69	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	R361H	G12	No	69.0
MSK-P-0014633	63	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	63.0
MSK-P-0014635	72	Male	White	PDAC	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	72.0
MSK-P-0014641	75	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12D	R175H	No	No	G12	Yes	75.0
MSK-P-0014670	52	Male	White	PDAC	Primary	Alive	G12D	Y220C	No	G386V	G12	Yes	52.0
MSK-P-0014684	58	Male	White	PDAC	Metastasis	Deceased	G12R	T256P	No	No	G12	Yes	58.0
MSK-P-0014690	67	Female	White	PDAC	Primary	Deceased	G12D	Y234C	No	No	G12	Yes	67.0
MSK-P-0014704	72	Male	NA	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	72.0
MSK-P-0014727	69	Female	White	PDAC	Primary	Deceased	G12D	H214R	No	No	G12	Yes	69.0
MSK-P-0014738	69	Female	Other	PDAC	Primary	Alive	G12D	V216M	No	No	G12	Yes	69.0
MSK-P-0014823	76	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	76.0
MSK-P-0014849	67	Female	White	PDAC	Primary	Deceased	G12D	R213L	No	G386A	G12	Yes	67.0
MSK-P-0014859	63	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	63.0
MSK-P-0014890	48	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	48.0
MSK-P-0014914	56	Female	White	PDAC	Primary	Alive	G12D	A138P	No	No	G12	Yes	56.0
MSK-P-0014930	63	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	63.0
MSK-P-0014967	67	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	67.0
MSK-P-0014977	52	Male	White	Adenosquamous carcinoma	Metastasis	Alive	G12D	No	No	No	G12	No	52.0
MSK-P-0015009	56	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	56.0
MSK-P-0015040	60	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	60.0
MSK-P-0015108	72	Female	Asian	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0015120	68	Female	White	PDAC	Primary	Deceased	G12R	C238G	No	No	G12	Yes	68.0
MSK-P-0015123	80	Male	White	PDAC	Metastasis	Alive	G12R	R248W	No	No	G12	Yes	80.0
MSK-P-0015140	79	Female	White	PNET	Metastasis	Deceased	V14I	R175H	No	No	Other	Yes	79.0
MSK-P-0015175	71	Female	White	PDAC	Primary	Deceased	G12V	R273C	No	Y353C	G12	Yes	71.0
MSK-P-0015180	72	Male	White	Carcinoma, NOS	Primary	Deceased	G12V	P250L	No	No	G12	Yes	72.0
MSK-P-0015193	71	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0015212	77	Male	White	PDAC	Metastasis	Deceased	Q61R	S241C	No	No	Q61	Yes	77.0
MSK-P-0015218	64	Male	White	PDAC	Metastasis	Deceased	G12R	V272M	No	No	G12	Yes	64.0
MSK-P-0015219	71	Female	White	Adenosquamous carcinoma	Metastasis	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0015232	73	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	73.0
MSK-P-0015236	83	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	83.0
MSK-P-0015255	68	Male	White	PDAC	Primary	Alive	G12V	L130R	No	No	G12	Yes	68.0
MSK-P-0015328	76	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0015330	50	Male	NA	PNET	Primary	Alive	No	No	No	No	No	No	50.0
MSK-P-0015340	80	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	80.0
MSK-P-0015362	69	Female	Asian	PDAC	Primary	Deceased	G12V	C242F	No	No	G12	Yes	69.0
MSK-P-0015384	52	Female	White	PDAC	Primary	Deceased	Q61H	R273H	No	R361C	Q61	Yes	52.0
MSK-P-0015389	59	Male	White	PDAC	Primary	Alive	G12D	L194H	No	No	G12	Yes	59.0
MSK-P-0015390	72	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0015400	68	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	68.0
MSK-P-0015422	64	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0015432	40	Female	Asian	PDAC	Primary	Deceased	No	No	No	No	No	No	40.0
MSK-P-0015453	64	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	64.0
MSK-P-0015481	68	Female	White	Carcinoma, NOS	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0015497	63	Male	White	IPMN	Primary	Alive	G12V	No	No	No	G12	No	63.0
MSK-P-0015528	67	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	67.0
MSK-P-0015537	47	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	47.0
MSK-P-0015541	79	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	79.0
MSK-P-0015555	67	Male	Other	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	67.0
MSK-P-0015567	79	Male	NA	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	79.0
MSK-P-0015594	52	Female	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	52.0
MSK-P-0015614	34	Male	Asian	PDAC	Primary	Deceased	No	No	No	No	No	No	34.0
MSK-P-0015668	59	Male	White	PDAC	Metastasis	Deceased	G12D	Y205H	No	No	G12	Yes	59.0
MSK-P-0015672	65	Female	White	PDAC	Primary	Deceased	G12V	G266V	No	No	G12	Yes	65.0
MSK-P-0015675	75	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	75.0
MSK-P-0015683	67	Male	White	PDAC	Primary	Alive	G12V	R273C	No	No	G12	Yes	67.0
MSK-P-0015701	44	Female	White	PDAC	Metastasis	Deceased	G12D	R282W	No	No	G12	Yes	44.0
MSK-P-0015703	75	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	75.0
MSK-P-0015705	65	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12D	V272E	No	No	G12	Yes	65.0
MSK-P-0015714	85	Female	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	85.0
MSK-P-0015723	71	Female	White	PNET	Metastasis	Deceased	No	P190S	No	No	No	Yes	71.0
MSK-P-0015729	59	Female	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	59.0
MSK-P-0015733	72	Male	White	PDAC	Metastasis	Alive	G12V	R337L	No	No	G12	Yes	72.0
MSK-P-0015746	80	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	80.0
MSK-P-0015769	68	Male	White	PDAC	Primary	Deceased	G12R	L130P	No	No	G12	Yes	68.0
MSK-P-0015795	67	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	67.0
MSK-P-0015802	79	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	79.0
MSK-P-0015818	52	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	52.0
MSK-P-0015820	80	Male	White	PDAC	Primary	Deceased	G12V	Y163C	No	No	G12	Yes	80.0
MSK-P-0015824	54	Male	Other	PDAC	Primary	Deceased	Q61H	F109S	H83Y	No	Q61	Yes	54.0
MSK-P-0015829	63	Female	White	PDAC	Primary	Alive	G12V	H193R	No	No	G12	Yes	63.0
MSK-P-0015857	64	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0015872	72	Male	White	PDAC	Primary	Deceased	G12_G13delinsAC	No	No	No	G12\|G13	No	72.0
MSK-P-0015883	56	Female	White	PDAC	Primary	Deceased	G12V	Y126D	No	No	G12	Yes	56.0
MSK-P-0015914	NA	NA	NA	PNET	Metastasis	NA	No	No	No	No	No	No	NA
MSK-P-0015918	58	Female	White	PDAC	Primary	Deceased	G12V	No	No	Q116E	G12	No	58.0
MSK-P-0015935	59	Female	White	PNET	Metastasis	Alive	No	I255T	No	No	No	Yes	59.0
MSK-P-0015939	75	Male	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	75.0
MSK-P-0015971	52	Female	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	52.0
MSK-P-0016011	65	Female	White	PDAC	Primary	Alive	No	No	No	P356H	No	No	65.0
MSK-P-0016137	48	Female	Other	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	48.0
MSK-P-0016193	22	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	22.0
MSK-P-0016201	60	Female	Asian	PDAC	Primary	Alive	G12V	No	No	No	G12	No	60.0
MSK-P-0016242	56	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0016253	68	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	68.0
MSK-P-0016267	64	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	64.0
MSK-P-0016268	76	Male	White	PDAC	Primary	Deceased	Q61H	C275Y	No	No	Q61	Yes	76.0
MSK-P-0016292	59	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	R361C	G12	No	59.0
MSK-P-0016359	80	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	80.0
MSK-P-0016372	85	Male	White	PDAC	Metastasis	Alive	G12V	Q136P	No	No	G12	Yes	85.0
MSK-P-0016377	64	Female	White	PDAC	Primary	Deceased	Q61H	R249W	No	No	Q61	Yes	64.0
MSK-P-0016388	48	Male	White	PDAC	Primary	Deceased	G12V	R248Q	No	No	G12	Yes	48.0
MSK-P-0016390	44	Male	White	PDAC	Metastasis	Alive	G12D	F270C	No	No	G12	Yes	44.0
MSK-P-0016407	40	Male	White	PDAC	Primary	Deceased	G12V	No	No	D351G	G12	No	40.0
MSK-P-0016434	72	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0016438	52	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	52.0
MSK-P-0016483	50	Male	Black/African-American	PNET	Metastasis	Deceased	No	No	No	No	No	No	50.0
MSK-P-0016497	75	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	75.0
MSK-P-0016554	84	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	84.0
MSK-P-0016577	59	Male	Asian	PDAC	Metastasis	Deceased	G12V	M237I	No	No	G12	Yes	59.0
MSK-P-0016579	80	Male	White	PDAC	Metastasis	Deceased	G12D	E285K	No	No	G12	Yes	80.0
MSK-P-0016583	56	Male	Asian	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0016585	72	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	72.0
MSK-P-0016597	73	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	73.0
MSK-P-0016605	60	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	60.0
MSK-P-0016615	84	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12D	No	No	No	G12	No	84.0
MSK-P-0016616	68	Female	White	PDAC	Primary	Deceased	No	No	No	R531W	No	No	68.0
MSK-P-0016623	76	Female	NA	Adenosquamous carcinoma	Primary	Alive	G12D	T284P	No	No	G12	Yes	76.0
MSK-P-0016625	55	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	55.0
MSK-P-0016660	64	Male	White	Carcinoma, NOS	Primary	Alive	G12D	No	No	No	G12	No	64.0
MSK-P-0016685	52	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	52.0
MSK-P-0016694	63	Male	White	PDAC	Primary	Deceased	G12D	R248Q	No	No	G12	Yes	63.0
MSK-P-0016710	52	Female	White	PDAC	Metastasis	Deceased	G12V	R273H	No	No	G12	Yes	52.0
MSK-P-0016717	44	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	44.0
MSK-P-0016748	62	Male	White	PDAC	Primary	Deceased	Q61L	No	No	No	Q61	No	62.0
MSK-P-0016771	62	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	62.0
MSK-P-0016774	64	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	64.0
MSK-P-0016797	72	Female	White	PDAC	Primary	Deceased	G12V	S127F	No	No	G12	Yes	72.0
MSK-P-0016817	80	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	80.0
MSK-P-0016873	56	Female	White	PDAC	Primary	Deceased	G12D	R248Q	No	No	G12	Yes	56.0
MSK-P-0016899	76	Male	Black/African-American	Adenosquamous carcinoma	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0016901	62	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	62.0
MSK-P-0016926	77	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	77.0
MSK-P-0016939	65	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	R361H	G12	No	65.0
MSK-P-0016950	52	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	52.0
MSK-P-0016973	73	Female	Asian	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	73.0
MSK-P-0016992	64	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0016993	59	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	59.0
MSK-P-0017012	46	Female	Asian	PNET	Primary	Alive	No	No	No	No	No	No	46.0
MSK-P-0017040	77	Female	Black/African-American	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	77.0
MSK-P-0017052	73	Male	White	PDAC	Primary	Alive	G12V	R248Q	No	No	G12	Yes	73.0
MSK-P-0017058	60	Male	White	PDAC	Metastasis	Deceased	G12V	R273C	No	No	G12	Yes	60.0
MSK-P-0017121	68	Female	White	PDAC	Primary	Deceased	G12R	R248Q	No	No	G12	Yes	68.0
MSK-P-0017171	80	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	80.0
MSK-P-0017188	69	Male	White	PDAC	Metastasis	Deceased	Q61R	No	No	No	Q61	No	69.0
MSK-P-0017189	51	Female	White	PDAC	Primary	Deceased	G12R	G245C	No	No	G12	Yes	51.0
MSK-P-0017191	79	Female	White	PDAC	Primary	Alive	G12V	No	No	W101R	G12	No	79.0
MSK-P-0017197	48	Male	White	PDAC	Primary	Deceased	G12D	R273C	No	No	G12	Yes	48.0
MSK-P-0017258	63	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	63.0
MSK-P-0017333	67	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	67.0
MSK-P-0017348	63	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	63.0
MSK-P-0017349	60	Male	White	PDAC	Metastasis	Deceased	G12R	No	H83Y	No	G12	No	60.0
MSK-P-0017355	68	Female	White	PDAC	Primary	Alive	G12C	V143M	No	No	G12	Yes	68.0
MSK-P-0017391	60	Male	Black/African-American	PNET	Primary	Alive	No	No	No	No	No	No	60.0
MSK-P-0017392	64	Male	White	PDAC	Metastasis	Alive	G12D	R175H	A5G	No	G12	Yes	64.0
MSK-P-0017429	51	Male	White	PDAC	Primary	Deceased	G12V	R248W	No	No	G12	Yes	51.0
MSK-P-0017446	68	Female	White	PDAC	Primary	Deceased	Q61K	No	No	No	Q61	No	68.0
MSK-P-0017466	52	Female	White	PNET	Primary	Deceased	No	L130V	No	No	No	Yes	52.0
MSK-P-0017476	NA	NA	NA	PDAC	Primary	NA	G12R	No	No	No	G12	No	NA
MSK-P-0017480	52	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	52.0
MSK-P-0017498	72	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0017505	85	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	85.0
MSK-P-0017552	62	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	62.0
MSK-P-0017557	76	Male	Asian	PDAC	Primary	Alive	G12D	No	No	No	G12	No	76.0
MSK-P-0017588	76	Female	White	PDAC	Primary	Deceased	G12R	R282W	No	No	G12	Yes	76.0
MSK-P-0017653	56	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0017660	64	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0017692	46	Male	Asian	PDAC	Metastasis	Deceased	No	No	No	No	No	No	46.0
MSK-P-0017760	62	Female	Asian	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	62.0
MSK-P-0017761	47	Male	Black/African-American	PDAC	Metastasis	Alive	No	F109S	No	No	No	Yes	47.0
MSK-P-0017762	40	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	40.0
MSK-P-0017776	63	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
MSK-P-0017779	81	Female	White	PDAC	Primary	Deceased	G12D	M237I	No	No	G12	Yes	81.0
MSK-P-0017825	56	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0017852	32	Male	Other	PNET	Metastasis	Alive	No	No	No	No	No	No	32.0
MSK-P-0017853	60	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	60.0
MSK-P-0017887	46	Male	White	PDAC	Primary	Alive	G12D	V216M	No	No	G12	Yes	46.0
MSK-P-0017893	68	Male	White	PDAC	Primary	Deceased	G12D	R248Q	No	No	G12	Yes	68.0
MSK-P-0017900	64	Male	NA	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	64.0
MSK-P-0017901	64	Female	NA	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0017923	64	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	64.0
MSK-P-0017981	65	Male	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	65.0
MSK-P-0018012	68	Male	White	PDAC	Primary	Deceased	G12D	F134V	No	No	G12	Yes	68.0
MSK-P-0018013	62	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	62.0
MSK-P-0018036	71	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0018061	64	Female	White	Carcinoma, NOS	Primary	Alive	G12R	No	No	No	G12	No	64.0
MSK-P-0018094	72	Female	Black/African-American	PDAC	Primary	Alive	No	R175H	No	No	No	Yes	72.0
MSK-P-0018112	63	Female	White	PDAC	Metastasis	Deceased	G12R,I46M	Y234C	No	No	G12\|Other	Yes	63.0
MSK-P-0018135	52	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	52.0
MSK-P-0018141	64	Male	White	PDAC	Primary	Deceased	G12V	No	No	A406V	G12	No	64.0
MSK-P-0018150	48	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	48.0
MSK-P-0018156	51	Female	White	Carcinoma, NOS	Metastasis	Deceased	G12D	R282W	No	No	G12	Yes	51.0
MSK-P-0018157	76	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	76.0
MSK-P-0018210	71	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	71.0
MSK-P-0018226	69	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	69.0
MSK-P-0018232	56	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	56.0
MSK-P-0018246	55	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	55.0
MSK-P-0018265	60	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	60.0
MSK-P-0018267	72	Female	White	PDAC	Primary	Deceased	Q61H	Q136P	No	No	Q61	Yes	72.0
MSK-P-0018278	68	Male	White	Carcinoma, NOS	Metastasis	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0018279	76	Male	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	76.0
MSK-P-0018293	64	Female	White	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	64.0
MSK-P-0018303	77	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	77.0
MSK-P-0018336	67	Female	White	PDAC	Primary	Alive	G12R	M237I	No	No	G12	Yes	67.0
MSK-P-0018351	75	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	75.0
MSK-P-0018354	56	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0018378	65	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	65.0
MSK-P-0018390	62	Male	NA	PDAC	Metastasis	Deceased	G12D	Y205N	No	No	G12	Yes	62.0
MSK-P-0018398	85	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	85.0
MSK-P-0018410	64	Female	Black/African-American	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	64.0
MSK-P-0018417	71	Female	White	PDAC	Primary	Deceased	G12D	P250L	No	No	G12	Yes	71.0
MSK-P-0018468	64	Female	White	PDAC	Metastasis	Deceased	G12R	R248Q	No	No	G12	Yes	64.0
MSK-P-0018469	60	Male	White	PDAC	Primary	Deceased	No	A159D	No	No	No	Yes	60.0
MSK-P-0018509	38	Male	Other	PDAC	Metastasis	Deceased	G12D	V172F	No	No	G12	Yes	38.0
MSK-P-0018529	52	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	52.0
MSK-P-0018537	71	Female	White	PDAC	Primary	Deceased	G12D	C275Y	No	No	G12	Yes	71.0
MSK-P-0018540	46	Female	Black/African-American	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	46.0
MSK-P-0018559	72	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	72.0
MSK-P-0018565	72	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	72.0
MSK-P-0018639	84	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	84.0
MSK-P-0018643	63	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	63.0
MSK-P-0018648	67	Female	White	PDAC	Primary	Alive	No	S127Y	No	No	No	Yes	67.0
MSK-P-0018695	55	Female	NA	Adenosquamous carcinoma	Metastasis	Deceased	No	No	No	No	No	No	55.0
MSK-P-0018698	47	Female	White	PDAC	Primary	Deceased	G12R	No	No	V492G	G12	No	47.0
MSK-P-0018706	68	Male	Black/African-American	PDAC	Primary	Deceased	G12C	Y236C	No	No	G12	Yes	68.0
MSK-P-0018708	56	Female	White	PDAC	Primary	Deceased	G12R	R175H	No	No	G12	Yes	56.0
MSK-P-0018725	52	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	52.0
MSK-P-0018818	60	Female	White	PDAC	Metastasis	Deceased	G12D	No	H83D	No	G12	No	60.0
MSK-P-0018822	68	Male	White	PDAC	Primary	Deceased	Q61L	No	No	No	Q61	No	68.0
MSK-P-0018828	63	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	63.0
MSK-P-0018848	64	Male	Other	PDAC	Metastasis	Deceased	G12V	R273H	No	No	G12	Yes	64.0
MSK-P-0018856	68	Female	Asian	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0018914	69	Male	White	PDAC	Primary	Deceased	Q61H	R175H	No	No	Q61	Yes	69.0
MSK-P-0018915	64	Female	Asian	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	64.0
MSK-P-0018942	69	Female	White	PDAC	Primary	Alive	G12D	G245S	No	A406V	G12	Yes	69.0
MSK-P-0018950	59	Female	White	PDAC	Primary	Deceased	G12R	S241F	No	No	G12	Yes	59.0
MSK-P-0018954	64	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	64.0
MSK-P-0018962	69	Male	White	PDAC	Primary	Alive	G12V	L111R	No	No	G12	Yes	69.0
MSK-P-0018981	58	Female	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	58.0
MSK-P-0019041	69	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	69.0
MSK-P-0019060	76	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0019077	68	Female	White	PDAC	Metastasis	Deceased	G12V	P250L	No	No	G12	Yes	68.0
MSK-P-0019112	48	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	48.0
MSK-P-0019122	55	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	55.0
MSK-P-0019123	80	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	80.0
MSK-P-0019132	51	Female	White	PDAC	Primary	Deceased	G12I	No	No	No	G12	No	51.0
MSK-P-0019135	77	Female	White	PDAC	Metastasis	Deceased	G12V	H168P	No	No	G12	Yes	77.0
MSK-P-0019139	68	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	68.0
MSK-P-0019163	65	Female	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	65.0
MSK-P-0019225	67	Female	White	PDAC	Primary	Alive	Q61R	I232F	No	No	Q61	Yes	67.0
MSK-P-0019249	62	Female	White	PDAC	Metastasis	Deceased	G12D	G245D	No	No	G12	Yes	62.0
MSK-P-0019251	48	Female	White	PDAC	Metastasis	Deceased	G12V	C135Y	No	L23S	G12	Yes	48.0
MSK-P-0019275	68	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0019281	48	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	48.0
MSK-P-0019307	40	Male	White	PDAC	Metastasis	Deceased	G12D	R249M	No	No	G12	Yes	40.0
MSK-P-0019318	79	Male	White	IPMN	Primary	Alive	G12D	No	No	No	G12	No	79.0
MSK-P-0019322	63	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	63.0
MSK-P-0019367	58	Female	NA	PNET	Primary	Alive	No	No	No	No	No	No	58.0
MSK-P-0019378	54	Female	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	54.0
MSK-P-0019384	51	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	51.0
MSK-P-0019389	72	Female	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	72.0
MSK-P-0019392	72	Female	White	Carcinoma, NOS	Primary	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0019427	77	Female	White	PDAC	Primary	Deceased	G12V	R273H	No	No	G12	Yes	77.0
MSK-P-0019429	76	Male	White	PDAC	Primary	Alive	Q61H	No	No	R496P	Q61	No	76.0
MSK-P-0019433	80	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	80.0
MSK-P-0019446	71	Female	White	PDAC	Primary	Deceased	G12D,G12V	No	No	No	G12	No	71.0
MSK-P-0019506	56	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	56.0
MSK-P-0019538	58	Male	Asian	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	58.0
MSK-P-0019551	67	Male	White	Adenosquamous carcinoma	Metastasis	Alive	G12D	No	No	No	G12	No	67.0
MSK-P-0019617	81	Female	Other	PDAC	Primary	Alive	G12D	Y220C	No	No	G12	Yes	81.0
MSK-P-0019618	48	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	48.0
MSK-P-0019628	84	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	C71F	G12	No	84.0
MSK-P-0019640	52	Female	White	PDAC	Primary	Deceased	G12V	V216M	No	No	G12	Yes	52.0
MSK-P-0019646	36	Female	NA	PNET	Metastasis	Deceased	A146V	No	No	G352E	Other	No	36.0
MSK-P-0019656	71	Female	NA	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	71.0
MSK-P-0019681	72	Male	White	PDAC	Primary	Deceased	G12D	No	No	R361H	G12	No	72.0
MSK-P-0019724	64	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	64.0
MSK-P-0019728	60	Female	White	PDAC	Primary	Deceased	G12V	P151S	No	No	G12	Yes	60.0
MSK-P-0019735	72	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0019736	71	Male	White	PDAC	Primary	Alive	No	I195S	No	No	No	Yes	71.0
MSK-P-0019753	58	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	58.0
MSK-P-0019761	50	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	50.0
MSK-P-0019789	54	Female	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	54.0
MSK-P-0019807	43	Female	White	Pancreatoblastoma	Primary	Alive	No	No	No	No	No	No	43.0
MSK-P-0019823	59	Female	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	59.0
MSK-P-0019855	76	Male	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	76.0
MSK-P-0019859	44	Female	Black/African-American	PDAC	Metastasis	Deceased	No	No	No	No	No	No	44.0
MSK-P-0019867	75	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	75.0
MSK-P-0019874	84	Male	White	PDAC	Primary	Deceased	G12D	C275Y	No	No	G12	Yes	84.0
MSK-P-0019879	76	Female	White	PDAC	Primary	Deceased	G12D	R175H	No	R361C	G12	Yes	76.0
MSK-P-0019906	47	Female	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	47.0
MSK-P-0019938	56	Female	White	PDAC	Primary	Deceased	G12V	K132Q	No	No	G12	Yes	56.0
MSK-P-0019946	34	Female	White	PDAC	Primary	Deceased	G12D	S127Y	No	No	G12	Yes	34.0
MSK-P-0019956	59	Female	White	PDAC	Primary	Deceased	G12D	G266R	No	No	G12	Yes	59.0
MSK-P-0019965	67	Male	White	PDAC	Metastasis	Deceased	G12V	R273H	No	No	G12	Yes	67.0
MSK-P-0020010	72	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	72.0
MSK-P-0020018	64	Male	White	PDAC	Primary	Alive	G12V	Y234C	No	No	G12	Yes	64.0
MSK-P-0020024	72	Male	White	Acinar cell carcinoma	Primary	Deceased	No	No	H83Y	No	No	No	72.0
MSK-P-0020028	68	Male	White	PDAC	Primary	Alive	G12D	R273H	No	No	G12	Yes	68.0
MSK-P-0020039	80	Female	White	PDAC	Primary	Deceased	G12D	H179N	No	No	G12	Yes	80.0
MSK-P-0020077	58	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	58.0
MSK-P-0020085	75	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	75.0
MSK-P-0020103	68	Male	Asian	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0020174	62	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12D	No	No	No	G12	No	62.0
MSK-P-0020179	68	Male	Black/African-American	PDAC	Metastasis	Deceased	No	No	No	No	No	No	68.0
MSK-P-0020181	43	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	43.0
MSK-P-0020213	54	Male	White	PDAC	Metastasis	Deceased	G12D	V157G	No	No	G12	Yes	54.0
MSK-P-0020264	50	Male	White	PDAC	Primary	Deceased	G12D	G244V	No	No	G12	Yes	50.0
MSK-P-0020326	52	Male	Asian	PDAC	Primary	Deceased	No	No	No	No	No	No	52.0
MSK-P-0020334	60	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0020339	83	Male	White	PDAC	Primary	Deceased	G12V	No	No	D351G	G12	No	83.0
MSK-P-0020349	68	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	68.0
MSK-P-0020377	56	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0020407	54	Female	White	PDAC	Primary	Deceased	G12V	No	No	L364S	G12	No	54.0
MSK-P-0020474	71	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	71.0
MSK-P-0020488	72	Female	White	PDAC	Primary	Deceased	Q61R	No	No	F339S,V350G	Q61	No	72.0
MSK-P-0020504	48	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	48.0
MSK-P-0020526	80	Male	White	PNET	Metastasis	Deceased	G12D	G245S	No	No	G12	Yes	80.0
MSK-P-0020541	36	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	36.0
MSK-P-0020548	73	Female	Asian	PDAC	Metastasis	Deceased	G12D	R273S	No	No	G12	Yes	73.0
MSK-P-0020609	64	Female	White	PDAC	Primary	Deceased	G12R	R282W	No	No	G12	Yes	64.0
MSK-P-0020612	60	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	60.0
MSK-P-0020625	56	Male	NA	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0020646	56	Female	White	PDAC	Primary	Deceased	G12V	R248W	No	No	G12	Yes	56.0
MSK-P-0020651	69	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	69.0
MSK-P-0020665	52	Female	White	PDAC	Primary	Deceased	G12A	No	No	No	G12	No	52.0
MSK-P-0020684	76	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	76.0
MSK-P-0020716	64	Male	White	PDAC	Primary	Deceased	G12R	C141Y	No	No	G12	Yes	64.0
MSK-P-0020763	80	Male	White	PDAC	Metastasis	Deceased	G12D	No	H83D	No	G12	No	80.0
MSK-P-0020769	64	Male	White	Adenosquamous carcinoma	Primary	Deceased	No	No	No	No	No	No	64.0
MSK-P-0020790	71	Female	White	PDAC	Metastasis	Alive	G12D	R248Q	No	No	G12	Yes	71.0
MSK-P-0020793	63	Female	White	PDAC	Primary	Deceased	G12D	I195T	No	No	G12	Yes	63.0
MSK-P-0020805	68	Female	NA	PDAC	Primary	Alive	G12V	P278A	No	No	G12	Yes	68.0
MSK-P-0020827	47	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	47.0
MSK-P-0020841	62	Female	White	PDAC	Primary	Deceased	G12V	V272L	No	No	G12	Yes	62.0
MSK-P-0020867	64	Female	White	PDAC	Primary	Deceased	G12V	R282W	No	No	G12	Yes	64.0
MSK-P-0020870	58	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	58.0
MSK-P-0020922	79	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	79.0
MSK-P-0020935	76	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	76.0
MSK-P-0020939	55	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	55.0
MSK-P-0020947	55	Female	White	PDAC	Metastasis	Deceased	G12V	Y220C	No	No	G12	Yes	55.0
MSK-P-0020952	72	Male	White	PDAC	Primary	Deceased	G12V	G199V	No	No	G12	Yes	72.0
MSK-P-0020960	72	Male	White	PDAC	Metastasis	Deceased	G12D	V157F	No	No	G12	Yes	72.0
MSK-P-0020967	60	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	60.0
MSK-P-0020977	63	Female	White	PDAC	Metastasis	Deceased	G12R	S127F	No	No	G12	Yes	63.0
MSK-P-0021000	<18	Female	White	Pancreatoblastoma	Primary	Alive	No	No	No	No	No	No	17.0
MSK-P-0021002	72	Male	White	PDAC	Metastasis	Deceased	G12D	M237I	No	No	G12	Yes	72.0
MSK-P-0021014	76	Female	White	PDAC	Primary	Deceased	No	Y126C	No	No	No	Yes	76.0
MSK-P-0021026	72	Female	White	PDAC	Primary	Alive	G12D	R280I	No	No	G12	Yes	72.0
MSK-P-0021043	62	Female	White	PDAC	Primary	Alive	G12V	R273C	No	No	G12	Yes	62.0
MSK-P-0021091	69	Male	White	PDAC	Metastasis	Alive	G12D	No	No	W524R	G12	No	69.0
MSK-P-0021151	60	Male	White	PDAC	Primary	Deceased	G12V	G245S	No	No	G12	Yes	60.0
MSK-P-0021156	71	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	71.0
MSK-P-0021168	81	Male	White	PDAC	Primary	Alive	G12V	R282W	No	No	G12	Yes	81.0
MSK-P-0021217	59	Male	White	Carcinoma, NOS	Primary	Deceased	G12D	G244S	No	No	G12	Yes	59.0
MSK-P-0021222	84	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	84.0
MSK-P-0021249	76	Female	White	PDAC	Metastasis	Alive	G12R	R282W	No	No	G12	Yes	76.0
MSK-P-0021269	69	Female	NA	PDAC	Primary	Alive	No	No	No	No	No	No	69.0
MSK-P-0021273	48	Male	White	PDAC	Metastasis	Deceased	G12D	R273C	No	No	G12	Yes	48.0
MSK-P-0021301	73	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	73.0
MSK-P-0021321	56	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	56.0
MSK-P-0021341	60	Male	White	PDAC	Metastasis	Deceased	Q61R	No	No	No	Q61	No	60.0
MSK-P-0021347	77	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	77.0
MSK-P-0021350	59	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	59.0
MSK-P-0021354	72	Male	White	PDAC	Primary	Deceased	G12D	P151S	No	No	G12	Yes	72.0
MSK-P-0021356	79	Female	White	PDAC	Primary	Deceased	G12R	L130R	No	No	G12	Yes	79.0
MSK-P-0021373	56	Male	Black/African-American	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0021379	63	Female	Other	PDAC	Primary	Alive	G12D	L130R	No	No	G12	Yes	63.0
MSK-P-0021399	80	Female	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	80.0
MSK-P-0021472	65	Male	White	PDAC	Primary	Deceased	G12D	C275Y	No	No	G12	Yes	65.0
MSK-P-0021473	72	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	72.0
MSK-P-0021475	77	Female	NA	PDAC	Metastasis	Deceased	Q61H	R248W	No	No	Q61	Yes	77.0
MSK-P-0021496	65	Male	White	Carcinoma, NOS	Metastasis	Deceased	Q61R	No	No	No	Q61	No	65.0
MSK-P-0021501	71	Male	Black/African-American	PDAC	Primary	Deceased	G12R	R273C	No	No	G12	Yes	71.0
MSK-P-0021520	87	Female	White	IPMN	Primary	Alive	G12V	No	No	No	G12	No	87.0
MSK-P-0021575	73	Female	White	PDAC	Metastasis	Deceased	G12D	R337C	No	No	G12	Yes	73.0
MSK-P-0021583	67	Male	White	PDAC	Primary	Deceased	G12D	R248W	No	No	G12	Yes	67.0
MSK-P-0021591	59	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	59.0
MSK-P-0021681	60	Female	White	PDAC	Metastasis	Alive	G12D	R175H	H83Y	No	G12	Yes	60.0
MSK-P-0021682	68	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0021705	72	Female	White	PDAC	Primary	Deceased	G12V	R248Q	No	No	G12	Yes	72.0
MSK-P-0021721	71	Male	White	PDAC	Primary	Deceased	G12V	R273C	No	No	G12	Yes	71.0
MSK-P-0021757	63	Female	White	PDAC	Primary	Deceased	No	I195T	No	No	No	Yes	63.0
MSK-P-0021768	44	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	44.0
MSK-P-0021800	75	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	75.0
MSK-P-0021805	76	Male	NA	PDAC	Metastasis	Deceased	G12V	P190L	No	No	G12	Yes	76.0
MSK-P-0021830	60	Male	White	PDAC	Primary	Alive	G12R	No	No	R361C	G12	No	60.0
MSK-P-0021870	68	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0021917	31	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	31.0
MSK-P-0021919	40	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	40.0
MSK-P-0021935	76	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	76.0
MSK-P-0021940	51	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	51.0
MSK-P-0021967	71	Male	White	Carcinoma, NOS	Metastasis	Deceased	G12V	No	No	No	G12	No	71.0
MSK-P-0021972	88	Female	White	PDAC	Primary	Deceased	G12V	G245S	No	No	G12	Yes	88.0
MSK-P-0022023	48	Male	Black/African-American	PDAC	Primary	Deceased	Q61H	No	No	D351A	Q61	No	48.0
MSK-P-0022024	59	Male	Asian	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	59.0
MSK-P-0022027	44	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	E330K	G12	No	44.0
MSK-P-0022028	75	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	75.0
MSK-P-0022041	69	Male	Asian	PDAC	Primary	Alive	G12V	R273C	No	R361H	G12	Yes	69.0
MSK-P-0022085	64	Female	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	64.0
MSK-P-0022102	62	Male	White	PDAC	Metastasis	Deceased	G12D	G266R	No	No	G12	Yes	62.0
MSK-P-0022107	56	Female	NA	PDAC	Primary	Alive	G12V	No	No	No	G12	No	56.0
MSK-P-0022112	68	Male	NA	PDAC	Metastasis	Deceased	G12D	R282W	H83Y	No	G12	Yes	68.0
MSK-P-0022128	54	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	54.0
MSK-P-0022134	72	Female	NA	PNET	Primary	Alive	No	No	No	No	No	No	72.0
MSK-P-0022145	55	Male	White	PDAC	Primary	Alive	G12V	R175H	No	No	G12	Yes	55.0
MSK-P-0022153	76	Male	Black/African-American	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	76.0
MSK-P-0022155	80	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	80.0
MSK-P-0022156	76	Female	White	Acinar cell carcinoma	Primary	Alive	No	No	No	E330V	No	No	76.0
MSK-P-0022157	32	Male	Asian	PNET	Metastasis	Deceased	No	No	No	No	No	No	32.0
MSK-P-0022239	60	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	60.0
MSK-P-0022245	83	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	83.0
MSK-P-0022246	51	Female	White	PDAC	Metastasis	Alive	G12V	V173M	No	No	G12	Yes	51.0
MSK-P-0022292	68	Male	NA	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	68.0
MSK-P-0022294	36	Male	NA	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	36.0
MSK-P-0022319	72	Male	White	PDAC	Primary	Alive	G12R	No	No	L109R	G12	No	72.0
MSK-P-0022325	76	Male	White	PDAC	Primary	Deceased	G12D	Y163C	No	No	G12	Yes	76.0
MSK-P-0022327	52	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	52.0
MSK-P-0022349	62	Male	White	PDAC	Metastasis	Deceased	G12D	R273C	No	S504R	G12	Yes	62.0
MSK-P-0022370	75	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	75.0
MSK-P-0022375	59	Male	White	Adenosquamous carcinoma	Metastasis	Deceased	G12D	H193R	No	No	G12	Yes	59.0
MSK-P-0022394	76	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0022402	63	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	63.0
MSK-P-0022435	55	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	55.0
MSK-P-0022472	55	Male	White	PDAC	Metastasis	Deceased	G12D	H168R	No	No	G12	Yes	55.0
MSK-P-0022504	64	Male	White	PDAC	Primary	Alive	G12V	R248W	No	No	G12	Yes	64.0
MSK-P-0022524	68	Female	White	PDAC	Metastasis	Alive	No	No	A68T	No	No	No	68.0
MSK-P-0022540	59	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	59.0
MSK-P-0022563	67	Female	White	PDAC	Metastasis	Alive	A11_G12delinsGC	No	No	No	G12\|Other	No	67.0
MSK-P-0022599	76	Female	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0022606	84	Male	White	PDAC	Metastasis	Deceased	G12D	I195S	No	No	G12	Yes	84.0
MSK-P-0022639	50	Male	Other	PNET	Metastasis	Deceased	No	R273C	No	No	No	Yes	50.0
MSK-P-0022652	63	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	63.0
MSK-P-0022675	63	Male	White	PDAC	Metastasis	Deceased	G12D	H179R	No	No	G12	Yes	63.0
MSK-P-0022692	51	Male	White	PDAC	Metastasis	Deceased	G12D	H179Y	No	No	G12	Yes	51.0
MSK-P-0022717	59	Male	White	PDAC	Primary	Deceased	G12R	R175H	No	No	G12	Yes	59.0
MSK-P-0022720	73	Male	White	PNET	Metastasis	Deceased	No	E286K	No	No	No	Yes	73.0
MSK-P-0022746	44	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	44.0
MSK-P-0022756	64	Male	Asian	PDAC	Primary	Deceased	G12V	V157F	No	No	G12	Yes	64.0
MSK-P-0022760	60	Male	Asian	PDAC	Primary	Deceased	G12D	R273H	No	R361H	G12	Yes	60.0
MSK-P-0022786	69	Female	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	69.0
MSK-P-0022793	64	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0022801	52	Female	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	52.0
MSK-P-0022811	69	Female	White	PDAC	Metastasis	Deceased	G12R	R282W	No	No	G12	Yes	69.0
MSK-P-0022817	71	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	71.0
MSK-P-0022820	72	Male	White	PDAC	Primary	Deceased	G12D	A161T	No	No	G12	Yes	72.0
MSK-P-0022826	60	Male	Other	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0022828	60	Male	White	PDAC	Metastasis	Deceased	G12D	N239S	No	No	G12	Yes	60.0
MSK-P-0022835	56	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	56.0
MSK-P-0022839	24	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	24.0
MSK-P-0022841	62	Female	White	PDAC	Metastasis	Deceased	G12D	E258G	No	No	G12	Yes	62.0
MSK-P-0022868	76	Male	Asian	PNET	Primary	Alive	No	No	No	No	No	No	76.0
MSK-P-0022883	40	Female	White	PDAC	Primary	Alive	Q61L	No	No	No	Q61	No	40.0
MSK-P-0022946	68	Female	White	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	68.0
MSK-P-0022955	63	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	63.0
MSK-P-0022971	60	Female	White	PDAC	Metastasis	Deceased	G12C	No	No	No	G12	No	60.0
MSK-P-0022983	46	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	46.0
MSK-P-0022988	64	Male	NA	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	64.0
MSK-P-0022990	69	Male	White	PDAC	Primary	Alive	G12R	R175H	No	No	G12	Yes	69.0
MSK-P-0023009	67	Female	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	67.0
MSK-P-0023013	65	Female	Other	PDAC	Primary	Deceased	G12V	R248W	No	No	G12	Yes	65.0
MSK-P-0023018	79	Male	White	PDAC	Primary	Deceased	G12D	R175H	No	G386V	G12	Yes	79.0
MSK-P-0023025	68	Male	White	PDAC	Primary	Deceased	G12V	K132T	No	No	G12	Yes	68.0
MSK-P-0023044	>89	Female	White	PDAC	Primary	Deceased	G12D	G245S	No	No	G12	Yes	90.0
MSK-P-0023068	56	Female	White	PDAC	Metastasis	Deceased	G12D	V272L	No	P130S	G12	Yes	56.0
MSK-P-0023087	56	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0023104	58	Female	Black/African-American	PDAC	Primary	Deceased	G12V	No	No	G510E	G12	No	58.0
MSK-P-0023118	62	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	62.0
MSK-P-0023152	65	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	65.0
MSK-P-0023158	83	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	83.0
MSK-P-0023166	75	Female	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	75.0
MSK-P-0023195	76	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	76.0
MSK-P-0023197	80	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	80.0
MSK-P-0023211	77	Female	Asian	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	77.0
MSK-P-0023215	55	Male	White	PDAC	Metastasis	Alive	I188L	No	No	No	Other	No	55.0
MSK-P-0023290	56	Male	NA	PDAC	Primary	Alive	G12D	P250L	No	No	G12	Yes	56.0
MSK-P-0023291	56	Male	NA	PDAC	Primary	Alive	G12D	C275Y	No	No	G12	Yes	56.0
MSK-P-0023293	84	Female	NA	PDAC	Primary	Alive	G12D	No	No	No	G12	No	84.0
MSK-P-0023299	75	Male	Black/African-American	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	75.0
MSK-P-0023312	76	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	76.0
MSK-P-0023341	79	Male	White	PDAC	Metastasis	Deceased	G12D	H179R	Q50P	No	G12	Yes	79.0
MSK-P-0023354	75	Female	White	PDAC	Primary	Alive	G12V	P177S	No	I383K	G12	Yes	75.0
MSK-P-0023359	72	Male	White	PDAC	Primary	Alive	G12D	P278S	No	No	G12	Yes	72.0
MSK-P-0023385	71	Male	White	PDAC	Metastasis	Deceased	G12D	V272M	No	No	G12	Yes	71.0
MSK-P-0023391	59	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	59.0
MSK-P-0023400	52	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	52.0
MSK-P-0023410	69	Male	Black/African-American	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	69.0
MSK-P-0023428	65	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	65.0
MSK-P-0023455	81	Male	White	PDAC	Primary	Alive	G12R	H168L	No	No	G12	Yes	81.0
MSK-P-0023466	69	Male	White	PDAC	Primary	Alive	Q61H	R248Q	No	No	Q61	Yes	69.0
MSK-P-0023475	59	Female	White	PDAC	Primary	Deceased	G12D,G12V	T125M	No	R361H	G12	Yes	59.0
MSK-P-0023478	73	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	73.0
MSK-P-0023529	65	Male	Asian	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	65.0
MSK-P-0023530	65	Female	Black/African-American	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	65.0
MSK-P-0023541	>89	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	90.0
MSK-P-0023571	77	Male	White	PDAC	Metastasis	Deceased	G12D	C176Y	No	No	G12	Yes	77.0
MSK-P-0023585	83	Male	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	83.0
MSK-P-0023599	71	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0023635	59	Male	White	PDAC	Metastasis	Deceased	G12V	No	L130Q	D351Y	G12	No	59.0
MSK-P-0023646	58	Female	White	PDAC	Metastasis	Deceased	G12D	C135F	No	No	G12	Yes	58.0
MSK-P-0023677	68	Male	White	PDAC	Metastasis	Deceased	Q61H	K132N	No	No	Q61	Yes	68.0
MSK-P-0023682	79	Male	White	PDAC	Metastasis	Deceased	G12D	C275Y	No	No	G12	Yes	79.0
MSK-P-0023714	77	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	77.0
MSK-P-0023717	60	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	60.0
MSK-P-0023719	68	Female	White	Adenosquamous carcinoma	Primary	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0023721	48	Male	Asian	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	48.0
MSK-P-0023732	48	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	48.0
MSK-P-0023743	56	Male	White	PDAC	Primary	Deceased	G12V	C275S	No	No	G12	Yes	56.0
MSK-P-0023756	56	Male	White	PDAC	Primary	Alive	G12R	L145Q	No	No	G12	Yes	56.0
MSK-P-0023786	79	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	79.0
MSK-P-0023795	83	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	83.0
MSK-P-0023837	62	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	62.0
MSK-P-0023851	56	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0023898	88	Male	White	PDAC	Primary	Deceased	G12R	N131Y	No	C363F	G12	Yes	88.0
MSK-P-0023906	58	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	58.0
MSK-P-0023913	48	Female	Asian	PDAC	Metastasis	Deceased	G12D	S127P	No	No	G12	Yes	48.0
MSK-P-0023916	73	Female	White	PDAC	Primary	Deceased	G12V	Y236H	No	No	G12	Yes	73.0
MSK-P-0023965	80	Male	White	PDAC	Primary	Deceased	G12D	C242Y	No	Q116K	G12	Yes	80.0
MSK-P-0023990	80	Male	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	80.0
MSK-P-0024023	80	Male	Asian	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	80.0
MSK-P-0024065	60	Male	White	Adenosquamous carcinoma	Metastasis	Deceased	G12D	V173M	No	No	G12	Yes	60.0
MSK-P-0024111	73	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	73.0
MSK-P-0024133	69	Male	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	69.0
MSK-P-0024147	59	Male	NA	PDAC	Metastasis	Alive	A11_G12delinsHV	No	No	No	G12\|Other	No	59.0
MSK-P-0024202	56	Male	Asian	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	56.0
MSK-P-0024238	60	Male	White	PDAC	Primary	Deceased	G12V	G245S	No	No	G12	Yes	60.0
MSK-P-0024244	59	Male	White	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	59.0
MSK-P-0024268	58	Male	White	PDAC	Primary	Deceased	G12D	R248W	No	No	G12	Yes	58.0
MSK-P-0024315	79	Female	White	PDAC	Primary	Deceased	G12D	V157F	No	No	G12	Yes	79.0
MSK-P-0024328	67	Male	NA	PDAC	Metastasis	Deceased	G12D	No	No	Y133N	G12	No	67.0
MSK-P-0024338	50	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	50.0
MSK-P-0024345	72	Male	White	PDAC	Primary	Deceased	Q61H	R175H	No	No	Q61	Yes	72.0
MSK-P-0024354	44	Female	White	PNET	Metastasis	Deceased	G12D	S241Y	No	No	G12	Yes	44.0
MSK-P-0024358	54	Male	White	PDAC	Metastasis	Alive	G12D	I195T	No	No	G12	Yes	54.0
MSK-P-0024367	56	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	56.0
MSK-P-0024429	60	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0024462	68	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	68.0
MSK-P-0024465	72	Female	Asian	PNET	Metastasis	Deceased	No	No	No	No	No	No	72.0
MSK-P-0024508	48	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	48.0
MSK-P-0024532	62	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	62.0
MSK-P-0024533	68	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0024537	64	Male	White	PDAC	Metastasis	Deceased	G12D	E180K	No	No	G12	Yes	64.0
MSK-P-0024552	>89	Male	White	PDAC	Metastasis	Deceased	G12D	P278A	No	No	G12	Yes	90.0
MSK-P-0024556	71	Female	Other	PDAC	Primary	Deceased	G12R	R175H	No	No	G12	Yes	71.0
MSK-P-0024569	56	Male	Black/African-American	PNET	Metastasis	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0024573	72	Male	White	PDAC	Metastasis	Deceased	G12V	Y236C	No	No	G12	Yes	72.0
MSK-P-0024579	72	Male	White	PDAC	Primary	Deceased	G12V	V274G	No	No	G12	Yes	72.0
MSK-P-0024583	71	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	71.0
MSK-P-0024587	68	Male	White	PDAC	Metastasis	Deceased	G12D	I195T	No	No	G12	Yes	68.0
MSK-P-0024590	76	Male	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	76.0
MSK-P-0024591	68	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	No	No	T521P	G12	No	68.0
MSK-P-0024594	36	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	36.0
MSK-P-0024613	58	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	58.0
MSK-P-0024640	50	Male	White	PDAC	Primary	Deceased	G12D	S106R	No	No	G12	Yes	50.0
MSK-P-0024641	75	Male	White	PDAC	Primary	Deceased	G12R	C135Y	No	No	G12	Yes	75.0
MSK-P-0024644	58	Female	Asian	PDAC	Primary	Deceased	G13D	No	No	No	G13	No	58.0
MSK-P-0024653	68	Female	White	PDAC	Primary	Deceased	G12R	P190L	No	No	G12	Yes	68.0
MSK-P-0024666	44	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	44.0
MSK-P-0024671	75	Male	White	PDAC	Primary	Deceased	G12V	C176W	No	No	G12	Yes	75.0
MSK-P-0024770	62	Female	Asian	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	62.0
MSK-P-0024793	72	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	72.0
MSK-P-0024828	63	Male	Asian	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	63.0
MSK-P-0024833	64	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0024873	58	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	58.0
MSK-P-0024896	73	Male	White	PDAC	Primary	Alive	G12V	G245S	No	No	G12	Yes	73.0
MSK-P-0024931	65	Female	White	PDAC	Primary	Alive	G12A	No	No	No	G12	No	65.0
MSK-P-0024952	65	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	65.0
MSK-P-0024953	28	Male	Other	PNET	Metastasis	Deceased	No	No	No	No	No	No	28.0
MSK-P-0024998	58	Female	White	Solid pseudopapillary tumor	Primary	Alive	No	No	No	R361H	No	No	58.0
MSK-P-0025008	60	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	60.0
MSK-P-0025085	80	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	80.0
MSK-P-0025112	68	Female	White	PDAC	Primary	Alive	G12R	R175H	No	No	G12	Yes	68.0
MSK-P-0025188	80	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	80.0
MSK-P-0025272	62	Female	Other	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	62.0
MSK-P-0025273	69	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	69.0
MSK-P-0025283	NA	NA	NA	PDAC	Metastasis	NA	G12R	No	No	No	G12	No	NA
MSK-P-0025341	68	Female	White	PDAC	Metastasis	Alive	Q61H	No	No	No	Q61	No	68.0
MSK-P-0025342	60	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0025356	54	Male	White	PDAC	Metastasis	Deceased	G12V	R273H	No	A118V	G12	Yes	54.0
MSK-P-0025359	73	Female	Black/African-American	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	73.0
MSK-P-0025361	52	Male	Black/African-American	PDAC	Primary	Deceased	G12D	R248Q	No	No	G12	Yes	52.0
MSK-P-0025381	71	Female	White	PDAC	Primary	Deceased	No	A159T	No	R361H	No	Yes	71.0
MSK-P-0025387	52	Male	Other	PDAC	Primary	Alive	G12D	No	No	No	G12	No	52.0
MSK-P-0025395	65	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	65.0
MSK-P-0025400	72	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0025452	60	Male	White	PDAC	Primary	Deceased	G12V	F270L	No	No	G12	Yes	60.0
MSK-P-0025490	72	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	72.0
MSK-P-0025493	65	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	65.0
MSK-P-0025548	84	Male	White	PDAC	Primary	Deceased	G12R	No	No	D355G	G12	No	84.0
MSK-P-0025570	71	Female	White	PDAC	Primary	Deceased	G12D	K132N	No	No	G12	Yes	71.0
MSK-P-0025589	60	Male	White	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	60.0
MSK-P-0025599	72	Male	White	PDAC	Primary	Deceased	G12V	V218E	No	No	G12	Yes	72.0
MSK-P-0025679	62	Male	Asian	PNET	Metastasis	Alive	No	No	No	No	No	No	62.0
MSK-P-0025682	34	Female	White	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	34.0
MSK-P-0025687	64	Male	NA	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	64.0
MSK-P-0025689	55	Male	White	PDAC	Primary	Alive	G12R	P151H	No	No	G12	Yes	55.0
MSK-P-0025693	44	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	44.0
MSK-P-0025757	60	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0025768	56	Male	White	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	56.0
MSK-P-0025779	63	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	63.0
MSK-P-0025840	50	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	50.0
MSK-P-0025841	71	Male	White	PDAC	Primary	Deceased	Q61R	C238Y	No	No	Q61	Yes	71.0
MSK-P-0025856	67	Male	White	PDAC	Primary	Deceased	G12D	V274L	No	No	G12	Yes	67.0
MSK-P-0025871	64	Female	White	PDAC	Primary	Deceased	G12D	V274D	No	No	G12	Yes	64.0
MSK-P-0025875	67	Female	White	PDAC	Primary	Alive	G12V	F109V	No	No	G12	Yes	67.0
MSK-P-0025893	60	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	60.0
MSK-P-0025913	48	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	48.0
MSK-P-0025919	69	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	69.0
MSK-P-0025921	68	Male	White	PDAC	Primary	Deceased	G12V	R273H	No	No	G12	Yes	68.0
MSK-P-0025922	83	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	83.0
MSK-P-0025951	56	Female	White	PDAC	Metastasis	Deceased	G12V	A161T	No	No	G12	Yes	56.0
MSK-P-0025976	80	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	80.0
MSK-P-0026036	60	Female	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	60.0
MSK-P-0026064	NA	NA	NA	PNET	Metastasis	NA	No	No	No	No	No	No	NA
MSK-P-0026116	60	Male	Asian	PDAC	Primary	Alive	No	No	No	No	No	No	60.0
MSK-P-0026119	64	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	64.0
MSK-P-0026123	56	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0026165	54	Male	White	PDAC	Primary	Deceased	G12V	C135Y	No	No	G12	Yes	54.0
MSK-P-0026172	68	Female	White	PDAC	Primary	Alive	G12D	L257Q	C72G,F90L	No	G12	Yes	68.0
MSK-P-0026188	58	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	58.0
MSK-P-0026204	64	Male	White	PDAC	Metastasis	Deceased	G12V	Y234C	No	No	G12	Yes	64.0
MSK-P-0026273	69	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	69.0
MSK-P-0026285	84	Male	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	84.0
MSK-P-0026305	72	Female	NA	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	72.0
MSK-P-0026364	79	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	79.0
MSK-P-0026387	25	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	25.0
MSK-P-0026391	59	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	59.0
MSK-P-0026448	62	Male	Asian	PDAC	Primary	Alive	No	No	No	No	No	No	62.0
MSK-P-0026470	75	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	75.0
MSK-P-0026541	69	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	69.0
MSK-P-0026694	55	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	55.0
MSK-P-0026717	84	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	84.0
MSK-P-0026734	72	Male	Asian	PDAC	Primary	Deceased	No	No	No	No	No	No	72.0
MSK-P-0026773	71	Male	NA	PDAC	Primary	Deceased	No	No	No	No	No	No	71.0
MSK-P-0026790	50	Male	Other	PDAC	Metastasis	Alive	G12D	No	H83Y	No	G12	No	50.0
MSK-P-0026794	76	Male	Black/African-American	PDAC	Primary	Deceased	G12L	G266E	No	No	G12	Yes	76.0
MSK-P-0026831	77	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	77.0
MSK-P-0026842	60	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0026843	67	Male	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	67.0
MSK-P-0026848	69	Male	White	IPMN	Primary	Alive	G13D	No	No	No	G13	No	69.0
MSK-P-0026857	60	Male	Other	PNET	Primary	Alive	No	No	No	No	No	No	60.0
MSK-P-0026858	71	Female	White	PDAC	Metastasis	Deceased	G12A	No	No	No	G12	No	71.0
MSK-P-0026910	72	Female	Other	PDAC	Primary	Alive	G12D	C242Y	H83Y	No	G12	Yes	72.0
MSK-P-0026911	60	Female	White	PDAC	Metastasis	Deceased	G12V	R248Q	No	No	G12	Yes	60.0
MSK-P-0026930	65	Female	White	PDAC	Metastasis	Deceased	G12C	R282W	No	No	G12	Yes	65.0
MSK-P-0026963	72	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0027029	56	Female	White	PDAC	Metastasis	Deceased	G12R	E286K	No	No	G12	Yes	56.0
MSK-P-0027032	72	Male	White	PDAC	Metastasis	Alive	G12V	T125M	No	No	G12	Yes	72.0
MSK-P-0027033	59	Male	White	PDAC	Metastasis	Alive	Q61R	R248Q	No	No	Q61	Yes	59.0
MSK-P-0027046	71	Male	White	PDAC	Primary	Deceased	Q61R	No	No	No	Q61	No	71.0
MSK-P-0027085	72	Female	White	PDAC	Primary	Deceased	G12D	R248Q	No	R361H	G12	Yes	72.0
MSK-P-0027127	68	Female	White	PDAC	Primary	Alive	Q61H	V272L	No	No	Q61	Yes	68.0
MSK-P-0027138	60	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0027144	73	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	73.0
MSK-P-0027149	58	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	58.0
MSK-P-0027157	68	Male	White	PDAC	Primary	Deceased	G12D	No	No	R361H	G12	No	68.0
MSK-P-0027159	46	Male	Other	PNET	Primary	Alive	No	No	No	No	No	No	46.0
MSK-P-0027186	59	Female	White	PDAC	Primary	Deceased	G12D	Y205C	No	No	G12	Yes	59.0
MSK-P-0027189	60	Female	White	PDAC	Primary	Deceased	No	D281Y	No	R361H	No	Yes	60.0
MSK-P-0027191	64	Male	White	PNET	Primary	Deceased	No	No	No	V163M	No	No	64.0
MSK-P-0027194	71	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	71.0
MSK-P-0027274	62	Male	Other	PDAC	Primary	Deceased	G12V	R282W	No	No	G12	Yes	62.0
MSK-P-0027299	67	Female	Asian	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	67.0
MSK-P-0027303	51	Female	NA	PDAC	Primary	Alive	G12V	R248W	No	No	G12	Yes	51.0
MSK-P-0027311	69	Male	White	PDAC	Primary	Alive	G12V	V173M	No	G386V	G12	Yes	69.0
MSK-P-0027319	52	Female	Black/African-American	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	52.0
MSK-P-0027323	64	Female	Black/African-American	PDAC	Primary	Alive	G12R	R158P	No	No	G12	Yes	64.0
MSK-P-0027348	72	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	72.0
MSK-P-0027354	71	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	71.0
MSK-P-0027394	60	Male	NA	PDAC	Primary	Alive	G12V	No	No	No	G12	No	60.0
MSK-P-0027411	58	Male	White	PDAC	Primary	Deceased	G12A	H179N	No	No	G12	Yes	58.0
MSK-P-0027412	68	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	68.0
MSK-P-0027418	52	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	52.0
MSK-P-0027420	71	Female	Black/African-American	PDAC	Primary	Deceased	G12R	A161T	No	No	G12	Yes	71.0
MSK-P-0027421	64	Female	White	PDAC	Metastasis	Deceased	G12R	P151R	No	No	G12	Yes	64.0
MSK-P-0027444	69	Male	White	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	69.0
MSK-P-0027524	75	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	75.0
MSK-P-0027553	56	Female	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	56.0
MSK-P-0027602	44	Female	White	PDAC	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	44.0
MSK-P-0027620	36	Female	Other	PNET	Primary	Deceased	No	No	No	No	No	No	36.0
MSK-P-0027625	62	Male	White	PDAC	Metastasis	Deceased	G12V	R248W	H83Y	No	G12	Yes	62.0
MSK-P-0027627	59	Female	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	59.0
MSK-P-0027632	63	Female	White	PDAC	Primary	Alive	Q61H	C176F	No	No	Q61	Yes	63.0
MSK-P-0027641	65	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	65.0
MSK-P-0027653	51	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	51.0
MSK-P-0027682	58	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	58.0
MSK-P-0027694	64	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	64.0
MSK-P-0027721	56	Male	Asian	PDAC	Primary	Alive	G12D	No	No	No	G12	No	56.0
MSK-P-0027814	59	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	59.0
MSK-P-0027830	58	Female	White	PDAC	Primary	Alive	G12D	R248W	No	No	G12	Yes	58.0
MSK-P-0027837	54	Male	White	PDAC	Primary	Deceased	G12R	G266V	No	No	G12	Yes	54.0
MSK-P-0027883	47	Female	White	PDAC	Primary	Alive	G12V	C275Y	No	No	G12	Yes	47.0
MSK-P-0027891	76	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	76.0
MSK-P-0027919	64	Male	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	64.0
MSK-P-0027941	76	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0027992	62	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	62.0
MSK-P-0028015	85	Female	White	PDAC	Metastasis	Deceased	G12R	R248Q	No	No	G12	Yes	85.0
MSK-P-0028084	85	Female	White	PDAC	Primary	Alive	G12D	R273C	No	No	G12	Yes	85.0
MSK-P-0028109	81	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	81.0
MSK-P-0028118	72	Female	White	PDAC	Metastasis	Deceased	G12D	C238F	No	No	G12	Yes	72.0
MSK-P-0028120	67	Female	White	PDAC	Primary	Alive	G12R	R249S	No	No	G12	Yes	67.0
MSK-P-0028154	68	Female	Asian	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	68.0
MSK-P-0028158	87	Female	White	Carcinoma, NOS	Metastasis	Deceased	Q61R	No	No	No	Q61	No	87.0
MSK-P-0028164	63	Female	White	PDAC	Metastasis	Alive	G12V	S127F	No	No	G12	Yes	63.0
MSK-P-0028195	62	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	62.0
MSK-P-0028198	72	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	72.0
MSK-P-0028202	72	Female	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	72.0
MSK-P-0028207	56	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0028249	87	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	87.0
MSK-P-0028255	80	Female	White	PDAC	Primary	Deceased	Q61H	R175H	No	No	Q61	Yes	80.0
MSK-P-0028300	72	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0028314	59	Female	White	PDAC	Primary	Deceased	No	R273S	No	No	No	Yes	59.0
MSK-P-0028334	69	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	69.0
MSK-P-0028362	62	Female	White	PDAC	Primary	Deceased	No	G266R	No	No	No	Yes	62.0
MSK-P-0028363	NA	NA	NA	PDAC	Primary	NA	No	No	No	No	No	No	NA
MSK-P-0028419	58	Male	Other	PDAC	Metastasis	Deceased	G12D	V274G	No	No	G12	Yes	58.0
MSK-P-0028420	35	Female	Asian	PDAC	Metastasis	Deceased	No	No	No	No	No	No	35.0
MSK-P-0028425	59	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	59.0
MSK-P-0028428	60	Male	White	PDAC	Metastasis	Deceased	G12V	P151T	H83Y	No	G12	Yes	60.0
MSK-P-0028470	52	Male	White	PDAC	Metastasis	Deceased	G12D	P151A	No	No	G12	Yes	52.0
MSK-P-0028490	72	Male	White	PDAC	Metastasis	Deceased	G12D	No	H83Y	No	G12	No	72.0
MSK-P-0028531	67	Female	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	67.0
MSK-P-0028536	72	Female	Asian	PDAC	Primary	Alive	G12D	Y236D	No	No	G12	Yes	72.0
MSK-P-0028543	76	Female	White	PDAC	Metastasis	Deceased	Q61K	No	No	No	Q61	No	76.0
MSK-P-0028577	76	Female	White	PDAC	Primary	Deceased	G12R	No	No	R361H	G12	No	76.0
MSK-P-0028585	58	Female	Black/African-American	PDAC	Metastasis	Deceased	G12D	F270S	No	No	G12	Yes	58.0
MSK-P-0028603	69	Male	White	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	69.0
MSK-P-0028618	54	Female	Black/African-American	PDAC	Primary	Deceased	G12V	R248Q	No	No	G12	Yes	54.0
MSK-P-0028630	80	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	80.0
MSK-P-0028641	68	Female	White	PDAC	Metastasis	Deceased	G12V	Y236C	No	No	G12	Yes	68.0
MSK-P-0028676	72	Male	White	Adenosquamous carcinoma	Primary	Deceased	Q61H	G245S	No	No	Q61	Yes	72.0
MSK-P-0028677	60	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0028680	76	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	76.0
MSK-P-0028691	52	Female	Black/African-American	PNET	Metastasis	Deceased	G12V	K132R	No	No	G12	Yes	52.0
MSK-P-0028708	79	Female	White	PDAC	Metastasis	Deceased	G12D	V197M	No	No	G12	Yes	79.0
MSK-P-0028744	68	Male	White	PDAC	Primary	Alive	G12R	No	H83Y	No	G12	No	68.0
MSK-P-0028760	68	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0028779	76	Female	White	PDAC	Primary	Deceased	G12D	Y205D	No	No	G12	Yes	76.0
MSK-P-0028809	58	Female	Asian	PDAC	Metastasis	Deceased	No	G245V	No	No	No	Yes	58.0
MSK-P-0028869	62	Female	White	PDAC	Primary	Deceased	G12D	G245S	No	No	G12	Yes	62.0
MSK-P-0028870	64	Male	White	PDAC	Metastasis	Deceased	G12V	S241F	No	No	G12	Yes	64.0
MSK-P-0028878	47	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	47.0
MSK-P-0028923	73	Female	White	PDAC	Metastasis	Alive	G12D	R273H	No	No	G12	Yes	73.0
MSK-P-0028941	54	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	54.0
MSK-P-0028995	69	Male	White	PDAC	Metastasis	Alive	G12R	R248Q	No	No	G12	Yes	69.0
MSK-P-0029019	71	Female	White	PDAC	Primary	Alive	G12V	R175H	No	No	G12	Yes	71.0
MSK-P-0029023	50	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	50.0
MSK-P-0029058	56	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0029065	68	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	68.0
MSK-P-0029093	63	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	63.0
MSK-P-0029109	83	Female	White	PDAC	Primary	Alive	G12R	M237I	No	R361S	G12	Yes	83.0
MSK-P-0029138	80	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	80.0
MSK-P-0029153	58	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	58.0
MSK-P-0029156	56	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	56.0
MSK-P-0029168	54	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	54.0
MSK-P-0029229	65	Female	White	PDAC	Primary	Deceased	G12C	R248Q	No	No	G12	Yes	65.0
MSK-P-0029243	73	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	73.0
MSK-P-0029272	68	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0029281	68	Female	Other	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	68.0
MSK-P-0029282	64	Female	Black/African-American	PDAC	Primary	Deceased	G12V	L252P	No	No	G12	Yes	64.0
MSK-P-0029288	88	Female	Asian	PDAC	Primary	Alive	G12D	S241Y	No	No	G12	Yes	88.0
MSK-P-0029289	62	Female	White	PDAC	Primary	Alive	G12V	R280T	No	No	G12	Yes	62.0
MSK-P-0029377	58	Male	Asian	PDAC	Primary	Alive	G12V	R283P	No	No	G12	Yes	58.0
MSK-P-0029477	52	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	52.0
MSK-P-0029478	69	Female	White	PDAC	Primary	Alive	G12D	C176S	No	No	G12	Yes	69.0
MSK-P-0029527	79	Male	White	PDAC	Primary	Deceased	G12C	No	No	No	G12	No	79.0
MSK-P-0029549	75	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	75.0
MSK-P-0029562	63	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	63.0
MSK-P-0029566	81	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	81.0
MSK-P-0029579	67	Female	White	PDAC	Primary	Deceased	G12V	G245D	No	No	G12	Yes	67.0
MSK-P-0029588	71	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0029589	72	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	72.0
MSK-P-0029597	72	Male	White	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	72.0
MSK-P-0029599	67	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	67.0
MSK-P-0029615	63	Male	Asian	PDAC	Metastasis	Deceased	G12V	V272L	No	No	G12	Yes	63.0
MSK-P-0029649	54	Male	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	54.0
MSK-P-0029654	59	Male	NA	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	59.0
MSK-P-0029665	75	Female	White	PDAC	Primary	Alive	G12R	R282W	No	No	G12	Yes	75.0
MSK-P-0029719	60	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0029749	55	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	55.0
MSK-P-0029760	68	Male	Other	PDAC	Metastasis	Alive	Q61R	G245S	No	No	Q61	Yes	68.0
MSK-P-0029780	52	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	52.0
MSK-P-0029781	71	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	71.0
MSK-P-0029816	65	Female	White	PDAC	Primary	Deceased	G12V	R248Q	No	No	G12	Yes	65.0
MSK-P-0029819	64	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	64.0
MSK-P-0029823	60	Female	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	60.0
MSK-P-0029824	55	Male	Asian	PDAC	Metastasis	Deceased	G12V	H193R	No	No	G12	Yes	55.0
MSK-P-0029827	68	Male	White	Adenosquamous carcinoma	Primary	Alive	G12D	Y234H	No	No	G12	Yes	68.0
MSK-P-0029870	62	Male	White	PDAC	Primary	Alive	G12V	R248W	No	No	G12	Yes	62.0
MSK-P-0029916	68	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	68.0
MSK-P-0029976	56	Male	Black/African-American	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0029982	65	Male	White	PDAC	Metastasis	Alive	G12V	R273C	No	No	G12	Yes	65.0
MSK-P-0029986	69	Male	White	PDAC	Primary	Deceased	G13D	R273H	No	No	G13	Yes	69.0
MSK-P-0029996	60	Male	NA	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	60.0
MSK-P-0030011	72	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	72.0
MSK-P-0030024	64	Male	White	PDAC	Primary	Deceased	Q61H	R249S	No	No	Q61	Yes	64.0
MSK-P-0030144	68	Female	White	PDAC	Primary	Alive	G12D	G245S	No	No	G12	Yes	68.0
MSK-P-0030148	64	Female	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	64.0
MSK-P-0030183	58	Female	Other	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	58.0
MSK-P-0030198	62	Male	NA	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	62.0
MSK-P-0030211	48	Male	NA	PDAC	Metastasis	Deceased	No	No	No	R361C	No	No	48.0
MSK-P-0030213	48	Male	White	PDAC	Metastasis	Alive	G12V	R175H	No	No	G12	Yes	48.0
MSK-P-0030218	75	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	75.0
MSK-P-0030219	76	Male	White	PDAC	Primary	Deceased	G12D	R175H	No	G508D	G12	Yes	76.0
MSK-P-0030264	68	Female	White	PDAC	Metastasis	Alive	G12D	E171G	No	No	G12	Yes	68.0
MSK-P-0030289	55	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	V350F	G12	No	55.0
MSK-P-0030327	65	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	65.0
MSK-P-0030360	60	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	60.0
MSK-P-0030377	36	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	36.0
MSK-P-0030407	69	Male	White	PDAC	Primary	Alive	G12R	H193R	No	No	G12	Yes	69.0
MSK-P-0030442	65	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	65.0
MSK-P-0030448	36	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	36.0
MSK-P-0030506	>89	Male	White	PDAC	Primary	Deceased	G12V	R273L	No	No	G12	Yes	90.0
MSK-P-0030513	48	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	48.0
MSK-P-0030523	71	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	71.0
MSK-P-0030558	80	Male	White	PDAC	Primary	Alive	G12R	G266E	No	No	G12	Yes	80.0
MSK-P-0030559	56	Female	White	PDAC	Metastasis	Deceased	G12V	I254N	No	No	G12	Yes	56.0
MSK-P-0030684	69	Female	White	PDAC	Primary	Deceased	G12V	Y236C	No	No	G12	Yes	69.0
MSK-P-0030702	55	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	55.0
MSK-P-0030749	62	Female	White	PDAC	Metastasis	Deceased	G12V	I255N	No	No	G12	Yes	62.0
MSK-P-0030773	76	Male	White	PDAC	Metastasis	Deceased	Q61R	L194R	No	No	Q61	Yes	76.0
MSK-P-0030778	58	Male	White	PNET	Primary	Deceased	No	H179D	No	No	No	Yes	58.0
MSK-P-0030787	46	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	46.0
MSK-P-0030794	43	Male	Asian	Acinar cell carcinoma	Primary	Alive	No	No	No	L536P	No	No	43.0
MSK-P-0030824	52	Male	White	PDAC	Primary	Deceased	G12R	F134L	No	No	G12	Yes	52.0
MSK-P-0030826	NA	NA	NA	PDAC	Metastasis	NA	G12V	R273H	No	No	G12	Yes	NA
MSK-P-0030833	56	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0030841	59	Female	White	PDAC	Primary	Alive	G12R	No	H83D	No	G12	No	59.0
MSK-P-0030846	80	Male	White	PDAC	Primary	Deceased	Q61K	No	No	No	Q61	No	80.0
MSK-P-0030887	60	Male	Black/African-American	Adenosquamous carcinoma	Primary	Alive	No	C238R	No	No	No	Yes	60.0
MSK-P-0030891	60	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	60.0
MSK-P-0030894	59	Male	White	PDAC	Primary	Deceased	G12D	Y220C	No	No	G12	Yes	59.0
MSK-P-0030910	62	Female	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	62.0
MSK-P-0030975	>89	Female	White	PDAC	Primary	Deceased	Q61H	R248Q	No	No	Q61	Yes	90.0
MSK-P-0031014	64	Female	NA	PDAC	Primary	Alive	G12A	No	No	No	G12	No	64.0
MSK-P-0031025	56	Female	White	PDAC	Metastasis	Deceased	G12D	Y220C	No	No	G12	Yes	56.0
MSK-P-0031051	85	Male	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	85.0
MSK-P-0031084	56	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0031131	50	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	50.0
MSK-P-0031143	69	Female	Asian	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	69.0
MSK-P-0031148	64	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	64.0
MSK-P-0031153	58	Female	Other	PDAC	Primary	Deceased	Q61H	S241F	No	No	Q61	Yes	58.0
MSK-P-0031179	52	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	52.0
MSK-P-0031187	65	Male	NA	PDAC	Primary	Alive	G12D	R248Q	No	No	G12	Yes	65.0
MSK-P-0031192	56	Female	White	PDAC	Primary	Deceased	Q61L	No	No	No	Q61	No	56.0
MSK-P-0031200	76	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0031225	55	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	55.0
MSK-P-0031228	54	Male	Asian	PDAC	Metastasis	Deceased	G12D	R273C	No	No	G12	Yes	54.0
MSK-P-0031230	72	Male	White	PDAC	Primary	Alive	G12R	R248Q	No	No	G12	Yes	72.0
MSK-P-0031231	56	Male	Asian	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0031245	69	Male	White	PDAC	Metastasis	Deceased	G12R	P151H	No	No	G12	Yes	69.0
MSK-P-0031255	64	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12V	No	No	No	G12	No	64.0
MSK-P-0031263	63	Female	Black/African-American	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	63.0
MSK-P-0031305	67	Male	Other	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	67.0
MSK-P-0031327	85	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	85.0
MSK-P-0031328	76	Female	White	PDAC	Primary	Deceased	G12D	No	No	I240K	G12	No	76.0
MSK-P-0031338	56	Male	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	56.0
MSK-P-0031352	64	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0031372	59	Female	White	PDAC	Primary	Alive	G12D	Y220C	No	No	G12	Yes	59.0
MSK-P-0031393	72	Male	White	PDAC	Primary	Deceased	G12D	No	H83Y	No	G12	No	72.0
MSK-P-0031394	81	Female	White	PDAC	Metastasis	Deceased	G13D	No	No	No	G13	No	81.0
MSK-P-0031405	64	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	64.0
MSK-P-0031410	44	Female	Asian	PDAC	Metastasis	Alive	No	No	No	No	No	No	44.0
MSK-P-0031431	84	Male	White	PDAC	Primary	Alive	No	No	No	R361C	No	No	84.0
MSK-P-0031453	67	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	67.0
MSK-P-0031463	65	Male	Black/African-American	Adenosquamous carcinoma	Primary	Alive	G12D	P190L	No	No	G12	Yes	65.0
MSK-P-0031464	56	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	56.0
MSK-P-0031492	47	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	47.0
MSK-P-0031506	59	Female	White	PDAC	Primary	Alive	G12V	K132N	No	No	G12	Yes	59.0
MSK-P-0031530	63	Female	White	PDAC	Primary	Deceased	G12D	H193Y	No	No	G12	Yes	63.0
MSK-P-0031531	68	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0031556	56	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	56.0
MSK-P-0031582	68	Female	White	PDAC	Primary	Alive	G12V	P190T	No	No	G12	Yes	68.0
MSK-P-0031595	69	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	69.0
MSK-P-0031655	71	Female	Asian	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	71.0
MSK-P-0031659	76	Female	White	PDAC	Metastasis	Deceased	G12R	I195T	No	No	G12	Yes	76.0
MSK-P-0031701	48	Female	Asian	PDAC	Primary	Alive	No	No	No	No	No	No	48.0
MSK-P-0031811	48	Male	White	PDAC	Metastasis	Deceased	G13D	No	No	No	G13	No	48.0
MSK-P-0031824	62	Male	White	PDAC	Metastasis	Deceased	No	S241F	No	No	No	Yes	62.0
MSK-P-0031836	76	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	76.0
MSK-P-0031843	72	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	72.0
MSK-P-0031847	63	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	63.0
MSK-P-0031849	68	Female	NA	PDAC	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0031864	60	Female	Asian	PDAC	Metastasis	Deceased	G12V	H193L	No	No	G12	Yes	60.0
MSK-P-0031874	65	Male	White	PDAC	Metastasis	Alive	G12V	R273C	No	No	G12	Yes	65.0
MSK-P-0031881	68	Male	White	PDAC	Primary	Alive	G12R	Y126C	H83Y	No	G12	Yes	68.0
MSK-P-0031884	48	Female	White	PDAC	Primary	Alive	G12V	R175H	D84N	No	G12	Yes	48.0
MSK-P-0031885	48	Female	White	PDAC	Primary	Alive	G12V	R282W	No	No	G12	Yes	48.0
MSK-P-0031915	60	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	60.0
MSK-P-0031918	77	Female	White	PDAC	Primary	Deceased	G12D	E285K	No	E330K	G12	Yes	77.0
MSK-P-0031938	68	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	68.0
MSK-P-0031940	56	Female	White	PDAC	Primary	Deceased	G12R	G245V	No	No	G12	Yes	56.0
MSK-P-0031952	68	Male	White	PDAC	Primary	Deceased	G12H	No	No	No	G12	No	68.0
MSK-P-0031964	56	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	56.0
MSK-P-0031967	55	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	55.0
MSK-P-0031988	59	Male	White	PDAC	Metastasis	Deceased	G12D	S127F	No	No	G12	Yes	59.0
MSK-P-0031999	77	Male	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	77.0
MSK-P-0032012	88	Female	Asian	PDAC	Metastasis	Alive	G12C	No	No	No	G12	No	88.0
MSK-P-0032031	31	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	31.0
MSK-P-0032041	51	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	51.0
MSK-P-0032056	64	Female	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	64.0
MSK-P-0032078	69	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	69.0
MSK-P-0032109	76	Female	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	76.0
MSK-P-0032152	67	Male	NA	PDAC	Metastasis	Deceased	No	No	No	No	No	No	67.0
MSK-P-0032169	76	Male	White	PDAC	Primary	Deceased	G12V	C176R	No	V492F	G12	Yes	76.0
MSK-P-0032195	64	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	L533P	G12	No	64.0
MSK-P-0032218	84	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	84.0
MSK-P-0032229	67	Female	White	PDAC	Primary	Alive	G12D	G266R	No	No	G12	Yes	67.0
MSK-P-0032232	55	Male	Asian	PDAC	Primary	Alive	G12R	No	No	No	G12	No	55.0
MSK-P-0032235	44	Female	White	PDAC	Metastasis	Alive	Q61H,L120S	E224D	No	No	Q61\|Other	Yes	44.0
MSK-P-0032312	76	Female	White	PDAC	Primary	Deceased	G12R	No	No	R361H	G12	No	76.0
MSK-P-0032336	51	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	51.0
MSK-P-0032341	81	Male	White	PDAC	Primary	Deceased	G12V	R273C	No	No	G12	Yes	81.0
MSK-P-0032346	68	Male	White	PDAC	Metastasis	Deceased	G12V	T155N	No	No	G12	Yes	68.0
MSK-P-0032364	85	Female	Other	PDAC	Primary	Alive	G12V	No	No	D537G	G12	No	85.0
MSK-P-0032401	71	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	71.0
MSK-P-0032403	>89	Female	White	PDAC	Primary	Deceased	G12R	R248W	No	L536P	G12	Yes	90.0
MSK-P-0032426	84	Male	White	PDAC	Primary	Deceased	G12R	R248Q	No	No	G12	Yes	84.0
MSK-P-0032448	64	Female	Other	PDAC	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	64.0
MSK-P-0032535	62	Male	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	62.0
MSK-P-0032627	72	Male	White	PDAC	Primary	Alive	G12D	No	No	A118V	G12	No	72.0
MSK-P-0032629	43	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	43.0
MSK-P-0032631	71	Male	White	PDAC	Metastasis	Deceased	V44L,Q61L	No	No	No	Q61\|Other	No	71.0
MSK-P-0032637	64	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	64.0
MSK-P-0032638	71	Female	NA	PDAC	Metastasis	Alive	G12D	R158H	No	No	G12	Yes	71.0
MSK-P-0032661	52	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	52.0
MSK-P-0032671	76	Male	White	PDAC	Primary	Deceased	G12V	C135F	No	No	G12	Yes	76.0
MSK-P-0032677	58	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12V	No	No	No	G12	No	58.0
MSK-P-0032725	62	Male	Black/African-American	PDAC	Primary	Deceased	G12V	R196P	V51D	No	G12	Yes	62.0
MSK-P-0032744	64	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0032749	76	Male	White	PDAC	Metastasis	Alive	G12D	R273C	No	No	G12	Yes	76.0
MSK-P-0032756	64	Female	White	PDAC	Primary	Alive	G12V	T256P	No	G365D	G12	Yes	64.0
MSK-P-0032775	59	Male	White	PDAC	Metastasis	Alive	G12R	No	No	W99C	G12	No	59.0
MSK-P-0032825	71	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	G245S	No	No	G12	Yes	71.0
MSK-P-0032869	71	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	71.0
MSK-P-0032952	79	Male	Black/African-American	PNET	Metastasis	Alive	No	No	No	No	No	No	79.0
MSK-P-0032981	56	Female	White	PDAC	Metastasis	Deceased	G12V	H214R	No	No	G12	Yes	56.0
MSK-P-0033017	51	Male	White	PDAC	Primary	Alive	G12D	Y220S	No	No	G12	Yes	51.0
MSK-P-0033031	88	Male	White	PDAC	Metastasis	Deceased	No	P151R	No	No	No	Yes	88.0
MSK-P-0033041	71	Female	White	Adenosquamous carcinoma	Primary	Alive	G12V	R282W	No	No	G12	Yes	71.0
MSK-P-0033080	56	Female	Black/African-American	PDAC	Metastasis	Deceased	G12R	C141R	No	No	G12	Yes	56.0
MSK-P-0033102	69	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	69.0
MSK-P-0033171	83	Male	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	83.0
MSK-P-0033201	40	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	40.0
MSK-P-0033208	34	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	34.0
MSK-P-0033255	56	Female	White	PDAC	Metastasis	Deceased	G12V	L137Q	No	No	G12	Yes	56.0
MSK-P-0033257	46	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	46.0
MSK-P-0033299	77	Male	White	PDAC	Primary	Deceased	G12V	R248Q	No	No	G12	Yes	77.0
MSK-P-0033306	68	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0033307	51	Female	Other	PDAC	Primary	Alive	Q61H	R273H	No	D537G	Q61	Yes	51.0
MSK-P-0033329	72	Female	White	PDAC	Metastasis	Deceased	G12V	H179Y	No	No	G12	Yes	72.0
MSK-P-0033330	79	Female	Black/African-American	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	79.0
MSK-P-0033343	76	Male	White	PDAC	Primary	Deceased	Q61L	No	No	No	Q61	No	76.0
MSK-P-0033383	72	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	72.0
MSK-P-0033428	72	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0033439	68	Female	White	PDAC	Primary	Deceased	G12D	No	L16Q	No	G12	No	68.0
MSK-P-0033518	52	Male	NA	PDAC	Primary	Alive	G12V	No	No	No	G12	No	52.0
MSK-P-0033545	62	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	62.0
MSK-P-0033560	72	Male	White	PDAC	Metastasis	Deceased	G12R	H214R	No	No	G12	Yes	72.0
MSK-P-0033578	69	Female	NA	PDAC	Primary	Deceased	No	No	No	No	No	No	69.0
MSK-P-0033596	64	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	64.0
MSK-P-0033599	76	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0033719	47	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	R361H	G12	No	47.0
MSK-P-0033739	60	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	60.0
MSK-P-0033760	48	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	48.0
MSK-P-0033850	76	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	76.0
MSK-P-0033899	55	Male	White	PNET	Primary	Alive	No	P82L	No	No	No	Yes	55.0
MSK-P-0033980	75	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	75.0
MSK-P-0033982	76	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0034033	55	Male	White	PDAC	Primary	Deceased	G12D	R248Q	No	No	G12	Yes	55.0
MSK-P-0034059	58	Female	White	PDAC	Primary	Deceased	G12D	R248Q	No	L47P	G12	Yes	58.0
MSK-P-0034082	56	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0034085	73	Male	White	PDAC	Primary	Alive	G12R	M237I	No	W524C	G12	Yes	73.0
MSK-P-0034139	79	Male	Black/African-American	PNET	Primary	Alive	No	No	No	No	No	No	79.0
MSK-P-0034222	60	Male	White	PDAC	Metastasis	Deceased	G12D	R248W	No	No	G12	Yes	60.0
MSK-P-0034261	67	Male	White	PDAC	Metastasis	Deceased	G12V	R273H	No	R496H	G12	Yes	67.0
MSK-P-0034275	76	Male	White	PDAC	Primary	Deceased	G12V	No	L65P	No	G12	No	76.0
MSK-P-0034324	51	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	51.0
MSK-P-0034447	48	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12D	No	No	No	G12	No	48.0
MSK-P-0034506	76	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	76.0
MSK-P-0034624	38	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	38.0
MSK-P-0034628	72	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	72.0
MSK-P-0034641	72	Female	White	PDAC	Metastasis	Deceased	G12D	C275F	No	No	G12	Yes	72.0
MSK-P-0034702	72	Male	White	PDAC	Primary	Deceased	G13D	No	No	No	G13	No	72.0
MSK-P-0034708	65	Female	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	65.0
MSK-P-0034709	54	Female	Other	PDAC	Primary	Deceased	G12D	G245V	No	No	G12	Yes	54.0
MSK-P-0034714	39	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	39.0
MSK-P-0034773	51	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	51.0
MSK-P-0034817	76	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	76.0
MSK-P-0034859	64	Male	White	PDAC	Metastasis	Deceased	G12V	K132N	No	No	G12	Yes	64.0
MSK-P-0034930	64	Male	White	PDAC	Primary	Alive	G12V	D259Y	No	No	G12	Yes	64.0
MSK-P-0034932	65	Female	White	PDAC	Metastasis	Deceased	G12D	P152L	P81R	No	G12	Yes	65.0
MSK-P-0034939	80	Female	White	PDAC	Metastasis	Deceased	G12R	G266E	H83Y	No	G12	Yes	80.0
MSK-P-0035025	60	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	60.0
MSK-P-0035029	55	Female	White	PDAC	Primary	Deceased	G12D	Y126N	H83R	No	G12	Yes	55.0
MSK-P-0035079	79	Female	White	PDAC	Primary	Deceased	G12D	T155P	No	No	G12	Yes	79.0
MSK-P-0035083	48	Male	White	PDAC	Primary	Deceased	G12V	Y163C	No	No	G12	Yes	48.0
MSK-P-0035105	64	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0035141	62	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	62.0
MSK-P-0035279	69	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	69.0
MSK-P-0035323	72	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0035370	64	Male	White	PDAC	Metastasis	Deceased	G12V	S241C	No	No	G12	Yes	64.0
MSK-P-0035434	76	Female	Black/African-American	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	76.0
MSK-P-0035442	69	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	69.0
MSK-P-0035458	63	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	63.0
MSK-P-0035470	60	Female	White	Adenosquamous carcinoma	Primary	Alive	G12V	R282W	No	No	G12	Yes	60.0
MSK-P-0035486	77	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	77.0
MSK-P-0035509	36	Female	Black/African-American	PNET	Metastasis	Deceased	No	No	No	No	No	No	36.0
MSK-P-0035518	59	Female	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	59.0
MSK-P-0035521	76	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0035524	68	Male	Asian	PDAC	Primary	Alive	G12V	R273C	No	No	G12	Yes	68.0
MSK-P-0035525	80	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	80.0
MSK-P-0035547	58	Female	White	PDAC	Metastasis	Deceased	G12R	G245S	No	No	G12	Yes	58.0
MSK-P-0035552	62	Female	Asian	PDAC	Primary	Deceased	No	No	No	No	No	No	62.0
MSK-P-0035573	69	Male	White	PDAC	Primary	Alive	G12V	R175H	No	No	G12	Yes	69.0
MSK-P-0035577	62	Male	NA	PDAC	Metastasis	Deceased	G12D	K132N	No	No	G12	Yes	62.0
MSK-P-0035579	48	Male	Black/African-American	PDAC	Primary	Deceased	G12D	P250L	No	No	G12	Yes	48.0
MSK-P-0035624	64	Female	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	64.0
MSK-P-0035641	56	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0035724	68	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0035730	79	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	79.0
MSK-P-0035736	67	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	67.0
MSK-P-0035737	71	Male	White	PDAC	Primary	Alive	G12R	R273C	No	No	G12	Yes	71.0
MSK-P-0035767	56	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	56.0
MSK-P-0035776	68	Male	White	PDAC	Metastasis	Deceased	G12D	R248Q	No	R361H	G12	Yes	68.0
MSK-P-0035780	76	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	76.0
MSK-P-0035781	58	Female	NA	Adenosquamous carcinoma	Primary	Alive	G12V	R175H	No	No	G12	Yes	58.0
MSK-P-0035785	62	Female	White	PDAC	Primary	Deceased	No	F113V	No	No	No	Yes	62.0
MSK-P-0035817	51	Male	White	PDAC	Primary	Alive	G12C	R337C,R175H	No	No	G12	Yes	51.0
MSK-P-0035833	80	Female	White	PDAC	Primary	Alive	G12V	G245V	A21P	No	G12	Yes	80.0
MSK-P-0035839	75	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	75.0
MSK-P-0036010	62	Male	NA	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	62.0
MSK-P-0036018	54	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	54.0
MSK-P-0036088	64	Male	Asian	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	64.0
MSK-P-0036093	81	Male	Asian	PDAC	Primary	Deceased	G12R	No	H83Y	No	G12	No	81.0
MSK-P-0036094	75	Female	White	PDAC	Primary	Alive	G12R	G245C	No	No	G12	Yes	75.0
MSK-P-0036108	60	Female	White	PDAC	Primary	Deceased	G12V	L194V	No	No	G12	Yes	60.0
MSK-P-0036115	69	Female	White	PDAC	Primary	Deceased	G12D	F270L	No	D493N	G12	Yes	69.0
MSK-P-0036116	56	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	G386V	G12	No	56.0
MSK-P-0036117	76	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0036130	72	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	P190L	No	R361S	G12	Yes	72.0
MSK-P-0036158	38	Female	White	PDAC	Metastasis	Alive	G12D	C238S	No	No	G12	Yes	38.0
MSK-P-0036252	52	Female	Black/African-American	PDAC	Primary	Deceased	No	R175H	No	No	No	Yes	52.0
MSK-P-0036262	80	Female	White	Adenosquamous carcinoma	Primary	Deceased	G12R	No	No	No	G12	No	80.0
MSK-P-0036265	67	Female	Asian	PDAC	Metastasis	Alive	No	No	No	No	No	No	67.0
MSK-P-0036269	84	Female	Asian	PDAC	Primary	Deceased	G12D	No	No	D351G	G12	No	84.0
MSK-P-0036270	73	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	73.0
MSK-P-0036295	83	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	83.0
MSK-P-0036360	65	Female	White	PDAC	Metastasis	Deceased	G12D	R282W	No	No	G12	Yes	65.0
MSK-P-0036388	76	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	76.0
MSK-P-0036423	64	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0036432	51	Female	Asian	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	51.0
MSK-P-0036443	80	Male	White	PDAC	Primary	Alive	Q61H	C275F	No	No	Q61	Yes	80.0
MSK-P-0036533	67	Female	White	PDAC	Primary	Alive	G12V	No	L63Q	No	G12	No	67.0
MSK-P-0036591	64	Male	Black/African-American	PDAC	Metastasis	Alive	G12R	E285K	No	R361C	G12	Yes	64.0
MSK-P-0036597	80	Female	White	PDAC	Primary	Deceased	Q61R	No	No	No	Q61	No	80.0
MSK-P-0036610	60	Male	White	PDAC	Primary	Deceased	G12V	F113V	No	No	G12	Yes	60.0
MSK-P-0036646	44	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	44.0
MSK-P-0036665	56	Female	Black/African-American	PDAC	Metastasis	Alive	G12V	R248W	No	No	G12	Yes	56.0
MSK-P-0036713	65	Male	White	PDAC	Metastasis	Alive	G12R	L194R	No	No	G12	Yes	65.0
MSK-P-0036716	79	Male	White	PDAC	Primary	Alive	G12R	R175H	No	No	G12	Yes	79.0
MSK-P-0036723	60	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	60.0
MSK-P-0036743	72	Female	White	PDAC	Primary	Alive	G12D	R175H	D108G	No	G12	Yes	72.0
MSK-P-0036811	76	Female	White	PDAC	Primary	Alive	G12V	Y220C	No	No	G12	Yes	76.0
MSK-P-0036857	43	Female	White	Mucinous adenocarcinoma	Primary	Alive	G12D	H179R	No	No	G12	Yes	43.0
MSK-P-0036883	69	Female	NA	PDAC	Primary	Alive	G12R	V172D	No	No	G12	Yes	69.0
MSK-P-0036906	40	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	40.0
MSK-P-0036919	52	Female	NA	PDAC	Primary	Alive	G12V	No	No	No	G12	No	52.0
MSK-P-0036923	68	Male	White	PDAC	Primary	Deceased	G12R	R248W	No	No	G12	Yes	68.0
MSK-P-0036946	NA	NA	NA	PDAC	Metastasis	NA	G12D	No	No	No	G12	No	NA
MSK-P-0036976	72	Female	White	PDAC	Primary	Deceased	G12V	G245S	No	No	G12	Yes	72.0
MSK-P-0037067	51	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	51.0
MSK-P-0037083	60	Male	White	PDAC	Metastasis	Deceased	G12D	R248G	No	No	G12	Yes	60.0
MSK-P-0037093	75	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	75.0
MSK-P-0037098	56	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0037141	64	Female	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	64.0
MSK-P-0037148	56	Male	White	PDAC	Metastasis	Deceased	G12D	R282W	No	No	G12	Yes	56.0
MSK-P-0037191	60	Male	White	PDAC	Metastasis	Alive	G12V	R175H	No	No	G12	Yes	60.0
MSK-P-0037192	65	Female	Asian	PDAC	Primary	Alive	G12D	H193L	No	No	G12	Yes	65.0
MSK-P-0037218	80	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	80.0
MSK-P-0037239	80	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	80.0
MSK-P-0037253	54	Female	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	54.0
MSK-P-0037291	76	Male	White	PDAC	Primary	Deceased	G12R	R110C	No	No	G12	Yes	76.0
MSK-P-0037352	48	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	48.0
MSK-P-0037366	71	Male	White	PDAC	Primary	Deceased	G12D	Y220C	No	No	G12	Yes	71.0
MSK-P-0037374	83	Female	White	PDAC	Primary	Alive	G12D	Y220C	No	No	G12	Yes	83.0
MSK-P-0037398	63	Male	White	PDAC	Primary	Deceased	G12D	M237I	No	No	G12	Yes	63.0
MSK-P-0037400	60	Male	White	PDAC	Primary	Deceased	G12D	A138V	No	No	G12	Yes	60.0
MSK-P-0037442	58	Male	White	PDAC	Metastasis	Alive	Q61R	R273C	No	No	Q61	Yes	58.0
MSK-P-0037474	76	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	76.0
MSK-P-0037487	48	Male	Black/African-American	PDAC	Primary	Alive	G12D	No	No	No	G12	No	48.0
MSK-P-0037510	54	Female	White	PDAC	Primary	Alive	Q61H	H179R	No	No	Q61	Yes	54.0
MSK-P-0037527	55	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	55.0
MSK-P-0037529	77	Female	White	PDAC	Primary	Alive	G12C	H178P	No	No	G12	Yes	77.0
MSK-P-0037544	76	Female	White	PDAC	Metastasis	Deceased	G12D	No	H83D	No	G12	No	76.0
MSK-P-0037557	51	Female	Black/African-American	PNET	Metastasis	Alive	No	No	No	No	No	No	51.0
MSK-P-0037613	64	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0037614	76	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	76.0
MSK-P-0037647	60	Female	White	PDAC	Metastasis	Deceased	G12R	R282W	No	No	G12	Yes	60.0
MSK-P-0037684	30	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	30.0
MSK-P-0037754	71	Male	White	PDAC	Primary	Deceased	G12V	R282W	No	No	G12	Yes	71.0
MSK-P-0037788	65	Female	White	PDAC	Primary	Alive	G12D	I251F	No	No	G12	Yes	65.0
MSK-P-0037803	60	Female	White	PDAC	Metastasis	Deceased	G12S	No	No	No	G12	No	60.0
MSK-P-0037806	72	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	72.0
MSK-P-0037834	72	Male	Asian	PDAC	Primary	Deceased	No	No	No	No	No	No	72.0
MSK-P-0037857	71	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	71.0
MSK-P-0037888	63	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	63.0
MSK-P-0037920	76	Male	White	PDAC	Metastasis	Deceased	G12D	I195F	No	No	G12	Yes	76.0
MSK-P-0037923	67	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	67.0
MSK-P-0037989	88	Male	White	PDAC	Primary	Deceased	G12D	R273H	L94P	No	G12	Yes	88.0
MSK-P-0038037	65	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	65.0
MSK-P-0038052	54	Male	White	PDAC	Metastasis	Deceased	G12R	E258G	A102V	No	G12	Yes	54.0
MSK-P-0038074	64	Female	White	PDAC	Primary	Deceased	G12V	No	No	R515G,D351N	G12	No	64.0
MSK-P-0038083	76	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0038090	69	Female	White	PDAC	Primary	Deceased	G12D	R248W	No	No	G12	Yes	69.0
MSK-P-0038210	59	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	59.0
MSK-P-0038241	80	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	80.0
MSK-P-0038292	48	Male	Black/African-American	PDAC	Primary	Deceased	G12V	R273C	No	No	G12	Yes	48.0
MSK-P-0038335	68	Female	White	PDAC	Metastasis	Deceased	G12L	R248W	No	No	G12	Yes	68.0
MSK-P-0038338	62	Female	White	PDAC	Metastasis	Alive	Q61H	No	No	No	Q61	No	62.0
MSK-P-0038371	68	Male	White	PDAC	Metastasis	Deceased	G12D	P190R	No	No	G12	Yes	68.0
MSK-P-0038402	64	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0038465	75	Male	White	PDAC	Primary	Deceased	G12D	C176F	No	No	G12	Yes	75.0
MSK-P-0038511	88	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	88.0
MSK-P-0038539	48	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	48.0
MSK-P-0038541	71	Female	White	PDAC	Metastasis	Deceased	G12D	R282W	No	No	G12	Yes	71.0
MSK-P-0038555	68	Female	White	PDAC	Primary	Deceased	A66S,Q61R	S215R	No	No	Q61\|Other	Yes	68.0
MSK-P-0038557	71	Female	Black/African-American	PDAC	Metastasis	Deceased	G12D	G245C	R87_E88delinsWK	No	G12	Yes	71.0
MSK-P-0038594	80	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	80.0
MSK-P-0038625	63	Female	Black/African-American	PDAC	Primary	Alive	G12V	No	No	No	G12	No	63.0
MSK-P-0038642	75	Male	White	PDAC	Primary	Deceased	G12D	L145R	No	No	G12	Yes	75.0
MSK-P-0038656	69	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	69.0
MSK-P-0038685	60	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0038752	76	Male	White	PDAC	Primary	Deceased	G12R	F134L	No	No	G12	Yes	76.0
MSK-P-0038757	64	Female	White	PDAC	Primary	Alive	G12R	R248Q	No	No	G12	Yes	64.0
MSK-P-0038776	84	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	84.0
MSK-P-0038793	65	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	M246V	No	No	G12	Yes	65.0
MSK-P-0038795	71	Male	White	PDAC	Primary	Alive	G12D	No	D108G	No	G12	No	71.0
MSK-P-0038802	68	Female	White	PDAC	Primary	Deceased	G12R	R273C	No	No	G12	Yes	68.0
MSK-P-0038805	56	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	56.0
MSK-P-0038811	72	Male	White	Adenosquamous carcinoma	Metastasis	Deceased	G12D	No	No	No	G12	No	72.0
MSK-P-0038813	50	Male	White	PDAC	Metastasis	Deceased	G12A	No	No	No	G12	No	50.0
MSK-P-0038814	88	Male	White	PDAC	Metastasis	Deceased	No	Y234C	No	No	No	Yes	88.0
MSK-P-0038815	54	Female	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	54.0
MSK-P-0038819	56	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	56.0
MSK-P-0038951	58	Female	White	IPMN	Primary	Alive	No	No	No	No	No	No	58.0
MSK-P-0039020	62	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	62.0
MSK-P-0039085	38	Male	Asian	PDAC	Primary	Deceased	G12V	No	No	R361H	G12	No	38.0
MSK-P-0039143	63	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	V157F	No	R361H	G12	Yes	63.0
MSK-P-0039144	80	Female	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	80.0
MSK-P-0039169	30	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	30.0
MSK-P-0039185	68	Male	White	PDAC	Primary	Alive	No	No	G35A,P38H	No	No	No	68.0
MSK-P-0039247	68	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	68.0
MSK-P-0039271	55	Male	Other	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	55.0
MSK-P-0039285	69	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	69.0
MSK-P-0039356	80	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	80.0
MSK-P-0039366	58	Female	White	PDAC	Primary	Deceased	Q61L	No	No	No	Q61	No	58.0
MSK-P-0039400	44	Male	White	PDAC	Primary	Deceased	Q61H	H168R	No	No	Q61	Yes	44.0
MSK-P-0039419	59	Female	White	PNET	Metastasis	Alive	No	S241Y	No	No	No	Yes	59.0
MSK-P-0039423	67	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	67.0
MSK-P-0039445	68	Female	White	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	68.0
MSK-P-0039456	65	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	65.0
MSK-P-0039457	68	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0039461	68	Male	Other	PDAC	Primary	Deceased	G12R	I195N	No	No	G12	Yes	68.0
MSK-P-0039510	55	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	55.0
MSK-P-0039523	60	Male	Black/African-American	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	60.0
MSK-P-0039568	84	Female	White	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	84.0
MSK-P-0039601	67	Male	White	PDAC	Primary	Deceased	G12R,K147R	No	No	No	G12\|Other	No	67.0
MSK-P-0039646	69	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	69.0
MSK-P-0039724	72	Female	White	PDAC	Metastasis	Alive	G12V	H193R	No	No	G12	Yes	72.0
MSK-P-0039733	52	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	52.0
MSK-P-0039736	58	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	58.0
MSK-P-0039794	73	Female	White	PDAC	Metastasis	Deceased	G12R	S240R	No	No	G12	Yes	73.0
MSK-P-0039817	59	Male	Other	PDAC	Primary	Deceased	G12V	R175H	No	R361C	G12	Yes	59.0
MSK-P-0039866	51	Male	Black/African-American	PDAC	Primary	Deceased	G12D	I254S	No	No	G12	Yes	51.0
MSK-P-0039888	81	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	81.0
MSK-P-0039939	68	Male	White	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	68.0
MSK-P-0039947	65	Male	White	PDAC	Metastasis	Deceased	G12D	N131I	No	No	G12	Yes	65.0
MSK-P-0039967	76	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	76.0
MSK-P-0039984	68	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0040031	72	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	72.0
MSK-P-0040033	68	Female	White	PDAC	Primary	Deceased	G12D	R273C	No	No	G12	Yes	68.0
MSK-P-0040130	40	Male	Asian	PDAC	Primary	Alive	G12D	No	No	No	G12	No	40.0
MSK-P-0040152	75	Male	White	PDAC	Primary	Alive	G12D	R248W	No	L47P	G12	Yes	75.0
MSK-P-0040159	76	Male	White	PDAC	Primary	Alive	G12V	R282W	No	No	G12	Yes	76.0
MSK-P-0040178	68	Male	White	PDAC	Primary	Deceased	G12D	No	No	P356L	G12	No	68.0
MSK-P-0040202	56	Female	White	PDAC	Metastasis	Deceased	G12D	R280T	No	No	G12	Yes	56.0
MSK-P-0040229	60	Male	White	PDAC	Primary	Deceased	Q61H	Y163C	No	No	Q61	Yes	60.0
MSK-P-0040241	64	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0040248	69	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	69.0
MSK-P-0040256	72	Male	White	PDAC	Primary	Alive	G12V	Y234C	No	No	G12	Yes	72.0
MSK-P-0040257	68	Male	White	PDAC	Metastasis	Alive	G12D	Y220C	No	No	G12	Yes	68.0
MSK-P-0040294	69	Male	White	PDAC	Primary	Alive	G12V	G266E	No	No	G12	Yes	69.0
MSK-P-0040302	51	Female	Asian	PDAC	Primary	Deceased	G12D	C238Y	No	No	G12	Yes	51.0
MSK-P-0040332	80	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	80.0
MSK-P-0040340	50	Male	White	PDAC	Primary	Alive	G12V	R248Q	No	No	G12	Yes	50.0
MSK-P-0040369	71	Female	White	PDAC	Metastasis	Alive	G12V	V173L	P81N	No	G12	Yes	71.0
MSK-P-0040447	58	Male	Other	PDAC	Metastasis	Deceased	G12D	P190L	No	No	G12	Yes	58.0
MSK-P-0040495	40	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	40.0
MSK-P-0040534	65	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	65.0
MSK-P-0040572	79	Female	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	79.0
MSK-P-0040582	75	Male	White	PDAC	Metastasis	Deceased	G12D	C238W	No	No	G12	Yes	75.0
MSK-P-0040604	44	Male	White	PDAC	Primary	Deceased	No	G245S	No	No	No	Yes	44.0
MSK-P-0040632	39	Male	Other	PDAC	Primary	Alive	G12D	R110L	No	No	G12	Yes	39.0
MSK-P-0040641	28	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	28.0
MSK-P-0040687	56	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	56.0
MSK-P-0040692	72	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	72.0
MSK-P-0040746	87	Female	White	PDAC	Primary	Deceased	No	No	R46K	No	No	No	87.0
MSK-P-0040777	76	Male	White	PDAC	Metastasis	Deceased	G12D	V143A	No	No	G12	Yes	76.0
MSK-P-0040778	64	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	64.0
MSK-P-0040802	75	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	75.0
MSK-P-0040808	>89	Male	White	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	90.0
MSK-P-0040845	69	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	69.0
MSK-P-0040885	56	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	56.0
MSK-P-0040895	64	Female	Asian	PDAC	Primary	Deceased	G12D	S241F	No	No	G12	Yes	64.0
MSK-P-0040925	68	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	68.0
MSK-P-0040951	72	Female	White	PDAC	Metastasis	Alive	Q61H	No	No	No	Q61	No	72.0
MSK-P-0040973	64	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	64.0
MSK-P-0040985	46	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	46.0
MSK-P-0041028	54	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	54.0
MSK-P-0041033	68	Male	White	PDAC	Primary	Alive	G12D	P278L	No	No	G12	Yes	68.0
MSK-P-0041071	55	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	V172F	No	No	G12	Yes	55.0
MSK-P-0041119	68	Female	White	PDAC	Metastasis	Deceased	Q61H	S241F	No	No	Q61	Yes	68.0
MSK-P-0041123	76	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0041127	54	Male	Asian	PDAC	Primary	Alive	G12V	R273H	No	No	G12	Yes	54.0
MSK-P-0041216	60	Male	Other	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	60.0
MSK-P-0041265	83	Male	White	PDAC	Primary	Deceased	G12R	No	No	D360V	G12	No	83.0
MSK-P-0041281	60	Female	White	PDAC	Metastasis	Deceased	G12V	C238Y	H83Y	No	G12	Yes	60.0
MSK-P-0041298	62	Female	White	PDAC	Primary	Deceased	G12D	H179Y	No	No	G12	Yes	62.0
MSK-P-0041324	80	Female	Black/African-American	PDAC	Primary	Alive	G12V	R273C	No	No	G12	Yes	80.0
MSK-P-0041341	64	Male	Black/African-American	PDAC	Primary	Deceased	Q61H	R248Q	No	No	Q61	Yes	64.0
MSK-P-0041354	69	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	69.0
MSK-P-0041369	71	Male	White	PDAC	Primary	Deceased	No	I232S	No	No	No	Yes	71.0
MSK-P-0041373	72	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0041386	76	Female	White	PDAC	Primary	Deceased	G12V	G266E	No	R372N	G12	Yes	76.0
MSK-P-0041452	67	Male	White	PDAC	Primary	Deceased	G12C	No	No	No	G12	No	67.0
MSK-P-0041476	73	Male	White	PDAC	Primary	Deceased	G12D	C176S	No	No	G12	Yes	73.0
MSK-P-0041478	52	Male	White	PDAC	Primary	Deceased	G12D	Y234C	No	No	G12	Yes	52.0
MSK-P-0041517	64	Female	Black/African-American	PDAC	Primary	Alive	G12V	No	No	No	G12	No	64.0
MSK-P-0041530	64	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	64.0
MSK-P-0041548	44	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	44.0
MSK-P-0041550	76	Female	Other	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	76.0
MSK-P-0041552	50	Female	Black/African-American	PNET	Metastasis	Alive	No	No	No	No	No	No	50.0
MSK-P-0041568	68	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	68.0
MSK-P-0041570	65	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	65.0
MSK-P-0041574	84	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	84.0
MSK-P-0041604	55	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	55.0
MSK-P-0041606	48	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	48.0
MSK-P-0041644	50	Male	White	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	50.0
MSK-P-0041682	64	Male	White	PDAC	Metastasis	Alive	G12V	L145Q	No	No	G12	Yes	64.0
MSK-P-0041862	79	Male	White	PDAC	Primary	Deceased	G12V	V173M	No	No	G12	Yes	79.0
MSK-P-0041885	60	Female	White	Acinar cell carcinoma	Primary	Deceased	No	No	No	No	No	No	60.0
MSK-P-0041900	76	Male	White	PDAC	Primary	Deceased	G12V	R282W	H83Y	No	G12	Yes	76.0
MSK-P-0041971	65	Male	Asian	PDAC	Metastasis	Deceased	No	No	No	No	No	No	65.0
MSK-P-0041983	79	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	79.0
MSK-P-0041989	73	Female	NA	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	73.0
MSK-P-0042067	67	Male	Black/African-American	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	67.0
MSK-P-0042226	68	Male	White	PDAC	Primary	Deceased	G12R	M133R	No	No	G12	Yes	68.0
MSK-P-0042232	68	Male	White	PDAC	Metastasis	Alive	G12D	G244S	No	No	G12	Yes	68.0
MSK-P-0042238	58	Male	White	PDAC	Metastasis	Deceased	G12D	R273C	No	No	G12	Yes	58.0
MSK-P-0042259	58	Female	Asian	PDAC	Primary	Alive	G12V	No	No	No	G12	No	58.0
MSK-P-0042269	56	Female	White	PDAC	Metastasis	Deceased	G12V	R337C	No	No	G12	Yes	56.0
MSK-P-0042280	54	Female	White	PDAC	Primary	Deceased	G12D	H179R	No	No	G12	Yes	54.0
MSK-P-0042345	35	Female	Other	PDAC	Primary	Deceased	G12V	C242F	No	No	G12	Yes	35.0
MSK-P-0042352	39	Female	NA	PDAC	Primary	Alive	G12V	No	No	No	G12	No	39.0
MSK-P-0042370	67	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	67.0
MSK-P-0042377	56	Male	White	PDAC	Metastasis	Deceased	G12D	M133R	No	P356L	G12	Yes	56.0
MSK-P-0042388	73	Male	Asian	PDAC	Metastasis	Deceased	G12V	Y205D	No	C499R	G12	Yes	73.0
MSK-P-0042391	69	Male	White	PDAC	Metastasis	Alive	Q61K	No	No	No	Q61	No	69.0
MSK-P-0042398	68	Male	White	PDAC	Metastasis	Deceased	G12R	C176Y	No	No	G12	Yes	68.0
MSK-P-0042403	59	Female	White	PNET	Metastasis	Deceased	G12V	No	No	No	G12	No	59.0
MSK-P-0042404	50	Female	Asian	PDAC	Metastasis	Deceased	Q61R	H179L	No	No	Q61	Yes	50.0
MSK-P-0042418	63	Female	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	63.0
MSK-P-0042493	72	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0042517	60	Female	White	PDAC	Metastasis	Deceased	G12D	R248W	L64P	No	G12	Yes	60.0
MSK-P-0042523	54	Male	Asian	PDAC	Metastasis	Deceased	G12V	R273H	No	No	G12	Yes	54.0
MSK-P-0042530	60	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	60.0
MSK-P-0042532	76	Male	White	PDAC	Primary	Alive	G12D	Y220C	No	No	G12	Yes	76.0
MSK-P-0042546	62	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	62.0
MSK-P-0042604	76	Male	White	PDAC	Primary	Alive	G12D	Y236C	L63R	No	G12	Yes	76.0
MSK-P-0042665	52	Female	Black/African-American	PDAC	Primary	Deceased	G12D	R248Q	No	No	G12	Yes	52.0
MSK-P-0042666	51	Male	White	PDAC	Primary	Deceased	Q61R	No	No	No	Q61	No	51.0
MSK-P-0042705	71	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0042709	44	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	44.0
MSK-P-0042710	67	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	67.0
MSK-P-0042715	64	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	64.0
MSK-P-0042743	85	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	85.0
MSK-P-0042780	64	Female	Other	PDAC	Metastasis	Deceased	No	No	No	No	No	No	64.0
MSK-P-0042810	54	Male	White	PDAC	Primary	Deceased	G12D	C176Y	No	No	G12	Yes	54.0
MSK-P-0042814	65	Female	White	PDAC	Metastasis	Deceased	G12V	R273H	No	No	G12	Yes	65.0
MSK-P-0042828	80	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	80.0
MSK-P-0042832	59	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	59.0
MSK-P-0042882	77	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	A161T	No	P130S	G12	Yes	77.0
MSK-P-0042894	68	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	68.0
MSK-P-0042959	76	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	76.0
MSK-P-0042982	64	Female	Asian	PDAC	Primary	Deceased	G12V	C275Y	No	No	G12	Yes	64.0
MSK-P-0042983	64	Female	White	PDAC	Primary	Deceased	G12R	G262V	No	No	G12	Yes	64.0
MSK-P-0042989	40	Male	Asian	PDAC	Primary	Deceased	G12C	No	No	No	G12	No	40.0
MSK-P-0043004	58	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	58.0
MSK-P-0043039	63	Female	Asian	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
MSK-P-0043063	62	Female	White	PNET	Primary	Alive	No	C275Y	No	No	No	Yes	62.0
MSK-P-0043080	44	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	44.0
MSK-P-0043092	72	Female	Black/African-American	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0043109	65	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	65.0
MSK-P-0043113	64	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	64.0
MSK-P-0043119	77	Female	Asian	PDAC	Primary	Alive	G12V	R175H	No	No	G12	Yes	77.0
MSK-P-0043145	76	Female	White	PDAC	Primary	Deceased	G12R	R175H	No	No	G12	Yes	76.0
MSK-P-0043162	76	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0043171	63	Male	White	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	63.0
MSK-P-0043220	73	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	73.0
MSK-P-0043223	65	Male	White	PDAC	Metastasis	Alive	G12R	M237I	P114H	No	G12	Yes	65.0
MSK-P-0043346	56	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0043392	48	Male	White	PDAC	Metastasis	Alive	Q61L	No	No	No	Q61	No	48.0
MSK-P-0043398	59	Female	White	PDAC	Primary	Deceased	No	R248W	No	No	No	Yes	59.0
MSK-P-0043404	79	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	79.0
MSK-P-0043418	56	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	56.0
MSK-P-0043534	64	Male	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0043556	44	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	44.0
MSK-P-0043568	79	Male	White	PDAC	Primary	Deceased	G12C	No	No	A118V	G12	No	79.0
MSK-P-0043574	76	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	76.0
MSK-P-0043580	69	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	69.0
MSK-P-0043586	56	Female	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	56.0
MSK-P-0043647	56	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0043650	72	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0043660	72	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	72.0
MSK-P-0043661	67	Male	Asian	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	67.0
MSK-P-0043687	73	Female	White	PDAC	Metastasis	Deceased	G12D	No	H83Y	No	G12	No	73.0
MSK-P-0043720	62	Female	Black/African-American	PDAC	Primary	Deceased	G12D	P278L	No	No	G12	Yes	62.0
MSK-P-0043721	84	Male	White	PDAC	Metastasis	Alive	G12V	No	No	R361H	G12	No	84.0
MSK-P-0043725	31	Female	Black/African-American	PNET	Metastasis	Deceased	No	No	No	No	No	No	31.0
MSK-P-0043729	75	Female	Other	PDAC	Primary	Deceased	Q61H	M237I	No	No	Q61	Yes	75.0
MSK-P-0043836	72	Male	White	Acinar cell carcinoma	Primary	Deceased	No	No	No	R361C	No	No	72.0
MSK-P-0043903	63	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	63.0
MSK-P-0043928	76	Male	White	PDAC	Primary	Deceased	G12D	S241F	No	No	G12	Yes	76.0
MSK-P-0043954	56	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	56.0
MSK-P-0043961	52	Female	White	PDAC	Primary	Deceased	G12D	H168R	No	No	G12	Yes	52.0
MSK-P-0044007	62	Female	White	PDAC	Metastasis	Alive	G12V	R282W	No	No	G12	Yes	62.0
MSK-P-0044029	58	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	58.0
MSK-P-0044031	54	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	54.0
MSK-P-0044044	64	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	64.0
MSK-P-0044062	64	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	64.0
MSK-P-0044116	72	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0044117	54	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	54.0
MSK-P-0044135	63	Male	Asian	PDAC	Metastasis	Deceased	G12D	L257P	No	No	G12	Yes	63.0
MSK-P-0044137	69	Male	White	PDAC	Metastasis	Alive	G12V	R248W	No	No	G12	Yes	69.0
MSK-P-0044167	67	Male	NA	PDAC	Metastasis	Alive	G12V	R175H	No	No	G12	Yes	67.0
MSK-P-0044170	56	Male	NA	PDAC	Metastasis	Deceased	G12D	R282W	No	No	G12	Yes	56.0
MSK-P-0044171	72	Male	White	PDAC	Primary	Deceased	G12V	R175H	No	G386D	G12	Yes	72.0
MSK-P-0044178	68	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	68.0
MSK-P-0044183	72	Male	White	PDAC	Primary	Alive	G12D	S127F	No	No	G12	Yes	72.0
MSK-P-0044210	68	Female	Black/African-American	PDAC	Primary	Alive	G12V	M237I	No	No	G12	Yes	68.0
MSK-P-0044215	67	Female	White	PDAC	Metastasis	Deceased	G12R	G245S,S227F	No	No	G12	Yes	67.0
MSK-P-0044222	44	Male	White	PDAC	Primary	Alive	G12V	S106R	No	Y95H	G12	Yes	44.0
MSK-P-0044259	60	Female	NA	PDAC	Primary	Deceased	G12D	No	No	R361H	G12	No	60.0
MSK-P-0044286	39	Male	White	PDAC	Primary	Deceased	G12D	V272E	No	No	G12	Yes	39.0
MSK-P-0044296	56	Female	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	56.0
MSK-P-0044298	65	Male	Black/African-American	PDAC	Primary	Alive	G12D	Y234H	No	No	G12	Yes	65.0
MSK-P-0044438	72	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	72.0
MSK-P-0044459	67	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	67.0
MSK-P-0044478	62	Female	Black/African-American	PDAC	Primary	Deceased	G12V	S241P	No	No	G12	Yes	62.0
MSK-P-0044487	60	Female	White	PDAC	Metastasis	Alive	G12V	C238Y	No	No	G12	Yes	60.0
MSK-P-0044512	84	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	84.0
MSK-P-0044534	71	Female	Asian	PDAC	Primary	Alive	G12D	S127F	No	No	G12	Yes	71.0
MSK-P-0044604	69	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	69.0
MSK-P-0044641	48	Female	Black/African-American	PDAC	Primary	Alive	G12R	K132E	No	No	G12	Yes	48.0
MSK-P-0044655	58	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	58.0
MSK-P-0044659	52	Male	Other	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	52.0
MSK-P-0044663	64	Male	Other	PDAC	Primary	Alive	G12R	V173M	No	No	G12	Yes	64.0
MSK-P-0044755	72	Male	White	PDAC	Metastasis	Alive	Q61H	No	No	No	Q61	No	72.0
MSK-P-0044765	60	Male	NA	PDAC	Metastasis	Deceased	G12R	R175H	No	No	G12	Yes	60.0
MSK-P-0044786	69	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	69.0
MSK-P-0044792	76	Male	White	PNET	Metastasis	Deceased	No	R273C	No	No	No	Yes	76.0
MSK-P-0044801	80	Female	Asian	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	80.0
MSK-P-0044832	64	Male	White	PDAC	Primary	Alive	G12V	R213L	No	No	G12	Yes	64.0
MSK-P-0044841	54	Male	Asian	PDAC	Primary	Alive	No	E271K	No	No	No	Yes	54.0
MSK-P-0044920	65	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	65.0
MSK-P-0044971	72	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	G386S,R361C	G12	No	72.0
MSK-P-0044972	64	Male	Other	PDAC	Primary	Deceased	G12R	I195T	No	No	G12	Yes	64.0
MSK-P-0044986	69	Male	White	PDAC	Primary	Deceased	G12V	C238R	No	No	G12	Yes	69.0
MSK-P-0045004	64	Male	White	Carcinoma, NOS	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0045007	52	Female	White	PDAC	Metastasis	Deceased	G12D	Y234H	No	D537V	G12	Yes	52.0
MSK-P-0045049	52	Male	White	PDAC	Metastasis	Deceased	G12V	C238R	No	No	G12	Yes	52.0
MSK-P-0045095	63	Female	White	PDAC	Primary	Alive	G12V	A159V	No	No	G12	Yes	63.0
MSK-P-0045123	54	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	54.0
MSK-P-0045137	72	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0045160	77	Male	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	77.0
MSK-P-0045212	68	Female	NA	PDAC	Metastasis	Deceased	G12D	R175G	No	No	G12	Yes	68.0
MSK-P-0045224	54	Female	NA	PDAC	Metastasis	Alive	G12V	G245S	No	No	G12	Yes	54.0
MSK-P-0045273	69	Male	Asian	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	69.0
MSK-P-0045290	63	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	63.0
MSK-P-0045379	72	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0045416	84	Male	White	PDAC	Primary	Deceased	No	R175H	No	No	No	Yes	84.0
MSK-P-0045466	60	Male	White	PDAC	Metastasis	Alive	No	No	P114H	No	No	No	60.0
MSK-P-0045517	68	Male	White	PDAC	Primary	Deceased	G12D	A159V	No	No	G12	Yes	68.0
MSK-P-0045558	72	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0045615	69	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	69.0
MSK-P-0045616	71	Female	White	PDAC	Metastasis	Deceased	Q61H	C242S	No	No	Q61	Yes	71.0
MSK-P-0045618	58	Male	White	PDAC	Primary	Deceased	G12D	G245S	No	No	G12	Yes	58.0
MSK-P-0045619	80	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	80.0
MSK-P-0045620	54	Male	White	Adenosquamous carcinoma	Metastasis	Deceased	G12V	No	No	No	G12	No	54.0
MSK-P-0045654	72	Female	White	PDAC	Metastasis	Alive	Q61H	No	No	No	Q61	No	72.0
MSK-P-0045674	62	Female	Black/African-American	PDAC	Primary	Alive	G12D	No	No	No	G12	No	62.0
MSK-P-0045719	68	Male	Other	PNET	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0045723	58	Female	White	PDAC	Primary	Alive	Q61R	No	No	No	Q61	No	58.0
MSK-P-0045732	76	Female	White	PDAC	Primary	Alive	G12V	R175H	No	R380T	G12	Yes	76.0
MSK-P-0045733	64	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	64.0
MSK-P-0045739	64	Male	White	PDAC	Primary	Alive	G12V	I195T	No	No	G12	Yes	64.0
MSK-P-0045743	71	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0045817	80	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	80.0
MSK-P-0045849	60	Female	White	PDAC	Primary	Deceased	G12V	No	No	R361C	G12	No	60.0
MSK-P-0045857	64	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0045866	75	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	75.0
MSK-P-0045868	65	Male	White	PDAC	Primary	Deceased	G12V	F270L	No	No	G12	Yes	65.0
MSK-P-0045897	64	Female	White	PDAC	Metastasis	Deceased	G13D	No	No	No	G13	No	64.0
MSK-P-0045926	63	Male	White	PDAC	Primary	Alive	G12R	H214R	No	No	G12	Yes	63.0
MSK-P-0045968	63	Female	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
MSK-P-0045973	64	Female	Asian	PDAC	Primary	Alive	No	R248W	No	No	No	Yes	64.0
MSK-P-0045997	58	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	58.0
MSK-P-0046062	71	Female	White	PDAC	Primary	Deceased	G12D	F109V	No	No	G12	Yes	71.0
MSK-P-0046081	71	Female	White	PDAC	Primary	Deceased	G12V,G12D	No	No	No	G12	No	71.0
MSK-P-0046090	69	Female	White	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	69.0
MSK-P-0046093	68	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0046105	67	Female	White	PDAC	Primary	Alive	No	R273L	No	No	No	Yes	67.0
MSK-P-0046230	76	Male	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	76.0
MSK-P-0046240	72	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	72.0
MSK-P-0046248	48	Male	White	PDAC	Primary	Deceased	G12D	G105C	No	No	G12	Yes	48.0
MSK-P-0046267	71	Male	White	PDAC	Primary	Deceased	G12V	H193R	No	No	G12	Yes	71.0
MSK-P-0046270	68	Female	Black/African-American	PDAC	Primary	Alive	G12R	No	No	No	G12	No	68.0
MSK-P-0046277	56	Male	White	PNET	Metastasis	Alive	G12V	R282W	No	No	G12	Yes	56.0
MSK-P-0046279	60	Male	White	PDAC	Primary	Deceased	G12V	R273G	No	No	G12	Yes	60.0
MSK-P-0046290	52	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	52.0
MSK-P-0046299	64	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0046309	77	Female	Black/African-American	PDAC	Primary	Alive	G12D	C176S	No	No	G12	Yes	77.0
MSK-P-0046321	84	Male	White	PDAC	Metastasis	Alive	G12D	R248W	No	No	G12	Yes	84.0
MSK-P-0046399	68	Female	Asian	PDAC	Primary	Alive	G12D	No	No	No	G12	No	68.0
MSK-P-0046434	>89	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	90.0
MSK-P-0046455	71	Male	White	PDAC	Primary	Deceased	G12D	Y205C	No	No	G12	Yes	71.0
MSK-P-0046456	67	Male	White	PDAC	Metastasis	Deceased	G12D	R213Q	No	No	G12	Yes	67.0
MSK-P-0046467	68	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	C115W	G12	No	68.0
MSK-P-0046479	69	Male	White	PDAC	Primary	Deceased	G12D	C275F	No	No	G12	Yes	69.0
MSK-P-0046493	69	Female	White	PDAC	Primary	Alive	Q61H	R175H	No	No	Q61	Yes	69.0
MSK-P-0046515	77	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	77.0
MSK-P-0046570	68	Female	White	PDAC	Metastasis	Deceased	G12V	Y220H	No	No	G12	Yes	68.0
MSK-P-0046603	76	Male	White	PDAC	Metastasis	Deceased	No	P152L	No	No	No	Yes	76.0
MSK-P-0046623	51	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	51.0
MSK-P-0046629	56	Male	White	PDAC	Primary	Alive	G12V	R175H	No	No	G12	Yes	56.0
MSK-P-0046664	56	Female	NA	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	56.0
MSK-P-0046672	60	Male	White	PDAC	Metastasis	Deceased	G12D	H214R	No	No	G12	Yes	60.0
MSK-P-0046693	32	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	32.0
MSK-P-0046697	47	Female	Other	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	47.0
MSK-P-0046715	71	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	71.0
MSK-P-0046789	73	Female	White	PDAC	Metastasis	Deceased	G12V	V157F	No	No	G12	Yes	73.0
MSK-P-0046791	58	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	58.0
MSK-P-0046808	64	Male	White	PDAC	Primary	Deceased	G12V	Y220N	No	No	G12	Yes	64.0
MSK-P-0046834	48	Male	White	PDAC	Primary	Alive	G12C	R248W	No	No	G12	Yes	48.0
MSK-P-0046851	76	Male	White	PDAC	Primary	Deceased	G12D	R267Q	No	No	G12	Yes	76.0
MSK-P-0046889	72	Female	Asian	PDAC	Metastasis	Alive	No	No	No	No	No	No	72.0
MSK-P-0046890	68	Female	NA	PDAC	Primary	Alive	G12R	No	No	No	G12	No	68.0
MSK-P-0046914	80	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	80.0
MSK-P-0046955	63	Female	White	PDAC	Primary	Deceased	G12V	R213L	No	No	G12	Yes	63.0
MSK-P-0046971	56	Female	White	PDAC	Primary	Alive	G12V	R248Q	P48L	No	G12	Yes	56.0
MSK-P-0047010	87	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	87.0
MSK-P-0047049	54	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	54.0
MSK-P-0047080	68	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	68.0
MSK-P-0047091	56	Female	NA	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	56.0
MSK-P-0047113	72	Female	White	PDAC	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	72.0
MSK-P-0047126	67	Male	White	Acinar cell carcinoma	Primary	Deceased	No	No	No	No	No	No	67.0
MSK-P-0047157	76	Female	White	PDAC	Metastasis	Alive	G12V	P190L	No	No	G12	Yes	76.0
MSK-P-0047189	69	Female	White	PDAC	Primary	Alive	G12V	R282W	No	No	G12	Yes	69.0
MSK-P-0047198	79	Male	Black/African-American	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	79.0
MSK-P-0047201	43	Female	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	43.0
MSK-P-0047236	68	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	68.0
MSK-P-0047260	72	Female	White	PDAC	Primary	Alive	G12R	Y220C	No	No	G12	Yes	72.0
MSK-P-0047293	68	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0047358	67	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	67.0
MSK-P-0047445	69	Male	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	69.0
MSK-P-0047448	58	Male	Black/African-American	PDAC	Primary	Alive	G12V	No	No	No	G12	No	58.0
MSK-P-0047459	58	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	58.0
MSK-P-0047487	68	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	68.0
MSK-P-0047499	56	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	56.0
MSK-P-0047501	48	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	48.0
MSK-P-0047514	63	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	63.0
MSK-P-0047561	44	Female	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	44.0
MSK-P-0047669	48	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	48.0
MSK-P-0047672	73	Female	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	73.0
MSK-P-0047710	77	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	77.0
MSK-P-0047714	38	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	38.0
MSK-P-0047772	81	Male	White	PDAC	Primary	Alive	G12V	Y234C	No	No	G12	Yes	81.0
MSK-P-0047816	59	Male	White	PDAC	Metastasis	Alive	G12V	M237I	No	No	G12	Yes	59.0
MSK-P-0047823	64	Female	Asian	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	64.0
MSK-P-0047846	60	Male	Asian	PDAC	Metastasis	Deceased	G12D	No	No	D493G	G12	No	60.0
MSK-P-0047848	72	Male	Asian	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0047851	59	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	59.0
MSK-P-0047852	67	Male	NA	PDAC	Metastasis	Deceased	G12D	C135F	No	No	G12	Yes	67.0
MSK-P-0047894	55	Male	White	PDAC	Metastasis	Deceased	G12D	I255F	No	No	G12	Yes	55.0
MSK-P-0047896	68	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	68.0
MSK-P-0048010	72	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	72.0
MSK-P-0048039	68	Female	NA	PDAC	Primary	Deceased	G12D	R248Q	No	No	G12	Yes	68.0
MSK-P-0048064	72	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	72.0
MSK-P-0048155	54	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	54.0
MSK-P-0048175	68	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	68.0
MSK-P-0048215	51	Male	White	PDAC	Primary	Alive	Q61H	E258K	No	No	Q61	Yes	51.0
MSK-P-0048229	48	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	48.0
MSK-P-0048234	60	Male	NA	PDAC	Primary	Alive	G12D	No	No	D355E	G12	No	60.0
MSK-P-0048236	72	Female	White	PDAC	Primary	Alive	G12D	S127P	No	No	G12	Yes	72.0
MSK-P-0048247	34	Male	NA	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	34.0
MSK-P-0048272	64	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0048274	56	Male	NA	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	56.0
MSK-P-0048284	64	Female	NA	PDAC	Metastasis	Deceased	G12D	I195N	No	No	G12	Yes	64.0
MSK-P-0048390	72	Male	Black/African-American	PDAC	Primary	Deceased	No	No	No	No	No	No	72.0
MSK-P-0048491	72	Male	Asian	Carcinoma, NOS	Primary	Deceased	No	No	No	No	No	No	72.0
MSK-P-0048492	75	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	75.0
MSK-P-0048503	60	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	60.0
MSK-P-0048512	54	Male	Other	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	54.0
MSK-P-0048548	76	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0048558	71	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	71.0
MSK-P-0048629	72	Male	Asian	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	72.0
MSK-P-0048663	25	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	25.0
MSK-P-0048704	48	Male	White	PDAC	Primary	Deceased	G12S	R175H	No	W101C	G12	Yes	48.0
MSK-P-0048748	63	Male	White	PDAC	Metastasis	Alive	G12R	G245S	No	No	G12	Yes	63.0
MSK-P-0048767	48	Female	White	PDAC	Metastasis	Alive	G12R	R273H	No	No	G12	Yes	48.0
MSK-P-0048811	64	Female	White	PDAC	Metastasis	Alive	G12D	R248W	H83Y	No	G12	Yes	64.0
MSK-P-0048815	72	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0048846	64	Male	White	PDAC	Metastasis	Alive	No	C135F	No	No	No	Yes	64.0
MSK-P-0048924	52	Female	White	PDAC	Metastasis	Deceased	G12C	No	No	No	G12	No	52.0
MSK-P-0048982	56	Male	Asian	PDAC	Primary	Deceased	No	V172F	No	No	No	Yes	56.0
MSK-P-0048987	84	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	84.0
MSK-P-0048994	68	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	68.0
MSK-P-0048996	71	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	71.0
MSK-P-0049002	69	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	69.0
MSK-P-0049030	69	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	69.0
MSK-P-0049038	79	Female	White	Adenosquamous carcinoma	Primary	Alive	G12D	R282G	No	No	G12	Yes	79.0
MSK-P-0049039	67	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	67.0
MSK-P-0049059	32	Male	Black/African-American	Solid pseudopapillary tumor	Primary	Alive	No	No	No	No	No	No	32.0
MSK-P-0049081	59	Male	Black/African-American	PNET	Metastasis	Alive	No	No	No	No	No	No	59.0
MSK-P-0049090	62	Male	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	62.0
MSK-P-0049113	52	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	52.0
MSK-P-0049139	64	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	64.0
MSK-P-0049186	65	Female	White	PDAC	Metastasis	Alive	G12V	Y126H	No	No	G12	Yes	65.0
MSK-P-0049262	76	Female	White	PDAC	Metastasis	Deceased	G13D	Y234N	No	No	G13	Yes	76.0
MSK-P-0049269	72	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	72.0
MSK-P-0049288	48	Male	White	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	48.0
MSK-P-0049334	64	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	64.0
MSK-P-0049335	54	Female	NA	PDAC	Primary	Alive	G12V	No	No	No	G12	No	54.0
MSK-P-0049336	76	Male	White	Adenosquamous carcinoma	Primary	Deceased	G13P	H179P	L32P	No	G13	Yes	76.0
MSK-P-0049347	71	Male	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	71.0
MSK-P-0049353	75	Male	White	PDAC	Primary	Alive	G12V	R273L	P48Q	R361S	G12	Yes	75.0
MSK-P-0049364	69	Female	White	PDAC	Metastasis	Alive	G12R	No	No	R361H	G12	No	69.0
MSK-P-0049368	72	Female	White	PDAC	Primary	Alive	No	R248Q	No	No	No	Yes	72.0
MSK-P-0049381	71	Female	White	PDAC	Primary	Deceased	G12D	No	No	L57F	G12	No	71.0
MSK-P-0049409	65	Male	Asian	PDAC	Primary	Deceased	G12V	C238S	No	No	G12	Yes	65.0
MSK-P-0049416	55	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	55.0
MSK-P-0049443	76	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	76.0
MSK-P-0049456	75	Male	White	PDAC	Primary	Alive	G12R	R273C	No	No	G12	Yes	75.0
MSK-P-0049460	68	Male	NA	PDAC	Metastasis	Alive	G12D	H193D	No	G386D	G12	Yes	68.0
MSK-P-0049481	72	Male	White	PDAC	Primary	Deceased	Q61H	E258K	No	No	Q61	Yes	72.0
MSK-P-0049501	72	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	72.0
MSK-P-0049535	72	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	72.0
MSK-P-0049552	76	Female	White	PDAC	Metastasis	Deceased	G12C	C176Y	No	No	G12	Yes	76.0
MSK-P-0049553	76	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0049557	80	Male	Asian	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	80.0
MSK-P-0049572	84	Female	White	IPMN	Primary	Alive	No	No	No	No	No	No	84.0
MSK-P-0049612	72	Female	White	PDAC	Primary	Deceased	G12R	R175H	No	No	G12	Yes	72.0
MSK-P-0049634	59	Male	White	PDAC	Metastasis	Deceased	G12R	R248W	No	No	G12	Yes	59.0
MSK-P-0049637	77	Male	White	PDAC	Primary	Deceased	No	No	No	L533R	No	No	77.0
MSK-P-0049671	75	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	75.0
MSK-P-0049678	54	Male	White	PDAC	Primary	Deceased	G12V	R282W	No	No	G12	Yes	54.0
MSK-P-0049763	68	Female	Other	PDAC	Metastasis	Alive	G12D	No	No	W99C	G12	No	68.0
MSK-P-0049780	64	Female	White	PDAC	Metastasis	Alive	G12R	V274F	No	No	G12	Yes	64.0
MSK-P-0049781	58	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	58.0
MSK-P-0049796	67	Male	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	67.0
MSK-P-0049869	80	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	80.0
MSK-P-0049874	68	Female	White	PDAC	Primary	Deceased	G12D	Y220C	No	No	G12	Yes	68.0
MSK-P-0049898	65	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	65.0
MSK-P-0049948	72	Male	White	PDAC	Primary	Deceased	G12R	R248W	No	No	G12	Yes	72.0
MSK-P-0049991	73	Female	White	PDAC	Primary	Deceased	G12V	V218E	No	No	G12	Yes	73.0
MSK-P-0050004	75	Male	White	PDAC	Primary	Deceased	G12V	K120R	No	No	G12	Yes	75.0
MSK-P-0050168	65	Female	White	PDAC	Primary	Deceased	G12D	R249T	No	Y513H	G12	Yes	65.0
MSK-P-0050182	72	Male	White	PDAC	Metastasis	Alive	Q61H	No	No	V126G	Q61	No	72.0
MSK-P-0050186	63	Male	White	PDAC	Primary	Deceased	G12R	K132N	H83Y	No	G12	Yes	63.0
MSK-P-0050199	69	Male	White	PDAC	Primary	Alive	G12D	L257R	No	No	G12	Yes	69.0
MSK-P-0050209	52	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	52.0
MSK-P-0050210	60	Male	Asian	PNET	Primary	Alive	No	No	No	No	No	No	60.0
MSK-P-0050221	69	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	69.0
MSK-P-0050262	68	Female	Black/African-American	PNET	Primary	Alive	No	R248W	No	No	No	Yes	68.0
MSK-P-0050272	67	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	R361C	G12	No	67.0
MSK-P-0050275	63	Female	White	PDAC	Metastasis	Deceased	Q61H	L130V	No	No	Q61	Yes	63.0
MSK-P-0050280	56	Female	NA	PDAC	Primary	Alive	G12V	P278S	No	D537G	G12	Yes	56.0
MSK-P-0050283	72	Male	White	PDAC	Primary	Alive	G12D	G245V	No	No	G12	Yes	72.0
MSK-P-0050310	80	Male	Black/African-American	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	80.0
MSK-P-0050311	72	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0050312	63	Female	White	PDAC	Metastasis	Deceased	G12V	C176Y	L130R	No	G12	Yes	63.0
MSK-P-0050420	71	Female	White	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	71.0
MSK-P-0050425	64	Female	White	PDAC	Primary	Deceased	G12V	P278T	No	No	G12	Yes	64.0
MSK-P-0050428	80	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	80.0
MSK-P-0050449	73	Female	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	73.0
MSK-P-0050469	63	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	63.0
MSK-P-0050509	81	Female	White	PDAC	Metastasis	Deceased	No	R282W	No	No	No	Yes	81.0
MSK-P-0050511	76	Male	White	PDAC	Metastasis	Deceased	G13D	R248Q	No	No	G13	Yes	76.0
MSK-P-0050514	76	Female	White	PDAC	Primary	Alive	G12D	R248W	No	L47R	G12	Yes	76.0
MSK-P-0050524	59	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	59.0
MSK-P-0050530	73	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	73.0
MSK-P-0050533	79	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	79.0
MSK-P-0050618	52	Female	Asian	PDAC	Metastasis	Alive	G12V	C141Y	No	No	G12	Yes	52.0
MSK-P-0050642	72	Female	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	72.0
MSK-P-0050650	76	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	76.0
MSK-P-0050652	56	Male	White	PDAC	Primary	Alive	G12R	H214R	No	No	G12	Yes	56.0
MSK-P-0050666	52	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	52.0
MSK-P-0050673	56	Male	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	56.0
MSK-P-0050674	76	Male	White	PDAC	Metastasis	Deceased	G12D	M237I	No	No	G12	Yes	76.0
MSK-P-0050699	40	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	40.0
MSK-P-0050743	62	Male	White	PDAC	Primary	Deceased	G12D	Y236C	No	No	G12	Yes	62.0
MSK-P-0050744	68	Male	White	PDAC	Primary	Deceased	G12D	Y234C	H83Y	No	G12	Yes	68.0
MSK-P-0050747	72	Female	White	PDAC	Primary	Alive	G12V	M237I	No	No	G12	Yes	72.0
MSK-P-0050748	56	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	56.0
MSK-P-0050750	55	Female	White	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	55.0
MSK-P-0050764	69	Male	White	PDAC	Metastasis	Deceased	Q61H	E286K	No	No	Q61	Yes	69.0
MSK-P-0050774	76	Female	White	PDAC	Metastasis	Alive	G12L	No	No	No	G12	No	76.0
MSK-P-0050838	71	Male	Asian	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0050857	71	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	71.0
MSK-P-0050863	76	Female	White	PDAC	Primary	Alive	G12V	V274G	No	No	G12	Yes	76.0
MSK-P-0050928	64	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	64.0
MSK-P-0050943	40	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	40.0
MSK-P-0050967	73	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	73.0
MSK-P-0050982	77	Female	White	PDAC	Metastasis	Deceased	G12D	R273L	No	No	G12	Yes	77.0
MSK-P-0050984	55	Female	White	PDAC	Metastasis	Deceased	G12V	G245S	No	No	G12	Yes	55.0
MSK-P-0050985	68	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0050990	>89	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	90.0
MSK-P-0051013	34	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	34.0
MSK-P-0051026	72	Female	White	PDAC	Metastasis	Deceased	Q61H	V197M	No	No	Q61	Yes	72.0
MSK-P-0051028	73	Male	White	PDAC	Primary	Alive	G12V	R273H	No	No	G12	Yes	73.0
MSK-P-0051049	60	Female	White	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	60.0
MSK-P-0051064	69	Female	White	PDAC	Metastasis	Deceased	G12V	D281N	No	No	G12	Yes	69.0
MSK-P-0051072	55	Female	White	PDAC	Primary	Deceased	G12V	G245V	No	No	G12	Yes	55.0
MSK-P-0051095	72	Female	White	PDAC	Primary	Alive	G12R	P152L	No	No	G12	Yes	72.0
MSK-P-0051249	65	Male	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	65.0
MSK-P-0051265	68	Female	NA	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	68.0
MSK-P-0051284	51	Female	Other	PDAC	Primary	Alive	G12V	No	No	R361C	G12	No	51.0
MSK-P-0051345	64	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0051425	62	Male	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	62.0
MSK-P-0051438	84	Male	White	PDAC	Metastasis	Deceased	G12R	R273H	No	No	G12	Yes	84.0
MSK-P-0051469	72	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	72.0
MSK-P-0051479	62	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	62.0
MSK-P-0051480	22	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	22.0
MSK-P-0051495	83	Male	NA	PDAC	Primary	Alive	G12D	R248W	No	G508D	G12	Yes	83.0
MSK-P-0051529	44	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	44.0
MSK-P-0051557	64	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	64.0
MSK-P-0051650	65	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	65.0
MSK-P-0051719	56	Male	Asian	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0051743	75	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	75.0
MSK-P-0051757	56	Male	White	PDAC	Metastasis	Alive	G12R	No	No	R361C	G12	No	56.0
MSK-P-0051770	54	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	54.0
MSK-P-0051777	62	Female	White	PDAC	Primary	Alive	G12D	V157I	No	No	G12	Yes	62.0
MSK-P-0051782	80	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	80.0
MSK-P-0051783	56	Male	White	PDAC	Primary	Alive	G12V	C238F	No	No	G12	Yes	56.0
MSK-P-0051817	73	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	73.0
MSK-P-0051846	75	Female	White	PDAC	Metastasis	Alive	G12D	Y220C	No	No	G12	Yes	75.0
MSK-P-0051847	72	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0051850	75	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	75.0
MSK-P-0051853	67	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	67.0
MSK-P-0051866	83	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	R361H	G12	No	83.0
MSK-P-0051893	64	Female	White	PDAC	Primary	Alive	G12V	No	H83Y	No	G12	No	64.0
MSK-P-0051897	80	Female	White	PDAC	Primary	Alive	G12V	R248W	No	No	G12	Yes	80.0
MSK-P-0051900	72	Female	White	PDAC	Primary	Deceased	G12D	D259F	No	No	G12	Yes	72.0
MSK-P-0051906	54	Male	Asian	PDAC	Metastasis	Deceased	Q61L	No	No	No	Q61	No	54.0
MSK-P-0051911	63	Male	Asian	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
MSK-P-0051940	55	Female	Asian	PDAC	Primary	Alive	G12V	R175H	No	No	G12	Yes	55.0
MSK-P-0051965	56	Female	NA	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0051968	75	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	75.0
MSK-P-0052027	68	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0052043	72	Female	White	PDAC	Primary	Deceased	No	R249M	No	No	No	Yes	72.0
MSK-P-0052094	60	Female	NA	PDAC	Primary	Alive	G12D	R248W	No	No	G12	Yes	60.0
MSK-P-0052128	56	Female	Asian	PDAC	Primary	Alive	G12R	No	No	No	G12	No	56.0
MSK-P-0052142	77	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	77.0
MSK-P-0052200	69	Female	White	PDAC	Metastasis	Deceased	G12R	G245V	No	No	G12	Yes	69.0
MSK-P-0052227	50	Female	White	PNET	Primary	Alive	No	G244S	No	No	No	Yes	50.0
MSK-P-0052230	55	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	55.0
MSK-P-0052264	72	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	72.0
MSK-P-0052268	71	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0052283	65	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	65.0
MSK-P-0052300	69	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	69.0
MSK-P-0052307	69	Male	White	PDAC	Primary	Deceased	G12V	I195N	No	No	G12	Yes	69.0
MSK-P-0052322	65	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	65.0
MSK-P-0052323	52	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	52.0
MSK-P-0052325	67	Male	Asian	PDAC	Primary	Alive	G12D	No	No	R361C	G12	No	67.0
MSK-P-0052354	76	Male	White	PDAC	Primary	Alive	G12R	Y220C	No	No	G12	Yes	76.0
MSK-P-0052382	65	Female	Asian	PDAC	Primary	Deceased	G12R,G12C	No	No	No	G12	No	65.0
MSK-P-0052573	47	Male	Black/African-American	PDAC	Primary	Alive	G12V	No	No	No	G12	No	47.0
MSK-P-0052669	76	Male	White	PDAC	Primary	Alive	G12R	C238Y	No	No	G12	Yes	76.0
MSK-P-0052715	80	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	80.0
MSK-P-0052783	68	Male	NA	PNET	Metastasis	Alive	No	No	No	No	No	No	68.0
MSK-P-0052798	68	Female	Asian	PDAC	Metastasis	Alive	Q61H	V157F	No	No	Q61	Yes	68.0
MSK-P-0052800	62	Female	White	PDAC	Metastasis	Alive	G12V	V216M	N42K	No	G12	Yes	62.0
MSK-P-0052820	65	Male	Other	PNET	Metastasis	Deceased	G12R	No	No	No	G12	No	65.0
MSK-P-0052822	67	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	67.0
MSK-P-0052834	67	Male	White	PDAC	Primary	Deceased	G12D	C242F	No	No	G12	Yes	67.0
MSK-P-0052846	44	Female	White	PDAC	Primary	Alive	G12R	L264V,R273H	No	No	G12	Yes	44.0
MSK-P-0052849	56	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0052868	71	Female	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	71.0
MSK-P-0052971	63	Female	Asian	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
MSK-P-0052972	63	Female	Black/African-American	PDAC	Primary	Alive	A146V	No	No	No	Other	No	63.0
MSK-P-0052981	71	Male	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	71.0
MSK-P-0053039	54	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	54.0
MSK-P-0053058	77	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	77.0
MSK-P-0053068	80	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	80.0
MSK-P-0053071	72	Female	White	PDAC	Primary	Alive	G12D	No	A68V	No	G12	No	72.0
MSK-P-0053076	62	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	62.0
MSK-P-0053126	51	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	51.0
MSK-P-0053144	46	Female	White	PDAC	Primary	Alive	G12V	Y163C	No	No	G12	Yes	46.0
MSK-P-0053159	56	Female	Asian	PDAC	Primary	Alive	G12V	V173G	P48L	R361C	G12	Yes	56.0
MSK-P-0053161	69	Female	White	PDAC	Primary	Deceased	G12D	P151S	No	No	G12	Yes	69.0
MSK-P-0053171	77	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12D	No	No	D512I	G12	No	77.0
MSK-P-0053217	63	Male	White	PDAC	Primary	Deceased	G12D	C176L	No	No	G12	Yes	63.0
MSK-P-0053248	58	Female	White	PDAC	Primary	Alive	G12V	M246K	No	No	G12	Yes	58.0
MSK-P-0053271	59	Female	NA	PDAC	Metastasis	Alive	G12D	R248W	No	No	G12	Yes	59.0
MSK-P-0053281	58	Male	White	PDAC	Metastasis	Alive	G12V	R273H	A20E	No	G12	Yes	58.0
MSK-P-0053309	62	Female	White	PDAC	Metastasis	Deceased	G12R	R273C	No	No	G12	Yes	62.0
MSK-P-0053319	72	Male	White	PDAC	Primary	Deceased	G12V	R175H,M133T	No	No	G12	Yes	72.0
MSK-P-0053332	67	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	67.0
MSK-P-0053340	60	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	60.0
MSK-P-0053355	40	Male	Black/African-American	PDAC	Metastasis	Deceased	G12V	C176W	No	No	G12	Yes	40.0
MSK-P-0053372	60	Female	Black/African-American	PDAC	Metastasis	Alive	G12D	R282W	No	No	G12	Yes	60.0
MSK-P-0053434	73	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	73.0
MSK-P-0053464	72	Female	NA	PDAC	Metastasis	Deceased	Q61H	L252P	No	No	Q61	Yes	72.0
MSK-P-0053480	52	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	52.0
MSK-P-0053482	72	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	72.0
MSK-P-0053490	72	Female	White	PDAC	Primary	Deceased	G12D	K132Q	No	No	G12	Yes	72.0
MSK-P-0053493	84	Male	White	PDAC	Metastasis	Deceased	G12R	R174W	No	No	G12	Yes	84.0
MSK-P-0053527	76	Female	White	PDAC	Primary	Deceased	G12D	L194H	No	No	G12	Yes	76.0
MSK-P-0053548	79	Female	NA	PDAC	Primary	Alive	G12D	No	No	H92Y	G12	No	79.0
MSK-P-0053560	67	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	67.0
MSK-P-0053589	46	Male	Black/African-American	PDAC	Primary	Deceased	G12V	V157G	No	No	G12	Yes	46.0
MSK-P-0053598	64	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	64.0
MSK-P-0053648	62	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	62.0
MSK-P-0053663	76	Female	White	PDAC	Metastasis	Deceased	Q61R	No	No	No	Q61	No	76.0
MSK-P-0053664	56	Female	NA	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0053673	62	Male	Black/African-American	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	62.0
MSK-P-0053682	76	Female	Asian	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	76.0
MSK-P-0053733	68	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0053772	62	Female	Asian	PDAC	Metastasis	Deceased	G12V	R248Q	No	G365D	G12	Yes	62.0
MSK-P-0053773	71	Female	White	PDAC	Primary	Alive	L19F,G12V	H179R	No	No	G12\|Other	Yes	71.0
MSK-P-0053785	64	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	64.0
MSK-P-0053787	80	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	80.0
MSK-P-0053818	64	Female	White	PDAC	Metastasis	Deceased	G12D	P278L	No	G508V	G12	Yes	64.0
MSK-P-0053836	73	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	73.0
MSK-P-0053865	67	Male	White	PDAC	Primary	Alive	G12R	R175H	No	No	G12	Yes	67.0
MSK-P-0053920	71	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	71.0
MSK-P-0053927	75	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	75.0
MSK-P-0053936	59	Male	White	PDAC	Metastasis	Deceased	Q61R	S215I	No	No	Q61	Yes	59.0
MSK-P-0053942	38	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	38.0
MSK-P-0053972	65	Male	White	PDAC	Primary	Alive	G12R	K132R	No	No	G12	Yes	65.0
MSK-P-0053978	80	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	80.0
MSK-P-0054001	73	Male	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	73.0
MSK-P-0054006	80	Male	White	PDAC	Metastasis	Deceased	G12D	L130R	No	No	G12	Yes	80.0
MSK-P-0054014	84	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	84.0
MSK-P-0054020	83	Female	White	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	83.0
MSK-P-0054029	76	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	76.0
MSK-P-0054036	76	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	76.0
MSK-P-0054041	52	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	52.0
MSK-P-0054047	69	Female	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	69.0
MSK-P-0054069	80	Female	White	PDAC	Metastasis	Deceased	G12V	C141Y	No	No	G12	Yes	80.0
MSK-P-0054120	62	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	62.0
MSK-P-0054145	63	Female	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	63.0
MSK-P-0054157	69	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	69.0
MSK-P-0054169	72	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	72.0
MSK-P-0054193	52	Male	NA	PDAC	Metastasis	Alive	G12D	No	H83Y	No	G12	No	52.0
MSK-P-0054195	72	Female	NA	PDAC	Primary	Alive	G12V	No	No	No	G12	No	72.0
MSK-P-0054212	71	Male	Black/African-American	PDAC	Primary	Alive	G12V	No	No	No	G12	No	71.0
MSK-P-0054254	68	Male	Asian	PDAC	Primary	Deceased	G12V	C238Y	No	No	G12	Yes	68.0
MSK-P-0054269	76	Female	White	PDAC	Primary	Alive	G12D,A146V	V218E	No	No	G12\|Other	Yes	76.0
MSK-P-0054285	63	Female	White	PDAC	Primary	Deceased	G12D	Y163C	No	No	G12	Yes	63.0
MSK-P-0054316	71	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	71.0
MSK-P-0054337	64	Male	White	PDAC	Primary	Deceased	G12C	R273H	No	No	G12	Yes	64.0
MSK-P-0054357	69	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	69.0
MSK-P-0054390	63	Female	White	PDAC	Primary	Alive	G12V	F270V	No	No	G12	Yes	63.0
MSK-P-0054420	64	Male	White	PDAC	Metastasis	Deceased	G12D	R273S	No	No	G12	Yes	64.0
MSK-P-0054434	63	Female	Asian	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	63.0
MSK-P-0054464	76	Male	NA	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	76.0
MSK-P-0054514	56	Female	White	PDAC	Primary	Deceased	G12V	R280I	No	No	G12	Yes	56.0
MSK-P-0054515	40	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	40.0
MSK-P-0054516	64	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0054529	76	Male	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	76.0
MSK-P-0054542	72	Male	White	PDAC	Primary	Alive	No	C238S	No	No	No	Yes	72.0
MSK-P-0054549	46	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	46.0
MSK-P-0054570	62	Female	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	62.0
MSK-P-0054572	73	Male	White	PDAC	Metastasis	Deceased	G12D	R248Q	No	L540H	G12	Yes	73.0
MSK-P-0054580	68	Male	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	68.0
MSK-P-0054582	77	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	77.0
MSK-P-0054595	68	Male	NA	PDAC	Primary	Deceased	G12R	G245S	No	No	G12	Yes	68.0
MSK-P-0054603	69	Male	NA	PDAC	Primary	Alive	No	No	No	No	No	No	69.0
MSK-P-0054669	80	Male	White	PDAC	Primary	Deceased	G12D	C176Y	No	No	G12	Yes	80.0
MSK-P-0054683	72	Female	White	PDAC	Primary	Deceased	G12D	P278L	No	No	G12	Yes	72.0
MSK-P-0054696	63	Male	White	PDAC	Metastasis	Alive	G12V	K132R	No	D355E	G12	Yes	63.0
MSK-P-0054697	68	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0054720	71	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	71.0
MSK-P-0054768	72	Female	White	PDAC	Primary	Deceased	G12R,G12V	R282W	No	No	G12	Yes	72.0
MSK-P-0054800	64	Male	White	PDAC	Metastasis	Deceased	G12V	C238R	No	No	G12	Yes	64.0
MSK-P-0054821	76	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	76.0
MSK-P-0054849	65	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	65.0
MSK-P-0054860	52	Male	NA	PNET	Primary	Alive	No	No	No	No	No	No	52.0
MSK-P-0054882	64	Male	Black/African-American	PDAC	Primary	Alive	G12D	No	No	No	G12	No	64.0
MSK-P-0054890	77	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	77.0
MSK-P-0054897	71	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	71.0
MSK-P-0054905	60	Female	White	PDAC	Metastasis	Alive	G12R	C135Y	No	No	G12	Yes	60.0
MSK-P-0054907	56	Male	White	PDAC	Primary	Alive	G12L	No	No	No	G12	No	56.0
MSK-P-0054910	68	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	68.0
MSK-P-0054942	59	Male	Asian	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	59.0
MSK-P-0054974	72	Male	White	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	72.0
MSK-P-0054976	58	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	58.0
MSK-P-0054979	76	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0054989	68	Male	White	PDAC	Primary	Deceased	G12D	M133K	No	R361C	G12	Yes	68.0
MSK-P-0054996	81	Male	Asian	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	81.0
MSK-P-0054998	68	Male	Asian	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	68.0
MSK-P-0055011	77	Female	White	PDAC	Primary	Alive	G12D	R181H,R175H	No	No	G12	Yes	77.0
MSK-P-0055026	NA	NA	NA	PDAC	Primary	NA	G12D	R175H	No	No	G12	Yes	NA
MSK-P-0055027	75	Female	White	PDAC	Primary	Deceased	G12D	G245D	No	No	G12	Yes	75.0
MSK-P-0055047	65	Male	White	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	65.0
MSK-P-0055061	67	Female	Black/African-American	PDAC	Metastasis	Alive	G12V	D259V	No	No	G12	Yes	67.0
MSK-P-0055078	68	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0055114	68	Female	White	PDAC	Primary	Alive	G12D	P278H	No	No	G12	Yes	68.0
MSK-P-0055208	36	Female	White	PDAC	Primary	Alive	G12V	H214R	No	No	G12	Yes	36.0
MSK-P-0055240	44	Female	Asian	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	44.0
MSK-P-0055276	52	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	52.0
MSK-P-0055310	71	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	71.0
MSK-P-0055311	72	Female	Asian	PDAC	Metastasis	Deceased	G12V	Y220C	No	No	G12	Yes	72.0
MSK-P-0055368	65	Male	NA	PDAC	Primary	Alive	G12D	C124R	No	No	G12	Yes	65.0
MSK-P-0055395	68	Male	White	PDAC	Primary	Alive	G12R	G245S	No	No	G12	Yes	68.0
MSK-P-0055467	69	Female	White	PDAC	Metastasis	Alive	No	C238R	No	No	No	Yes	69.0
MSK-P-0055492	67	Female	Black/African-American	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	67.0
MSK-P-0055521	85	Male	White	PDAC	Metastasis	Deceased	G13D	G245S	No	No	G13	Yes	85.0
MSK-P-0055556	84	Male	White	PDAC	Primary	Deceased	G12R	R273C	No	No	G12	Yes	84.0
MSK-P-0055618	72	Male	White	PDAC	Metastasis	Deceased	G12V	G266R	No	No	G12	Yes	72.0
MSK-P-0055664	44	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	44.0
MSK-P-0055670	71	Female	White	PDAC	Metastasis	Deceased	G12V	L130H	No	V350F	G12	Yes	71.0
MSK-P-0055698	67	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	67.0
MSK-P-0055699	52	Male	Asian	PDAC	Primary	Alive	G12D	No	No	No	G12	No	52.0
MSK-P-0055701	64	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	64.0
MSK-P-0055704	40	Male	Asian	PDAC	Primary	Alive	No	No	No	No	No	No	40.0
MSK-P-0055706	67	Female	White	PDAC	Primary	Alive	G12D	R181P	No	No	G12	Yes	67.0
MSK-P-0055798	52	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	52.0
MSK-P-0055816	55	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	55.0
MSK-P-0055828	80	Male	Asian	PDAC	Primary	Deceased	G12V	No	No	G386S	G12	No	80.0
MSK-P-0055870	71	Male	White	PDAC	Primary	Deceased	No	G245S	No	No	No	Yes	71.0
MSK-P-0055883	34	Female	White	PDAC	Primary	Alive	G12D	G266V	No	No	G12	Yes	34.0
MSK-P-0055885	62	Female	White	PDAC	Primary	Alive	G12V	No	No	H92Y	G12	No	62.0
MSK-P-0055899	67	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	67.0
MSK-P-0055925	63	Female	White	PDAC	Metastasis	Alive	Q61R	R248Q	No	No	Q61	Yes	63.0
MSK-P-0055948	71	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	71.0
MSK-P-0055949	81	Female	White	PDAC	Primary	Deceased	Q61R	No	No	No	Q61	No	81.0
MSK-P-0055952	67	Male	White	PDAC	Primary	Alive	G12V	S127P	No	No	G12	Yes	67.0
MSK-P-0055976	69	Male	White	PDAC	Primary	Alive	G12V	R248Q	No	No	G12	Yes	69.0
MSK-P-0056003	44	Female	White	PNET	Metastasis	Alive	G12C	No	No	No	G12	No	44.0
MSK-P-0056105	83	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	83.0
MSK-P-0056106	48	Female	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	48.0
MSK-P-0056109	83	Male	White	PDAC	Unknown	Deceased	Q61H	V157F	No	No	Q61	Yes	83.0
MSK-P-0056128	71	Male	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	71.0
MSK-P-0056183	83	Female	White	PDAC	Metastasis	Deceased	G12V	L145P	No	No	G12	Yes	83.0
MSK-P-0056228	64	Male	White	PDAC	Primary	Deceased	G12R	R280T	No	No	G12	Yes	64.0
MSK-P-0056250	79	Female	White	Carcinoma, NOS	Primary	Deceased	G12D	V216M	No	No	G12	Yes	79.0
MSK-P-0056279	77	Female	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	77.0
MSK-P-0056295	80	Female	Asian	PDAC	Primary	Alive	G12D	No	No	No	G12	No	80.0
MSK-P-0056314	72	Female	White	PDAC	Metastasis	Alive	G12V	R273H	No	No	G12	Yes	72.0
MSK-P-0056343	75	Male	Asian	PDAC	Metastasis	Deceased	G12D	No	P48L	No	G12	No	75.0
MSK-P-0056414	42	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	42.0
MSK-P-0056468	71	Female	White	PDAC	Primary	Alive	G12R	G262V	No	No	G12	Yes	71.0
MSK-P-0056469	73	Female	Asian	PDAC	Primary	Deceased	G12D	S127T	No	No	G12	Yes	73.0
MSK-P-0056538	50	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	50.0
MSK-P-0056579	64	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	64.0
MSK-P-0056605	84	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12D	Y220D	No	No	G12	Yes	84.0
MSK-P-0056606	75	Female	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	75.0
MSK-P-0056621	52	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	52.0
MSK-P-0056625	72	Female	White	PDAC	Primary	Alive	No	G266V	No	No	No	Yes	72.0
MSK-P-0056801	76	Female	White	PDAC	Primary	Alive	G12R	R248W	No	No	G12	Yes	76.0
MSK-P-0056843	76	Male	White	PDAC	Metastasis	Alive	Q61R	No	No	No	Q61	No	76.0
MSK-P-0056896	73	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	73.0
MSK-P-0056926	56	Male	White	PDAC	Primary	Alive	G12R	No	H83Y	No	G12	No	56.0
MSK-P-0056960	64	Female	White	PDAC	Primary	Alive	G12R	No	No	R361C	G12	No	64.0
MSK-P-0057003	64	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0057007	68	Male	White	PDAC	Primary	Deceased	G12R	F113C	No	No	G12	Yes	68.0
MSK-P-0057059	87	Female	White	PDAC	Primary	Alive	No	Y220C	No	No	No	Yes	87.0
MSK-P-0057065	56	Male	White	PDAC	Metastasis	Deceased	G12D	R248Q	H83Y	No	G12	Yes	56.0
MSK-P-0057090	64	Female	White	PDAC	Primary	Alive	G12R	R273C	No	No	G12	Yes	64.0
MSK-P-0057092	77	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	77.0
MSK-P-0057118	52	Female	White	PDAC	Primary	Alive	G12D	I255N	No	No	G12	Yes	52.0
MSK-P-0057178	65	Male	Asian	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	65.0
MSK-P-0057187	64	Female	Asian	PDAC	Primary	Alive	G12D	V272M	No	No	G12	Yes	64.0
MSK-P-0057240	69	Female	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	69.0
MSK-P-0057268	72	Female	White	PDAC	Metastasis	Deceased	G12C	V157F	No	No	G12	Yes	72.0
MSK-P-0057290	64	Female	Asian	PDAC	Primary	Deceased	G12V	R249S	No	No	G12	Yes	64.0
MSK-P-0057316	48	Male	Other	PDAC	Primary	Alive	Q61H	Y163C	H83Y	No	Q61	Yes	48.0
MSK-P-0057372	72	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	72.0
MSK-P-0057378	72	Female	White	PDAC	Primary	Deceased	G12V	Y220C	L63R	No	G12	Yes	72.0
MSK-P-0057387	69	Female	White	PDAC	Primary	Alive	G12V	Y205C	No	No	G12	Yes	69.0
MSK-P-0057457	59	Female	White	PDAC	Primary	Alive	G12R	R273C	No	No	G12	Yes	59.0
MSK-P-0057495	21	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	21.0
MSK-P-0057564	71	Female	White	PDAC	Primary	Alive	Q61K	No	No	No	Q61	No	71.0
MSK-P-0057568	69	Female	White	PDAC	Primary	Alive	G12D	R248Q	No	No	G12	Yes	69.0
MSK-P-0057576	44	Male	White	PDAC	Primary	Deceased	G12V	L130P	L104R	No	G12	Yes	44.0
MSK-P-0057598	64	Female	Other	PDAC	Primary	Alive	G12R	I255T	No	No	G12	Yes	64.0
MSK-P-0057663	75	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	75.0
MSK-P-0057745	56	Male	Black/African-American	PDAC	Primary	Deceased	G12D	R280G	No	No	G12	Yes	56.0
MSK-P-0057750	56	Male	NA	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	56.0
MSK-P-0057811	63	Male	White	PDAC	Primary	Deceased	G12D	G244S	No	No	G12	Yes	63.0
MSK-P-0057818	71	Female	NA	PDAC	Primary	Deceased	Q61H	F109S	No	No	Q61	Yes	71.0
MSK-P-0057821	73	Male	White	PDAC	Metastasis	Deceased	Q61R	No	No	No	Q61	No	73.0
MSK-P-0057825	79	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	79.0
MSK-P-0057839	68	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12D	No	No	No	G12	No	68.0
MSK-P-0057897	55	Male	Asian	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	55.0
MSK-P-0057978	47	Female	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	47.0
MSK-P-0058007	50	Male	Asian	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	50.0
MSK-P-0058029	67	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	67.0
MSK-P-0058043	68	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	W99G	G12	No	68.0
MSK-P-0058060	50	Female	White	Adenosquamous carcinoma	Primary	Alive	G12R	No	No	No	G12	No	50.0
MSK-P-0058069	56	Female	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	56.0
MSK-P-0058070	72	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0058077	77	Male	NA	PDAC	Metastasis	Deceased	No	No	No	No	No	No	77.0
MSK-P-0058157	76	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	76.0
MSK-P-0058230	69	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	69.0
MSK-P-0058233	64	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0058263	80	Male	White	PDAC	Primary	Deceased	G12V	R273C	No	No	G12	Yes	80.0
MSK-P-0058295	67	Male	Asian	Adenosquamous carcinoma	Primary	Deceased	Q61H	K132R	No	No	Q61	Yes	67.0
MSK-P-0058328	67	Male	White	PDAC	Primary	Deceased	G12R	R248Q	No	No	G12	Yes	67.0
MSK-P-0058376	72	Male	White	PDAC	Primary	Deceased	G12L	R267P	No	No	G12	Yes	72.0
MSK-P-0058383	56	Male	Other	PDAC	Metastasis	Deceased	G12V	C141Y	No	No	G12	Yes	56.0
MSK-P-0058393	47	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	47.0
MSK-P-0058401	72	Female	White	Carcinoma, NOS	Primary	Deceased	G12R	R175G	No	No	G12	Yes	72.0
MSK-P-0058418	77	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	77.0
MSK-P-0058427	55	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	55.0
MSK-P-0058475	75	Female	White	PDAC	Primary	Alive	G12R	R273H	No	No	G12	Yes	75.0
MSK-P-0058482	68	Female	White	PDAC	Metastasis	Deceased	G12V	Y220C	No	No	G12	Yes	68.0
MSK-P-0058520	48	Male	White	PDAC	Metastasis	Alive	G12R	No	No	L536I	G12	No	48.0
MSK-P-0058523	64	Female	NA	PDAC	Metastasis	Deceased	Q61R	E286A	No	No	Q61	Yes	64.0
MSK-P-0058567	69	Male	White	PDAC	Metastasis	Deceased	G12I	No	No	No	G12	No	69.0
MSK-P-0058569	42	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	42.0
MSK-P-0058589	36	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	36.0
MSK-P-0058598	NA	NA	NA	PDAC	Primary	NA	G12R	No	No	No	G12	No	NA
MSK-P-0058635	75	Male	Asian	Carcinoma, NOS	Primary	Deceased	G12V	No	No	No	G12	No	75.0
MSK-P-0058661	71	Male	White	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	71.0
MSK-P-0058668	76	Male	White	PDAC	Primary	Alive	G12R	C135R	No	G352R	G12	Yes	76.0
MSK-P-0058722	67	Female	Asian	PDAC	Primary	Alive	Q61H	Y236C	No	No	Q61	Yes	67.0
MSK-P-0058723	80	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	80.0
MSK-P-0058737	63	Male	White	PDAC	Primary	Alive	Q61R	No	No	N129H	Q61	No	63.0
MSK-P-0058738	48	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	48.0
MSK-P-0058740	67	Female	White	PDAC	Primary	Alive	G12C	Y126D	No	No	G12	Yes	67.0
MSK-P-0058814	75	Female	White	PDAC	Primary	Alive	G12V	L194R	No	No	G12	Yes	75.0
MSK-P-0058820	73	Female	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	73.0
MSK-P-0058897	77	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	77.0
MSK-P-0058930	73	Male	White	PDAC	Primary	Alive	Q61H	No	H83Y	No	Q61	No	73.0
MSK-P-0058978	80	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	80.0
MSK-P-0058989	68	Female	White	PDAC	Primary	Alive	G12V	C275Y	Q50R	No	G12	Yes	68.0
MSK-P-0059019	81	Male	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	81.0
MSK-P-0059054	77	Male	NA	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	77.0
MSK-P-0059097	80	Female	White	PDAC	Primary	Alive	G12V	H193L	No	No	G12	Yes	80.0
MSK-P-0059100	76	Male	Asian	PDAC	Metastasis	Alive	G12R	R175H	No	No	G12	Yes	76.0
MSK-P-0059101	63	Female	Other	PNET	Primary	Alive	No	No	No	No	No	No	63.0
MSK-P-0059112	63	Female	White	PDAC	Primary	Alive	G12R	R273H	No	A118V	G12	Yes	63.0
MSK-P-0059138	73	Female	White	PDAC	Primary	Alive	G12V	Y163C	No	No	G12	Yes	73.0
MSK-P-0059139	71	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	71.0
MSK-P-0059182	64	Male	White	PDAC	Primary	Alive	G12V	R175H	No	R361C	G12	Yes	64.0
MSK-P-0059184	>89	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	90.0
MSK-P-0059240	56	Male	White	PDAC	Metastasis	Alive	G12V	No	No	G386D	G12	No	56.0
MSK-P-0059295	68	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0059304	77	Male	White	PDAC	Primary	Alive	G12R	C242F	No	No	G12	Yes	77.0
MSK-P-0059374	69	Male	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	69.0
MSK-P-0059411	60	Male	White	PDAC	Primary	Deceased	G12R	C176R	H83Y	No	G12	Yes	60.0
MSK-P-0059412	68	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	68.0
MSK-P-0059421	65	Male	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	65.0
MSK-P-0059439	88	Female	White	PDAC	Primary	Alive	G12V	R175H	No	No	G12	Yes	88.0
MSK-P-0059443	84	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	84.0
MSK-P-0059454	62	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	62.0
MSK-P-0059470	80	Female	White	PDAC	Primary	Alive	G12V	R248W	No	No	G12	Yes	80.0
MSK-P-0059471	72	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	72.0
MSK-P-0059511	76	Female	White	PDAC	Primary	Alive	G12D	Y205C	No	No	G12	Yes	76.0
MSK-P-0059536	72	Male	Asian	PDAC	Metastasis	Deceased	No	No	No	No	No	No	72.0
MSK-P-0059570	52	Female	NA	PDAC	Metastasis	Deceased	No	R282W	No	No	No	Yes	52.0
MSK-P-0059571	72	Male	White	PDAC	Primary	Alive	G12D	R273C	No	A118V	G12	Yes	72.0
MSK-P-0059646	81	Female	White	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	81.0
MSK-P-0059668	75	Male	NA	PDAC	Metastasis	Alive	G12V	H193R	No	No	G12	Yes	75.0
MSK-P-0059675	87	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	87.0
MSK-P-0059682	56	Female	NA	PDAC	Primary	Alive	G12V	No	No	No	G12	No	56.0
MSK-P-0059747	48	Male	Other	PDAC	Metastasis	Alive	No	No	No	No	No	No	48.0
MSK-P-0059750	43	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	43.0
MSK-P-0059783	85	Female	White	PDAC	Primary	Deceased	G12R	R273H	No	G510E	G12	Yes	85.0
MSK-P-0059856	73	Female	White	PDAC	Primary	Deceased	G12A	No	No	No	G12	No	73.0
MSK-P-0059881	56	Male	White	PDAC	Metastasis	Deceased	G12V	T211I	No	No	G12	Yes	56.0
MSK-P-0059885	80	Male	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	80.0
MSK-P-0059937	76	Female	White	PDAC	Primary	Alive	G12V	R175H	No	No	G12	Yes	76.0
MSK-P-0059961	56	Male	White	PDAC	Primary	Alive	G12V	R273H	No	No	G12	Yes	56.0
MSK-P-0059963	64	Male	White	PDAC	Primary	Alive	G12D	Y220C	No	D493Y	G12	Yes	64.0
MSK-P-0059987	73	Female	Black/African-American	PDAC	Primary	Alive	G12R	No	No	No	G12	No	73.0
MSK-P-0060003	51	Male	White	PDAC	Metastasis	Alive	G12D	H193R	No	No	G12	Yes	51.0
MSK-P-0060013	54	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	54.0
MSK-P-0060035	65	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	65.0
MSK-P-0060037	84	Male	White	PDAC	Primary	Alive	Q61L	E285K	No	No	Q61	Yes	84.0
MSK-P-0060060	55	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	55.0
MSK-P-0060067	63	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	63.0
MSK-P-0060075	80	Female	White	PDAC	Primary	Deceased	G12D	I251F	G55D	No	G12	Yes	80.0
MSK-P-0060108	67	Female	White	PDAC	Primary	Deceased	G12L	No	No	No	G12	No	67.0
MSK-P-0060125	68	Female	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	68.0
MSK-P-0060195	88	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	88.0
MSK-P-0060211	73	Female	White	PDAC	Primary	Alive	Q61H	F270L	No	No	Q61	Yes	73.0
MSK-P-0060244	63	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	63.0
MSK-P-0060252	58	Male	Other	PDAC	Primary	Alive	K117N	No	H83Y	No	Other	No	58.0
MSK-P-0060256	64	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	64.0
MSK-P-0060334	NA	NA	NA	PDAC	Metastasis	NA	G12D	R175H	No	No	G12	Yes	NA
MSK-P-0060387	56	Male	White	PDAC	Metastasis	Deceased	G12R	R282W	No	No	G12	Yes	56.0
MSK-P-0060409	73	Female	White	PDAC	Primary	Alive	G12V	V172F	No	No	G12	Yes	73.0
MSK-P-0060473	65	Female	White	PDAC	Metastasis	Deceased	G12D	R273C	No	No	G12	Yes	65.0
MSK-P-0060475	71	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	71.0
MSK-P-0060478	40	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	40.0
MSK-P-0060485	72	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0060510	69	Male	White	PDAC	Primary	Deceased	No	No	L63P	No	No	No	69.0
MSK-P-0060559	59	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	59.0
MSK-P-0060618	64	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	64.0
MSK-P-0060652	73	Female	Black/African-American	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	73.0
MSK-P-0060686	71	Female	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	71.0
MSK-P-0060711	64	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
MSK-P-0060792	79	Male	White	PDAC	Metastasis	Deceased	Q61L	No	No	No	Q61	No	79.0
MSK-P-0060812	65	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	65.0
MSK-P-0060844	72	Female	White	PDAC	Primary	Deceased	No	R273H	No	No	No	Yes	72.0
MSK-P-0060874	58	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	58.0
MSK-P-0060894	77	Male	White	PDAC	Primary	Deceased	G12R	G245S	No	No	G12	Yes	77.0
MSK-P-0060912	75	Male	White	PDAC	Primary	Deceased	G12V	V203M	No	No	G12	Yes	75.0
MSK-P-0060938	62	Female	Other	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	62.0
MSK-P-0060941	NA	NA	NA	PDAC	Primary	NA	G12R	No	No	D493G	G12	No	NA
MSK-P-0060954	60	Female	White	PDAC	Primary	Deceased	G12D	R282W	No	No	G12	Yes	60.0
MSK-P-0060984	60	Female	White	PDAC	Primary	Alive	G12A	No	No	No	G12	No	60.0
MSK-P-0061080	72	Female	White	PDAC	Primary	Deceased	G12D	E171G	D84F	No	G12	Yes	72.0
MSK-P-0061104	71	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	71.0
MSK-P-0061147	68	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	68.0
MSK-P-0061176	59	Female	White	PDAC	Primary	Alive	G12D	C238Y	No	No	G12	Yes	59.0
MSK-P-0061181	69	Female	Asian	PDAC	Primary	Deceased	G12V	E285K	No	No	G12	Yes	69.0
MSK-P-0061194	68	Female	NA	PDAC	Primary	Deceased	No	No	No	No	No	No	68.0
MSK-P-0061197	65	Female	Black/African-American	PDAC	Primary	Alive	G12D	No	No	No	G12	No	65.0
MSK-P-0061201	75	Female	White	PDAC	Metastasis	Alive	G12R	R175H	No	No	G12	Yes	75.0
MSK-P-0061214	62	Male	White	PDAC	Metastasis	Deceased	G12V	No	D108G	No	G12	No	62.0
MSK-P-0061230	67	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	67.0
MSK-P-0061242	52	Female	White	PDAC	Metastasis	Alive	G12D	R248Q	No	No	G12	Yes	52.0
MSK-P-0061253	52	Male	White	PDAC	Metastasis	Deceased	G12V	H179R	L63Q	No	G12	Yes	52.0
MSK-P-0061254	69	Female	White	PDAC	Metastasis	Alive	G12V	No	L97P	A118V	G12	No	69.0
MSK-P-0061258	77	Male	White	PDAC	Metastasis	Alive	G12C	No	No	No	G12	No	77.0
MSK-P-0061268	58	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	58.0
MSK-P-0061284	75	Female	Asian	PDAC	Primary	Alive	G12R	No	No	No	G12	No	75.0
MSK-P-0061289	52	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	52.0
MSK-P-0061298	68	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	68.0
MSK-P-0061327	85	Male	Asian	PDAC	Primary	Deceased	No	R175H	No	No	No	Yes	85.0
MSK-P-0061368	68	Male	White	PDAC	Metastasis	Deceased	Q61K	R273H	No	No	Q61	Yes	68.0
MSK-P-0061387	62	Male	White	PDAC	Metastasis	Deceased	G12R	R175H	No	No	G12	Yes	62.0
MSK-P-0061391	44	Male	Asian	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	44.0
MSK-P-0061484	62	Female	Asian	PDAC	Primary	Alive	G12V	No	No	No	G12	No	62.0
MSK-P-0061523	76	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	76.0
MSK-P-0061570	54	Female	White	PDAC	Primary	Deceased	G12D	No	L16Q	No	G12	No	54.0
MSK-P-0061598	56	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	56.0
MSK-P-0061618	54	Female	White	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	54.0
MSK-P-0061672	60	Female	Black/African-American	PDAC	Primary	Deceased	G12R	G245D	No	No	G12	Yes	60.0
MSK-P-0061677	65	Male	White	PDAC	Metastasis	Deceased	No	G266R	No	No	No	Yes	65.0
MSK-P-0061736	55	Female	Asian	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	55.0
MSK-P-0061781	68	Female	Black/African-American	PDAC	Primary	Deceased	G12D	H179L	No	No	G12	Yes	68.0
MSK-P-0061783	77	Male	White	PDAC	Primary	Alive	No	D281G	No	No	No	Yes	77.0
MSK-P-0061802	79	Male	White	PDAC	Metastasis	Deceased	G12V	No	D84N	No	G12	No	79.0
MSK-P-0061818	80	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	80.0
MSK-P-0061836	73	Male	White	PDAC	Metastasis	Deceased	G12V	F134C	No	S5C	G12	Yes	73.0
MSK-P-0061870	72	Female	NA	PDAC	Metastasis	Deceased	G12D	R273C	No	No	G12	Yes	72.0
MSK-P-0061874	73	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	73.0
MSK-P-0061930	75	Female	White	IPMN	Primary	Deceased	Q61K	No	No	No	Q61	No	75.0
MSK-P-0061945	72	Female	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	72.0
MSK-P-0061971	47	Male	NA	PDAC	Primary	Alive	No	No	No	No	No	No	47.0
MSK-P-0061976	62	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	62.0
MSK-P-0061981	71	Male	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0062026	69	Female	White	IOPN	Primary	Alive	G12R	No	No	No	G12	No	69.0
MSK-P-0062030	46	Male	Asian	PDAC	Metastasis	Deceased	Q61R	C238Y	No	No	Q61	Yes	46.0
MSK-P-0062035	56	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	56.0
MSK-P-0062055	64	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	64.0
MSK-P-0062075	69	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	69.0
MSK-P-0062125	62	Male	White	PDAC	Primary	Alive	Q61H	No	H83Y	R361H	Q61	No	62.0
MSK-P-0062126	60	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	60.0
MSK-P-0062129	80	Male	White	PDAC	Primary	Alive	G12D	P151S	No	No	G12	Yes	80.0
MSK-P-0062164	68	Male	Black/African-American	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	68.0
MSK-P-0062181	76	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	76.0
MSK-P-0062211	72	Female	White	PDAC	Primary	Deceased	G12V	No	A21D	No	G12	No	72.0
MSK-P-0062264	68	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	68.0
MSK-P-0062269	68	Male	White	PDAC	Metastasis	Deceased	G12R	G244C	No	No	G12	Yes	68.0
MSK-P-0062279	73	Male	White	PDAC	Primary	Alive	G12D	R273H	No	No	G12	Yes	73.0
MSK-P-0062309	43	Male	White	PDAC	Metastasis	Alive	G12L	No	No	No	G12	No	43.0
MSK-P-0062310	84	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	84.0
MSK-P-0062316	81	Female	White	PDAC	Primary	Alive	G12V	S127T	No	No	G12	Yes	81.0
MSK-P-0062426	77	Female	White	PDAC	Primary	Alive	G12R	Y126H	No	No	G12	Yes	77.0
MSK-P-0062459	72	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	72.0
MSK-P-0062526	64	Male	White	PDAC	Primary	Alive	No	R248W	No	No	No	Yes	64.0
MSK-P-0062574	84	Male	White	PDAC	Primary	Alive	No	R248Q	No	No	No	Yes	84.0
MSK-P-0062605	72	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0062673	52	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	52.0
MSK-P-0062683	48	Female	White	PDAC	Metastasis	Alive	G12D	R174_R175delinsSG	No	No	G12	Yes	48.0
MSK-P-0062709	69	Female	Asian	PDAC	Primary	Deceased	G12D	R248W	No	L109P	G12	Yes	69.0
MSK-P-0062729	76	Male	White	PDAC	Metastasis	Deceased	No	C135Y	No	No	No	Yes	76.0
MSK-P-0062788	51	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	51.0
MSK-P-0062806	55	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	R249S	No	No	G12	Yes	55.0
MSK-P-0062810	84	Female	White	PDAC	Primary	Deceased	G12V	R175H	No	G365D	G12	Yes	84.0
MSK-P-0062813	72	Female	White	PDAC	Metastasis	Alive	G12D	M246V	No	No	G12	Yes	72.0
MSK-P-0062838	72	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	72.0
MSK-P-0062839	83	Male	White	PDAC	Metastasis	Deceased	G12V	K132N	No	No	G12	Yes	83.0
MSK-P-0062914	69	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	69.0
MSK-P-0062953	72	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	72.0
MSK-P-0062965	68	Female	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	68.0
MSK-P-0063001	71	Female	White	PDAC	Primary	Alive	G12D	V274F	No	No	G12	Yes	71.0
MSK-P-0063013	56	Female	White	PDAC	Primary	Deceased	G12V	P278S	No	No	G12	Yes	56.0
MSK-P-0063033	72	Male	White	PDAC	Primary	Deceased	G12V	I195A	No	No	G12	Yes	72.0
MSK-P-0063052	65	Female	White	PDAC	Metastasis	Deceased	G12C	P151T	V51D	No	G12	Yes	65.0
MSK-P-0063136	76	Female	White	PDAC	Primary	Alive	G12R	No	T77S	No	G12	No	76.0
MSK-P-0063147	60	Female	NA	PDAC	Primary	Alive	G12V	V173M	No	No	G12	Yes	60.0
MSK-P-0063152	81	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	81.0
MSK-P-0063169	56	Female	White	PDAC	Primary	Alive	G12D	Y236C	No	No	G12	Yes	56.0
MSK-P-0063170	80	Female	White	PDAC	Primary	Alive	G12V	Y163C	No	No	G12	Yes	80.0
MSK-P-0063203	NA	NA	NA	PDAC	Primary	NA	Q61R	V143M	No	No	Q61	Yes	NA
MSK-P-0063204	50	Male	White	PDAC	Primary	Alive	G12D	R248W	No	No	G12	Yes	50.0
MSK-P-0063230	72	Female	NA	PDAC	Primary	Alive	G12V	R175H	No	No	G12	Yes	72.0
MSK-P-0063232	68	Male	White	PDAC	Primary	Alive	G12D	E224D	No	No	G12	Yes	68.0
MSK-P-0063239	67	Female	White	PDAC	Metastasis	Deceased	G12D	M246V	No	No	G12	Yes	67.0
MSK-P-0063244	59	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	59.0
MSK-P-0063290	69	Female	White	Adenosquamous carcinoma	Primary	Alive	G12V	No	No	No	G12	No	69.0
MSK-P-0063291	69	Male	White	PDAC	Primary	Deceased	G12D	R175H	No	R361H	G12	Yes	69.0
MSK-P-0063305	60	Female	Black/African-American	PNET	Metastasis	Alive	No	No	No	No	No	No	60.0
MSK-P-0063347	63	Male	White	Carcinoma, NOS	Primary	Alive	Q61H	No	No	No	Q61	No	63.0
MSK-P-0063444	72	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0063465	62	Male	White	PDAC	Metastasis	Deceased	G12V	C135Y	No	No	G12	Yes	62.0
MSK-P-0063528	48	Female	White	Carcinoma, NOS	Metastasis	Alive	G12V	No	No	No	G12	No	48.0
MSK-P-0063533	59	Male	White	PDAC	Primary	Alive	G12C	No	No	R361C	G12	No	59.0
MSK-P-0063555	44	Male	Asian	PDAC	Metastasis	Deceased	Q61R	R282W	No	No	Q61	Yes	44.0
MSK-P-0063581	60	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	60.0
MSK-P-0063628	63	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	63.0
MSK-P-0063699	47	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	47.0
MSK-P-0063701	60	Female	NA	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	60.0
MSK-P-0063712	60	Male	White	PDAC	Primary	Alive	G12D	C135W	No	No	G12	Yes	60.0
MSK-P-0063876	69	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	69.0
MSK-P-0063877	71	Male	White	PDAC	Primary	Alive	G12R	No	No	T349P	G12	No	71.0
MSK-P-0063880	64	Male	Asian	PDAC	Primary	Deceased	G12D	Y234C	No	No	G12	Yes	64.0
MSK-P-0063899	47	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	47.0
MSK-P-0063910	68	Female	White	PDAC	Primary	Alive	G12R	R273H	No	No	G12	Yes	68.0
MSK-P-0063914	56	Female	Black/African-American	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	56.0
MSK-P-0063916	64	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	64.0
MSK-P-0064021	27	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	27.0
MSK-P-0064024	81	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	Y131N	G12	No	81.0
MSK-P-0064034	42	Female	NA	PDAC	Metastasis	Alive	G12D	No	H83D	No	G12	No	42.0
MSK-P-0064054	65	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	65.0
MSK-P-0064067	48	Male	White	PDAC	Primary	Alive	G12D	G245S	No	No	G12	Yes	48.0
MSK-P-0064069	65	Male	NA	PDAC	Primary	Alive	G12D	G245V	No	No	G12	Yes	65.0
MSK-P-0064070	54	Male	White	PDAC	Metastasis	Deceased	G12D	R280G	H83Y	E526V	G12	Yes	54.0
MSK-P-0064074	60	Female	White	PDAC	Primary	Alive	G12D	T125K	No	No	G12	Yes	60.0
MSK-P-0064093	76	Male	NA	PDAC	Primary	Alive	No	R175H	No	R361G	No	Yes	76.0
MSK-P-0064128	64	Female	White	PDAC	Primary	Alive	G12R	R273C	No	V112G,F119L	G12	Yes	64.0
MSK-P-0064147	73	Male	White	PDAC	Primary	Deceased	G12R	G266V	No	No	G12	Yes	73.0
MSK-P-0064149	44	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	44.0
MSK-P-0064172	68	Male	NA	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0064178	60	Male	White	PDAC	Primary	Alive	G12D	Y205D	No	G365V	G12	Yes	60.0
MSK-P-0064199	44	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	44.0
MSK-P-0064233	63	Female	NA	PDAC	Primary	Alive	G12D	No	No	No	G12	No	63.0
MSK-P-0064234	79	Female	White	PDAC	Primary	Alive	Q61R	No	H83Y	No	Q61	No	79.0
MSK-P-0064274	59	Female	White	PDAC	Metastasis	Alive	G12V	Y220C	No	No	G12	Yes	59.0
MSK-P-0064338	63	Female	White	PDAC	Primary	Deceased	G12V	R273H	No	R361H	G12	Yes	63.0
MSK-P-0064368	48	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	48.0
MSK-P-0064404	64	Male	Asian	PDAC	Primary	Alive	G12D	No	No	A118V	G12	No	64.0
MSK-P-0064417	62	Female	Asian	PDAC	Primary	Deceased	G12D	R273L	No	No	G12	Yes	62.0
MSK-P-0064418	76	Male	White	PDAC	Primary	Alive	G12S	R282W	No	No	G12	Yes	76.0
MSK-P-0064424	73	Female	White	PDAC	Primary	Alive	G12R	L257P	No	No	G12	Yes	73.0
MSK-P-0064462	67	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	67.0
MSK-P-0064465	81	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	81.0
MSK-P-0064466	63	Male	NA	PDAC	Primary	Alive	G12D	No	No	No	G12	No	63.0
MSK-P-0064469	67	Male	NA	PDAC	Metastasis	Deceased	Q61R	No	No	No	Q61	No	67.0
MSK-P-0064501	58	Male	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	58.0
MSK-P-0064518	58	Female	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	58.0
MSK-P-0064531	60	Female	Asian	PDAC	Primary	Alive	No	No	No	R361H	No	No	60.0
MSK-P-0064533	64	Male	White	PDAC	Metastasis	Deceased	G12V	R248Q	No	No	G12	Yes	64.0
MSK-P-0064542	69	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	69.0
MSK-P-0064545	73	Female	Black/African-American	PNET	Primary	Alive	No	No	No	No	No	No	73.0
MSK-P-0064558	62	Female	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	62.0
MSK-P-0064679	72	Female	White	PDAC	Primary	Alive	G12D	R273H	No	No	G12	Yes	72.0
MSK-P-0064683	67	Male	White	PDAC	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	67.0
MSK-P-0064697	67	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	67.0
MSK-P-0064701	48	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	48.0
MSK-P-0064712	50	Male	White	PDAC	Metastasis	Alive	G12V	L130V	No	No	G12	Yes	50.0
MSK-P-0064726	64	Male	White	PDAC	Primary	Alive	G12R	A159P	A73G	No	G12	Yes	64.0
MSK-P-0064742	72	Male	White	PDAC	Primary	Deceased	Q61H	G245C	No	No	Q61	Yes	72.0
MSK-P-0064758	67	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	67.0
MSK-P-0064764	59	Male	White	Acinar cell carcinoma	Primary	Deceased	No	Y163H	No	No	No	Yes	59.0
MSK-P-0064773	60	Male	White	PDAC	Metastasis	Deceased	G12V	R248Q	No	No	G12	Yes	60.0
MSK-P-0064776	72	Male	White	PDAC	Metastasis	Alive	G12V	R273H	No	No	G12	Yes	72.0
MSK-P-0064780	52	Male	White	PDAC	Metastasis	Deceased	G12D	R337L	No	No	G12	Yes	52.0
MSK-P-0064824	71	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	71.0
MSK-P-0064873	56	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	56.0
MSK-P-0064904	62	Female	NA	PDAC	Metastasis	Alive	G12V	R175H	No	No	G12	Yes	62.0
MSK-P-0064914	64	Male	White	PDAC	Primary	Alive	No	G266E	No	No	No	Yes	64.0
MSK-P-0064958	72	Female	White	Carcinoma, NOS	Primary	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0065029	52	Female	NA	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	52.0
MSK-P-0065030	56	Male	Black/African-American	PDAC	Primary	Alive	G12V	No	No	No	G12	No	56.0
MSK-P-0065035	67	Female	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	67.0
MSK-P-0065087	69	Female	White	PDAC	Metastasis	Alive	G12D	R248Q	No	No	G12	Yes	69.0
MSK-P-0065101	88	Male	White	PDAC	Primary	Alive	G12D	R110H	No	R361H	G12	Yes	88.0
MSK-P-0065134	76	Male	White	PDAC	Primary	Deceased	G12R	L194R	No	No	G12	Yes	76.0
MSK-P-0065136	50	Male	White	PDAC	Primary	Deceased	G12V	E285K	No	No	G12	Yes	50.0
MSK-P-0065143	67	Female	White	PDAC	Primary	Deceased	G12V	K132N	No	No	G12	Yes	67.0
MSK-P-0065170	67	Male	White	PDAC	Primary	Alive	G12V	R273C	No	No	G12	Yes	67.0
MSK-P-0065184	72	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0065190	68	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	68.0
MSK-P-0065219	62	Male	Other	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	62.0
MSK-P-0065234	69	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	P356L	G12	No	69.0
MSK-P-0065240	58	Male	White	PDAC	Metastasis	Deceased	Q61K	No	D74V	No	Q61	No	58.0
MSK-P-0065265	62	Male	White	PDAC	Metastasis	Deceased	G12I	No	No	No	G12	No	62.0
MSK-P-0065270	63	Female	White	PDAC	Primary	Alive	No	C242Y	No	No	No	Yes	63.0
MSK-P-0065271	64	Male	White	PDAC	Metastasis	Alive	G12V	D281Y	No	G352E	G12	Yes	64.0
MSK-P-0065291	65	Male	White	Solid pseudopapillary tumor	Metastasis	Alive	No	No	No	No	No	No	65.0
MSK-P-0065314	72	Male	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	72.0
MSK-P-0065316	64	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	64.0
MSK-P-0065398	71	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	71.0
MSK-P-0065406	64	Female	White	PDAC	Metastasis	Deceased	G12V	S215I	No	No	G12	Yes	64.0
MSK-P-0065409	64	Male	Asian	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	64.0
MSK-P-0065438	71	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	71.0
MSK-P-0065461	71	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	71.0
MSK-P-0065540	72	Female	White	PDAC	Primary	Alive	G12D	R273H	H83Y	No	G12	Yes	72.0
MSK-P-0065552	62	Male	White	PDAC	Primary	Alive	G12D	R282W	No	No	G12	Yes	62.0
MSK-P-0065557	51	Female	White	PDAC	Metastasis	Deceased	G12D	Y126N	No	No	G12	Yes	51.0
MSK-P-0065609	67	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	67.0
MSK-P-0065624	56	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0065653	79	Male	White	PDAC	Primary	Deceased	G12D	L194R	No	H132Y	G12	Yes	79.0
MSK-P-0065659	76	Male	White	Acinar cell carcinoma	Primary	Deceased	No	No	No	No	No	No	76.0
MSK-P-0065693	50	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	50.0
MSK-P-0065718	72	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	72.0
MSK-P-0065722	72	Male	Asian	PDAC	Metastasis	Deceased	A146P	No	No	R361H	Other	No	72.0
MSK-P-0065731	76	Male	White	PDAC	Primary	Alive	G12R	R248Q	No	No	G12	Yes	76.0
MSK-P-0065735	46	Female	White	PDAC	Primary	Deceased	G12D	G245S	No	No	G12	Yes	46.0
MSK-P-0065742	62	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	62.0
MSK-P-0065744	77	Female	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	77.0
MSK-P-0065825	75	Male	White	PDAC	Primary	Alive	G12C	P190L	P48L	No	G12	Yes	75.0
MSK-P-0065860	73	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	73.0
MSK-P-0065911	59	Male	White	PDAC	Primary	Alive	G12D	I232F	No	No	G12	Yes	59.0
MSK-P-0065921	67	Male	White	PDAC	Primary	Alive	G12V	No	No	R361H	G12	No	67.0
MSK-P-0065926	75	Female	Asian	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	75.0
MSK-P-0065990	64	Male	White	PDAC	Primary	Alive	G12R	C135R	No	No	G12	Yes	64.0
MSK-P-0065995	77	Female	White	PDAC	Metastasis	Deceased	Q61H	H193Y	No	No	Q61	Yes	77.0
MSK-P-0066012	71	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	71.0
MSK-P-0066049	80	Female	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	80.0
MSK-P-0066076	51	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	51.0
MSK-P-0066085	56	Male	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	56.0
MSK-P-0066090	72	Male	White	PDAC	Metastasis	Alive	G12V	Y220C	No	No	G12	Yes	72.0
MSK-P-0066168	68	Female	Other	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	68.0
MSK-P-0066178	73	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	73.0
MSK-P-0066193	72	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0066207	54	Male	Asian	PDAC	Primary	Alive	G12D	No	No	No	G12	No	54.0
MSK-P-0066226	81	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	81.0
MSK-P-0066254	NA	NA	NA	PDAC	Metastasis	NA	G12D	C275W	No	No	G12	Yes	NA
MSK-P-0066257	64	Female	White	Adenosquamous carcinoma	Primary	Alive	G12R	No	No	No	G12	No	64.0
MSK-P-0066258	80	Male	White	PDAC	Primary	Deceased	G12V	I254S	H83Y	No	G12	Yes	80.0
MSK-P-0066259	81	Female	White	PDAC	Metastasis	Alive	G12V	K132N	No	No	G12	Yes	81.0
MSK-P-0066275	79	Male	White	PDAC	Primary	Deceased	G12D	L265P	No	No	G12	Yes	79.0
MSK-P-0066304	64	Male	Black/African-American	PDAC	Primary	Deceased	G12D	K132Q	No	No	G12	Yes	64.0
MSK-P-0066331	56	Male	White	PDAC	Metastasis	Alive	G12D	Y234C	No	No	G12	Yes	56.0
MSK-P-0066338	58	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	58.0
MSK-P-0066393	64	Male	Asian	PDAC	Primary	Deceased	G12V	R273H	No	No	G12	Yes	64.0
MSK-P-0066586	84	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	84.0
MSK-P-0066597	54	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	54.0
MSK-P-0066612	64	Male	Black/African-American	PDAC	Metastasis	Alive	Q61H	R337C	No	E330K	Q61	Yes	64.0
MSK-P-0066654	75	Male	White	PDAC	Primary	Deceased	G12D	G266E	No	No	G12	Yes	75.0
MSK-P-0066659	65	Male	White	PDAC	Metastasis	Alive	G12V	P250L	No	No	G12	Yes	65.0
MSK-P-0066661	72	Male	Asian	PDAC	Metastasis	Alive	G12D	R273C	No	No	G12	Yes	72.0
MSK-P-0066663	59	Male	White	PDAC	Primary	Alive	G12V	V216M	No	A406T	G12	Yes	59.0
MSK-P-0066664	77	Male	White	PDAC	Metastasis	Alive	G12V	K120N	No	No	G12	Yes	77.0
MSK-P-0066692	83	Female	Asian	PDAC	Primary	Deceased	G12V	V172D	No	P356S	G12	Yes	83.0
MSK-P-0066732	72	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	72.0
MSK-P-0066757	77	Female	White	PDAC	Primary	Alive	G12D	P151S	No	No	G12	Yes	77.0
MSK-P-0066836	68	Female	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	68.0
MSK-P-0066937	63	Female	White	PDAC	Primary	Deceased	G12D	E285K	No	No	G12	Yes	63.0
MSK-P-0066943	76	Male	White	PDAC	Primary	Deceased	G12R	H193L	A85_A86delinsVP	No	G12	Yes	76.0
MSK-P-0066988	54	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	54.0
MSK-P-0067017	58	Female	White	PDAC	Primary	Alive	G12V	P177R	No	No	G12	Yes	58.0
MSK-P-0067035	56	Female	White	PDAC	Metastasis	Deceased	Q61H	Y220C	No	R361C	Q61	Yes	56.0
MSK-P-0067038	62	Female	White	PDAC	Metastasis	Alive	Q61R	R249M	H83Y	No	Q61	Yes	62.0
MSK-P-0067039	67	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	67.0
MSK-P-0067047	48	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	48.0
MSK-P-0067074	60	Female	White	PDAC	Primary	Deceased	G12D	G245S	No	No	G12	Yes	60.0
MSK-P-0067129	72	Male	White	PDAC	Primary	Alive	G12D	Y163C	No	No	G12	Yes	72.0
MSK-P-0067163	51	Male	White	PDAC	Primary	Alive	G12V	R158H	No	No	G12	Yes	51.0
MSK-P-0067194	64	Male	White	PDAC	Metastasis	Alive	G12D	R273H	Q50R	No	G12	Yes	64.0
MSK-P-0067207	75	Female	White	PDAC	Primary	Alive	G12R	R273C	No	No	G12	Yes	75.0
MSK-P-0067210	72	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0067218	64	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	64.0
MSK-P-0067253	67	Female	White	IPMN	Primary	Alive	G12D	No	No	No	G12	No	67.0
MSK-P-0067269	72	Female	White	PDAC	Primary	Alive	G12V	H168R	No	No	G12	Yes	72.0
MSK-P-0067294	77	Male	White	PDAC	Primary	Alive	Q61L	No	No	No	Q61	No	77.0
MSK-P-0067339	46	Male	Asian	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	46.0
MSK-P-0067364	64	Female	White	PDAC	Primary	Alive	No	R175H	No	No	No	Yes	64.0
MSK-P-0067371	60	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	60.0
MSK-P-0067380	56	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	56.0
MSK-P-0067387	72	Female	White	PDAC	Primary	Alive	No	Y205F	No	No	No	Yes	72.0
MSK-P-0067407	64	Male	White	PDAC	Metastasis	Alive	G12R	G244C	No	No	G12	Yes	64.0
MSK-P-0067431	56	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	56.0
MSK-P-0067481	72	Female	White	PDAC	Primary	Alive	G12D	K132R	No	R361L	G12	Yes	72.0
MSK-P-0067486	72	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	72.0
MSK-P-0067525	56	Female	Black/African-American	PDAC	Primary	Alive	No	C242W	No	D360V	No	Yes	56.0
MSK-P-0067539	42	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	42.0
MSK-P-0067551	75	Female	White	PDAC	Metastasis	Alive	G12V	M246T	No	No	G12	Yes	75.0
MSK-P-0067600	75	Female	Asian	PDAC	Metastasis	Alive	G12V	No	No	I94S	G12	No	75.0
MSK-P-0067601	69	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	69.0
MSK-P-0067604	64	Male	White	PDAC	Primary	Deceased	Q61K	R282W	No	No	Q61	Yes	64.0
MSK-P-0067621	65	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	65.0
MSK-P-0067622	68	Female	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	68.0
MSK-P-0067651	76	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	76.0
MSK-P-0067667	69	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	69.0
MSK-P-0067694	68	Male	White	PDAC	Metastasis	Deceased	G12V	R273C	H83D	No	G12	Yes	68.0
MSK-P-0067696	60	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	60.0
MSK-P-0067777	69	Female	White	PDAC	Metastasis	Deceased	G12V	T155_R156delinsNC	No	No	G12	Yes	69.0
MSK-P-0067790	67	Male	White	PDAC	Metastasis	Alive	G12D	Y220C	No	No	G12	Yes	67.0
MSK-P-0067817	64	Female	White	PDAC	Primary	Alive	G12D	No	No	R361C	G12	No	64.0
MSK-P-0067821	68	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	68.0
MSK-P-0067849	79	Male	White	PDAC	Metastasis	Deceased	G12V	M237I	No	No	G12	Yes	79.0
MSK-P-0067853	79	Male	White	PDAC	Metastasis	Alive	G12V	No	No	L533P	G12	No	79.0
MSK-P-0067872	71	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	71.0
MSK-P-0067974	72	Female	White	PDAC	Primary	Alive	G12V	R273C	No	No	G12	Yes	72.0
MSK-P-0067994	>89	Male	White	PDAC	Primary	Deceased	G12D	Y163C	No	A118V	G12	Yes	90.0
MSK-P-0068026	56	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	56.0
MSK-P-0068034	73	Female	White	PDAC	Primary	Alive	G12R,E143K	R249T	No	No	G12\|Other	Yes	73.0
MSK-P-0068038	56	Male	White	PDAC	Metastasis	Alive	Q61H	No	No	No	Q61	No	56.0
MSK-P-0068058	69	Female	White	PNET	Metastasis	Alive	G12D	No	No	No	G12	No	69.0
MSK-P-0068084	72	Male	White	IPMN	Primary	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0068088	76	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	76.0
MSK-P-0068093	62	Female	White	PDAC	Primary	Alive	G12R	R248W	No	No	G12	Yes	62.0
MSK-P-0068117	56	Female	White	PDAC	Primary	Alive	No	F109C	No	No	No	Yes	56.0
MSK-P-0068122	72	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	72.0
MSK-P-0068171	64	Male	Asian	PDAC	Primary	Alive	G12D	No	No	No	G12	No	64.0
MSK-P-0068194	69	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	69.0
MSK-P-0068210	<18	Female	Black/African-American	PNET	Primary	Alive	No	No	No	No	No	No	17.0
MSK-P-0068216	69	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	69.0
MSK-P-0068243	54	Female	White	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	54.0
MSK-P-0068258	71	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	71.0
MSK-P-0068371	71	Female	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	71.0
MSK-P-0068429	77	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	D52H	G12	No	77.0
MSK-P-0068443	72	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	72.0
MSK-P-0068477	64	Female	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	64.0
MSK-P-0068510	50	Female	White	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	50.0
MSK-P-0068550	77	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	77.0
MSK-P-0068652	64	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	64.0
MSK-P-0068682	58	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	58.0
MSK-P-0068740	72	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	72.0
MSK-P-0068788	71	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	71.0
MSK-P-0068820	58	Male	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	58.0
MSK-P-0068826	63	Male	White	PDAC	Primary	Alive	Q61H	H193L	No	No	Q61	Yes	63.0
MSK-P-0068899	56	Male	White	PDAC	Primary	Deceased	G12D	H193R	No	No	G12	Yes	56.0
MSK-P-0068900	77	Female	White	PDAC	Unknown	Deceased	G12D	G245V	No	No	G12	Yes	77.0
MSK-P-0068973	76	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	76.0
MSK-P-0068977	60	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	60.0
MSK-P-0069044	75	Female	Asian	PDAC	Primary	Alive	G12V	No	No	No	G12	No	75.0
MSK-P-0069114	80	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	80.0
MSK-P-0069150	64	Male	Asian	PDAC	Primary	Alive	G12D	No	No	No	G12	No	64.0
MSK-P-0069194	68	Female	White	PDAC	Metastasis	Alive	Q61R	C242S	No	No	Q61	Yes	68.0
MSK-P-0069208	>89	Male	White	PDAC	Primary	Alive	G12V	I255S	No	No	G12	Yes	90.0
MSK-P-0069255	47	Male	Asian	PDAC	Metastasis	Deceased	G12V	S215I	No	No	G12	Yes	47.0
MSK-P-0069258	64	Female	NA	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	64.0
MSK-P-0069262	68	Female	White	PDAC	Metastasis	Alive	G12A	No	No	R361C	G12	No	68.0
MSK-P-0069281	75	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	75.0
MSK-P-0069311	65	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	65.0
MSK-P-0069319	71	Male	Black/African-American	PNET	Primary	Alive	No	No	No	No	No	No	71.0
MSK-P-0069404	80	Female	White	PDAC	Primary	Deceased	No	No	No	R361C	No	No	80.0
MSK-P-0069551	76	Female	White	PDAC	Primary	Alive	G12V	R273C	No	No	G12	Yes	76.0
MSK-P-0069556	79	Male	White	PDAC	Primary	Alive	G12V	R175H	No	No	G12	Yes	79.0
MSK-P-0069563	62	Male	White	PDAC	Metastasis	Alive	G12D	A138V	No	No	G12	Yes	62.0
MSK-P-0069586	72	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	72.0
MSK-P-0069589	64	Female	White	PNET	Primary	Alive	No	No	No	G386V	No	No	64.0
MSK-P-0069594	54	Male	Asian	PDAC	Primary	Alive	G12D	Y163C	No	E526K	G12	Yes	54.0
MSK-P-0069621	52	Female	Asian	PDAC	Primary	Alive	G12V	No	No	No	G12	No	52.0
MSK-P-0069658	87	Male	White	PDAC	Primary	Alive	G12V	R273C	No	No	G12	Yes	87.0
MSK-P-0069666	73	Female	White	Carcinoma, NOS	Primary	Alive	G12D	G244C	No	No	G12	Yes	73.0
MSK-P-0069710	63	Male	NA	PDAC	Primary	Alive	G12V	No	No	No	G12	No	63.0
MSK-P-0069716	71	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	71.0
MSK-P-0069799	77	Female	Black/African-American	PDAC	Primary	Alive	G12R	No	No	No	G12	No	77.0
MSK-P-0069872	60	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	60.0
MSK-P-0069874	80	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	80.0
MSK-P-0070120	83	Male	White	PDAC	Primary	Alive	G12D	R282G	No	No	G12	Yes	83.0
MSK-P-0070130	68	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	68.0
MSK-P-0070191	60	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	60.0
MSK-P-0070252	77	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	77.0
MSK-P-0070253	69	Male	White	PDAC	Primary	Alive	G12V	R273H	No	No	G12	Yes	69.0
MSK-P-0070274	67	Male	White	PDAC	Metastasis	Alive	G12V	R273C	No	No	G12	Yes	67.0
MSK-P-0070365	63	Female	Asian	PDAC	Primary	Alive	G12D	C176Y	No	No	G12	Yes	63.0
MSK-P-0070450	55	Male	White	PDAC	Metastasis	Deceased	G12D	G262V	No	No	G12	Yes	55.0
MSK-P-0070465	65	Female	Asian	PDAC	Metastasis	Alive	G12D	R248W	No	No	G12	Yes	65.0
MSK-P-0070610	67	Male	White	PDAC	Primary	Alive	G12D	R273H	H83Y	No	G12	Yes	67.0
MSK-P-0070625	55	Male	White	Carcinoma, NOS	Primary	Alive	Q61K	R156P	No	No	Q61	Yes	55.0
MSK-P-0070628	64	Female	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	64.0
MSK-P-0070648	55	Male	Black/African-American	PDAC	Primary	Alive	Q61K	No	No	W524C	Q61	No	55.0
MSK-P-0070649	72	Female	Asian	PDAC	Metastasis	Alive	Q61H	Y163C	No	No	Q61	Yes	72.0
MSK-P-0070674	73	Female	White	PDAC	Metastasis	Deceased	G12V	No	H83Y	No	G12	No	73.0
MSK-P-0070809	88	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	88.0
MSK-P-0070821	60	Male	Other	PDAC	Metastasis	Alive	G12V	H179Y	No	No	G12	Yes	60.0
MSK-P-0070827	63	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	63.0
MSK-P-0070830	77	Female	Asian	PDAC	Metastasis	Deceased	Q61H	I255S	No	R361H	Q61	Yes	77.0
MSK-P-0070842	87	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	87.0
MSK-P-0070953	64	Female	White	PDAC	Primary	Alive	G12V	G266E	No	No	G12	Yes	64.0
MSK-P-0070957	76	Male	White	Adenosquamous carcinoma	Primary	Alive	G12D	No	No	No	G12	No	76.0
MSK-P-0070963	52	Male	Other	Carcinoma, NOS	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	52.0
MSK-P-0071011	83	Male	White	PDAC	Primary	Deceased	G12D	R273C	No	No	G12	Yes	83.0
MSK-P-0071027	88	Male	White	PDAC	Primary	Deceased	G12V	F113V	R24G	No	G12	Yes	88.0
MSK-P-0071031	38	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	38.0
MSK-P-0071037	76	Male	White	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	76.0
MSK-P-0071039	80	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	80.0
MSK-P-0071044	55	Male	White	PDAC	Primary	Alive	G12V	H193Y	No	No	G12	Yes	55.0
MSK-P-0071052	73	Male	White	PDAC	Metastasis	Alive	G12V	R248Q	No	No	G12	Yes	73.0
MSK-P-0071063	67	Male	White	PDAC	Primary	Alive	G12D	M246K	No	No	G12	Yes	67.0
MSK-P-0071067	64	Male	White	PDAC	Primary	Alive	G12R	A138V	No	No	G12	Yes	64.0
MSK-P-0071074	68	Male	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	68.0
MSK-P-0071082	67	Female	White	PDAC	Primary	Alive	G12R	R273H	No	R361H	G12	Yes	67.0
MSK-P-0071090	65	Male	White	PDAC	Primary	Alive	G12D	R248Q	No	No	G12	Yes	65.0
MSK-P-0071091	60	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	60.0
MSK-P-0071114	67	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	67.0
MSK-P-0071169	60	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	60.0
MSK-P-0071254	58	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	R361H	G12	No	58.0
MSK-P-0071271	52	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	52.0
MSK-P-0071277	79	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	79.0
MSK-P-0071329	76	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	76.0
MSK-P-0071360	81	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	81.0
MSK-P-0071378	81	Female	Black/African-American	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	81.0
MSK-P-0071406	76	Male	White	Adenosquamous carcinoma	Primary	Alive	Q61H	Y220C	No	No	Q61	Yes	76.0
MSK-P-0071451	68	Male	White	PDAC	Primary	Alive	Q61R	No	No	R361H	Q61	No	68.0
MSK-P-0071537	64	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	64.0
MSK-P-0071606	73	Male	White	PDAC	Primary	Deceased	G12D	No	H83Y	No	G12	No	73.0
MSK-P-0071637	69	Male	NA	PDAC	Primary	Alive	G12D	V217G	No	No	G12	Yes	69.0
MSK-P-0071703	72	Male	Asian	PDAC	Primary	Alive	G12D	No	No	No	G12	No	72.0
MSK-P-0071778	75	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	75.0
MSK-P-0071805	64	Female	Asian	PDAC	Primary	Alive	G12R	No	No	No	G12	No	64.0
MSK-P-0071866	62	Female	Asian	PDAC	Primary	Deceased	G12V	K132N	No	No	G12	Yes	62.0
MSK-P-0071878	65	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	65.0
MSK-P-0071881	65	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	65.0
MSK-P-0071882	50	Male	White	PDAC	Primary	Alive	G12V	T155N	No	No	G12	Yes	50.0
MSK-P-0071899	68	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	68.0
MSK-P-0071901	63	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	63.0
MSK-P-0071909	60	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	60.0
MSK-P-0071935	71	Male	White	PDAC	Primary	Alive	G12V	R273C	No	No	G12	Yes	71.0
MSK-P-0071937	75	Male	White	PDAC	Primary	Deceased	G12V	Y236H	No	No	G12	Yes	75.0
MSK-P-0071940	68	Male	White	PDAC	Primary	Alive	G12V	H193N	No	No	G12	Yes	68.0
MSK-P-0071946	64	Male	Black/African-American	PNET	Primary	Alive	No	No	No	No	No	No	64.0
MSK-P-0072072	71	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	71.0
MSK-P-0072089	68	Male	White	PDAC	Primary	Alive	G12V	A161T	No	No	G12	Yes	68.0
MSK-P-0072150	>89	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	90.0
MSK-P-0072198	50	Male	Asian	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	50.0
MSK-P-0072232	72	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	72.0
MSK-P-0072260	65	Male	Other	PDAC	Primary	Alive	G12V	I232T	No	D355V	G12	Yes	65.0
MSK-P-0072263	54	Male	White	PDAC	Primary	Alive	No	L130F	No	No	No	Yes	54.0
MSK-P-0072294	79	Female	White	PDAC	Primary	Alive	Q61H	M133K	No	No	Q61	Yes	79.0
MSK-P-0072296	68	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	68.0
MSK-P-0072398	72	Female	White	PDAC	Primary	Alive	G12V	H179Y	No	No	G12	Yes	72.0
MSK-P-0072481	71	Male	White	Adenosquamous carcinoma	Primary	Alive	G12V	R282W	No	No	G12	Yes	71.0
MSK-P-0072490	65	Male	Black/African-American	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	65.0
MSK-P-0072525	72	Male	White	PDAC	Metastasis	Alive	G12V	V157G	No	No	G12	Yes	72.0
MSK-P-0072534	56	Female	White	PDAC	Metastasis	Deceased	G12V	P278S	No	No	G12	Yes	56.0
MSK-P-0072540	72	Male	White	PDAC	Primary	Alive	G12V	R273C	No	No	G12	Yes	72.0
MSK-P-0072551	72	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	72.0
MSK-P-0072591	64	Male	NA	PDAC	Primary	Alive	G12V	No	No	No	G12	No	64.0
MSK-P-0072618	62	Female	Black/African-American	PDAC	Primary	Alive	G12C	R267G	No	No	G12	Yes	62.0
MSK-P-0072744	68	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	68.0
MSK-P-0072751	67	Female	NA	PDAC	Primary	Alive	No	No	No	No	No	No	67.0
MSK-P-0072760	75	Female	Other	PDAC	Primary	Alive	G12R	R175H	No	No	G12	Yes	75.0
MSK-P-0072768	68	Female	White	PDAC	Primary	Alive	No	F113V	No	No	No	Yes	68.0
MSK-P-0072785	47	Male	Other	PDAC	Primary	Alive	G12R	G266E	No	No	G12	Yes	47.0
MSK-P-0072829	63	Female	NA	PDAC	Primary	Alive	G12D	No	No	No	G12	No	63.0
MSK-P-0072840	72	Male	White	PDAC	Primary	Alive	No	G244D	No	No	No	Yes	72.0
MSK-P-0072921	68	Female	NA	PDAC	Primary	Alive	G12D	No	No	No	G12	No	68.0
MSK-P-0073007	59	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	59.0
MSK-P-0073017	72	Male	Black/African-American	PDAC	Primary	Alive	G12D	C242F	No	No	G12	Yes	72.0
MSK-P-0073028	60	Female	Black/African-American	PDAC	Primary	Alive	G12V	H193R	No	No	G12	Yes	60.0
MSK-P-0073029	63	Female	Asian	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	63.0
MSK-P-0073110	72	Female	White	PDAC	Primary	Alive	G12D	R248Q	No	No	G12	Yes	72.0
MSK-P-0073163	85	Male	Asian	PDAC	Primary	Deceased	G12V	M237I	No	No	G12	Yes	85.0
MSK-P-0073169	75	Female	Asian	PDAC	Primary	Deceased	G12V	H179Y	No	No	G12	Yes	75.0
MSK-P-0073183	60	Female	White	PDAC	Metastasis	Alive	G12D	R273C	No	W101C	G12	Yes	60.0
MSK-P-0073197	59	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	59.0
MSK-P-0073239	72	Female	White	PDAC	Primary	Alive	G12D	C141Y	No	No	G12	Yes	72.0
MSK-P-0073308	48	Female	White	PDAC	Primary	Alive	G12A	No	No	No	G12	No	48.0
MSK-P-0073320	73	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	73.0
MSK-P-0073325	64	Female	Asian	PDAC	Primary	Alive	G12V	No	No	No	G12	No	64.0
MSK-P-0073448	73	Female	Asian	PDAC	Primary	Alive	G12D	No	No	No	G12	No	73.0
MSK-P-0073450	64	Female	White	PDAC	Metastasis	Alive	G12D	R248Q	P81L	No	G12	Yes	64.0
MSK-P-0073528	64	Male	Asian	PDAC	Primary	Alive	No	No	No	No	No	No	64.0
MSK-P-0073587	79	Female	NA	PDAC	Primary	Deceased	Q61R	H193R	No	No	Q61	Yes	79.0
MSK-P-0073640	60	Male	White	PDAC	Metastasis	Deceased	G12D	M246R	No	No	G12	Yes	60.0
MSK-P-0073641	75	Female	White	PDAC	Primary	Alive	G12L	No	No	No	G12	No	75.0
MSK-P-0073644	73	Female	Other	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	73.0
MSK-P-0073660	75	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	75.0
MSK-P-0073690	65	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	65.0
MSK-P-0073694	76	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	76.0
MSK-P-0073744	54	Female	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	54.0
MSK-P-0073828	80	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	80.0
MSK-P-0073844	80	Female	White	PDAC	Primary	Alive	G12R	R175H	No	G386D	G12	Yes	80.0
MSK-P-0073867	64	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	64.0
MSK-P-0074023	69	Male	White	Adenosquamous carcinoma	Metastasis	Alive	G12V	R248Q	D108V	No	G12	Yes	69.0
MSK-P-0074094	64	Male	White	PDAC	Metastasis	Deceased	G12V	D259Y	No	No	G12	Yes	64.0
MSK-P-0074121	63	Female	Black/African-American	PDAC	Primary	Alive	G12R	I195T	No	No	G12	Yes	63.0
MSK-P-0074136	63	Male	White	Carcinoma, NOS	Primary	Alive	No	No	No	No	No	No	63.0
MSK-P-0074137	47	Male	White	PDAC	Metastasis	Alive	G12D	H214R	No	No	G12	Yes	47.0
MSK-P-0074281	77	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	77.0
MSK-P-0074295	68	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	68.0
NKI-1AFD	58	Female	NA	PDAC	Primary	Alive	G12V	No	No	No	G12	No	58.0
NKI-2489	51	Male	NA	PDAC	Primary	Alive	No	R273H	No	No	No	Yes	51.0
NKI-2FY3	65	Female	NA	PDAC	Primary	Alive	No	No	No	No	No	No	65.0
NKI-2YND	66	Male	NA	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	66.0
NKI-5MUB	77	Female	NA	PDAC	Metastasis	Alive	No	No	No	No	No	No	77.0
NKI-7RDD	62	Female	NA	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	62.0
NKI-7W58	62	Female	NA	PDAC	Metastasis	Alive	G12R	N239D	No	No	G12	Yes	62.0
NKI-7Y0P	68	Female	NA	PDAC	Primary	Alive	G12D	C238Y	No	No	G12	Yes	68.0
NKI-B5MK	47	Male	NA	PNET	Metastasis	Alive	No	No	No	No	No	No	47.0
NKI-BZ6M	64	Male	NA	PDAC	Metastasis	Alive	No	No	No	No	No	No	64.0
NKI-CSSD	47	Male	NA	PDAC	Metastasis	Alive	G12D	Y220C	No	No	G12	Yes	47.0
NKI-CTKB	43	Female	NA	PNET	Metastasis	Alive	No	No	No	No	No	No	43.0
NKI-EPA3	50	Male	NA	PNET	Metastasis	Deceased	No	No	No	No	No	No	50.0
NKI-FK58	58	Male	NA	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	58.0
NKI-G6BJ	78	Female	NA	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	78.0
NKI-HO41	75	Male	NA	PDAC	Primary	Deceased	No	No	No	No	No	No	75.0
NKI-KE2O	70	Male	NA	PDAC	Metastasis	Alive	G12D	R273H	No	No	G12	Yes	70.0
NKI-M5G9	67	Male	NA	PDAC	Metastasis	Deceased	G12V	G266E	No	No	G12	Yes	67.0
NKI-NKIC	63	Male	NA	PNET	Metastasis	Deceased	No	No	No	No	No	No	63.0
NKI-OAHH	66	Male	NA	PDAC	Primary	Deceased	No	No	No	No	No	No	66.0
NKI-PDRJ	70	Male	NA	PNET	Primary	Alive	No	No	No	No	No	No	70.0
NKI-PE2E	63	Female	NA	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	63.0
NKI-RI3E	52	Male	NA	PDAC	Metastasis	Alive	G12D	I195N	No	No	G12	Yes	52.0
NKI-S4J2	62	Female	NA	PDAC	Metastasis	Deceased	No	No	No	No	No	No	62.0
NKI-SSDF	48	Male	NA	PNET	Metastasis	Alive	No	No	No	No	No	No	48.0
NKI-TB0W	62	Male	NA	PDAC	Primary	Alive	G12D	C176S	No	No	G12	Yes	62.0
NKI-TBYG	56	Male	NA	PNET	Metastasis	Deceased	No	No	No	No	No	No	56.0
NKI-TSUW	47	Male	NA	PDAC	Metastasis	Alive	Q61H	R282W	No	No	Q61	Yes	47.0
NKI-UWV5	54	Male	NA	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	54.0
NKI-W4MV	65	Male	NA	PDAC	NA or Heme	Alive	G12D	No	No	No	G12	No	65.0
NKI-Z2Q7	65	Female	NA	PDAC	Primary	Deceased	No	No	No	No	No	No	65.0
NKI-ZV40	54	Male	NA	PDAC	Primary	Alive	No	No	No	No	No	No	54.0
PROV-0048d247	77	Male	NA	PDAC	Metastasis	Deceased	No	No	No	No	No	No	77.0
PROV-012650ee04	72	Male	White	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	72.0
PROV-018d34e2a5	56	Female	Other	PDAC	Not Collected	Alive	Q61H	Y220C	No	W524C	Q61	Yes	56.0
PROV-01d6c1df32	75	Male	White	PDAC	Not Collected	Alive	G12C	R248Q	No	No	G12	Yes	75.0
PROV-01e9132489	85	Female	White	Carcinoma, NOS	Not Collected	Deceased	G12D	No	No	R361H	G12	No	85.0
PROV-022392631b	70	Female	White	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	70.0
PROV-024226b8	45	Female	NA	PDAC	Primary	Alive	No	No	No	No	No	No	45.0
PROV-02794a67ee	78	Female	White	PDAC	Not Collected	Deceased	G12V	No	No	No	G12	No	78.0
PROV-03a8f5505d	76	Female	White	PDAC	Not Collected	Deceased	Q61_E62delinsRK	R273C	No	C127S	Q61\|Other	Yes	76.0
PROV-03bcdeb46a	57	Female	Other	PDAC	Not Collected	Alive	G12D	R337C,R181C,R110H	No	No	G12	Yes	57.0
PROV-0420815c59	83	Female	White	PDAC	Not Collected	Deceased	G12R	No	No	No	G12	No	83.0
PROV-0420c99a2c	76	Male	White	PDAC	Not Collected	Alive	Q61H	No	No	No	Q61	No	76.0
PROV-048f4fcec7	NA	NA	Other	PDAC	Not Collected	Alive	G12R	No	No	No	G12	No	NA
PROV-05391df621	63	Male	Other	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	63.0
PROV-065358f21d	72	Female	Other	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	72.0
PROV-09d360e2ab	57	Female	Other	PDAC	Not Collected	Alive	G12V	No	L63P	No	G12	No	57.0
PROV-0a959cb249	81	Male	Other	PDAC	Not Collected	Alive	K117R,G12D	No	No	No	G12\|Other	No	81.0
PROV-0b573d1e9b	75	Male	White	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	75.0
PROV-0bb7b70333	78	Female	White	PDAC	Not Collected	Deceased	G12R	No	No	No	G12	No	78.0
PROV-0bbb8e83aa	79	Female	White	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	79.0
PROV-0cb48cbaba	73	Female	White	Adenosquamous carcinoma	Not Collected	Alive	G12D	No	No	No	G12	No	73.0
PROV-0d2f749f3e	77	Female	Other	PDAC	Not Collected	Alive	No	No	No	No	No	No	77.0
PROV-0e0bd194	71	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	71.0
PROV-0e0e173ced	80	Female	Other	PDAC	Not Collected	Deceased	G12V	No	H83Y	No	G12	No	80.0
PROV-0edbc4ac	58	Male	Black/African-American	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	58.0
PROV-0f23735989	78	Female	White	PDAC	Not Collected	Alive	Q61L	No	No	No	Q61	No	78.0
PROV-0f687fa04c	55	Female	Other	PDAC	Not Collected	Alive	G12V	R273H	No	No	G12	Yes	55.0
PROV-104fdb9bbb	70	Female	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	70.0
PROV-11d627e4a8	83	Female	NA	PDAC	Not Collected	Alive	G12D	R175H	No	No	G12	Yes	83.0
PROV-1223fa0527	83	Female	White	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	83.0
PROV-1268a360	62	Male	NA	PDAC	Primary	Alive	G12F	No	No	No	G12	No	62.0
PROV-12c2acc5	77	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	77.0
PROV-13a8db0a64	76	Male	White	PDAC	Not Collected	Alive	G12D	E286K	No	No	G12	Yes	76.0
PROV-13ca14ce37	86	Male	Other	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	86.0
PROV-13cf564864	50	Male	Other	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	50.0
PROV-14c67ce9f0	66	Male	Black/African-American	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	66.0
PROV-154574e215	81	Female	Other	PDAC	Not Collected	Deceased	G12V	R110P	No	No	G12	Yes	81.0
PROV-15668cfd6e	78	Male	Asian	PDAC	Not Collected	Deceased	G12V	No	No	No	G12	No	78.0
PROV-159b1c2e77	54	Male	NA	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	54.0
PROV-15d1ebbeb9	48	Male	White	PDAC	Not Collected	Alive	No	No	No	No	No	No	48.0
PROV-15d47df3da	71	Female	Asian	PDAC	Not Collected	Alive	G12R	No	No	No	G12	No	71.0
PROV-15f2febfed	68	Male	NA	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	68.0
PROV-160c301ae8	52	Female	NA	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	52.0
PROV-16d1939da7	69	Male	Other	PDAC	Not Collected	Alive	G12V	R175H	No	No	G12	Yes	69.0
PROV-185654af	77	Female	White	PDAC	Primary	Deceased	G13D	No	No	No	G13	No	77.0
PROV-191504a088	62	Female	White	PDAC	Not Collected	Alive	G12R	C238G	No	No	G12	Yes	62.0
PROV-19f9ad37	69	Female	White	PDAC	Primary	Alive	G12C	No	No	No	G12	No	69.0
PROV-1ac4f2b9	73	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	73.0
PROV-1ba57f62	66	Male	White	PDAC	Primary	Alive	F82S,G12D	No	No	No	G12\|Other	No	66.0
PROV-1ccddd3c	60	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	60.0
PROV-1d40518c72	50	Male	White	Adenosquamous carcinoma	Not Collected	Alive	G12D	R249W	No	No	G12	Yes	50.0
PROV-1e2fea471c	77	Female	White	PDAC	Not Collected	Alive	No	No	No	No	No	No	77.0
PROV-1eb5e168a6	76	Female	White	PDAC	Not Collected	Deceased	G12V	No	No	No	G12	No	76.0
PROV-200a33d4	>89	Male	NA	PDAC	Primary	Alive	G12R	No	No	No	G12	No	90.0
PROV-200d4236bd	39	Female	Other	PDAC	Not Collected	Deceased	G13D	R273H	No	No	G13	Yes	39.0
PROV-201bd1ba67	63	Male	Other	PDAC	Not Collected	Alive	Q61H	R175H	No	R361C	Q61	Yes	63.0
PROV-2105cbe43c	>89	Female	White	PDAC	Not Collected	Deceased	G12V	I195T	No	No	G12	Yes	90.0
PROV-2130eb4806	79	Female	White	PDAC	Not Collected	Deceased	G12C	No	No	No	G12	No	79.0
PROV-217a44ea77	>89	Male	White	Carcinoma, NOS	Not Collected	Deceased	G12D	Y234D	No	No	G12	Yes	90.0
PROV-2267df79	58	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	58.0
PROV-25001bdaeb	63	Male	Other	PDAC	Not Collected	Alive	Q61R	No	No	No	Q61	No	63.0
PROV-253857563a	74	Female	White	PDAC	Not Collected	Alive	G12R	No	No	No	G12	No	74.0
PROV-2614112718	64	Male	NA	PDAC	Not Collected	Alive	Q61R	V217G	No	D351G	Q61	Yes	64.0
PROV-26a45711b2	67	Male	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	67.0
PROV-26cb131080	75	Female	Other	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	75.0
PROV-271854da51	77	Female	White	PDAC	Not Collected	Alive	G12V	G279R	No	No	G12	Yes	77.0
PROV-272684ea	65	Male	Black/African-American	PDAC	Primary	Deceased	G12F	No	No	No	G12	No	65.0
PROV-28305dc7f2	52	Female	White	Carcinoma, NOS	Not Collected	Alive	G12D	R248W	No	No	G12	Yes	52.0
PROV-2936738cab	76	Female	White	PNET	Not Collected	Alive	No	No	No	No	No	No	76.0
PROV-295da8df5f	68	Male	White	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	68.0
PROV-29f4dfff5c	49	Female	Other	PDAC	Not Collected	Alive	G12D	R282W	No	No	G12	Yes	49.0
PROV-2c1b0c85ca	68	Male	White	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	68.0
PROV-2c544c36b1	81	Female	White	PDAC	Not Collected	Alive	G12R	No	No	No	G12	No	81.0
PROV-2d2f3357e4	73	Male	White	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	73.0
PROV-2d60619b	60	Male	NA	PDAC	Primary	Deceased	G12F	No	No	No	G12	No	60.0
PROV-2deb398434	83	Female	White	PDAC	Not Collected	Deceased	G12D	No	No	D537E	G12	No	83.0
PROV-2e42f526c0	57	Male	White	PDAC	Not Collected	Alive	Q61R	No	No	No	Q61	No	57.0
PROV-2f78fb923f	53	Male	White	PDAC	Not Collected	Deceased	G12V	S241C	No	No	G12	Yes	53.0
PROV-310fbc44b7	50	Male	White	PDAC	Not Collected	Deceased	G12V	Y126C	No	No	G12	Yes	50.0
PROV-311dc4d435	74	Male	Other	PDAC	Not Collected	Alive	G12D	V143M	No	No	G12	Yes	74.0
PROV-311edc51bc	58	Male	White	PDAC	Not Collected	Alive	G12V	C238F	No	No	G12	Yes	58.0
PROV-31e4a9e8ce	60	Male	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	60.0
PROV-31fc2ecac9	67	Female	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	67.0
PROV-326692b8	>89	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	90.0
PROV-328df677	66	Female	White	PDAC	Primary	Alive	G12F	No	No	No	G12	No	66.0
PROV-32f2211d	69	Male	White	PDAC	Primary	Alive	G12C	No	No	No	G12	No	69.0
PROV-3352f227f9	53	Female	White	PDAC	Not Collected	Deceased	G12V	No	No	No	G12	No	53.0
PROV-33cc4e9128	71	Female	Other	PDAC	Not Collected	Alive	G12D	R248W	No	No	G12	Yes	71.0
PROV-33d2daded1	56	Female	White	PDAC	Not Collected	Alive	G12D	F134V	No	No	G12	Yes	56.0
PROV-340ddf0ff2	72	Female	Other	PDAC	Not Collected	Alive	G12R	Y220C	No	No	G12	Yes	72.0
PROV-343210f011	63	Female	Other	PDAC	Not Collected	Alive	G12V	P278S	No	No	G12	Yes	63.0
PROV-3445ea0960	77	Male	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	77.0
PROV-360c0b8324	60	Female	White	PDAC	Not Collected	Alive	G12D	E286K	H83Y	No	G12	Yes	60.0
PROV-37c2ad7616	78	Male	Other	PDAC	Not Collected	Alive	G12C	R282W,K164E	No	No	G12	Yes	78.0
PROV-3923ae7236	79	Female	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	79.0
PROV-398a388901	87	Male	Other	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	87.0
PROV-39c394ea9e	74	Female	White	PDAC	Not Collected	Alive	G12D	C238F	No	H92Y,R361G	G12	Yes	74.0
PROV-3b0792ee95	65	Female	White	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	65.0
PROV-3c48a33b9e	60	Male	White	PDAC	Not Collected	Alive	G12V	G244V	No	No	G12	Yes	60.0
PROV-3cc34506fb	78	Male	White	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	78.0
PROV-3cd254e253	81	Male	Other	PDAC	Not Collected	Deceased	G12D	R282W	No	No	G12	Yes	81.0
PROV-3eea1c0ecb	71	Male	Other	PDAC	Not Collected	Alive	G12D	Y163C	H83Y	No	G12	Yes	71.0
PROV-3f43d5bc	79	Male	White	PDAC	Primary	Alive	G12F	No	No	No	G12	No	79.0
PROV-41055834b9	82	Female	White	PDAC	Not Collected	Alive	G12V	Y236C	N42K	No	G12	Yes	82.0
PROV-419c9a46b5	62	Male	White	PDAC	Not Collected	Deceased	G13D	Y236C	No	No	G13	Yes	62.0
PROV-419dc98f33	63	Female	Other	PDAC	Not Collected	Alive	G12V	R273C	No	No	G12	Yes	63.0
PROV-41a3ee7040	63	Female	White	PDAC	Not Collected	Alive	G12D	R248Q	No	L495R	G12	Yes	63.0
PROV-420ae16b65	56	Male	NA	PDAC	Not Collected	Deceased	G12R	No	No	No	G12	No	56.0
PROV-435d0dbdc2	74	Male	White	PDAC	Not Collected	Alive	G12R	P151S	No	No	G12	Yes	74.0
PROV-455264fd57	63	Male	Other	PDAC	Not Collected	Alive	G12C	No	No	No	G12	No	63.0
PROV-4617ef2e83	57	Male	White	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	57.0
PROV-4664205fa6	83	Female	White	Carcinoma, NOS	Not Collected	Alive	G12V	No	No	No	G12	No	83.0
PROV-46afe1c533	84	Male	White	PDAC	Not Collected	Alive	G12D	R273C	No	K428M	G12	Yes	84.0
PROV-4716e2e6bd	>89	Male	White	PDAC	Not Collected	Deceased	G12D	No	No	N285K	G12	No	90.0
PROV-47532a0f09	62	Male	Other	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	62.0
PROV-4820cfd690	82	Female	White	PDAC	Not Collected	Deceased	G12V	No	No	No	G12	No	82.0
PROV-48305295ed	63	Male	White	PDAC	Not Collected	Alive	G12D	C238G	No	No	G12	Yes	63.0
PROV-486205ae7c	36	Female	White	Carcinoma, NOS	Not Collected	Alive	No	No	No	No	No	No	36.0
PROV-48804223	62	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	62.0
PROV-48c48eb104	71	Female	White	PDAC	Not Collected	Alive	G12R	R337C	No	No	G12	Yes	71.0
PROV-4b905660bd	71	Female	Other	PDAC	Not Collected	Alive	G12D	D259Y	No	No	G12	Yes	71.0
PROV-4bf592d0d8	65	Male	White	PDAC	Not Collected	Deceased	G12R	R175H	No	No	G12	Yes	65.0
PROV-4cae0a72ae	81	Male	White	PDAC	Not Collected	Alive	Q61H	No	No	No	Q61	No	81.0
PROV-4ce729223f	75	Male	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	75.0
PROV-4ddde5d22c	65	Male	Other	PNET	Not Collected	Alive	No	No	No	No	No	No	65.0
PROV-4e123d4971	66	Male	White	Adenosquamous carcinoma	Not Collected	Alive	G12V	No	No	No	G12	No	66.0
PROV-4e6efdfd3f	48	Male	Other	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	48.0
PROV-4f4d823170	71	Female	Asian	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	71.0
PROV-50e620f7	75	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	75.0
PROV-51267e130a	83	Male	White	PDAC	Not Collected	Deceased	G12R	No	No	No	G12	No	83.0
PROV-53215a0250	80	Male	Other	PDAC	Not Collected	Deceased	G12V	F134L	No	No	G12	Yes	80.0
PROV-5396d7f8e1	72	Male	White	PDAC	Not Collected	Alive	G12D	R248W	No	S504R	G12	Yes	72.0
PROV-54a51c107a	68	Female	White	PDAC	Not Collected	Deceased	G12D	H179R	No	No	G12	Yes	68.0
PROV-552eb5a6ee	55	Male	White	Carcinoma, NOS	Not Collected	Alive	No	R175H	No	No	No	Yes	55.0
PROV-55631b1cc1	88	Female	Black/African-American	PDAC	Not Collected	Deceased	G12R	V157G	No	No	G12	Yes	88.0
PROV-55b22a5318	68	Female	NA	PDAC	Not Collected	Alive	G12D	V173L	No	No	G12	Yes	68.0
PROV-579f363da2	73	Male	NA	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	73.0
PROV-5845b1a7bf	76	Female	White	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	76.0
PROV-585534f8e5	72	Female	NA	PDAC	Not Collected	Alive	G12R	F113V	No	No	G12	Yes	72.0
PROV-585cedba	80	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	80.0
PROV-58c217a7a4	74	Male	Other	PDAC	Not Collected	Alive	G12V	G244V	No	No	G12	Yes	74.0
PROV-5a5af1b373	71	Male	Other	PDAC	Not Collected	Alive	G12D	G245S	No	No	G12	Yes	71.0
PROV-5aedbdd2	69	Male	Asian	PDAC	Primary	Deceased	G12F	No	No	No	G12	No	69.0
PROV-5b6123a4	38	Female	White	Carcinoma, NOS	Primary	Alive	G12F	No	No	No	G12	No	38.0
PROV-5bde5db4	50	Male	NA	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	50.0
PROV-5dbd216be5	87	Male	White	PDAC	Not Collected	Deceased	G12D	M237K	No	No	G12	Yes	87.0
PROV-5dcc8ef315	71	Male	NA	PDAC	Not Collected	Alive	G12D	Y234H	No	No	G12	Yes	71.0
PROV-5edc5512da	78	Male	Other	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	78.0
PROV-5f8917f10b	67	Female	Other	PDAC	Not Collected	Alive	G12R	No	No	No	G12	No	67.0
PROV-5fc292578c	68	Male	White	IPMN	Not Collected	Alive	G12D	No	No	No	G12	No	68.0
PROV-5fe8222a	69	Female	White	IPMN	Primary	Alive	No	No	No	No	No	No	69.0
PROV-5feeac303f	59	Female	White	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	59.0
PROV-60c87e9a4a	67	Male	White	PDAC	Not Collected	Deceased	G12D	H193R	R87L	No	G12	Yes	67.0
PROV-62f1743d8f	54	Male	NA	Carcinoma, NOS	Not Collected	Alive	G12V	R213P	No	No	G12	Yes	54.0
PROV-64706c7829	75	Female	NA	PDAC	Not Collected	Alive	No	R175H	No	No	No	Yes	75.0
PROV-64829cf170	75	Male	NA	PDAC	Not Collected	Alive	G12R	No	No	No	G12	No	75.0
PROV-64e4474d23	65	Female	Other	PDAC	Not Collected	Alive	G12R	No	No	No	G12	No	65.0
PROV-65c2de2a73	74	Female	Other	PDAC	Not Collected	Alive	G12V	No	No	G65V	G12	No	74.0
PROV-6737959efb	63	Female	NA	PDAC	Not Collected	Alive	G12V	S127P	No	No	G12	Yes	63.0
PROV-6884c444	78	Male	White	PDAC	Primary	Alive	G12D	G279E	No	No	G12	Yes	78.0
PROV-68e1377ae4	70	Female	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	70.0
PROV-6a373d4b7f	79	Male	Other	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	79.0
PROV-6b30d50ab8	83	Female	Other	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	83.0
PROV-6b767f3d2a	73	Male	White	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	73.0
PROV-6c49ae37ed	69	Male	Other	PDAC	Not Collected	Alive	G12V	C135Y	H66P	S504N	G12	Yes	69.0
PROV-6cae8632e1	69	Female	Other	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	69.0
PROV-6d1ecab0	72	Female	White	PDAC	Metastasis	Alive	G12F	No	No	No	G12	No	72.0
PROV-6d623f9b48	46	Male	White	PDAC	Not Collected	Deceased	G12D	H193N	No	No	G12	Yes	46.0
PROV-6d7a10e091	57	Female	NA	PDAC	Not Collected	Alive	G12R	V272L	No	No	G12	Yes	57.0
PROV-6daa2686	69	Female	White	PDAC	Primary	Deceased	G12F	No	No	No	G12	No	69.0
PROV-6e14f1affa	71	Male	NA	PDAC	Not Collected	Alive	G12D	C135R	No	No	G12	Yes	71.0
PROV-6e29f94b21	72	Female	Asian	PDAC	Not Collected	Deceased	G12V	No	No	No	G12	No	72.0
PROV-6eb22009ce	61	Male	NA	PDAC	Not Collected	Deceased	G12D	P151A	No	R361H	G12	Yes	61.0
PROV-70665e81bd	84	Male	Other	PDAC	Not Collected	Deceased	G12V	C275Y	No	No	G12	Yes	84.0
PROV-70efdfc829	66	Male	Other	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	66.0
PROV-71904250	85	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	85.0
PROV-72808a42	66	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	66.0
PROV-72f54874	84	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	84.0
PROV-732ab4c7e0	51	Male	White	PDAC	Not Collected	Alive	G12D	R273H	No	No	G12	Yes	51.0
PROV-734ac5b92c	68	Female	White	PDAC	Not Collected	Alive	G12R	No	No	No	G12	No	68.0
PROV-7519234ba5	50	Female	White	PDAC	Not Collected	Alive	No	No	No	No	No	No	50.0
PROV-75340fae	78	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	78.0
PROV-755d047874	60	Male	NA	PDAC	Not Collected	Deceased	G12V	No	No	No	G12	No	60.0
PROV-759dbd7432	79	Male	Other	PDAC	Not Collected	Alive	G12R	S241A	H83Y	No	G12	Yes	79.0
PROV-75ea15a0	61	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	61.0
PROV-760f420d4e	72	Male	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	72.0
PROV-7630f86dfb	72	Female	White	PDAC	Not Collected	Alive	G12V	P278S	No	No	G12	Yes	72.0
PROV-7785ada5a1	63	Male	Other	PDAC	Not Collected	Alive	G12D	Y220N	No	No	G12	Yes	63.0
PROV-778eedfb62	58	Male	Other	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	58.0
PROV-786958d0ea	78	Female	NA	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	78.0
PROV-794ee38116	70	Male	White	PDAC	Not Collected	Deceased	G12V	V272M	No	No	G12	Yes	70.0
PROV-79a8727d7a	66	Female	White	PDAC	Not Collected	Deceased	Q61H	G245V	No	No	Q61	Yes	66.0
PROV-79ea54c4	63	Male	Asian	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	63.0
PROV-7c96b967aa	76	Male	White	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	76.0
PROV-7d1a778f	71	Male	White	PDAC	Primary	Alive	G12D	R248W	No	No	G12	Yes	71.0
PROV-7dc9b13ac6	60	Female	Black/African-American	PDAC	Not Collected	Deceased	G12D	V157F	No	No	G12	Yes	60.0
PROV-7f744e5cb9	55	Female	Other	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	55.0
PROV-7fb6b331bd	55	Female	White	PDAC	Not Collected	Deceased	G12V	M237I	No	No	G12	Yes	55.0
PROV-801c90a544	75	Male	White	Acinar cell carcinoma	Not Collected	Alive	No	No	No	No	No	No	75.0
PROV-811542e8	72	Female	White	PDAC	Primary	Deceased	Q61H	G245D	No	No	Q61	Yes	72.0
PROV-8153877d	72	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	72.0
PROV-8161da3c1b	80	Male	White	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	80.0
PROV-8267ce5d92	81	Female	White	PDAC	Not Collected	Alive	G12D	R248Q	No	No	G12	Yes	81.0
PROV-8334b004c5	75	Male	NA	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	75.0
PROV-84f7abbd	63	Male	White	PDAC	Metastasis	Alive	G12F	No	No	No	G12	No	63.0
PROV-85ee8d256c	56	Male	White	PDAC	Not Collected	Alive	G12R	Y205D	No	No	G12	Yes	56.0
PROV-86a2564308	65	Female	Other	PDAC	Not Collected	Alive	G12D	L257Q	P48L	No	G12	Yes	65.0
PROV-86abd9a299	80	Female	White	PDAC	Not Collected	Alive	G12R	R248G	No	No	G12	Yes	80.0
PROV-88b57487f7	62	Male	White	PDAC	Not Collected	Deceased	G12R	No	No	No	G12	No	62.0
PROV-891c4a257e	52	Female	White	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	52.0
PROV-894eaf2a	61	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	61.0
PROV-89707d4a04	70	Female	Other	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	70.0
PROV-89e7e1747b	50	Male	Other	PDAC	Not Collected	Alive	G12V	R175H	No	No	G12	Yes	50.0
PROV-8a55920833	77	Female	White	PDAC	Not Collected	Deceased	G12D	R175H	No	No	G12	Yes	77.0
PROV-8a758defb4	57	Male	White	PDAC	Not Collected	Alive	G12V	L194F	H83Y	No	G12	Yes	57.0
PROV-8c62543bf6	72	Female	White	PDAC	Not Collected	Deceased	No	No	No	No	No	No	72.0
PROV-8c784af42c	67	Female	White	PDAC	Not Collected	Deceased	G12D	No	H83R	I58V	G12	No	67.0
PROV-8c9a895d19	65	Male	White	PDAC	Not Collected	Alive	No	R175H	No	No	No	Yes	65.0
PROV-8d561bc0e9	59	Female	White	PDAC	Not Collected	Deceased	Q61H	I195T	No	No	Q61	Yes	59.0
PROV-8d90567174	67	Female	Other	PDAC	Not Collected	Alive	G12D	R248Q	No	No	G12	Yes	67.0
PROV-8e547f4ca1	65	Female	White	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	65.0
PROV-8efa13e4e0	65	Male	Other	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	65.0
PROV-8f0cfc5320	<18	Male	Other	PDAC	Not Collected	Alive	Q61H	No	No	No	Q61	No	17.0
PROV-8fd79290e6	74	Female	White	PDAC	Not Collected	Alive	G12V	R248Q	No	No	G12	Yes	74.0
PROV-90dcf31efb	58	Male	Other	PDAC	Not Collected	Alive	G13R	No	No	No	G13	No	58.0
PROV-91dc5f4576	60	Female	Other	PDAC	Not Collected	Alive	G12V	R248W	H83Y	No	G12	Yes	60.0
PROV-9398f45ca9	48	Male	NA	PDAC	Not Collected	Alive	No	No	No	No	No	No	48.0
PROV-951fd47cfb	57	Male	Other	PDAC	Not Collected	Alive	G12D	P151S	No	No	G12	Yes	57.0
PROV-95e45c95d8	63	Female	NA	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	63.0
PROV-9600cd977d	66	Male	Asian	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	66.0
PROV-9695c500b4	64	Male	White	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	64.0
PROV-972cd2fe00	70	Male	Other	PDAC	Not Collected	Alive	G12R	No	No	No	G12	No	70.0
PROV-98052eef	63	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	63.0
PROV-98337d94	61	Female	White	PDAC	Primary	Alive	G12F	No	No	No	G12	No	61.0
PROV-989ef5b0ee	64	Male	Asian	PDAC	Not Collected	Alive	G12V,G13D	No	No	No	G12\|G13	No	64.0
PROV-98fc7352	>89	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	90.0
PROV-99ef23ee46	74	Female	White	PDAC	Not Collected	Alive	G12D	R175H	No	No	G12	Yes	74.0
PROV-9aafda2709	70	Male	White	PDAC	Not Collected	Deceased	G12D	R248W	No	No	G12	Yes	70.0
PROV-9bbe976583	72	Female	White	PDAC	Not Collected	Deceased	G12D	N235S,A159V	No	No	G12	Yes	72.0
PROV-9bdd11ad	59	Male	Black/African-American	PDAC	Primary	Alive	G12F	No	No	No	G12	No	59.0
PROV-9ce133766e	77	Female	Other	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	77.0
PROV-9d8d81e2	72	Male	Asian	PDAC	Primary	Alive	No	No	No	No	No	No	72.0
PROV-9d9479acd1	71	Female	NA	PDAC	Not Collected	Alive	G12V	R175H	No	No	G12	Yes	71.0
PROV-9e2653320d	64	Female	White	PDAC	Not Collected	Alive	G12D	H193R	No	No	G12	Yes	64.0
PROV-9eceb94c0c	57	Male	Other	Carcinoma, NOS	Not Collected	Alive	G12D	R175H	No	No	G12	Yes	57.0
PROV-9ee92187d2	71	Male	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	71.0
PROV-9f217b2252	37	Male	Other	PDAC	Not Collected	Alive	Q61H	No	No	No	Q61	No	37.0
PROV-9f2ba7e81d	69	Male	Other	PDAC	Not Collected	Alive	G12R	R273H	No	No	G12	Yes	69.0
PROV-a059366ab5	78	Female	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	78.0
PROV-a0a77e14be	74	Female	Other	PDAC	Not Collected	Alive	G12D	V173M	No	No	G12	Yes	74.0
PROV-a31551b7	81	Female	NA	PDAC	Primary	Alive	No	No	No	No	No	No	81.0
PROV-a31ad6a877	65	Male	Other	PDAC	Not Collected	Deceased	G12V	No	No	No	G12	No	65.0
PROV-a4634658	67	Female	White	PDAC	Metastasis	Alive	G12D	L194R	No	No	G12	Yes	67.0
PROV-a5b7e6534c	68	Female	White	PDAC	Not Collected	Deceased	G12D	R282W	No	No	G12	Yes	68.0
PROV-a60433dbe7	85	Female	White	Carcinoma, NOS	Not Collected	Alive	G12R	No	No	No	G12	No	85.0
PROV-a612462a5d	50	Male	NA	PDAC	Not Collected	Alive	G12D	V172D	No	No	G12	Yes	50.0
PROV-a63acf89	71	Male	White	PDAC	Primary	Deceased	G12F	No	No	No	G12	No	71.0
PROV-a7ad55f9b2	86	Female	White	PDAC	Not Collected	Deceased	G12D	R248Q	No	No	G12	Yes	86.0
PROV-a7b50ef9a3	73	Female	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	73.0
PROV-a7de3da823	72	Female	Other	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	72.0
PROV-a8d86dab84	66	Male	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	66.0
PROV-a946f6d58b	85	Female	White	PDAC	Not Collected	Deceased	G12D	S127F	No	No	G12	Yes	85.0
PROV-aa4544ea1a	70	Male	Other	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	70.0
PROV-aad5c3053f	61	Male	Other	PDAC	Not Collected	Alive	G12V	No	L63P	No	G12	No	61.0
PROV-abd9c352	68	Female	White	PDAC	Primary	Alive	G12F	No	No	No	G12	No	68.0
PROV-aca8f6bfca	63	Male	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	63.0
PROV-acff897e	55	Male	Black/African-American	PDAC	Primary	Alive	No	No	No	No	No	No	55.0
PROV-ae7d226c55	88	Female	White	PDAC	Not Collected	Deceased	G12D	M237I	No	No	G12	Yes	88.0
PROV-ae7e6a24a3	61	Female	White	PDAC	Not Collected	Alive	G12V	No	No	A39G	G12	No	61.0
PROV-ae8fd86c10	70	Male	White	PDAC	Not Collected	Alive	G12D	E285K	No	No	G12	Yes	70.0
PROV-aef1a0e650	70	Male	White	PDAC	Not Collected	Deceased	G12V	K132R	No	No	G12	Yes	70.0
PROV-aef947fbb3	49	Male	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	49.0
PROV-b018be6aa1	70	Female	White	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	70.0
PROV-b2f2cf5e72	77	Female	Other	PDAC	Not Collected	Alive	G12V	K132N	No	No	G12	Yes	77.0
PROV-b44b96a278	NA	NA	Other	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	NA
PROV-b4aa8c1e48	74	Female	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	74.0
PROV-b58f4754	67	Female	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	67.0
PROV-b6aa267452	87	Male	NA	PDAC	Not Collected	Alive	G12D	R175H	No	No	G12	Yes	87.0
PROV-b76f6fd134	63	Male	White	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	63.0
PROV-b80f3d86fd	62	Male	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	62.0
PROV-b859ee6aa8	41	Male	Black/African-American	PDAC	Not Collected	Deceased	G12V	I195T	No	No	G12	Yes	41.0
PROV-b963166529	73	Male	White	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	73.0
PROV-baabaf8bc8	64	Male	NA	PDAC	Not Collected	Alive	G12R	K132N	No	No	G12	Yes	64.0
PROV-bc3f3edf50	49	Female	White	PDAC	Not Collected	Alive	No	No	No	No	No	No	49.0
PROV-bcafc4d83c	58	Female	NA	PDAC	Not Collected	Alive	G12D	G266E	No	No	G12	Yes	58.0
PROV-bd56e46258	66	Female	White	PDAC	Not Collected	Deceased	G12D	No	No	W524C	G12	No	66.0
PROV-bd82535154	68	Male	Other	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	68.0
PROV-bd82d64a	64	Male	White	PDAC	Primary	Alive	G12F	No	No	No	G12	No	64.0
PROV-bdebb1b9c7	52	Male	White	PNET	Not Collected	Alive	No	No	No	No	No	No	52.0
PROV-be0e3fe90a	71	Male	Asian	PDAC	Not Collected	Deceased	G12R	R110P	No	No	G12	Yes	71.0
PROV-be103b2f20	75	Female	White	PDAC	Not Collected	Deceased	G12R	No	No	No	G12	No	75.0
PROV-be551e6ca1	74	Female	NA	Carcinoma, NOS	Not Collected	Deceased	G12D	I255S	No	No	G12	Yes	74.0
PROV-bece8e166b	76	Female	White	PDAC	Not Collected	Alive	G12R	No	No	No	G12	No	76.0
PROV-bf87bbda9a	67	Female	Other	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	67.0
PROV-c1268d26	63	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	63.0
PROV-c1c0a85af5	88	Male	Other	PDAC	Not Collected	Alive	G12V	No	I49S	No	G12	No	88.0
PROV-c27d73576c	77	Male	Other	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	77.0
PROV-c2b6f394ba	73	Male	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	73.0
PROV-c34cf45d04	73	Male	Other	PDAC	Not Collected	Alive	G13D	No	No	No	G13	No	73.0
PROV-c3f4f839	63	Male	White	PDAC	Primary	Alive	G12C	No	No	No	G12	No	63.0
PROV-c5b0fd65	70	Male	NA	PDAC	Primary	Alive	No	No	No	No	No	No	70.0
PROV-c7da729c5c	62	Male	Other	PDAC	Not Collected	Alive	G12R	No	No	No	G12	No	62.0
PROV-c908bbc980	87	Female	White	Carcinoma, NOS	Not Collected	Deceased	G12D	No	No	No	G12	No	87.0
PROV-c93e221abc	83	Female	Other	PDAC	Not Collected	Alive	Q61L	No	No	No	Q61	No	83.0
PROV-c9ba2ef4d3	72	Female	Other	PDAC	Not Collected	Alive	No	No	No	No	No	No	72.0
PROV-ca18a1164d	74	Male	NA	Adenosquamous carcinoma	Not Collected	Alive	G12D	P151R	No	No	G12	Yes	74.0
PROV-caf99cc6	18	Female	Asian	PDAC	Primary	Alive	No	No	No	No	No	No	18.0
PROV-cd56257df7	62	Female	Other	Carcinoma, NOS	Not Collected	Alive	G12V	No	No	No	G12	No	62.0
PROV-cea734c98e	66	Female	Other	PDAC	Not Collected	Alive	G12R	R248W	No	No	G12	Yes	66.0
PROV-cefc28d9f9	56	Female	Asian	PDAC	Not Collected	Alive	G12D	G245S	No	No	G12	Yes	56.0
PROV-cf1c108660	56	Female	White	PDAC	Not Collected	Alive	G12D	C135F	No	No	G12	Yes	56.0
PROV-cf2596f0b4	68	Male	Other	PDAC	Not Collected	Alive	G12D	R273H	No	No	G12	Yes	68.0
PROV-d128bf0db6	72	Female	Other	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	72.0
PROV-d143d26560	56	Female	White	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	56.0
PROV-d27171c94e	75	Male	White	PDAC	Not Collected	Alive	G12D	R248W	No	No	G12	Yes	75.0
PROV-d2d385c39a	49	Male	Other	PDAC	Not Collected	Alive	G12D	H179R	No	No	G12	Yes	49.0
PROV-d3d567173c	37	Female	Other	Carcinoma, NOS	Not Collected	Alive	G12C	No	No	No	G12	No	37.0
PROV-d46ba1a9fd	>89	Female	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	90.0
PROV-d4e4f86518	69	Male	Other	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	69.0
PROV-d5de850fbf	76	Female	White	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	76.0
PROV-d5f774a6e7	80	Male	White	PDAC	Not Collected	Alive	No	No	No	No	No	No	80.0
PROV-d6f96ae3fd	68	Female	White	PDAC	Not Collected	Alive	G12D	No	No	Q224L	G12	No	68.0
PROV-d77e3c38	68	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	68.0
PROV-d7838b96aa	60	Female	Other	PDAC	Not Collected	Alive	G12V	V216M	No	No	G12	Yes	60.0
PROV-d8c9423b24	62	Male	White	PDAC	Not Collected	Alive	Q61H	No	No	No	Q61	No	62.0
PROV-d9606072	55	Male	White	PDAC	Primary	Alive	G12C	No	No	No	G12	No	55.0
PROV-d9b3b90e	82	Female	White	PDAC	Primary	Deceased	G12F	No	No	No	G12	No	82.0
PROV-d9ce349fed	62	Male	White	PDAC	Not Collected	Deceased	G12V	R273H	G55V	No	G12	Yes	62.0
PROV-d9fbf66543	46	Female	White	PDAC	Not Collected	Alive	No	R290C,T125M	No	No	No	Yes	46.0
PROV-da2a1fc74a	69	Male	White	PDAC	Not Collected	Deceased	Q61R	Y163C	No	No	Q61	Yes	69.0
PROV-da94ff67	67	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	67.0
PROV-dab80aa358	69	Female	White	PDAC	Not Collected	Alive	No	No	No	No	No	No	69.0
PROV-db2728be	66	Male	White	PDAC	Primary	Alive	G12D	Y236N	No	No	G12	Yes	66.0
PROV-dc406756	59	Male	White	PDAC	Primary	Deceased	G12C	No	No	No	G12	No	59.0
PROV-dc810d6f33	59	Male	White	PDAC	Not Collected	Alive	G12C	G245S	No	No	G12	Yes	59.0
PROV-dd4e9f1b40	66	Female	White	PDAC	Not Collected	Deceased	G12D	C242S	No	No	G12	Yes	66.0
PROV-ddcb2ca5ec	64	Female	NA	PDAC	Not Collected	Alive	Q61R	No	No	No	Q61	No	64.0
PROV-de2b51b0d1	63	Male	White	PDAC	Not Collected	Deceased	G12D	M237K	No	No	G12	Yes	63.0
PROV-decf79122d	83	Male	White	PDAC	Not Collected	Deceased	G12V	No	No	No	G12	No	83.0
PROV-dee50486b2	73	Male	White	PDAC	Not Collected	Alive	G12V	P278R	H83Y	No	G12	Yes	73.0
PROV-df843b3cae	47	Female	NA	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	47.0
PROV-e17d0e8e1f	65	Female	Asian	PDAC	Not Collected	Deceased	G12V	R175H	No	No	G12	Yes	65.0
PROV-e183668871	51	Male	Other	PDAC	Not Collected	Alive	G12D	G245S	No	No	G12	Yes	51.0
PROV-e188932e6d	67	Female	Other	PDAC	Not Collected	Alive	G12D	R282W	No	No	G12	Yes	67.0
PROV-e2c80fa790	67	Male	NA	PDAC	Not Collected	Alive	V14G,G12D	K164E	No	No	G12\|Other	Yes	67.0
PROV-e431c56f	55	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	55.0
PROV-e4817136	67	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	67.0
PROV-e4a68149f3	74	Female	Other	PDAC	Not Collected	Alive	G12R	L194R	No	No	G12	Yes	74.0
PROV-e4bf993a	62	Male	White	PDAC	Primary	Alive	G12V	Y234C	No	No	G12	Yes	62.0
PROV-e5d41aef	65	Female	White	PDAC	Primary	Deceased	G12R	No	No	L104R	G12	No	65.0
PROV-e68492833e	68	Male	White	PDAC	Not Collected	Deceased	G12D	Y220C	No	No	G12	Yes	68.0
PROV-e868346b65	78	Female	White	PDAC	Not Collected	Deceased	G12R	R282W	No	No	G12	Yes	78.0
PROV-e959939369	59	Female	White	PDAC	Not Collected	Deceased	G12V	S241F	No	No	G12	Yes	59.0
PROV-ea6a44f187	51	Female	White	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	51.0
PROV-ea9369f2a7	81	Male	Black/African-American	Acinar cell carcinoma	Not Collected	Alive	A146T	R158C	No	No	Other	Yes	81.0
PROV-eabdd1b6	62	Male	White	PDAC	Primary	Alive	G12F	No	No	No	G12	No	62.0
PROV-eafbb6c48c	72	Female	White	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	72.0
PROV-eb191b2677	73	Female	White	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	73.0
PROV-eb685312	67	Male	Other	PDAC	Primary	Alive	No	No	No	No	No	No	67.0
PROV-ec0802cd6e	53	Male	White	PDAC	Not Collected	Deceased	G12D	R175H	No	T63I	G12	Yes	53.0
PROV-ec7e9acd5c	40	Female	Other	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	40.0
PROV-ed37bd32a2	57	Female	White	PDAC	Not Collected	Alive	Q61H	P190L	No	No	Q61	Yes	57.0
PROV-ed8dc785a7	74	Female	White	PDAC	Not Collected	Alive	No	R175H	No	No	No	Yes	74.0
PROV-ee9707bf26	70	Female	White	PDAC	Not Collected	Alive	Q61H,T20M	No	No	No	Q61\|Other	No	70.0
PROV-eec929296a	55	Male	Other	PDAC	Not Collected	Alive	G12D	Y220D	No	No	G12	Yes	55.0
PROV-ef344d02	75	Female	White	PDAC	Primary	Alive	G12F	No	No	No	G12	No	75.0
PROV-ef871672af	75	Female	Other	PDAC	Not Collected	Alive	G12V	K132E	No	No	G12	Yes	75.0
PROV-efb219886e	61	Female	White	PDAC	Not Collected	Alive	No	No	No	No	No	No	61.0
PROV-efce6000cf	74	Female	Black/African-American	PDAC	Not Collected	Deceased	G12V	R273H	No	No	G12	Yes	74.0
PROV-f018c29e46	64	Female	Other	PDAC	Not Collected	Alive	G12D	G245S	No	No	G12	Yes	64.0
PROV-f1404f6fec	68	Male	White	PDAC	Not Collected	Alive	G12D	C176Y	No	No	G12	Yes	68.0
PROV-f1c63d8fc8	83	Male	NA	PDAC	Not Collected	Alive	G12D	G245C	No	No	G12	Yes	83.0
PROV-f2216c1778	70	Male	White	PDAC	Not Collected	Deceased	G12D	G266E	No	No	G12	Yes	70.0
PROV-f2a0e779b2	51	Female	White	PDAC	Not Collected	Deceased	G12D	G244D	No	No	G12	Yes	51.0
PROV-f34d2265db	45	Male	Other	PDAC	Not Collected	Alive	G12D	C176F	No	No	G12	Yes	45.0
PROV-f3b932ac	55	Female	White	PDAC	Metastasis	Deceased	G12D	P151H	No	No	G12	Yes	55.0
PROV-f3fa48d7d5	60	Male	Other	PDAC	Not Collected	Alive	G12D	No	No	No	G12	No	60.0
PROV-f40cbf4266	62	Female	White	PDAC	Not Collected	Deceased	G12R	R273C	No	No	G12	Yes	62.0
PROV-f42b6ff606	70	Female	Other	PDAC	Not Collected	Alive	G12R	C141Y	No	No	G12	Yes	70.0
PROV-f4ec9e8f5a	73	Male	White	Acinar cell carcinoma	Not Collected	Alive	No	No	No	No	No	No	73.0
PROV-f7b8bcdc	64	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	64.0
PROV-f9634abf19	59	Female	Other	PDAC	Not Collected	Deceased	No	No	No	No	No	No	59.0
PROV-f9c389d6	64	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	64.0
PROV-fa2379d322	80	Male	White	PDAC	Not Collected	Deceased	G12D	Y220C	No	No	G12	Yes	80.0
PROV-facce672c8	68	Female	White	PDAC	Not Collected	Alive	G12R	No	No	No	G12	No	68.0
PROV-fbc615463c	75	Male	White	PDAC	Not Collected	Alive	G12C	C176F	No	No	G12	Yes	75.0
PROV-fbc812f4e1	73	Female	White	PDAC	Not Collected	Deceased	G12V	No	No	No	G12	No	73.0
PROV-fcb9075746	73	Male	NA	PDAC	Not Collected	Alive	G12R	No	No	No	G12	No	73.0
PROV-fdb7fa11db	68	Female	White	PDAC	Not Collected	Deceased	G12V	R175H	No	No	G12	Yes	68.0
PROV-fe1031efff	65	Male	NA	PDAC	Not Collected	Alive	G12V	No	No	No	G12	No	65.0
PROV-feea753563	58	Female	White	PDAC	Not Collected	Alive	G13P	Y234C	E69G	No	G13	Yes	58.0
PROV-ffac0f88aa	59	Female	White	PDAC	Not Collected	Alive	G12D	R282W	No	No	G12	Yes	59.0
SCI-0359477662	68	Female	NA	Adenosquamous carcinoma	Primary	Alive	G12D	No	No	No	G12	No	68.0
SCI-0464226662	66	Male	Black/African-American	PDAC	Primary	Deceased	G12V	No	No	Q334H	G12	No	66.0
SCI-1111052662	73	Male	Asian	Acinar cell carcinoma	Primary	Deceased	No	No	No	No	No	No	73.0
SCI-1733996662	60	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	60.0
SCI-2251976662	66	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	66.0
SCI-2448726662	68	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	68.0
SCI-2538202662	66	Male	White	PDAC	Primary	Deceased	G12D	Y220C	No	No	G12	Yes	66.0
SCI-2711136662	63	Male	White	IPMN	Metastasis	Deceased	N116S	No	No	No	Other	No	63.0
SCI-2997277662	57	Male	NA	PDAC	Metastasis	Deceased	Q61H	R175H	No	No	Q61	Yes	57.0
SCI-3500892662	53	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	53.0
SCI-3679872662	58	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	58.0
SCI-4031642662	77	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	77.0
SCI-4309416662	60	Male	White	PNET	Primary	Deceased	No	C141F	No	No	No	Yes	60.0
SCI-4346622662	70	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	D355A	G12	No	70.0
SCI-4366727662	57	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	57.0
SCI-5189206662	64	Male	Asian	PDAC	Metastasis	Deceased	G12D	P278T	No	No	G12	Yes	64.0
SCI-5201882662	57	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	57.0
SCI-5839676662	56	Female	White	PDAC	Primary	Alive	G12V	No	H83Y	No	G12	No	56.0
SCI-6238377662	60	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	60.0
SCI-6340036662	60	Female	Black/African-American	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	60.0
SCI-6407407662	72	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	72.0
SCI-6666212662	69	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	69.0
SCI-6679016662	78	Female	White	PDAC	Metastasis	Alive	G12R	R282W	No	No	G12	Yes	78.0
SCI-6790217662	61	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12V	No	No	No	G12	No	61.0
SCI-7113632662	54	Female	Asian	PDAC	Primary	Alive	G12V	No	No	No	G12	No	54.0
SCI-7340016662	74	Female	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	74.0
SCI-7552047662	65	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	65.0
SCI-7586306662	61	Female	Asian	PDAC	Metastasis	Deceased	G12R	S215I	No	No	G12	Yes	61.0
SCI-8618126662	77	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	77.0
SCI-8757046662	67	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	67.0
SCI-8817492662	72	Male	White	PDAC	Metastasis	Deceased	No	R175H,R283S	No	No	No	Yes	72.0
SCI-8985132662	76	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	76.0
SCI-9123927662	49	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	49.0
SCI-9223746662	62	Female	Black/African-American	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	62.0
SCI-9258492662	42	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	42.0
SCI-9553002662	63	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	63.0
UCSF-1015	48	Male	White	Pancreatoblastoma	Metastasis	Deceased	No	No	No	No	No	No	48.0
UCSF-1035	69	Male	White	PDAC	Primary	Deceased	G12D	K132N	No	G508D	G12	Yes	69.0
UCSF-1043	50	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	50.0
UCSF-10493	64	Male	White	PDAC	Primary	Deceased	G12D	R158L	No	No	G12	Yes	64.0
UCSF-1066	59	Female	Other	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	59.0
UCSF-1077	<18	Female	Other	Solid pseudopapillary tumor	Not Collected	Alive	No	No	No	No	No	No	17.0
UCSF-10787	64	Female	NA	PDAC	Metastasis	Alive	G12D	H168R	No	No	G12	Yes	64.0
UCSF-10792	69	Male	White	PDAC	Metastasis	Deceased	G12R	R175H	No	No	G12	Yes	69.0
UCSF-10819	66	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	66.0
UCSF-10857	76	Male	White	PDAC	Primary	Deceased	G12V	No	No	G386V	G12	No	76.0
UCSF-10868	61	Male	Asian	PDAC	Metastasis	Deceased	G12D	Y234C	H83Y	No	G12	Yes	61.0
UCSF-1096	57	Female	Asian	PDAC	Metastasis	Deceased	G12V	R273H	No	No	G12	Yes	57.0
UCSF-11096	62	Male	Asian	PDAC	Metastasis	Deceased	No	No	No	No	No	No	62.0
UCSF-11114	61	Female	White	PDAC	Primary	Alive	G12C	R249M	No	No	G12	Yes	61.0
UCSF-1114	64	Male	White	PDAC	Primary	Deceased	G12D	C176F	No	No	G12	Yes	64.0
UCSF-11268	82	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	82.0
UCSF-1130	40	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	R282W	No	R361C	G12	Yes	40.0
UCSF-11357	71	Male	Asian	PNET	Metastasis	Alive	No	No	No	No	No	No	71.0
UCSF-11366	70	Male	Other	PDAC	Metastasis	Deceased	Q61H	R175H	No	No	Q61	Yes	70.0
UCSF-11395	35	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	35.0
UCSF-1140	56	Male	Asian	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	56.0
UCSF-11423	71	Female	White	PDAC	Primary	Deceased	G12D	M133K	E88K	No	G12	Yes	71.0
UCSF-11457	80	Male	Other	PDAC	Metastasis	Deceased	G12V	R248Q	No	R361C	G12	Yes	80.0
UCSF-11465	60	Male	White	PDAC	Primary	Alive	No	No	No	F119I	No	No	60.0
UCSF-1157	71	Male	White	PDAC	Primary	Deceased	G12V	No	No	D351E	G12	No	71.0
UCSF-11605	77	Female	Asian	PDAC	Primary	Alive	No	No	No	No	No	No	77.0
UCSF-1167	47	Female	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	47.0
UCSF-11685	67	Female	White	Serous cystadenoma	Primary	Alive	No	No	No	No	No	No	67.0
UCSF-11698	72	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	72.0
UCSF-11755	71	Male	White	PDAC	Primary	Alive	G12R	G244S	R24P	No	G12	Yes	71.0
UCSF-11851	64	Female	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	64.0
UCSF-1195	62	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	62.0
UCSF-11977	69	Male	White	PDAC	Metastasis	Deceased	G12D	M246T	No	No	G12	Yes	69.0
UCSF-1198	55	Male	White	PDAC	Metastasis	Deceased	G12D	No	H83Y	No	G12	No	55.0
UCSF-1200	57	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	57.0
UCSF-12036	80	Male	Other	PDAC	Metastasis	Deceased	Q61H	R282W	No	K428T	Q61	Yes	80.0
UCSF-12116	71	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	71.0
UCSF-12131	82	Female	Asian	PDAC	Primary	Deceased	G12D	A161D	No	No	G12	Yes	82.0
UCSF-12142	57	Male	White	PDAC	Primary	Deceased	G12R	L194R	No	No	G12	Yes	57.0
UCSF-12146	83	Male	Asian	PNET	Metastasis	Alive	G12V	Y220C	No	No	G12	Yes	83.0
UCSF-12187	71	Female	White	PDAC	Metastasis	Deceased	Q61L	Y163C	No	No	Q61	Yes	71.0
UCSF-12277	65	Male	Asian	PDAC	Primary	Deceased	G12V	R249G	No	No	G12	Yes	65.0
UCSF-1228	77	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	77.0
UCSF-12311	65	Male	Asian	PDAC	Primary	Alive	G12V	No	No	No	G12	No	65.0
UCSF-12336	59	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	59.0
UCSF-12359	74	Female	Asian	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	74.0
UCSF-12411	52	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	52.0
UCSF-12478	84	Female	Other	PDAC	Primary	Deceased	Q61L	No	No	No	Q61	No	84.0
UCSF-12490	52	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	52.0
UCSF-12522	63	Female	White	PDAC	Metastasis	Deceased	G12D	No	L94Q	No	G12	No	63.0
UCSF-12563	73	Female	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	73.0
UCSF-12565	56	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	56.0
UCSF-12610	87	Male	Asian	PDAC	Primary	Deceased	G12V	G244C	No	No	G12	Yes	87.0
UCSF-1262	58	Male	White	PDAC	Not Collected	Deceased	G12D	No	D108G	No	G12	No	58.0
UCSF-12655	51	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	51.0
UCSF-12758	66	Female	White	Acinar cell carcinoma	Primary	Alive	No	No	No	No	No	No	66.0
UCSF-12801	<18	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	17.0
UCSF-12820	64	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	64.0
UCSF-12853	66	Female	White	Acinar cell carcinoma	Metastasis	Alive	G12I	G244D	No	No	G12	Yes	66.0
UCSF-12882	47	Male	Asian	PDAC	Primary	Deceased	No	No	No	No	No	No	47.0
UCSF-12895	77	Male	White	PDAC	Metastasis	Deceased	G12V	P250S,G105S	No	No	G12	Yes	77.0
UCSF-12912	64	Female	Asian	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
UCSF-12928	74	Female	Black/African-American	PDAC	Metastasis	Deceased	G12C	No	No	No	G12	No	74.0
UCSF-1307	63	Female	White	PDAC	Metastasis	Deceased	G12D	R273C	No	No	G12	Yes	63.0
UCSF-13107	73	Female	White	PDAC	Metastasis	Alive	Q61H	No	No	No	Q61	No	73.0
UCSF-1316	73	Male	White	PDAC	Metastasis	Deceased	G12R	No	P81H	No	G12	No	73.0
UCSF-13225	66	Female	White	PNET	Primary	Alive	G12D	Y220C	No	No	G12	Yes	66.0
UCSF-1324	69	Female	Black/African-American	PDAC	Primary	Deceased	G12R	R248W	No	No	G12	Yes	69.0
UCSF-1325	75	Male	Asian	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	75.0
UCSF-13264	67	Female	Asian	PDAC	Primary	Alive	No	No	No	No	No	No	67.0
UCSF-13283	82	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	82.0
UCSF-1329	62	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	62.0
UCSF-1330	63	Female	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	63.0
UCSF-13324	68	Male	White	PDAC	Primary	Alive	G12R	No	H83Y	No	G12	No	68.0
UCSF-13343	37	Male	Other	PDAC	Metastasis	Deceased	No	No	No	No	No	No	37.0
UCSF-1338	49	Male	White	Cystic tumor	Metastasis	Alive	No	No	No	No	No	No	49.0
UCSF-13456	81	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	81.0
UCSF-1365	76	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	76.0
UCSF-13663	68	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	68.0
UCSF-13707	61	Male	Asian	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	61.0
UCSF-1372	47	Male	White	PNET	Primary	Deceased	No	G266V	No	No	No	Yes	47.0
UCSF-13808	61	Male	Asian	PDAC	Metastasis	Deceased	G12V	R175H	No	I179V	G12	Yes	61.0
UCSF-13825	53	Male	White	PDAC	Metastasis	Deceased	G12D	V157F	No	No	G12	Yes	53.0
UCSF-13830	70	Female	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	70.0
UCSF-1392	58	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	58.0
UCSF-13941	68	Male	White	PDAC	Primary	Deceased	G12V	I195T	No	No	G12	Yes	68.0
UCSF-14001	60	Male	White	PDAC	Primary	Alive	G12D	C176Y	No	No	G12	Yes	60.0
UCSF-14023	62	Female	White	PNET	Metastasis	Deceased	No	E285K	No	No	No	Yes	62.0
UCSF-14101	78	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	78.0
UCSF-14128	76	Male	Asian	PNET	Metastasis	Alive	No	No	No	No	No	No	76.0
UCSF-14154	71	Male	Asian	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	71.0
UCSF-14195	76	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	76.0
UCSF-14267	78	Male	White	PDAC	Metastasis	Deceased	G12C	No	No	No	G12	No	78.0
UCSF-1427	55	Male	Other	PNET	Primary	Deceased	No	No	No	No	No	No	55.0
UCSF-14303	72	Female	White	PDAC	Primary	Deceased	G12V	R175H	H83Y	No	G12	Yes	72.0
UCSF-14305	39	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	39.0
UCSF-1434	62	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	62.0
UCSF-1458	71	Female	White	PDAC	Primary	Alive	G12D	R248W	No	No	G12	Yes	71.0
UCSF-14602	65	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	65.0
UCSF-14641	55	Female	Other	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	55.0
UCSF-1471	60	Female	White	Adenosquamous carcinoma	Primary	Deceased	G12D	No	H83Y	No	G12	No	60.0
UCSF-1477	72	Male	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	72.0
UCSF-14778	50	Male	Asian	PDAC	Primary	Deceased	G12D	C176Y	No	No	G12	Yes	50.0
UCSF-1478	63	Male	White	PNET	Metastasis	Deceased	No	No	No	T77I	No	No	63.0
UCSF-148	34	Female	Other	PNET	Metastasis	Deceased	No	P151H	No	No	No	Yes	34.0
UCSF-14890	78	Female	White	PDAC	Metastasis	Deceased	G12R	R213L	No	No	G12	Yes	78.0
UCSF-14975	54	Male	Other	PDAC	Metastasis	Alive	G12V	R273C	No	No	G12	Yes	54.0
UCSF-14998	80	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	80.0
UCSF-15002	84	Male	Asian	PDAC	Primary	Deceased	Q61H	R248W	No	No	Q61	Yes	84.0
UCSF-15068	65	Male	White	PNET	Primary	Alive	No	R248Q	No	No	No	Yes	65.0
UCSF-15304	41	Female	NA	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	41.0
UCSF-15443	63	Male	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	63.0
UCSF-15446	86	Female	Asian	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	86.0
UCSF-15449	73	Female	Asian	PDAC	Primary	Alive	G12V	No	No	No	G12	No	73.0
UCSF-15467	30	Female	Other	PDAC	Metastasis	Alive	G12D	R273C	No	No	G12	Yes	30.0
UCSF-15475	69	Female	White	PDAC	Primary	Deceased	G12D	L194R	No	No	G12	Yes	69.0
UCSF-15491	41	Male	Asian	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	41.0
UCSF-15569	69	Female	White	PDAC	Metastasis	Deceased	G12R	R273H	No	No	G12	Yes	69.0
UCSF-15829	39	Male	Black/African-American	PDAC	Primary	Alive	G12D	R248W	No	No	G12	Yes	39.0
UCSF-15903	44	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	44.0
UCSF-16003	54	Female	Black/African-American	PDAC	Primary	Alive	G12V	R273H	No	No	G12	Yes	54.0
UCSF-16009	63	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	63.0
UCSF-16017	52	Female	White	PDAC	Primary	Alive	G12C	No	No	No	G12	No	52.0
UCSF-16027	65	Male	White	PDAC	Metastasis	Deceased	G12D	M237I	No	No	G12	Yes	65.0
UCSF-16032	61	Male	Black/African-American	Cystic tumor	Not Collected	Alive	No	No	No	No	No	No	61.0
UCSF-16058	68	Male	White	PDAC	Primary	Alive	No	V173L	No	No	No	Yes	68.0
UCSF-16121	83	Female	White	Cystic tumor	Not Collected	Alive	No	No	No	No	No	No	83.0
UCSF-16164	61	Male	White	PDAC	Not Collected	Alive	No	No	No	No	No	No	61.0
UCSF-16251	46	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	46.0
UCSF-16282	64	Male	Other	Cystic tumor	Not Collected	Alive	No	No	No	No	No	No	64.0
UCSF-1630	63	Male	Asian	PDAC	Primary	Alive	G12V	No	No	No	G12	No	63.0
UCSF-16323	69	Female	Other	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	69.0
UCSF-16348	69	Male	White	Cystic tumor	Not Collected	Alive	G12V	No	No	No	G12	No	69.0
UCSF-16349	73	Female	White	Cystic tumor	Not Collected	Alive	No	No	No	No	No	No	73.0
UCSF-16367	60	Female	Asian	PDAC	Primary	Alive	No	No	No	No	No	No	60.0
UCSF-16457	57	Female	Asian	PDAC	Metastasis	Deceased	G12D	V272M	No	No	G12	Yes	57.0
UCSF-16534	62	Male	Asian	PDAC	Metastasis	Deceased	G13D	No	No	No	G13	No	62.0
UCSF-16540	79	Female	Asian	PDAC	Primary	Alive	Q61H	V272G	No	No	Q61	Yes	79.0
UCSF-1656	53	Female	White	PDAC	Metastasis	Deceased	G12V	P151H	No	No	G12	Yes	53.0
UCSF-16601	64	Female	White	PDAC	Primary	Deceased	G12V	R337C	No	No	G12	Yes	64.0
UCSF-1668	67	Female	Asian	PDAC	Metastasis	Alive	G12D	R282W	D153Y	No	G12	Yes	67.0
UCSF-1679	75	Female	White	PDAC	Primary	Deceased	G12D	No	No	D415H,K428N	G12	No	75.0
UCSF-1682	65	Female	White	PDAC	Metastasis	Deceased	G12A	Y126C	No	No	G12	Yes	65.0
UCSF-1718	66	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	66.0
UCSF-1755	60	Female	White	PDAC	Primary	Alive	G12V	P190L	No	No	G12	Yes	60.0
UCSF-1790	72	Male	White	PDAC	Primary	Deceased	G12D	A74V	No	No	G12	Yes	72.0
UCSF-1823	61	Female	White	PDAC	Primary	Deceased	G12D	Y163C	No	No	G12	Yes	61.0
UCSF-2301	<18	Female	Other	Solid pseudopapillary tumor	Metastasis	Alive	No	No	No	No	No	No	17.0
UCSF-2349	61	Male	White	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	61.0
UCSF-2374	54	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	54.0
UCSF-2404	73	Male	Asian	PDAC	Primary	Deceased	G12V	No	H83Y	No	G12	No	73.0
UCSF-2519	81	Male	White	PDAC	Primary	Deceased	Q61K	No	No	No	Q61	No	81.0
UCSF-2604	73	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	73.0
UCSF-2636	35	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	35.0
UCSF-2654	33	Female	White	PDAC	Metastasis	Deceased	No	R175H	No	V72G	No	Yes	33.0
UCSF-2680	70	Male	White	PDAC	Not Collected	Deceased	G12V	No	No	No	G12	No	70.0
UCSF-2716	71	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	71.0
UCSF-2719	57	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	57.0
UCSF-2778	64	Male	White	PDAC	Not Collected	Deceased	G12R	P250L	No	No	G12	Yes	64.0
UCSF-2818	47	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	47.0
UCSF-2845	65	Male	Black/African-American	PNET	Metastasis	Deceased	No	No	No	No	No	No	65.0
UCSF-2994	84	Female	White	PDAC	Not Collected	Deceased	G12D	No	No	No	G12	No	84.0
UCSF-2996	63	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	63.0
UCSF-3131	75	Male	White	PDAC	Primary	Deceased	G12D	S127F	H83Y	No	G12	Yes	75.0
UCSF-3139	68	Male	White	PNET	Metastasis	Deceased	G12R	No	H83D	L540R	G12	No	68.0
UCSF-3153	47	Female	Other	PDAC	Primary	Alive	No	No	No	No	No	No	47.0
UCSF-3276	51	Female	White	PDAC	Metastasis	Deceased	G12V	No	D84N	No	G12	No	51.0
UCSF-3325	63	Male	White	PNET	Metastasis	Alive	No	Y220S	No	No	No	Yes	63.0
UCSF-3376	70	Male	Other	PNET	Primary	Deceased	No	No	No	No	No	No	70.0
UCSF-3398	62	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	62.0
UCSF-3403	66	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	66.0
UCSF-3459	72	Male	White	PDAC	Primary	Deceased	G12D	P177S,R158C	No	No	G12	Yes	72.0
UCSF-3460	70	Female	White	PDAC	Metastasis	Alive	G12D	V274A	No	No	G12	Yes	70.0
UCSF-3527	76	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	76.0
UCSF-354	45	Male	White	PDAC	Primary	Deceased	G12D	C176F	No	No	G12	Yes	45.0
UCSF-3600	80	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	80.0
UCSF-3602	46	Male	White	PDAC	Primary	Deceased	No	No	D74N	No	No	No	46.0
UCSF-418	76	Female	Asian	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	76.0
UCSF-453	72	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	72.0
UCSF-492	63	Female	Asian	PNET	Metastasis	Deceased	No	No	No	No	No	No	63.0
UCSF-496	76	Male	White	PDAC	Metastasis	Deceased	G12V	R273H	No	No	G12	Yes	76.0
UCSF-529	71	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	71.0
UCSF-532	62	Male	Asian	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	62.0
UCSF-543	77	Female	NA	PNET	Metastasis	Alive	No	No	No	No	No	No	77.0
UCSF-556	64	Female	White	PNET	Not Collected	Deceased	No	R248W	No	No	No	Yes	64.0
UCSF-569	<18	Male	NA	Pancreatoblastoma	Metastasis	Deceased	No	No	No	No	No	No	17.0
UCSF-570	73	Male	Asian	PDAC	Metastasis	Deceased	No	No	No	No	No	No	73.0
UCSF-584	49	Female	NA	PDAC	Primary	Alive	G12V	R273C	No	No	G12	Yes	49.0
UCSF-651	64	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	64.0
UCSF-677	66	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	66.0
UCSF-710	63	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
UCSF-748	69	Male	White	PNET	Metastasis	Deceased	G12C	No	No	No	G12	No	69.0
UCSF-749	60	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	60.0
UCSF-769	57	Male	White	PDAC	Metastasis	Deceased	G12D	Y163C	No	No	G12	Yes	57.0
UCSF-771	60	Female	White	PDAC	Metastasis	Deceased	G12V	V218G	No	No	G12	Yes	60.0
UCSF-793	76	Male	White	PDAC	Metastasis	Deceased	No	C135Y	No	No	No	Yes	76.0
UCSF-803	42	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	42.0
UCSF-859	48	Male	Asian	PDAC	Metastasis	Deceased	G12R	Y220C	No	No	G12	Yes	48.0
UCSF-866	48	Male	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	48.0
UCSF-894	69	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	69.0
UCSF-916	60	Male	White	PDAC	Primary	Deceased	G12V	R337C	G23V	No	G12	Yes	60.0
UCSF-919	72	Male	White	PDAC	Primary	Deceased	G12R	R158L	No	No	G12	Yes	72.0
UCSF-947	57	Female	Asian	PDAC	Metastasis	Deceased	G12R	I254T	No	No	G12	Yes	57.0
UCSF-964	68	Female	White	PDAC	Metastasis	Deceased	G12V	R273C	No	No	G12	Yes	68.0
UHN-003188	38	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	38.0
UHN-046384	58	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	58.0
UHN-054022	58	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	58.0
UHN-067569	49	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	49.0
UHN-070535	29	Female	White	Solid pseudopapillary tumor	Metastasis	Deceased	No	No	No	No	No	No	29.0
UHN-108856	58	Male	White	Mucinous adenocarcinoma	Primary	Deceased	No	No	No	No	No	No	58.0
UHN-109320	77	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	77.0
UHN-109421	34	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	34.0
UHN-110785	57	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	57.0
UHN-117184	71	Male	White	PDAC	Primary	Deceased	E62A,Q61R	R196P	G55D	No	Q61\|Other	Yes	71.0
UHN-128295	52	Female	White	PDAC	Primary	Deceased	G12R	R213L	No	No	G12	Yes	52.0
UHN-131215	62	Female	White	PDAC	Primary	Deceased	G12V	R248W	No	No	G12	Yes	62.0
UHN-148952	57	Female	White	PDAC	Metastasis	Deceased	G12D	H168L	No	G510R	G12	Yes	57.0
UHN-150428	62	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	62.0
UHN-172897	70	Female	White	PDAC	Metastasis	Deceased	G12D	G245S	No	No	G12	Yes	70.0
UHN-179759	36	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	36.0
UHN-182316	47	Female	White	PDAC	Primary	Alive	G12D	G245S	No	No	G12	Yes	47.0
UHN-206717	67	Female	White	PDAC	Metastasis	Deceased	No	Y205C	No	No	No	Yes	67.0
UHN-210895	65	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	65.0
UHN-225652	69	Male	White	PDAC	Primary	Deceased	G12V	R337C	No	No	G12	Yes	69.0
UHN-227059	46	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	46.0
UHN-249589	60	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	60.0
UHN-258666	45	Female	White	PDAC	Primary	Deceased	Q61H	V173M	No	No	Q61	Yes	45.0
UHN-284788	76	Female	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	76.0
UHN-292333	77	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	77.0
UHN-301209	44	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	44.0
UHN-302224	48	Male	White	Carcinoma, NOS	Primary	Alive	No	No	No	No	No	No	48.0
UHN-309729	72	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	72.0
UHN-314189	65	Female	White	PDAC	Primary	Deceased	No	S127F	No	No	No	Yes	65.0
UHN-352518	63	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	63.0
UHN-357960	66	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	66.0
UHN-384109	69	Male	White	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	69.0
UHN-386350	77	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	77.0
UHN-421373	64	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	G334V	No	No	G12	Yes	64.0
UHN-441081	59	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	59.0
UHN-452275	56	Male	White	PDAC	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	56.0
UHN-471846	67	Male	White	PDAC	Primary	Deceased	G12D	No	No	G352V	G12	No	67.0
UHN-515398	36	Male	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	36.0
UHN-520138	67	Female	White	PDAC	Metastasis	Deceased	G12R	I251F	No	No	G12	Yes	67.0
UHN-545102	74	Male	White	PDAC	Primary	Deceased	G12R	P278S	No	No	G12	Yes	74.0
UHN-550383	71	Female	Asian	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	71.0
UHN-587620	41	Male	White	PDAC	Metastasis	Deceased	No	C135Y	No	No	No	Yes	41.0
UHN-597756	58	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	58.0
UHN-644875	55	Male	White	PDAC	Primary	Deceased	G12V	G245C	No	No	G12	Yes	55.0
UHN-648393	69	Male	White	Adenosquamous carcinoma	Metastasis	Deceased	No	No	No	No	No	No	69.0
UHN-656019	69	Female	Other	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	69.0
UHN-682623	52	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	52.0
UHN-683062	38	Female	Asian	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	38.0
UHN-714673	58	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	58.0
UHN-717942	55	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	55.0
UHN-802981	52	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	52.0
UHN-821349	72	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	72.0
UHN-832386	49	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	49.0
UHN-835765	70	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	70.0
UHN-841034	79	Female	Black/African-American	Acinar cell carcinoma	Primary	Deceased	No	No	No	No	No	No	79.0
UHN-859248	54	Male	Asian	PDAC	Metastasis	Deceased	No	Y220C	No	No	No	Yes	54.0
UHN-868588	56	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	56.0
UHN-873266	74	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	74.0
UHN-893105	65	Male	White	PDAC	Primary	Deceased	G12V	P151S	No	No	G12	Yes	65.0
UHN-895776	73	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	73.0
UHN-910748	48	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	48.0
UHN-938846	45	Female	White	PDAC	Metastasis	Alive	G12V	R248W	No	No	G12	Yes	45.0
UHN-938864	67	Female	White	Acinar cell carcinoma	Primary	Deceased	No	No	No	No	No	No	67.0
UHN-947804	68	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	68.0
UHN-949521	39	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	39.0
UHN-953150	68	Female	White	Mucinous adenocarcinoma	Primary	Deceased	No	No	No	No	No	No	68.0
UHN-967946	56	Female	White	PNET	Primary	Deceased	G12D	No	No	No	G12	No	56.0
UHN-970084	71	Male	White	PDAC	Metastasis	Deceased	No	S185N	No	No	No	Yes	71.0
UHN-971072	66	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	66.0
UHN-975152	55	Male	Asian	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	55.0
UHN-995802	65	Female	Asian	PNET	Metastasis	Deceased	No	No	No	No	No	No	65.0
UHN-OCT024571	68	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	68.0
UHN-OCT026252	53	Male	Other	PDAC	Metastasis	Deceased	G12V	D281E	No	No	G12	Yes	53.0
UHN-OCT035777	65	Male	NA	PNET	Metastasis	Alive	No	No	No	No	No	No	65.0
UHN-OCT038943	67	Male	Asian	PDAC	Primary	Deceased	G12V	V157F	H83Y	No	G12	Yes	67.0
UHN-OCT054624	65	Female	Asian	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	65.0
UHN-OCT055005	62	Female	Asian	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	62.0
UHN-OCT063703	74	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	74.0
UHN-OCT075778	57	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	57.0
UHN-OCT117256	74	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	74.0
UHN-OCT131715	43	Male	NA	PNET	Primary	Alive	No	No	No	No	No	No	43.0
UHN-OCT132429	64	Male	White	PDAC	Metastasis	Alive	G12V	C275Y	No	No	G12	Yes	64.0
UHN-OCT133452	61	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	61.0
UHN-OCT147300	72	Female	White	PDAC	Metastasis	Deceased	G12D	C242R	No	No	G12	Yes	72.0
UHN-OCT147687	51	Female	White	PDAC	Metastasis	Alive	G12V	C275R	No	No	G12	Yes	51.0
UHN-OCT164254	59	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	59.0
UHN-OCT188535	56	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	56.0
UHN-OCT221276	68	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	68.0
UHN-OCT226161	54	Male	Asian	PDAC	Metastasis	Alive	G12D	S215G	No	No	G12	Yes	54.0
UHN-OCT227029	66	Female	Asian	PDAC	Primary	Deceased	G12D	V157F	No	No	G12	Yes	66.0
UHN-OCT241634	71	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	71.0
UHN-OCT242648	61	Female	White	Solid pseudopapillary tumor	Metastasis	Alive	No	No	No	No	No	No	61.0
UHN-OCT247215	69	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	69.0
UHN-OCT251352	69	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	69.0
UHN-OCT251821	61	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	61.0
UHN-OCT254457	60	Male	Black/African-American	PDAC	Metastasis	Alive	G12D	Y234C	No	No	G12	Yes	60.0
UHN-OCT258179	47	Male	NA	PNET	Primary	Alive	No	No	No	No	No	No	47.0
UHN-OCT271391	68	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	68.0
UHN-OCT296767	63	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	63.0
UHN-OCT304772	49	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	R361H	G12	No	49.0
UHN-OCT316449	67	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	67.0
UHN-OCT318263	50	Male	NA	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	50.0
UHN-OCT318516	48	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	48.0
UHN-OCT323145	63	Male	NA	PNET	Metastasis	Deceased	No	No	No	No	No	No	63.0
UHN-OCT334027	64	Female	Black/African-American	PDAC	Primary	Alive	G12R	S241F	No	No	G12	Yes	64.0
UHN-OCT408333	72	Male	NA	PDAC	Primary	Alive	G12V	R248W	No	No	G12	Yes	72.0
UHN-OCT412020	64	Male	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	64.0
UHN-OCT420047	62	Female	Asian	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	62.0
UHN-OCT420107	75	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	75.0
UHN-OCT440752	72	Female	White	PDAC	Primary	Alive	Q61R	No	No	No	Q61	No	72.0
UHN-OCT442821	61	Female	NA	PNET	Primary	Alive	No	No	No	No	No	No	61.0
UHN-OCT490639	65	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	65.0
UHN-OCT498829	68	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	68.0
UHN-OCT508828	58	Female	White	PDAC	Primary	Alive	Q61H	No	No	No	Q61	No	58.0
UHN-OCT511767	65	Female	Other	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	65.0
UHN-OCT526513	68	Male	White	PDAC	Metastasis	Deceased	G12R	G266E	H83Y	No	G12	Yes	68.0
UHN-OCT533833	52	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	52.0
UHN-OCT540562	76	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	76.0
UHN-OCT559487	71	Female	White	PDAC	Primary	Deceased	G12D	R158G	No	No	G12	Yes	71.0
UHN-OCT565726	61	Male	NA	PNET	Primary	Alive	No	No	No	No	No	No	61.0
UHN-OCT588460	79	Female	White	PDAC	Metastasis	Deceased	G12V	Y163H	No	No	G12	Yes	79.0
UHN-OCT590540	59	Female	Asian	PNET	Metastasis	Alive	No	No	No	No	No	No	59.0
UHN-OCT598971	66	Male	White	PNET	Primary	Deceased	G12D	No	No	No	G12	No	66.0
UHN-OCT604196	74	Female	White	PDAC	Metastasis	Alive	G12D	H193N	No	No	G12	Yes	74.0
UHN-OCT621241	43	Female	Asian	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	43.0
UHN-OCT626671	49	Female	Black/African-American	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	49.0
UHN-OCT627128	53	Female	White	PDAC	Metastasis	Deceased	G13D	No	No	No	G13	No	53.0
UHN-OCT634506	71	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	71.0
UHN-OCT638161	61	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	61.0
UHN-OCT638461	62	Female	White	PDAC	Primary	Deceased	G12R	G266V	No	No	G12	Yes	62.0
UHN-OCT661236	40	Male	Other	PNET	Metastasis	Alive	No	No	No	No	No	No	40.0
UHN-OCT692307	69	Female	White	PDAC	Primary	Deceased	G12V	R175H	No	No	G12	Yes	69.0
UHN-OCT711104	56	Female	White	PDAC	Primary	Deceased	G12V	H179Y	No	No	G12	Yes	56.0
UHN-OCT712038	46	Female	Asian	PDAC	Primary	Alive	G12V	No	H83Y	R361C	G12	No	46.0
UHN-OCT720035	51	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	51.0
UHN-OCT742340	73	Male	White	PDAC	Metastasis	Deceased	G12S	No	No	No	G12	No	73.0
UHN-OCT758714	35	Female	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	35.0
UHN-OCT776979	74	Male	White	PDAC	Primary	Alive	No	G244A	No	No	No	Yes	74.0
UHN-OCT778023	41	Male	White	PNET	Primary	Alive	No	No	No	No	No	No	41.0
UHN-OCT779714	59	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	59.0
UHN-OCT849938	62	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	62.0
UHN-OCT864125	71	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	71.0
UHN-OCT873335	69	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	69.0
UHN-OCT874548	75	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	75.0
UHN-OCT878856	50	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	50.0
UHN-OCT886607	60	Female	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	60.0
UHN-OCT892553	64	Female	White	PDAC	Metastasis	Deceased	G13D	No	No	No	G13	No	64.0
UHN-OCT900427	60	Female	Asian	PNET	Metastasis	Deceased	No	No	No	No	No	No	60.0
UHN-OCT902610	61	Male	White	PDAC	Primary	Alive	No	R273C	No	No	No	Yes	61.0
UHN-OCT917361	80	Male	NA	PNET	Metastasis	Deceased	No	No	No	No	No	No	80.0
UHN-OCT918433	81	Male	White	Adenosquamous carcinoma	Primary	Deceased	G12R	R248Q	No	No	G12	Yes	81.0
UHN-OCT946692	69	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	69.0
UHN-OCT947598	64	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	64.0
UHN-OCT957190	66	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	66.0
UHN-OCT966814	67	Female	White	Adenosquamous carcinoma	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	67.0
UHN-OCT967890	64	Male	White	PDAC	Primary	Alive	G12D	R248Q	H83Y	No	G12	Yes	64.0
UHN-OCT969293	79	Female	Black/African-American	PDAC	Primary	Alive	G12D	R282W	No	R361H	G12	Yes	79.0
UHN-OCT973343	69	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	69.0
VHIO-018	59	Female	White	PDAC	Primary	Deceased	G12D	C275F	No	No	G12	Yes	59.0
VHIO-023	62	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	62.0
VHIO-041	65	Male	White	PDAC	Primary	Deceased	G12D	V216M	No	No	G12	Yes	65.0
VHIO-046	59	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	59.0
VHIO-048	66	Male	White	PDAC	Metastasis	Deceased	G12D	E258K	No	No	G12	Yes	66.0
VHIO-054	75	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	75.0
VHIO-055	68	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	68.0
VHIO-057	55	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	55.0
VHIO-067	71	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	71.0
VHIO-070	49	Male	White	PDAC	Metastasis	Deceased	Q61R	No	No	No	Q61	No	49.0
VHIO-075	51	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	51.0
VHIO-076	54	Female	White	PDAC	Metastasis	Deceased	G12R	R248Q	No	No	G12	Yes	54.0
VHIO-1000	67	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	67.0
VHIO-1010	65	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	65.0
VHIO-1013	52	Male	White	PDAC	Primary	Deceased	G12D	H214R	No	No	G12	Yes	52.0
VHIO-1021	59	Female	White	PDAC	Primary	Deceased	G12V	R273H	No	No	G12	Yes	59.0
VHIO-1026	73	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	73.0
VHIO-1027	53	Female	White	PDAC	Primary	Deceased	Q61H	D208V	No	No	Q61	Yes	53.0
VHIO-1031	75	Male	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	75.0
VHIO-1034	43	Female	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	43.0
VHIO-1038	50	Female	White	PDAC	Metastasis	Deceased	G12D	L194R	No	No	G12	Yes	50.0
VHIO-1039	58	Female	White	PDAC	Primary	Deceased	G12V	R273C	No	No	G12	Yes	58.0
VHIO-1043	75	Male	White	PDAC	Primary	Alive	G12D	C242Y	No	No	G12	Yes	75.0
VHIO-1045	66	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	G386D	G12	No	66.0
VHIO-110	62	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	62.0
VHIO-112	79	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	79.0
VHIO-114	59	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	59.0
VHIO-1156	66	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	66.0
VHIO-1183	57	Male	White	PDAC	Primary	Deceased	G12D	A161D	No	No	G12	Yes	57.0
VHIO-1184	57	Male	White	PDAC	Primary	Deceased	G12D	R282W	G101W	No	G12	Yes	57.0
VHIO-1185	63	Male	White	PDAC	Primary	Alive	G12V	I195T	No	No	G12	Yes	63.0
VHIO-1186	61	Female	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	61.0
VHIO-1187	71	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	71.0
VHIO-1188	64	Female	White	PDAC	Primary	Alive	G12R	No	No	No	G12	No	64.0
VHIO-1193	79	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	79.0
VHIO-1194	67	Female	White	PDAC	Primary	Alive	G12V	P151R	No	No	G12	Yes	67.0
VHIO-1197	62	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	62.0
VHIO-1198	77	Female	White	PDAC	Primary	Alive	G12D	Y220C	No	No	G12	Yes	77.0
VHIO-1202	66	Female	White	PDAC	Primary	Deceased	G12V	R248Q	No	No	G12	Yes	66.0
VHIO-1205	75	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	75.0
VHIO-1206	79	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	79.0
VHIO-1211	65	Female	White	PDAC	Metastasis	Alive	G13D	No	No	No	G13	No	65.0
VHIO-1215	71	Male	White	PDAC	Metastasis	Deceased	G12D	M133I,F134V	No	No	G12	Yes	71.0
VHIO-1216	49	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	49.0
VHIO-1223	72	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	72.0
VHIO-1227	83	Female	White	PDAC	Primary	Alive	Q61R	V172D	No	No	Q61	Yes	83.0
VHIO-1228	78	Female	White	PDAC	Primary	Alive	G12V	C275Y	No	No	G12	Yes	78.0
VHIO-1232	71	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	71.0
VHIO-1235	63	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	63.0
VHIO-1236	71	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	71.0
VHIO-1238	58	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	58.0
VHIO-1240	57	Male	Black/African-American	PDAC	Primary	Alive	G12V	No	No	No	G12	No	57.0
VHIO-1245	78	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	78.0
VHIO-142	60	Male	White	PDAC	Metastasis	Deceased	G12D	Y220D	No	No	G12	Yes	60.0
VHIO-164	61	Female	White	PDAC	Primary	Deceased	G12D	N239S	No	No	G12	Yes	61.0
VHIO-166	79	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	79.0
VHIO-168	68	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	68.0
VHIO-173	56	Female	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	56.0
VHIO-176	66	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	66.0
VHIO-191	75	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	75.0
VHIO-233	64	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	64.0
VHIO-239	73	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	73.0
VHIO-251	67	Female	White	PDAC	Metastasis	Deceased	G12V	R248W	No	No	G12	Yes	67.0
VHIO-281	51	Male	White	PDAC	Metastasis	Deceased	G12R	R248Q	No	No	G12	Yes	51.0
VHIO-321	46	Female	White	PDAC	Primary	Deceased	G12D	M133R	No	No	G12	Yes	46.0
VHIO-339	60	Male	White	PDAC	Primary	Alive	No	F134C	No	No	No	Yes	60.0
VHIO-351	49	Female	White	PDAC	Primary	Deceased	G12R	R273C	No	R361H	G12	Yes	49.0
VHIO-381	61	Female	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	61.0
VHIO-383	60	Female	White	PDAC	Metastasis	Deceased	G12R	N239S	No	No	G12	Yes	60.0
VHIO-409	46	Female	White	PDAC	Primary	Deceased	G12C	R248W	No	No	G12	Yes	46.0
VHIO-426	41	Male	White	PDAC	Primary	Deceased	G12D	H193R	No	No	G12	Yes	41.0
VHIO-443	53	Female	White	PDAC	Metastasis	Alive	G13P	I255F	No	No	G13	Yes	53.0
VHIO-458	58	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	58.0
VHIO-465	59	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	59.0
VHIO-467	53	Male	White	PDAC	Metastasis	Deceased	G12V	L194R	No	No	G12	Yes	53.0
VHIO-469	56	Female	White	PNET	Metastasis	Deceased	G12V	No	No	Y353C	G12	No	56.0
VHIO-475	44	Male	White	PDAC	Primary	Deceased	G12L	No	No	No	G12	No	44.0
VHIO-477	71	Female	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	71.0
VHIO-478	52	Female	White	PDAC	Metastasis	Deceased	G12R	I195T	No	No	G12	Yes	52.0
VHIO-479	58	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	58.0
VHIO-480	60	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	60.0
VHIO-481	63	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
VHIO-482	55	Male	White	PDAC	Primary	Deceased	G12D	V143A	No	No	G12	Yes	55.0
VHIO-491	74	Male	White	PDAC	Primary	Deceased	No	R248Q	No	No	No	Yes	74.0
VHIO-504	55	Female	White	PDAC	Metastasis	Alive	G12R	R248W	No	No	G12	Yes	55.0
VHIO-509	46	Female	White	PDAC	Primary	Deceased	G12R	R248W	No	No	G12	Yes	46.0
VHIO-512	71	Female	White	PDAC	Primary	Deceased	G12V	G266E	No	No	G12	Yes	71.0
VHIO-516	53	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	53.0
VHIO-517	50	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	50.0
VHIO-518	66	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	66.0
VHIO-521	74	Female	White	PDAC	Metastasis	Deceased	G12D	Y234C	No	No	G12	Yes	74.0
VHIO-523	69	Male	White	PDAC	Metastasis	Deceased	No	R175H	No	No	No	Yes	69.0
VHIO-524	53	Male	Black/African-American	PDAC	Primary	Alive	No	No	No	No	No	No	53.0
VHIO-537	29	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	29.0
VHIO-539	58	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	58.0
VHIO-540	68	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	68.0
VHIO-547	69	Male	White	PDAC	Primary	Alive	G12R	C176Y	No	No	G12	Yes	69.0
VHIO-553	58	Female	White	PDAC	Metastasis	Alive	G12D	G105D	No	No	G12	Yes	58.0
VHIO-560	55	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	55.0
VHIO-566	84	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	84.0
VHIO-569	70	Female	White	PDAC	Metastasis	Deceased	G12C	No	No	No	G12	No	70.0
VHIO-572	66	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	66.0
VHIO-583	84	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	84.0
VHIO-586	59	Female	White	PDAC	Primary	Alive	G12V	E258D	No	No	G12	Yes	59.0
VHIO-590	64	Female	White	PDAC	Primary	Deceased	G12V	G245S	No	No	G12	Yes	64.0
VHIO-594	69	Male	White	PDAC	Metastasis	Deceased	G12V	R248W	No	No	G12	Yes	69.0
VHIO-601	58	Female	White	PDAC	Primary	Deceased	G12V	C242G	No	No	G12	Yes	58.0
VHIO-607	59	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	59.0
VHIO-608	36	Female	White	Solid pseudopapillary tumor	Metastasis	Alive	No	No	No	No	No	No	36.0
VHIO-609	67	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	67.0
VHIO-611	74	Male	White	PDAC	Metastasis	Alive	No	R273H	No	No	No	Yes	74.0
VHIO-616	70	Female	White	PDAC	Metastasis	Deceased	G12V	G266V	Q50R	R361C	G12	Yes	70.0
VHIO-619	66	Female	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	66.0
VHIO-621	54	Male	White	PDAC	Primary	Deceased	G12D	R248Q	No	No	G12	Yes	54.0
VHIO-627	55	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	55.0
VHIO-633	82	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	82.0
VHIO-635	54	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	54.0
VHIO-644	68	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	68.0
VHIO-671	58	Male	White	PDAC	Primary	Deceased	Q61H	R175H	No	No	Q61	Yes	58.0
VHIO-673	75	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	75.0
VHIO-688	56	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	56.0
VHIO-695	55	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	55.0
VHIO-705	49	Female	White	PDAC	Metastasis	Deceased	G12D	C176F	No	No	G12	Yes	49.0
VHIO-707	70	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	70.0
VHIO-716	65	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	65.0
VHIO-717	55	Female	White	PDAC	Metastasis	Deceased	Q61H	No	No	No	Q61	No	55.0
VHIO-719	80	Female	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	80.0
VHIO-726	53	Male	White	PDAC	Primary	Alive	Q61R	No	No	No	Q61	No	53.0
VHIO-734	64	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	64.0
VHIO-736	34	Female	White	PDAC	Metastasis	Deceased	G13D	No	No	No	G13	No	34.0
VHIO-742	70	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	70.0
VHIO-751	53	Female	White	PDAC	Metastasis	Deceased	G12C	No	No	No	G12	No	53.0
VHIO-763	59	Female	White	PDAC	Primary	Alive	G12D	R175H	No	No	G12	Yes	59.0
VHIO-770	73	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	73.0
VHIO-771	63	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	63.0
VHIO-779	69	Male	White	PDAC	Primary	Deceased	G12D	R175H	No	No	G12	Yes	69.0
VHIO-783	67	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	67.0
VHIO-788	53	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	53.0
VHIO-791	57	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	57.0
VHIO-798	63	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	63.0
VHIO-799	63	Male	White	PDAC	Primary	Deceased	G12D	E286Q	No	No	G12	Yes	63.0
VHIO-803	67	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	R361H	G12	No	67.0
VHIO-807	48	Male	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	48.0
VHIO-810	71	Male	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	71.0
VHIO-811	72	Male	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	72.0
VHIO-812	68	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	68.0
VHIO-813	69	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	69.0
VHIO-820	75	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	75.0
VHIO-829	73	Female	White	PDAC	Metastasis	Deceased	G12D	P151S	No	No	G12	Yes	73.0
VHIO-831	69	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	69.0
VHIO-838	75	Male	White	PDAC	Primary	Deceased	G12V	A88T,R248Q	No	No	G12	Yes	75.0
VHIO-840	53	Female	White	PDAC	Metastasis	Deceased	G12D	V172F	No	No	G12	Yes	53.0
VHIO-850	58	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	58.0
VHIO-861	71	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	71.0
VHIO-869	64	Male	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	64.0
VHIO-878	69	Male	White	PNET	Metastasis	Alive	G12V	No	No	No	G12	No	69.0
VHIO-879	60	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	60.0
VHIO-883	59	Female	White	PDAC	Metastasis	Deceased	G12D	P151R	D14G	No	G12	Yes	59.0
VHIO-884	57	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	57.0
VHIO-887	42	Male	White	PDAC	Primary	Deceased	G12R	R282W	No	No	G12	Yes	42.0
VHIO-901	50	Female	White	PDAC	Metastasis	Deceased	G12D	M237V	No	R361H	G12	Yes	50.0
VHIO-903	54	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	54.0
VHIO-906	64	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
VHIO-913	79	Male	White	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	79.0
VHIO-915	62	Male	White	PDAC	Metastasis	Deceased	G12D	R273C	No	No	G12	Yes	62.0
VHIO-923	55	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	55.0
VHIO-927	59	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	59.0
VHIO-939	67	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	67.0
VHIO-940	70	Male	White	PDAC	Primary	Deceased	G12R	V216M	No	No	G12	Yes	70.0
VHIO-941	68	Male	White	Adenosquamous carcinoma	Primary	Alive	G12D	G245S	No	No	G12	Yes	68.0
VHIO-944	56	Male	Other	PDAC	Unknown	Alive	G12D	R282W	No	R361H	G12	Yes	56.0
VHIO-948	57	Male	White	PDAC	Primary	Deceased	G12D	C238Y	No	No	G12	Yes	57.0
VHIO-953	67	Male	White	PDAC	Metastasis	Deceased	G12V	R282W	No	No	G12	Yes	67.0
VHIO-962	60	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	60.0
VHIO-975	42	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	42.0
VHIO-977	60	Male	White	PDAC	Primary	Deceased	G12D	H179D	No	R361H	G12	Yes	60.0
VHIO-978	56	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	56.0
VHIO-990	67	Male	White	PDAC	Primary	Deceased	G12C	Y205H	No	No	G12	Yes	67.0
VHIO-991	73	Female	White	PDAC	Metastasis	Deceased	G12D	A161T	No	No	G12	Yes	73.0
VHIO-994	67	Male	White	PDAC	Primary	Deceased	G12V	L194R	No	No	G12	Yes	67.0
VHIO-995	72	Female	White	Carcinoma, NOS	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	72.0
VHIO-997	73	Female	White	PDAC	Primary	Alive	G12D	C238R	No	No	G12	Yes	73.0
VICC-100620	70	Female	White	PDAC	Primary	Deceased	G12D	No	No	D537G	G12	No	70.0
VICC-104273	71	Male	White	PDAC	Primary	Deceased	G12V	R273H	No	No	G12	Yes	71.0
VICC-104320	67	Female	White	PDAC	Metastasis	Deceased	G12D	R273H	No	No	G12	Yes	67.0
VICC-109723	57	Male	White	PDAC	Metastasis	Deceased	G12V	V274L	No	No	G12	Yes	57.0
VICC-116902	63	Female	White	PDAC	Metastasis	Deceased	G12D	R175H	A86D	No	G12	Yes	63.0
VICC-116906	54	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	54.0
VICC-124701	74	Female	White	PDAC	Primary	Deceased	G12D	R273H	No	No	G12	Yes	74.0
VICC-136796	43	Female	Black/African-American	PDAC	Metastasis	Deceased	G12R	H193R	No	No	G12	Yes	43.0
VICC-141530	41	Female	White	PDAC	Primary	Deceased	No	No	H83Y	No	No	No	41.0
VICC-143092	47	Male	White	PDAC	Primary	Alive	G12V	P177R	P38L	No	G12	Yes	47.0
VICC-145289	65	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	65.0
VICC-154852	60	Female	White	PDAC	Primary	Deceased	G12D	R248Q	No	No	G12	Yes	60.0
VICC-158315	53	Female	White	PDAC	Primary	Deceased	G12D	R273C	No	No	G12	Yes	53.0
VICC-164363	56	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	56.0
VICC-166424	75	Male	White	PDAC	Metastasis	Deceased	Q61H	N239S	No	No	Q61	Yes	75.0
VICC-175200	63	Female	White	PDAC	Metastasis	Deceased	G12V	R248W	No	No	G12	Yes	63.0
VICC-176067	50	Female	White	PDAC	Metastasis	Deceased	G12V	R175H	No	No	G12	Yes	50.0
VICC-181416	39	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	39.0
VICC-186509	65	Male	White	PDAC	Primary	Deceased	G12V	L257Q	No	No	G12	Yes	65.0
VICC-186579	50	Female	White	PDAC	Primary	Deceased	G12D	R158H	No	No	G12	Yes	50.0
VICC-205475	37	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	37.0
VICC-206802	71	Male	Black/African-American	PDAC	Primary	Deceased	A146V	No	No	No	Other	No	71.0
VICC-209073	68	Male	White	PDAC	Primary	Deceased	G12V	Y220C	No	No	G12	Yes	68.0
VICC-225407	73	Male	White	PDAC	Metastasis	Deceased	G13R	No	No	No	G13	No	73.0
VICC-225822	71	Male	NA	PDAC	Metastasis	Deceased	G12D	E286K	No	No	G12	Yes	71.0
VICC-233619	69	Female	White	PDAC	Metastasis	Deceased	D33H,G12C	P152L	No	No	G12\|Other	Yes	69.0
VICC-235767	52	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	52.0
VICC-240161	66	Male	White	PDAC	Metastasis	Deceased	G12D	N131I	P114H	No	G12	Yes	66.0
VICC-241856	50	Female	White	Solid pseudopapillary tumor	Metastasis	Alive	No	No	No	No	No	No	50.0
VICC-242202	47	Male	NA	PDAC	Metastasis	Deceased	G12D	No	No	R496H	G12	No	47.0
VICC-245423	<18	Female	Black/African-American	Pancreatoblastoma	Primary	Alive	No	No	No	No	No	No	17.0
VICC-245893	81	Female	White	PDAC	Unknown	Deceased	G12V	No	No	No	G12	No	81.0
VICC-255801	63	Male	Black/African-American	PDAC	Metastasis	Deceased	G12R	L130R	No	No	G12	Yes	63.0
VICC-261118	41	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	41.0
VICC-266006	72	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	72.0
VICC-274498	47	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	47.0
VICC-279297	71	Male	White	PDAC	Metastasis	Alive	Q61H	No	No	No	Q61	No	71.0
VICC-285990	40	Male	White	PDAC	Metastasis	Deceased	No	E258D	No	No	No	Yes	40.0
VICC-289439	45	Male	White	PDAC	Primary	Deceased	G12R	H179R	No	No	G12	Yes	45.0
VICC-307271	64	Female	White	PDAC	Metastasis	Deceased	G12V	R273C	No	No	G12	Yes	64.0
VICC-308053	63	Female	White	PDAC	Metastasis	Deceased	G12V	P190L	No	No	G12	Yes	63.0
VICC-309197	70	Female	White	PDAC	Primary	Deceased	G12R	No	No	No	G12	No	70.0
VICC-316049	68	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	68.0
VICC-316564	57	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	57.0
VICC-322752	58	Female	White	PDAC	Primary	Deceased	Q61R	R175H	No	No	Q61	Yes	58.0
VICC-329078	57	Female	NA	PDAC	Primary	Deceased	G12A	M133T	No	No	G12	Yes	57.0
VICC-332184	67	Male	White	PDAC	Primary	Deceased	G12D	G245V	No	No	G12	Yes	67.0
VICC-332303	71	Male	White	PDAC	Metastasis	Deceased	G12_G13delinsVD	Y205C	No	No	G12\|G13	Yes	71.0
VICC-336377	64	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
VICC-342704	60	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	60.0
VICC-353604	50	Male	White	PDAC	Metastasis	Deceased	G12V	Q331H	No	No	G12	Yes	50.0
VICC-368886	65	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	65.0
VICC-381460	65	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	65.0
VICC-408077	58	Male	White	PDAC	Metastasis	Deceased	G12D	C176S	No	No	G12	Yes	58.0
VICC-413218	67	Female	White	PDAC	Metastasis	Deceased	G12D	R248W	No	No	G12	Yes	67.0
VICC-414156	73	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	73.0
VICC-417820	61	Female	White	PDAC	Unknown	Deceased	Q61H	No	No	R361H	Q61	No	61.0
VICC-421729	60	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	60.0
VICC-429093	61	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	61.0
VICC-432064	73	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	73.0
VICC-435884	70	Male	White	PDAC	Metastasis	Deceased	G12D	E285K	No	No	G12	Yes	70.0
VICC-442737	39	Female	White	PNET	Metastasis	Alive	No	No	No	No	No	No	39.0
VICC-443395	42	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	42.0
VICC-444111	59	Female	White	PDAC	Metastasis	Deceased	G12D	C275Y	No	No	G12	Yes	59.0
VICC-463583	66	Male	White	PDAC	Metastasis	Deceased	G12D	C238S	No	No	G12	Yes	66.0
VICC-477565	73	Female	Black/African-American	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	73.0
VICC-480089	53	Male	White	PDAC	Primary	Deceased	No	R175H	H83Y	No	No	Yes	53.0
VICC-518721	72	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	72.0
VICC-523368	48	Female	Black/African-American	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	48.0
VICC-524775	76	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	D351G	G12	No	76.0
VICC-525717	69	Female	White	PDAC	Metastasis	Deceased	Q61R	No	No	No	Q61	No	69.0
VICC-531988	65	Female	NA	PDAC	Primary	Alive	G12V	No	No	No	G12	No	65.0
VICC-533147	73	Female	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	73.0
VICC-545225	52	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	52.0
VICC-547494	56	Female	NA	PDAC	Metastasis	Deceased	No	R273C	No	No	No	Yes	56.0
VICC-549886	44	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	44.0
VICC-557899	35	Female	White	PDAC	Metastasis	Deceased	G13D	K132E	No	No	G13	Yes	35.0
VICC-560931	72	Male	White	PNET	Metastasis	Deceased	G12R	No	No	No	G12	No	72.0
VICC-562073	69	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	69.0
VICC-578340	58	Male	White	Carcinoma, NOS	Primary	Deceased	G12V	No	No	No	G12	No	58.0
VICC-589101	54	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	54.0
VICC-605684	69	Female	White	PDAC	Primary	Deceased	G13D,A11G	No	No	No	G13\|Other	No	69.0
VICC-607136	53	Female	NA	PDAC	Metastasis	Deceased	G12D	N239S	No	No	G12	Yes	53.0
VICC-607475	50	Female	White	PDAC	Metastasis	Deceased	G12D	R175H	No	R361C	G12	Yes	50.0
VICC-613062	48	Female	White	PNET	Primary	Deceased	No	No	No	No	No	No	48.0
VICC-623307	62	Male	Black/African-American	PDAC	Metastasis	Deceased	G12D	R282W	No	No	G12	Yes	62.0
VICC-631535	67	Male	White	PDAC	Metastasis	Deceased	No	Y220C	No	No	No	Yes	67.0
VICC-635705	70	Female	White	PDAC	Metastasis	Deceased	G12V	G245S	No	No	G12	Yes	70.0
VICC-639099	75	Male	White	PDAC	Metastasis	Deceased	G12V	Y205C	No	No	G12	Yes	75.0
VICC-644243	64	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
VICC-646240	79	Female	Asian	PDAC	Metastasis	Deceased	G12D	Y236C	No	No	G12	Yes	79.0
VICC-650961	55	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	55.0
VICC-668911	60	Female	White	PDAC	Metastasis	Alive	G12R	No	No	No	G12	No	60.0
VICC-670525	54	Male	White	PNET	Metastasis	Alive	No	No	No	No	No	No	54.0
VICC-674247	69	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	69.0
VICC-675369	37	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	37.0
VICC-682399	62	Female	White	PDAC	Metastasis	Alive	G12D	P278R	No	G386V	G12	Yes	62.0
VICC-682641	64	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	G365R	G12	No	64.0
VICC-685062	64	Male	White	Acinar cell carcinoma	Metastasis	Deceased	No	Y220H	No	No	No	Yes	64.0
VICC-698200	77	Female	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	77.0
VICC-708913	59	Male	White	PDAC	Metastasis	Deceased	G12D	G245S	No	No	G12	Yes	59.0
VICC-709419	54	Female	White	PNET	Primary	Alive	No	No	No	No	No	No	54.0
VICC-711398	60	Female	White	PDAC	Primary	Alive	G12D	E258G	No	No	G12	Yes	60.0
VICC-727725	53	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	53.0
VICC-734088	50	Female	NA	PDAC	Primary	Deceased	G12R	Y220C	No	No	G12	Yes	50.0
VICC-737679	64	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	64.0
VICC-746269	61	Female	White	PDAC	Primary	Deceased	G12D	Y220C	No	No	G12	Yes	61.0
VICC-749233	60	Female	White	PDAC	Primary	Deceased	G12R	R273H	No	No	G12	Yes	60.0
VICC-771800	69	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	69.0
VICC-780126	54	Female	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	54.0
VICC-783509	47	Male	White	PDAC	Metastasis	Deceased	G12D	No	E69G	No	G12	No	47.0
VICC-793238	55	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	55.0
VICC-807136	64	Female	White	PDAC	Metastasis	Alive	Q61K	S215R	No	No	Q61	Yes	64.0
VICC-807665	69	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	69.0
VICC-811256	49	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	49.0
VICC-823856	75	Male	Other	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	75.0
VICC-824975	70	Female	White	PDAC	Metastasis	Deceased	G12D	R175H	No	No	G12	Yes	70.0
VICC-832669	43	Female	Black/African-American	PNET	Metastasis	Alive	No	No	No	No	No	No	43.0
VICC-847871	70	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	70.0
VICC-856096	41	Male	Asian	PNET	Metastasis	Alive	No	No	No	No	No	No	41.0
VICC-859676	62	Male	White	PDAC	Metastasis	Deceased	G12R	G266V	No	No	G12	Yes	62.0
VICC-862421	63	Female	White	PDAC	Metastasis	Deceased	G12D	R248Q	No	No	G12	Yes	63.0
VICC-863832	68	Male	White	PDAC	Primary	Deceased	Q61H	No	No	No	Q61	No	68.0
VICC-889978	75	Female	White	PDAC	Primary	Alive	G12L	P278H	No	No	G12	Yes	75.0
VICC-900633	61	Female	White	PDAC	Primary	Deceased	G12D	No	V82G	No	G12	No	61.0
VICC-901805	73	Female	White	PDAC	Primary	Deceased	G12V	E258G	No	No	G12	Yes	73.0
VICC-909299	59	Male	White	PDAC	Metastasis	Deceased	G12C	No	No	No	G12	No	59.0
VICC-915567	56	Female	White	PDAC	Metastasis	Deceased	G12D	No	H83Y	No	G12	No	56.0
VICC-921500	18	Female	White	Solid pseudopapillary tumor	Metastasis	Alive	No	No	No	No	No	No	18.0
VICC-936268	66	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	66.0
VICC-949084	65	Male	White	PDAC	Metastasis	Deceased	G12R	R282W	No	No	G12	Yes	65.0
VICC-954188	69	Female	White	PDAC	Metastasis	Alive	G12V	R248Q	No	No	G12	Yes	69.0
VICC-963585	43	Female	White	PDAC	Primary	Deceased	G12D	I255F	No	No	G12	Yes	43.0
VICC-969908	67	Male	White	PDAC	Metastasis	Deceased	G12D	V143E	No	No	G12	Yes	67.0
VICC-973504	50	Female	NA	PDAC	Metastasis	Deceased	G12V	M237I	No	No	G12	Yes	50.0
VICC-974158	51	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	51.0
VICC-982872	71	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	71.0
VICC-987621	74	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	74.0
WAKE-F1022	70	Female	White	Acinar cell carcinoma	Unknown	Deceased	No	T125M	No	No	No	Yes	70.0
WAKE-F1026	67	Female	White	Acinar cell carcinoma	Primary	Deceased	G12R	No	No	No	G12	No	67.0
WAKE-F1050	66	Female	White	Acinar cell carcinoma	Primary	Deceased	No	No	No	No	No	No	66.0
WAKE-F1093	69	Female	White	Acinar cell carcinoma	Primary	Deceased	No	No	No	No	No	No	69.0
WAKE-F1100	65	Male	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	65.0
WAKE-F1187	46	Male	White	PDAC	Primary	Deceased	No	R175H	No	No	No	Yes	46.0
WAKE-F1195	58	Male	White	PDAC	Unknown	Deceased	G12R	No	No	No	G12	No	58.0
WAKE-F1202	56	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	56.0
WAKE-F1203	65	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	65.0
WAKE-F1240	54	Female	White	Acinar cell carcinoma	Primary	Deceased	No	V216M	No	No	No	Yes	54.0
WAKE-F1298	56	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	56.0
WAKE-F1312	49	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	49.0
WAKE-F1343	71	Female	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	H132N	No	No	71.0
WAKE-F1344	69	Male	White	PNET	Metastasis	Deceased	No	R337P	No	No	No	Yes	69.0
WAKE-F1356	68	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	68.0
WAKE-F1378	61	Female	White	Acinar cell carcinoma	Metastasis	Deceased	No	No	No	No	No	No	61.0
WAKE-F1383	58	Male	Black/African-American	PDAC	Primary	Deceased	No	No	No	No	No	No	58.0
WAKE-F1676	64	Male	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	64.0
WAKE-F1687	76	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	76.0
WAKE-F1691	67	Male	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	67.0
WAKE-F1703	55	Female	Black/African-American	PDAC	Unknown	Deceased	No	No	No	No	No	No	55.0
WAKE-F1724	64	Male	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	64.0
WAKE-F1739	48	Male	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	48.0
WAKE-F1740	72	Female	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	72.0
WAKE-F1745	74	Female	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	74.0
WAKE-F1753	76	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	76.0
WAKE-F1763	80	Female	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	80.0
WAKE-F1774	66	Female	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	66.0
WAKE-F1779	62	Female	Black/African-American	PDAC	Unknown	Deceased	No	No	No	No	No	No	62.0
WAKE-F1780	66	Female	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	66.0
WAKE-F1796	72	Female	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	72.0
WAKE-F1809	87	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	87.0
WAKE-F1813	62	Female	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	62.0
WAKE-F1815	52	Male	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	52.0
WAKE-F1819	58	Male	Black/African-American	PDAC	Unknown	Deceased	No	No	No	No	No	No	58.0
WAKE-F1836	74	Female	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	74.0
WAKE-F1837	62	Female	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	62.0
WAKE-F1853	78	Female	Black/African-American	PDAC	Unknown	Deceased	No	No	No	No	No	No	78.0
WAKE-F1860	78	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	78.0
WAKE-F1869	30	Male	Black/African-American	PDAC	Unknown	Deceased	No	No	No	No	No	No	30.0
WAKE-F1875	74	Male	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	74.0
WAKE-F1899	72	Female	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	72.0
WAKE-F1907	74	Female	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	74.0
WAKE-F1909	58	Male	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	58.0
WAKE-F1923	68	Male	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	68.0
WAKE-F1929	78	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	78.0
WAKE-F1994	69	Male	White	PNET	Primary	Deceased	No	No	No	No	No	No	69.0
WAKE-F1996	65	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	65.0
WAKE-F1999	75	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	75.0
WAKE-F2100	70	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	70.0
WAKE-F2121	44	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	44.0
WAKE-F2144	70	Male	White	PDAC	Primary	Deceased	G12D	R273L	No	No	G12	Yes	70.0
WAKE-F2184	66	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	66.0
WAKE-F2187	68	Male	White	Acinar cell carcinoma	Metastasis	Deceased	G12V	No	No	No	G12	No	68.0
WAKE-F2188	67	Female	Black/African-American	PDAC	Metastasis	Deceased	No	No	No	No	No	No	67.0
WAKE-F2189	72	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	72.0
WAKE-F2203	56	Female	White	PDAC	Primary	Deceased	G12D	G154D	No	No	G12	Yes	56.0
WAKE-F2205	75	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	75.0
WAKE-F2208	70	Female	White	PDAC	Unknown	Deceased	Q61P	No	No	No	Q61	No	70.0
WAKE-F2221	69	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	69.0
WAKE-F2254	63	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
WAKE-F2258	61	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	61.0
WAKE-F2275	71	Male	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	71.0
WAKE-F2291	63	Male	White	PDAC	Primary	Deceased	G12V	No	H83N	No	G12	No	63.0
WAKE-F2309	67	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	67.0
WAKE-F2315	58	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	58.0
WAKE-F2320	64	Male	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	64.0
WAKE-F2327	81	Male	White	PDAC	Metastasis	Deceased	G12D	R273L	No	No	G12	Yes	81.0
WAKE-F2365	65	Male	White	PNET	Metastasis	Deceased	No	No	No	No	No	No	65.0
WAKE-F2366	48	Male	White	PDAC	Metastasis	Deceased	G12V	R175L	No	No	G12	Yes	48.0
WAKE-F2370	73	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	73.0
WAKE-F2377	69	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	69.0
WAKE-F2387	58	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	58.0
WAKE-F2394	62	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	62.0
WAKE-F2395	52	Male	White	PDAC	Primary	Deceased	No	No	No	No	No	No	52.0
WAKE-F2442	53	Male	White	PDAC	Metastasis	Deceased	G12V	R175L	No	No	G12	Yes	53.0
WAKE-F2447	81	Male	White	PDAC	Primary	Deceased	G12V	No	No	D351A	G12	No	81.0
WAKE-F2451	69	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	69.0
WAKE-F2453	79	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	79.0
WAKE-F2462	71	Male	White	PDAC	Primary	Deceased	G12V	G245C	No	No	G12	Yes	71.0
WAKE-F2476	62	Male	Black/African-American	PDAC	Primary	Deceased	G12D	M246T	No	No	G12	Yes	62.0
WAKE-F2478	70	Male	Black/African-American	PDAC	Primary	Deceased	G12S	I195S	No	No	G12	Yes	70.0
WAKE-F2483	71	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	71.0
WAKE-F2493	55	Female	Black/African-American	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	55.0
WAKE-F2495	74	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	74.0
WAKE-F2498	65	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	65.0
WAKE-F2519	74	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	74.0
WAKE-F2537	82	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	82.0
WAKE-F2616	67	Female	White	PDAC	Metastasis	Deceased	G12D	G245C	No	No	G12	Yes	67.0
WAKE-F2619	60	Female	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	60.0
WAKE-F2649	61	Female	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	61.0
WAKE-F2667	68	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	68.0
WAKE-F2676	64	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	64.0
WAKE-F2685	56	Female	White	PDAC	Metastasis	Deceased	No	V173G	No	No	No	Yes	56.0
WAKE-F2695	71	Male	White	PDAC	Metastasis	Deceased	G12D	No	No	No	G12	No	71.0
WAKE-F2702	53	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	53.0
WAKE-F2704	76	Male	White	PDAC	Metastasis	Deceased	G12V	No	D84Y	No	G12	No	76.0
WAKE-F2705	50	Female	White	PDAC	Primary	Deceased	No	No	No	G352R	No	No	50.0
WAKE-F2709	69	Female	Asian	PDAC	Primary	Deceased	G12D	N239H	No	No	G12	Yes	69.0
WAKE-F2721	68	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	68.0
WAKE-F2731	69	Male	White	PDAC	Metastasis	Deceased	No	Y236H	No	No	No	Yes	69.0
WAKE-F2773	53	Male	White	PDAC	Primary	Deceased	G12D	T211N	No	No	G12	Yes	53.0
WAKE-F2784	63	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	63.0
WAKE-F2786	57	Male	Black/African-American	PDAC	Metastasis	Deceased	No	No	No	No	No	No	57.0
WAKE-F2791	60	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	60.0
WAKE-F2829	68	Male	White	PDAC	Metastasis	Deceased	G12V	R273L	No	No	G12	Yes	68.0
WAKE-F2837	70	Male	White	PDAC	Unknown	Deceased	No	No	No	No	No	No	70.0
WAKE-F2846	69	Female	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	69.0
WAKE-F2848	45	Male	White	PDAC	Primary	Deceased	G12V	R273L	No	No	G12	Yes	45.0
WAKE-F2879	51	Male	Black/African-American	PDAC	Metastasis	Deceased	No	Q165K	No	No	No	Yes	51.0
WAKE-F2882	79	Female	White	PDAC	Primary	Deceased	G12D	G266E	No	No	G12	Yes	79.0
WAKE-F2883	64	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	64.0
WAKE-F2906	72	Female	Black/African-American	PDAC	Primary	Deceased	No	No	No	No	No	No	72.0
WAKE-F2911	70	Male	Black/African-American	PDAC	Primary	Deceased	G12S	No	No	C363G	G12	No	70.0
WAKE-F2914	74	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	74.0
WAKE-F2918	79	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	79.0
WAKE-F2930	59	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	59.0
WAKE-F2953	60	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	60.0
WAKE-F2985	64	Male	Other	PDAC	Metastasis	Deceased	No	No	No	No	No	No	64.0
WAKE-F2990	69	Female	White	PDAC	Primary	Deceased	G13V	No	No	No	G13	No	69.0
WAKE-F3015	63	Female	Black/African-American	PDAC	Metastasis	Deceased	No	No	No	No	No	No	63.0
YALE-TPL1011	73	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	73.0
YALE-TPL1060	71	Female	White	PDAC	Primary	Alive	G12V	No	No	No	G12	No	71.0
YALE-TPL1079	48	Male	White	PDAC	Metastasis	Alive	G12V	No	No	R361H	G12	No	48.0
YALE-TPL1125	73	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	73.0
YALE-TPL1138	51	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	51.0
YALE-TPL1155	55	Male	White	PDAC	Metastasis	Deceased	No	No	No	No	No	No	55.0
YALE-TPL1156	72	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	72.0
YALE-TPL1163	82	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	82.0
YALE-TPL1177	75	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	75.0
YALE-TPL1219	84	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	84.0
YALE-TPL1246	87	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	87.0
YALE-TPL1263	57	Female	White	PDAC	Primary	Deceased	No	No	No	No	No	No	57.0
YALE-TPL1270	54	Female	White	PDAC	Primary	Alive	No	No	No	No	No	No	54.0
YALE-TPL1278	36	Female	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	36.0
YALE-TPL128	66	Female	White	PDAC	Primary	Alive	G12D	Y220C	No	No	G12	Yes	66.0
YALE-TPL1282	75	Male	Other	PDAC	Metastasis	Alive	No	No	No	No	No	No	75.0
YALE-TPL1295	55	Female	White	Acinar cell carcinoma	Metastasis	Alive	No	No	No	No	No	No	55.0
YALE-TPL1307	71	Male	NA	PDAC	Metastasis	Deceased	No	No	No	No	No	No	71.0
YALE-TPL1311	78	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	78.0
YALE-TPL1320	77	Female	White	Adenosquamous carcinoma	Metastasis	Alive	No	No	No	No	No	No	77.0
YALE-TPL1321	64	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	64.0
YALE-TPL1332	83	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	83.0
YALE-TPL155	81	Female	Black/African-American	PDAC	Primary	Deceased	G12D	P250L	No	No	G12	Yes	81.0
YALE-TPL162	56	Female	Other	PDAC	Metastasis	Alive	No	H179R	No	No	No	Yes	56.0
YALE-TPL212	56	Female	White	PDAC	Metastasis	Deceased	G12V	No	No	No	G12	No	56.0
YALE-TPL218	72	Male	White	PDAC	Metastasis	Alive	G12V	C141Y	No	No	G12	Yes	72.0
YALE-TPL252	72	Male	NA	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	72.0
YALE-TPL278	59	Male	White	PDAC	Primary	Alive	G12V	R273H	No	No	G12	Yes	59.0
YALE-TPL284	49	Male	White	PDAC	Metastasis	Alive	G12D	L194F	No	No	G12	Yes	49.0
YALE-TPL288	59	Female	Other	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	59.0
YALE-TPL30	77	Female	White	PDAC	Metastasis	Alive	G12D	P151S	No	No	G12	Yes	77.0
YALE-TPL325	64	Female	White	PDAC	Metastasis	Deceased	G12D	H179L	No	No	G12	Yes	64.0
YALE-TPL346	66	Female	White	PDAC	Metastasis	Deceased	G12V	G245S	No	No	G12	Yes	66.0
YALE-TPL354	73	Female	White	PDAC	Metastasis	Deceased	G12V	Y126C	No	No	G12	Yes	73.0
YALE-TPL388	56	Female	Black/African-American	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	56.0
YALE-TPL44	52	Female	White	PDAC	Primary	Deceased	G12V	L194R	No	No	G12	Yes	52.0
YALE-TPL443	63	Female	White	PDAC	Metastasis	Alive	G12V	G244R	No	No	G12	Yes	63.0
YALE-TPL450	64	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	64.0
YALE-TPL466	69	Female	Asian	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	69.0
YALE-TPL478	56	Female	White	PDAC	Primary	Alive	G12R	R282W	No	No	G12	Yes	56.0
YALE-TPL514	75	Male	White	PDAC	Metastasis	Deceased	G12V	C176R	No	No	G12	Yes	75.0
YALE-TPL52	78	Female	White	PDAC	Metastasis	Alive	G12V	R158G	No	No	G12	Yes	78.0
YALE-TPL532	74	Male	White	PDAC	Metastasis	Alive	G12V	No	No	No	G12	No	74.0
YALE-TPL565	71	Male	White	PDAC	Metastasis	Alive	G12V	Y220C	No	No	G12	Yes	71.0
YALE-TPL569	67	Female	White	PDAC	Primary	Alive	G12D	V272E	No	No	G12	Yes	67.0
YALE-TPL574	60	Male	White	Carcinoma, NOS	Primary	Deceased	G12D	No	No	No	G12	No	60.0
YALE-TPL58	67	Female	White	PDAC	Primary	Deceased	G12V	No	No	No	G12	No	67.0
YALE-TPL580	62	Female	White	PDAC	Metastasis	Alive	G12D	L257P	No	No	G12	Yes	62.0
YALE-TPL588	68	Male	White	PDAC	Primary	Alive	G12V	I195T	No	No	G12	Yes	68.0
YALE-TPL652	53	Male	White	PDAC	Primary	Alive	No	No	No	No	No	No	53.0
YALE-TPL66	65	Female	White	PDAC	Metastasis	Alive	E62V,Q61R	P278S	No	No	Q61\|Other	Yes	65.0
YALE-TPL666	76	Female	Black/African-American	PDAC	Metastasis	Deceased	G12R	No	No	No	G12	No	76.0
YALE-TPL681	80	Female	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	80.0
YALE-TPL689	79	Male	White	PDAC	Primary	Deceased	G12D	G266V	No	V370D	G12	Yes	79.0
YALE-TPL701	77	Male	White	PDAC	Primary	Deceased	G12D	No	No	No	G12	No	77.0
YALE-TPL763	55	Female	White	PDAC	Metastasis	Alive	G12D	Y220C	No	No	G12	Yes	55.0
YALE-TPL789	68	Male	White	PDAC	Metastasis	Deceased	No	G244D	D108H	No	No	Yes	68.0
YALE-TPL799	57	Male	White	PDAC	Metastasis	Alive	G12D	No	No	R361G	G12	No	57.0
YALE-TPL841	66	Female	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	66.0
YALE-TPL864	64	Female	White	PDAC	Metastasis	Alive	Q61H	No	No	G386V	Q61	No	64.0
YALE-TPL893	60	Female	NA	PDAC	Metastasis	Alive	G12R	No	H83Y	No	G12	No	60.0
YALE-TPL900	59	Female	White	PDAC	Primary	Alive	Q61H	S241F	No	No	Q61	Yes	59.0
YALE-TPL906	68	Male	White	PDAC	Metastasis	Alive	G12D	No	No	No	G12	No	68.0
YALE-TPL913	66	Male	White	PDAC	Primary	Alive	G12D	No	No	No	G12	No	66.0
YALE-TPL914	67	Female	White	PDAC	Primary	Alive	Q61H	No	No	R361H	Q61	No	67.0
YALE-TPL918	79	Male	White	PDAC	Metastasis	Alive	No	No	No	No	No	No	79.0
YALE-TPL936	60	Male	White	PDAC	Metastasis	Alive	Q61H	R175H	No	W524C	Q61	Yes	60.0
YALE-TPL937	58	Female	Black/African-American	PDAC	Metastasis	Alive	G12D	R175H	No	No	G12	Yes	58.0
YALE-TPL951	82	Male	White	PDAC	Metastasis	Alive	G12D	T211I	No	No	G12	Yes	82.0
YALE-TPL952	62	Female	White	PDAC	Metastasis	Deceased	G12V	G244D	No	No	G12	Yes	62.0
YALE-TPL984	76	Female	White	PDAC	Metastasis	Alive	G12V	C238Y	No	No	G12	Yes	76.0
YALE-TPL990	63	Female	White	Carcinoma, NOS	Primary	Alive	Q61H	No	No	No	Q61	No	63.0
YALE-TPL992	70	Male	White	PDAC	Primary	Alive	G12D	S241C	H83Y	No	G12	Yes	70.0

Overview

Help

Age at Sample Sequencing

Diagnosis

Tumor Type

Race

KRAS Missense Mutation

TP53 Missense Mutation

Patient Statistics

Help

Sex

Age at Sample Sequencing

Race

Tumour Statistics

Help

Tumor Type

Missense Mutation - KRAS

Missense Mutation - TP53

Cohort Summary

Help

Variant Identification

Oncoplot help

Top genes:

LolliPlot help

Select gene (Top 250 mutated):

Somatic Interactions help

TCGA Compare help

Drug Prediction

Cancer Genome Interpreter (CGI) help

% of patients for alluvial plot:

CGI Biomarker CGI Bioactivity

Gene	Protein Alteration	Alteration Match	Drug	Effect	Tumour	Evidence
CTNNB1	S33A	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	S33A	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
NOTCH2	V276G	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NRAS	Q61R	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
NRAS	Q61R	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
NRAS	Q61R	Complete Match	MEK inhibitor	Responsive	CM	Late trials
NRAS	Q61R	Complete Match	BRAF inhibitor	Resistant	CM	Early trials
NRAS	Q61R	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CM	Early trials
NRAS	Q61R	Complete Match	HSP90 inhibitor	Responsive	CM	Pre-clinical
NRAS	Q61R	Complete Match	MEK inhibitor	Responsive	AML, LUAD, ALL	Pre-clinical
NRAS	Q61R	Complete Match	Pan-RAF inhibitor	Responsive	CM	Case report
NRAS	Q61R	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
NRAS	Q61R	Complete Match	ERK inhibitor	Responsive	CM	Case report
NRAS	Q61R	Complete Match	MEK inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
NRAS	Q61R	Complete Match	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NRAS	Q61R	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	MYMA	Pre-clinical
NRAS	Q61R	Different Mutation	ERK inhibitor	Responsive	CANCER	Pre-clinical
KRAS	G12V	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12V	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12V	Complete Match	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12V	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12V	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12V	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12V	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12V	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12V	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12V	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12V	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12V	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12V	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12V	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12V	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12V	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12V	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12V	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12V	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12V	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12V	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12V	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12V	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12V	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12V	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12V	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12V	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12V	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12V	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12V	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12V	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12V	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12V	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12V	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12V	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12V	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	E221*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E221*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E221*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E221*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E221*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E221*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E221*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E221*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E221*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E221*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E221*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E221*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E221*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E221*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E221*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KRAS	G12D	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12D	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12D	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12D	Complete Match	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12D	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12D	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12D	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12D	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12D	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12D	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12D	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12D	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12D	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12D	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12D	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12D	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12D	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12D	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12D	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12D	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12D	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12D	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12D	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12D	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12D	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12D	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12D	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12D	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12D	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12D	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12D	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12D	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12D	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12D	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12D	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12D	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	R175H	Complete Match	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R175H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R175H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R175H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R175H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R175H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R175H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R175H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R175H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R175H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R175H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
AKT3	splice_donor_variant	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
FLT1	splice_donor_variant	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	R	Pre-clinical
FBXW7	G499C	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	G499C	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	G499C	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	G499C	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
TSC2	splice_donor_variant	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	splice_donor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	splice_donor_variant	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	splice_donor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	splice_donor_variant	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	splice_donor_variant	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	splice_donor_variant	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
ROS1	W1803L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	W1803L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	W1803L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	W1803L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	W1803L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
MET	S960L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
MSH2	splice_acceptor_variant	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
MSH2	splice_acceptor_variant	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRAF	E611*	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	E611*	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	E611*	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	E611*	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
ALK	H368Q	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	H368Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	H368Q	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	H368Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	H368Q	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	H368Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	H368Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	H368Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	H368Q	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	H368Q	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	H368Q	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	H368Q	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	H368Q	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	H368Q	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	H368Q	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	H368Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	H368Q	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	H368Q	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	H368Q	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
TP53	R273H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R273H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R273H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R273H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R273H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R273H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R273H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R273H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R273H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R273H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R273H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R273H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R273H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R273H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R273H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2D	E3117), MLL2 MUT (G3666	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
NF2	splice_acceptor_variant	Complete Match	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	splice_acceptor_variant	Complete Match	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	splice_acceptor_variant	Complete Match	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	splice_acceptor_variant	Complete Match	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	splice_acceptor_variant	Complete Match	MTOR inhibitor	Responsive	MEN	Pre-clinical
NF2	splice_acceptor_variant	Complete Match	Lapatinib (ERBB2 inhibitor)	Responsive	NF, SCHW	Early trials
NF2	splice_acceptor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	splice_acceptor_variant	Complete Match	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	splice_acceptor_variant	Complete Match	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	splice_acceptor_variant	Complete Match	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	splice_acceptor_variant	Complete Match	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	splice_acceptor_variant	Complete Match	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	splice_acceptor_variant	Complete Match	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	splice_acceptor_variant	Complete Match	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	splice_acceptor_variant	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	splice_acceptor_variant	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	splice_acceptor_variant	Different Alteration	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	splice_acceptor_variant	Different Alteration	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	splice_acceptor_variant	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	splice_acceptor_variant	Different Alteration	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	splice_acceptor_variant	Different Alteration	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	splice_acceptor_variant	Different Alteration	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	splice_acceptor_variant	Different Alteration	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	splice_acceptor_variant	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	splice_acceptor_variant	Different Alteration	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	splice_acceptor_variant	Different Alteration	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	splice_acceptor_variant	Different Alteration	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	splice_acceptor_variant	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	splice_acceptor_variant	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	SCHW, NF	Early trials
NF2	splice_acceptor_variant	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	splice_acceptor_variant	Different Alteration	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	splice_acceptor_variant	Different Alteration	MTOR inhibitor	Responsive	MEN	Pre-clinical
NOTCH1	Q1155H	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	Q1155H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRD4	P867T	Different Alteration	BET inhibitor	Responsive	NMC	Case report
BCOR	E948*	Complete Match	Enzastaurin (PKCb inhibitor)	Responsive	ST	Pre-clinical
ABL1	R674W	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	R674W	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R674W	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	R674W	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R674W	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	R674W	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
KRAS	G12R	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12R	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12R	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12R	Complete Match	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12R	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12R	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12R	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12R	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12R	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12R	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12R	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12R	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12R	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12R	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12R	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12R	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12R	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12R	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12R	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12R	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12R	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12R	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12R	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12R	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12R	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12R	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12R	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12R	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12R	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12R	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12R	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12R	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12R	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12R	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12R	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12R	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	M237I	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	M237I	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	M237I	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	M237I	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	M237I	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	M237I	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M237I	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M237I	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M237I	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	M237I	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	M237I	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	M237I	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M237I	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	M237I	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M237I	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R196*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R196*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R196*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R196*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R196*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R196*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R196*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R196*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R196*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R196*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R196*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R196*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R196*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R196*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R196*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FBXW7	splice_acceptor_variant	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	splice_acceptor_variant	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	splice_acceptor_variant	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	splice_acceptor_variant	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
TP53	I162F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I162F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I162F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I162F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I162F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I162F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I162F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I162F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I162F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I162F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I162F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I162F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I162F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I162F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I162F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KRAS	Q61K	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61K	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61K	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	Q61K	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	Q61K	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	Q61K	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	Q61K	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	Q61K	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61K	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61K	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	Q61K	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	Q61K	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61K	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	Q61K	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	Q61K	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	Q61K	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	Q61K	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	Q61K	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	Q61K	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	Q61K	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61K	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	Q61K	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61K	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	Q61K	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	Q61K	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61K	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	Q61K	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61K	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	Q61K	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	Q61K	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	Q61K	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	Q61K	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	Q61K	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61K	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61K	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	Q61K	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61K	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	Q61K	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61K	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	Q61K	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	Q61K	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	Q61K	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	R248G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R248G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R248G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R248G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R248G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R248G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R248G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R248G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R248G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R248G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R248G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	E1205D	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
APC	R1450), APC MUT (S943	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
ALK	E152D	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	E152D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	E152D	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	E152D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	E152D	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	E152D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	E152D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	E152D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	E152D	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	E152D	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	E152D	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	E152D	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	E152D	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	E152D	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	E152D	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	E152D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	E152D	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	E152D	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	E152D	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ATM	R250*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R250*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R250*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R250*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R250*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R250*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R250*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R250*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R250*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R250*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R250*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R250*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R250*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
JAK2	K850N	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
PIK3CA	R88Q	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	R88Q	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	R88Q	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	R88Q	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	R88Q	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	R88Q	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	R88Q	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	R88Q	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	R88Q	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	R88Q	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	R88Q	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	R88Q	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	R88Q	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	R88Q	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
PTEN	E7*	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	E7*	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	E7*	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	E7*	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	E7*	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	E7*	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	E7*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	E7*	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	E7*	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	E7*	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	E7*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	E7*	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	E7*	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	E7*	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	E7*	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	E7*	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	E7*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	E7*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	E7*	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	E7*	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	E7*	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	E7*	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	E7*	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	E7*	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	E7*	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PDGFRA	M900L), PDGFRA MUT* (R585K	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
PBRM1	R710*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	R710*	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	R710*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	R710*	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	R710*	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
KRAS	A146T	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	A146T	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	A146T	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	A146T	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	A146T	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	A146T	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	A146T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	A146T	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	A146T	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	A146T	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	A146T	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	A146T	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	A146T	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	A146T	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	A146T	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	A146T	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	A146T	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	A146T	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	A146T	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	A146T	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	A146T	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	A146T	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	A146T	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	A146T	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	A146T	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	A146T	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	A146T	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	A146T	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	A146T	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	A146T	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	A146T	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	A146T	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	A146T	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	A146T	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	A146T	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	A146T	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	A146T	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	A146T	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	A146T	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	A146T	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	A146T	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	A146T	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
FAT1	E1147), FAT1 MUT (R2597	Complete Match	BET inhibitor	Responsive	HNSC	Pre-clinical
FLT1	R224*	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	R	Pre-clinical
FBXW7	E369*	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	E369*	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	E369*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	E369*	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
TSC1	E813*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC1	E813*	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC1	E813*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA	FDA guidelines
TSC1	E813*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	ST, S	Case report
TSC1	E813*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	R	Case report
TSC1	E813*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	GCA	FDA guidelines
TSC1	E813*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Case report
TP53	R213*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R213*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R213*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R213*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R213*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R213*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R213*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R213*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R213*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R213*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R213*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R213*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R213*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R213*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R213*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	Y1631H), ROS1 MUT* (E2201*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	Y1631H), ROS1 MUT* (E2201*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	Y1631H), ROS1 MUT* (E2201*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	Y1631H), ROS1 MUT* (E2201*	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	Y1631H), ROS1 MUT* (E2201*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
KMT2A	S3643R), MLL MUT* (L2037I), MLL MUT* (V1443A), MLL MUT* (R173*	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S3643R), MLL MUT* (L2037I), MLL MUT* (V1443A), MLL MUT* (R173*	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S3643R), MLL MUT* (L2037I), MLL MUT* (V1443A), MLL MUT* (R173*	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S3643R), MLL MUT* (L2037I), MLL MUT* (V1443A), MLL MUT* (R173*	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S3643R), MLL MUT* (L2037I), MLL MUT* (V1443A), MLL MUT* (R173*	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S3643R), MLL MUT* (L2037I), MLL MUT* (V1443A), MLL MUT* (R173*	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NTRK1	D109Y	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	D109Y	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	D109Y	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	D109Y	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
BCOR	S214*	Complete Match	Enzastaurin (PKCb inhibitor)	Responsive	ST	Pre-clinical
TP53	R248W	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R248W	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R248W	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R248W	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R248W	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R248W	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R248W	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248W	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248W	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R248W	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R248W	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R248W	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248W	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R248W	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248W	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KRAS	G12C	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12C	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12C	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12C	Complete Match	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12C	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12C	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12C	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12C	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12C	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12C	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12C	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12C	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12C	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12C	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12C	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12C	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12C	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12C	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12C	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12C	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12C	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12C	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12C	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12C	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12C	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12C	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12C	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12C	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12C	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12C	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12C	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12C	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12C	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12C	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12C	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12C	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12C	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12C	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12C	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12C	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12C	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
KRAS	Q61H	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61H	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61H	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	Q61H	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	Q61H	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	Q61H	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	Q61H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	Q61H	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61H	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61H	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	Q61H	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	Q61H	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61H	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	Q61H	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	Q61H	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	Q61H	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	Q61H	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	Q61H	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	Q61H	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	Q61H	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61H	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	Q61H	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61H	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	Q61H	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	Q61H	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61H	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	Q61H	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61H	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	Q61H	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	Q61H	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	Q61H	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	Q61H	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	Q61H	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61H	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61H	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	Q61H	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61H	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	Q61H	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61H	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	Q61H	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	Q61H	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	Q61H	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	P278R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P278R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P278R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P278R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P278R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P278R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P278R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P278R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P278R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P278R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P278R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P278R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P278R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P278R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P278R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	H1926Y	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	H1926Y	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	H1926Y	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	H1926Y	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	H1926Y	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ATR	Q39*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATR	Q39*	Complete Match	Olaparib (PARP inhibitor)	Responsive	CANCER, OV	Pre-clinical
ATR	Q39*	Different Alteration	Olaparib (PARP inhibitor)	Responsive	OV, CANCER	Pre-clinical
TP53	A138V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	A138V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	A138V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	A138V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	A138V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	A138V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	A138V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A138V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A138V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	A138V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	A138V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	A138V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A138V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	A138V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A138V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	splice_donor_variant	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	splice_donor_variant	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	splice_donor_variant	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	splice_donor_variant	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	splice_donor_variant	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	splice_donor_variant	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	splice_donor_variant	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	splice_donor_variant	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	splice_donor_variant	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	splice_donor_variant	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	splice_donor_variant	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	splice_donor_variant	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	splice_donor_variant	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	splice_donor_variant	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	splice_donor_variant	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	N267D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	N267D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	N267D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	N267D	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	N267D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
CHEK2	Q358*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
CHEK2	Q358*	Different Alteration	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
SMARCA4	R381*	Complete Match	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	R381*	Complete Match	AURKA inhibitor	Responsive	NSCLC	Pre-clinical
SMARCA4	R381*	Complete Match	EZH2 inhibitor	Responsive	OV	Case report
SMARCA4	R381*	Different Alteration	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	R381*	Different Alteration	EZH2 inhibitor	Responsive	OV	Case report
PTPRD	E1682*	Complete Match	IGF1R inhibitor	Responsive	S	Case report
TP53	C176G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C176G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C176G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C176G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C176G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C176G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C176G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C176G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C176G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C176G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C176G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	M2255I	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	M2255I	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	D259V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	D259V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	D259V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	D259V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	D259V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	D259V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	D259V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D259V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D259V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	D259V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	D259V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	D259V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D259V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	D259V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D259V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FGFR2	A140T	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	A140T	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
TP53	R282W	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R282W	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R282W	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R282W	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R282W	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R282W	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R282W	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R282W	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R282W	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R282W	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R282W	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R282W	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R282W	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R282W	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R282W	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	NCCN guidelines
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	G469A	Complete Match	ERK inhibitor	Responsive	HNSC, BT	Case report
BRAF	G469A	Complete Match	EGFR TK inhibitor	Resistant	LUAD	Case report
BRAF	G469A), BRAF MUT (G469*	Different Mutation	MEK inhibitor	Responsive	CM	Case report
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	BRAF inhibitor	Responsive	CM	Case report
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	BRAF inhibitor;HSP90 inhibitor	Responsive	CM	Pre-clinical
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	G469A), BRAF MUT (G469*	Different Mutation	MEK inhibitor	Responsive	TH	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	BRAF inhibitor;PI3K pathway inhibitor	Responsive	CM	Pre-clinical
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	G469A), BRAF MUT (G469*	Different Mutation	BRAF inhibitor;CDK2/4 inhibitor	Responsive	CM	Pre-clinical
BRAF	G469A), BRAF MUT (G469*	Different Mutation	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	G469A), BRAF MUT (G469*	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	G469A), BRAF MUT (G469*	Different Mutation	BRAF inhibitor	Responsive	OV	Case report
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469A), BRAF MUT (G469*	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	G469A), BRAF MUT (G469*	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	G469A), BRAF MUT (G469*	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	G469A), BRAF MUT (G469*	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	G469A), BRAF MUT (G469*	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TP53	R273C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R273C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R273C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R273C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R273C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R273C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R273C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R273C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R273C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R273C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R273C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R273C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R273C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R273C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R273C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
MET	H1097R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
CDKN2A	E33*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E33*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E33*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	E33*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E33*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E33*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E33*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E33*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
BCR	V590M	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
BCR	V590M	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
BCR	V590M	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	V590M	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	V590M	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
BCR	V590M	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
NTRK1	H151Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	H151Q	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	H151Q	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	H151Q	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
NOTCH1	G2126A	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	G2126A	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRD4	I300V	Different Alteration	BET inhibitor	Responsive	NMC	Case report
BCR	H184Q	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
BCR	H184Q	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
BCR	H184Q	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	H184Q	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	H184Q	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
BCR	H184Q	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ROS1	Y1593F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	Y1593F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	Y1593F	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	Y1593F	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	Y1593F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ERBB4	R47*	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	CM	Pre-clinical
ERBB4	R47*	Different Mutation	ERBB2 inhibitor	Resistant	BRCA	Case report
ERBB4	R47*	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
PDGFRA	S643Y	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
TP53	R156C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R156C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R156C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R156C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R156C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R156C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R156C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R156C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R156C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R156C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R156C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R156C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R156C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R156C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R156C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
DNMT3A	splice_donor_variant	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
NOTCH1	G49C	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	G49C	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BCR	M998I	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
BCR	M998I	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
BCR	M998I	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	M998I	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	M998I	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
BCR	M998I	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ROS1	A87T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	A87T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	A87T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	A87T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	A87T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
TP53	Q331*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q331*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q331*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q331*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q331*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q331*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q331*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q331*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q331*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q331*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q331*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q331*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q331*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q331*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q331*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ESR1	S341L	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
JAK2	G276A	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
TP53	P151S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P151S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P151S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P151S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P151S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P151S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P151S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P151S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P151S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P151S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P151S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P151S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P151S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P151S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P151S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH2	R1719Q	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
CDKN2A	H83Y	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	H83Y	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	H83Y	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	H83Y	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	H83Y	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	H83Y	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	H83Y	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	H83Y	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
TP53	M246V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	M246V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	M246V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	M246V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	M246V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	M246V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M246V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M246V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M246V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	M246V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	M246V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	M246V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M246V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	M246V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M246V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	T1379M	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	T1379M	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	K132M	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	K132M	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	K132M	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	K132M	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	K132M	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	K132M	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	K132M	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K132M	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K132M	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	K132M	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	K132M	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	K132M	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K132M	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	K132M	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K132M	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRD4	S795F	Different Alteration	BET inhibitor	Responsive	NMC	Case report
TP53	Q144P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q144P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q144P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q144P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q144P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q144P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q144P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q144P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q144P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q144P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q144P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q144P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q144P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q144P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q144P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RNF43	R132*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
TP53	Y220C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y220C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y220C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y220C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y220C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y220C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y220C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y220C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y220C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y220C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y220C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y220C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y220C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y220C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y220C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H214R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H214R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H214R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H214R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H214R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H214R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H214R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H214R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H214R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H214R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H214R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H214R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H214R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H214R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H214R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R249S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R249S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R249S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R249S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R249S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R249S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R249S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R249S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R249S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R249S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R249S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R249S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R249S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R249S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R249S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ABL1	V268L	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	V268L	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	V268L	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	V268L	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	V268L	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	V268L	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
TP53	M133K	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	M133K	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	M133K	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	M133K	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	M133K	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	M133K	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M133K	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M133K	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M133K	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	M133K	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	M133K	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	M133K	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M133K	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	M133K	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M133K	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRAF	V600E	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	V600E	Complete Match	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	V600E	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	NCCN guidelines
BRAF	V600E	Complete Match	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600E	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600E	Complete Match	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600E	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	V600E	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	V600E	Different Mutation	ERK inhibitor	Responsive	HNSC, BT	Case report
BRAF	V600E	Complete Match	EGFR TK inhibitor	Resistant	LUAD	Case report
BRAF	V600E	Different Mutation	MEK inhibitor	Responsive	CM	Case report
BRAF	V600E	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	V600E	Different Mutation	BRAF inhibitor	Responsive	CM	Case report
BRAF	V600E	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	V600E	Complete Match	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	V600E	Complete Match	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	V600E	Complete Match	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	V600E	Complete Match	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	V600E	Complete Match	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	V600E	Complete Match	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	V600E	Complete Match	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	V600E	Complete Match	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	V600E	Complete Match	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	V600E	Complete Match	BRAF inhibitor;HSP90 inhibitor	Responsive	CM	Pre-clinical
BRAF	V600E	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	V600E	Complete Match	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	V600E	Complete Match	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	V600E	Complete Match	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	V600E	Complete Match	MEK inhibitor	Responsive	TH	Early trials
BRAF	V600E	Complete Match	BRAF inhibitor;PI3K pathway inhibitor	Responsive	CM	Pre-clinical
BRAF	V600E	Complete Match	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	V600E	Complete Match	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	V600E	Complete Match	Vemurafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600E	Complete Match	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	V600E	Complete Match	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	V600E	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	V600E	Complete Match	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	V600E	Complete Match	BRAF inhibitor;CDK2/4 inhibitor	Responsive	CM	Pre-clinical
BRAF	V600E	Complete Match	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	V600E	Complete Match	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	V600E	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	V600E	Complete Match	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	V600E	Complete Match	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	V600E	Complete Match	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	V600E	Complete Match	BRAF inhibitor	Responsive	OV	Case report
BRAF	V600E	Complete Match	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	V600E	Complete Match	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600E	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	V600E	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	V600E	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	V600E	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	V600E	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
FBXW7	R479Q	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	R479Q	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	R479Q	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	R479Q	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
ESR1	A148T	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
JAK2	D894G	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
TP53	E51*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E51*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E51*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E51*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E51*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E51*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E51*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E51*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E51*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E51*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E51*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E51*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E51*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E51*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E51*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	intron_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	intron_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	intron_variant	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	intron_variant	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	intron_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
TP53	Q192*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q192*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q192*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q192*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q192*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q192*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q192*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q192*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q192*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q192*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q192*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q192*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q192*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q192*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q192*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	splice_acceptor_variant	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	splice_acceptor_variant	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	splice_acceptor_variant	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	splice_acceptor_variant	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	splice_acceptor_variant	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	splice_acceptor_variant	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	splice_acceptor_variant	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	splice_acceptor_variant	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
TP53	S215I	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S215I	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S215I	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S215I	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S215I	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S215I	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S215I	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S215I	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S215I	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S215I	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S215I	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S215I	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S215I	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S215I	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S215I	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C135Y	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C135Y	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C135Y	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C135Y	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C135Y	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C135Y	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C135Y	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C135Y	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C135Y	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C135Y	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C135Y	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C135Y	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C135Y	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C135Y	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C135Y	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	Y129*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	Y129*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	Y129*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	Y129*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	Y129*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	Y129*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	Y129*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	Y129*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
BCR	T634M	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
BCR	T634M	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
BCR	T634M	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	T634M	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	T634M	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
BCR	T634M	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
RAF1	T310A	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	T310A	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	T310A	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
CDKN2A	W110*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	W110*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	W110*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	W110*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	W110*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	W110*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	W110*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	W110*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	G101W	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	G101W	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	G101W	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	G101W	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	G101W	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	G101W	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	G101W	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	G101W	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
TP53	splice_acceptor_variant	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	splice_acceptor_variant	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	splice_acceptor_variant	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	splice_acceptor_variant	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	splice_acceptor_variant	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	splice_acceptor_variant	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	splice_acceptor_variant	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	splice_acceptor_variant	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	splice_acceptor_variant	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	splice_acceptor_variant	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	splice_acceptor_variant	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	splice_acceptor_variant	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	splice_acceptor_variant	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	splice_acceptor_variant	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	splice_acceptor_variant	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FGFR3	K403R	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	K403R	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	K403R	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TP53	C135*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C135*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C135*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C135*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C135*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C135*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C135*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C135*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C135*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C135*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C135*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C135*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C135*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C135*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C135*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	R58*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R58*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R58*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	R58*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R58*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R58*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R58*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R58*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
NF1	splice_donor_variant	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NF1	splice_donor_variant	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	HNC	Case report
NF1	splice_donor_variant	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	splice_donor_variant	Complete Match	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	splice_donor_variant	Complete Match	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_donor_variant	Complete Match	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	splice_donor_variant	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	splice_donor_variant	Complete Match	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	splice_donor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	NF	Late trials
NF1	splice_donor_variant	Complete Match	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	splice_donor_variant	Complete Match	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	splice_donor_variant	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	MPN, PLEN	Pre-clinical
NF1	splice_donor_variant	Complete Match	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_donor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	HNC, SG	Case report
NF1	splice_donor_variant	Complete Match	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	splice_donor_variant	Complete Match	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	splice_donor_variant	Complete Match	MEK inhibitor	Responsive	LK, G	Pre-clinical
NF1	splice_donor_variant	Complete Match	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	splice_donor_variant	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	splice_donor_variant	Complete Match	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_donor_variant	Complete Match	MTOR inhibitor	Responsive	LK, G, MPN	Pre-clinical
NF1	splice_donor_variant	Complete Match	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	splice_donor_variant	Complete Match	Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor)	Responsive	HC	Case report
NF1	splice_donor_variant	Complete Match	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	splice_donor_variant	Complete Match	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	splice_donor_variant	Complete Match	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	splice_donor_variant	Complete Match	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	splice_donor_variant	Complete Match	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	splice_donor_variant	Complete Match	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	splice_donor_variant	Complete Match	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_donor_variant	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	splice_donor_variant	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	splice_donor_variant	Complete Match	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_donor_variant	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	splice_donor_variant	Complete Match	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	splice_donor_variant	Complete Match	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	splice_donor_variant	Different Alteration	MTOR inhibitor	Responsive	MPN, G, LK	Pre-clinical
NF1	splice_donor_variant	Different Alteration	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	splice_donor_variant	Different Alteration	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	splice_donor_variant	Different Alteration	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	splice_donor_variant	Different Alteration	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_donor_variant	Different Alteration	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	splice_donor_variant	Different Alteration	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	splice_donor_variant	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	splice_donor_variant	Different Alteration	MEK inhibitor	Responsive	G, LK	Pre-clinical
NF1	splice_donor_variant	Different Alteration	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	splice_donor_variant	Different Alteration	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	splice_donor_variant	Different Alteration	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	splice_donor_variant	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	splice_donor_variant	Different Alteration	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_donor_variant	Different Alteration	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	splice_donor_variant	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	splice_donor_variant	Different Alteration	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	splice_donor_variant	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SG, HNC	Case report
NF1	splice_donor_variant	Different Alteration	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	splice_donor_variant	Different Alteration	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	splice_donor_variant	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	splice_donor_variant	Different Alteration	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	splice_donor_variant	Different Alteration	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	splice_donor_variant	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	splice_donor_variant	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	PLEN, MPN	Pre-clinical
NF1	splice_donor_variant	Different Alteration	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	splice_donor_variant	Different Alteration	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	splice_donor_variant	Different Alteration	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_donor_variant	Different Alteration	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	splice_donor_variant	Different Alteration	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	splice_donor_variant	Different Alteration	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_donor_variant	Different Alteration	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
STK11	splice_donor_variant	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	splice_donor_variant	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	splice_donor_variant	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	splice_donor_variant	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	splice_donor_variant	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	splice_donor_variant	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	splice_donor_variant	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	splice_donor_variant	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	splice_donor_variant	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	splice_donor_variant	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	splice_donor_variant	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	splice_donor_variant	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
TP53	H179R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H179R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H179R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H179R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H179R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H179R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H179R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H179R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H179R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H179R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H179R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H179R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H179R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H179R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H179R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	R80*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R80*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R80*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	R80*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R80*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R80*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R80*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R80*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
TP53	G266E	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G266E	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G266E	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G266E	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G266E	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G266E	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G266E	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G266E	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G266E	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G266E	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G266E	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G266E	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G266E	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G266E	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G266E	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH2	I2304T	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ROS1	P1282S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	P1282S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	P1282S	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	P1282S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	P1282S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
RB1	R320*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	R320*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R320*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R320*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	R320*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R320*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R320*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
NOTCH1	R2313Q	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R2313Q	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
KRAS	G12A	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12A	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12A	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12A	Complete Match	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12A	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12A	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12A	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12A	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12A	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12A	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12A	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12A	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12A	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12A	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12A	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12A	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12A	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12A	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12A	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12A	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12A	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12A	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12A	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12A	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12A	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12A	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12A	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12A	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12A	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12A	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12A	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12A	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12A	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12A	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12A	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12A	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12A	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12A	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12A	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12A	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12A	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12A	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
FBXW7	R465C	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	R465C	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	R465C	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	R465C	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
TP53	R273S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R273S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R273S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R273S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R273S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R273S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R273S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R273S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R273S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R273S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R273S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R273S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R273S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R273S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R273S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NTRK3	R582W	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R582W	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R582W	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
BRD4	P307T	Different Alteration	BET inhibitor	Responsive	NMC	Case report
JAK2	N646H	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
BRCA2	R2336H	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	R2336H	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	R2336H	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	R2336H	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	R2336H	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	R2336H	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	R2336H	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	R2336H	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	R2336H	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	R2336H	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	R2336H	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	R2336H	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	R2336H	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	R2336H	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
TP53	R337L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R337L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R337L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R337L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R337L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R337L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R337L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R337L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R337L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R337L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R337L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R337L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R337L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R337L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R337L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V172D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V172D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V172D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V172D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V172D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V172D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V172D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V172D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V172D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V172D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V172D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V172D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V172D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V172D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V172D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	I803M	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	I803M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	I803M	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	I803M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	I803M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	I803M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	I803M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	I803M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	I803M	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
RB1	splice_donor_variant	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	splice_donor_variant	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	splice_donor_variant	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	splice_donor_variant	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	splice_donor_variant	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	splice_donor_variant	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	splice_donor_variant	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
SF3B1	K741E	Different Mutation	Spliceosome inhibitor	Responsive	CANCER	Pre-clinical
NTRK3	N392S	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	N392S	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	N392S	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NOTCH2	P2300S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BCOR	E401*	Complete Match	Enzastaurin (PKCb inhibitor)	Responsive	ST	Pre-clinical
TP53	R248Q	Complete Match	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R248Q	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R248Q	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R248Q	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R248Q	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R248Q	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R248Q	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248Q	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248Q	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R248Q	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R248Q	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R248Q	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248Q	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R248Q	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248Q	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H179Y	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H179Y	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H179Y	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H179Y	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H179Y	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H179Y	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H179Y	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H179Y	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H179Y	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H179Y	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H179Y	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H179Y	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H179Y	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H179Y	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H179Y	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
SETD2	Y1671*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	Y1671*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G245S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G245S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G245S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G245S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G245S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G245S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G245S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G245S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G245S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G245S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G245S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G245S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G245S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G245S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G245S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	N2050S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	N2050S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	L130P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L130P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L130P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L130P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L130P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L130P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L130P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L130P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L130P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L130P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L130P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L130P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L130P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L130P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L130P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	K132R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	K132R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	K132R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	K132R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	K132R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	K132R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	K132R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K132R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K132R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	K132R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	K132R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	K132R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K132R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	K132R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K132R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
MET	A105V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
JAK2	I136L	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
SMARCB1	Y248*	Complete Match	HDAC inhibitor	Responsive	MRT	Pre-clinical
SMARCB1	Y248*	Complete Match	EZH2 inhibitor	Responsive	MRT	Case report
SMARCB1	Y248*	Different Alteration	EZH2 inhibitor	Responsive	MRT	Case report
BRD4	P311A	Different Alteration	BET inhibitor	Responsive	NMC	Case report
BRAF	G106R	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	G106R	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	G106R	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	G106R	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TP53	C135R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C135R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C135R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C135R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C135R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C135R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C135R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C135R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C135R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C135R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C135R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C135R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C135R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C135R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C135R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RNF43	CdsStartSNV	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
MET	N375D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
FAT1	splice_donor_variant	Complete Match	BET inhibitor	Responsive	HNSC	Pre-clinical
CDKN1B	splice_acceptor_variant	Complete Match	CDK2/4 inhibitor	Responsive	CANCER	Pre-clinical
CDKN1B	splice_acceptor_variant	Different Alteration	CDK2/4 inhibitor	Responsive	CANCER	Pre-clinical
MET	S691), MET MUT (IntronicBlockSubstitution	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
NOTCH1	G2345C	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	G2345C	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ERBB4	K125E), ERBB4 MUT* (K137R), ERBB4 MUT* (intron_variant	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
EGFR	intron_variant	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	intron_variant	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
ALK	T1211A	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	T1211A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	T1211A	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	T1211A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	T1211A	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	T1211A	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	T1211A	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	T1211A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	T1211A	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	T1211A	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	T1211A	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	T1211A	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	T1211A	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	T1211A	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	T1211A	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	T1211A	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	T1211A	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	T1211A	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	T1211A	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
PIK3CA	I348T	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	I348T	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	I348T	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	I348T	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	I348T	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	I348T	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	I348T	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	I348T	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	I348T	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	I348T	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	I348T	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	I348T	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	I348T	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	I348T	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Complete Match	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PDGFRA	E571E), PDGFRA MUT* (E571K), PDGFRA MUT* (I562V	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
KIT	M541I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	AML	Pre-clinical
KIT	M541I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	HES, ALL, MDS, SM, ECL, MDPS, CML	FDA guidelines
KIT	M541I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	M541I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Pre-clinical
KIT	M541I	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Case report
KIT	M541I	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CANCER	Pre-clinical
KIT	M541I	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	SM	Early trials
KIT	M541I	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Case report
KIT	M541I	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	M541I	Different Mutation	HSP90 inhibitor	Responsive	GIST	Early trials
KIT	M541I	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Early trials
KIT	M541I	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	M541I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	GIST	FDA guidelines
KIT	M541I	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	M541I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Responsive	CM	Late trials;NCCN guidelines
KIT	M541I	Different Mutation	Regorafenib (Pan-kinase inhibitor)	Responsive	GIST	FDA guidelines
KIT	M541I	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	M541I	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	CM	Late trials
KIT	M541I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	M541I	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	FDA guidelines
KIT	M541I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	CM	Early trials
KIT	M541I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	THYM	Case report
KIT	M541I	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	M541I	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	M541I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KIT	M541I	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	M541I	Different Mutation	HSP90 inhibitor	Responsive	GIST	Pre-clinical
KIT	M541I	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Pre-clinical
KIT	M541I	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Pre-clinical
KIT	M541I	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	Late trials
KIT	M541I	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	GIST	Pre-clinical
KIT	M541I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Late trials
KIT	M541I	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	M541I	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	GIST	Early trials
KIT	M541I	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	M541I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	M541I	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	M541I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	CM	Case report
KIT	M541I	Different Alteration	Sunitinib (Pan-TK inhibitor)	No Responsive	CM	Early trials
KIT	M541I	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	No Responsive	CM	Early trials
FGFR2	C555Y), FGFR2 MUT* (intron_variant), FGFR2 MUT* (intron_variant), FGFR2 MUT* (intron_variant	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	C555Y), FGFR2 MUT* (intron_variant), FGFR2 MUT* (intron_variant), FGFR2 MUT* (intron_variant	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
RET	intron_variant), RET MUT* (D933G	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	intron_variant), RET MUT* (D933G	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	intron_variant), RET MUT* (D933G	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	intron_variant), RET MUT* (D933G	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	intron_variant), RET MUT* (D933G	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	intron_variant), RET MUT* (D933G	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	intron_variant), RET MUT* (D933G	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	intron_variant), RET MUT* (D933G	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	intron_variant), RET MUT* (D933G	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
MET	K1262R), MET MUT* (Y1252C), MET MUT* (F1218L), MET MUT* (K1208K), MET MUT* (K1208R), MET MUT* (I1123V), MET MUT* (intron_variant), MET MUT* (T1024A), MET MUT* (V370A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
BRAF	K439K), BRAF MUT* (R443R), BRAF MUT* (D448G), BRAF MUT* (intron_variant	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	K439K), BRAF MUT* (R443R), BRAF MUT* (D448G), BRAF MUT* (intron_variant	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	K439K), BRAF MUT* (R443R), BRAF MUT* (D448G), BRAF MUT* (intron_variant	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	K439K), BRAF MUT* (R443R), BRAF MUT* (D448G), BRAF MUT* (intron_variant	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
GNAQ	Q209R	Complete Match	Selumetinib (MEK inhibitor)	Responsive	CM	Early trials
GNAQ	Q209R	Complete Match	HDAC inhibitor	Responsive	CM	Pre-clinical
GNAQ	Q209R	Complete Match	PKC inhibitor	Responsive	CM	Pre-clinical
GNAQ	Q209R	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
EGFR	N103K	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	N103K	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
POLE	W1624*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
POLE	W1624*	Complete Match	PD1 Ab inhibitor	Responsive	COREAD	Case report
POLE	W1624*	Different Mutation	PD1 Ab inhibitor	Responsive	G, ED	Case report
POLE	W1624*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
CDKN2B	splice_donor_variant	Complete Match	CDK4/6 inhibitor	Responsive	G, CANCER	Pre-clinical
CDKN2B	splice_donor_variant	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
TP53	Y234N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y234N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y234N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y234N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y234N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y234N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y234N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y234N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y234N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y234N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y234N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y234N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y234N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y234N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y234N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	Q2386R	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	Q2386R	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ERBB4	S341*	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	CM	Pre-clinical
ERBB4	S341*	Different Mutation	ERBB2 inhibitor	Resistant	BRCA	Case report
ERBB4	S341*	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
TP53	T211I	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T211I	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T211I	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T211I	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T211I	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T211I	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T211I	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T211I	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T211I	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T211I	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T211I	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T211I	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T211I	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T211I	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T211I	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	F134L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	F134L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	F134L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	F134L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	F134L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	F134L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	F134L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F134L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F134L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	F134L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	F134L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	F134L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F134L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	F134L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F134L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PIK3CA	H1047R	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	H1047R	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	H1047R	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	H1047R	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	H1047R	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	H1047R	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	H1047R	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	H1047R	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	H1047R	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	H1047R	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	H1047R	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	H1047R	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	H1047R	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	H1047R	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
ROS1	L1620F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	L1620F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	L1620F	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	L1620F	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	L1620F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
EGFR	L861P	Different Alteration	Cetuximab (EGFR mAb inhibitor)	Responsive	COREAD	FDA guidelines
EGFR	L861P	Different Alteration	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
EGFR	L861P	Different Mutation	Rindopepimut (Vaccine)	Responsive	GB	Late trials
EGFR	L861P	Complete Match	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	L861P	Complete Match	Gefitinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	L861P	Complete Match	HSP90 inhibitor	Responsive	L	Early trials
EGFR	L861P	Complete Match	Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	L861P	Complete Match	MEK inhibitor	Responsive	L	Pre-clinical
EGFR	L861P	Complete Match	EGFR TK inhibitor	Responsive	L	Late trials
EGFR	L861P	Complete Match	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	NCCN guidelines
EGFR	L861P	Different Mutation	Osimertinib (EGFR inhibitor)	Resistant	L	Early trials
EGFR	L861P	Different Mutation	EGFR-TKI's (EGFR inhibitor)	Resistant	L	Late trials
EGFR	L861P	Different Mutation	HSP90 inhibitor	Responsive	L	Case report
EGFR	L861P	Different Mutation	EGFR inhibitor	Resistant	L	Late trials
EGFR	L861P	Different Mutation	Poziotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	L861P	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Pre-clinical
EGFR	L861P	Different Mutation	HSP90 inhibitor (HSP90 inhibitor)	Responsive	L	Early trials
EGFR	L861P	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	G	Pre-clinical
EGFR	L861P	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	L861P	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	L861P	Different Mutation	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
EGFR	L861P	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Responsive	COREAD	Case report
EGFR	L861P	Different Mutation	novel EGFR mAb inhibitor	Responsive	COREAD	Early trials
EGFR	L861P	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	L861P	Different Mutation	Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor)	Responsive	HNC	Case report
EGFR	L861P	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	L861P	Different Mutation	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Case report
EGFR	L861P	Different Mutation	EGFR inhibitor	Responsive	L	Early trials
EGFR	L861P	Different Mutation	Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	L861P	Different Mutation	Erlotinib (EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	L861P	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	L861P	Different Mutation	EGFR inhibitor	Responsive	NSCLC	Late trials
EGFR	L861P	Different Mutation	Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	L861P	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	L861P	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	L861P	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	L	Late trials
EGFR	L861P	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Pre-clinical
EGFR	L861P	Different Mutation	Erlotinib (EGFR inhibitor)	No Responsive	L	Case report
EGFR	L861P	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	ED	Case report
EGFR	L861P	Different Mutation	EGFR inhibitor	No Responsive	G	Early trials
EGFR	L861P	Different Mutation	EGFR inhibitor	Resistant	NSCLC	Case report
EGFR	L861P	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	L861P	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant;Resistant	COREAD	Pre-clinical;Case report
EGFR	L861P	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Responsive	HNC	Case report
EGFR	L861P	Different Alteration	Gefitinib (EGFR inhibitor)	Responsive	ED	Late trials
EGFR	L861P	Different Alteration	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Early trials
EGFR	L861P	Different Alteration	EGFR inhibitor	Responsive	HNSC	Case report
EGFR	L861P	Different Alteration	EGFR inhibitor	No Responsive	G	Early trials
EGFR	L861P	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	L	Early trials
EGFR	L861P	Different Alteration	EGFR mAb inhibitor	Responsive	COREAD	Late trials
EGFR	L861P	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	L861P	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
IDH1	R132C	Complete Match	Venetoclax (BCL2 inhibitor)	Responsive	AML	Early trials
IDH1	R132C	Complete Match	IDH1 inhibitor	Responsive	AML	Early trials
IDH1	R132C	Complete Match	AG-120 (IDH1 inhibitor)	Responsive	G	Early trials
IDH1	R132C	Complete Match	Dasatinib (BCR-ABL inhibitor)	Responsive	CH	Early trials
IDH1	R132C	Complete Match	Ivosidenib (IDH1 inhibitor)	Responsive	AML	Early trials
IDH1	R132C	Complete Match	BCL2 inhibitor	Responsive	AML	Pre-clinical
IDH1	R132C	Complete Match	BCL2 inhibitor (BCL2 inhibitor)	Responsive	AML	Pre-clinical
IDH1	R132C	Complete Match	Dasatinib (BCR-ABL inhibitor)	Responsive	BT	Pre-clinical
IDH1	R132C	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
PIK3CA	E545K	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	E545K	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	E545K	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	E545K	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	E545K	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	E545K	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	E545K	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	E545K	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	E545K	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	E545K	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	E545K	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	E545K	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	E545K	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	E545K	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
FBXW7	R465L	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	R465L	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	R465L	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	R465L	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
PTEN	R130Q), ERBB2 MUT (R678Q	Different Alteration	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
ERBB2	R678Q	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	R678Q	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	R678Q	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	ST, BRCA, GEJA	FDA guidelines
ERBB2	R678Q	Different Alteration	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	R678Q	Different Alteration	MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor)	Responsive	SOLID	Early trials
ERBB2	R678Q	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	R678Q	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	R678Q	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER, BRCA	Pre-clinical
ERBB2	R678Q	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	CANCER	Early trials
ERBB2	R678Q	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Case report
ERBB2	R678Q	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA, LUAD	Case report
ERBB2	R678Q	Different Mutation	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	L	Early trials
ERBB2	R678Q	Different Mutation	Neratinib (ERBB2 inhibitor)	Resistant	BRCA	Case report
ERBB2	R678Q	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	R678Q	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	LUAD	Case report
ERBB2	R678Q	Different Mutation	Lapatinib (ERBB2 inhibitor)	Resistant	BRCA	Pre-clinical
ERBB2	R678Q	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB2	R678Q	Complete Match	Temsirolimus (MTOR inhibitor)	Responsive	LUAD	Early trials
ERBB2	R678Q	Complete Match	Dacomitinib (Pan ERBB inhibitor)	Responsive	NSCLC	Early trials
ERBB2	R678Q	Complete Match	Neratinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	R678Q	Different Mutation	ERBB2 inhibitor	Responsive	LUAD	Early trials
ERBB2	R678Q	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Early trials
ERBB2	R678Q	Different Mutation	ERBB2 mAb inhibitor	Responsive	LUAD	Early trials
ERBB2	R678Q	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	R678Q	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	R678Q	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	LUAD	Early trials
ERBB2	R678Q	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BRCA	Late trials
ERBB2	R678Q	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	BT	Early trials
ERBB2	R678Q	Different Alteration	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Responsive	COREAD	Late trials
ERBB2	R678Q	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	OV	Early trials
ERBB2	R678Q	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BLCA	Case report
ERBB2	R678Q	Different Alteration	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	COREAD	Case report
ERBB2	R678Q	Different Alteration	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
ERBB2	R678Q	Different Alteration	Osimertinib (EGFR inhibitor)	Resistant	LUAD	Case report
ERBB2	R678Q	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	BT	Early trials
ERBB2	R678Q	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Early trials
ERBB2	R678Q	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	BT	Early trials
ERBB2	R678Q	Different Alteration	Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor)	Responsive	BRCA	Early trials
ERBB2	R678Q	Different Alteration	HER2 inhibitor;CDK4/6 inhibitor	Responsive	BRCA	Pre-clinical
ERBB2	R678Q	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	R678Q	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	ST	Early trials
ERBB2	R678Q	Different Alteration	Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
ERBB2	R678Q	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	ST, GEJA	FDA guidelines
ERBB2	R678Q	Different Alteration	ERBB2 inhibitor;CDK4/6 inhibitor	Responsive	BRCA	Pre-clinical
ERBB2	R678Q	Different Alteration	Ado-Trastuzumab Emtansine (EGFR mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	R678Q	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	HNC	Case report
ERBB2	R678Q	Different Alteration	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Late trials
ERBB2	R678Q	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	No Responsive	ED	Early trials
ERBB2	R678Q	Different Alteration	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Responsive	ED	Pre-clinical
ERBB2	R678Q	Different Alteration	Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy)	Responsive	ST	Early trials
ERBB2	R678Q	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	ST	Case report
ERBB2	R678Q	Different Alteration	EGFR inhibitor	Resistant	LUAD	Pre-clinical
PTEN	R130Q	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	R130Q	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	R130Q	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	R130Q	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	R130Q	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	R130Q	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	R130Q	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	R130Q	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	R130Q	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	R130Q	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	R130Q	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	R130Q	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	R130Q	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	R130Q	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	R130Q	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	R130Q	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	R130Q	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	R130Q	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	R130Q	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	R130Q	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	R130Q	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	R130Q	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	R130Q	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	R130Q	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	R130Q	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
TP53	L194R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L194R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L194R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L194R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L194R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L194R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L194R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L194R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L194R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L194R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L194R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L194R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L194R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L194R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L194R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
EGFR	intron_variant), EGFR MUT* (intron_variant	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	intron_variant), EGFR MUT* (intron_variant	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
MET	F389L), MET MUT* (K380K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
TP53	R282Q	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R282Q	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R282Q	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R282Q	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R282Q	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R282Q	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R282Q	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R282Q	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R282Q	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R282Q	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R282Q	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R282Q	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R282Q	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R282Q	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R282Q	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R156P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R156P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R156P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R156P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R156P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R156P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R156P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R156P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R156P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R156P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R156P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R156P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R156P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R156P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R156P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FGFR3	L684L	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	L684L	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	L684L	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TP53	I195S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I195S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I195S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I195S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I195S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I195S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I195S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I195S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I195S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I195S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I195S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I195S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I195S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I195S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I195S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	T140A	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
TP53	C176Y	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C176Y	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C176Y	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C176Y	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C176Y	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C176Y	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C176Y	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176Y	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176Y	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C176Y	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C176Y	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C176Y	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176Y	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C176Y	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176Y	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	P114R	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	P114R	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	P114R	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	P114R	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	P114R	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	P114R	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	P114R	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	P114R	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
CTNNB1	T41A	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	T41A	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
PTEN	F271S	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	F271S	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	F271S	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	F271S	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	F271S	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	F271S	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	F271S	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	F271S	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	F271S	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	F271S	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	F271S	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	F271S	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	F271S	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	F271S	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	F271S	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	F271S	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	F271S	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	F271S	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	F271S	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	F271S	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	F271S	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	F271S	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	F271S	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	F271S	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	F271S	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
TP53	Q136*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q136*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q136*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q136*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q136*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q136*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q136*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q136*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q136*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q136*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q136*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q136*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q136*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q136*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q136*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PIK3CA	D350G), PIK3CA MUT (R349Q	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	D350G), PIK3CA MUT (R349Q	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	D350G), PIK3CA MUT (R349Q	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	D350G), PIK3CA MUT (R349Q	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	D350G), PIK3CA MUT (R349Q	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	D350G), PIK3CA MUT (R349Q	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	D350G), PIK3CA MUT (R349Q	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	D350G), PIK3CA MUT (R349Q	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	D350G), PIK3CA MUT (R349Q	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	D350G), PIK3CA MUT (R349Q	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	D350G), PIK3CA MUT (R349Q	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	D350G), PIK3CA MUT (R349Q	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	D350G), PIK3CA MUT (R349Q	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	D350G), PIK3CA MUT (R349Q	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
BRAF	intron_variant	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	intron_variant	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	intron_variant	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	intron_variant	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
KRAS	G13D	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G13D	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G13D	Complete Match	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G13D	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G13D	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G13D	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G13D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G13D	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13D	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G13D	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G13D	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G13D	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G13D	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G13D	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G13D	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G13D	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G13D	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G13D	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G13D	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G13D	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13D	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G13D	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13D	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G13D	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G13D	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G13D	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G13D	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G13D	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G13D	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G13D	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G13D	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G13D	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G13D	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G13D	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13D	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G13D	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13D	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G13D	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G13D	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G13D	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G13D	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G13D	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	G266V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G266V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G266V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G266V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G266V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G266V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G266V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G266V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G266V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G266V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G266V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G266V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G266V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G266V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G266V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FGFR3	P401T	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	P401T	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	P401T	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
KMT2A	P3433T	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P3433T	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P3433T	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P3433T	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P3433T	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P3433T	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
AKT3	S210Y	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
KRAS	Q61R	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61R	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61R	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	Q61R	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	Q61R	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	Q61R	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	Q61R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	Q61R	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61R	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61R	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	Q61R	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	Q61R	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61R	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	Q61R	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	Q61R	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	Q61R	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	Q61R	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	Q61R	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	Q61R	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	Q61R	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61R	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	Q61R	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61R	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	Q61R	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	Q61R	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61R	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	Q61R	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61R	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	Q61R	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	Q61R	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	Q61R	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	Q61R	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	Q61R	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61R	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61R	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	Q61R	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61R	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	Q61R	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61R	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	Q61R	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	Q61R	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	Q61R	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
NOTCH1	R2372Q	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R2372Q	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	V274F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V274F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V274F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V274F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V274F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V274F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V274F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V274F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V274F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V274F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V274F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V274F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V274F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V274F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V274F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2A	S462*	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S462*	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S462*	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S462*	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S462*	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S462*	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ATM	Q1970*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	Q1970*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	Q1970*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	Q1970*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	Q1970*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q1970*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q1970*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	Q1970*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q1970*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q1970*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q1970*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	Q1970*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q1970*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
KRAS	G13H	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G13H	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G13H	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G13H	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G13H	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G13H	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G13H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G13H	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13H	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G13H	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G13H	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G13H	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G13H	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G13H	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G13H	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G13H	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G13H	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G13H	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G13H	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G13H	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13H	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G13H	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13H	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G13H	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G13H	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G13H	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G13H	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G13H	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G13H	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G13H	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G13H	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G13H	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G13H	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G13H	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13H	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G13H	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13H	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G13H	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G13H	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G13H	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G13H	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G13H	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
PBRM1	Y1167*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	Y1167*	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	Y1167*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	Y1167*	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	Y1167*	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
ABL1	G626S	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	G626S	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G626S	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	G626S	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G626S	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	G626S	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
GNAS	R201H	Complete Match	JAK inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q435*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q435*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q435*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q435*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ROS1	R1121T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	R1121T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	R1121T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	R1121T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	R1121T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
BRD4	T195M	Different Alteration	BET inhibitor	Responsive	NMC	Case report
TP53	S127F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S127F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S127F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S127F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S127F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S127F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S127F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S127F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S127F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S127F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S127F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S127F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S127F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S127F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S127F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PIK3R1	splice_acceptor_variant	Complete Match	AKT inhibitor	Responsive	G	Pre-clinical
PIK3R1	splice_acceptor_variant	Complete Match	PI3K pathway inhibitor	Responsive	ED	Case report
KRAS	Q61L	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61L	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61L	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	Q61L	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	Q61L	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	Q61L	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	Q61L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	Q61L	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61L	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61L	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	Q61L	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	Q61L	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61L	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	Q61L	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	Q61L	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	Q61L	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	Q61L	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	Q61L	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	Q61L	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	Q61L	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61L	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	Q61L	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61L	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	Q61L	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	Q61L	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61L	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	Q61L	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61L	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	Q61L	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	Q61L	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	Q61L	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	Q61L	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	Q61L	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61L	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61L	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	Q61L	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61L	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	Q61L	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61L	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	Q61L	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	Q61L	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	Q61L	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	L257R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L257R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L257R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L257R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L257R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L257R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L257R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L257R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L257R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L257R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L257R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L257R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L257R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L257R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L257R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E286K	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E286K	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E286K	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E286K	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E286K	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E286K	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E286K	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E286K	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E286K	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E286K	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E286K	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E286K	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E286K	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E286K	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E286K	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BCR	A102T	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
BCR	A102T	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
BCR	A102T	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	A102T	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	A102T	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
BCR	A102T	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	L302F	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	L302F	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	L302F	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	L302F	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	L302F	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	L302F	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
TP53	R282G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R282G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R282G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R282G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R282G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R282G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R282G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R282G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R282G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R282G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R282G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R282G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R282G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R282G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R282G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	A159V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	A159V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	A159V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	A159V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	A159V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	A159V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	A159V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A159V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A159V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	A159V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	A159V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	A159V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A159V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	A159V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A159V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ALK	P1112L	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	P1112L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	P1112L	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	P1112L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	P1112L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	P1112L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P1112L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	P1112L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P1112L	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P1112L	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	P1112L	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	P1112L	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	P1112L	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	P1112L	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	P1112L	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	P1112L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	P1112L	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	P1112L	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P1112L	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ARID1A	R1721*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1721*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1721*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	R1721*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
RB1	R445*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	R445*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R445*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R445*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	R445*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R445*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R445*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
GNAS	R201C	Complete Match	JAK inhibitor	Responsive	CANCER	Pre-clinical
ROS1	L1872V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	L1872V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	L1872V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	L1872V	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	L1872V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
TP53	V272L), TP53 MUT (R158C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V272L), TP53 MUT (R158C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V272L), TP53 MUT (R158C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V272L), TP53 MUT (R158C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V272L), TP53 MUT (R158C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V272L), TP53 MUT (R158C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V272L), TP53 MUT (R158C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V272L), TP53 MUT (R158C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V272L), TP53 MUT (R158C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V272L), TP53 MUT (R158C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V272L), TP53 MUT (R158C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V272L), TP53 MUT (R158C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V272L), TP53 MUT (R158C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V272L), TP53 MUT (R158C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V272L), TP53 MUT (R158C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ABL1	G634C	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	G634C	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G634C	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	G634C	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G634C	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	G634C	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
TP53	E271K	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E271K	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E271K	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E271K	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E271K	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E271K	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E271K	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E271K	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E271K	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E271K	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E271K	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E271K	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E271K	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E271K	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E271K	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NTRK3	intron_variant	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	intron_variant	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	intron_variant	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61H), KRAS MUT (E63D	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	Q61H), KRAS MUT (E63D	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	Q61H), KRAS MUT (E63D	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	Q61H), KRAS MUT (E63D	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61H), KRAS MUT (E63D	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	Q61H), KRAS MUT (E63D	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	Q61H), KRAS MUT (E63D	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	Q61H), KRAS MUT (E63D	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	Q61H), KRAS MUT (E63D	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	Q61H), KRAS MUT (E63D	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61H), KRAS MUT (E63D	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	Q61H), KRAS MUT (E63D	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61H), KRAS MUT (E63D	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	Q61H), KRAS MUT (E63D	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	Q61H), KRAS MUT (E63D	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	Q61H), KRAS MUT (E63D	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	Q61H), KRAS MUT (E63D	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	Q61H), KRAS MUT (E63D	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61H), KRAS MUT (E63D	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	Q61H), KRAS MUT (E63D	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	Q61H), KRAS MUT (E63D	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
SETD2	K141*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	K141*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
U2AF1	Q157R	Complete Match	FLT3 inhibitor	Responsive	CANCER	Pre-clinical
NOTCH1	G54C	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	G54C	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
STK11	Y246*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	Y246*	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	Y246*	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	Y246*	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	Y246*	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	Y246*	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y246*	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y246*	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	Y246*	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	Y246*	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	Y246*	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y246*	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y246*), KRAS MUT (G12R	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	Y246*), KRAS MUT (G12R	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	Y246*), KRAS MUT (G12R	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	Y246*), KRAS MUT (G12R	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
ATM	R447*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R447*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R447*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R447*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R447*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R447*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R447*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R447*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R447*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R447*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R447*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R447*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R447*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
PIK3CA	E545G	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	E545G	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	E545G	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	E545G	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	E545G	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	E545G	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	E545G	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	E545G	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	E545G	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	E545G	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	E545G	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	E545G	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	E545G	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	E545G	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
NOTCH1	A950V	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	A950V	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
U2AF1	S34F	Complete Match	FLT3 inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	splice_donor_variant	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	splice_donor_variant	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	splice_donor_variant	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	splice_donor_variant	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
NTRK1	A500P	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	A500P	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	A500P	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	A500P	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
TP53	G266R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G266R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G266R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G266R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G266R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G266R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G266R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G266R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G266R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G266R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G266R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G266R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G266R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G266R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G266R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ABL1	intron_variant	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	intron_variant	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	intron_variant	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	intron_variant	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	intron_variant	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	intron_variant	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
MSH2	E561*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
MSH2	E561*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
KMT2A	T2233I	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	T2233I	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	T2233I	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	T2233I	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	T2233I	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	T2233I	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
BRAF	V765L	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	V765L	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	V765L	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	V765L	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TP53	H193D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H193D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H193D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H193D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H193D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H193D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H193D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H193D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H193D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H193D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H193D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H193D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H193D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H193D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H193D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
JAK2	P279L	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
BRAF	P318L	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	P318L	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	P318L	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	P318L	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TP53	V157G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V157G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V157G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V157G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V157G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V157G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V157G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V157G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V157G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V157G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V157G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V157G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V157G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V157G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V157G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C242Y	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C242Y	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C242Y	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C242Y	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C242Y	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C242Y	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C242Y	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C242Y	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C242Y	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C242Y	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C242Y	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C242Y	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C242Y	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C242Y	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C242Y	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	V1115M	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ROS1	R1311Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	R1311Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	R1311Q	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	R1311Q	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	R1311Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
TP53	V274G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V274G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V274G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V274G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V274G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V274G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V274G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V274G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V274G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V274G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V274G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V274G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V274G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V274G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V274G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH2	A147S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	R333C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R333C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R333C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R333C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R333C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R333C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R333C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R333C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R333C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R333C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R333C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R333C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R333C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R333C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R333C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RAF1	V312M	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	V312M	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	V312M	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
MSH2	A636P), MSH2 MUT (G208*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
MSH2	A636P), MSH2 MUT (G208*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
KMT2A	S2159F	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S2159F	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S2159F	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S2159F	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S2159F	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S2159F	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NRAS	G13V	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
NRAS	G13V	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
NRAS	G13V	Different Mutation	MEK inhibitor	Responsive	CM	Late trials
NRAS	G13V	Different Mutation	BRAF inhibitor	Resistant	CM	Early trials
NRAS	G13V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CM	Early trials
NRAS	G13V	Complete Match	HSP90 inhibitor	Responsive	CM	Pre-clinical
NRAS	G13V	Complete Match	MEK inhibitor	Responsive	AML, LUAD, ALL	Pre-clinical
NRAS	G13V	Complete Match	Pan-RAF inhibitor	Responsive	CM	Case report
NRAS	G13V	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
NRAS	G13V	Complete Match	ERK inhibitor	Responsive	CM	Case report
NRAS	G13V	Complete Match	MEK inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
NRAS	G13V	Complete Match	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NRAS	G13V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	MYMA	Pre-clinical
NRAS	G13V	Different Mutation	ERK inhibitor	Responsive	CANCER	Pre-clinical
JAK2	G963V	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
CTNNB1	S33C	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	S33C	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
CTNNB1	D32H	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	D32H	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
PDGFRA	D1071N), PDGFRA MUT* (D1069G	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
TP53	V157D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V157D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V157D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V157D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V157D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V157D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V157D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V157D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V157D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V157D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V157D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V157D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V157D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V157D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V157D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRD4	P35H	Different Alteration	BET inhibitor	Responsive	NMC	Case report
ABL1	D739N), ABL1 MUT* (D207N	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	D739N), ABL1 MUT* (D207N	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	D739N), ABL1 MUT* (D207N	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	D739N), ABL1 MUT* (D207N	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	D739N), ABL1 MUT* (D207N	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	D739N), ABL1 MUT* (D207N	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
JAK2	R234H	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
SMARCA4	splice_acceptor_variant	Complete Match	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	splice_acceptor_variant	Complete Match	AURKA inhibitor	Responsive	NSCLC	Pre-clinical
SMARCA4	splice_acceptor_variant	Complete Match	EZH2 inhibitor	Responsive	OV	Case report
SMARCA4	splice_acceptor_variant	Different Alteration	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	splice_acceptor_variant	Different Alteration	EZH2 inhibitor	Responsive	OV	Case report
PDGFRA	R481S	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
FANCC	splice_donor_variant	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
FANCC	splice_donor_variant	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
FLT1	splice_acceptor_variant	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	R	Pre-clinical
FGFR2	P808S	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	P808S	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
TP53	D281N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	D281N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	D281N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	D281N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	D281N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	D281N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	D281N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D281N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D281N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	D281N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	D281N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	D281N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D281N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	D281N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D281N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RB1	splice_acceptor_variant	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	splice_acceptor_variant	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	splice_acceptor_variant	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	splice_acceptor_variant	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	splice_acceptor_variant	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	splice_acceptor_variant	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	splice_acceptor_variant	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
CDKN2A	G45D	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	G45D	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	G45D	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	G45D	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	G45D	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	G45D	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	G45D	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	G45D	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
KMT2A	V1304I	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	V1304I	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	V1304I	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	V1304I	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	V1304I	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	V1304I	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NOTCH1	R1627H	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1627H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRD4	G319D	Different Alteration	BET inhibitor	Responsive	NMC	Case report
BRAF	A246V	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	A246V	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	A246V	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	A246V	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
VHL	G114D	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
CDKN2A	D108Y	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	D108Y	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	D108Y	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	D108Y	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	D108Y	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	D108Y	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	D108Y	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	D108Y	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
JAK2	P796T	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
TP53	K132*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	K132*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	K132*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	K132*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	K132*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	K132*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	K132*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K132*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K132*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	K132*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	K132*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	K132*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K132*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	K132*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K132*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PTEN	Q87*	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Q87*	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Q87*	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	Q87*	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	Q87*	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	Q87*	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Q87*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Q87*	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	Q87*	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	Q87*	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Q87*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Q87*	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	Q87*	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Q87*	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	Q87*	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Q87*	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	Q87*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Q87*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Q87*	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	Q87*	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Q87*	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Q87*	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Q87*	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	Q87*	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Q87*	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
CDH1	splice_acceptor_variant	Complete Match	Bicalutamide (AR inhibitor)	Responsive	BRCA	Pre-clinical
ATM	W57*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	W57*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	W57*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	W57*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	W57*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	W57*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	W57*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	W57*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	W57*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	W57*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	W57*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	W57*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	W57*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
NTRK1	S146L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	S146L	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	S146L	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	S146L	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
TP53	Y205D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y205D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y205D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y205D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y205D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y205D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y205D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y205D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y205D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y205D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y205D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y205D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y205D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y205D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y205D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M237K	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	M237K	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	M237K	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	M237K	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	M237K	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	M237K	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M237K	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M237K	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M237K	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	M237K	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	M237K	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	M237K	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M237K	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	M237K	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M237K	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRAF	Y633H	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	Y633H	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	Y633H	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	Y633H	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TP53	E258D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E258D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E258D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E258D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E258D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E258D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E258D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E258D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E258D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E258D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E258D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E258D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E258D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E258D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E258D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ESR1	S301C	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
TP53	P278S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P278S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P278S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P278S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P278S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P278S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P278S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P278S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P278S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P278S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P278S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P278S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P278S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P278S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P278S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S241F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S241F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S241F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S241F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S241F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S241F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S241F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S241F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S241F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S241F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S241F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S241F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S241F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S241F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S241F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y163C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y163C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y163C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y163C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y163C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y163C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y163C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y163C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y163C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y163C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y163C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y163C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y163C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y163C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y163C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	P1039Q	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	P1039Q	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	P1039Q	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	P1039Q	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	P1039Q	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	P1039Q	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	P1039Q	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	P1039Q	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	P1039Q	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
BRD4	A38D	Different Alteration	BET inhibitor	Responsive	NMC	Case report
TP53	R156H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R156H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R156H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R156H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R156H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R156H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R156H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R156H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R156H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R156H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R156H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R156H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R156H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R156H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R156H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ALK	G221A	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	G221A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	G221A	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	G221A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	G221A	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	G221A	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G221A	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	G221A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G221A	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G221A	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	G221A	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	G221A	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	G221A	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	G221A	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	G221A	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	G221A	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	G221A	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	G221A	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G221A	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
PDGFRA	V10I	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
BRCA2	K944*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	K944*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	K944*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	K944*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	K944*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	K944*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	K944*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	K944*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	K944*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	K944*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	K944*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	K944*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	K944*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	K944*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
ERBB4	S1124G	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
NOTCH1	R176Q	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R176Q	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
CTNNB1	D32Y	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	D32Y	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
KMT2A	N1499H	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	N1499H	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	N1499H	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	N1499H	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	N1499H	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	N1499H	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ARID1A	E1958*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1958*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1958*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E1958*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ROS1	F901L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	F901L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	F901L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	F901L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	F901L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
TP53	R273L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R273L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R273L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R273L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R273L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R273L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R273L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R273L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R273L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R273L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R273L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R273L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R273L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R273L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R273L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	R1722*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1722*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1722*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	R1722*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	C275Y	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C275Y	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C275Y	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C275Y	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C275Y	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C275Y	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C275Y	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C275Y	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C275Y	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C275Y	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C275Y	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C275Y	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C275Y	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C275Y	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C275Y	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TSC2	W1194*	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	W1194*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	W1194*	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	W1194*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	W1194*	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	W1194*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	W1194*	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
KRAS	G13V	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G13V	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G13V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G13V	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G13V	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G13V	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G13V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G13V	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13V	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G13V	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G13V	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G13V	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G13V	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G13V	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G13V	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G13V	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G13V	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G13V	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G13V	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G13V	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13V	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G13V	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13V	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G13V	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G13V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G13V	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G13V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G13V	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G13V	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G13V	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G13V	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G13V	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G13V	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G13V	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G13V	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13V	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G13V	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G13V	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G13V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G13V	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G13V	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
ALK	V569G	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	V569G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	V569G	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	V569G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	V569G	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	V569G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	V569G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	V569G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	V569G	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	V569G	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	V569G	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	V569G	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	V569G	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	V569G	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	V569G	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	V569G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	V569G	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	V569G	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	V569G	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ROS1	P1028S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	P1028S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	P1028S	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	P1028S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	P1028S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
BRAF	3-UTRSNV	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	3-UTRSNV	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	3-UTRSNV	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	3-UTRSNV	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
NOTCH2	A3F	Different Mutation	Mk-0752 (Gamma secretase inhibitor)	Responsive	ALL, AML, BRCA	Early trials
NOTCH2	A3F	Different Mutation	OMP-59R5 (NOTCH2 inhibitor)	Responsive	SOLID	Early trials
NOTCH2	A3F	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ROS1	A459S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	A459S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	A459S	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	A459S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	A459S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
KMT2A	L767H	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	L767H	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	L767H	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	L767H	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	L767H	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	L767H	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ARID1A	Y454*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y454*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y454*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Y454*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	C141W	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C141W	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C141W	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C141W	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C141W	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C141W	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C141W	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141W	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141W	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C141W	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C141W	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C141W	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141W	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C141W	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141W	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E258G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E258G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E258G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E258G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E258G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E258G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E258G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E258G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E258G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E258G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E258G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E258G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E258G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E258G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E258G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRCA2	splice_acceptor_variant	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	splice_acceptor_variant	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	splice_acceptor_variant	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	splice_acceptor_variant	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	splice_acceptor_variant	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	splice_acceptor_variant	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	splice_acceptor_variant	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	splice_acceptor_variant	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	splice_acceptor_variant	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	splice_acceptor_variant	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	splice_acceptor_variant	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	splice_acceptor_variant	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	splice_acceptor_variant	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	splice_acceptor_variant	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
TP53	Q144*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q144*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q144*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q144*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q144*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q144*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q144*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q144*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q144*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q144*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q144*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q144*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q144*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q144*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q144*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
MET	L14F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
ARID1A	E2032*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E2032*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E2032*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E2032*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
SETD2	E1983*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	E1983*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R248L), TP53 MUT (E346*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R248L), TP53 MUT (E346*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R248L), TP53 MUT (E346*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R248L), TP53 MUT (E346*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R248L), TP53 MUT (E346*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R248L), TP53 MUT (E346*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R248L), TP53 MUT (E346*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248L), TP53 MUT (E346*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248L), TP53 MUT (E346*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R248L), TP53 MUT (E346*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R248L), TP53 MUT (E346*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R248L), TP53 MUT (E346*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248L), TP53 MUT (E346*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R248L), TP53 MUT (E346*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248L), TP53 MUT (E346*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	N235D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	N235D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	N235D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	N235D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	N235D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	N235D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	N235D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N235D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N235D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	N235D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	N235D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	N235D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N235D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	N235D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N235D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	E222K	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	E222K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	E222K	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	E222K	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E222K	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E222K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	E222K	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E222K	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E222K	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
PIK3CA	G118D	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	G118D	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	G118D	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	G118D	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	G118D	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	G118D	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	G118D	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	G118D	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	G118D	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	G118D	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	G118D	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	G118D	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	G118D	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	G118D	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
BAP1	CdsStartSNV	Complete Match	EZH2 inhibitor	Responsive	MESO	Pre-clinical
BAP1	CdsStartSNV	Complete Match	PARP inhibitor	Responsive	R, CANCER	Pre-clinical
BAP1	CdsStartSNV	Complete Match	HDAC inhibitor	Responsive	CM	Pre-clinical
BAP1	CdsStartSNV	Different Alteration	PARP inhibitor	Responsive	CANCER, R	Pre-clinical
BAP1	CdsStartSNV	Different Alteration	EZH2 inhibitor	Responsive	MESO	Pre-clinical
BAP1	CdsStartSNV	Different Alteration	HDAC inhibitor	Responsive	CM	Pre-clinical
TP53	N239D), TP53 MUT (E294*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	N239D), TP53 MUT (E294*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	N239D), TP53 MUT (E294*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	N239D), TP53 MUT (E294*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	N239D), TP53 MUT (E294*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	N239D), TP53 MUT (E294*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	N239D), TP53 MUT (E294*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N239D), TP53 MUT (E294*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N239D), TP53 MUT (E294*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	N239D), TP53 MUT (E294*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	N239D), TP53 MUT (E294*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	N239D), TP53 MUT (E294*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N239D), TP53 MUT (E294*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	N239D), TP53 MUT (E294*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N239D), TP53 MUT (E294*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	D281_T284delDRRT	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	D281_T284delDRRT	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	D281_T284delDRRT	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	D281_T284delDRRT	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	D281_T284delDRRT	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	D281_T284delDRRT	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	D281_T284delDRRT	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D281_T284delDRRT	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D281_T284delDRRT	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	D281_T284delDRRT	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	D281_T284delDRRT	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	D281_T284delDRRT	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D281_T284delDRRT	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	D281_T284delDRRT	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D281_T284delDRRT	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	P992L	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	P992L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	P992L	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	P992L	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	P992L	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	P992L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	P992L	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	P992L	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	P992L	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
RET	D1031N	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	D1031N	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	D1031N	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	D1031N	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	D1031N	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	D1031N	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	D1031N	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	D1031N	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	D1031N	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
PDGFRA	R979C	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
TP53	G199*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G199*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G199*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G199*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G199*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G199*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G199*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G199*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G199*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G199*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G199*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G199*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G199*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G199*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G199*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	splice_acceptor_variant), ATM MUT (E2479*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	splice_acceptor_variant), ATM MUT (E2479*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	splice_acceptor_variant), ATM MUT (E2479*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	splice_acceptor_variant), ATM MUT (E2479*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	splice_acceptor_variant), ATM MUT (E2479*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	splice_acceptor_variant), ATM MUT (E2479*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	splice_acceptor_variant), ATM MUT (E2479*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	splice_acceptor_variant), ATM MUT (E2479*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	splice_acceptor_variant), ATM MUT (E2479*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	splice_acceptor_variant), ATM MUT (E2479*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	splice_acceptor_variant), ATM MUT (E2479*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	splice_acceptor_variant), ATM MUT (E2479*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	splice_acceptor_variant), ATM MUT (E2479*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
TP53	V216G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V216G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V216G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V216G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V216G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V216G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V216G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V216G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V216G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V216G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V216G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V216G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V216G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V216G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V216G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN1A	W49*	Complete Match	CDK2/4 inhibitor	Responsive	CANCER	Pre-clinical
CDKN1A	W49*	Different Alteration	CDK2/4 inhibitor	Responsive	CANCER	Pre-clinical
STK11	E138*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	E138*	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	E138*	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	E138*	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	E138*	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	E138*	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	E138*	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	E138*	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	E138*	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	E138*	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	E138*	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	E138*	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	E138*), KRAS MUT (G12D	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	E138*), KRAS MUT (G12D	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	E138*), KRAS MUT (G12D	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	E138*), KRAS MUT (G12D	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
TP53	C242S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C242S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C242S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C242S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C242S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C242S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C242S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C242S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C242S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C242S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C242S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C242S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C242S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C242S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C242S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P190L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P190L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P190L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P190L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P190L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P190L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P190L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P190L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P190L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P190L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P190L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P190L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P190L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P190L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P190L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E171*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E171*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E171*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E171*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E171*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E171*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E171*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E171*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E171*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E171*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E171*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E171*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E171*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E171*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E171*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB2	L313I	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	L313I	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	L313I	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	ST, BRCA, GEJA	FDA guidelines
ERBB2	L313I	Different Alteration	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	L313I	Different Alteration	MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor)	Responsive	SOLID	Early trials
ERBB2	L313I	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	L313I	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	L313I	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER, BRCA	Pre-clinical
ERBB2	L313I	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	CANCER	Early trials
ERBB2	L313I	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Case report
ERBB2	L313I	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA, LUAD	Case report
ERBB2	L313I	Different Mutation	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	L	Early trials
ERBB2	L313I	Different Mutation	Neratinib (ERBB2 inhibitor)	Resistant	BRCA	Case report
ERBB2	L313I	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	L313I	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	LUAD	Case report
ERBB2	L313I	Different Mutation	Lapatinib (ERBB2 inhibitor)	Resistant	BRCA	Pre-clinical
ERBB2	L313I	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB2	L313I	Complete Match	Temsirolimus (MTOR inhibitor)	Responsive	LUAD	Early trials
ERBB2	L313I	Complete Match	Dacomitinib (Pan ERBB inhibitor)	Responsive	NSCLC	Early trials
ERBB2	L313I	Complete Match	Neratinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	L313I	Different Mutation	ERBB2 inhibitor	Responsive	LUAD	Early trials
ERBB2	L313I	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Early trials
ERBB2	L313I	Different Mutation	ERBB2 mAb inhibitor	Responsive	LUAD	Early trials
ERBB2	L313I	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	L313I	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	L313I	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	LUAD	Early trials
ERBB2	L313I	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BRCA	Late trials
ERBB2	L313I	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	BT	Early trials
ERBB2	L313I	Different Alteration	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Responsive	COREAD	Late trials
ERBB2	L313I	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	OV	Early trials
ERBB2	L313I	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BLCA	Case report
ERBB2	L313I	Different Alteration	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	COREAD	Case report
ERBB2	L313I	Different Alteration	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
ERBB2	L313I	Different Alteration	Osimertinib (EGFR inhibitor)	Resistant	LUAD	Case report
ERBB2	L313I	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	BT	Early trials
ERBB2	L313I	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Early trials
ERBB2	L313I	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	BT	Early trials
ERBB2	L313I	Different Alteration	Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor)	Responsive	BRCA	Early trials
ERBB2	L313I	Different Alteration	HER2 inhibitor;CDK4/6 inhibitor	Responsive	BRCA	Pre-clinical
ERBB2	L313I	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	L313I	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	ST	Early trials
ERBB2	L313I	Different Alteration	Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
ERBB2	L313I	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	ST, GEJA	FDA guidelines
ERBB2	L313I	Different Alteration	ERBB2 inhibitor;CDK4/6 inhibitor	Responsive	BRCA	Pre-clinical
ERBB2	L313I	Different Alteration	Ado-Trastuzumab Emtansine (EGFR mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	L313I	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	HNC	Case report
ERBB2	L313I	Different Alteration	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Late trials
ERBB2	L313I	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	No Responsive	ED	Early trials
ERBB2	L313I	Different Alteration	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Responsive	ED	Pre-clinical
ERBB2	L313I	Different Alteration	Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy)	Responsive	ST	Early trials
ERBB2	L313I	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	ST	Case report
ERBB2	L313I	Different Alteration	EGFR inhibitor	Resistant	LUAD	Pre-clinical
ALK	R1061Q	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1061Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	R1061Q	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	R1061Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	R1061Q	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	R1061Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R1061Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	R1061Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R1061Q	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R1061Q	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	R1061Q	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	R1061Q	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	R1061Q	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1061Q	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1061Q	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	R1061Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	R1061Q	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	R1061Q	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R1061Q	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ERBB4	C824Y	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ATM	R1875*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R1875*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R1875*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R1875*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R1875*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R1875*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R1875*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R1875*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R1875*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R1875*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R1875*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R1875*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R1875*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
NTRK1	E223Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	E223Q	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	E223Q	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	E223Q	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
ERBB4	G516V	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
FGFR2	P23H	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	P23H	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
NOTCH2	A1154V	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ESR1	R243H	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
SETD2	R1492*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	R1492*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I232N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I232N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I232N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I232N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I232N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I232N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I232N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I232N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I232N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I232N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I232N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I232N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I232N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I232N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I232N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
DNMT3A	R882C	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
NTRK1	A425G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	A425G	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	A425G	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	A425G	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
TP53	R248Q), TP53 MUT (D208V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R248Q), TP53 MUT (D208V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R248Q), TP53 MUT (D208V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R248Q), TP53 MUT (D208V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R248Q), TP53 MUT (D208V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R248Q), TP53 MUT (D208V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248Q), TP53 MUT (D208V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248Q), TP53 MUT (D208V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R248Q), TP53 MUT (D208V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R248Q), TP53 MUT (D208V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R248Q), TP53 MUT (D208V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248Q), TP53 MUT (D208V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R248Q), TP53 MUT (D208V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248Q), TP53 MUT (D208V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L130H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L130H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L130H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L130H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L130H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L130H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L130H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L130H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L130H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L130H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L130H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L130H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L130H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L130H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L130H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L257P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L257P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L257P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L257P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L257P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L257P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L257P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L257P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L257P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L257P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L257P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L257P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L257P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L257P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L257P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	R348Q	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R348Q	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R348Q	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R348Q	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R348Q	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R348Q	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R348Q	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R348Q	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R348Q	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ROS1	T2195S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	T2195S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	T2195S	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	T2195S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	T2195S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
AKT3	R270H	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
ROS1	V1254A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	V1254A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	V1254A	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	V1254A	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	V1254A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
MET	T495I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
ERBB4	D518G	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
TP53	H179D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H179D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H179D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H179D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H179D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H179D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H179D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H179D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H179D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H179D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H179D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H179D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H179D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H179D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H179D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	E26*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E26*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E26*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	E26*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E26*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E26*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E26*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E26*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
EGFR	A289V	Different Alteration	Cetuximab (EGFR mAb inhibitor)	Responsive	COREAD	FDA guidelines
EGFR	A289V	Different Alteration	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
EGFR	A289V	Different Mutation	Rindopepimut (Vaccine)	Responsive	GB	Late trials
EGFR	A289V	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	A289V	Different Mutation	Gefitinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	A289V	Different Mutation	HSP90 inhibitor	Responsive	L	Early trials
EGFR	A289V	Different Mutation	Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	A289V	Different Mutation	MEK inhibitor	Responsive	L	Pre-clinical
EGFR	A289V	Different Mutation	EGFR TK inhibitor	Responsive	L	Late trials
EGFR	A289V	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	NCCN guidelines
EGFR	A289V	Different Mutation	Osimertinib (EGFR inhibitor)	Resistant	L	Early trials
EGFR	A289V	Different Mutation	EGFR-TKI's (EGFR inhibitor)	Resistant	L	Late trials
EGFR	A289V	Different Mutation	HSP90 inhibitor	Responsive	L	Case report
EGFR	A289V	Different Mutation	EGFR inhibitor	Resistant	L	Late trials
EGFR	A289V	Different Mutation	Poziotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	A289V	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Pre-clinical
EGFR	A289V	Different Mutation	HSP90 inhibitor (HSP90 inhibitor)	Responsive	L	Early trials
EGFR	A289V	Complete Match	Erlotinib (EGFR inhibitor)	Responsive	G	Pre-clinical
EGFR	A289V	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	A289V	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	A289V	Different Mutation	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
EGFR	A289V	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Responsive	COREAD	Case report
EGFR	A289V	Different Mutation	novel EGFR mAb inhibitor	Responsive	COREAD	Early trials
EGFR	A289V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	A289V	Different Mutation	Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor)	Responsive	HNC	Case report
EGFR	A289V	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	A289V	Different Mutation	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Case report
EGFR	A289V	Different Mutation	EGFR inhibitor	Responsive	L	Early trials
EGFR	A289V	Different Mutation	Erlotinib (EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	A289V	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	A289V	Different Mutation	EGFR inhibitor	Responsive	NSCLC	Late trials
EGFR	A289V	Different Mutation	Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	A289V	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	A289V	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	A289V	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	L	Late trials
EGFR	A289V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Pre-clinical
EGFR	A289V	Different Mutation	Erlotinib (EGFR inhibitor)	No Responsive	L	Case report
EGFR	A289V	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	ED	Case report
EGFR	A289V	Different Mutation	EGFR inhibitor	No Responsive	G	Early trials
EGFR	A289V	Different Mutation	EGFR inhibitor	Resistant	NSCLC	Case report
EGFR	A289V	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	A289V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant;Resistant	COREAD	Pre-clinical;Case report
EGFR	A289V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Responsive	HNC	Case report
EGFR	A289V	Different Alteration	Gefitinib (EGFR inhibitor)	Responsive	ED	Late trials
EGFR	A289V	Different Alteration	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Early trials
EGFR	A289V	Different Alteration	EGFR inhibitor	Responsive	HNSC	Case report
EGFR	A289V	Different Alteration	EGFR inhibitor	No Responsive	G	Early trials
EGFR	A289V	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	L	Early trials
EGFR	A289V	Different Alteration	EGFR mAb inhibitor	Responsive	COREAD	Late trials
EGFR	A289V	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	A289V	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
TP53	C242F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C242F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C242F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C242F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C242F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C242F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C242F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C242F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C242F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C242F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C242F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C242F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C242F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C242F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C242F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	G7D	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	G7D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	G7D	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	G7D	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	G7D	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	G7D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	G7D	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	G7D	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	G7D	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
CTNNB1	S37C	Complete Match	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	S37C	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
TP53	N239S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	N239S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	N239S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	N239S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	N239S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	N239S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	N239S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N239S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N239S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	N239S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	N239S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	N239S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N239S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	N239S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N239S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRD4	T298S	Different Alteration	BET inhibitor	Responsive	NMC	Case report
BRAF	D391N	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	D391N	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	D391N	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	D391N	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
NTRK1	V106M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	V106M	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	V106M	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	V106M	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
SF3B1	E622D	Different Mutation	Spliceosome inhibitor	Responsive	CANCER	Pre-clinical
JAK2	R1113H	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
TP53	V203E	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V203E	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V203E	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V203E	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V203E	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V203E	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V203E	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V203E	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V203E	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V203E	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V203E	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V203E	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V203E	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V203E	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V203E	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R306*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R306*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R306*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R306*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R306*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R306*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R306*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R306*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R306*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R306*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R306*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R306*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R306*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R306*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R306*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	D489E	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	D489E	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	D489E	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	D489E	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	D489E	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	D489E	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	D489E	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	D489E	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	D489E	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
TP53	V272M	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V272M	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V272M	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V272M	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V272M	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V272M	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V272M	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V272M	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V272M	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V272M	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V272M	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V272M	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V272M	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V272M	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V272M	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PIK3CA	E542K	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	E542K	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	E542K	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	E542K	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	E542K	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	E542K	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	E542K	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	E542K	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	E542K	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	E542K	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	E542K	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	E542K	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	E542K	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	E542K	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
TP53	R342*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R342*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R342*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R342*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R342*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R342*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R342*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R342*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R342*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R342*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R342*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R342*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R342*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R342*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R342*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	V2054G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	V2054G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	V2054G	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	V2054G	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	V2054G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ARID1A	Y1211fs1	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y1211fs1	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y1211fs1	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Y1211fs1	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	A161T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	A161T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	A161T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	A161T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	A161T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	A161T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	A161T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A161T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A161T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	A161T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	A161T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	A161T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A161T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	A161T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A161T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E224D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E224D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E224D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E224D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E224D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E224D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E224D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E224D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E224D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E224D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E224D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E224D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E224D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E224D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E224D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FGFR3	IntronicBlockSubstitution	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	IntronicBlockSubstitution	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	IntronicBlockSubstitution	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
KRAS	G12F	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12F	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12F	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12F	Complete Match	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12F	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12F	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12F	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12F	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12F	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12F	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12F	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12F	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12F	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12F	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12F	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12F	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12F	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12F	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12F	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12F	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12F	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12F	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12F	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12F	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12F	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12F	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12F	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12F	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12F	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12F	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12F	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12F	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12F	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12F	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12F	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12F	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12F	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12F	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12F	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12F	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12F	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	W91*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	W91*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	W91*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	W91*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	W91*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	W91*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	W91*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	W91*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	W91*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	W91*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	W91*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	W91*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	W91*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	W91*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	W91*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
JAK2	G417S	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
RET	V223M	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	V223M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	V223M	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	V223M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	V223M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	V223M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	V223M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	V223M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	V223M	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
TP53	Y236C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y236C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y236C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y236C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y236C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y236C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y236C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y236C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y236C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y236C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y236C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y236C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y236C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y236C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y236C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L257Q	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L257Q	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L257Q	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L257Q	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L257Q	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L257Q	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L257Q	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L257Q	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L257Q	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L257Q	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L257Q	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L257Q	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L257Q	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L257Q	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L257Q	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
VHL	G114S	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
BRAF	G469S	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	G469S	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	G469S	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	NCCN guidelines
BRAF	G469S	Different Mutation	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469S	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469S	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469S	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	G469S	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	G469S	Different Mutation	ERK inhibitor	Responsive	HNSC, BT	Case report
BRAF	G469S	Different Mutation	EGFR TK inhibitor	Resistant	LUAD	Case report
BRAF	G469S	Different Mutation	MEK inhibitor	Responsive	CM	Case report
BRAF	G469S	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	G469S	Different Mutation	BRAF inhibitor	Responsive	CM	Case report
BRAF	G469S	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	G469S	Different Mutation	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	G469S	Different Mutation	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	G469S	Different Mutation	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	G469S	Different Mutation	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	G469S	Different Mutation	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	G469S	Different Mutation	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	G469S	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	G469S	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	G469S	Different Mutation	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	G469S	Different Mutation	BRAF inhibitor;HSP90 inhibitor	Responsive	CM	Pre-clinical
BRAF	G469S	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	G469S	Different Mutation	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	G469S	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	G469S	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	G469S	Different Mutation	MEK inhibitor	Responsive	TH	Early trials
BRAF	G469S	Different Mutation	BRAF inhibitor;PI3K pathway inhibitor	Responsive	CM	Pre-clinical
BRAF	G469S	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	G469S	Different Mutation	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	G469S	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469S	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	G469S	Different Mutation	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	G469S	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	G469S	Different Mutation	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	G469S	Different Mutation	BRAF inhibitor;CDK2/4 inhibitor	Responsive	CM	Pre-clinical
BRAF	G469S	Different Mutation	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	G469S	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	G469S	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	G469S	Different Mutation	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	G469S	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	G469S	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	G469S	Different Mutation	BRAF inhibitor	Responsive	OV	Case report
BRAF	G469S	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	G469S	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469S	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	G469S	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	G469S	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	G469S	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	G469S	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
NOTCH1	V2529I	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	V2529I	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	M700I	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	M700I	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	M700I	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NOTCH1	P2469S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	P2469S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
SRSF2	P95H	Complete Match	Spliceosome inhibitor	Responsive	AML	Pre-clinical
FGFR2	L258F	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	L258F	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
TP53	H193L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H193L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H193L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H193L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H193L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H193L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H193L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H193L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H193L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H193L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H193L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H193L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H193L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H193L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H193L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RB1	C712*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	C712*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	C712*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	C712*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	C712*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	C712*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	C712*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
NOTCH2	S2379F	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	V172F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V172F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V172F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V172F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V172F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V172F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V172F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V172F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V172F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V172F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V172F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V172F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V172F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V172F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V172F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ALK	A1200V	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	A1200V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	A1200V	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	A1200V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	A1200V	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	A1200V	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A1200V	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	A1200V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A1200V	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A1200V	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	A1200V	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	A1200V	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	A1200V	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	A1200V	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	A1200V	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	A1200V	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	A1200V	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	A1200V	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A1200V	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
JAK2	H608R	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
TP53	V173G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V173G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V173G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V173G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V173G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V173G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V173G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V173G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V173G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V173G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V173G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V173G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V173G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V173G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V173G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2A	S70N	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S70N	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S70N	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S70N	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S70N	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S70N	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
KMT2A	G1160S	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	G1160S	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	G1160S	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	G1160S	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	G1160S	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	G1160S	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ESR1	CdsStartSNV	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
ERBB4	R1112C	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ATM	R110*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R110*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R110*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R110*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R110*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R110*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R110*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R110*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R110*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R110*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R110*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R110*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R110*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ARID1A	R1446*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1446*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1446*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	R1446*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
JAK2	S523P	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
TP53	L145P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L145P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L145P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L145P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L145P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L145P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L145P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L145P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L145P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L145P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L145P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L145P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L145P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L145P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L145P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ESR1	A59V	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
MET	intron_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
BRAF	L485F	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	L485F	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	L485F	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	L485F	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
EGFR	R671C	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	R671C	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
FGFR3	M69V	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	M69V	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	M69V	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
STK11	W332*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	W332*	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	W332*	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	W332*	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	W332*	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	W332*	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	W332*	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	W332*	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	W332*	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	W332*	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	W332*	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	W332*	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	W332*), KRAS MUT (G12R	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	W332*), KRAS MUT (G12R	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	W332*), KRAS MUT (G12R	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	W332*), KRAS MUT (G12R	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
TP53	R175G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R175G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R175G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R175G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R175G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R175G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R175G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R175G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R175G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R175G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R175G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RAF1	S259Y	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	S259Y	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	S259Y	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
TP53	E258K	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E258K	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E258K	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E258K	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E258K	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E258K	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E258K	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E258K	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E258K	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E258K	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E258K	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E258K	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E258K	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E258K	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E258K	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	V126D	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	V126D	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	V126D	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	V126D	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	V126D	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	V126D	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	V126D	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	V126D	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
JAK2	G834D	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
CTNNB1	S33Y	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	S33Y	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
DNMT3A	R882H	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
TP53	E294*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E294*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E294*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E294*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E294*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E294*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E294*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E294*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E294*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E294*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E294*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E294*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E294*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E294*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E294*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E339*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E339*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E339*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E339*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E339*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E339*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E339*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E339*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E339*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E339*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E339*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E339*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E339*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E339*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E339*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	R1276*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1276*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1276*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	R1276*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
STK11	Y60*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	Y60*	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	Y60*	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	Y60*	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	Y60*	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	Y60*	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y60*	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y60*	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	Y60*	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	Y60*	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	Y60*	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y60*	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y60*), KRAS MUT (G12V	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	Y60*), KRAS MUT (G12V	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	Y60*), KRAS MUT (G12V	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	Y60*), KRAS MUT (G12V	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
TP53	V157F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V157F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V157F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V157F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V157F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V157F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V157F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V157F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V157F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V157F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V157F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V157F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V157F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V157F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V157F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	H83Y), CDKN2A MUT (W110*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	H83Y), CDKN2A MUT (W110*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	H83Y), CDKN2A MUT (W110*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	H83Y), CDKN2A MUT (W110*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	H83Y), CDKN2A MUT (W110*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	H83Y), CDKN2A MUT (W110*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	H83Y), CDKN2A MUT (W110*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	H83Y), CDKN2A MUT (W110*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
NOTCH1	V2110E	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	V2110E	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	V173L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V173L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V173L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V173L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V173L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V173L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V173L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V173L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V173L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V173L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V173L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V173L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V173L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V173L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V173L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NTRK1	R214W	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R214W	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R214W	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R214W	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
FGFR3	K715K	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	K715K	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	K715K	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TP53	G245V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G245V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G245V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G245V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G245V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G245V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G245V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G245V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G245V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G245V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G245V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G245V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G245V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G245V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G245V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH2	S2222R	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRCA1	R1443*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA1	R1443*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA1	R1443*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA1	R1443*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	R1443*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	R1443*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Case report
BRCA1	R1443*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA1	R1443*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA1	R1443*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	R1443*	Complete Match	PARP inhibitor	Responsive	PA	Case report
BRCA1	R1443*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	R1443*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
TP53	E285K	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E285K	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E285K	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E285K	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E285K	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E285K	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E285K	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E285K	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E285K	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E285K	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E285K	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E285K	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E285K	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E285K	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E285K	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V216M	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V216M	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V216M	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V216M	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V216M	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V216M	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V216M	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V216M	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V216M	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V216M	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V216M	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V216M	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V216M	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V216M	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V216M	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S215G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S215G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S215G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S215G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S215G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S215G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S215G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S215G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S215G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S215G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S215G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S215G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S215G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S215G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S215G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PBRM1	E441*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	E441*	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	E441*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	E441*	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	E441*	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
TMPRSS2	intron_variant	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	intron_variant	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
TP53	G244D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G244D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G244D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G244D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G244D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G244D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G244D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G244D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G244D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G244D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G244D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G244D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G244D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G244D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G244D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NTRK1	R157H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R157H	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R157H	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R157H	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
NRG1	R438H	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	R438H	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
ERBB4	R544Q	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
TP53	P152L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P152L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P152L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P152L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P152L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P152L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P152L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P152L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P152L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P152L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P152L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P152L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P152L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P152L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P152L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RNF43	R519*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
CDKN2A	E119Qfs*18	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E119Qfs*18	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E119Qfs*18	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	E119Qfs*18	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E119Qfs*18	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E119Qfs*18	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E119Qfs*18	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E119Qfs*18	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
MET	P4T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
JAK2	T7M	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
BCOR	Q990*	Complete Match	Enzastaurin (PKCb inhibitor)	Responsive	ST	Pre-clinical
TP53	G245D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G245D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G245D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G245D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G245D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G245D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G245D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G245D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G245D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G245D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G245D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G245D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G245D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G245D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G245D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRD4	intron_variant	Different Alteration	BET inhibitor	Responsive	NMC	Case report
BRAF	D663Y	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	D663Y	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	D663Y	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	D663Y	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TP53	S241C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S241C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S241C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S241C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S241C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S241C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S241C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S241C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S241C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S241C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S241C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S241C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S241C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S241C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S241C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P250S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P250S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P250S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P250S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P250S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P250S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P250S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P250S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P250S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P250S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P250S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P250S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P250S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P250S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P250S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	V412M	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	V412M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	V412M	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	V412M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	V412M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	V412M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	V412M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	V412M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	V412M	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
NTRK1	V710M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	V710M	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	V710M	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	V710M	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
KMT2A	R2127*	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	R2127*	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	R2127*	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	R2127*	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	R2127*	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	R2127*	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
CBL	C384R	Complete Match	JAK inhibitor	Responsive	MDPS	Pre-clinical
CBL	C384R	Complete Match	Dasatinib (BCR-ABL inhibitor)	Responsive	MDPS	Pre-clinical
TP53	R273P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R273P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R273P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R273P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R273P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R273P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R273P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R273P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R273P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R273P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R273P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R273P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R273P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R273P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R273P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2A	T542M	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	T542M	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	T542M	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	T542M	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	T542M	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	T542M	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ALK	E1400D	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	E1400D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	E1400D	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	E1400D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	E1400D	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	E1400D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	E1400D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	E1400D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	E1400D	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	E1400D	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	E1400D	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	E1400D	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	E1400D	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	E1400D	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	E1400D	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	E1400D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	E1400D	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	E1400D	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	E1400D	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
TP53	E287*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E287*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E287*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E287*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E287*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E287*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E287*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E287*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E287*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E287*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E287*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E287*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E287*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E287*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E287*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRAF	CdsStopSNV	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	CdsStopSNV	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	CdsStopSNV	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	CdsStopSNV	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
FGFR3	C545Y	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	C545Y	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	C545Y	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
VHL	F76Lfs*51	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
CDKN2A	splice_donor_variant	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	splice_donor_variant	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	splice_donor_variant	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	splice_donor_variant	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	splice_donor_variant	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	splice_donor_variant	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	splice_donor_variant	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	splice_donor_variant	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
RAF1	R40P	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	R40P	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	R40P	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
NTRK3	T269M	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	T269M	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	T269M	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
TP53	S127T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S127T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S127T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S127T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S127T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S127T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S127T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S127T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S127T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S127T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S127T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S127T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S127T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S127T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S127T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH2	D1151N	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
FGFR2	R479G	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	R479G	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
BRD4	V422I	Different Alteration	BET inhibitor	Responsive	NMC	Case report
TP53	Y327*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y327*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y327*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y327*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y327*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y327*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y327*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y327*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y327*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y327*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y327*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y327*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y327*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y327*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y327*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
MET	G1137A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
SETD2	E581*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	E581*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
TMPRSS2	P83L	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	P83L	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
ERBB4	T176P	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ERCC2	splice_acceptor_variant	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ERCC2	splice_acceptor_variant	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ERCC2	splice_acceptor_variant	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
EGFR	E534K), EGFR MUT* (S161N	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	E534K), EGFR MUT* (S161N	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
ATM	W1750*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	W1750*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	W1750*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	W1750*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	W1750*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	W1750*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	W1750*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	W1750*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	W1750*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	W1750*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	W1750*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	W1750*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	W1750*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ARID1A	splice_acceptor_variant	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	splice_acceptor_variant	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	splice_acceptor_variant	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	splice_acceptor_variant	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ABL1	T544I), ABL1 MUT* (A102V	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	T544I), ABL1 MUT* (A102V	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	T544I), ABL1 MUT* (A102V	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	T544I), ABL1 MUT* (A102V	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	T544I), ABL1 MUT* (A102V	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	T544I), ABL1 MUT* (A102V	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
SETD2	G1231*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	G1231*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
PTEN	splice_donor_variant	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	splice_donor_variant	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	splice_donor_variant	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	splice_donor_variant	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	splice_donor_variant	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	splice_donor_variant	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	splice_donor_variant	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	splice_donor_variant	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	splice_donor_variant	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	splice_donor_variant	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	splice_donor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	splice_donor_variant	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	splice_donor_variant	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	splice_donor_variant	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	splice_donor_variant	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	splice_donor_variant	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	splice_donor_variant	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	splice_donor_variant	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	splice_donor_variant	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	splice_donor_variant	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	splice_donor_variant	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	splice_donor_variant	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	splice_donor_variant	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	splice_donor_variant	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	splice_donor_variant	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PDGFRA	S1057F), PDGFRA MUT* (G439D), PDGFRA MUT* (intron_variant), PDGFRA MUT* (G177S	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
PML	intron_variant	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	intron_variant	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	intron_variant	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
KIT	V555I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	AML	Pre-clinical
KIT	V555I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	HES, ALL, MDS, SM, ECL, MDPS, CML	FDA guidelines
KIT	V555I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	V555I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Pre-clinical
KIT	V555I	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Case report
KIT	V555I	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CANCER	Pre-clinical
KIT	V555I	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	SM	Early trials
KIT	V555I	Complete Match	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Case report
KIT	V555I	Complete Match	Dasatinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	V555I	Complete Match	HSP90 inhibitor	Responsive	GIST	Early trials
KIT	V555I	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Early trials
KIT	V555I	Complete Match	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	V555I	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	GIST	FDA guidelines
KIT	V555I	Complete Match	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	V555I	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Responsive	CM	Late trials;NCCN guidelines
KIT	V555I	Complete Match	Regorafenib (Pan-kinase inhibitor)	Responsive	GIST	FDA guidelines
KIT	V555I	Complete Match	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	V555I	Complete Match	Sunitinib (Pan-TK inhibitor)	Responsive	CM	Late trials
KIT	V555I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	V555I	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	FDA guidelines
KIT	V555I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	CM	Early trials
KIT	V555I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	THYM	Case report
KIT	V555I	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	V555I	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	V555I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KIT	V555I	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	V555I	Different Mutation	HSP90 inhibitor	Responsive	GIST	Pre-clinical
KIT	V555I	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Pre-clinical
KIT	V555I	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Pre-clinical
KIT	V555I	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	V555I	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	Late trials
KIT	V555I	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	GIST	Pre-clinical
KIT	V555I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Late trials
KIT	V555I	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	V555I	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	GIST	Early trials
KIT	V555I	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	V555I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	V555I	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	V555I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	CM	Case report
KIT	V555I	Different Alteration	Sunitinib (Pan-TK inhibitor)	No Responsive	CM	Early trials
KIT	V555I	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	No Responsive	CM	Early trials
FGFR3	P300L), FGFR3 MUT* (D147N	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	P300L), FGFR3 MUT* (D147N	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	P300L), FGFR3 MUT* (D147N	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TMPRSS2	G254D	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	G254D	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
RET	G1082D	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	G1082D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	G1082D	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	G1082D	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	G1082D	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	G1082D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	G1082D	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	G1082D	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	G1082D	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ROS1	W119), ROS1 MUT (P1454S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	W119), ROS1 MUT (P1454S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	W119), ROS1 MUT (P1454S	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	W119), ROS1 MUT (P1454S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	W119), ROS1 MUT (P1454S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
KMT2A	P3791S), MLL MUT* (P2129S), MLL MUT* (P1684S	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P3791S), MLL MUT* (P2129S), MLL MUT* (P1684S	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P3791S), MLL MUT* (P2129S), MLL MUT* (P1684S	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P3791S), MLL MUT* (P2129S), MLL MUT* (P1684S	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P3791S), MLL MUT* (P2129S), MLL MUT* (P1684S	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P3791S), MLL MUT* (P2129S), MLL MUT* (P1684S	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NF1	W2225*	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NF1	W2225*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	HNC	Case report
NF1	W2225*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	W2225*	Complete Match	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	W2225*	Complete Match	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NF1	W2225*	Complete Match	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	W2225*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	W2225*	Complete Match	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	W2225*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	NF	Late trials
NF1	W2225*	Complete Match	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	W2225*	Complete Match	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	W2225*	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	MPN, PLEN	Pre-clinical
NF1	W2225*	Complete Match	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	W2225*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	HNC, SG	Case report
NF1	W2225*	Complete Match	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	W2225*	Complete Match	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	W2225*	Complete Match	MEK inhibitor	Responsive	LK, G	Pre-clinical
NF1	W2225*	Complete Match	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	W2225*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	W2225*	Complete Match	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	W2225*	Complete Match	MTOR inhibitor	Responsive	LK, G, MPN	Pre-clinical
NF1	W2225*	Complete Match	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	W2225*	Complete Match	Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor)	Responsive	HC	Case report
NF1	W2225*	Complete Match	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	W2225*	Complete Match	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	W2225*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	W2225*	Complete Match	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	W2225*	Complete Match	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	W2225*	Complete Match	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	W2225*	Complete Match	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	W2225*	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	W2225*	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	W2225*	Complete Match	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	W2225*	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	W2225*	Complete Match	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	W2225*	Complete Match	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	W2225*	Different Alteration	MTOR inhibitor	Responsive	MPN, G, LK	Pre-clinical
NF1	W2225*	Different Alteration	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	W2225*	Different Alteration	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	W2225*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	W2225*	Different Alteration	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	W2225*	Different Alteration	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	W2225*	Different Alteration	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	W2225*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	W2225*	Different Alteration	MEK inhibitor	Responsive	G, LK	Pre-clinical
NF1	W2225*	Different Alteration	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	W2225*	Different Alteration	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	W2225*	Different Alteration	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	W2225*	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	W2225*	Different Alteration	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	W2225*	Different Alteration	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	W2225*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	W2225*	Different Alteration	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	W2225*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SG, HNC	Case report
NF1	W2225*	Different Alteration	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	W2225*	Different Alteration	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	W2225*	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	W2225*	Different Alteration	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	W2225*	Different Alteration	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	W2225*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	W2225*	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	PLEN, MPN	Pre-clinical
NF1	W2225*	Different Alteration	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	W2225*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	W2225*	Different Alteration	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	W2225*	Different Alteration	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	W2225*	Different Alteration	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	W2225*	Different Alteration	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	W2225*	Different Alteration	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NTRK1	G221S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	G221S	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	G221S	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	G221S	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
NOTCH2	Q2409*	Complete Match	Mk-0752 (Gamma secretase inhibitor)	Responsive	ALL, AML, BRCA	Early trials
NOTCH2	Q2409*	Complete Match	OMP-59R5 (NOTCH2 inhibitor)	Responsive	SOLID	Early trials
NOTCH2	Q2409), NOTCH2 MUT (G1076D	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	splice_donor_variant	Different Mutation	Gamma secretase inhibitor	Responsive	CANCER	Early trials
NOTCH1	splice_donor_variant	Different Mutation	Gamma secretase inhibitor;CDK4 inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	splice_donor_variant	Different Mutation	Gamma secretase inhibitor;MTOR inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	splice_donor_variant	Different Mutation	Gamma secretase inhibitor	Responsive;Responsive	ALL	Early trials;Pre-clinical
NOTCH1	splice_donor_variant	Different Mutation	NOTCH1 inhibitor	Responsive	ADCC	Case report
NOTCH1	splice_donor_variant	Different Mutation	OMP-52M51 (NOTCH1 inhibitor)	Responsive	CANCER	Early trials
NOTCH1	splice_donor_variant	Different Mutation	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	splice_donor_variant	Complete Match	Gamma secretase inhibitor	Responsive	MCL	Pre-clinical
NOTCH1	splice_donor_variant), NOTCH1 MUT* (P284S), NOTCH1 MUT* (intron_variant), NOTCH1 MUT* (G1072D), NOTCH1 MUT* (V1288A	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	splice_donor_variant), NOTCH1 MUT* (P284S), NOTCH1 MUT* (intron_variant), NOTCH1 MUT* (G1072D), NOTCH1 MUT* (V1288A	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRD4	A80T), BRD4 MUT* (P760L	Different Alteration	BET inhibitor	Responsive	NMC	Case report
BRAF	A404V	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	A404V	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	A404V	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	A404V	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
BCOR	Q848*	Complete Match	Enzastaurin (PKCb inhibitor)	Responsive	ST	Pre-clinical
STK11	R304W	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	R304W	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	R304W	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	R304W	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	R304W	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	R304W	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	R304W	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	R304W	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	R304W	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	R304W	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	R304W	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	R304W	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
FBXW7	R278*	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	R278*	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	R278*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	R278*	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
TP53	R267W	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R267W	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R267W	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R267W	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R267W	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R267W	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R267W	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R267W	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R267W	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R267W	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R267W	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R267W	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R267W	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R267W	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R267W	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	P574T	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ARID1A	W1023*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	W1023*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	W1023*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	W1023*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	C242G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C242G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C242G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C242G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C242G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C242G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C242G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C242G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C242G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C242G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C242G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C242G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C242G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C242G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C242G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L265P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L265P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L265P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L265P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L265P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L265P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L265P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L265P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L265P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L265P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L265P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L265P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L265P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L265P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L265P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PTEN	Y315*	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y315*	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y315*	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	Y315*	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	Y315*	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	Y315*	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y315*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y315*	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	Y315*	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	Y315*	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y315*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y315*	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	Y315*	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y315*	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	Y315*	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y315*	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	Y315*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y315*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y315*	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	Y315*	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y315*	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y315*	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y315*	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	Y315*	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y315*	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
KMT2D	R2830*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
PIK3CA	E545Q	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	E545Q	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	E545Q	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	E545Q	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	E545Q	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	E545Q	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	E545Q	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	E545Q	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	E545Q	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	E545Q	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	E545Q	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	E545Q	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	E545Q	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	E545Q	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
TP53	Y126D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y126D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y126D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y126D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y126D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y126D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y126D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y126D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y126D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y126D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y126D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y126D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y126D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y126D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y126D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PIK3CA	V105A	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	V105A	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	V105A	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	V105A	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	V105A	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	V105A	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	V105A	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	V105A	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	V105A	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	V105A	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	V105A	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	V105A	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	V105A	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	V105A	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
PTEN	M270I	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	M270I	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	M270I	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	M270I	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	M270I	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	M270I	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	M270I	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	M270I	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	M270I	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	M270I	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	M270I	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	M270I	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	M270I	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	M270I	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	M270I	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	M270I	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	M270I	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	M270I	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	M270I	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	M270I	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	M270I	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	M270I	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	M270I	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	M270I	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	M270I	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
FGFR2	R447W	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	R447W	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
ATM	E1978*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	E1978*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	E1978*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	E1978*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	E1978*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	E1978*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E1978*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	E1978*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E1978*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E1978*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E1978*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	E1978*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	E1978*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
TP53	V274A	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V274A	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V274A	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V274A	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V274A	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V274A	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V274A	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V274A	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V274A	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V274A	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V274A	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V274A	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V274A	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V274A	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V274A	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
DNMT3A	E667*	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
FANCA	E1023*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Case report
FANCA	E1023*	Different Alteration	Olaparib (PARP inhibitor)	Responsive	PRAD	Case report
BRCA1	splice_acceptor_variant	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA1	splice_acceptor_variant	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA1	splice_acceptor_variant	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA1	splice_acceptor_variant	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	splice_acceptor_variant	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	splice_acceptor_variant	Complete Match	WEE1 inhibitor	Responsive	CANCER	Case report
BRCA1	splice_acceptor_variant	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA1	splice_acceptor_variant	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA1	splice_acceptor_variant	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	splice_acceptor_variant	Complete Match	PARP inhibitor	Responsive	PA	Case report
BRCA1	splice_acceptor_variant	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	splice_acceptor_variant	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
AKT3	R465Q	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
PDGFRA	D983H	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
PML	D417H	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	D417H	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	D417H	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
SMARCA4	R1189*	Complete Match	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	R1189*	Complete Match	AURKA inhibitor	Responsive	NSCLC	Pre-clinical
SMARCA4	R1189*	Complete Match	EZH2 inhibitor	Responsive	OV	Case report
SMARCA4	R1189*	Different Alteration	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	R1189*	Different Alteration	EZH2 inhibitor	Responsive	OV	Case report
RNF43	Q8*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
CDKN2A	D108G	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	D108G	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	D108G	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	D108G	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	D108G	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	D108G	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	D108G	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	D108G	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	E120*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E120*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E120*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	E120*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E120*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E120*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E120*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E120*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
ABL1	T692M	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	T692M	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	T692M	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	T692M	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	T692M	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	T692M	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
TP53	E204*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E204*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E204*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E204*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E204*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E204*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E204*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E204*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E204*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E204*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E204*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E204*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E204*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E204*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E204*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRAF	N368D	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	N368D	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	N368D	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	N368D	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TP53	A159P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	A159P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	A159P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	A159P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	A159P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	A159P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	A159P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A159P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A159P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	A159P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	A159P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	A159P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A159P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	A159P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A159P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	A87V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	A87V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	A87V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	A87V	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	A87V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
TP53	P151H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P151H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P151H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P151H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P151H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P151H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P151H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P151H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P151H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P151H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P151H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P151H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P151H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P151H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P151H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PALB2	Q740*	Complete Match	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	Q740*	Complete Match	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	Q740*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
PALB2	Q740*	Complete Match	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	Q740*	Different Alteration	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	Q740*	Different Alteration	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	Q740*	Different Alteration	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	Q740*	Different Alteration	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
ARID1A	Q1473), ARID1A MUT (E1006	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1473), ARID1A MUT (E1006	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1473), ARID1A MUT (E1006	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q1473), ARID1A MUT (E1006	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ABL1	G701S	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	G701S	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G701S	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	G701S	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G701S	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	G701S	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
PTCH1	R1394*	Complete Match	Vismodegib (SHH inhibitor)	Responsive	BCC, MB	FDA guidelines
PTCH1	R1394*	Complete Match	Foretinib (MET inhibitor)	Responsive	MB	Pre-clinical
PTCH1	R1394*	Complete Match	SMO inhibitor	Responsive	MB	Pre-clinical
TP53	Y234C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y234C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y234C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y234C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y234C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y234C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y234C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y234C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y234C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y234C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y234C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y234C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y234C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y234C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y234C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	Y44*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	Y44*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	Y44*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	Y44*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	Y44*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	Y44*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	Y44*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	Y44*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	R58), CDKN2A MUT (R80	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R58), CDKN2A MUT (R80	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R58), CDKN2A MUT (R80	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	R58), CDKN2A MUT (R80	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R58), CDKN2A MUT (R80	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R58), CDKN2A MUT (R80	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R58), CDKN2A MUT (R80	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R58), CDKN2A MUT (R80	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
RNF43	E380*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
FGFR3	A150P	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	A150P	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	A150P	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TP53	C238R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C238R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C238R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C238R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C238R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C238R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C238R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C238R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C238R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C238R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C238R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C238R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C238R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C238R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C238R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ABL1	G744Efs*29	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	CML	European LeukemiaNet guidelines
ABL1	G744Efs*29	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Resistant	CML	European LeukemiaNet guidelines
ABL1	G744Efs*29	Different Mutation	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	NCCN guidelines
ABL1	G744Efs*29	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	NCCN guidelines
ABL1	G744Efs*29	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Resistant	CML	European LeukemiaNet guidelines
ABL1	G744Efs*29	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CML	NCCN guidelines
ABL1	G744Efs*29	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML	FDA guidelines
ABL1	G744Efs*29	Different Mutation	BCR-ABL inhibitor	Resistant	CML	European LeukemiaNet guidelines
ABL1	G744Efs*29	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	ALL	FDA guidelines
ABL1	G744Efs*29	Different Mutation	Axitinib (VEGFR inhibitor)	Responsive	CANCER	Pre-clinical
ABL1	G744Efs*29	Different Mutation	Bosutinib (BCR-ABL inhibitor)	Resistant	CML	European LeukemiaNet guidelines
ABL1	G744Efs*29	Different Mutation	Cabozantinib (Pan-kinase inhibitor)	Responsive	CANCER	Pre-clinical
ABL1	G744Efs*29	Different Mutation	Crizotinib (ALK inhibitor)	Responsive	CANCER	Pre-clinical
ABL1	G744Efs*29	Different Mutation	Vandetanib (Pan-TK inhibitor)	Responsive	CANCER	Pre-clinical
ABL1	G744Efs*29	Different Mutation	Foretinib (MET inhibitor)	Responsive	CANCER	Pre-clinical
ABL1	G744Efs*29	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	G744Efs*29	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G744Efs*29	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	G744Efs*29	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G744Efs*29	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	G744Efs*29	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
STK11	K44*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	K44*	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	K44*	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	K44*	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	K44*	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	K44*	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	K44*	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	K44*	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	K44*	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	K44*	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	K44*	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	K44*	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	K44*), KRAS MUT (G12R	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	K44*), KRAS MUT (G12R	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	K44*), KRAS MUT (G12R	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	K44*), KRAS MUT (G12R	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
JAK2	I35T	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
ARID1A	S1992*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S1992*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S1992*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	S1992*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
NRG1	intron_variant	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	intron_variant	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
BRD4	S1215P	Different Alteration	BET inhibitor	Responsive	NMC	Case report
BRCA2	E2663V	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	E2663V	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	E2663V	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	E2663V	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	E2663V	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	E2663V	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	E2663V	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	E2663V	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	E2663V	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	E2663V	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	E2663V	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	E2663V	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	E2663V	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	E2663V	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
NOTCH1	G2427S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	G2427S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ERBB4	T1057I	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ROS1	E1366K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	E1366K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	E1366K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	E1366K	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	E1366K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ERBB4	A17S	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
TP53	E271V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E271V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E271V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E271V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E271V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E271V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E271V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E271V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E271V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E271V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E271V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E271V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E271V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E271V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E271V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	I258T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	I258T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	I258T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	I258T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	I258T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ALK	Q300*	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q300*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	Q300*	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	Q300*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	Q300*	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	Q300*	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	Q300*	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	Q300*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	Q300*	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	Q300*	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	Q300*	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	Q300*	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	Q300*	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q300*	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q300*	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	Q300*	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	Q300*	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	Q300*	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	Q300*	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
FBXW7	Y545C	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	Y545C	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	Y545C	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	Y545C	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
TP53	Y205F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y205F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y205F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y205F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y205F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y205F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y205F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y205F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y205F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y205F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y205F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y205F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y205F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y205F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y205F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RB1	R255*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	R255*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R255*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R255*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	R255*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R255*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R255*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
TP53	V272L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V272L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V272L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V272L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V272L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V272L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V272L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V272L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V272L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V272L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V272L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V272L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V272L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V272L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V272L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	G276*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	G276*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	G276*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	G276*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
PML	S634N	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	S634N	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	S634N	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
NOTCH2	R1607P	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ARID1A	R1989*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1989*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1989*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	R1989*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ERBB4	G400S	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
TP53	H193R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H193R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H193R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H193R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H193R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H193R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H193R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H193R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H193R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H193R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H193R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H193R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H193R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H193R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H193R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H193N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H193N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H193N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H193N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H193N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H193N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H193N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H193N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H193N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H193N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H193N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H193N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H193N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H193N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H193N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KRAS	G13E	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G13E	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G13E	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G13E	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G13E	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G13E	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G13E	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G13E	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13E	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G13E	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G13E	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G13E	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G13E	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G13E	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G13E	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G13E	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G13E	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G13E	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G13E	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G13E	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13E	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G13E	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13E	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G13E	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G13E	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G13E	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G13E	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G13E	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G13E	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G13E	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G13E	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G13E	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G13E	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G13E	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13E	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G13E	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13E	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G13E	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G13E	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G13E	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G13E	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G13E	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
ERCC6	splice_acceptor_variant	Complete Match	Cisplatin (Chemotherapy)	Responsive	OV	Pre-clinical
SF3B1	K700E	Complete Match	Spliceosome inhibitor	Responsive	CANCER	Pre-clinical
CTNNB1	G34V	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	G34V	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
PML	R872C	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	R872C	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	R872C	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
ALK	intron_variant	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	intron_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	intron_variant	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	intron_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	intron_variant	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	intron_variant	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	intron_variant	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	intron_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	intron_variant	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	intron_variant	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	intron_variant	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	intron_variant	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	intron_variant	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	intron_variant	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	intron_variant	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	intron_variant	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	intron_variant	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	intron_variant	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	intron_variant	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
SF3B1	K666E	Different Mutation	Spliceosome inhibitor	Responsive	CANCER	Pre-clinical
ROS1	G816L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	G816L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	G816L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	G816L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	G816L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ERBB4	R81*	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	CM	Pre-clinical
ERBB4	R81*	Different Mutation	ERBB2 inhibitor	Resistant	BRCA	Case report
ERBB4	R81), ERBB4 MUT (R95C	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ERBB3	G284R	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	CANCER	Pre-clinical
ERBB3	G284R	Complete Match	Lapatinib (ERBB2 inhibitor)	Responsive	CANCER	Pre-clinical
ERBB3	G284R	Complete Match	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB3	G284R	Complete Match	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BLCA	Case report
ERBB3	G284R	Complete Match	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB3	G284R	Complete Match	ERBB3 mAb inhibitor	Responsive	CANCER	Pre-clinical
ERBB3	G284R	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Early trials
APC	R1450), APC MUT (R564	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
ATM	E642*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	E642*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	E642*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	E642*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	E642*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	E642*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E642*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	E642*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E642*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E642*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E642*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	E642*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	E642*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
PIK3R1	E458*	Complete Match	AKT inhibitor	Responsive	G	Pre-clinical
PIK3R1	E458*	Complete Match	PI3K pathway inhibitor	Responsive	ED	Case report
PIK3CA	R88Q), PIK3CA MUT (G118D	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	R88Q), PIK3CA MUT (G118D	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	R88Q), PIK3CA MUT (G118D	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	R88Q), PIK3CA MUT (G118D	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	R88Q), PIK3CA MUT (G118D	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	R88Q), PIK3CA MUT (G118D	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	R88Q), PIK3CA MUT (G118D	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	R88Q), PIK3CA MUT (G118D	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	R88Q), PIK3CA MUT (G118D	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	R88Q), PIK3CA MUT (G118D	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	R88Q), PIK3CA MUT (G118D	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	R88Q), PIK3CA MUT (G118D	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	R88Q), PIK3CA MUT (G118D	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	R88Q), PIK3CA MUT (G118D	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
PTEN	F145C), PTEN MUT (P38S	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	F145C), PTEN MUT (P38S	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	F145C), PTEN MUT (P38S	Complete Match	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	F145C), PTEN MUT (P38S	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	F145C), PTEN MUT (P38S	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	F145C), PTEN MUT (P38S	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	F145C), PTEN MUT (P38S	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	F145C), PTEN MUT (P38S	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	F145C), PTEN MUT (P38S	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	F145C), PTEN MUT (P38S	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	F145C), PTEN MUT (P38S	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	F145C), PTEN MUT (P38S	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	F145C), PTEN MUT (P38S	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	F145C), PTEN MUT (P38S	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	F145C), PTEN MUT (P38S	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	F145C), PTEN MUT (P38S	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	F145C), PTEN MUT (P38S	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	F145C), PTEN MUT (P38S	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	F145C), PTEN MUT (P38S	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	F145C), PTEN MUT (P38S	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	F145C), PTEN MUT (P38S	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	F145C), PTEN MUT (P38S	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	F145C), PTEN MUT (P38S	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	F145C), PTEN MUT (P38S	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	F145C), PTEN MUT (P38S	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
ROS1	R1506I), ROS1 MUT* (R2210I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	R1506I), ROS1 MUT* (R2210I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	R1506I), ROS1 MUT* (R2210I	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	R1506I), ROS1 MUT* (R2210I	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	R1506I), ROS1 MUT* (R2210I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
RB1	E137), RB1 MUT (E466	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	E137), RB1 MUT (E466	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	E137), RB1 MUT (E466	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	E137), RB1 MUT (E466	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	E137), RB1 MUT (E466	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	E137), RB1 MUT (E466	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	E137), RB1 MUT (E466	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
BCOR	splice_acceptor_variant	Complete Match	Enzastaurin (PKCb inhibitor)	Responsive	ST	Pre-clinical
JAK2	L55Q	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
NOTCH2	L775V	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
PIK3CA	R108H	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	R108H	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	R108H	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	R108H	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	R108H	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	R108H	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	R108H	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	R108H	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	R108H	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	R108H	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	R108H	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	R108H	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	R108H	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	R108H	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
CDKN2A	E69*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E69*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E69*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	E69*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E69*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E69*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E69*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E69*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
JAK2	N986K	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
TP53	E349*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E349*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E349*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E349*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E349*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E349*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E349*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E349*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E349*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E349*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E349*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E349*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E349*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E349*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E349*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TMPRSS2	P406S	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	P406S	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
VHL	V74G	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
ERBB2	V842I	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	V842I	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	V842I	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	ST, BRCA, GEJA	FDA guidelines
ERBB2	V842I	Different Alteration	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	V842I	Different Alteration	MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor)	Responsive	SOLID	Early trials
ERBB2	V842I	Complete Match	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	V842I	Complete Match	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	V842I	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER, BRCA	Pre-clinical
ERBB2	V842I	Complete Match	Neratinib (ERBB2 inhibitor)	Responsive	CANCER	Early trials
ERBB2	V842I	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	CANCER	Early trials
ERBB2	V842I	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Case report
ERBB2	V842I	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA, LUAD	Case report
ERBB2	V842I	Different Mutation	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	L	Early trials
ERBB2	V842I	Different Mutation	Neratinib (ERBB2 inhibitor)	Resistant	BRCA	Case report
ERBB2	V842I	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	V842I	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	LUAD	Case report
ERBB2	V842I	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	V842I	Different Mutation	Lapatinib (ERBB2 inhibitor)	Resistant	BRCA	Pre-clinical
ERBB2	V842I	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB2	V842I	Complete Match	Temsirolimus (MTOR inhibitor)	Responsive	LUAD	Early trials
ERBB2	V842I	Complete Match	Dacomitinib (Pan ERBB inhibitor)	Responsive	NSCLC	Early trials
ERBB2	V842I	Complete Match	Neratinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	V842I	Different Mutation	ERBB2 inhibitor	Responsive	LUAD	Early trials
ERBB2	V842I	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Early trials
ERBB2	V842I	Different Mutation	ERBB2 mAb inhibitor	Responsive	LUAD	Early trials
ERBB2	V842I	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	V842I	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	V842I	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	LUAD	Early trials
ERBB2	V842I	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BRCA	Late trials
ERBB2	V842I	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	BT	Early trials
ERBB2	V842I	Different Alteration	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Responsive	COREAD	Late trials
ERBB2	V842I	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	OV	Early trials
ERBB2	V842I	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BLCA	Case report
ERBB2	V842I	Different Alteration	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	COREAD	Case report
ERBB2	V842I	Different Alteration	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
ERBB2	V842I	Different Alteration	Osimertinib (EGFR inhibitor)	Resistant	LUAD	Case report
ERBB2	V842I	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	BT	Early trials
ERBB2	V842I	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Early trials
ERBB2	V842I	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	BT	Early trials
ERBB2	V842I	Different Alteration	Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor)	Responsive	BRCA	Early trials
ERBB2	V842I	Different Alteration	HER2 inhibitor;CDK4/6 inhibitor	Responsive	BRCA	Pre-clinical
ERBB2	V842I	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	V842I	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	ST	Early trials
ERBB2	V842I	Different Alteration	Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
ERBB2	V842I	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	ST, GEJA	FDA guidelines
ERBB2	V842I	Different Alteration	ERBB2 inhibitor;CDK4/6 inhibitor	Responsive	BRCA	Pre-clinical
ERBB2	V842I	Different Alteration	Ado-Trastuzumab Emtansine (EGFR mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	V842I	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	HNC	Case report
ERBB2	V842I	Different Alteration	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Late trials
ERBB2	V842I	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	No Responsive	ED	Early trials
ERBB2	V842I	Different Alteration	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Responsive	ED	Pre-clinical
ERBB2	V842I	Different Alteration	Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy)	Responsive	ST	Early trials
ERBB2	V842I	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	ST	Case report
ERBB2	V842I	Different Alteration	EGFR inhibitor	Resistant	LUAD	Pre-clinical
TP53	I195T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I195T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I195T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I195T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I195T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I195T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I195T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I195T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I195T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I195T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I195T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I195T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I195T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I195T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I195T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	E621K	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	E621K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	E621K	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	E621K	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E621K	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E621K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	E621K	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E621K	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E621K	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
NOTCH1	A2452P	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	A2452P	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
FGFR2	T125S	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	T125S	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
ERBB4	E1287*	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
JAK2	H886R	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
RB1	R467*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	R467*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R467*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R467*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	R467*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R467*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R467*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
TP53	W146*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	W146*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	W146*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	W146*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	W146*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	W146*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	W146*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	W146*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	W146*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	W146*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	W146*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	W146*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	W146*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	W146*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	W146*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	R87P	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R87P	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R87P	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	R87P	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R87P	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R87P	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R87P	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R87P	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
TP53	C176*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C176*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C176*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C176*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C176*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C176*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C176*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C176*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C176*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C176*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C176*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C141*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C141*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C141*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C141*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C141*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C141*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C141*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C141*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C141*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C141*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C141*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	D153H	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	D153H	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	D153H	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	D153H	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	D153H	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	D153H	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	D153H	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	D153H	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
KMT2A	S3479A	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S3479A	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S3479A	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S3479A	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S3479A	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S3479A	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
KMT2A	N2484S	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	N2484S	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	N2484S	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	N2484S	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	N2484S	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	N2484S	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
TMPRSS2	A299T	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	A299T	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
TP53	C238F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C238F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C238F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C238F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C238F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C238F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C238F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C238F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C238F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C238F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C238F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C238F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C238F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C238F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C238F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
SETD2	Q2292), SETD2 MUT (Q2329	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	Q2292), SETD2 MUT (Q2329	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
KMT2A	V2596A	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	V2596A	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	V2596A	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	V2596A	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	V2596A	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	V2596A	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ERBB4	V1134M	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
TP53	T155N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T155N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T155N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T155N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T155N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T155N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T155N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T155N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T155N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T155N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T155N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T155N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T155N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T155N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T155N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	K1178*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	K1178*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	K1178*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	K1178*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	K1178*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	K1178*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	K1178*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	K1178*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	K1178*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	K1178*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	K1178*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	K1178*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	K1178*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
TP53	I251F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I251F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I251F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I251F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I251F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I251F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I251F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I251F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I251F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I251F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I251F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I251F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I251F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I251F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I251F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ABL1	S915L	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	S915L	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	S915L	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	S915L	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	S915L	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	S915L	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ATM	K2756*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	K2756*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	K2756*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	K2756*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	K2756*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	K2756*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	K2756*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	K2756*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	K2756*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	K2756*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	K2756*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	K2756*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	K2756*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ARID1A	Q566*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q566*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q566*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q566*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E1733*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1733*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1733*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E1733*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
EGFR	P1101L	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	P1101L	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
ABL1	R819W	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	R819W	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R819W	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	R819W	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R819W	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	R819W	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
TP53	R249W	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R249W	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R249W	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R249W	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R249W	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R249W	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R249W	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R249W	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R249W	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R249W	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R249W	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R249W	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R249W	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R249W	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R249W	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	R2095H	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R2095H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	R175H), TP53 MUT (H178P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R175H), TP53 MUT (H178P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R175H), TP53 MUT (H178P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R175H), TP53 MUT (H178P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R175H), TP53 MUT (H178P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R175H), TP53 MUT (H178P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (H178P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (H178P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R175H), TP53 MUT (H178P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R175H), TP53 MUT (H178P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (H178P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H), TP53 MUT (H178P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R175H), TP53 MUT (H178P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H), TP53 MUT (H178P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	Q50P	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	Q50P	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	Q50P	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	Q50P	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	Q50P	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	Q50P	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	Q50P	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	Q50P	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
MSH2	CdsStartSNV	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
MSH2	CdsStartSNV	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
TP53	C275R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C275R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C275R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C275R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C275R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C275R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C275R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C275R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C275R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C275R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C275R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C275R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C275R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C275R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C275R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ESR1	T311M	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
ALK	M1615T	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	M1615T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	M1615T	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	M1615T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	M1615T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	M1615T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	M1615T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	M1615T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	M1615T	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	M1615T	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	M1615T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	M1615T	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	M1615T	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	M1615T	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	M1615T	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	M1615T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	M1615T	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	M1615T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	M1615T	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
TMPRSS2	E426A	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	E426A	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
RB1	Q762*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	Q762*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	Q762*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	Q762*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	Q762*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	Q762*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	Q762*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
NOTCH2	K974R	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ALK	A149V	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	A149V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	A149V	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	A149V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	A149V	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	A149V	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A149V	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	A149V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A149V	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A149V	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	A149V	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	A149V	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	A149V	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	A149V	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	A149V	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	A149V	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	A149V	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	A149V	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A149V	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
FGFR3	D513N	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	D513N	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	D513N	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TP53	R248W), TP53 MUT (N131S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R248W), TP53 MUT (N131S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R248W), TP53 MUT (N131S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R248W), TP53 MUT (N131S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R248W), TP53 MUT (N131S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R248W), TP53 MUT (N131S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R248W), TP53 MUT (N131S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248W), TP53 MUT (N131S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248W), TP53 MUT (N131S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R248W), TP53 MUT (N131S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R248W), TP53 MUT (N131S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R248W), TP53 MUT (N131S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248W), TP53 MUT (N131S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R248W), TP53 MUT (N131S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248W), TP53 MUT (N131S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
VHL	R167Q	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
RET	N783T	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	N783T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	N783T	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	N783T	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	N783T	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	N783T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	N783T	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	N783T	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	N783T	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
NOTCH2	R1895C	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ABL1	R170K	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	R170K	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R170K	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	R170K	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R170K	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	R170K	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
NRAS	G12C	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
NRAS	G12C	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
NRAS	G12C	Different Mutation	MEK inhibitor	Responsive	CM	Late trials
NRAS	G12C	Different Mutation	BRAF inhibitor	Resistant	CM	Early trials
NRAS	G12C	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CM	Early trials
NRAS	G12C	Complete Match	HSP90 inhibitor	Responsive	CM	Pre-clinical
NRAS	G12C	Complete Match	MEK inhibitor	Responsive	AML, LUAD, ALL	Pre-clinical
NRAS	G12C	Complete Match	Pan-RAF inhibitor	Responsive	CM	Case report
NRAS	G12C	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
NRAS	G12C	Complete Match	ERK inhibitor	Responsive	CM	Case report
NRAS	G12C	Complete Match	MEK inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
NRAS	G12C	Complete Match	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NRAS	G12C	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	MYMA	Pre-clinical
NRAS	G12C	Complete Match	ERK inhibitor	Responsive	CANCER	Pre-clinical
TP53	L130V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L130V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L130V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L130V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L130V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L130V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L130V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L130V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L130V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L130V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L130V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L130V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L130V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L130V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L130V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	K994R	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ROS1	P743L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	P743L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	P743L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	P743L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	P743L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
PIK3CA	E545A	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	E545A	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	E545A	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	E545A	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	E545A	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	E545A	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	E545A	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	E545A	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	E545A	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	E545A	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	E545A	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	E545A	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	E545A	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	E545A	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
EGFR	C157S	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	C157S	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
NOTCH2	N1102S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ARID1A	Y316*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y316*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y316*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Y316*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	V272Q	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V272Q	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V272Q	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V272Q	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V272Q	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V272Q	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V272Q	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V272Q	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V272Q	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V272Q	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V272Q	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V272Q	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V272Q	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V272Q	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V272Q	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	I1231T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	I1231T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	I1231T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	I1231T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	I1231T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
TP53	M169_H179delinsG	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	M169_H179delinsG	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	M169_H179delinsG	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	M169_H179delinsG	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	M169_H179delinsG	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	M169_H179delinsG	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M169_H179delinsG	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M169_H179delinsG	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M169_H179delinsG	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	M169_H179delinsG	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	M169_H179delinsG	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	M169_H179delinsG	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M169_H179delinsG	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	M169_H179delinsG	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M169_H179delinsG	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ALK	S350L	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	S350L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	S350L	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	S350L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	S350L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	S350L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	S350L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	S350L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	S350L	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	S350L	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	S350L	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	S350L	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	S350L	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	S350L	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	S350L	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	S350L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	S350L	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	S350L	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	S350L	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ATM	E2446*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	E2446*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	E2446*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	E2446*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	E2446*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	E2446*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E2446*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	E2446*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E2446*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E2446*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E2446*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	E2446*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	E2446*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
NTRK3	splice_donor_variant	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	splice_donor_variant	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	splice_donor_variant	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
CDKN2A	P48R	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	P48R	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	P48R	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	P48R	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	P48R	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	P48R	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	P48R	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	P48R	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
SETD2	R368*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	R368*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
RET	G344S	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	G344S	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	G344S	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	G344S	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	G344S	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	G344S	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	G344S	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	G344S	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	G344S	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
BRCA2	Q2859), BRCA2 MUT (Q1736	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	Q2859), BRCA2 MUT (Q1736	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q2859), BRCA2 MUT (Q1736	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	Q2859), BRCA2 MUT (Q1736	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	Q2859), BRCA2 MUT (Q1736	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	Q2859), BRCA2 MUT (Q1736	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	Q2859), BRCA2 MUT (Q1736	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	Q2859), BRCA2 MUT (Q1736	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q2859), BRCA2 MUT (Q1736	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q2859), BRCA2 MUT (Q1736	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q2859), BRCA2 MUT (Q1736	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q2859), BRCA2 MUT (Q1736	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	Q2859), BRCA2 MUT (Q1736	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q2859), BRCA2 MUT (Q1736	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
ERBB4	R103H	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
CTNNB1	S37F	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	S37F	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
NOTCH2	S1564R	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
KMT2D	Q827*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
TSC2	Q1752*	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	Q1752*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	Q1752*	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	Q1752*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	Q1752*	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	Q1752*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	Q1752*	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
ARID1A	D322Afs*41	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	D322Afs*41	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	D322Afs*41	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	D322Afs*41	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
NOTCH2	G1408D	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
FANCA	R52*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Case report
FANCA	R52*	Different Alteration	Olaparib (PARP inhibitor)	Responsive	PRAD	Case report
NOTCH1	R1824W	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1824W	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	C135W	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C135W	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C135W	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C135W	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C135W	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C135W	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C135W	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C135W	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C135W	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C135W	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C135W	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C135W	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C135W	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C135W	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C135W	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TMPRSS2	A139P	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	A139P	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
SF3B1	K666N	Complete Match	Spliceosome inhibitor	Responsive	CANCER	Pre-clinical
HRAS	G13R	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	CER	Pre-clinical
HRAS	G13R	Complete Match	MEK inhibitor +/- MTOR inhibitor	Responsive	AML	Pre-clinical
HRAS	G13R	Complete Match	MTOR inhibitor	Responsive	CESC	Pre-clinical
HRAS	G13R	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	Responsive	CANCER	Early trials
CDKN2A	C72*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	C72*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	C72*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	C72*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	C72*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	C72*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	C72*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	C72*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
NOTCH2	R1410C	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
CDKN2A	W15*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	W15*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	W15*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	W15*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	W15*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	W15*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	W15*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	W15*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
NOTCH1	T2063K	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	T2063K	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRCA2	Q175*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	Q175*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q175*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	Q175*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	Q175*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	Q175*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	Q175*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	Q175*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q175*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q175*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q175*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q175*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	Q175*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q175*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y500*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y500*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y500*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Y500*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TMPRSS2	S370Y	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	S370Y	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
PML	R816Q	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	R816Q	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	R816Q	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
PALB2	Y1183*	Complete Match	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	Y1183*	Complete Match	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	Y1183*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
PALB2	Y1183*	Complete Match	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	Y1183*	Different Alteration	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	Y1183*	Different Alteration	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	Y1183*	Different Alteration	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	Y1183*	Different Alteration	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
ATM	G1016*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	G1016*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	G1016*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	G1016*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	G1016*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	G1016*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	G1016*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	G1016*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	G1016*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	G1016*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	G1016*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	G1016*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	G1016*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
FLT1	E345*	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	R	Pre-clinical
TP53	A138D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	A138D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	A138D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	A138D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	A138D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	A138D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	A138D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A138D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A138D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	A138D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	A138D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	A138D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A138D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	A138D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A138D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
STK11	splice_donor_variant), KRAS MUT (G12R	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	splice_donor_variant), KRAS MUT (G12R	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	splice_donor_variant), KRAS MUT (G12R	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	splice_donor_variant), KRAS MUT (G12R	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
PDGFRA	Y206*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
TP53	F134S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	F134S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	F134S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	F134S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	F134S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	F134S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	F134S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F134S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F134S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	F134S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	F134S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	F134S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F134S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	F134S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F134S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRD4	P224R	Different Alteration	BET inhibitor	Responsive	NMC	Case report
TP53	Y236N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y236N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y236N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y236N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y236N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y236N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y236N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y236N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y236N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y236N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y236N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y236N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y236N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y236N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y236N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L130R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L130R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L130R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L130R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L130R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L130R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L130R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L130R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L130R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L130R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L130R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L130R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L130R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L130R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L130R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	N754S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	N754S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
KMT2A	S3030N	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S3030N	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S3030N	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S3030N	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S3030N	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S3030N	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
CDKN2A	M53I	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	M53I	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	M53I	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	M53I	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	M53I	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	M53I	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	M53I	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	M53I	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
FGFR3	A429V	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	A429V	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	A429V	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
NTRK3	P330Q	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	P330Q	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	P330Q	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NOTCH1	V2153M	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	V2153M	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
KMT2A	T3537A	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	T3537A	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	T3537A	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	T3537A	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	T3537A	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	T3537A	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
TP53	R280T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R280T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R280T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R280T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R280T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R280T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R280T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R280T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R280T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R280T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R280T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R280T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R280T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R280T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R280T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRCA2	Q2539*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	Q2539*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q2539*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	Q2539*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	Q2539*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	Q2539*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	Q2539*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	Q2539*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q2539*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q2539*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q2539*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q2539*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	Q2539*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q2539*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
TP53	Q38*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q38*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q38*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q38*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q38*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q38*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q38*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q38*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q38*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q38*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q38*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q38*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q38*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q38*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q38*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
SRSF2	P95A	Complete Match	Spliceosome inhibitor	Responsive	AML	Pre-clinical
PALB2	splice_acceptor_variant	Complete Match	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	splice_acceptor_variant	Complete Match	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	splice_acceptor_variant	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
PALB2	splice_acceptor_variant	Complete Match	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	splice_acceptor_variant	Different Alteration	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	splice_acceptor_variant	Different Alteration	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	splice_acceptor_variant	Different Alteration	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	splice_acceptor_variant	Different Alteration	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
NTRK1	F367L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	F367L	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	F367L	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	F367L	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
MET	A48T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
JAK2	R564L	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
RAF1	R215C	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	R215C	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	R215C	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
STK11	splice_acceptor_variant	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	splice_acceptor_variant	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	splice_acceptor_variant	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	splice_acceptor_variant	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	splice_acceptor_variant	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	splice_acceptor_variant	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	splice_acceptor_variant	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	splice_acceptor_variant	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	splice_acceptor_variant	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	splice_acceptor_variant	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	splice_acceptor_variant	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	splice_acceptor_variant	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	splice_acceptor_variant), KRAS MUT (G12V	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	splice_acceptor_variant), KRAS MUT (G12V	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	splice_acceptor_variant), KRAS MUT (G12V	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	splice_acceptor_variant), KRAS MUT (G12V	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
BRCA2	K2271*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	K2271*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	K2271*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	K2271*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	K2271*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	K2271*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	K2271*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	K2271*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	K2271*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	K2271*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	K2271*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	K2271*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	K2271*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	K2271*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
FGFR3	D786N	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	D786N	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	D786N	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
MET	IntronicBlockSubstitution	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
MET	T613N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
TP53	Y220S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y220S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y220S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y220S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y220S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y220S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y220S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y220S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y220S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y220S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y220S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y220S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y220S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y220S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y220S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	T1987I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	T1987I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	T1987I	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	T1987I	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	T1987I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
TSC1	R245*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC1	R245*	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC1	R245*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA	FDA guidelines
TSC1	R245*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	ST, S	Case report
TSC1	R245*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	R	Case report
TSC1	R245*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	GCA	FDA guidelines
TSC1	R245*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Case report
FBXW7	R505C	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	R505C	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	R505C	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	R505C	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
NTRK3	C320G	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	C320G	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	C320G	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
SF3B1	R625C	Different Mutation	Spliceosome inhibitor	Responsive	CANCER	Pre-clinical
TP53	F134V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	F134V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	F134V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	F134V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	F134V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	F134V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	F134V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F134V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F134V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	F134V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	F134V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	F134V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F134V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	F134V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F134V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NRG1	A240V	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	A240V	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
ESR1	N53H	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
BRCA1	E143*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA1	E143*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA1	E143*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA1	E143*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	E143*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	E143*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Case report
BRCA1	E143*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA1	E143*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA1	E143*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	E143*	Complete Match	PARP inhibitor	Responsive	PA	Case report
BRCA1	E143*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	E143*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
ERBB4	P224L	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
TP53	P278L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P278L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P278L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P278L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P278L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P278L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P278L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P278L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P278L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P278L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P278L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P278L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P278L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P278L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P278L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TSC2	W1740*	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	W1740*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	W1740*	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	W1740*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	W1740*	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	W1740*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	W1740*	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
JAK2	L359I	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
ROS1	S2242T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	S2242T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	S2242T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	S2242T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	S2242T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
NOTCH1	S458L	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	S458L	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ALK	M596T	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	M596T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	M596T	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	M596T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	M596T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	M596T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	M596T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	M596T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	M596T	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	M596T	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	M596T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	M596T	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	M596T	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	M596T	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	M596T	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	M596T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	M596T	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	M596T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	M596T	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
PDGFRA	T281M	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
KMT2A	S1440T	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S1440T	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S1440T	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S1440T	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S1440T	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S1440T	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ARID1A	Q780*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q780*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q780*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q780*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
NRG1	V114L	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	V114L	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
NOTCH2	H107R	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ALK	A1601T	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	A1601T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	A1601T	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	A1601T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	A1601T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	A1601T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A1601T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	A1601T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A1601T	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A1601T	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	A1601T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	A1601T	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	A1601T	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	A1601T	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	A1601T	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	A1601T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	A1601T	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	A1601T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A1601T	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
TP53	Y126C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y126C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y126C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y126C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y126C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y126C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y126C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y126C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y126C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y126C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y126C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y126C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y126C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y126C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y126C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q52*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q52*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q52*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q52*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q52*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q52*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q52*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q52*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q52*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q52*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q52*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q52*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q52*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q52*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q52*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	C312R	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	C312R	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NRG1	A472V	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	A472V	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
ERBB4	D113N	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ARID1A	Q1066*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1066*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1066*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q1066*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
FGFR3	D785D	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	D785D	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	D785D	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
NTRK1	T434M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	T434M	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	T434M	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	T434M	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
NTRK1	V170L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	V170L	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	V170L	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	V170L	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
ARID1A	K1047*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	K1047*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	K1047*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	K1047*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	Q235*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	Q235*	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	Q235*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	Q235*	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	Q235*	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
RNF43	R145*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
NOTCH1	intron_variant	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	intron_variant	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRAF	D213G	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	D213G	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	D213G	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	D213G	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
ALK	F856S	Different Mutation	Crizotinib (ALK inhibitor)	Responsive	G	Pre-clinical
ALK	F856S	Different Mutation	Ceritinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	F856S	Different Mutation	Crizotinib (ALK inhibitor)	Resistant	LUAD	Case report
ALK	F856S	Complete Match	Crizotinib (ALK inhibitor)	Responsive	AML	Pre-clinical
ALK	F856S	Different Mutation	Alectinib (ALK inhibitor)	Resistant	LUAD	Case report
ALK	F856S	Different Mutation	Brigatinib (Pan-TK inhibitor)	Responsive	LUAD	Case report
ALK	F856S	Different Mutation	Crizotinib (ALK inhibitor)	Resistant	NSCLC	Case report
ALK	F856S	Different Mutation	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	LUAD	Pre-clinical
ALK	F856S	Complete Match	Crizotinib (ALK inhibitor)	Resistant	NSCLC	Clinical trials
ALK	F856S	Different Mutation	Ceritinib (ALK inhibitor)	Resistant	LUAD	Case report
ALK	F856S	Different Mutation	Crizotinib (ALK inhibitor)	Resistant	G	Pre-clinical
ALK	F856S	Different Mutation	novel ALK inhibitor	Responsive	LUAD	Pre-clinical
ALK	F856S	Different Alteration	Crizotinib (ALK inhibitor)	Resistant	LUAD	Case report
ALK	F856S	Different Alteration	Crizotinib (ALK inhibitor)	Resistant	NSCLC	Clinical trials
ALK	F856S	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	LUAD	Case report
ALK	F856S	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	F856S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	F856S	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	F856S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	F856S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	F856S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	F856S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	F856S	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	F856S	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	F856S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	F856S	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	F856S	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	F856S	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	F856S	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	F856S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	F856S	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	F856S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	F856S	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
NOTCH1	G2245R	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	G2245R	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
RET	G183D	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	G183D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	G183D	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	G183D	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	G183D	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	G183D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	G183D	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	G183D	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	G183D	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
KMT2D	G1281*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
ERBB4	M501V	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
BAP1	E212*	Complete Match	EZH2 inhibitor	Responsive	MESO	Pre-clinical
BAP1	E212*	Complete Match	PARP inhibitor	Responsive	R, CANCER	Pre-clinical
BAP1	E212*	Complete Match	HDAC inhibitor	Responsive	CM	Pre-clinical
BAP1	E212*	Different Alteration	PARP inhibitor	Responsive	CANCER, R	Pre-clinical
BAP1	E212*	Different Alteration	EZH2 inhibitor	Responsive	MESO	Pre-clinical
BAP1	E212*	Different Alteration	HDAC inhibitor	Responsive	CM	Pre-clinical
RET	A228P	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	A228P	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	A228P	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	A228P	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	A228P	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	A228P	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	A228P	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	A228P	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	A228P	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
KRAS	G12I	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12I	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12I	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12I	Complete Match	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12I	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12I	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12I	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12I	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12I	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12I	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12I	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12I	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12I	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12I	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12I	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12I	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12I	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12I	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12I	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12I	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12I	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12I	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12I	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12I	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12I	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12I	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12I	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12I	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12I	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12I	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12I	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12I	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12I	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12I	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12I	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12I	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12I	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12I	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12I	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12I	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12I	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12I	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	S166*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S166*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S166*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S166*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S166*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S166*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S166*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S166*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S166*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S166*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S166*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S166*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S166*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S166*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S166*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M246R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	M246R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	M246R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	M246R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	M246R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	M246R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M246R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M246R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M246R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	M246R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	M246R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	M246R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M246R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	M246R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M246R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CRLF2	D202N	Different Alteration	MTOR inhibitor	Responsive	ALL	Pre-clinical
CRLF2	D202N	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
ARID1A	Y551*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y551*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y551*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Y551*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
PIK3R1	splice_donor_variant	Complete Match	AKT inhibitor	Responsive	G	Pre-clinical
PIK3R1	splice_donor_variant	Complete Match	PI3K pathway inhibitor	Responsive	ED	Case report
TMPRSS2	V335M	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	V335M	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
KMT2A	P2988R	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P2988R	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P2988R	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P2988R	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P2988R	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P2988R	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
KMT2D	R2915*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
NOTCH2	S106P	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	Y205*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y205*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y205*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y205*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y205*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y205*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y205*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y205*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y205*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y205*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y205*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y205*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y205*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y205*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y205*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FANCA	Q343*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Case report
FANCA	Q343*	Different Alteration	Olaparib (PARP inhibitor)	Responsive	PRAD	Case report
PIK3CA	P366R	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	P366R	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	P366R	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	P366R	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	P366R	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	P366R	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	P366R	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	P366R	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	P366R	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	P366R	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	P366R	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	P366R	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	P366R	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	P366R	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
RB1	E72*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	E72*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	E72*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	E72*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	E72*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	E72*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	E72*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
NRG1	N383H	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	N383H	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
ALK	W243*	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	W243*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	W243*	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	W243*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	W243*	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	W243*	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	W243*	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	W243*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	W243*	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	W243*	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	W243*	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	W243*	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	W243*	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	W243*	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	W243*	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	W243*	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	W243*	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	W243*	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	W243*	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ABL1	T974I), ABL1 MUT* (A922T), ABL1 MUT* (S840N	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	T974I), ABL1 MUT* (A922T), ABL1 MUT* (S840N	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	T974I), ABL1 MUT* (A922T), ABL1 MUT* (S840N	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	T974I), ABL1 MUT* (A922T), ABL1 MUT* (S840N	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	T974I), ABL1 MUT* (A922T), ABL1 MUT* (S840N	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	T974I), ABL1 MUT* (A922T), ABL1 MUT* (S840N	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
PIK3R1	S565N	Complete Match	AKT inhibitor	Responsive	G	Pre-clinical
PIK3R1	S565N	Complete Match	PI3K pathway inhibitor	Responsive	ED	Case report
PTEN	H123Y	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	H123Y	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	H123Y	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	H123Y	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	H123Y	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	H123Y	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	H123Y	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	H123Y	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	H123Y	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	H123Y	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	H123Y	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	H123Y	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	H123Y	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	H123Y	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	H123Y	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	H123Y	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	H123Y	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	H123Y	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	H123Y	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	H123Y	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	H123Y	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	H123Y	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	H123Y	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	H123Y	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	H123Y	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
FGFR2	S689F	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	S689F	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
TSC2	splice_donor_variant), TSC2 MUT (splice_acceptor_variant	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	splice_donor_variant), TSC2 MUT (splice_acceptor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	splice_donor_variant), TSC2 MUT (splice_acceptor_variant	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	splice_donor_variant), TSC2 MUT (splice_acceptor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	splice_donor_variant), TSC2 MUT (splice_acceptor_variant	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	splice_donor_variant), TSC2 MUT (splice_acceptor_variant	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	splice_donor_variant), TSC2 MUT (splice_acceptor_variant	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
TMPRSS2	T378I	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	T378I	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
RET	splice_donor_variant	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	splice_donor_variant	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	splice_donor_variant	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	splice_donor_variant	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	splice_donor_variant	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	splice_donor_variant	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	splice_donor_variant	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	splice_donor_variant	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	splice_donor_variant	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ROS1	splice_acceptor_variant), ROS1 MUT* (Y1487*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	splice_acceptor_variant), ROS1 MUT* (Y1487*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	splice_acceptor_variant), ROS1 MUT* (Y1487*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	splice_acceptor_variant), ROS1 MUT* (Y1487*	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	splice_acceptor_variant), ROS1 MUT* (Y1487*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
CDK12	W1043*	Complete Match	PARP inhibitor	Responsive	OV	Pre-clinical
CDK12	W1043*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
MET	P857L), MET MUT* (P628L), MET MUT* (Q524*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
KMT2A	G3033S), MLL MUT* (Q1308*	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	G3033S), MLL MUT* (Q1308*	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	G3033S), MLL MUT* (Q1308*	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	G3033S), MLL MUT* (Q1308*	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	G3033S), MLL MUT* (Q1308*	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	G3033S), MLL MUT* (Q1308*	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NOTCH2	splice_donor_variant	Different Mutation	Mk-0752 (Gamma secretase inhibitor)	Responsive	ALL, AML, BRCA	Early trials
NOTCH2	splice_donor_variant	Different Mutation	OMP-59R5 (NOTCH2 inhibitor)	Responsive	SOLID	Early trials
NOTCH2	splice_donor_variant), NOTCH2 MUT* (A1096V), NOTCH2 MUT* (S1275F	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	G263R), NOTCH1 MUT* (V1745M), NOTCH1 MUT* (P2199L	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	G263R), NOTCH1 MUT* (V1745M), NOTCH1 MUT* (P2199L	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRD4	G178R), BRD4 MUT* (E323K	Different Alteration	BET inhibitor	Responsive	NMC	Case report
BRCA2	Q1658*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	Q1658*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q1658*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	Q1658*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	Q1658*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	Q1658*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	Q1658*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	Q1658*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q1658*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q1658*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q1658*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q1658*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	Q1658*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q1658*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
TMPRSS2	V329M	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	V329M	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
NOTCH2	I2282V	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
MET	V13M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
MET	V504F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
NOTCH1	L2419F	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	L2419F	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	R1661Q	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1661Q	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
PML	A271V	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	A271V	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	A271V	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
RET	K471M	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	K471M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	K471M	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	K471M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	K471M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	K471M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	K471M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	K471M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	K471M	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
PIK3CA	H1047L	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	H1047L	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	H1047L	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	H1047L	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	H1047L	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	H1047L	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	H1047L	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	H1047L	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	H1047L	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	H1047L	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	H1047L	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	H1047L	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	H1047L	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	H1047L	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
RNF43	R132), RNF43 MUT (R145	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
NTRK3	Y353F	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	Y353F	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	Y353F	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
TP53	C176F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C176F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C176F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C176F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C176F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C176F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C176F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C176F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C176F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C176F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C176F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RNF43	G29*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
FGFR2	A97T	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	A97T	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
PALB2	Q430*	Complete Match	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	Q430*	Complete Match	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	Q430*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
PALB2	Q430*	Complete Match	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	Q430*	Different Alteration	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	Q430*	Different Alteration	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	Q430*	Different Alteration	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	Q430*	Different Alteration	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
PBRM1	Q1348*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	Q1348*	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	Q1348*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	Q1348*	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	Q1348*	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V217G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V217G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V217G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V217G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V217G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V217G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V217G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V217G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V217G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V217G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V217G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V217G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V217G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V217G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V217G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	Q501*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q501*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q501*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q501*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
BRD4	A792V	Different Alteration	BET inhibitor	Responsive	NMC	Case report
BRCA2	splice_donor_variant	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	splice_donor_variant	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	splice_donor_variant	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	splice_donor_variant	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	splice_donor_variant	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	splice_donor_variant	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	splice_donor_variant	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	splice_donor_variant	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	splice_donor_variant	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	splice_donor_variant	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	splice_donor_variant	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	splice_donor_variant	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	splice_donor_variant	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	splice_donor_variant	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
CDKN2A	Q50H	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	Q50H	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	Q50H	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	Q50H	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	Q50H	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	Q50H	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	Q50H	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	Q50H	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
TP53	C238Y	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C238Y	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C238Y	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C238Y	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C238Y	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C238Y	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C238Y	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C238Y	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C238Y	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C238Y	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C238Y	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C238Y	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C238Y	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C238Y	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C238Y	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NTRK3	D50N	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	D50N	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	D50N	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
VHL	CdsStartSNV	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
ATM	E1091*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	E1091*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	E1091*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	E1091*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	E1091*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	E1091*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E1091*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	E1091*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E1091*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E1091*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E1091*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	E1091*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	E1091*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
CDKN2A	E10*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E10*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E10*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	E10*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E10*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E10*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E10*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E10*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
NF2	E204*	Complete Match	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	E204*	Complete Match	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	E204*	Complete Match	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	E204*	Complete Match	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	E204*	Complete Match	MTOR inhibitor	Responsive	MEN	Pre-clinical
NF2	E204*	Complete Match	Lapatinib (ERBB2 inhibitor)	Responsive	NF, SCHW	Early trials
NF2	E204*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	E204*	Complete Match	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	E204*	Complete Match	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	E204*	Complete Match	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	E204*	Complete Match	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	E204*	Complete Match	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	E204*	Complete Match	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	E204*	Complete Match	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	E204*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	E204*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	E204*	Different Alteration	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	E204*	Different Alteration	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	E204*	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	E204*	Different Alteration	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	E204*	Different Alteration	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	E204*	Different Alteration	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	E204*	Different Alteration	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	E204*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	E204*	Different Alteration	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	E204*	Different Alteration	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	E204*	Different Alteration	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	E204*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	E204*	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	SCHW, NF	Early trials
NF2	E204*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	E204*	Different Alteration	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	E204*	Different Alteration	MTOR inhibitor	Responsive	MEN	Pre-clinical
NOTCH2	K1768R	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ARID1A	Q944*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q944*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q944*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q944*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
CDK12	Q937*	Complete Match	PARP inhibitor	Responsive	OV	Pre-clinical
CDK12	Q937*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
TP53	E258Q	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E258Q	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E258Q	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E258Q	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E258Q	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E258Q	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E258Q	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E258Q	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E258Q	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E258Q	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E258Q	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E258Q	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E258Q	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E258Q	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E258Q	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	N239D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	N239D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	N239D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	N239D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	N239D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	N239D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	N239D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N239D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N239D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	N239D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	N239D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	N239D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N239D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	N239D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N239D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NRAS	G12V	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
NRAS	G12V	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
NRAS	G12V	Different Mutation	MEK inhibitor	Responsive	CM	Late trials
NRAS	G12V	Different Mutation	BRAF inhibitor	Resistant	CM	Early trials
NRAS	G12V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CM	Early trials
NRAS	G12V	Complete Match	HSP90 inhibitor	Responsive	CM	Pre-clinical
NRAS	G12V	Complete Match	MEK inhibitor	Responsive	AML, LUAD, ALL	Pre-clinical
NRAS	G12V	Complete Match	Pan-RAF inhibitor	Responsive	CM	Case report
NRAS	G12V	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
NRAS	G12V	Complete Match	ERK inhibitor	Responsive	CM	Case report
NRAS	G12V	Complete Match	MEK inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
NRAS	G12V	Complete Match	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NRAS	G12V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	MYMA	Pre-clinical
NRAS	G12V	Different Mutation	ERK inhibitor	Responsive	CANCER	Pre-clinical
TP53	T125M	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T125M	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T125M	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T125M	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T125M	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T125M	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T125M	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T125M	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T125M	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T125M	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T125M	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T125M	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T125M	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T125M	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T125M	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C141Y), TP53 MUT (P250L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C141Y), TP53 MUT (P250L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C141Y), TP53 MUT (P250L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C141Y), TP53 MUT (P250L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C141Y), TP53 MUT (P250L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C141Y), TP53 MUT (P250L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C141Y), TP53 MUT (P250L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141Y), TP53 MUT (P250L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141Y), TP53 MUT (P250L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C141Y), TP53 MUT (P250L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C141Y), TP53 MUT (P250L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C141Y), TP53 MUT (P250L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141Y), TP53 MUT (P250L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C141Y), TP53 MUT (P250L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141Y), TP53 MUT (P250L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NF1	R816*	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NF1	R816*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	HNC	Case report
NF1	R816*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	R816*	Complete Match	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	R816*	Complete Match	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NF1	R816*	Complete Match	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	R816*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	R816*	Complete Match	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	R816*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	NF	Late trials
NF1	R816*	Complete Match	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	R816*	Complete Match	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	R816*	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	MPN, PLEN	Pre-clinical
NF1	R816*	Complete Match	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	R816*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	HNC, SG	Case report
NF1	R816*	Complete Match	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	R816*	Complete Match	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	R816*	Complete Match	MEK inhibitor	Responsive	LK, G	Pre-clinical
NF1	R816*	Complete Match	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	R816*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	R816*	Complete Match	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	R816*	Complete Match	MTOR inhibitor	Responsive	LK, G, MPN	Pre-clinical
NF1	R816*	Complete Match	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	R816*	Complete Match	Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor)	Responsive	HC	Case report
NF1	R816*	Complete Match	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	R816*	Complete Match	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	R816*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	R816*	Complete Match	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	R816*	Complete Match	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	R816*	Complete Match	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	R816*	Complete Match	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	R816*	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	R816*	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	R816*	Complete Match	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	R816*	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	R816*	Complete Match	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	R816*	Complete Match	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	R816*	Different Alteration	MTOR inhibitor	Responsive	MPN, G, LK	Pre-clinical
NF1	R816*	Different Alteration	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	R816*	Different Alteration	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	R816*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	R816*	Different Alteration	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	R816*	Different Alteration	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	R816*	Different Alteration	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	R816*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	R816*	Different Alteration	MEK inhibitor	Responsive	G, LK	Pre-clinical
NF1	R816*	Different Alteration	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	R816*	Different Alteration	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	R816*	Different Alteration	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	R816*	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	R816*	Different Alteration	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	R816*	Different Alteration	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	R816*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	R816*	Different Alteration	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	R816*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SG, HNC	Case report
NF1	R816*	Different Alteration	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	R816*	Different Alteration	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	R816*	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	R816*	Different Alteration	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	R816*	Different Alteration	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	R816*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	R816*	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	PLEN, MPN	Pre-clinical
NF1	R816*	Different Alteration	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	R816*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	R816*	Different Alteration	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	R816*	Different Alteration	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	R816*	Different Alteration	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	R816*	Different Alteration	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	R816*	Different Alteration	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
BCOR	R1217*	Complete Match	Enzastaurin (PKCb inhibitor)	Responsive	ST	Pre-clinical
ARID1A	S334*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S334*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S334*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	S334*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
BRAF	G464V	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	G464V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	G464V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	NCCN guidelines
BRAF	G464V	Different Mutation	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G464V	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G464V	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G464V	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	G464V	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	G464V	Different Mutation	ERK inhibitor	Responsive	HNSC, BT	Case report
BRAF	G464V	Different Mutation	EGFR TK inhibitor	Resistant	LUAD	Case report
BRAF	G464V	Different Mutation	MEK inhibitor	Responsive	CM	Case report
BRAF	G464V	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	G464V	Different Mutation	BRAF inhibitor	Responsive	CM	Case report
BRAF	G464V	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	G464V	Different Mutation	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	G464V	Different Mutation	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	G464V	Different Mutation	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	G464V	Different Mutation	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	G464V	Different Mutation	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	G464V	Different Mutation	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	G464V	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	G464V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	G464V	Different Mutation	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	G464V	Different Mutation	BRAF inhibitor;HSP90 inhibitor	Responsive	CM	Pre-clinical
BRAF	G464V	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	G464V	Different Mutation	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	G464V	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	G464V	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	G464V	Different Mutation	MEK inhibitor	Responsive	TH	Early trials
BRAF	G464V	Different Mutation	BRAF inhibitor;PI3K pathway inhibitor	Responsive	CM	Pre-clinical
BRAF	G464V	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	G464V	Different Mutation	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	G464V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	G464V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	G464V	Different Mutation	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	G464V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	G464V	Different Mutation	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	G464V	Different Mutation	BRAF inhibitor;CDK2/4 inhibitor	Responsive	CM	Pre-clinical
BRAF	G464V	Different Mutation	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	G464V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	G464V	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	G464V	Different Mutation	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	G464V	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	G464V	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	G464V	Different Mutation	BRAF inhibitor	Responsive	OV	Case report
BRAF	G464V	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	G464V	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	G464V	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	G464V	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	G464V	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	G464V	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	G464V	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TP53	T256P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T256P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T256P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T256P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T256P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T256P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T256P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T256P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T256P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T256P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T256P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T256P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T256P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T256P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T256P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FGFR2	K406E	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	K406E	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
ERBB4	L1180I	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ARID1A	S138*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S138*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S138*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	S138*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ERBB4	V840I	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
NTRK1	S603C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	S603C	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	S603C	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	S603C	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
CDH1	CdsStopSNV	Complete Match	Bicalutamide (AR inhibitor)	Responsive	BRCA	Pre-clinical
KMT2A	P412L	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P412L	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P412L	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P412L	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P412L	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P412L	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ATM	E1325*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	E1325*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	E1325*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	E1325*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	E1325*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	E1325*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E1325*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	E1325*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E1325*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E1325*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E1325*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	E1325*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	E1325*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RNF43	R113*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
ROS1	M1643I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	M1643I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	M1643I	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	M1643I	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	M1643I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ERBB4	R1304W	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
JAK2	T969R	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
FAT1	Q824*	Complete Match	BET inhibitor	Responsive	HNSC	Pre-clinical
ERBB4	G182C	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	E17K	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	E17K	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
TP53	E286G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E286G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E286G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E286G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E286G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E286G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E286G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E286G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E286G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E286G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E286G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E286G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E286G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E286G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E286G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	E1058G	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	E1058G	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	E1058G	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	E1058G	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E1058G	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E1058G	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	E1058G	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E1058G	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E1058G	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
RNF43	splice_donor_variant	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
RET	intron_variant	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	intron_variant	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	intron_variant	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	intron_variant	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	intron_variant	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	intron_variant	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	intron_variant	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	intron_variant	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	intron_variant	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
KMT2A	P172S	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P172S	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P172S	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P172S	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P172S	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P172S	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NOTCH2	R2347C	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ALK	A1230T	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	A1230T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	A1230T	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	A1230T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	A1230T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	A1230T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A1230T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	A1230T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A1230T	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A1230T	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	A1230T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	A1230T	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	A1230T	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	A1230T	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	A1230T	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	A1230T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	A1230T	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	A1230T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A1230T	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
MET	P1382S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
NTRK3	N714S	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	N714S	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	N714S	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
CDKN2A	D108V	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	D108V	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	D108V	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	D108V	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	D108V	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	D108V	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	D108V	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	D108V	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
TP53	G245C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G245C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G245C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G245C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G245C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G245C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G245C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G245C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G245C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G245C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G245C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G245C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G245C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G245C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G245C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRD4	R413C	Different Alteration	BET inhibitor	Responsive	NMC	Case report
TP53	R213L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R213L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R213L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R213L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R213L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R213L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R213L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R213L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R213L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R213L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R213L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R213L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R213L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R213L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R213L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KRAS	G12L	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12L	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12L	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12L	Complete Match	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12L	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12L	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12L	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12L	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12L	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12L	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12L	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12L	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12L	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12L	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12L	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12L	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12L	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12L	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12L	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12L	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12L	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12L	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12L	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12L	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12L	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12L	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12L	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12L	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12L	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12L	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12L	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12L	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12L	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12L	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12L	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12L	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12L	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12L	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12L	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12L	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12L	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	Y126N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y126N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y126N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y126N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y126N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y126N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y126N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y126N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y126N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y126N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y126N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y126N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y126N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y126N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y126N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	splice_acceptor_variant	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	splice_acceptor_variant	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	splice_acceptor_variant	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	splice_acceptor_variant	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	splice_acceptor_variant	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	splice_acceptor_variant	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	splice_acceptor_variant	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	splice_acceptor_variant	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	splice_acceptor_variant	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	splice_acceptor_variant	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	splice_acceptor_variant	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	splice_acceptor_variant	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	splice_acceptor_variant	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ROS1	N1272S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	N1272S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	N1272S	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	N1272S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	N1272S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
BRAF	E24D	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	E24D	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	E24D	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	E24D	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TP53	W53*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	W53*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	W53*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	W53*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	W53*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	W53*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	W53*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	W53*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	W53*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	W53*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	W53*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	W53*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	W53*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	W53*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	W53*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	C655F	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	C655F	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R745Q	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R745Q	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R745Q	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
ERBB4	T731M	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ATM	E347*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	E347*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	E347*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	E347*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	E347*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	E347*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E347*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	E347*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E347*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E347*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E347*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	E347*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	E347*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
NRG1	M42V	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	M42V	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
AKT3	intron_variant	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
BRAF	G596D	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	G596D	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	G596D	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	NCCN guidelines
BRAF	G596D	Different Mutation	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G596D	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G596D	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G596D	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	G596D	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	G596D	Different Mutation	ERK inhibitor	Responsive	HNSC, BT	Case report
BRAF	G596D	Different Mutation	EGFR TK inhibitor	Resistant	LUAD	Case report
BRAF	G596D	Different Mutation	MEK inhibitor	Responsive	CM	Case report
BRAF	G596D	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	G596D	Different Mutation	BRAF inhibitor	Responsive	CM	Case report
BRAF	G596D	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	G596D	Different Mutation	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	G596D	Different Mutation	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	G596D	Different Mutation	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	G596D	Different Mutation	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	G596D	Different Mutation	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	G596D	Different Mutation	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	G596D	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	G596D	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	G596D	Different Mutation	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	G596D	Different Mutation	BRAF inhibitor;HSP90 inhibitor	Responsive	CM	Pre-clinical
BRAF	G596D	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	G596D	Different Mutation	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	G596D	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	G596D	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	G596D	Different Mutation	MEK inhibitor	Responsive	TH	Early trials
BRAF	G596D	Different Mutation	BRAF inhibitor;PI3K pathway inhibitor	Responsive	CM	Pre-clinical
BRAF	G596D	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	G596D	Different Mutation	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	G596D	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	G596D	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	G596D	Different Mutation	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	G596D	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	G596D	Different Mutation	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	G596D	Different Mutation	BRAF inhibitor;CDK2/4 inhibitor	Responsive	CM	Pre-clinical
BRAF	G596D	Different Mutation	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	G596D	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	G596D	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	G596D	Different Mutation	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	G596D	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	G596D	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	G596D	Different Mutation	BRAF inhibitor	Responsive	OV	Case report
BRAF	G596D	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	G596D	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	G596D	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	G596D	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	G596D	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	G596D	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	G596D	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TP53	I251N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I251N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I251N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I251N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I251N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I251N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I251N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I251N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I251N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I251N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I251N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I251N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I251N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I251N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I251N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2A	S316L	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S316L	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S316L	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S316L	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S316L	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S316L	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
RB1	W516*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	W516*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	W516*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	W516*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	W516*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	W516*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	W516*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
BCOR	splice_donor_variant	Complete Match	Enzastaurin (PKCb inhibitor)	Responsive	ST	Pre-clinical
NOTCH2	E723K	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ROS1	M1655T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	M1655T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	M1655T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	M1655T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	M1655T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
BRD4	T28A	Different Alteration	BET inhibitor	Responsive	NMC	Case report
ARID1A	Q583*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q583*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q583*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q583*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
NTRK3	R116Q	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R116Q	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R116Q	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
PBRM1	E1189*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	E1189*	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	E1189*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	E1189*	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	E1189*	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
BRD4	S891L	Different Alteration	BET inhibitor	Responsive	NMC	Case report
EGFR	L828S	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	L828S	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
PBRM1	E970*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	E970*	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	E970*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	E970*	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	E970*	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
NOTCH1	E198K	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	E198K	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
KRAS	L19F	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	L19F	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	L19F	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	L19F	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	L19F	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	L19F	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	L19F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	L19F	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	L19F	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	L19F	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	L19F	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	L19F	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	L19F	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	L19F	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	L19F	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	L19F	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	L19F	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	L19F	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	L19F	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	L19F	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	L19F	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	L19F	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	L19F	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	L19F	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	L19F	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	L19F	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	L19F	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	L19F	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	L19F	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	L19F	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	L19F	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	L19F	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	L19F	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	L19F	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	L19F	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	L19F	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	L19F	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	L19F	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	L19F	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	L19F	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	L19F	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	L19F	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
ALK	D885G	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	D885G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	D885G	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	D885G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	D885G	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	D885G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	D885G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	D885G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	D885G	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	D885G	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	D885G	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	D885G	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	D885G	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	D885G	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	D885G	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	D885G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	D885G	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	D885G	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	D885G	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
KMT2A	E2419K	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	E2419K	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	E2419K	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	E2419K	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	E2419K	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	E2419K	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NTRK3	G67E	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	G67E	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	G67E	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
FGFR3	intron_variant	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	intron_variant	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	intron_variant	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TP53	Y103*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y103*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y103*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y103*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y103*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y103*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y103*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y103*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y103*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y103*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y103*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y103*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y103*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y103*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y103*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G266*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G266*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G266*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G266*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G266*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G266*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G266*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G266*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G266*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G266*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G266*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G266*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G266*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G266*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G266*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NTRK1	R686P	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R686P	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R686P	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R686P	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
ROS1	K2111N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	K2111N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	K2111N	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	K2111N	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	K2111N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
MET	G578R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
CTNNB1	S45F	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	S45F	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
NRG1	A547T	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	A547T	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
ABL1	E431D	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	E431D	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	E431D	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	E431D	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	E431D	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	E431D	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
NTRK3	R116W	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R116W	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R116W	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
TP53	Q167*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q167*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q167*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q167*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q167*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q167*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q167*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q167*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q167*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q167*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q167*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q167*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q167*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q167*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q167*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
EGFR	R999H	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	R999H	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
APC	R1450*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
ALK	D1270G	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	D1270G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	D1270G	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	D1270G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	D1270G	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	D1270G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	D1270G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	D1270G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	D1270G	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	D1270G	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	D1270G	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	D1270G	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	D1270G	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	D1270G	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	D1270G	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	D1270G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	D1270G	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	D1270G	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	D1270G	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ABL1	G254R	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	CML	European LeukemiaNet guidelines
ABL1	G254R	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Resistant	CML	European LeukemiaNet guidelines
ABL1	G254R	Different Mutation	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	NCCN guidelines
ABL1	G254R	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	NCCN guidelines
ABL1	G254R	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Resistant	CML	European LeukemiaNet guidelines
ABL1	G254R	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CML	NCCN guidelines
ABL1	G254R	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML	FDA guidelines
ABL1	G254R	Different Mutation	BCR-ABL inhibitor	Resistant	CML	European LeukemiaNet guidelines
ABL1	G254R	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	ALL	FDA guidelines
ABL1	G254R	Different Mutation	Axitinib (VEGFR inhibitor)	Responsive	CANCER	Pre-clinical
ABL1	G254R	Different Mutation	Bosutinib (BCR-ABL inhibitor)	Resistant	CML	European LeukemiaNet guidelines
ABL1	G254R	Different Mutation	Cabozantinib (Pan-kinase inhibitor)	Responsive	CANCER	Pre-clinical
ABL1	G254R	Different Mutation	Crizotinib (ALK inhibitor)	Responsive	CANCER	Pre-clinical
ABL1	G254R	Different Mutation	Vandetanib (Pan-TK inhibitor)	Responsive	CANCER	Pre-clinical
ABL1	G254R	Different Mutation	Foretinib (MET inhibitor)	Responsive	CANCER	Pre-clinical
ABL1	G254R), ABL1 MUT* (T204M	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	G254R), ABL1 MUT* (T204M	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G254R), ABL1 MUT* (T204M	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	G254R), ABL1 MUT* (T204M	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G254R), ABL1 MUT* (T204M	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	G254R), ABL1 MUT* (T204M	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
SETD2	R2040*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	R2040*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	R850*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	R850*	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	R850*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	R850*	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	R850*	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
FBXW7	R689W	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	R689W	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	R689W	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	R689W	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
TMPRSS2	G179R	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	G179R	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
RET	R231C	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R231C	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R231C	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R231C	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R231C	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R231C	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R231C	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R231C	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R231C	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
RNF43	R371*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
KMT2D	R2801*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
KMT2A	R1264*	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	R1264*	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	R1264*	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	R1264*	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	R1264*	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	R1264*	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NOTCH2	A2319V	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
CDKN2A	E61*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E61*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E61*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	E61*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E61*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E61*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E61*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E61*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
NTRK3	P383T	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	P383T	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	P383T	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
ABL1	R589C	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	R589C	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R589C	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	R589C	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R589C	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	R589C	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
AKT3	R325*	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
PBRM1	splice_donor_variant	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	splice_donor_variant	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	splice_donor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	splice_donor_variant	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	splice_donor_variant	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PML	G461A	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	G461A	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	G461A	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
ERBB4	Y807C	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ALK	splice_acceptor_variant	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	splice_acceptor_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	splice_acceptor_variant	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	splice_acceptor_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	splice_acceptor_variant	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	splice_acceptor_variant	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	splice_acceptor_variant	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	splice_acceptor_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	splice_acceptor_variant	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	splice_acceptor_variant	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	splice_acceptor_variant	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	splice_acceptor_variant	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	splice_acceptor_variant	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	splice_acceptor_variant	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	splice_acceptor_variant	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	splice_acceptor_variant	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	splice_acceptor_variant	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	splice_acceptor_variant	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	splice_acceptor_variant	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
SMARCB1	R53*	Complete Match	HDAC inhibitor	Responsive	MRT	Pre-clinical
SMARCB1	R53*	Complete Match	EZH2 inhibitor	Responsive	MRT	Case report
SMARCB1	R53*	Different Alteration	EZH2 inhibitor	Responsive	MRT	Case report
PIK3R1	N564D	Complete Match	AKT inhibitor	Responsive	G	Pre-clinical
PIK3R1	N564D	Complete Match	PI3K pathway inhibitor	Responsive	ED	Case report
FBXW7	Y519C	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	Y519C	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	Y519C	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	Y519C	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FGFR2	N403S	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	N403S	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
RNF43	R650*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
KMT2D	W339*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
NOTCH2	G736*	Different Mutation	Mk-0752 (Gamma secretase inhibitor)	Responsive	ALL, AML, BRCA	Early trials
NOTCH2	G736*	Different Mutation	OMP-59R5 (NOTCH2 inhibitor)	Responsive	SOLID	Early trials
NOTCH2	G736), NOTCH2 MUT (G1707D	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	R1663W	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1663W	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
DNMT3A	splice_donor_variant), DNMT3A MUT (Q656*	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
NOTCH1	T2132M	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	T2132M	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ERBB4	S522L	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
EGFR	S198N	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	S198N	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
RAF1	D486G	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	D486G	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	D486G	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
CRLF2	P196L	Different Alteration	MTOR inhibitor	Responsive	ALL	Pre-clinical
CRLF2	P196L	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
ERBB4	R782Q	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
PDGFRA	intron_variant	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
ABL1	R473*	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	R473*	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R473*	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	R473*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R473*	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	R473*	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
TP53	G245F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G245F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G245F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G245F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G245F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G245F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G245F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G245F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G245F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G245F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G245F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G245F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G245F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G245F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G245F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	intron_variant), ALK MUT* (R1549I	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
NOTCH1	E1583D	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	E1583D	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
KMT2A	K1457E	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	K1457E	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	K1457E	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	K1457E	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	K1457E	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	K1457E	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ALK	Q39E	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q39E	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	Q39E	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	Q39E	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	Q39E	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	Q39E	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	Q39E	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	Q39E	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	Q39E	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	Q39E	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	Q39E	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	Q39E	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	Q39E	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q39E	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q39E	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	Q39E	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	Q39E	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	Q39E	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	Q39E	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	S455L	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	S455L	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
ARID1A	P1553Rfs*12	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	P1553Rfs*12	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	P1553Rfs*12	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	P1553Rfs*12	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
FGFR3	L589V	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	L589V	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	L589V	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
ROS1	W1289G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	W1289G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	W1289G	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	W1289G	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	W1289G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
CTNNB1	S45P	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	S45P	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
ALK	K572N	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	K572N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	K572N	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	K572N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	K572N	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	K572N	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	K572N	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	K572N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	K572N	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	K572N	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	K572N	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	K572N	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	K572N	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	K572N	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	K572N	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	K572N	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	K572N	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	K572N	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	K572N	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
RET	R177W	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R177W	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R177W	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R177W	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R177W	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R177W	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R177W	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R177W	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R177W	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ESR1	M490T	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
TP53	Q317*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q317*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q317*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q317*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q317*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q317*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q317*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q317*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q317*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q317*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q317*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q317*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q317*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q317*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q317*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ALK	P1469S	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	P1469S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	P1469S	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	P1469S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	P1469S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	P1469S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P1469S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	P1469S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P1469S	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P1469S	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	P1469S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	P1469S	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	P1469S	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	P1469S	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	P1469S	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	P1469S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	P1469S	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	P1469S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P1469S	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ATM	Q1970*), ATM MUT (splice_donor_variant	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	Q1970*), ATM MUT (splice_donor_variant	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	Q1970*), ATM MUT (splice_donor_variant	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	Q1970*), ATM MUT (splice_donor_variant	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	Q1970*), ATM MUT (splice_donor_variant	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q1970*), ATM MUT (splice_donor_variant	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q1970*), ATM MUT (splice_donor_variant	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	Q1970*), ATM MUT (splice_donor_variant	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q1970*), ATM MUT (splice_donor_variant	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q1970*), ATM MUT (splice_donor_variant	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q1970*), ATM MUT (splice_donor_variant	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	Q1970*), ATM MUT (splice_donor_variant	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q1970*), ATM MUT (splice_donor_variant	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	L2447*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	L2447*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	L2447*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	L2447*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	L2447*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	L2447*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	L2447*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	L2447*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	L2447*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	L2447*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	L2447*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	L2447*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	L2447*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ZNRF3	R245*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Pre-clinical
NTRK1	M375I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	M375I	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	M375I	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	M375I	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
TP53	Y205S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y205S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y205S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y205S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y205S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y205S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y205S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y205S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y205S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y205S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y205S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y205S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y205S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y205S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y205S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRD4	R616W	Different Alteration	BET inhibitor	Responsive	NMC	Case report
ABL1	N231S	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	N231S	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	N231S	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	N231S	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	N231S	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	N231S	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ROS1	S744R), ROS1 MUT* (K2319I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	S744R), ROS1 MUT* (K2319I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	S744R), ROS1 MUT* (K2319I	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	S744R), ROS1 MUT* (K2319I	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	S744R), ROS1 MUT* (K2319I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ABL1	V1031M	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	V1031M	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	V1031M	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	V1031M	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	V1031M	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	V1031M	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
MSH2	Q314*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
MSH2	Q314*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
TSC2	splice_acceptor_variant	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	splice_acceptor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	splice_acceptor_variant	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	splice_acceptor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	splice_acceptor_variant	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	splice_acceptor_variant	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	splice_acceptor_variant	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
TP53	E326*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E326*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E326*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E326*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E326*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E326*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E326*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E326*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E326*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E326*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E326*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E326*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E326*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E326*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E326*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FGFR2	T395A	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	T395A	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
PDGFRA	T16S	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
NOTCH2	T1716I	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	T2455A	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	T2455A	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	S183*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S183*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S183*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S183*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S183*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S183*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S183*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S183*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S183*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S183*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S183*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S183*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S183*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S183*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S183*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ESR1	M264V	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
CDKN2A	Q50R	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	Q50R	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	Q50R	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	Q50R	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	Q50R	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	Q50R	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	Q50R	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	Q50R	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
EGFR	L1077F	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	L1077F	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
JAK2	Q1112*	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
CHEK2	splice_acceptor_variant	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
CHEK2	splice_acceptor_variant	Different Alteration	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
ALK	C1255F	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	C1255F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	C1255F	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	C1255F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	C1255F	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	C1255F	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	C1255F	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	C1255F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	C1255F	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	C1255F	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	C1255F	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	C1255F	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	C1255F	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	C1255F	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	C1255F	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	C1255F	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	C1255F	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	C1255F	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	C1255F	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ROS1	R2039H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	R2039H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	R2039H	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	R2039H	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	R2039H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
NOTCH2	D1533V	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	R196P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R196P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R196P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R196P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R196P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R196P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R196P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R196P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R196P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R196P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R196P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R196P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R196P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R196P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R196P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PIK3CA	Q546K	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	Q546K	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	Q546K	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	Q546K	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	Q546K	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	Q546K	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	Q546K	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	Q546K	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	Q546K	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	Q546K	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	Q546K	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	Q546K	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	Q546K	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	Q546K	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
ROS1	R1182S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	R1182S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	R1182S	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	R1182S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	R1182S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
NOTCH1	Y2116N	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	Y2116N	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	T125K	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T125K	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T125K	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T125K	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T125K	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T125K	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T125K	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T125K	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T125K	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T125K	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T125K	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T125K	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T125K	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T125K	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T125K	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C124*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C124*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C124*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C124*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C124*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C124*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C124*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C124*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C124*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C124*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C124*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C124*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C124*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C124*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C124*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH2	R1875W	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ATM	splice_donor_variant	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	splice_donor_variant	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	splice_donor_variant	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	splice_donor_variant	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	splice_donor_variant	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	splice_donor_variant	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	splice_donor_variant	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	splice_donor_variant	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	splice_donor_variant	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	splice_donor_variant	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	splice_donor_variant	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	splice_donor_variant	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	splice_donor_variant	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
MSH2	CdsStopSNV	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
MSH2	CdsStopSNV	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
TP53	C135F), TP53 MUT (V157I	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C135F), TP53 MUT (V157I	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C135F), TP53 MUT (V157I	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C135F), TP53 MUT (V157I	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C135F), TP53 MUT (V157I	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C135F), TP53 MUT (V157I	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C135F), TP53 MUT (V157I	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C135F), TP53 MUT (V157I	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C135F), TP53 MUT (V157I	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C135F), TP53 MUT (V157I	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C135F), TP53 MUT (V157I	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C135F), TP53 MUT (V157I	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C135F), TP53 MUT (V157I	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C135F), TP53 MUT (V157I	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C135F), TP53 MUT (V157I	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NF2	Y221*	Complete Match	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	Y221*	Complete Match	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	Y221*	Complete Match	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	Y221*	Complete Match	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	Y221*	Complete Match	MTOR inhibitor	Responsive	MEN	Pre-clinical
NF2	Y221*	Complete Match	Lapatinib (ERBB2 inhibitor)	Responsive	NF, SCHW	Early trials
NF2	Y221*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	Y221*	Complete Match	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	Y221*	Complete Match	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	Y221*	Complete Match	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	Y221*	Complete Match	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	Y221*	Complete Match	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	Y221*	Complete Match	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	Y221*	Complete Match	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	Y221*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	Y221*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	Y221*	Different Alteration	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	Y221*	Different Alteration	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	Y221*	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	Y221*	Different Alteration	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	Y221*	Different Alteration	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	Y221*	Different Alteration	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	Y221*	Different Alteration	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	Y221*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	Y221*	Different Alteration	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	Y221*	Different Alteration	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	Y221*	Different Alteration	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	Y221*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	Y221*	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	SCHW, NF	Early trials
NF2	Y221*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	Y221*	Different Alteration	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	Y221*	Different Alteration	MTOR inhibitor	Responsive	MEN	Pre-clinical
NTRK1	R583C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R583C	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R583C	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R583C	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
TP53	R267P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R267P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R267P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R267P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R267P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R267P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R267P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R267P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R267P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R267P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R267P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R267P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R267P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R267P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R267P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PALB2	K1124Qfs*30	Complete Match	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	K1124Qfs*30	Complete Match	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	K1124Qfs*30	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
PALB2	K1124Qfs*30	Complete Match	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	K1124Qfs*30	Different Alteration	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	K1124Qfs*30	Different Alteration	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	K1124Qfs*30	Different Alteration	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	K1124Qfs*30	Different Alteration	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
PML	splice_donor_variant	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	splice_donor_variant	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	splice_donor_variant	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
MET	P822S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
NOTCH2	P2297H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	V1172M	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	V1172M	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRD4	Y412C	Different Alteration	BET inhibitor	Responsive	NMC	Case report
ROS1	D331V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	D331V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	D331V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	D331V	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	D331V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
NTRK1	A549V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	A549V	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	A549V	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	A549V	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
ERBB4	P1297L	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
NOTCH1	D1021H	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	D1021H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	P278T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P278T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P278T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P278T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P278T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P278T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P278T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P278T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P278T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P278T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P278T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P278T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P278T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P278T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P278T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NTRK1	R119C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R119C	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R119C	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R119C	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
ARID1A	E2023*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E2023*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E2023*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E2023*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
BRCA2	K3083*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	K3083*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	K3083*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	K3083*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	K3083*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	K3083*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	K3083*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	K3083*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	K3083*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	K3083*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	K3083*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	K3083*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	K3083*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	K3083*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
TP53	E56*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E56*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E56*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E56*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E56*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E56*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E56*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E56*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E56*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E56*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E56*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E56*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E56*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E56*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E56*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y205H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y205H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y205H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y205H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y205H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y205H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y205H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y205H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y205H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y205H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y205H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y205H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y205H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y205H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y205H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FGFR2	intron_variant	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	intron_variant	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
MET	V427I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
ERBB4	F689Y	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
KMT2A	splice_acceptor_variant	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	splice_acceptor_variant	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	splice_acceptor_variant	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	splice_acceptor_variant	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	splice_acceptor_variant	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	splice_acceptor_variant	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ARID1A	R750*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R750*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R750*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	R750*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ROS1	T454M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	T454M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	T454M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	T454M	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	T454M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ALK	G850R	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	G850R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	G850R	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	G850R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	G850R	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	G850R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G850R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	G850R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G850R	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G850R	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	G850R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	G850R	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	G850R	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	G850R	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	G850R	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	G850R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	G850R	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	G850R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G850R	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ALK	S929C	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	S929C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	S929C	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	S929C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	S929C	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	S929C	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	S929C	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	S929C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	S929C	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	S929C	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	S929C	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	S929C	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	S929C	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	S929C	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	S929C	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	S929C	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	S929C	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	S929C	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	S929C	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
PDGFB	intron_variant	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	DFS	FDA guidelines
CTNNB1	D32N	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	D32N	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
ESR1	intron_variant	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
ABL1	A647V	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	A647V	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	A647V	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	A647V	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	A647V	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	A647V	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
RNF43	S468*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
PML	S774G	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	S774G	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	S774G	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
NTRK1	R49G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R49G	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R49G	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R49G	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
ATR	splice_acceptor_variant	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATR	splice_acceptor_variant	Complete Match	Olaparib (PARP inhibitor)	Responsive	CANCER, OV	Pre-clinical
ATR	splice_acceptor_variant	Different Alteration	Olaparib (PARP inhibitor)	Responsive	OV, CANCER	Pre-clinical
PML	G448R	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	G448R	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	G448R	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
TP53	T125T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T125T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T125T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T125T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T125T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T125T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T125T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T125T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T125T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T125T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T125T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T125T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T125T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T125T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T125T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	G1915R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	G1915R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	G1915R	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	G1915R	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	G1915R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ALK	V827I	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	V827I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	V827I	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	V827I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	V827I	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	V827I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	V827I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	V827I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	V827I	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	V827I	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	V827I	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	V827I	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	V827I	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	V827I	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	V827I	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	V827I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	V827I	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	V827I	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	V827I	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ARID1A	Q1409*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1409*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1409*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q1409*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
FGFR3	S804S	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	S804S	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	S804S	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
BRD4	I820V	Different Alteration	BET inhibitor	Responsive	NMC	Case report
PDGFRA	A509V	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
EGFR	A289D	Different Alteration	Cetuximab (EGFR mAb inhibitor)	Responsive	COREAD	FDA guidelines
EGFR	A289D	Different Alteration	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
EGFR	A289D	Different Mutation	Rindopepimut (Vaccine)	Responsive	GB	Late trials
EGFR	A289D	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	A289D	Different Mutation	Gefitinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	A289D	Different Mutation	HSP90 inhibitor	Responsive	L	Early trials
EGFR	A289D	Different Mutation	Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	A289D	Different Mutation	MEK inhibitor	Responsive	L	Pre-clinical
EGFR	A289D	Different Mutation	EGFR TK inhibitor	Responsive	L	Late trials
EGFR	A289D	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	NCCN guidelines
EGFR	A289D	Different Mutation	Osimertinib (EGFR inhibitor)	Resistant	L	Early trials
EGFR	A289D	Different Mutation	EGFR-TKI's (EGFR inhibitor)	Resistant	L	Late trials
EGFR	A289D	Different Mutation	HSP90 inhibitor	Responsive	L	Case report
EGFR	A289D	Different Mutation	EGFR inhibitor	Resistant	L	Late trials
EGFR	A289D	Different Mutation	Poziotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	A289D	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Pre-clinical
EGFR	A289D	Different Mutation	HSP90 inhibitor (HSP90 inhibitor)	Responsive	L	Early trials
EGFR	A289D	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	G	Pre-clinical
EGFR	A289D	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	A289D	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	A289D	Different Mutation	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
EGFR	A289D	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Responsive	COREAD	Case report
EGFR	A289D	Different Mutation	novel EGFR mAb inhibitor	Responsive	COREAD	Early trials
EGFR	A289D	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	A289D	Different Mutation	Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor)	Responsive	HNC	Case report
EGFR	A289D	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	A289D	Different Mutation	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Case report
EGFR	A289D	Different Mutation	EGFR inhibitor	Responsive	L	Early trials
EGFR	A289D	Different Mutation	Erlotinib (EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	A289D	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	A289D	Different Mutation	EGFR inhibitor	Responsive	NSCLC	Late trials
EGFR	A289D	Different Mutation	Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	A289D	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	A289D	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	A289D	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	L	Late trials
EGFR	A289D	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Pre-clinical
EGFR	A289D	Different Mutation	Erlotinib (EGFR inhibitor)	No Responsive	L	Case report
EGFR	A289D	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	ED	Case report
EGFR	A289D	Different Mutation	EGFR inhibitor	No Responsive	G	Early trials
EGFR	A289D	Different Mutation	EGFR inhibitor	Resistant	NSCLC	Case report
EGFR	A289D	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	A289D	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant;Resistant	COREAD	Pre-clinical;Case report
EGFR	A289D	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Responsive	HNC	Case report
EGFR	A289D	Different Alteration	Gefitinib (EGFR inhibitor)	Responsive	ED	Late trials
EGFR	A289D	Different Alteration	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Early trials
EGFR	A289D	Different Alteration	EGFR inhibitor	Responsive	HNSC	Case report
EGFR	A289D	Different Alteration	EGFR inhibitor	No Responsive	G	Early trials
EGFR	A289D	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	L	Early trials
EGFR	A289D	Different Alteration	EGFR mAb inhibitor	Responsive	COREAD	Late trials
EGFR	A289D	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	A289D	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
TP53	C176R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C176R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C176R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C176R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C176R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C176R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C176R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C176R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C176R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C176R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C176R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NTRK3	F161V	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	F161V	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	F161V	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
PTEN	R173H	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	R173H	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	R173H	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	R173H	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	R173H	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	R173H	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	R173H	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	R173H	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	R173H	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	R173H	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	R173H	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	R173H	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	R173H	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	R173H	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	R173H	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	R173H	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	R173H	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	R173H	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	R173H	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	R173H	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	R173H	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	R173H	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	R173H	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	R173H	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	R173H	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
TP53	E180*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E180*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E180*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E180*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E180*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E180*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E180*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E180*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E180*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E180*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E180*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E180*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E180*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E180*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E180*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V143A	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V143A	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V143A	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V143A	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V143A	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V143A	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V143A	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V143A	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V143A	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V143A	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V143A	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V143A	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V143A	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V143A	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V143A	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NTRK3	L653I	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	L653I	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	L653I	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
ERBB4	L155H	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ERBB4	R847H	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ROS1	R118*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	R118*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	R118*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	R118*	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	R118*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
RB1	R500*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	R500*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R500*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R500*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	R500*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R500*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R500*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
KMT2A	S2741C	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S2741C	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S2741C	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S2741C	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S2741C	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S2741C	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NTRK1	intron_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	intron_variant	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	intron_variant	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	intron_variant	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
CRLF2	splice_donor_variant	Different Alteration	MTOR inhibitor	Responsive	ALL	Pre-clinical
CRLF2	splice_donor_variant	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
MET	P668S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
EGFR	D1063G	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	D1063G	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
TP53	R248L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R248L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R248L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R248L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R248L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R248L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R248L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R248L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R248L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R248L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R248L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	F270S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	F270S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	F270S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	F270S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	F270S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	F270S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	F270S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F270S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F270S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	F270S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	F270S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	F270S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F270S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	F270S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F270S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CRLF2	I35N	Different Alteration	MTOR inhibitor	Responsive	ALL	Pre-clinical
CRLF2	I35N	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	D238N	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	D238N	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NF1	K1099*	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NF1	K1099*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	HNC	Case report
NF1	K1099*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	K1099*	Complete Match	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	K1099*	Complete Match	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NF1	K1099*	Complete Match	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	K1099*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	K1099*	Complete Match	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	K1099*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	NF	Late trials
NF1	K1099*	Complete Match	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	K1099*	Complete Match	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	K1099*	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	MPN, PLEN	Pre-clinical
NF1	K1099*	Complete Match	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	K1099*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	HNC, SG	Case report
NF1	K1099*	Complete Match	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	K1099*	Complete Match	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	K1099*	Complete Match	MEK inhibitor	Responsive	LK, G	Pre-clinical
NF1	K1099*	Complete Match	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	K1099*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	K1099*	Complete Match	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	K1099*	Complete Match	MTOR inhibitor	Responsive	LK, G, MPN	Pre-clinical
NF1	K1099*	Complete Match	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	K1099*	Complete Match	Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor)	Responsive	HC	Case report
NF1	K1099*	Complete Match	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	K1099*	Complete Match	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	K1099*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	K1099*	Complete Match	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	K1099*	Complete Match	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	K1099*	Complete Match	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	K1099*	Complete Match	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	K1099*	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	K1099*	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	K1099*	Complete Match	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	K1099*	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	K1099*	Complete Match	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	K1099*	Complete Match	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	K1099*	Different Alteration	MTOR inhibitor	Responsive	MPN, G, LK	Pre-clinical
NF1	K1099*	Different Alteration	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	K1099*	Different Alteration	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	K1099*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	K1099*	Different Alteration	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	K1099*	Different Alteration	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	K1099*	Different Alteration	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	K1099*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	K1099*	Different Alteration	MEK inhibitor	Responsive	G, LK	Pre-clinical
NF1	K1099*	Different Alteration	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	K1099*	Different Alteration	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	K1099*	Different Alteration	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	K1099*	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	K1099*	Different Alteration	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	K1099*	Different Alteration	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	K1099*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	K1099*	Different Alteration	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	K1099*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SG, HNC	Case report
NF1	K1099*	Different Alteration	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	K1099*	Different Alteration	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	K1099*	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	K1099*	Different Alteration	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	K1099*	Different Alteration	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	K1099*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	K1099*	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	PLEN, MPN	Pre-clinical
NF1	K1099*	Different Alteration	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	K1099*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	K1099*	Different Alteration	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	K1099*	Different Alteration	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	K1099*	Different Alteration	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	K1099*	Different Alteration	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	K1099*	Different Alteration	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
ARID1A	P729Lfs*85	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	P729Lfs*85	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	P729Lfs*85	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	P729Lfs*85	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
NF2	E129*	Complete Match	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	E129*	Complete Match	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	E129*	Complete Match	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	E129*	Complete Match	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	E129*	Complete Match	MTOR inhibitor	Responsive	MEN	Pre-clinical
NF2	E129*	Complete Match	Lapatinib (ERBB2 inhibitor)	Responsive	NF, SCHW	Early trials
NF2	E129*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	E129*	Complete Match	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	E129*	Complete Match	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	E129*	Complete Match	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	E129*	Complete Match	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	E129*	Complete Match	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	E129*	Complete Match	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	E129*	Complete Match	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	E129*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	E129*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	E129*	Different Alteration	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	E129*	Different Alteration	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	E129*	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	E129*	Different Alteration	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	E129*	Different Alteration	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	E129*	Different Alteration	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	E129*	Different Alteration	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	E129*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	E129*	Different Alteration	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	E129*	Different Alteration	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	E129*	Different Alteration	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	E129*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	E129*	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	SCHW, NF	Early trials
NF2	E129*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	E129*	Different Alteration	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	E129*	Different Alteration	MTOR inhibitor	Responsive	MEN	Pre-clinical
BRAF	D594G	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	D594G	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	D594G	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	NCCN guidelines
BRAF	D594G	Different Mutation	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	D594G	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	D594G	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	D594G	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	D594G	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	D594G	Different Mutation	ERK inhibitor	Responsive	HNSC, BT	Case report
BRAF	D594G	Different Mutation	EGFR TK inhibitor	Resistant	LUAD	Case report
BRAF	D594G	Different Mutation	MEK inhibitor	Responsive	CM	Case report
BRAF	D594G	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	D594G	Different Mutation	BRAF inhibitor	Responsive	CM	Case report
BRAF	D594G	Complete Match	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	D594G	Different Mutation	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	D594G	Different Mutation	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	D594G	Different Mutation	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	D594G	Different Mutation	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	D594G	Different Mutation	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	D594G	Different Mutation	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	D594G	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	D594G	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	D594G	Different Mutation	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	D594G	Different Mutation	BRAF inhibitor;HSP90 inhibitor	Responsive	CM	Pre-clinical
BRAF	D594G	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	D594G	Different Mutation	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	D594G	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	D594G	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	D594G	Different Mutation	MEK inhibitor	Responsive	TH	Early trials
BRAF	D594G	Different Mutation	BRAF inhibitor;PI3K pathway inhibitor	Responsive	CM	Pre-clinical
BRAF	D594G	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	D594G	Different Mutation	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	D594G	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	D594G	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	D594G	Different Mutation	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	D594G	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	D594G	Different Mutation	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	D594G	Different Mutation	BRAF inhibitor;CDK2/4 inhibitor	Responsive	CM	Pre-clinical
BRAF	D594G	Different Mutation	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	D594G	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	D594G	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	D594G	Different Mutation	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	D594G	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	D594G	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	D594G	Different Mutation	BRAF inhibitor	Responsive	OV	Case report
BRAF	D594G	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	D594G	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	D594G	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	D594G	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	D594G	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	D594G	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	D594G	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
ARID1A	R1528*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1528*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1528*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	R1528*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
PML	P26S	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	P26S	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	P26S	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
TP53	L201*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L201*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L201*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L201*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L201*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L201*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L201*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L201*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L201*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L201*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L201*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L201*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L201*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L201*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L201*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	R1212C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	R1212C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	R1212C	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	R1212C	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	R1212C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ERCC2	Y339*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ERCC2	Y339*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ERCC2	Y339*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
RET	E527K	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	E527K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	E527K	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	E527K	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E527K	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E527K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	E527K	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E527K	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E527K	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ROS1	E1244D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	E1244D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	E1244D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	E1244D	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	E1244D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
NTRK1	R654H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R654H	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R654H	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R654H	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
TP53	Y163N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y163N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y163N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y163N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y163N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y163N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y163N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y163N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y163N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y163N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y163N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y163N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y163N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y163N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y163N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P177R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P177R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P177R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P177R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P177R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P177R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P177R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P177R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P177R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P177R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P177R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P177R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P177R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P177R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P177R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	V1739M	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	V1739M	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
RNF43	Y177*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
TP53	R249M	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R249M	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R249M	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R249M	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R249M	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R249M	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R249M	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R249M	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R249M	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R249M	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R249M	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R249M	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R249M	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R249M	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R249M	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
DNMT3A	splice_acceptor_variant	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
TP53	D259Y	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	D259Y	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	D259Y	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	D259Y	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	D259Y	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	D259Y	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	D259Y	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D259Y	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D259Y	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	D259Y	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	D259Y	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	D259Y	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D259Y	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	D259Y	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D259Y	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E298*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E298*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E298*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E298*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E298*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E298*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E298*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E298*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E298*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E298*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E298*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E298*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E298*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E298*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E298*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	R368C	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R368C	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R368C	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R368C	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R368C	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R368C	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R368C	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R368C	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R368C	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
NOTCH2	intron_variant	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ERCC4	W193*	Complete Match	Cisplatin (Chemotherapy)	Responsive	OV	Pre-clinical
TP53	G244S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G244S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G244S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G244S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G244S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G244S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G244S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G244S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G244S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G244S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G244S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G244S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G244S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G244S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G244S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
STK11	P89Afs*6	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	P89Afs*6	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	P89Afs*6	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	P89Afs*6	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	P89Afs*6	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	P89Afs*6	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	P89Afs*6	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	P89Afs*6	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	P89Afs*6	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	P89Afs*6	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	P89Afs*6	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	P89Afs*6	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
KMT2A	N3267Y	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	N3267Y	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	N3267Y	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	N3267Y	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	N3267Y	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	N3267Y	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ATM	E2145*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	E2145*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	E2145*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	E2145*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	E2145*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	E2145*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E2145*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	E2145*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E2145*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E2145*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E2145*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	E2145*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	E2145*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
TP53	C141Y	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C141Y	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C141Y	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C141Y	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C141Y	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C141Y	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C141Y	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141Y	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141Y	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C141Y	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C141Y	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C141Y	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141Y	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C141Y	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141Y	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	P820S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	P820S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
AKT3	K20E	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
ALK	R1120W	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1120W	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	R1120W	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	R1120W	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	R1120W	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	R1120W	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R1120W	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	R1120W	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R1120W	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R1120W	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	R1120W	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	R1120W	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	R1120W	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1120W	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1120W	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	R1120W	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	R1120W	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	R1120W	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R1120W	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
FGFR3	C597F	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	C597F	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	C597F	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant), KRAS MUT (G12D	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant), KRAS MUT (G12D	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant), KRAS MUT (G12D	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	splice_acceptor_variant), STK11 MUT (splice_acceptor_variant), KRAS MUT (G12D	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
FGFR3	H208Y	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	H208Y	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	H208Y	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TP53	C135G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C135G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C135G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C135G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C135G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C135G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C135G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C135G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C135G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C135G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C135G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C135G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C135G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C135G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C135G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RB1	N849Kfs*2	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	N849Kfs*2	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	N849Kfs*2	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	N849Kfs*2	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	N849Kfs*2	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	N849Kfs*2	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	N849Kfs*2	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
CTNNB1	G34E	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	G34E	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
KMT2D	Q2553*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
TP53	G244A	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G244A	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G244A	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G244A	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G244A	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G244A	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G244A	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G244A	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G244A	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G244A	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G244A	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G244A	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G244A	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G244A	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G244A	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P151R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P151R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P151R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P151R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P151R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P151R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P151R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P151R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P151R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P151R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P151R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P151R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P151R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P151R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P151R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	S12*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	S12*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	S12*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	S12*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	S12*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	S12*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	S12*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	S12*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
NOTCH1	D1064N	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	D1064N	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ATM	R1882*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R1882*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R1882*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R1882*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R1882*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R1882*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R1882*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R1882*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R1882*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R1882*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R1882*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R1882*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R1882*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
BRD4	N852K	Different Alteration	BET inhibitor	Responsive	NMC	Case report
PML	A502S	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	A502S	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	A502S	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
CDKN2A	Q50*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	Q50*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	Q50*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	Q50*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	Q50*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	Q50*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	Q50*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	Q50*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
ALK	R510Q	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	R510Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	R510Q	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	R510Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	R510Q	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	R510Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R510Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	R510Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R510Q	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R510Q	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	R510Q	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	R510Q	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	R510Q	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	R510Q	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	R510Q	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	R510Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	R510Q	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	R510Q	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R510Q	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
TMPRSS2	T324N	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	T324N	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
NTRK3	N338H	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	N338H	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	N338H	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NRG1	L546I	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	L546I	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
TP53	I195N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I195N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I195N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I195N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I195N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I195N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I195N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I195N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I195N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I195N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I195N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I195N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I195N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I195N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I195N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TMPRSS2	A139T	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	A139T	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
ESR1	R158H	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
TP53	I232F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I232F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I232F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I232F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I232F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I232F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I232F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I232F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I232F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I232F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I232F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I232F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I232F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I232F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I232F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E258*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E258*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E258*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E258*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E258*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E258*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E258*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E258*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E258*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E258*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E258*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E258*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E258*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E258*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E258*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH2	I531V	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
CDKN2A	E88*	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E88*	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E88*	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	E88*	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E88*	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	E88*	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	E88*	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	E88*	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
TP53	V197G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V197G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V197G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V197G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V197G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V197G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V197G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V197G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V197G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V197G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V197G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V197G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V197G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V197G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V197G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRD4	R410C	Different Alteration	BET inhibitor	Responsive	NMC	Case report
NTRK1	I510F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	I510F	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	I510F	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	I510F	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
ERBB4	R196H	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ALK	S1038F	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	S1038F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	S1038F	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	S1038F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	S1038F	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	S1038F	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	S1038F	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	S1038F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	S1038F	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	S1038F	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	S1038F	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	S1038F	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	S1038F	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	S1038F	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	S1038F	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	S1038F	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	S1038F	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	S1038F	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	S1038F	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
NTRK3	N35D	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	N35D	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	N35D	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
CDKN2A	D84Y	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	D84Y	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	D84Y	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	D84Y	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	D84Y	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	D84Y	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	D84Y	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	D84Y	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
NOTCH2	S2103C	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NRG1	T591M	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	T591M	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
SMARCA4	Q722*	Complete Match	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	Q722*	Complete Match	AURKA inhibitor	Responsive	NSCLC	Pre-clinical
SMARCA4	Q722*	Complete Match	EZH2 inhibitor	Responsive	OV	Case report
SMARCA4	Q722*	Different Alteration	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	Q722*	Different Alteration	EZH2 inhibitor	Responsive	OV	Case report
TP53	R158L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R158L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R158L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R158L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R158L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R158L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R158L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R158L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R158L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R158L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R158L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R158L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R158L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R158L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R158L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G262V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G262V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G262V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G262V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G262V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G262V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G262V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G262V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G262V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G262V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G262V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G262V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G262V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G262V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G262V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NTRK1	D596N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	D596N	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	D596N	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	D596N	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
BRAF	T491S	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	T491S	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	T491S	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	T491S	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
DNMT3A	Q692*	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
RNF43	S262*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
MET	N642S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
RNF43	C309*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
NOTCH1	G1072S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	G1072S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRD4	T221M	Different Alteration	BET inhibitor	Responsive	NMC	Case report
APC	R2204*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
CRLF2	G195_P200delinsVPDTYR	Different Alteration	MTOR inhibitor	Responsive	ALL	Pre-clinical
CRLF2	G195_P200delinsVPDTYR	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
NRG1	N305K	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	N305K	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
NTRK3	H825R	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	H825R	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	H825R	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
PTEN	D92G	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	D92G	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	D92G	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	D92G	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	D92G	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	D92G	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	D92G	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	D92G	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	D92G	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	D92G	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	D92G	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	D92G	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	D92G	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	D92G	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	D92G	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	D92G	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	D92G	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	D92G	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	D92G	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	D92G	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	D92G	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	D92G	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	D92G	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	D92G	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	D92G	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
ROS1	R1212H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	R1212H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	R1212H	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	R1212H	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	R1212H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
SETD2	Q1272*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	Q1272*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
RNF43	S41*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
ALK	Y587F	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	Y587F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	Y587F	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	Y587F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	Y587F	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	Y587F	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	Y587F	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	Y587F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	Y587F	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	Y587F	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	Y587F	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	Y587F	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	Y587F	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	Y587F	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	Y587F	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	Y587F	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	Y587F	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	Y587F	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	Y587F	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
MET	V1014I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
KMT2A	W619C	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	W619C	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	W619C	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	W619C	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	W619C	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	W619C	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
TP53	V218G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V218G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V218G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V218G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V218G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V218G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V218G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V218G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V218G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V218G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V218G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V218G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V218G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V218G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V218G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KRAS	Q61A	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61A	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61A	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	Q61A	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	Q61A	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	Q61A	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	Q61A	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	Q61A	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61A	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61A	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	Q61A	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	Q61A	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61A	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	Q61A	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	Q61A	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	Q61A	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	Q61A	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	Q61A	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	Q61A	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	Q61A	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61A	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	Q61A	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61A	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	Q61A	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	Q61A	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61A	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	Q61A	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61A	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	Q61A	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	Q61A	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	Q61A	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	Q61A	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	Q61A	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61A	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61A	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	Q61A	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61A	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	Q61A	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61A	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	Q61A	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	Q61A	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	Q61A	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
FGFR2	E778D	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	E778D	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
KMT2A	R2890C	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	R2890C	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	R2890C	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	R2890C	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	R2890C	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	R2890C	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NOTCH1	Q2384E	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	Q2384E	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH2	D1848Y	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	Y220N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y220N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y220N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y220N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y220N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y220N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y220N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y220N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y220N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y220N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y220N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y220N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y220N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y220N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y220N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	E872G	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
KMT2D	Q4230*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
PML	R120W	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	R120W	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	R120W	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
BRCA2	E1812*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	E1812*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	E1812*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	E1812*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	E1812*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	E1812*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	E1812*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	E1812*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	E1812*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	E1812*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	E1812*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	E1812*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	E1812*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	E1812*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
RET	T636M	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	T636M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	T636M	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	T636M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	T636M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	T636M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	T636M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	T636M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	T636M	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
NOTCH1	intron_variant), NOTCH1 MUT* (A796V	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	intron_variant), NOTCH1 MUT* (A796V	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRAF	T395A	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	T395A	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	T395A	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	T395A	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
FGFR2	G584R	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	G584R	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
ESR1	V533M	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
JAK2	T842R	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
PML	A93G	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	A93G	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	A93G	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
TP53	F270L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	F270L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	F270L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	F270L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	F270L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	F270L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	F270L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F270L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F270L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	F270L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	F270L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	F270L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F270L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	F270L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F270L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	Q852*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	Q852*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	Q852*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	Q852*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	Q852*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q852*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q852*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	Q852*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q852*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q852*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q852*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	Q852*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q852*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
NRG1	R438C	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	R438C	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
ATM	R2849*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R2849*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R2849*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R2849*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R2849*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R2849*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R2849*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R2849*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R2849*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R2849*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R2849*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R2849*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R2849*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ARID1A	Y216*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y216*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y216*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Y216*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
NOTCH1	R1082H	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1082H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	R342P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R342P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R342P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R342P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R342P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R342P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R342P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R342P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R342P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R342P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R342P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R342P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R342P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R342P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R342P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NTRK3	R138Q	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R138Q	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R138Q	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
KMT2A	V661I	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	V661I	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	V661I	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	V661I	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	V661I	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	V661I	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ERBB4	R612Q	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
STAG2	splice_donor_variant	Complete Match	PARP inhibitor	Responsive	G	Pre-clinical
FBXW7	T463I	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	T463I	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	T463I	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	T463I	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
NOTCH1	R1438H	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1438H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
EGFR	H584Q	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	H584Q	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
TP53	C176S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C176S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C176S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C176S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C176S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C176S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C176S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C176S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C176S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C176S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C176S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I195F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I195F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I195F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I195F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I195F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I195F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I195F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I195F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I195F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I195F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I195F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I195F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I195F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I195F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I195F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2D	Q3953*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
TP53	Q167*), TP53 MUT (R175C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q167*), TP53 MUT (R175C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q167*), TP53 MUT (R175C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q167*), TP53 MUT (R175C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q167*), TP53 MUT (R175C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q167*), TP53 MUT (R175C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q167*), TP53 MUT (R175C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q167*), TP53 MUT (R175C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q167*), TP53 MUT (R175C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q167*), TP53 MUT (R175C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q167*), TP53 MUT (R175C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q167*), TP53 MUT (R175C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q167*), TP53 MUT (R175C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q167*), TP53 MUT (R175C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q167*), TP53 MUT (R175C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	E706K	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	E706K	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
FGFR3	R158W	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	R158W	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	R158W	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TP53	V216E	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V216E	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V216E	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V216E	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V216E	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V216E	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V216E	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V216E	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V216E	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V216E	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V216E	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V216E	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V216E	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V216E	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V216E	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ESR1	N63S	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
NTRK1	Y359*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	Y359*	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	Y359*	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	Y359*	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
BRAF	G209D	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	G209D	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	G209D	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	G209D	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
FGFR3	P300L	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	P300L	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	P300L	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
NTRK1	E480K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	E480K	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	E480K	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	E480K	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
KMT2A	R331Q	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	R331Q	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	R331Q	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	R331Q	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	R331Q	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	R331Q	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
TP53	E224*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E224*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E224*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E224*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E224*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E224*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E224*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E224*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E224*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E224*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E224*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E224*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E224*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E224*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E224*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	A1732V	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	A1732V	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	P250L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P250L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P250L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P250L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P250L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P250L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P250L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P250L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P250L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P250L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P250L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P250L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P250L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P250L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P250L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PIK3CA	E81K	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	E81K	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	E81K	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	E81K	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	E81K	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	E81K	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	E81K	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	E81K	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	E81K	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	E81K	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	E81K	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	E81K	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	E81K	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	E81K	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
TP53	Y126*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y126*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y126*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y126*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y126*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y126*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y126*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y126*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y126*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y126*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y126*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y126*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y126*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y126*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y126*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NTRK3	R507G	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R507G	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R507G	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
RET	R189G	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R189G	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R189G	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R189G	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R189G	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R189G	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R189G	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R189G	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R189G	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
PML	S84A	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	S84A	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	S84A	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
TP53	R249T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R249T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R249T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R249T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R249T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R249T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R249T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R249T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R249T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R249T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R249T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R249T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R249T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R249T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R249T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P151A	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P151A	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P151A	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P151A	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P151A	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P151A	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P151A	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P151A	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P151A	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P151A	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P151A	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P151A	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P151A	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P151A	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P151A	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R3008C), ATM MUT (K2756*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R3008C), ATM MUT (K2756*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R3008C), ATM MUT (K2756*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R3008C), ATM MUT (K2756*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R3008C), ATM MUT (K2756*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R3008C), ATM MUT (K2756*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R3008C), ATM MUT (K2756*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R3008C), ATM MUT (K2756*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R3008C), ATM MUT (K2756*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R3008C), ATM MUT (K2756*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R3008C), ATM MUT (K2756*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R3008C), ATM MUT (K2756*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R3008C), ATM MUT (K2756*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
STK11	splice_donor_variant), KRAS MUT (G12D	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	splice_donor_variant), KRAS MUT (G12D	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	splice_donor_variant), KRAS MUT (G12D	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	splice_donor_variant), KRAS MUT (G12D	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
SF3B1	G740E	Different Mutation	Spliceosome inhibitor	Responsive	CANCER	Pre-clinical
PDGFRA	A396T	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
CTNNB1	H36_S37delinsQF	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	H36_S37delinsQF	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
KMT2A	R2211Q	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	R2211Q	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	R2211Q	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	R2211Q	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	R2211Q	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	R2211Q	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NTRK1	G743*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	G743*	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	G743*	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	G743*	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
ERCC2	R683W	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ERCC2	R683W	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ERCC2	R683W	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ALK	G902R	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	G902R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	G902R	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	G902R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	G902R	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	G902R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G902R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	G902R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G902R	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G902R	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	G902R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	G902R	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	G902R	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	G902R	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	G902R	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	G902R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	G902R	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	G902R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G902R	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
MSH2	W117*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
MSH2	W117*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ALK	C480*	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	C480*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	C480*	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	C480*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	C480*	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	C480*	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	C480*	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	C480*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	C480*	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	C480*	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	C480*	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	C480*	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	C480*	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	C480*	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	C480*	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	C480*	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	C480*	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	C480*	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	C480*	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
PBRM1	S888*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	S888*	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	S888*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	S888*	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	S888*	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
FGFR3	Y107*	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	Y107*	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	Y107*	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
MET	Q265K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
KMT2A	S997R	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S997R	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S997R	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S997R	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S997R	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S997R	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ARID1A	Y815*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y815*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y815*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Y815*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	R282_R283delinsQG	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R282_R283delinsQG	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R282_R283delinsQG	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R282_R283delinsQG	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R282_R283delinsQG	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R282_R283delinsQG	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R282_R283delinsQG	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R282_R283delinsQG	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R282_R283delinsQG	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R282_R283delinsQG	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R282_R283delinsQG	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R282_R283delinsQG	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R282_R283delinsQG	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R282_R283delinsQG	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R282_R283delinsQG	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FGFR2	D651G	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	D651G	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
TP53	Y163*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y163*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y163*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y163*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y163*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y163*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y163*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y163*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y163*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y163*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y163*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y163*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y163*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y163*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y163*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2A	K1833R	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	K1833R	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	K1833R	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	K1833R	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	K1833R	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	K1833R	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
TMPRSS2	D211E	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	D211E	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
TP53	R213G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R213G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R213G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R213G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R213G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R213G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R213G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R213G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R213G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R213G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R213G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R213G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R213G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R213G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R213G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	N1221S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	N1221S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
RNF43	Q233*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
ARID1A	Y430*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y430*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y430*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Y430*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ERBB4	R544W	Complete Match	Lapatinib (ERBB2 inhibitor)	Responsive	CM	Pre-clinical
ERBB4	R544W	Different Mutation	ERBB2 inhibitor	Resistant	BRCA	Case report
ERBB4	R544W	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
DNMT3A	C494*	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
PDGFRA	P577L	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
TMPRSS2	R219W	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	R219W	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
ROS1	W1101*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	W1101*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	W1101*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	W1101*	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	W1101*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
FGFR2	Q285E	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	Q285E	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
ABL1	A1110V	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	A1110V	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	A1110V	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	A1110V	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	A1110V	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	A1110V	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
DNMT3A	I670Vfs*34), DNMT3A MUT (R736H	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
NTRK3	N79H	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	N79H	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	N79H	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NOTCH2	D549N	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ROS1	G1135E	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	G1135E	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	G1135E	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	G1135E	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	G1135E	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
CDKN2A	P114H	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	P114H	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	P114H	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	P114H	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	P114H	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	P114H	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	P114H	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	P114H	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
NRG1	S384C	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	S384C	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
TP53	V197M	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V197M	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V197M	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V197M	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V197M	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V197M	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V197M	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V197M	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V197M	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V197M	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V197M	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V197M	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V197M	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V197M	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V197M	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RAF1	R391S	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	R391S	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	R391S	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
NOTCH2	L1663V	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	Q165*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q165*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q165*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q165*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q165*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q165*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q165*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q165*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q165*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q165*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q165*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q165*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q165*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q165*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q165*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRAF	L505F	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	L505F	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	L505F	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	L505F	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
ALK	P835S	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	P835S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	P835S	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	P835S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	P835S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	P835S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P835S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	P835S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P835S	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P835S	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	P835S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	P835S	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	P835S	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	P835S	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	P835S	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	P835S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	P835S	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	P835S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P835S	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
RET	A639T	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	A639T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	A639T	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	A639T	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	A639T	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	A639T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	A639T	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	A639T	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	A639T	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
MET	R417*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
NOTCH1	T66N	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	T66N	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R326L	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R326L	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R326L	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
TP53	D281E	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	D281E	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	D281E	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	D281E	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	D281E	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	D281E	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	D281E	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D281E	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D281E	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	D281E	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	D281E	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	D281E	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D281E	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	D281E	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D281E	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FGFR3	CdsStopSNV	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	CdsStopSNV	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	CdsStopSNV	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
CDKN2A	A76Lfs*70	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	A76Lfs*70	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	A76Lfs*70	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	A76Lfs*70	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	A76Lfs*70	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	A76Lfs*70	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	A76Lfs*70	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	A76Lfs*70	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
KMT2A	F1938L	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	F1938L	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	F1938L	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	F1938L	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	F1938L	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	F1938L	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
MET	T273N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
TP53	T125P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T125P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T125P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T125P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T125P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T125P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T125P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T125P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T125P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T125P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T125P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T125P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T125P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T125P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T125P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	R1250Q	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
TP53	G244C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G244C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G244C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G244C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G244C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G244C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G244C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G244C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G244C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G244C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G244C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G244C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G244C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G244C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G244C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	A999V	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	A999V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	A999V	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	A999V	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	A999V	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	A999V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	A999V	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	A999V	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	A999V	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ATM	Q561*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	Q561*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	Q561*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	Q561*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	Q561*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q561*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q561*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	Q561*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q561*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q561*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q561*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	Q561*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q561*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
CRLF2	L56P	Different Alteration	MTOR inhibitor	Responsive	ALL	Pre-clinical
CRLF2	L56P	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
NOTCH2	D2040N	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
AKT3	G10V	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
TP53	S241Y	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S241Y	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S241Y	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S241Y	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S241Y	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S241Y	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S241Y	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S241Y	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S241Y	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S241Y	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S241Y	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S241Y	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S241Y	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S241Y	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S241Y	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RNF43	Q242*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
EGFR	M600T	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	M600T	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
TP53	V173M	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V173M	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V173M	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V173M	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V173M	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V173M	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V173M	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V173M	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V173M	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V173M	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V173M	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V173M	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V173M	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V173M	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V173M	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PIK3CA	Q546R	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	Q546R	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	Q546R	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	Q546R	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	Q546R	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	Q546R	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	Q546R	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	Q546R	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	Q546R	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	Q546R	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	Q546R	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	Q546R	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	Q546R	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	Q546R	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
PBRM1	Q64*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	Q64*	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	Q64*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	Q64*	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	Q64*	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
KMT2A	S3484Y	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S3484Y	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S3484Y	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S3484Y	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S3484Y	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S3484Y	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
TMPRSS2	T95M	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	T95M	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
KMT2D	R2635*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
TP53	C242W	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C242W	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C242W	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C242W	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C242W	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C242W	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C242W	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C242W	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C242W	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C242W	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C242W	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C242W	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C242W	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C242W	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C242W	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	Y1369*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y1369*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y1369*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Y1369*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	R283C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R283C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R283C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R283C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R283C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R283C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R283C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R283C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R283C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R283C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R283C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R283C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R283C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R283C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R283C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FGFR3	R805G	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	R805G	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	R805G	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
NTRK3	D50Y	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	D50Y	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	D50Y	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NOTCH2	A2018S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	T304fs1	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T304fs1	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T304fs1	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T304fs1	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T304fs1	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T304fs1	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T304fs1	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T304fs1	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T304fs1	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T304fs1	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T304fs1	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T304fs1	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T304fs1	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T304fs1	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T304fs1	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	R205W	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R205W	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R205W	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R205W	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R205W	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R205W	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R205W	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R205W	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R205W	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
TP53	A161D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	A161D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	A161D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	A161D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	A161D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	A161D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	A161D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A161D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A161D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	A161D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	A161D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	A161D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A161D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	A161D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A161D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TSC2	E1239*	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	E1239*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	E1239*	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	E1239*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	E1239*	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	E1239*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	E1239*	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
ABL1	G778S	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	G778S	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G778S	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	G778S	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G778S	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	G778S	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
PDGFRA	E262Q	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
DNMT3A	W305*	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
ALK	splice_donor_variant	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	splice_donor_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	splice_donor_variant	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	splice_donor_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	splice_donor_variant	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	splice_donor_variant	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	splice_donor_variant	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	splice_donor_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	splice_donor_variant	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	splice_donor_variant	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	splice_donor_variant	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	splice_donor_variant	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	splice_donor_variant	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	splice_donor_variant	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	splice_donor_variant	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	splice_donor_variant	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	splice_donor_variant	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	splice_donor_variant	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	splice_donor_variant	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ERBB4	P557S	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ATM	R1882), ATM MUT (R35	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R1882), ATM MUT (R35	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R1882), ATM MUT (R35	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R1882), ATM MUT (R35	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R1882), ATM MUT (R35	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R1882), ATM MUT (R35	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R1882), ATM MUT (R35	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R1882), ATM MUT (R35	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R1882), ATM MUT (R35	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R1882), ATM MUT (R35	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R1882), ATM MUT (R35	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R1882), ATM MUT (R35	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R1882), ATM MUT (R35	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
TP53	T125M), TP53 MUT (V203M	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T125M), TP53 MUT (V203M	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T125M), TP53 MUT (V203M	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T125M), TP53 MUT (V203M	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T125M), TP53 MUT (V203M	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T125M), TP53 MUT (V203M	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T125M), TP53 MUT (V203M	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T125M), TP53 MUT (V203M	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T125M), TP53 MUT (V203M	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T125M), TP53 MUT (V203M	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T125M), TP53 MUT (V203M	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T125M), TP53 MUT (V203M	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T125M), TP53 MUT (V203M	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T125M), TP53 MUT (V203M	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T125M), TP53 MUT (V203M	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ALK	G843R	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	G843R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	G843R	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	G843R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	G843R	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	G843R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G843R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	G843R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G843R	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G843R	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	G843R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	G843R	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	G843R	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	G843R	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	G843R	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	G843R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	G843R	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	G843R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G843R	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
KIT	L576P	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	AML	Pre-clinical
KIT	L576P	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	HES, ALL, MDS, SM, ECL, MDPS, CML	FDA guidelines
KIT	L576P	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	L576P	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Pre-clinical
KIT	L576P	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Case report
KIT	L576P	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CANCER	Pre-clinical
KIT	L576P	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	SM	Early trials
KIT	L576P	Complete Match	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Case report
KIT	L576P	Complete Match	Dasatinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	L576P	Complete Match	HSP90 inhibitor	Responsive	GIST	Early trials
KIT	L576P	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Early trials
KIT	L576P	Complete Match	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	L576P	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	GIST	FDA guidelines
KIT	L576P	Complete Match	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	L576P	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Responsive	CM	Late trials;NCCN guidelines
KIT	L576P	Complete Match	Regorafenib (Pan-kinase inhibitor)	Responsive	GIST	FDA guidelines
KIT	L576P	Complete Match	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	L576P	Complete Match	Sunitinib (Pan-TK inhibitor)	Responsive	CM	Late trials
KIT	L576P	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	L576P	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	FDA guidelines
KIT	L576P	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	CM	Early trials
KIT	L576P	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	THYM	Case report
KIT	L576P	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	L576P	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	L576P	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KIT	L576P	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	L576P	Different Mutation	HSP90 inhibitor	Responsive	GIST	Pre-clinical
KIT	L576P	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Pre-clinical
KIT	L576P	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Pre-clinical
KIT	L576P	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	L576P	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	Late trials
KIT	L576P	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	GIST	Pre-clinical
KIT	L576P	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Late trials
KIT	L576P	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	L576P	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	GIST	Early trials
KIT	L576P	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	L576P	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	L576P	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	L576P	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	CM	Case report
KIT	L576P	Different Alteration	Sunitinib (Pan-TK inhibitor)	No Responsive	CM	Early trials
KIT	L576P	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	No Responsive	CM	Early trials
FGFR2	P805A	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	P805A	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
ROS1	P1662R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	P1662R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	P1662R	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	P1662R	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	P1662R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
NOTCH1	T2240A	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	T2240A	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ROS1	splice_acceptor_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	splice_acceptor_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	splice_acceptor_variant	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	splice_acceptor_variant	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	splice_acceptor_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ROS1	V423A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	V423A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	V423A	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	V423A	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	V423A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
RNF43	W165*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
NOTCH2	F524L	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
RNF43	Q409*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
CDK12	S4*	Complete Match	PARP inhibitor	Responsive	OV	Pre-clinical
CDK12	S4*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
KMT2A	P1134L	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P1134L	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P1134L	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P1134L	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P1134L	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P1134L	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
AKT3	M400V	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
PML	Q660*	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	Q660*	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	Q660*	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
RAF1	P30S	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	P30S	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	P30S	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
PML	K821R	Different Alteration	Volasertib (PLK1 inhibitor)	Responsive	AML	Early trials
PML	K821R	Different Alteration	Tretinoin (Retinoid)	Responsive	APML	FDA guidelines
PML	K821R	Different Alteration	Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy)	Responsive	AML	FDA guidelines
ALK	R1212H	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1212H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	R1212H	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	R1212H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	R1212H	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	R1212H	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R1212H	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	R1212H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R1212H	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R1212H	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	R1212H	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	R1212H	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	R1212H	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1212H	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1212H	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	R1212H	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	R1212H	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	R1212H	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R1212H	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ARID1A	Q321*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q321*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q321*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q321*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
PTEN	W111*	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	W111*	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	W111*	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	W111*	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	W111*	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	W111*	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	W111*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	W111*	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	W111*	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	W111*	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	W111*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	W111*	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	W111*	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	W111*	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	W111*	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	W111*	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	W111*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	W111*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	W111*	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	W111*	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	W111*	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	W111*	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	W111*	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	W111*	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	W111*	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
ERBB4	G573S	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
RET	T488S	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	T488S	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	T488S	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	T488S	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	T488S	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	T488S	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	T488S	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	T488S	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	T488S	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
TP53	P151T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P151T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P151T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P151T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P151T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P151T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P151T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P151T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P151T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P151T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P151T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P151T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P151T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P151T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P151T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	splice_donor_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	splice_donor_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	splice_donor_variant	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	splice_donor_variant	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	splice_donor_variant	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ALK	V448D	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	V448D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	V448D	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	V448D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	V448D	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	V448D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	V448D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	V448D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	V448D	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	V448D	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	V448D	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	V448D	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	V448D	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	V448D	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	V448D	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	V448D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	V448D	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	V448D	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	V448D	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
RICTOR	L28Gfs*3	Different Alteration	MTORC1/2 inhibitor	Responsive	L	Case report
AKT3	P42H	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
TP53	E171G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E171G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E171G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E171G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E171G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E171G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E171G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E171G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E171G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E171G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E171G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E171G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E171G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E171G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E171G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH2	R869Q	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ERBB4	P1195S	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
U2AF1	Q157P	Complete Match	FLT3 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y126C), TP53 MUT (H214R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y126C), TP53 MUT (H214R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y126C), TP53 MUT (H214R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y126C), TP53 MUT (H214R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y126C), TP53 MUT (H214R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y126C), TP53 MUT (H214R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y126C), TP53 MUT (H214R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y126C), TP53 MUT (H214R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y126C), TP53 MUT (H214R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y126C), TP53 MUT (H214R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y126C), TP53 MUT (H214R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y126C), TP53 MUT (H214R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y126C), TP53 MUT (H214R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y126C), TP53 MUT (H214R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y126C), TP53 MUT (H214R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
SF3B1	R625S	Different Mutation	Spliceosome inhibitor	Responsive	CANCER	Pre-clinical
BRD4	A276T	Different Alteration	BET inhibitor	Responsive	NMC	Case report
STK11	Q170*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	Q170*	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	Q170*	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	Q170*	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	Q170*	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	Q170*	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Q170*	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Q170*	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	Q170*	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	Q170*	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	Q170*	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Q170*	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Q170*), KRAS MUT (G12D	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	Q170*), KRAS MUT (G12D	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	Q170*), KRAS MUT (G12D	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	Q170*), KRAS MUT (G12D	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
TP53	H193Y	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H193Y	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H193Y	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H193Y	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H193Y	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H193Y	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H193Y	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H193Y	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H193Y	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H193Y	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H193Y	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H193Y	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H193Y	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H193Y	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H193Y	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
STK11	Y60*), KRAS MUT (G12R	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	Y60*), KRAS MUT (G12R	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	Y60*), KRAS MUT (G12R	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	Y60*), KRAS MUT (G12R	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
TP53	T155I	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T155I	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T155I	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T155I	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T155I	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T155I	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T155I	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T155I	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T155I	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T155I	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T155I	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T155I	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T155I	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T155I	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T155I	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y236*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y236*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y236*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y236*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y236*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y236*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y236*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y236*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y236*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y236*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y236*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y236*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y236*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y236*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y236*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	L1033H	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	L1033H	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	L1033H	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	L1033H	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	L1033H	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	L1033H	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	L1033H	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	L1033H	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	L1033H	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
MET	T557A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
BAP1	splice_donor_variant	Complete Match	EZH2 inhibitor	Responsive	MESO	Pre-clinical
BAP1	splice_donor_variant	Complete Match	PARP inhibitor	Responsive	R, CANCER	Pre-clinical
BAP1	splice_donor_variant	Complete Match	HDAC inhibitor	Responsive	CM	Pre-clinical
BAP1	splice_donor_variant	Different Alteration	PARP inhibitor	Responsive	CANCER, R	Pre-clinical
BAP1	splice_donor_variant	Different Alteration	EZH2 inhibitor	Responsive	MESO	Pre-clinical
BAP1	splice_donor_variant	Different Alteration	HDAC inhibitor	Responsive	CM	Pre-clinical
ARID1A	S1151Rfs*9	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S1151Rfs*9	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S1151Rfs*9	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	S1151Rfs*9	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ERBB4	E874*	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	CM	Pre-clinical
ERBB4	E874*	Different Mutation	ERBB2 inhibitor	Resistant	BRCA	Case report
ERBB4	E874*	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ALK	K1205Q	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	K1205Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	K1205Q	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	K1205Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	K1205Q	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	K1205Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	K1205Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	K1205Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	K1205Q	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	K1205Q	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	K1205Q	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	K1205Q	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	K1205Q	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	K1205Q	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	K1205Q	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	K1205Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	K1205Q	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	K1205Q	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	K1205Q	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
BRCA2	K2013*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	K2013*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	K2013*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	K2013*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	K2013*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	K2013*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	K2013*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	K2013*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	K2013*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	K2013*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	K2013*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	K2013*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	K2013*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	K2013*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
RET	A1020V	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	A1020V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	A1020V	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	A1020V	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	A1020V	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	A1020V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	A1020V	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	A1020V	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	A1020V	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
BRD4	A589V	Different Alteration	BET inhibitor	Responsive	NMC	Case report
TP53	E62Afs*83	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E62Afs*83	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E62Afs*83	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E62Afs*83	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E62Afs*83	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E62Afs*83	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E62Afs*83	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E62Afs*83	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E62Afs*83	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E62Afs*83	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E62Afs*83	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E62Afs*83	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E62Afs*83	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E62Afs*83	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E62Afs*83	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ALK	A120D	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	A120D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	A120D	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	A120D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	A120D	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	A120D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A120D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	A120D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A120D	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A120D	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	A120D	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	A120D	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	A120D	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	A120D	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	A120D	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	A120D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	A120D	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	A120D	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A120D	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
FGFR2	A415T	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	A415T	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
ALK	G875R	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	G875R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	G875R	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	G875R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	G875R	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	G875R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G875R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	G875R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G875R	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G875R	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	G875R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	G875R	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	G875R	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	G875R	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	G875R	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	G875R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	G875R	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	G875R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G875R	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
CDH1	I612Nfs*16	Complete Match	Bicalutamide (AR inhibitor)	Responsive	BRCA	Pre-clinical
KMT2A	N2779S	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	N2779S	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	N2779S	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	N2779S	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	N2779S	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	N2779S	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ESR1	S338G	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
KMT2A	M2410V	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	M2410V	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	M2410V	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	M2410V	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	M2410V	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	M2410V	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NOTCH1	A2044T	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	A2044T	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRAF	K483T	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	K483T	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	K483T	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	K483T	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
ERBB4	R306H	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
TP53	K132E	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	K132E	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	K132E	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	K132E	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	K132E	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	K132E	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	K132E	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K132E	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K132E	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	K132E	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	K132E	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	K132E	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K132E	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	K132E	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K132E	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	L712P	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	L712P	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	L712P	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	L712P	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	L712P	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	L712P	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	L712P	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	L712P	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	L712P	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
KRAS	A146V	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	A146V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	A146V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	A146V	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	A146V	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	A146V	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	A146V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	A146V	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	A146V	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	A146V	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	A146V	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	A146V	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	A146V	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	A146V	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	A146V	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	A146V	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	A146V	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	A146V	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	A146V	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	A146V	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	A146V	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	A146V	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	A146V	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	A146V	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	A146V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	A146V	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	A146V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	A146V	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	A146V	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	A146V	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	A146V	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	A146V	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	A146V	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	A146V	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	A146V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	A146V	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	A146V	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	A146V	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	A146V	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	A146V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	A146V	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	A146V	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
RB1	Y325*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	Y325*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	Y325*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	Y325*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	Y325*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	Y325*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	Y325*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
NTRK3	T707M	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	T707M	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	T707M	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NOTCH2	P349S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	E271*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E271*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E271*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E271*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E271*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E271*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E271*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E271*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E271*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E271*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E271*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E271*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E271*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E271*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E271*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	S837*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	S837*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	S837*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	S837*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	S837*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	S837*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	S837*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	S837*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	S837*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	S837*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	S837*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	S837*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	S837*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
KMT2D	Y5426*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
PIK3CA	H1047R), PIK3CA MUT (E542K	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	H1047R), PIK3CA MUT (E542K	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	H1047R), PIK3CA MUT (E542K	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	H1047R), PIK3CA MUT (E542K	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	H1047R), PIK3CA MUT (E542K	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	H1047R), PIK3CA MUT (E542K	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	H1047R), PIK3CA MUT (E542K	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	H1047R), PIK3CA MUT (E542K	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	H1047R), PIK3CA MUT (E542K	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	H1047R), PIK3CA MUT (E542K	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	H1047R), PIK3CA MUT (E542K	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	H1047R), PIK3CA MUT (E542K	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	H1047R), PIK3CA MUT (E542K	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	H1047R), PIK3CA MUT (E542K	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
TP53	R213*), TP53 MUT (R273L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R213*), TP53 MUT (R273L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R213*), TP53 MUT (R273L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R213*), TP53 MUT (R273L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R213*), TP53 MUT (R273L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R213*), TP53 MUT (R273L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R213*), TP53 MUT (R273L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R213*), TP53 MUT (R273L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R213*), TP53 MUT (R273L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R213*), TP53 MUT (R273L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R213*), TP53 MUT (R273L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R213*), TP53 MUT (R273L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R213*), TP53 MUT (R273L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R213*), TP53 MUT (R273L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R213*), TP53 MUT (R273L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CTNNB1	S45P), CTNNB1 MUT (P44A	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	S45P), CTNNB1 MUT (P44A	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
ERBB4	R1139Q	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ALK	V503I	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	V503I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	V503I	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	V503I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	V503I	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	V503I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	V503I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	V503I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	V503I	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	V503I	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	V503I	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	V503I	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	V503I	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	V503I	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	V503I	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	V503I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	V503I	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	V503I	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	V503I	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
NTRK3	E360K	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	E360K	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	E360K	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NOTCH2	V1182I	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	V272G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V272G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V272G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V272G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V272G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V272G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V272G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V272G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V272G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V272G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V272G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V272G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V272G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V272G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V272G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
SETD2	splice_acceptor_variant	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	splice_acceptor_variant	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
PDGFRA	S636T	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
RNF43	Q22), RNF43 MUT (R337	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
JAK2	S1054R	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
ALK	V1045M	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	V1045M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	V1045M	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	V1045M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	V1045M	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	V1045M	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	V1045M	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	V1045M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	V1045M	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	V1045M	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	V1045M	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	V1045M	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	V1045M	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	V1045M	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	V1045M	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	V1045M	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	V1045M	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	V1045M	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	V1045M	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
TP53	S241A	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S241A	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S241A	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S241A	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S241A	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S241A	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S241A	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S241A	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S241A	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S241A	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S241A	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S241A	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S241A	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S241A	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S241A	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PIK3CA	Q546K), PIK3CA MUT (D538E	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	Q546K), PIK3CA MUT (D538E	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	Q546K), PIK3CA MUT (D538E	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	Q546K), PIK3CA MUT (D538E	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	Q546K), PIK3CA MUT (D538E	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	Q546K), PIK3CA MUT (D538E	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	Q546K), PIK3CA MUT (D538E	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	Q546K), PIK3CA MUT (D538E	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	Q546K), PIK3CA MUT (D538E	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	Q546K), PIK3CA MUT (D538E	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	Q546K), PIK3CA MUT (D538E	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	Q546K), PIK3CA MUT (D538E	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	Q546K), PIK3CA MUT (D538E	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	Q546K), PIK3CA MUT (D538E	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
JAK2	L805I	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
LRP1B	splice_donor_variant	Complete Match	Liposomal Doxorubicin (Chemotherapy)	Resistant	OV	Early trials
LRP1B	splice_donor_variant	Different Alteration	Liposomal Doxorubicin (Chemotherapy)	Resistant	OV	Early trials
ARID1A	Y447*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y447*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y447*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Y447*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	T253A	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T253A	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T253A	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T253A	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T253A	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T253A	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T253A	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T253A	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T253A	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T253A	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T253A	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T253A	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T253A	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T253A	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T253A	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RB1	R7*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	R7*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R7*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R7*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	R7*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R7*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R7*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
KMT2A	P2620S	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P2620S	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P2620S	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P2620S	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P2620S	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P2620S	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NOTCH1	R1234W	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1234W	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
EGFR	D1084N	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	D1084N	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
TP53	V216L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V216L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V216L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V216L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V216L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V216L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V216L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V216L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V216L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V216L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V216L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V216L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V216L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V216L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V216L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	G2262S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	G2262S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
PIK3CA	K111E	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	K111E	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	K111E	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	K111E	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	K111E	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	K111E	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	K111E	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	K111E	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	K111E	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	K111E	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	K111E	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	K111E	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	K111E	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	K111E	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
ATM	R2832C), ATM MUT (K2089*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R2832C), ATM MUT (K2089*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R2832C), ATM MUT (K2089*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R2832C), ATM MUT (K2089*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R2832C), ATM MUT (K2089*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R2832C), ATM MUT (K2089*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R2832C), ATM MUT (K2089*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R2832C), ATM MUT (K2089*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R2832C), ATM MUT (K2089*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R2832C), ATM MUT (K2089*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R2832C), ATM MUT (K2089*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R2832C), ATM MUT (K2089*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R2832C), ATM MUT (K2089*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RAF1	E286Q	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	E286Q	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	E286Q	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
BRD4	L247M	Different Alteration	BET inhibitor	Responsive	NMC	Case report
TP53	L194R), TP53 MUT (E271*), TP53 MUT (E287Q	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L194R), TP53 MUT (E271*), TP53 MUT (E287Q	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L194R), TP53 MUT (E271*), TP53 MUT (E287Q	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L194R), TP53 MUT (E271*), TP53 MUT (E287Q	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L194R), TP53 MUT (E271*), TP53 MUT (E287Q	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L194R), TP53 MUT (E271*), TP53 MUT (E287Q	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L194R), TP53 MUT (E271*), TP53 MUT (E287Q	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L194R), TP53 MUT (E271*), TP53 MUT (E287Q	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L194R), TP53 MUT (E271*), TP53 MUT (E287Q	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L194R), TP53 MUT (E271*), TP53 MUT (E287Q	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L194R), TP53 MUT (E271*), TP53 MUT (E287Q	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L194R), TP53 MUT (E271*), TP53 MUT (E287Q	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L194R), TP53 MUT (E271*), TP53 MUT (E287Q	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L194R), TP53 MUT (E271*), TP53 MUT (E287Q	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L194R), TP53 MUT (E271*), TP53 MUT (E287Q	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRD4	K99N	Different Alteration	BET inhibitor	Responsive	NMC	Case report
ABL1	V722I	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	V722I	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	V722I	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	V722I	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	V722I	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	V722I	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
TP53	L130F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L130F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L130F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L130F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L130F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L130F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L130F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L130F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L130F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L130F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L130F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L130F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L130F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L130F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L130F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
APC	E225*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
FANCC	R185*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
FANCC	R185*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
FGFR3	R498W	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	R498W	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	R498W	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
RAF1	L300P	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	L300P	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	L300P	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
PIK3CA	K111N	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	K111N	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	K111N	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	K111N	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	K111N	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	K111N	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	K111N	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	K111N	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	K111N	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	K111N	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	K111N	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	K111N	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	K111N	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	K111N	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
CDKN2A	D108H	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	D108H	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	D108H	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	D108H	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	D108H	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	D108H	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	D108H	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	D108H	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
KMT2D	E1832*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
ROS1	I1825M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	I1825M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	I1825M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	I1825M	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	I1825M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
KMT2A	A11T	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	A11T	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	A11T	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	A11T	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	A11T	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	A11T	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
BRAF	D677N	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	D677N	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	D677N	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	D677N	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
FGFR3	R439G	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	R439G	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	R439G	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
CDKN2A	I49N	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	I49N	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	I49N	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	I49N	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	I49N	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	I49N	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	I49N	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	I49N	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
NOTCH1	A150T	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	A150T	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NF2	E38*	Complete Match	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	E38*	Complete Match	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	E38*	Complete Match	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	E38*	Complete Match	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	E38*	Complete Match	MTOR inhibitor	Responsive	MEN	Pre-clinical
NF2	E38*	Complete Match	Lapatinib (ERBB2 inhibitor)	Responsive	NF, SCHW	Early trials
NF2	E38*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	E38*	Complete Match	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	E38*	Complete Match	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	E38*	Complete Match	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	E38*	Complete Match	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	E38*	Complete Match	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	E38*	Complete Match	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	E38*	Complete Match	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	E38*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	E38*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	E38*	Different Alteration	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	E38*	Different Alteration	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	E38*	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	E38*	Different Alteration	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	E38*	Different Alteration	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	E38*	Different Alteration	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	E38*	Different Alteration	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	E38*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	E38*	Different Alteration	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	E38*	Different Alteration	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	E38*	Different Alteration	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	E38*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	E38*	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	SCHW, NF	Early trials
NF2	E38*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	E38*	Different Alteration	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	E38*	Different Alteration	MTOR inhibitor	Responsive	MEN	Pre-clinical
CTNNB1	S33P	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	S33P	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
KMT2D	E1080*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
JAK2	W659R	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
PIK3R1	R557Q	Complete Match	AKT inhibitor	Responsive	G	Pre-clinical
PIK3R1	R557Q	Complete Match	PI3K pathway inhibitor	Responsive	ED	Case report
ALK	S1081R	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	S1081R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	S1081R	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	S1081R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	S1081R	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	S1081R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	S1081R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	S1081R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	S1081R	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	S1081R	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	S1081R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	S1081R	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	S1081R	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	S1081R	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	S1081R	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	S1081R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	S1081R	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	S1081R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	S1081R	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
CHEK2	splice_donor_variant	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
CHEK2	splice_donor_variant	Different Alteration	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
NTRK1	T734M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	T734M	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	T734M	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	T734M	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
TP53	E286*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E286*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E286*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E286*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E286*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E286*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E286*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E286*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E286*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E286*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E286*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E286*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E286*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E286*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E286*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	P877L	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	P877L	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	H179Q	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H179Q	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H179Q	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H179Q	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H179Q	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H179Q	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H179Q	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H179Q	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H179Q	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H179Q	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H179Q	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H179Q	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H179Q	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H179Q	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H179Q	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	I1051V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	I1051V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	I1051V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	I1051V	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	I1051V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
RET	A1019P	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	A1019P	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	A1019P	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	A1019P	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	A1019P	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	A1019P	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	A1019P	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	A1019P	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	A1019P	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
CDKN2A	L94Rfs*52	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	L94Rfs*52	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	L94Rfs*52	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	L94Rfs*52	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	L94Rfs*52	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	L94Rfs*52	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	L94Rfs*52	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	L94Rfs*52	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
KMT2A	T3577M	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	T3577M	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	T3577M	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	T3577M	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	T3577M	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	T3577M	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NF2	splice_donor_variant	Complete Match	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	splice_donor_variant	Complete Match	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	splice_donor_variant	Complete Match	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	splice_donor_variant	Complete Match	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	splice_donor_variant	Complete Match	MTOR inhibitor	Responsive	MEN	Pre-clinical
NF2	splice_donor_variant	Complete Match	Lapatinib (ERBB2 inhibitor)	Responsive	NF, SCHW	Early trials
NF2	splice_donor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	splice_donor_variant	Complete Match	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	splice_donor_variant	Complete Match	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	splice_donor_variant	Complete Match	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	splice_donor_variant	Complete Match	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	splice_donor_variant	Complete Match	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	splice_donor_variant	Complete Match	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	splice_donor_variant	Complete Match	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	splice_donor_variant	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	splice_donor_variant	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	splice_donor_variant	Different Alteration	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	splice_donor_variant	Different Alteration	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	splice_donor_variant	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	splice_donor_variant	Different Alteration	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	splice_donor_variant	Different Alteration	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	splice_donor_variant	Different Alteration	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	splice_donor_variant	Different Alteration	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	splice_donor_variant	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	splice_donor_variant	Different Alteration	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	splice_donor_variant	Different Alteration	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	splice_donor_variant	Different Alteration	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	splice_donor_variant	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	splice_donor_variant	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	SCHW, NF	Early trials
NF2	splice_donor_variant	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	splice_donor_variant	Different Alteration	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	splice_donor_variant	Different Alteration	MTOR inhibitor	Responsive	MEN	Pre-clinical
KMT2A	A3729T	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	A3729T	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	A3729T	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	A3729T	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	A3729T	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	A3729T	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
TP53	C229*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C229*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C229*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C229*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C229*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C229*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C229*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C229*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C229*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C229*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C229*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C229*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C229*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C229*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C229*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R202P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R202P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R202P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R202P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R202P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R202P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R202P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R202P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R202P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R202P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R202P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R202P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R202P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R202P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R202P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ALK	P1191P	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	P1191P	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	P1191P	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	P1191P	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	P1191P	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	P1191P	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P1191P	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	P1191P	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P1191P	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P1191P	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	P1191P	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	P1191P	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	P1191P	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	P1191P	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	P1191P	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	P1191P	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	P1191P	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	P1191P	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P1191P	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
PDGFRA	A663A	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
KIT	T544S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	AML	Pre-clinical
KIT	T544S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	HES, ALL, MDS, SM, ECL, MDPS, CML	FDA guidelines
KIT	T544S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	T544S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Pre-clinical
KIT	T544S	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Case report
KIT	T544S	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CANCER	Pre-clinical
KIT	T544S	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	SM	Early trials
KIT	T544S	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Case report
KIT	T544S	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	T544S	Different Mutation	HSP90 inhibitor	Responsive	GIST	Early trials
KIT	T544S	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Early trials
KIT	T544S	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	T544S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	GIST	FDA guidelines
KIT	T544S	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	T544S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Responsive	CM	Late trials;NCCN guidelines
KIT	T544S	Different Mutation	Regorafenib (Pan-kinase inhibitor)	Responsive	GIST	FDA guidelines
KIT	T544S	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	T544S	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	CM	Late trials
KIT	T544S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	T544S	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	FDA guidelines
KIT	T544S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	CM	Early trials
KIT	T544S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	THYM	Case report
KIT	T544S	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	T544S	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	T544S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KIT	T544S	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	T544S	Different Mutation	HSP90 inhibitor	Responsive	GIST	Pre-clinical
KIT	T544S	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Pre-clinical
KIT	T544S	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Pre-clinical
KIT	T544S	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	Late trials
KIT	T544S	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	GIST	Pre-clinical
KIT	T544S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Late trials
KIT	T544S	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	T544S	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	GIST	Early trials
KIT	T544S	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	T544S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	T544S	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	T544S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	CM	Case report
KIT	T544S	Different Alteration	Sunitinib (Pan-TK inhibitor)	No Responsive	CM	Early trials
KIT	T544S	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	No Responsive	CM	Early trials
RET	H784H	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	H784H	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	H784H	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	H784H	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	H784H	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	H784H	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	H784H	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	H784H	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	H784H	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
TP53	S240G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S240G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S240G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S240G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S240G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S240G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S240G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S240G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S240G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S240G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S240G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S240G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S240G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S240G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S240G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	IntronicDeletion	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
CDKN2A	R138K	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R138K	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R138K	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	R138K	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R138K	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R138K	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R138K	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R138K	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
KRAS	G12E	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12E	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12E	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12E	Complete Match	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12E	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12E	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12E	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12E	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12E	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12E	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12E	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12E	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12E	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12E	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12E	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12E	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12E	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12E	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12E	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12E	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12E	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12E	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12E	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12E	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12E	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12E	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12E	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12E	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12E	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12E	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12E	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12E	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12E	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12E	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12E	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12E	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12E	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12E	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12E	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12E	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12E	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12E	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	Y234*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y234*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y234*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y234*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y234*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y234*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y234*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y234*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y234*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y234*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y234*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y234*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y234*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y234*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y234*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y126H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y126H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y126H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y126H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y126H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y126H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y126H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y126H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y126H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y126H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y126H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y126H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y126H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y126H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y126H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S127P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S127P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S127P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S127P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S127P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S127P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S127P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S127P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S127P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S127P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S127P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S127P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S127P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S127P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S127P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRAF	G469A	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	G469A	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	G469A	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	NCCN guidelines
BRAF	G469A	Different Mutation	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469A	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469A	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469A	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	G469A	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	G469A	Different Mutation	MEK inhibitor	Responsive	CM	Case report
BRAF	G469A	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	G469A	Different Mutation	BRAF inhibitor	Responsive	CM	Case report
BRAF	G469A	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	G469A	Different Mutation	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	G469A	Different Mutation	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	G469A	Different Mutation	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	G469A	Different Mutation	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	G469A	Different Mutation	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	G469A	Different Mutation	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	G469A	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	G469A	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	G469A	Different Mutation	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	G469A	Different Mutation	BRAF inhibitor;HSP90 inhibitor	Responsive	CM	Pre-clinical
BRAF	G469A	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	G469A	Different Mutation	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	G469A	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	G469A	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	G469A	Different Mutation	MEK inhibitor	Responsive	TH	Early trials
BRAF	G469A	Different Mutation	BRAF inhibitor;PI3K pathway inhibitor	Responsive	CM	Pre-clinical
BRAF	G469A	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	G469A	Different Mutation	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	G469A	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469A	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	G469A	Different Mutation	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	G469A	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	G469A	Different Mutation	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	G469A	Different Mutation	BRAF inhibitor;CDK2/4 inhibitor	Responsive	CM	Pre-clinical
BRAF	G469A	Different Mutation	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	G469A	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	G469A	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	G469A	Different Mutation	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	G469A	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	G469A	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	G469A	Different Mutation	BRAF inhibitor	Responsive	OV	Case report
BRAF	G469A	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	G469A	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469A	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	G469A	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	G469A	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	G469A	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	G469A	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TP53	R248Q), TP53 MUT (splice_acceptor_variant	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R248Q), TP53 MUT (splice_acceptor_variant	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R248Q), TP53 MUT (splice_acceptor_variant	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R248Q), TP53 MUT (splice_acceptor_variant	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R248Q), TP53 MUT (splice_acceptor_variant	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R248Q), TP53 MUT (splice_acceptor_variant	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248Q), TP53 MUT (splice_acceptor_variant	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R248Q), TP53 MUT (splice_acceptor_variant	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R248Q), TP53 MUT (splice_acceptor_variant	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R248Q), TP53 MUT (splice_acceptor_variant	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R248Q), TP53 MUT (splice_acceptor_variant	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248Q), TP53 MUT (splice_acceptor_variant	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R248Q), TP53 MUT (splice_acceptor_variant	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R248Q), TP53 MUT (splice_acceptor_variant	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FGFR2	intron_variant), FGFR2 MUT* (V270V	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	intron_variant), FGFR2 MUT* (V270V	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
FGFR3	A797T), FGFR3 MUT* (R252W	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	A797T), FGFR3 MUT* (R252W	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	A797T), FGFR3 MUT* (R252W	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TP53	Y163C), TP53 MUT (E287K	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y163C), TP53 MUT (E287K	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y163C), TP53 MUT (E287K	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y163C), TP53 MUT (E287K	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y163C), TP53 MUT (E287K	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y163C), TP53 MUT (E287K	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y163C), TP53 MUT (E287K	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y163C), TP53 MUT (E287K	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y163C), TP53 MUT (E287K	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y163C), TP53 MUT (E287K	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y163C), TP53 MUT (E287K	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y163C), TP53 MUT (E287K	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y163C), TP53 MUT (E287K	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y163C), TP53 MUT (E287K	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y163C), TP53 MUT (E287K	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	intron_variant), RET MUT* (P766L), RET MUT* (intron_variant	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	intron_variant), RET MUT* (P766L), RET MUT* (intron_variant	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	intron_variant), RET MUT* (P766L), RET MUT* (intron_variant	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	intron_variant), RET MUT* (P766L), RET MUT* (intron_variant	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	intron_variant), RET MUT* (P766L), RET MUT* (intron_variant	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	intron_variant), RET MUT* (P766L), RET MUT* (intron_variant	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	intron_variant), RET MUT* (P766L), RET MUT* (intron_variant	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	intron_variant), RET MUT* (P766L), RET MUT* (intron_variant	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	intron_variant), RET MUT* (P766L), RET MUT* (intron_variant	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
NOTCH1	T1602I	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	T1602I	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	E198*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E198*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E198*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E198*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E198*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E198*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E198*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E198*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E198*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E198*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E198*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E198*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E198*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E198*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E198*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	splice_acceptor_variant), TP53 MUT (P278H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	splice_acceptor_variant), TP53 MUT (P278H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	splice_acceptor_variant), TP53 MUT (P278H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	splice_acceptor_variant), TP53 MUT (P278H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	splice_acceptor_variant), TP53 MUT (P278H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	splice_acceptor_variant), TP53 MUT (P278H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	splice_acceptor_variant), TP53 MUT (P278H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	splice_acceptor_variant), TP53 MUT (P278H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	splice_acceptor_variant), TP53 MUT (P278H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	splice_acceptor_variant), TP53 MUT (P278H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	splice_acceptor_variant), TP53 MUT (P278H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	splice_acceptor_variant), TP53 MUT (P278H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	splice_acceptor_variant), TP53 MUT (P278H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	splice_acceptor_variant), TP53 MUT (P278H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	splice_acceptor_variant), TP53 MUT (P278H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FGFR3	L690L	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	L690L	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	L690L	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TP53	L194R), TP53 MUT (M243I	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L194R), TP53 MUT (M243I	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L194R), TP53 MUT (M243I	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L194R), TP53 MUT (M243I	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L194R), TP53 MUT (M243I	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L194R), TP53 MUT (M243I	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L194R), TP53 MUT (M243I	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L194R), TP53 MUT (M243I	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L194R), TP53 MUT (M243I	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L194R), TP53 MUT (M243I	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L194R), TP53 MUT (M243I	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L194R), TP53 MUT (M243I	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L194R), TP53 MUT (M243I	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L194R), TP53 MUT (M243I	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L194R), TP53 MUT (M243I	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FBXW7	R465H	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	R465H	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	R465H	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	R465H	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
TP53	M133T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	M133T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	M133T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	M133T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	M133T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	M133T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M133T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M133T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M133T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	M133T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	M133T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	M133T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M133T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	M133T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M133T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I232S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I232S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I232S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I232S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I232S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I232S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I232S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I232S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I232S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I232S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I232S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I232S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I232S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I232S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I232S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
EGFR	L782F	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	L782F	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
FGFR3	P795L), FGFR3 MUT* (F273F	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	P795L), FGFR3 MUT* (F273F	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	P795L), FGFR3 MUT* (F273F	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
FGFR2	S267S	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	S267S	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
TP53	E339K	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E339K	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E339K	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E339K	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E339K	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E339K	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E339K	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E339K	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E339K	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E339K	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E339K	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E339K	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E339K	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E339K	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E339K	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	Q781), RET MUT (intron_variant), RET MUT* (L629L	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	Q781), RET MUT (intron_variant), RET MUT* (L629L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	Q781), RET MUT (intron_variant), RET MUT* (L629L	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	Q781), RET MUT (intron_variant), RET MUT* (L629L	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	Q781), RET MUT (intron_variant), RET MUT* (L629L	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	Q781), RET MUT (intron_variant), RET MUT* (L629L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	Q781), RET MUT (intron_variant), RET MUT* (L629L	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	Q781), RET MUT (intron_variant), RET MUT* (L629L	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	Q781), RET MUT (intron_variant), RET MUT* (L629L	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ERBB4	P943P	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
EGFR	P753S	Different Alteration	Cetuximab (EGFR mAb inhibitor)	Responsive	COREAD	FDA guidelines
EGFR	P753S	Different Alteration	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
EGFR	P753S	Different Mutation	Rindopepimut (Vaccine)	Responsive	GB	Late trials
EGFR	P753S	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	P753S	Different Mutation	Gefitinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	P753S	Different Mutation	HSP90 inhibitor	Responsive	L	Early trials
EGFR	P753S	Different Mutation	Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	P753S	Different Mutation	MEK inhibitor	Responsive	L	Pre-clinical
EGFR	P753S	Different Mutation	EGFR TK inhibitor	Responsive	L	Late trials
EGFR	P753S	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	NCCN guidelines
EGFR	P753S	Different Mutation	Osimertinib (EGFR inhibitor)	Resistant	L	Early trials
EGFR	P753S	Different Mutation	EGFR-TKI's (EGFR inhibitor)	Resistant	L	Late trials
EGFR	P753S	Different Mutation	HSP90 inhibitor	Responsive	L	Case report
EGFR	P753S	Different Mutation	EGFR inhibitor	Resistant	L	Late trials
EGFR	P753S	Different Mutation	Poziotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	P753S	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Pre-clinical
EGFR	P753S	Different Mutation	HSP90 inhibitor (HSP90 inhibitor)	Responsive	L	Early trials
EGFR	P753S	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	G	Pre-clinical
EGFR	P753S	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	P753S	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	P753S	Different Mutation	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
EGFR	P753S	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Responsive	COREAD	Case report
EGFR	P753S	Different Mutation	novel EGFR mAb inhibitor	Responsive	COREAD	Early trials
EGFR	P753S	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	P753S	Complete Match	Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor)	Responsive	HNC	Case report
EGFR	P753S	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	P753S	Different Mutation	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Case report
EGFR	P753S	Different Mutation	EGFR inhibitor	Responsive	L	Early trials
EGFR	P753S	Different Mutation	Erlotinib (EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	P753S	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	P753S	Different Mutation	EGFR inhibitor	Responsive	NSCLC	Late trials
EGFR	P753S	Different Mutation	Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	P753S	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	P753S	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	P753S	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	L	Late trials
EGFR	P753S	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Pre-clinical
EGFR	P753S	Different Mutation	Erlotinib (EGFR inhibitor)	No Responsive	L	Case report
EGFR	P753S	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	ED	Case report
EGFR	P753S	Different Mutation	EGFR inhibitor	No Responsive	G	Early trials
EGFR	P753S	Different Mutation	EGFR inhibitor	Resistant	NSCLC	Case report
EGFR	P753S	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	P753S	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant;Resistant	COREAD	Pre-clinical;Case report
EGFR	P753S	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Responsive	HNC	Case report
EGFR	P753S	Different Alteration	Gefitinib (EGFR inhibitor)	Responsive	ED	Late trials
EGFR	P753S	Different Alteration	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Early trials
EGFR	P753S	Different Alteration	EGFR inhibitor	Responsive	HNSC	Case report
EGFR	P753S	Different Alteration	EGFR inhibitor	No Responsive	G	Early trials
EGFR	P753S	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	L	Early trials
EGFR	P753S	Different Alteration	EGFR mAb inhibitor	Responsive	COREAD	Late trials
EGFR	P753S), EGFR MUT* (C775C	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	P753S), EGFR MUT* (C775C	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
ATM	R3008C	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R3008C	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R3008C	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R3008C	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R3008C	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R3008C	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R3008C	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R3008C	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R3008C	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R3008C	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R3008C	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R3008C	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R3008C	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
JAK2	K603K	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
PIK3CA	A1046V	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	A1046V	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	A1046V	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	A1046V	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	A1046V	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	A1046V	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	A1046V	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	A1046V	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	A1046V	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	A1046V	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	A1046V	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	A1046V	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	A1046V	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	A1046V	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
PDGFRA	C677Y	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
KIT	P573S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	AML	Pre-clinical
KIT	P573S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	HES, ALL, MDS, SM, ECL, MDPS, CML	FDA guidelines
KIT	P573S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	P573S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Pre-clinical
KIT	P573S	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Case report
KIT	P573S	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CANCER	Pre-clinical
KIT	P573S	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	SM	Early trials
KIT	P573S	Complete Match	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Case report
KIT	P573S	Complete Match	Dasatinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	P573S	Complete Match	HSP90 inhibitor	Responsive	GIST	Early trials
KIT	P573S	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Early trials
KIT	P573S	Complete Match	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	P573S	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	GIST	FDA guidelines
KIT	P573S	Complete Match	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	P573S	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Responsive	CM	Late trials;NCCN guidelines
KIT	P573S	Complete Match	Regorafenib (Pan-kinase inhibitor)	Responsive	GIST	FDA guidelines
KIT	P573S	Complete Match	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	P573S	Complete Match	Sunitinib (Pan-TK inhibitor)	Responsive	CM	Late trials
KIT	P573S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	P573S	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	FDA guidelines
KIT	P573S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	CM	Early trials
KIT	P573S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	THYM	Case report
KIT	P573S	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	P573S	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	P573S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KIT	P573S	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	P573S	Different Mutation	HSP90 inhibitor	Responsive	GIST	Pre-clinical
KIT	P573S	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Pre-clinical
KIT	P573S	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Pre-clinical
KIT	P573S	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	P573S	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	Late trials
KIT	P573S	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	GIST	Pre-clinical
KIT	P573S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Late trials
KIT	P573S	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	P573S	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	GIST	Early trials
KIT	P573S	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	P573S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	P573S	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	P573S	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	CM	Case report
KIT	P573S	Different Alteration	Sunitinib (Pan-TK inhibitor)	No Responsive	CM	Early trials
KIT	P573S	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	No Responsive	CM	Early trials
FBXW7	R505H	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	R505H	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	R505H	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	R505H	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FGFR3	S378S	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	S378S	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	S378S	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TP53	A189T), TP53 MUT (P191S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	A189T), TP53 MUT (P191S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	A189T), TP53 MUT (P191S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	A189T), TP53 MUT (P191S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	A189T), TP53 MUT (P191S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	A189T), TP53 MUT (P191S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	A189T), TP53 MUT (P191S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A189T), TP53 MUT (P191S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A189T), TP53 MUT (P191S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	A189T), TP53 MUT (P191S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	A189T), TP53 MUT (P191S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	A189T), TP53 MUT (P191S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A189T), TP53 MUT (P191S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	A189T), TP53 MUT (P191S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A189T), TP53 MUT (P191S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
MET	L998L), MET MUT* (R359Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
BRAF	G593D	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	G593D	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	G593D	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	G593D	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
VHL	P86S	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
CDKN2A	G139S	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	G139S	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	G139S	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	G139S	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	G139S	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	G139S	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	G139S	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	G139S	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
NRAS	G12D	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
NRAS	G12D	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
NRAS	G12D	Different Mutation	MEK inhibitor	Responsive	CM	Late trials
NRAS	G12D	Different Mutation	BRAF inhibitor	Resistant	CM	Early trials
NRAS	G12D	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CM	Early trials
NRAS	G12D	Complete Match	HSP90 inhibitor	Responsive	CM	Pre-clinical
NRAS	G12D	Complete Match	MEK inhibitor	Responsive	AML, LUAD, ALL	Pre-clinical
NRAS	G12D	Complete Match	Pan-RAF inhibitor	Responsive	CM	Case report
NRAS	G12D	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
NRAS	G12D	Complete Match	ERK inhibitor	Responsive	CM	Case report
NRAS	G12D	Complete Match	MEK inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
NRAS	G12D	Complete Match	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NRAS	G12D	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	MYMA	Pre-clinical
NRAS	G12D	Different Mutation	ERK inhibitor	Responsive	CANCER	Pre-clinical
BRAF	G469V	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	G469V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	G469V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	NCCN guidelines
BRAF	G469V	Different Mutation	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469V	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469V	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469V	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	G469V	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	G469V	Different Mutation	ERK inhibitor	Responsive	HNSC, BT	Case report
BRAF	G469V	Different Mutation	EGFR TK inhibitor	Resistant	LUAD	Case report
BRAF	G469V	Different Mutation	MEK inhibitor	Responsive	CM	Case report
BRAF	G469V	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	G469V	Different Mutation	BRAF inhibitor	Responsive	CM	Case report
BRAF	G469V	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	G469V	Different Mutation	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	G469V	Different Mutation	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	G469V	Different Mutation	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	G469V	Different Mutation	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	G469V	Different Mutation	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	G469V	Different Mutation	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	G469V	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	G469V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	G469V	Different Mutation	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	G469V	Different Mutation	BRAF inhibitor;HSP90 inhibitor	Responsive	CM	Pre-clinical
BRAF	G469V	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	G469V	Different Mutation	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	G469V	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	G469V	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	G469V	Different Mutation	MEK inhibitor	Responsive	TH	Early trials
BRAF	G469V	Different Mutation	BRAF inhibitor;PI3K pathway inhibitor	Responsive	CM	Pre-clinical
BRAF	G469V	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	G469V	Different Mutation	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	G469V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	G469V	Different Mutation	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	G469V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	G469V	Different Mutation	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	G469V	Different Mutation	BRAF inhibitor;CDK2/4 inhibitor	Responsive	CM	Pre-clinical
BRAF	G469V	Different Mutation	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	G469V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	G469V	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	G469V	Different Mutation	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	G469V	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	G469V	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	G469V	Different Mutation	BRAF inhibitor	Responsive	OV	Case report
BRAF	G469V	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	G469V	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	G469V	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	G469V	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	G469V	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	G469V	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	G469V	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
FGFR3	P260L	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	P260L	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	P260L	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TP53	V274D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V274D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V274D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V274D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V274D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V274D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V274D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V274D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V274D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V274D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V274D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V274D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V274D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V274D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V274D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E346*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E346*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E346*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E346*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E346*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E346*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E346*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E346*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E346*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E346*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E346*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E346*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E346*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E346*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E346*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
IDH1	R132H	Complete Match	Venetoclax (BCL2 inhibitor)	Responsive	AML	Early trials
IDH1	R132H	Complete Match	IDH1 inhibitor	Responsive	AML	Early trials
IDH1	R132H	Complete Match	AG-120 (IDH1 inhibitor)	Responsive	G	Early trials
IDH1	R132H	Complete Match	Dasatinib (BCR-ABL inhibitor)	Responsive	CH	Early trials
IDH1	R132H	Complete Match	Ivosidenib (IDH1 inhibitor)	Responsive	AML	Early trials
IDH1	R132H	Complete Match	BCL2 inhibitor	Responsive	AML	Pre-clinical
IDH1	R132H	Complete Match	BCL2 inhibitor (BCL2 inhibitor)	Responsive	AML	Pre-clinical
IDH1	R132H	Complete Match	Dasatinib (BCR-ABL inhibitor)	Responsive	BT	Pre-clinical
IDH1	R132H	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
TP53	P278H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P278H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P278H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P278H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P278H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P278H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P278H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P278H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P278H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P278H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P278H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P278H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P278H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P278H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P278H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KRAS	G12R), KRAS MUT (V14I	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12R), KRAS MUT (V14I	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12R), KRAS MUT (V14I	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12R), KRAS MUT (V14I	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12R), KRAS MUT (V14I	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12R), KRAS MUT (V14I	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12R), KRAS MUT (V14I	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12R), KRAS MUT (V14I	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12R), KRAS MUT (V14I	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12R), KRAS MUT (V14I	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12R), KRAS MUT (V14I	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12R), KRAS MUT (V14I	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12R), KRAS MUT (V14I	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12R), KRAS MUT (V14I	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12R), KRAS MUT (V14I	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12R), KRAS MUT (V14I	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12R), KRAS MUT (V14I	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12R), KRAS MUT (V14I	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12R), KRAS MUT (V14I	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12R), KRAS MUT (V14I	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	Y234H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y234H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y234H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y234H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y234H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y234H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y234H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y234H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y234H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y234H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y234H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y234H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y234H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y234H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y234H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R249G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R249G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R249G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R249G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R249G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R249G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R249G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R249G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R249G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R249G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R249G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R249G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R249G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R249G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R249G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	K132T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	K132T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	K132T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	K132T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	K132T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	K132T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	K132T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K132T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K132T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	K132T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	K132T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	K132T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K132T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	K132T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K132T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R158H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R158H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R158H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R158H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R158H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R158H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R158H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R158H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R158H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R158H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R158H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R158H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R158H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R158H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R158H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y220H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y220H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y220H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y220H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y220H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y220H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y220H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y220H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y220H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y220H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y220H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y220H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y220H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y220H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y220H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R175H), TP53 MUT (R248Q	Complete Match	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R175H), TP53 MUT (R248Q	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R175H), TP53 MUT (R248Q	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R175H), TP53 MUT (R248Q	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R175H), TP53 MUT (R248Q	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R175H), TP53 MUT (R248Q	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R175H), TP53 MUT (R248Q	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (R248Q	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (R248Q	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R175H), TP53 MUT (R248Q	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R175H), TP53 MUT (R248Q	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (R248Q	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H), TP53 MUT (R248Q	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R175H), TP53 MUT (R248Q	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H), TP53 MUT (R248Q	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T155N), TP53 MUT (N247I	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T155N), TP53 MUT (N247I	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T155N), TP53 MUT (N247I	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T155N), TP53 MUT (N247I	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T155N), TP53 MUT (N247I	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T155N), TP53 MUT (N247I	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T155N), TP53 MUT (N247I	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T155N), TP53 MUT (N247I	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T155N), TP53 MUT (N247I	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T155N), TP53 MUT (N247I	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T155N), TP53 MUT (N247I	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T155N), TP53 MUT (N247I	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T155N), TP53 MUT (N247I	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T155N), TP53 MUT (N247I	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T155N), TP53 MUT (N247I	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	Q598K	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
EGFR	L703L), EGFR MUT* (L104L	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	L703L), EGFR MUT* (L104L	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
ABL1	G383S	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	G383S	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G383S	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	G383S	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G383S	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	G383S	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
PDGFRA	V832M	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
TP53	R175H), TP53 MUT (P190L), TP53 MUT (M246I	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R175H), TP53 MUT (P190L), TP53 MUT (M246I	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R175H), TP53 MUT (P190L), TP53 MUT (M246I	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R175H), TP53 MUT (P190L), TP53 MUT (M246I	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R175H), TP53 MUT (P190L), TP53 MUT (M246I	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R175H), TP53 MUT (P190L), TP53 MUT (M246I	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (P190L), TP53 MUT (M246I	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (P190L), TP53 MUT (M246I	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R175H), TP53 MUT (P190L), TP53 MUT (M246I	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R175H), TP53 MUT (P190L), TP53 MUT (M246I	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (P190L), TP53 MUT (M246I	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H), TP53 MUT (P190L), TP53 MUT (M246I	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R175H), TP53 MUT (P190L), TP53 MUT (M246I	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H), TP53 MUT (P190L), TP53 MUT (M246I	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
EGFR	V742I	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	V742I	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
TP53	H179L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H179L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H179L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H179L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H179L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H179L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H179L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H179L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H179L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H179L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H179L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H179L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H179L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H179L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H179L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E336*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E336*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E336*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E336*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E336*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E336*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E336*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E336*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E336*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E336*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E336*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E336*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E336*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E336*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E336*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	Q626Q	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	Q626Q	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	Q626Q	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	Q626Q	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	Q626Q	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	Q626Q	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	Q626Q	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	Q626Q	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	Q626Q	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
TP53	L206*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L206*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L206*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L206*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L206*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L206*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L206*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L206*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L206*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L206*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L206*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L206*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L206*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L206*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L206*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	F270C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	F270C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	F270C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	F270C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	F270C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	F270C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	F270C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F270C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F270C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	F270C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	F270C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	F270C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F270C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	F270C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F270C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PDGFRA	H687Y	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
CDKN2A	W110), CDKN2A MUT (E120	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	W110), CDKN2A MUT (E120	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	W110), CDKN2A MUT (E120	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	W110), CDKN2A MUT (E120	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	W110), CDKN2A MUT (E120	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	W110), CDKN2A MUT (E120	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	W110), CDKN2A MUT (E120	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	W110), CDKN2A MUT (E120	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
FGFR3	G637G	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	G637G	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	G637G	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
CTNNB1	G34R	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	G34R	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
EGFR	R831H	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	R831H	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
PTEN	R335*	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	R335*	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	R335*	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	R335*	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	R335*	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	R335*	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	R335*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	R335*	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	R335*	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	R335*	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	R335*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	R335*	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	R335*	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	R335*	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	R335*	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	R335*	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	R335*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	R335*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	R335*	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	R335*	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	R335*	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	R335*	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	R335*	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	R335*	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	R335*	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
RET	N783K	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	N783K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	N783K	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	N783K	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	N783K	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	N783K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	N783K	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	N783K	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	N783K	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
TP53	V218A	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V218A	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V218A	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V218A	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V218A	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V218A	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V218A	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V218A	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V218A	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V218A	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V218A	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V218A	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V218A	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V218A	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V218A	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	V1599M	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	V1599M	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	F270I	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	F270I	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	F270I	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	F270I	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	F270I	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	F270I	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	F270I	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F270I	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F270I	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	F270I	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	F270I	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	F270I	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F270I	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	F270I	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F270I	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FGFR3	R805Q	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	R805Q	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	R805Q	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
APC	R876*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
FAT1	Q1441*	Complete Match	BET inhibitor	Responsive	HNSC	Pre-clinical
CRLF2	Q210*	Different Alteration	MTOR inhibitor	Responsive	ALL	Pre-clinical
CRLF2	Q210*	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
TP53	R280G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R280G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R280G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R280G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R280G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R280G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R280G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R280G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R280G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R280G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R280G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R280G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R280G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R280G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R280G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
SETD2	E2034*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	E2034*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
TSC1	K629*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC1	K629*	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC1	K629*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA	FDA guidelines
TSC1	K629*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	ST, S	Case report
TSC1	K629*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	R	Case report
TSC1	K629*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	GCA	FDA guidelines
TSC1	K629*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Case report
PTEN	splice_acceptor_variant	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	splice_acceptor_variant	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	splice_acceptor_variant	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	splice_acceptor_variant	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	splice_acceptor_variant	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	splice_acceptor_variant	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	splice_acceptor_variant	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	splice_acceptor_variant	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	splice_acceptor_variant	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	splice_acceptor_variant	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	splice_acceptor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	splice_acceptor_variant	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	splice_acceptor_variant	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	splice_acceptor_variant	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	splice_acceptor_variant	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	splice_acceptor_variant	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	splice_acceptor_variant	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	splice_acceptor_variant	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	splice_acceptor_variant	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	splice_acceptor_variant	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	splice_acceptor_variant	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	splice_acceptor_variant	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	splice_acceptor_variant	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	splice_acceptor_variant	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	splice_acceptor_variant	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
POLE	Q1430*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
POLE	Q1430*	Complete Match	PD1 Ab inhibitor	Responsive	COREAD	Case report
POLE	Q1430*	Different Mutation	PD1 Ab inhibitor	Responsive	G, ED	Case report
POLE	Q1430*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ARID1A	Q563*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q563*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q563*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q563*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
NOTCH1	I471T	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	I471T	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	Q136E	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q136E	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q136E	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q136E	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q136E	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q136E	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q136E	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q136E	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q136E	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q136E	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q136E	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q136E	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q136E	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q136E	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q136E	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
SETD2	S595*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	S595*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
KMT2A	P10L	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P10L	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P10L	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P10L	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P10L	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P10L	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
VHL	S65T	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
SETD2	Q2266*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	Q2266*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
EGFR	A1181P	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	A1181P	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
ARID1A	K1808*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	K1808*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	K1808*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	K1808*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
EGFR	A1118T	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	A1118T	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
JAK2	C787R	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
PALB2	R414*	Complete Match	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	R414*	Complete Match	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	R414*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
PALB2	R414*	Complete Match	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	R414*	Different Alteration	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	R414*	Different Alteration	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	R414*	Different Alteration	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	R414*	Different Alteration	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
FGFR3	G697S	Different Mutation	FGFR inhibitor	Responsive	MYMA	Pre-clinical
FGFR3	G697S	Different Mutation	Bortezomib (Proteasome inhibitor)	Responsive	MYMA	Pre-clinical
FGFR3	G697S	Different Mutation	FGFR inhibitor	Responsive	LUAD	Pre-clinical
FGFR3	G697S	Different Mutation	FGFR inhibitor	Resistant	MYMA	Pre-clinical
FGFR3	G697S	Complete Match	FGFR inhibitor	Responsive	BLCA	Early trials
FGFR3	G697S	Different Mutation	Bortezomib (Proteasome inhibitor)	Resistant	MYMA	Pre-clinical
FGFR3	G697S	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	G697S	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	G697S	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
KMT2A	K3557R), MLL MUT* (R1665C	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	K3557R), MLL MUT* (R1665C	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	K3557R), MLL MUT* (R1665C	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	K3557R), MLL MUT* (R1665C	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	K3557R), MLL MUT* (R1665C	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	K3557R), MLL MUT* (R1665C	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NOTCH1	R1523C	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1523C	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRD4	E1123K), BRD4 MUT* (H1136Y	Different Alteration	BET inhibitor	Responsive	NMC	Case report
KMT2D	Q3634*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
TP53	Y236D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y236D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y236D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y236D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y236D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y236D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y236D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y236D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y236D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y236D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y236D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y236D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y236D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y236D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y236D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	D24N	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
RNF43	W159*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
EGFR	A313S	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	A313S	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
AKT3	S238L	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
JAK2	G76A	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
IDH2	R140W	Different Mutation	AG-221 (IDH2 inhibitor)	Responsive	HEMATO	Early trials
IDH2	R140W	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	BT	Pre-clinical
IDH2	R140W	Different Mutation	Enasidenib (IDH2 inhibitor)	Responsive	AML	FDA guidelines
IDH2	R140W	Complete Match	Dasatinib (BCR-ABL inhibitor)	Responsive	CH	Early trials
IDH2	R140W	Complete Match	Venetoclax (BCL2 inhibitor)	Responsive	AML	Early trials
NF1	K50fs1	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NF1	K50fs1	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	HNC	Case report
NF1	K50fs1	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	K50fs1	Complete Match	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	K50fs1	Complete Match	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NF1	K50fs1	Complete Match	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	K50fs1	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	K50fs1	Complete Match	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	K50fs1	Complete Match	Everolimus (MTOR inhibitor)	Responsive	NF	Late trials
NF1	K50fs1	Complete Match	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	K50fs1	Complete Match	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	K50fs1	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	MPN, PLEN	Pre-clinical
NF1	K50fs1	Complete Match	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	K50fs1	Complete Match	Everolimus (MTOR inhibitor)	Responsive	HNC, SG	Case report
NF1	K50fs1	Complete Match	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	K50fs1	Complete Match	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	K50fs1	Complete Match	MEK inhibitor	Responsive	LK, G	Pre-clinical
NF1	K50fs1	Complete Match	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	K50fs1	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	K50fs1	Complete Match	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	K50fs1	Complete Match	MTOR inhibitor	Responsive	LK, G, MPN	Pre-clinical
NF1	K50fs1	Complete Match	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	K50fs1	Complete Match	Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor)	Responsive	HC	Case report
NF1	K50fs1	Complete Match	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	K50fs1	Complete Match	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	K50fs1	Complete Match	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	K50fs1	Complete Match	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	K50fs1	Complete Match	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	K50fs1	Complete Match	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	K50fs1	Complete Match	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	K50fs1	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	K50fs1	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	K50fs1	Complete Match	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	K50fs1	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	K50fs1	Complete Match	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	K50fs1	Complete Match	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	K50fs1	Different Alteration	MTOR inhibitor	Responsive	MPN, G, LK	Pre-clinical
NF1	K50fs1	Different Alteration	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	K50fs1	Different Alteration	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	K50fs1	Different Alteration	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	K50fs1	Different Alteration	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	K50fs1	Different Alteration	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	K50fs1	Different Alteration	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	K50fs1	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	K50fs1	Different Alteration	MEK inhibitor	Responsive	G, LK	Pre-clinical
NF1	K50fs1	Different Alteration	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	K50fs1	Different Alteration	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	K50fs1	Different Alteration	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	K50fs1	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	K50fs1	Different Alteration	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	K50fs1	Different Alteration	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	K50fs1	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	K50fs1	Different Alteration	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	K50fs1	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SG, HNC	Case report
NF1	K50fs1	Different Alteration	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	K50fs1	Different Alteration	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	K50fs1	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	K50fs1	Different Alteration	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	K50fs1	Different Alteration	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	K50fs1	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	K50fs1	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	PLEN, MPN	Pre-clinical
NF1	K50fs1	Different Alteration	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	K50fs1	Different Alteration	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	K50fs1	Different Alteration	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	K50fs1	Different Alteration	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	K50fs1	Different Alteration	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	K50fs1	Different Alteration	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	K50fs1	Different Alteration	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
TP53	K132N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	K132N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	K132N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	K132N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	K132N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	K132N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	K132N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K132N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K132N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	K132N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	K132N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	K132N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K132N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	K132N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K132N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH2	R1886H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
EGFR	L25V	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	L25V	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
ABL1	E38D	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	E38D	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	E38D	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	E38D	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	E38D	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	E38D	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ERBB3	V104L	Different Mutation	PI3K pathway inhibitor;MEK inhibitor	Responsive	CANCER	Pre-clinical
ERBB3	V104L	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	CANCER	Pre-clinical
ERBB3	V104L	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB3	V104L	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BLCA	Case report
ERBB3	V104L	Different Mutation	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB3	V104L	Different Mutation	ERBB3 mAb inhibitor	Responsive	CANCER	Pre-clinical
ERBB3	V104L	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Early trials
BRCA2	L2696*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	L2696*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	L2696*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	L2696*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	L2696*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	L2696*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	L2696*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	L2696*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	L2696*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	L2696*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	L2696*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	L2696*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	L2696*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	L2696*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
TP53	P190T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P190T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P190T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P190T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P190T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P190T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P190T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P190T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P190T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P190T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P190T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P190T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P190T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P190T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P190T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NTRK1	V578I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	V578I	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	V578I	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	V578I	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
ESR1	R211S	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
ROS1	L1672V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	L1672V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	L1672V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	L1672V	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	L1672V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
PIK3CA	D350N	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	D350N	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	D350N	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	D350N	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	D350N	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	D350N	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	D350N	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	D350N	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	D350N	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	D350N	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	D350N	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	D350N	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	D350N	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	D350N	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
KMT2D	Q5365*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
NTRK1	R507H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R507H	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R507H	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R507H	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
PIK3CA	E726K	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	E726K	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	E726K	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	E726K	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	E726K	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	E726K	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	E726K	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	E726K	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	E726K	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	E726K	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	E726K	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	E726K	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	E726K	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	E726K	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
APC	splice_donor_variant	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
JAK2	S507*	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
FGFR2	N123I	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	N123I	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
KRAS	G12C), KRAS MUT (G12D	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12C), KRAS MUT (G12D	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12C), KRAS MUT (G12D	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12C), KRAS MUT (G12D	Complete Match	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12C), KRAS MUT (G12D	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12C), KRAS MUT (G12D	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12C), KRAS MUT (G12D	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12C), KRAS MUT (G12D	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12C), KRAS MUT (G12D	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12C), KRAS MUT (G12D	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12C), KRAS MUT (G12D	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12C), KRAS MUT (G12D	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12C), KRAS MUT (G12D	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12C), KRAS MUT (G12D	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12C), KRAS MUT (G12D	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12C), KRAS MUT (G12D	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12C), KRAS MUT (G12D	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12C), KRAS MUT (G12D	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12C), KRAS MUT (G12D	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12C), KRAS MUT (G12D	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12C), KRAS MUT (G12D	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12C), KRAS MUT (G12D	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12C), KRAS MUT (G12D	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
NRAS	Q61K	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
NRAS	Q61K	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
NRAS	Q61K	Complete Match	MEK inhibitor	Responsive	CM	Late trials
NRAS	Q61K	Complete Match	BRAF inhibitor	Resistant	CM	Early trials
NRAS	Q61K	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CM	Early trials
NRAS	Q61K	Complete Match	HSP90 inhibitor	Responsive	CM	Pre-clinical
NRAS	Q61K	Complete Match	MEK inhibitor	Responsive	AML, LUAD, ALL	Pre-clinical
NRAS	Q61K	Complete Match	Pan-RAF inhibitor	Responsive	CM	Case report
NRAS	Q61K	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
NRAS	Q61K	Complete Match	ERK inhibitor	Responsive	CM	Case report
NRAS	Q61K	Complete Match	MEK inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
NRAS	Q61K	Complete Match	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NRAS	Q61K	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	MYMA	Pre-clinical
NRAS	Q61K	Different Mutation	ERK inhibitor	Responsive	CANCER	Pre-clinical
ALK	S1086L	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	S1086L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	S1086L	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	S1086L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	S1086L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	S1086L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	S1086L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	S1086L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	S1086L	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	S1086L	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	S1086L	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	S1086L	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	S1086L	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	S1086L	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	S1086L	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	S1086L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	S1086L	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	S1086L	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	S1086L	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
KMT2A	H2769R	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	H2769R	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	H2769R	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	H2769R	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	H2769R	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	H2769R	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ARID1A	E1766*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1766*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1766*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E1766*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
EGFR	S177L	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	S177L	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
ARID1A	L113Qfs*119	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	L113Qfs*119	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	L113Qfs*119	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	L113Qfs*119	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
SETD2	E95*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	E95*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
TSC2	CdsStartSNV	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	CdsStartSNV	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	CdsStartSNV	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	CdsStartSNV	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	CdsStartSNV	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	CdsStartSNV	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	CdsStartSNV	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
ARID1A	E2120*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E2120*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E2120*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E2120*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
RAF1	V537I	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	V537I	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	V537I	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
CDKN2A	H83Y), CDKN2A MUT (P48L	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	H83Y), CDKN2A MUT (P48L	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	H83Y), CDKN2A MUT (P48L	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	H83Y), CDKN2A MUT (P48L	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	H83Y), CDKN2A MUT (P48L	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	H83Y), CDKN2A MUT (P48L	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	H83Y), CDKN2A MUT (P48L	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	H83Y), CDKN2A MUT (P48L	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
ARID1A	L2279Vfs*106	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	L2279Vfs*106	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	L2279Vfs*106	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	L2279Vfs*106	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
KMT2A	D2713G	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	D2713G	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	D2713G	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	D2713G	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	D2713G	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	D2713G	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ATM	E2139*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	E2139*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	E2139*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	E2139*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	E2139*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	E2139*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E2139*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	E2139*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E2139*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E2139*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E2139*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	E2139*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	E2139*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
SETD2	S1442*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	S1442*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
PTEN	S229*	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	S229*	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	S229*	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	S229*	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	S229*	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	S229*	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	S229*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	S229*	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	S229*	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	S229*	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	S229*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	S229*	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	S229*	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	S229*	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	S229*	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	S229*	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	S229*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	S229*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	S229*	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	S229*	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	S229*	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	S229*	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	S229*	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	S229*	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	S229*	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
CDH1	E167*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	BRCA	Pre-clinical
POLE	Q345*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
POLE	Q345*	Complete Match	PD1 Ab inhibitor	Responsive	COREAD	Case report
POLE	Q345*	Complete Match	PD1 Ab inhibitor	Responsive	G, ED	Case report
POLE	Q345*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
PTEN	S59*	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	S59*	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	S59*	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	S59*	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	S59*	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	S59*	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	S59*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	S59*	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	S59*	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	S59*	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	S59*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	S59*	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	S59*	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	S59*	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	S59*	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	S59*	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	S59*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	S59*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	S59*	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	S59*	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	S59*	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	S59*	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	S59*	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	S59*	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	S59*	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
RAF1	S204T	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	S204T	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	S204T	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
NF1	E2753*	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NF1	E2753*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	HNC	Case report
NF1	E2753*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	E2753*	Complete Match	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	E2753*	Complete Match	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NF1	E2753*	Complete Match	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	E2753*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	E2753*	Complete Match	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	E2753*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	NF	Late trials
NF1	E2753*	Complete Match	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	E2753*	Complete Match	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	E2753*	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	MPN, PLEN	Pre-clinical
NF1	E2753*	Complete Match	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	E2753*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	HNC, SG	Case report
NF1	E2753*	Complete Match	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	E2753*	Complete Match	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	E2753*	Complete Match	MEK inhibitor	Responsive	LK, G	Pre-clinical
NF1	E2753*	Complete Match	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	E2753*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	E2753*	Complete Match	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	E2753*	Complete Match	MTOR inhibitor	Responsive	LK, G, MPN	Pre-clinical
NF1	E2753*	Complete Match	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	E2753*	Complete Match	Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor)	Responsive	HC	Case report
NF1	E2753*	Complete Match	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	E2753*	Complete Match	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	E2753*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	E2753*	Complete Match	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	E2753*	Complete Match	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	E2753*	Complete Match	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	E2753*	Complete Match	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	E2753*	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	E2753*	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	E2753*	Complete Match	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	E2753*	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	E2753*	Complete Match	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	E2753*	Complete Match	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	E2753*	Different Alteration	MTOR inhibitor	Responsive	MPN, G, LK	Pre-clinical
NF1	E2753*	Different Alteration	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	E2753*	Different Alteration	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	E2753*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	E2753*	Different Alteration	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	E2753*	Different Alteration	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	E2753*	Different Alteration	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	E2753*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	E2753*	Different Alteration	MEK inhibitor	Responsive	G, LK	Pre-clinical
NF1	E2753*	Different Alteration	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	E2753*	Different Alteration	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	E2753*	Different Alteration	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	E2753*	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	E2753*	Different Alteration	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	E2753*	Different Alteration	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	E2753*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	E2753*	Different Alteration	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	E2753*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SG, HNC	Case report
NF1	E2753*	Different Alteration	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	E2753*	Different Alteration	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	E2753*	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	E2753*	Different Alteration	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	E2753*	Different Alteration	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	E2753*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	E2753*	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	PLEN, MPN	Pre-clinical
NF1	E2753*	Different Alteration	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	E2753*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	E2753*	Different Alteration	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	E2753*	Different Alteration	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	E2753*	Different Alteration	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	E2753*	Different Alteration	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	E2753*	Different Alteration	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
AKT3	R66P	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
SETD2	Y2286*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	Y2286*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
NOTCH1	G919R	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	G919R	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
B2M	CdsStartSNV	Complete Match	PD1 Ab inhibitor	Resistant	CM	Case report
TP53	M246T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	M246T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	M246T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	M246T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	M246T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	M246T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M246T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M246T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M246T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	M246T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	M246T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	M246T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M246T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	M246T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M246T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PIK3R1	CdsStartSNV	Complete Match	AKT inhibitor	Responsive	G	Pre-clinical
PIK3R1	CdsStartSNV	Complete Match	PI3K pathway inhibitor	Responsive	ED	Case report
RAF1	Y458F	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	Y458F	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	Y458F	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
KMT2A	S2872*	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S2872*	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S2872*	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S2872*	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S2872*	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S2872*	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
AKT3	R478*	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
TP53	A161_I162delinsPS	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	A161_I162delinsPS	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	A161_I162delinsPS	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	A161_I162delinsPS	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	A161_I162delinsPS	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	A161_I162delinsPS	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	A161_I162delinsPS	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A161_I162delinsPS	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A161_I162delinsPS	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	A161_I162delinsPS	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	A161_I162delinsPS	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	A161_I162delinsPS	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A161_I162delinsPS	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	A161_I162delinsPS	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A161_I162delinsPS	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I254S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I254S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I254S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I254S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I254S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I254S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I254S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I254S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I254S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I254S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I254S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I254S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I254S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I254S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I254S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	P1300T	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
APC	E1544*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
TP53	F270V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	F270V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	F270V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	F270V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	F270V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	F270V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	F270V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F270V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F270V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	F270V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	F270V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	F270V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F270V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	F270V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F270V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH2	M1941I	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12R), KRAS MUT (G12V	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12R), KRAS MUT (G12V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12R), KRAS MUT (G12V	Complete Match	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12R), KRAS MUT (G12V	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12R), KRAS MUT (G12V	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12R), KRAS MUT (G12V	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12R), KRAS MUT (G12V	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12R), KRAS MUT (G12V	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12R), KRAS MUT (G12V	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12R), KRAS MUT (G12V	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12R), KRAS MUT (G12V	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12R), KRAS MUT (G12V	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12R), KRAS MUT (G12V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12R), KRAS MUT (G12V	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12R), KRAS MUT (G12V	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12R), KRAS MUT (G12V	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12R), KRAS MUT (G12V	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12R), KRAS MUT (G12V	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12R), KRAS MUT (G12V	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12R), KRAS MUT (G12V	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12R), KRAS MUT (G12V	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12R), KRAS MUT (G12V	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	L257R), TP53 MUT (K321*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L257R), TP53 MUT (K321*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L257R), TP53 MUT (K321*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L257R), TP53 MUT (K321*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L257R), TP53 MUT (K321*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L257R), TP53 MUT (K321*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L257R), TP53 MUT (K321*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L257R), TP53 MUT (K321*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L257R), TP53 MUT (K321*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L257R), TP53 MUT (K321*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L257R), TP53 MUT (K321*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L257R), TP53 MUT (K321*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L257R), TP53 MUT (K321*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L257R), TP53 MUT (K321*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L257R), TP53 MUT (K321*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NF2	R341*	Complete Match	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	R341*	Complete Match	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	R341*	Complete Match	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	R341*	Complete Match	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	R341*	Complete Match	MTOR inhibitor	Responsive	MEN	Pre-clinical
NF2	R341*	Complete Match	Lapatinib (ERBB2 inhibitor)	Responsive	NF, SCHW	Early trials
NF2	R341*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	R341*	Complete Match	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	R341*	Complete Match	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	R341*	Complete Match	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	R341*	Complete Match	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	R341*	Complete Match	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	R341*	Complete Match	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	R341*	Complete Match	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	R341*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	R341*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	R341*	Different Alteration	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	R341*	Different Alteration	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	R341*	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	R341*	Different Alteration	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	R341*	Different Alteration	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	R341*	Different Alteration	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	R341*	Different Alteration	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	R341*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	R341*	Different Alteration	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	R341*	Different Alteration	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	R341*	Different Alteration	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	R341*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	R341*	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	SCHW, NF	Early trials
NF2	R341*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	R341*	Different Alteration	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	R341*	Different Alteration	MTOR inhibitor	Responsive	MEN	Pre-clinical
TP53	E286Q	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E286Q	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E286Q	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E286Q	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E286Q	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E286Q	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E286Q	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E286Q	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E286Q	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E286Q	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E286Q	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E286Q	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E286Q	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E286Q	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E286Q	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
MET	E1138*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
KMT2A	D208H	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	D208H	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	D208H	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	D208H	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	D208H	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	D208H	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ROS1	N2220I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	N2220I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	N2220I	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	N2220I	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	N2220I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
TP53	P278A	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P278A	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P278A	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P278A	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P278A	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P278A	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P278A	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P278A	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P278A	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P278A	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P278A	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P278A	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P278A	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P278A	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P278A	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V173_R175delinsGG	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V173_R175delinsGG	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V173_R175delinsGG	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V173_R175delinsGG	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V173_R175delinsGG	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V173_R175delinsGG	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V173_R175delinsGG	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V173_R175delinsGG	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V173_R175delinsGG	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V173_R175delinsGG	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V173_R175delinsGG	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V173_R175delinsGG	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V173_R175delinsGG	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V173_R175delinsGG	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V173_R175delinsGG	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	A4V	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	A4V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	A4V	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	A4V	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	A4V	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	A4V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	A4V	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	A4V	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	A4V	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ERBB4	L1247M	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
KMT2A	Q1052*	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	Q1052*	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	Q1052*	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	Q1052*	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	Q1052*	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	Q1052*	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
AKT3	R166Q	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
TMPRSS2	V86M	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	V86M	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
BRD4	E718G	Different Alteration	BET inhibitor	Responsive	NMC	Case report
KMT2D	S4669*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
CTNNB1	D32G	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	D32G	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
RB1	Q217*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	Q217*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	Q217*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	Q217*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	Q217*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	Q217*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	Q217*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
NOTCH2	E1190K	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
PTEN	H61R	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	H61R	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	H61R	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	H61R	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	H61R	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	H61R	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	H61R	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	H61R	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	H61R	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	H61R	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	H61R	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	H61R	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	H61R	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	H61R	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	H61R	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	H61R	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	H61R	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	H61R	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	H61R	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	H61R	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	H61R	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	H61R	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	H61R	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	H61R	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	H61R	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
AKT1	E17K	Complete Match	BRAF inhibitor	Resistant	CM	Case report
AKT1	E17K	Complete Match	allosteric AKT inhibitor	Responsive	CANCER	Early trials
AKT1	E17K	Complete Match	non-allosteric AKT inhibitor	Responsive	CANCER	Early trials
AKT1	E17K	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
AKT1	E17K	Complete Match	Temsirolimus (MTOR inhibitor)	Responsive	ED	Early trials
AKT1	E17K	Complete Match	AKT inhibitor	Responsive	CANCER	Pre-clinical
AKT1	E17K	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	FH	Case report
TP53	N263Kfs*8	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	N263Kfs*8	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	N263Kfs*8	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	N263Kfs*8	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	N263Kfs*8	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	N263Kfs*8	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	N263Kfs*8	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N263Kfs*8	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N263Kfs*8	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	N263Kfs*8	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	N263Kfs*8	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	N263Kfs*8	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N263Kfs*8	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	N263Kfs*8	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N263Kfs*8	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S215R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S215R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S215R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S215R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S215R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S215R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S215R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S215R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S215R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S215R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S215R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S215R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S215R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S215R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S215R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RB1	R556*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	R556*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R556*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R556*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	R556*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R556*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R556*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
TP53	N131I	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	N131I	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	N131I	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	N131I	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	N131I	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	N131I	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	N131I	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N131I	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N131I	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	N131I	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	N131I	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	N131I	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N131I	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	N131I	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N131I	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RNF43	E110*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
ALK	I1116T	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	I1116T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	I1116T	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	I1116T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	I1116T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	I1116T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	I1116T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	I1116T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	I1116T	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	I1116T	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	I1116T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	I1116T	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	I1116T	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	I1116T	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	I1116T	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	I1116T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	I1116T	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	I1116T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	I1116T	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
RET	V276I	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	V276I	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	V276I	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	V276I	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	V276I	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	V276I	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	V276I	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	V276I	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	V276I	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
NTRK3	R201C	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R201C	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R201C	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NOTCH2	D2031Y	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ARID1A	Q1327*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1327*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1327*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q1327*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ERBB4	T1152N	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
TP53	P152R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P152R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P152R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P152R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P152R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P152R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P152R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P152R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P152R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P152R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P152R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P152R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P152R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P152R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P152R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
EGFR	E134*	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	E134*	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
ARID1A	S1798*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S1798*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S1798*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	S1798*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
SF3B1	R625H	Different Mutation	Spliceosome inhibitor	Responsive	CANCER	Pre-clinical
APC	Q222*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
TP53	T155P), TP53 MUT (R156L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T155P), TP53 MUT (R156L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T155P), TP53 MUT (R156L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T155P), TP53 MUT (R156L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T155P), TP53 MUT (R156L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T155P), TP53 MUT (R156L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T155P), TP53 MUT (R156L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T155P), TP53 MUT (R156L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T155P), TP53 MUT (R156L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T155P), TP53 MUT (R156L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T155P), TP53 MUT (R156L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T155P), TP53 MUT (R156L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T155P), TP53 MUT (R156L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T155P), TP53 MUT (R156L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T155P), TP53 MUT (R156L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
SETD2	E1200*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	E1200*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
KMT2D	K3551*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
TP53	S241P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S241P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S241P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S241P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S241P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S241P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S241P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S241P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S241P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S241P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S241P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S241P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S241P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S241P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S241P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	S103*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S103*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S103*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	S103*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ALK	G1100C	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	G1100C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	G1100C	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	G1100C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	G1100C	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	G1100C	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G1100C	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	G1100C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G1100C	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G1100C	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	G1100C	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	G1100C	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	G1100C	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	G1100C	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	G1100C	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	G1100C	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	G1100C	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	G1100C	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G1100C	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
RNF43	splice_acceptor_variant	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
NOTCH2	E710K	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	T555A	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	T555A	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
EPHA3	splice_acceptor_variant	Different Alteration	EPHA3 inhibitor	Responsive	CANCER	Pre-clinical
EPHA3	splice_donor_variant	Different Alteration	EPHA3 inhibitor	Responsive	CANCER	Pre-clinical
ERBB4	Q44K	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
CTNNB1	S45F), CTNNB1 MUT (S45C	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	S45F), CTNNB1 MUT (S45C	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
NTRK1	P311L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	P311L	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	P311L	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	P311L	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
AKT3	M117L	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
TP53	L188Q	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L188Q	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L188Q	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L188Q	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L188Q	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L188Q	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L188Q	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L188Q	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L188Q	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L188Q	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L188Q	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L188Q	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L188Q	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L188Q	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L188Q	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TSC1	R484Efs*48	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC1	R484Efs*48	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC1	R484Efs*48	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA	FDA guidelines
TSC1	R484Efs*48	Complete Match	Everolimus (MTOR inhibitor)	Responsive	ST, S	Case report
TSC1	R484Efs*48	Complete Match	Everolimus (MTOR inhibitor)	Responsive	R	Case report
TSC1	R484Efs*48	Complete Match	Everolimus (MTOR inhibitor)	Responsive	GCA	FDA guidelines
TSC1	R484Efs*48	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Case report
PTEN	L247*	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	L247*	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	L247*	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	L247*	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	L247*	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	L247*	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	L247*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	L247*	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	L247*	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	L247*	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	L247*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	L247*	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	L247*	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	L247*	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	L247*	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	L247*	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	L247*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	L247*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	L247*	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	L247*	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	L247*	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	L247*	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	L247*	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	L247*	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	L247*	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
TP53	Y236H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y236H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y236H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y236H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y236H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y236H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y236H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y236H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y236H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y236H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y236H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y236H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y236H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y236H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y236H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	I1517T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	I1517T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	I1517T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	I1517T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	I1517T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ROS1	A1919D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	A1919D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	A1919D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	A1919D	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	A1919D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
KMT2D	Q3333*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
TP53	I255F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I255F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I255F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I255F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I255F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I255F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I255F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I255F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I255F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I255F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I255F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I255F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I255F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I255F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I255F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRCA1	E1258*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA1	E1258*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA1	E1258*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA1	E1258*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	E1258*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	E1258*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Case report
BRCA1	E1258*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA1	E1258*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA1	E1258*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	E1258*	Complete Match	PARP inhibitor	Responsive	PA	Case report
BRCA1	E1258*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	E1258*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
MET	R359Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
FGFR2	R190Q	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	R190Q	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
CDKN2A	A86Wfs*31	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	A86Wfs*31	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	A86Wfs*31	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	A86Wfs*31	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	A86Wfs*31	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	A86Wfs*31	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	A86Wfs*31	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	A86Wfs*31	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
TP53	R209*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R209*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R209*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R209*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R209*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R209*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R209*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R209*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R209*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R209*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R209*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R209*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R209*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R209*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R209*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2D	splice_donor_variant	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
ARID1A	Q1212), ARID1A MUT (S350	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1212), ARID1A MUT (S350	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1212), ARID1A MUT (S350	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q1212), ARID1A MUT (S350	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
CDKN2A	P114L	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	P114L	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	P114L	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	P114L	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	P114L	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	P114L	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	P114L	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	P114L	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
TP53	Q100*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q100*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q100*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q100*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q100*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q100*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q100*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q100*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q100*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q100*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q100*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q100*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q100*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q100*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q100*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
MAP2K2	L46F	Complete Match	BRAF inhibitor	Resistant	CM	Pre-clinical
MAP2K2	L46F	Complete Match	MEK inhibitor	Resistant	CM	Pre-clinical
MAP2K2	L46F	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
MAP2K2	L46F	Different Mutation	MEK inhibitor	Resistant	CM	Case report
TP53	L194F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L194F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L194F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L194F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L194F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L194F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L194F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L194F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L194F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L194F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L194F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L194F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L194F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L194F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L194F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRCA1	Q1388*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA1	Q1388*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA1	Q1388*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA1	Q1388*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	Q1388*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	Q1388*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Case report
BRCA1	Q1388*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA1	Q1388*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA1	Q1388*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	Q1388*	Complete Match	PARP inhibitor	Responsive	PA	Case report
BRCA1	Q1388*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	Q1388*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
KMT2A	Q3086H	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	Q3086H	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	Q3086H	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	Q3086H	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	Q3086H	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	Q3086H	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
PIK3CA	H1047Y	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	H1047Y	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	H1047Y	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	H1047Y	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	H1047Y	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	H1047Y	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	H1047Y	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	H1047Y	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	H1047Y	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	H1047Y	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	H1047Y	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	H1047Y	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	H1047Y	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	H1047Y	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
TP53	C124L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C124L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C124L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C124L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C124L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C124L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C124L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C124L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C124L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C124L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C124L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C124L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C124L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C124L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C124L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRAF	V600R	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	V600R	Complete Match	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	V600R	Complete Match	Vemurafenib (BRAF inhibitor)	Responsive	CM	NCCN guidelines
BRAF	V600R	Different Mutation	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600R	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600R	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600R	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	V600R	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	V600R	Different Mutation	ERK inhibitor	Responsive	HNSC, BT	Case report
BRAF	V600R	Different Mutation	EGFR TK inhibitor	Resistant	LUAD	Case report
BRAF	V600R	Complete Match	MEK inhibitor	Responsive	CM	Case report
BRAF	V600R	Complete Match	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	V600R	Different Mutation	BRAF inhibitor	Responsive	CM	Case report
BRAF	V600R	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	V600R	Complete Match	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	V600R	Complete Match	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	V600R	Complete Match	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	V600R	Complete Match	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	V600R	Complete Match	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	V600R	Complete Match	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	V600R	Complete Match	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	V600R	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	V600R	Different Mutation	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	V600R	Different Mutation	BRAF inhibitor;HSP90 inhibitor	Responsive	CM	Pre-clinical
BRAF	V600R	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	V600R	Different Mutation	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	V600R	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	V600R	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	V600R	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	V600R	Different Mutation	MEK inhibitor	Responsive	TH	Early trials
BRAF	V600R	Different Mutation	BRAF inhibitor;PI3K pathway inhibitor	Responsive	CM	Pre-clinical
BRAF	V600R	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	V600R	Different Mutation	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	V600R	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600R	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	V600R	Different Mutation	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	V600R	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	V600R	Different Mutation	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	V600R	Different Mutation	BRAF inhibitor;CDK2/4 inhibitor	Responsive	CM	Pre-clinical
BRAF	V600R	Different Mutation	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	V600R	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	V600R	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	V600R	Different Mutation	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	V600R	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	V600R	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	V600R	Different Mutation	BRAF inhibitor	Responsive	OV	Case report
BRAF	V600R	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	V600R	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600R	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	V600R	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	V600R	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	V600R	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	V600R	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
RET	R897*	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R897*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R897*	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R897*	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R897*	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R897*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R897*	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R897*	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R897*	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
TP53	V274L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V274L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V274L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V274L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V274L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V274L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V274L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V274L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V274L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V274L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V274L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V274L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V274L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V274L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V274L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
VHL	F136Lfs*20	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
TSC1	S282*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC1	S282*	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC1	S282*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA	FDA guidelines
TSC1	S282*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	ST, S	Case report
TSC1	S282*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	R	Case report
TSC1	S282*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	GCA	FDA guidelines
TSC1	S282*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Case report
ERBB4	I481M	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
FBXW7	R689Q	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	R689Q	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	R689Q	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	R689Q	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
BRAF	N236K	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	N236K	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	N236K	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	N236K	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
RB1	E313*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	E313*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	E313*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	E313*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	E313*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	E313*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	E313*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
NOTCH1	V485L	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	V485L	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
PBRM1	R1160*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	R1160*	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	R1160*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	R1160*	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	R1160*	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
NTRK1	G89D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	G89D	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	G89D	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	G89D	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
NTRK3	E344D	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	E344D	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	E344D	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
EGFR	R574Q	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	R574Q	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
ALK	R1060H	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1060H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	R1060H	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	R1060H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	R1060H	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	R1060H	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R1060H	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	R1060H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R1060H	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R1060H	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	R1060H	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	R1060H	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	R1060H	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1060H	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1060H	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	R1060H	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	R1060H	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	R1060H	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R1060H	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
PIK3CA	C420R	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	C420R	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	C420R	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	C420R	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	C420R	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	C420R	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	C420R	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	C420R	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	C420R	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	C420R	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	C420R	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	C420R	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	C420R	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	C420R	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
NTRK1	F669V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	F669V	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	F669V	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	F669V	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
APC	R805*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
ALK	Q1188*	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q1188*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	Q1188*	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	Q1188*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	Q1188*	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	Q1188*	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	Q1188*	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	Q1188*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	Q1188*	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	Q1188*	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	Q1188*	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	Q1188*	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	Q1188*	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q1188*	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q1188*	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	Q1188*	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	Q1188*	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	Q1188*	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	Q1188*	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
FAT1	R2597*	Complete Match	BET inhibitor	Responsive	HNSC	Pre-clinical
FGFR2	K540E	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	K540E	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
KMT2A	P569L	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P569L	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P569L	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P569L	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P569L	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P569L	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ATM	Y1034*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	Y1034*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	Y1034*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	Y1034*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	Y1034*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	Y1034*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Y1034*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	Y1034*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Y1034*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Y1034*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Y1034*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	Y1034*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	Y1034*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
TP53	C141G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C141G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C141G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C141G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C141G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C141G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C141G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C141G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C141G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C141G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C141G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
SMARCA4	E1148*	Complete Match	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	E1148*	Complete Match	AURKA inhibitor	Responsive	NSCLC	Pre-clinical
SMARCA4	E1148*	Complete Match	EZH2 inhibitor	Responsive	OV	Case report
SMARCA4	E1148*	Different Alteration	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	E1148*	Different Alteration	EZH2 inhibitor	Responsive	OV	Case report
KMT2A	P436A	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P436A	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P436A	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P436A	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P436A	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P436A	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ERBB3	V104M	Different Mutation	PI3K pathway inhibitor;MEK inhibitor	Responsive	CANCER	Pre-clinical
ERBB3	V104M	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	CANCER	Pre-clinical
ERBB3	V104M	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB3	V104M	Complete Match	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BLCA	Case report
ERBB3	V104M	Different Mutation	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB3	V104M	Different Mutation	ERBB3 mAb inhibitor	Responsive	CANCER	Pre-clinical
ERBB3	V104M	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Early trials
TP53	P295Vfs*50	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P295Vfs*50	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P295Vfs*50	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P295Vfs*50	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P295Vfs*50	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P295Vfs*50	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P295Vfs*50	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P295Vfs*50	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P295Vfs*50	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P295Vfs*50	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P295Vfs*50	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P295Vfs*50	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P295Vfs*50	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P295Vfs*50	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P295Vfs*50	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
AKT3	I36T	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	K575T	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	K575T	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	K575T	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
ARID1A	Y2031*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y2031*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y2031*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Y2031*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	H168R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H168R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H168R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H168R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H168R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H168R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H168R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H168R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H168R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H168R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H168R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H168R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H168R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H168R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H168R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2A	Y3917C	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	Y3917C	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	Y3917C	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	Y3917C	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	Y3917C	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	Y3917C	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ARID1A	N1253Tfs*5	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	N1253Tfs*5	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	N1253Tfs*5	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	N1253Tfs*5	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
PIK3CA	N1044K	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	N1044K	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	N1044K	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	N1044K	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	N1044K	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	N1044K	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	N1044K	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	N1044K	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	N1044K	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	N1044K	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	N1044K	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	N1044K	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	N1044K	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	N1044K	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
FGFR3	R399H	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	R399H	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	R399H	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TP53	M133R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	M133R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	M133R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	M133R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	M133R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	M133R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M133R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M133R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M133R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	M133R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	M133R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	M133R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M133R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	M133R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M133R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R337C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R337C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R337C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R337C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R337C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R337C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R337C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R337C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R337C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R337C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R337C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R337C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R337C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R337C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R337C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	P48L	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	P48L	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	P48L	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	P48L	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	P48L	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	P48L	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	P48L	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	P48L	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
TSC2	splice_acceptor_variant), TSC2 MUT (Q785*	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	splice_acceptor_variant), TSC2 MUT (Q785*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	splice_acceptor_variant), TSC2 MUT (Q785*	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	splice_acceptor_variant), TSC2 MUT (Q785*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	splice_acceptor_variant), TSC2 MUT (Q785*	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	splice_acceptor_variant), TSC2 MUT (Q785*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	splice_acceptor_variant), TSC2 MUT (Q785*	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
NTRK1	R682C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R682C	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R682C	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R682C	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
FBXW7	Q220*	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	Q220*	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	Q220*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	Q220*	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
TSC2	G20Ffs*11	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	G20Ffs*11	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	G20Ffs*11	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	G20Ffs*11	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	G20Ffs*11	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	G20Ffs*11	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	G20Ffs*11	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
PTEN	R130*	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	R130*	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	R130*	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	R130*	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	R130*	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	R130*	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	R130*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	R130*	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	R130*	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	R130*	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	R130*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	R130*	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	R130*	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	R130*	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	R130*	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	R130*	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	R130*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	R130*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	R130*	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	R130*	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	R130*	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	R130*	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	R130*	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	R130*	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	R130*	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
JAK2	K776Q	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
NOTCH2	E2461K	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ARID1A	P690Afs*124	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	P690Afs*124	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	P690Afs*124	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	P690Afs*124	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ABL1	G626D	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	G626D	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G626D	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	G626D	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G626D	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	G626D	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
TP53	V147G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V147G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V147G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V147G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V147G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V147G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V147G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V147G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V147G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V147G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V147G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V147G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V147G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V147G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V147G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	V573L	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	V573L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	V573L	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	V573L	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	V573L	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	V573L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	V573L	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	V573L	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	V573L	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
MET	R143Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
ATM	Q1627*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	Q1627*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	Q1627*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	Q1627*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	Q1627*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q1627*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q1627*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	Q1627*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q1627*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q1627*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q1627*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	Q1627*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q1627*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RNF43	R337*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
ERBB4	P1206T	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
VHL	R167W	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
RNF43	E74*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
PTEN	Y68C	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y68C	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y68C	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	Y68C	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	Y68C	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	Y68C	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y68C	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y68C	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	Y68C	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	Y68C	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y68C	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y68C	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	Y68C	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y68C	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	Y68C	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y68C	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	Y68C	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y68C	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y68C	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	Y68C	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y68C	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y68C	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y68C	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	Y68C	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y68C	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
AKT3	L109M	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
IDH1	R132L	Complete Match	Venetoclax (BCL2 inhibitor)	Responsive	AML	Early trials
IDH1	R132L	Complete Match	IDH1 inhibitor	Responsive	AML	Early trials
IDH1	R132L	Complete Match	AG-120 (IDH1 inhibitor)	Responsive	G	Early trials
IDH1	R132L	Complete Match	Dasatinib (BCR-ABL inhibitor)	Responsive	CH	Early trials
IDH1	R132L	Complete Match	Ivosidenib (IDH1 inhibitor)	Responsive	AML	Early trials
IDH1	R132L	Complete Match	BCL2 inhibitor	Responsive	AML	Pre-clinical
IDH1	R132L	Complete Match	BCL2 inhibitor (BCL2 inhibitor)	Responsive	AML	Pre-clinical
IDH1	R132L	Complete Match	Dasatinib (BCR-ABL inhibitor)	Responsive	BT	Pre-clinical
IDH1	R132L	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
EGFR	N816S	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	N816S	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
PIK3R1	E439*	Complete Match	AKT inhibitor	Responsive	G	Pre-clinical
PIK3R1	E439*	Complete Match	PI3K pathway inhibitor	Responsive	ED	Case report
NTRK3	R201H	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R201H	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R201H	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NTRK3	R582Q	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R582Q	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R582Q	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
TP53	A138P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	A138P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	A138P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	A138P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	A138P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	A138P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	A138P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A138P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A138P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	A138P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	A138P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	A138P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A138P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	A138P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A138P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
MET	R242S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
TP53	C238G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C238G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C238G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C238G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C238G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C238G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C238G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C238G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C238G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C238G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C238G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C238G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C238G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C238G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C238G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KRAS	V14I	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	V14I	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	V14I	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	V14I	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	V14I	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	V14I	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	V14I	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	V14I	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	V14I	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	V14I	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	V14I	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	V14I	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	V14I	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	V14I	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	V14I	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	V14I	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	V14I	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	V14I	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	V14I	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	V14I	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	V14I	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	V14I	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	V14I	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	V14I	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	V14I	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	V14I	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	V14I	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	V14I	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	V14I	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	V14I	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	V14I	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	V14I	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	V14I	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	V14I	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	V14I	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	V14I	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	V14I	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	V14I	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	V14I	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	V14I	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	V14I	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	V14I	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
NOTCH2	A1654T	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ARID1A	Q1493*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1493*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1493*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q1493*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q789*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q789*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q789*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q789*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ATM	R2993*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R2993*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R2993*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R2993*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R2993*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R2993*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R2993*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R2993*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R2993*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R2993*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R2993*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R2993*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R2993*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
PTEN	Y65*	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y65*	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y65*	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	Y65*	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	Y65*	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	Y65*	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y65*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y65*	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	Y65*	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	Y65*	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y65*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y65*	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	Y65*	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y65*	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	Y65*	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y65*	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	Y65*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y65*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y65*	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	Y65*	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y65*	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y65*	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y65*	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	Y65*	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y65*	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
TP53	L194H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L194H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L194H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L194H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L194H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L194H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L194H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L194H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L194H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L194H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L194H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L194H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L194H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L194H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L194H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CRLF2	D176H	Different Alteration	MTOR inhibitor	Responsive	ALL	Pre-clinical
CRLF2	D176H	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
NTRK3	I783N	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	I783N	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	I783N	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
BRCA2	S1385*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	S1385*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	S1385*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	S1385*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	S1385*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	S1385*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	S1385*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	S1385*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	S1385*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	S1385*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	S1385*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	S1385*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	S1385*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	S1385*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
BRCA2	Q3295*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	Q3295*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q3295*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	Q3295*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	Q3295*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	Q3295*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	Q3295*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	Q3295*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q3295*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q3295*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q3295*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q3295*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	Q3295*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q3295*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
TP53	V272E	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V272E	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V272E	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V272E	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V272E	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V272E	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V272E	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V272E	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V272E	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V272E	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V272E	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V272E	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V272E	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V272E	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V272E	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P190S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P190S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P190S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P190S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P190S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P190S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P190S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P190S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P190S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P190S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P190S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P190S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P190S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P190S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P190S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	L1180F	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
AKT3	D219N), AKT3 MUT* (E226*	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
TP53	N131_F134delinsL	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	N131_F134delinsL	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	N131_F134delinsL	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	N131_F134delinsL	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	N131_F134delinsL	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	N131_F134delinsL	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	N131_F134delinsL	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N131_F134delinsL	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N131_F134delinsL	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	N131_F134delinsL	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	N131_F134delinsL	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	N131_F134delinsL	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N131_F134delinsL	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	N131_F134delinsL	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N131_F134delinsL	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KRAS	G12_G13delinsAC	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12_G13delinsAC	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12_G13delinsAC	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12_G13delinsAC	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12_G13delinsAC	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12_G13delinsAC	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12_G13delinsAC	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12_G13delinsAC	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12_G13delinsAC	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12_G13delinsAC	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12_G13delinsAC	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12_G13delinsAC	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12_G13delinsAC	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12_G13delinsAC	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12_G13delinsAC	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12_G13delinsAC	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12_G13delinsAC	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12_G13delinsAC	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12_G13delinsAC	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12_G13delinsAC	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12_G13delinsAC	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12_G13delinsAC	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12_G13delinsAC	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12_G13delinsAC	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12_G13delinsAC	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
FGFR1	K687E	Different Alteration	FGFR inhibitor	Responsive	ED	Case report
FGFR1	K687E	Different Alteration	FGFR inhibitor	Responsive	HNC	Pre-clinical
FGFR1	K687E	Different Alteration	FGFR inhibitor	Responsive;Responsive	LUSC	Case report;Early trials
FGFR1	K687E	Different Alteration	FGFR inhibitor	Responsive	BRCA	Early trials
NOTCH1	E556G	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	E556G	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ERBB4	H856Q	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
TP53	I255T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I255T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I255T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I255T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I255T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I255T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I255T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I255T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I255T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I255T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I255T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I255T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I255T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I255T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I255T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	L80R	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	L80R	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	L80R	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	L80R	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	L80R	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	L80R	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	L80R	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	L80R	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	L80R	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
RNF43	W302*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
TP53	Q136P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q136P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q136P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q136P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q136P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q136P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q136P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q136P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q136P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q136P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q136P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q136P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q136P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q136P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q136P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
EGFR	D761N	Different Alteration	Cetuximab (EGFR mAb inhibitor)	Responsive	COREAD	FDA guidelines
EGFR	D761N	Different Alteration	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
EGFR	D761N	Different Mutation	Rindopepimut (Vaccine)	Responsive	GB	Late trials
EGFR	D761N	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	D761N	Different Mutation	Gefitinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	D761N	Different Mutation	HSP90 inhibitor	Responsive	L	Early trials
EGFR	D761N	Different Mutation	Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	D761N	Different Mutation	MEK inhibitor	Responsive	L	Pre-clinical
EGFR	D761N	Different Mutation	EGFR TK inhibitor	Responsive	L	Late trials
EGFR	D761N	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	NCCN guidelines
EGFR	D761N	Different Mutation	Osimertinib (EGFR inhibitor)	Resistant	L	Early trials
EGFR	D761N	Different Mutation	EGFR-TKI's (EGFR inhibitor)	Resistant	L	Late trials
EGFR	D761N	Different Mutation	HSP90 inhibitor	Responsive	L	Case report
EGFR	D761N	Different Mutation	EGFR inhibitor	Resistant	L	Late trials
EGFR	D761N	Different Mutation	Poziotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	D761N	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Pre-clinical
EGFR	D761N	Different Mutation	HSP90 inhibitor (HSP90 inhibitor)	Responsive	L	Early trials
EGFR	D761N	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	G	Pre-clinical
EGFR	D761N	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	D761N	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	D761N	Different Mutation	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
EGFR	D761N	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Responsive	COREAD	Case report
EGFR	D761N	Different Mutation	novel EGFR mAb inhibitor	Responsive	COREAD	Early trials
EGFR	D761N	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	D761N	Different Mutation	Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor)	Responsive	HNC	Case report
EGFR	D761N	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	D761N	Different Mutation	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Case report
EGFR	D761N	Different Mutation	EGFR inhibitor	Responsive	L	Early trials
EGFR	D761N	Different Mutation	Erlotinib (EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	D761N	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	D761N	Different Mutation	EGFR inhibitor	Responsive	NSCLC	Late trials
EGFR	D761N	Different Mutation	Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	D761N	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	D761N	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	D761N	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	L	Late trials
EGFR	D761N	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Pre-clinical
EGFR	D761N	Different Mutation	Erlotinib (EGFR inhibitor)	No Responsive	L	Case report
EGFR	D761N	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	ED	Case report
EGFR	D761N	Different Mutation	EGFR inhibitor	No Responsive	G	Early trials
EGFR	D761N	Different Mutation	EGFR inhibitor	Resistant	NSCLC	Case report
EGFR	D761N	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	D761N	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant;Resistant	COREAD	Pre-clinical;Case report
EGFR	D761N	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Responsive	HNC	Case report
EGFR	D761N	Different Alteration	Gefitinib (EGFR inhibitor)	Responsive	ED	Late trials
EGFR	D761N	Different Alteration	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Early trials
EGFR	D761N	Different Alteration	EGFR inhibitor	Responsive	HNSC	Case report
EGFR	D761N	Different Alteration	EGFR inhibitor	No Responsive	G	Early trials
EGFR	D761N	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	L	Early trials
EGFR	D761N	Different Alteration	EGFR mAb inhibitor	Responsive	COREAD	Late trials
EGFR	D761N	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	D761N	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
KMT2D	E1816*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
FGFR3	E458V	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	E458V	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	E458V	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
DNMT3A	E408*	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
TSC2	Y130*	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	Y130*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	Y130*	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	Y130*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	Y130*	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	Y130*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	Y130*	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
ABL1	R764Q	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	R764Q	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R764Q	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	R764Q	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R764Q	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	R764Q	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	R738L	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	R738L	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R738L	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	R738L	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R738L	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	R738L	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
SETD2	R424*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	R424*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
PTEN	Y138C	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y138C	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y138C	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	Y138C	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	Y138C	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	Y138C	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y138C	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y138C	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	Y138C	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	Y138C	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y138C	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y138C	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	Y138C	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y138C	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	Y138C	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y138C	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	Y138C	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y138C	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y138C	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	Y138C	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y138C	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y138C	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y138C	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	Y138C	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y138C	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
FGFR3	G549R	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	G549R	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	G549R	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
ROS1	V612A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	V612A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	V612A	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	V612A	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	V612A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
KMT2A	R3889Q	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	R3889Q	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	R3889Q	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	R3889Q	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	R3889Q	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	R3889Q	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NTRK1	G91E	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	G91E	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	G91E	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	G91E	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
TP53	T284P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T284P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T284P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T284P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T284P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T284P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T284P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T284P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T284P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T284P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T284P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T284P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T284P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T284P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T284P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PTEN	C105F	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	C105F	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	C105F	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	C105F	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	C105F	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	C105F	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	C105F	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	C105F	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	C105F	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	C105F	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	C105F	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	C105F	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	C105F	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	C105F	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	C105F	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	C105F	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	C105F	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	C105F	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	C105F	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	C105F	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	C105F	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	C105F	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	C105F	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	C105F	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	C105F	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
ATM	Q1274*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	Q1274*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	Q1274*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	Q1274*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	Q1274*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q1274*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q1274*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	Q1274*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q1274*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q1274*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q1274*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	Q1274*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q1274*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ARID1A	Q1346*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1346*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1346*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q1346*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
SF3B1	R625G	Different Mutation	Spliceosome inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q589*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q589*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q589*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q589*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
FAT1	K1926*	Complete Match	BET inhibitor	Responsive	HNSC	Pre-clinical
TP53	V143M	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V143M	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V143M	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V143M	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V143M	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V143M	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V143M	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V143M	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V143M	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V143M	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V143M	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V143M	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V143M	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V143M	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V143M	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TSC2	splice_acceptor_variant), TSC2 MUT (splice_acceptor_variant	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	splice_acceptor_variant), TSC2 MUT (splice_acceptor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	splice_acceptor_variant), TSC2 MUT (splice_acceptor_variant	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	splice_acceptor_variant), TSC2 MUT (splice_acceptor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	splice_acceptor_variant), TSC2 MUT (splice_acceptor_variant	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	splice_acceptor_variant), TSC2 MUT (splice_acceptor_variant	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	splice_acceptor_variant), TSC2 MUT (splice_acceptor_variant	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
TP53	R213*), TP53 MUT (L130V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R213*), TP53 MUT (L130V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R213*), TP53 MUT (L130V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R213*), TP53 MUT (L130V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R213*), TP53 MUT (L130V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R213*), TP53 MUT (L130V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R213*), TP53 MUT (L130V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R213*), TP53 MUT (L130V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R213*), TP53 MUT (L130V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R213*), TP53 MUT (L130V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R213*), TP53 MUT (L130V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R213*), TP53 MUT (L130V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R213*), TP53 MUT (L130V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R213*), TP53 MUT (L130V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R213*), TP53 MUT (L130V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RNF43	E453*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
RET	E734K	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	E734K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	E734K	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	E734K	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E734K	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E734K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	E734K	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E734K	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E734K	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
NTRK3	E318K	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	E318K	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	E318K	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
BRD4	R1163Q	Different Alteration	BET inhibitor	Responsive	NMC	Case report
PTEN	Y88*	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y88*	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y88*	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	Y88*	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	Y88*	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	Y88*	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y88*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y88*	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	Y88*	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	Y88*	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y88*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y88*	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	Y88*	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y88*	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	Y88*	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y88*	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	Y88*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y88*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y88*	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	Y88*	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y88*	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y88*	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y88*	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	Y88*	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y88*	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
ESR1	V392I	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
TP53	Y205N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y205N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y205N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y205N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y205N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y205N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y205N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y205N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y205N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y205N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y205N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y205N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y205N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y205N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y205N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	V1970I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	V1970I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	V1970I	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	V1970I	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	V1970I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
KIT	D820Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	AML	Pre-clinical
KIT	D820Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	HES, ALL, MDS, SM, ECL, MDPS, CML	FDA guidelines
KIT	D820Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	D820Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Pre-clinical
KIT	D820Y	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Case report
KIT	D820Y	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CANCER	Pre-clinical
KIT	D820Y	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	SM	Early trials
KIT	D820Y	Complete Match	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Case report
KIT	D820Y	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	D820Y	Different Mutation	HSP90 inhibitor	Responsive	GIST	Early trials
KIT	D820Y	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Early trials
KIT	D820Y	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	D820Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	GIST	FDA guidelines
KIT	D820Y	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	D820Y	Complete Match	Regorafenib (Pan-kinase inhibitor)	Responsive	GIST	FDA guidelines
KIT	D820Y	Complete Match	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	D820Y	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	CM	Late trials
KIT	D820Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	D820Y	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	FDA guidelines
KIT	D820Y	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	CM	Early trials
KIT	D820Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	THYM	Case report
KIT	D820Y	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	D820Y	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	D820Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KIT	D820Y	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	D820Y	Complete Match	HSP90 inhibitor	Responsive	GIST	Pre-clinical
KIT	D820Y	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Pre-clinical
KIT	D820Y	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Pre-clinical
KIT	D820Y	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	Late trials
KIT	D820Y	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	GIST	Pre-clinical
KIT	D820Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Late trials
KIT	D820Y	Complete Match	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	D820Y	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	GIST	Early trials
KIT	D820Y	Complete Match	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	D820Y	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	D820Y	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	D820Y	Different Alteration	Sunitinib (Pan-TK inhibitor)	No Responsive	CM	Early trials
KIT	D820Y	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	No Responsive	CM	Early trials
CDKN2A	G89Afs*38	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	G89Afs*38	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	G89Afs*38	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	G89Afs*38	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	G89Afs*38	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	G89Afs*38	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	G89Afs*38	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	G89Afs*38	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
TP53	A159D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	A159D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	A159D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	A159D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	A159D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	A159D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	A159D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A159D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A159D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	A159D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	A159D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	A159D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A159D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	A159D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A159D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S127Y	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S127Y	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S127Y	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S127Y	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S127Y	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S127Y	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S127Y	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S127Y	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S127Y	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S127Y	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S127Y	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S127Y	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S127Y	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S127Y	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S127Y	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
JAK2	S936N	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
PIK3CA	V344G	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	V344G	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	V344G	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	V344G	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	V344G	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	V344G	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	V344G	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	V344G	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	V344G	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	V344G	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	V344G	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	V344G	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	V344G	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	V344G	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
STK11	Y131*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	Y131*	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	Y131*	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	Y131*	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	Y131*	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	Y131*	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y131*	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y131*	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	Y131*	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	Y131*	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	Y131*	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y131*	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y131*), KRAS MUT (Q61L	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	Y131*), KRAS MUT (Q61L	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	Y131*), KRAS MUT (Q61L	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	Y131*), KRAS MUT (Q61L	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
NOTCH1	R1962H	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1962H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
PIK3R1	K567N	Complete Match	AKT inhibitor	Responsive	G	Pre-clinical
PIK3R1	K567N	Complete Match	PI3K pathway inhibitor	Responsive	ED	Case report
PDGFRA	H974Q	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
ROS1	Q26*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	Q26*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	Q26*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	Q26*	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	Q26*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
BRAF	T241P	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	T241P	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	T241P	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	T241P	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TP53	H168P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H168P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H168P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H168P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H168P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H168P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H168P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H168P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H168P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H168P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H168P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H168P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H168P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H168P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H168P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PALB2	R1086*	Complete Match	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	R1086*	Complete Match	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	R1086*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
PALB2	R1086*	Complete Match	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	R1086*	Different Alteration	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	R1086*	Different Alteration	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	R1086*	Different Alteration	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	R1086*	Different Alteration	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
ESR1	R164T	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
BRCA2	E2872*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	E2872*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	E2872*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	E2872*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	E2872*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	E2872*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	E2872*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	E2872*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	E2872*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	E2872*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	E2872*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	E2872*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	E2872*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	E2872*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12D), KRAS MUT (G12V	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12D), KRAS MUT (G12V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12D), KRAS MUT (G12V	Complete Match	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12D), KRAS MUT (G12V	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (G12V	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12D), KRAS MUT (G12V	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12D), KRAS MUT (G12V	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12D), KRAS MUT (G12V	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12D), KRAS MUT (G12V	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12D), KRAS MUT (G12V	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12D), KRAS MUT (G12V	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (G12V	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12D), KRAS MUT (G12V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (G12V	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12D), KRAS MUT (G12V	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (G12V	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12D), KRAS MUT (G12V	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12D), KRAS MUT (G12V	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12D), KRAS MUT (G12V	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12D), KRAS MUT (G12V	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12D), KRAS MUT (G12V	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12D), KRAS MUT (G12V	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
NOTCH1	T586A	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	T586A	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	D1972N	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	D1972N	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
KMT2A	D2032N	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	D2032N	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	D2032N	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	D2032N	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	D2032N	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	D2032N	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
HRAS	Q61K	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	CER	Pre-clinical
HRAS	Q61K	Complete Match	MEK inhibitor +/- MTOR inhibitor	Responsive	AML	Pre-clinical
HRAS	Q61K	Complete Match	MTOR inhibitor	Responsive	CESC	Pre-clinical
HRAS	Q61K	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	Responsive	CANCER	Early trials
MET	G391R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
TP53	K132Q	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	K132Q	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	K132Q	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	K132Q	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	K132Q	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	K132Q	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	K132Q	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K132Q	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K132Q	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	K132Q	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	K132Q	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	K132Q	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K132Q	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	K132Q	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K132Q	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2A	A2323S	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	A2323S	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	A2323S	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	A2323S	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	A2323S	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	A2323S	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
APC	Q161*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
TP53	H179N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H179N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H179N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H179N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H179N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H179N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H179N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H179N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H179N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H179N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H179N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H179N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H179N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H179N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H179N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	R1662Q	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1662Q	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	G244V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G244V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G244V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G244V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G244V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G244V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G244V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G244V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G244V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G244V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G244V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G244V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G244V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G244V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G244V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PIK3CA	P539R	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	P539R	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	P539R	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	P539R	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	P539R	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	P539R	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	P539R	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	P539R	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	P539R	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	P539R	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	P539R	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	P539R	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	P539R	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	P539R	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
NTRK3	S775*	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	S775*	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	S775*	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
KMT2D	Q4103*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
FGFR3	N644S	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	N644S	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	N644S	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
ARID1A	R1335*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1335*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1335*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	R1335*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
PALB2	Q988*	Complete Match	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	Q988*	Complete Match	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	Q988*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
PALB2	Q988*	Complete Match	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	Q988*	Different Alteration	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	Q988*	Different Alteration	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	Q988*	Different Alteration	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	Q988*	Different Alteration	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
ABL1	R191H	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	R191H	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R191H	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	R191H	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R191H	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	R191H	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ALK	P117L	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	P117L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	P117L	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	P117L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	P117L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	P117L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P117L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	P117L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P117L	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P117L	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	P117L	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	P117L	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	P117L	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	P117L	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	P117L	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	P117L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	P117L	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	P117L	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P117L	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
MET	A1225V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
SMARCA4	R1077*	Complete Match	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	R1077*	Complete Match	AURKA inhibitor	Responsive	NSCLC	Pre-clinical
SMARCA4	R1077*	Complete Match	EZH2 inhibitor	Responsive	OV	Case report
SMARCA4	R1077*	Different Alteration	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	R1077*	Different Alteration	EZH2 inhibitor	Responsive	OV	Case report
TP53	G199V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G199V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G199V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G199V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G199V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G199V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G199V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G199V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G199V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G199V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G199V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G199V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G199V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G199V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G199V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CTNNB1	S33F	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	S33F	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
TP53	R280I	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R280I	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R280I	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R280I	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R280I	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R280I	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R280I	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R280I	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R280I	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R280I	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R280I	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R280I	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R280I	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R280I	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R280I	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	E141*	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	CM	Pre-clinical
ERBB4	E141*	Different Mutation	ERBB2 inhibitor	Resistant	BRCA	Case report
ERBB4	E141*	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
SETD2	Q1794*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	Q1794*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
RB1	Q471*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	Q471*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	Q471*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	Q471*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	Q471*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	Q471*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	Q471*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
KMT2A	R2078H	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	R2078H	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	R2078H	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	R2078H	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	R2078H	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	R2078H	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
RET	V706M	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	V706M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	V706M	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	V706M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	V706M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	V706M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	V706M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	V706M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	V706M	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ERCC2	R722W	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ERCC2	R722W	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ERCC2	R722W	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
TP53	R175H), TP53 MUT (E271*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R175H), TP53 MUT (E271*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R175H), TP53 MUT (E271*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R175H), TP53 MUT (E271*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R175H), TP53 MUT (E271*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R175H), TP53 MUT (E271*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (E271*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (E271*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R175H), TP53 MUT (E271*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R175H), TP53 MUT (E271*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (E271*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H), TP53 MUT (E271*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R175H), TP53 MUT (E271*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H), TP53 MUT (E271*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RB1	G865*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	G865*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	G865*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	G865*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	G865*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	G865*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	G865*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
RET	R694W	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R694W	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R694W	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R694W	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R694W	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R694W	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R694W	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R694W	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R694W	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
RET	T742M	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	T742M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	T742M	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	T742M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	T742M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	T742M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	T742M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	T742M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	T742M	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
STK11	D194N	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	D194N	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	D194N	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	D194N	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	D194N	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	D194N	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	D194N	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	D194N	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	D194N	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	D194N	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	D194N	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	D194N	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
PIK3R1	CdsStopSNV	Complete Match	AKT inhibitor	Responsive	G	Pre-clinical
PIK3R1	CdsStopSNV	Complete Match	PI3K pathway inhibitor	Responsive	ED	Case report
PDGFRA	A1014T	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
STK11	D194N), KRAS MUT (G12V	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	D194N), KRAS MUT (G12V	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	D194N), KRAS MUT (G12V	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	D194N), KRAS MUT (G12V	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
MET	H1154R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
KMT2A	R2207W	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	R2207W	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	R2207W	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	R2207W	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	R2207W	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	R2207W	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NTRK3	N278S	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	N278S	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	N278S	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NTRK3	R518H	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R518H	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R518H	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	S310F	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	S310F	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	S310F	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	ST, BRCA, GEJA	FDA guidelines
ERBB2	S310F	Different Alteration	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	S310F	Different Alteration	MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor)	Responsive	SOLID	Early trials
ERBB2	S310F	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	S310F	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	S310F	Complete Match	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER, BRCA	Pre-clinical
ERBB2	S310F	Complete Match	Neratinib (ERBB2 inhibitor)	Responsive	CANCER	Early trials
ERBB2	S310F	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	CANCER	Early trials
ERBB2	S310F	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Case report
ERBB2	S310F	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA, LUAD	Case report
ERBB2	S310F	Complete Match	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	L	Early trials
ERBB2	S310F	Different Mutation	Neratinib (ERBB2 inhibitor)	Resistant	BRCA	Case report
ERBB2	S310F	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	S310F	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	LUAD	Case report
ERBB2	S310F	Different Mutation	Lapatinib (ERBB2 inhibitor)	Resistant	BRCA	Pre-clinical
ERBB2	S310F	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB2	S310F	Complete Match	Temsirolimus (MTOR inhibitor)	Responsive	LUAD	Early trials
ERBB2	S310F	Complete Match	Dacomitinib (Pan ERBB inhibitor)	Responsive	NSCLC	Early trials
ERBB2	S310F	Complete Match	Neratinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	S310F	Different Mutation	ERBB2 inhibitor	Responsive	LUAD	Early trials
ERBB2	S310F	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Early trials
ERBB2	S310F	Different Mutation	ERBB2 mAb inhibitor	Responsive	LUAD	Early trials
ERBB2	S310F	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	S310F	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	S310F	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	LUAD	Early trials
ERBB2	S310F	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BRCA	Late trials
ERBB2	S310F	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	BT	Early trials
ERBB2	S310F	Different Alteration	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Responsive	COREAD	Late trials
ERBB2	S310F	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	OV	Early trials
ERBB2	S310F	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BLCA	Case report
ERBB2	S310F	Different Alteration	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	COREAD	Case report
ERBB2	S310F	Different Alteration	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
ERBB2	S310F	Different Alteration	Osimertinib (EGFR inhibitor)	Resistant	LUAD	Case report
ERBB2	S310F	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	BT	Early trials
ERBB2	S310F	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Early trials
ERBB2	S310F	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	BT	Early trials
ERBB2	S310F	Different Alteration	Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor)	Responsive	BRCA	Early trials
ERBB2	S310F	Different Alteration	HER2 inhibitor;CDK4/6 inhibitor	Responsive	BRCA	Pre-clinical
ERBB2	S310F	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	S310F	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	ST	Early trials
ERBB2	S310F	Different Alteration	Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
ERBB2	S310F	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	ST, GEJA	FDA guidelines
ERBB2	S310F	Different Alteration	ERBB2 inhibitor;CDK4/6 inhibitor	Responsive	BRCA	Pre-clinical
ERBB2	S310F	Different Alteration	Ado-Trastuzumab Emtansine (EGFR mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	S310F	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	HNC	Case report
ERBB2	S310F	Different Alteration	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Late trials
ERBB2	S310F	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	No Responsive	ED	Early trials
ERBB2	S310F	Different Alteration	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Responsive	ED	Pre-clinical
ERBB2	S310F	Different Alteration	Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy)	Responsive	ST	Early trials
ERBB2	S310F	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	ST	Case report
ERBB2	S310F	Different Alteration	EGFR inhibitor	Resistant	LUAD	Pre-clinical
BRCA2	Q1551*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	Q1551*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q1551*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	Q1551*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	Q1551*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	Q1551*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	Q1551*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	Q1551*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q1551*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q1551*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q1551*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q1551*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	Q1551*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q1551*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
KMT2D	Q4210*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
ERBB4	H647R	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
RB1	Q444*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	Q444*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	Q444*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	Q444*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	Q444*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	Q444*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	Q444*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
JAK2	N1085S	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
KMT2D	C255*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
RB1	L335*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	L335*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	L335*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	L335*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	L335*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	L335*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	L335*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
BCOR	S1437*	Complete Match	Enzastaurin (PKCb inhibitor)	Responsive	ST	Pre-clinical
BRD4	S601L	Different Alteration	BET inhibitor	Responsive	NMC	Case report
ARID1A	E2035*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E2035*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E2035*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E2035*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
U2AF1	S34Y	Complete Match	FLT3 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P177S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P177S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P177S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P177S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P177S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P177S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P177S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P177S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P177S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P177S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P177S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P177S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P177S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P177S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P177S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
VHL	V165D	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
TP53	H168L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H168L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H168L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H168L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H168L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H168L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H168L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H168L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H168L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H168L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H168L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H168L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H168L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H168L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H168L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	I1268T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	I1268T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	I1268T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	I1268T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	I1268T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
TP53	Q104*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q104*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q104*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q104*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q104*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q104*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q104*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q104*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q104*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q104*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q104*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q104*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q104*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q104*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q104*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C135F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C135F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C135F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C135F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C135F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C135F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C135F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C135F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C135F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C135F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C135F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C135F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C135F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C135F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C135F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ALK	M315I	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	M315I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	M315I	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	M315I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	M315I	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	M315I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	M315I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	M315I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	M315I	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	M315I	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	M315I	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	M315I	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	M315I	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	M315I	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	M315I	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	M315I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	M315I	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	M315I	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	M315I	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
NOTCH1	G1298V	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	G1298V	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
MET	G774C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
TP53	C275S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C275S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C275S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C275S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C275S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C275S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C275S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C275S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C275S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C275S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C275S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C275S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C275S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C275S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C275S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L145Q	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L145Q	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L145Q	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L145Q	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L145Q	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L145Q	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L145Q	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L145Q	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L145Q	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L145Q	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L145Q	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L145Q	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L145Q	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L145Q	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L145Q	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RB1	E539*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	E539*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	E539*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	E539*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	E539*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	E539*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	E539*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
NTRK1	V524F	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	V524F	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	V524F	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	V524F	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
KMT2D	E431*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
TP53	N131Y	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	N131Y	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	N131Y	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	N131Y	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	N131Y	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	N131Y	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	N131Y	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N131Y	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N131Y	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	N131Y	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	N131Y	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	N131Y	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N131Y	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	N131Y	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N131Y	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2A	S95V	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S95V	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S95V	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S95V	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S95V	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S95V	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
RAF1	E478K	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	E478K	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	E478K	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
RNF43	E149), RNF43 MUT (Q180	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
BRD4	L407V), BRD4 MUT* (D414N), BRD4 MUT* (G419S), BRD4 MUT* (R423P), BRD4 MUT* (D436H	Different Alteration	BET inhibitor	Responsive	NMC	Case report
ATM	Q445*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	Q445*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	Q445*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	Q445*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	Q445*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q445*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q445*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	Q445*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q445*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q445*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q445*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	Q445*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q445*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ARID1A	Q1519*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1519*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1519*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q1519*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
FBXW7	Q508*	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	Q508*	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	Q508*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	Q508*	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
MET	S701G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
TP53	E180K	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E180K	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E180K	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E180K	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E180K	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E180K	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E180K	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E180K	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E180K	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E180K	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E180K	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E180K	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E180K	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E180K	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E180K	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	C563S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	C563S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ATM	Y947*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	Y947*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	Y947*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	Y947*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	Y947*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	Y947*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Y947*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	Y947*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Y947*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Y947*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Y947*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	Y947*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	Y947*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
PBRM1	splice_acceptor_variant	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	splice_acceptor_variant	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	splice_acceptor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	splice_acceptor_variant	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	splice_acceptor_variant	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
BRAF	D565E	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	D565E	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	D565E	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	D565E	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TP53	C176W	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C176W	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C176W	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C176W	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C176W	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C176W	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C176W	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176W	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176W	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C176W	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C176W	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C176W	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176W	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C176W	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176W	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KIT	D60Vfs*9	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	AML	Pre-clinical
KIT	D60Vfs*9	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	HES, ALL, MDS, SM, ECL, MDPS, CML	FDA guidelines
KIT	D60Vfs*9	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	D60Vfs*9	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Pre-clinical
KIT	D60Vfs*9	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Case report
KIT	D60Vfs*9	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CANCER	Pre-clinical
KIT	D60Vfs*9	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	SM	Early trials
KIT	D60Vfs*9	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Case report
KIT	D60Vfs*9	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	D60Vfs*9	Different Mutation	HSP90 inhibitor	Responsive	GIST	Early trials
KIT	D60Vfs*9	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Early trials
KIT	D60Vfs*9	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	D60Vfs*9	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	GIST	FDA guidelines
KIT	D60Vfs*9	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	D60Vfs*9	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Responsive	CM	Late trials;NCCN guidelines
KIT	D60Vfs*9	Different Mutation	Regorafenib (Pan-kinase inhibitor)	Responsive	GIST	FDA guidelines
KIT	D60Vfs*9	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	D60Vfs*9	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	CM	Late trials
KIT	D60Vfs*9	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	D60Vfs*9	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	FDA guidelines
KIT	D60Vfs*9	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	CM	Early trials
KIT	D60Vfs*9	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	THYM	Case report
KIT	D60Vfs*9	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	D60Vfs*9	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	D60Vfs*9	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KIT	D60Vfs*9	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	D60Vfs*9	Different Mutation	HSP90 inhibitor	Responsive	GIST	Pre-clinical
KIT	D60Vfs*9	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Pre-clinical
KIT	D60Vfs*9	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Pre-clinical
KIT	D60Vfs*9	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	Late trials
KIT	D60Vfs*9	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	GIST	Pre-clinical
KIT	D60Vfs*9	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Late trials
KIT	D60Vfs*9	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	D60Vfs*9	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	GIST	Early trials
KIT	D60Vfs*9	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	D60Vfs*9	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	D60Vfs*9	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	D60Vfs*9	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	CM	Case report
KIT	D60Vfs*9	Different Alteration	Sunitinib (Pan-TK inhibitor)	No Responsive	CM	Early trials
KIT	D60Vfs*9	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	No Responsive	CM	Early trials
NOTCH2	R1069Q	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
PBRM1	K277*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	K277*	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	K277*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	K277*	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	K277*	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
BRCA2	Q1148*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	Q1148*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q1148*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	Q1148*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	Q1148*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	Q1148*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	Q1148*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	Q1148*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q1148*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q1148*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q1148*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q1148*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	Q1148*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q1148*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
TP53	A159T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	A159T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	A159T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	A159T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	A159T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	A159T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	A159T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A159T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A159T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	A159T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	A159T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	A159T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A159T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	A159T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A159T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PDGFRA	A921T	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
RNF43	Q379*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
BCOR	K395*	Complete Match	Enzastaurin (PKCb inhibitor)	Responsive	ST	Pre-clinical
TP53	V218E	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V218E	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V218E	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V218E	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V218E	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V218E	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V218E	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V218E	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V218E	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V218E	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V218E	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V218E	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V218E	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V218E	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V218E	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
EGFR	T1029M	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	T1029M	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
RNF43	V211Afs*40	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
CDKN2A	R58Gfs*84	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R58Gfs*84	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R58Gfs*84	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	R58Gfs*84	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R58Gfs*84	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R58Gfs*84	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R58Gfs*84	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R58Gfs*84	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
NTRK3	E360D	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	E360D	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	E360D	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
ATM	C465Efs*2	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	C465Efs*2	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	C465Efs*2	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	C465Efs*2	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	C465Efs*2	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	C465Efs*2	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	C465Efs*2	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	C465Efs*2	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	C465Efs*2	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	C465Efs*2	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	C465Efs*2	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	C465Efs*2	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	C465Efs*2	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
STK11	splice_donor_variant), KRAS MUT (G12V	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	splice_donor_variant), KRAS MUT (G12V	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	splice_donor_variant), KRAS MUT (G12V	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	splice_donor_variant), KRAS MUT (G12V	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
JAK2	splice_donor_variant	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
PIK3R1	R642*	Complete Match	AKT inhibitor	Responsive	G	Pre-clinical
PIK3R1	R642*	Complete Match	PI3K pathway inhibitor	Responsive	ED	Case report
NTRK3	W88), NTRK3 MUT (R169H	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	W88), NTRK3 MUT (R169H	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	W88), NTRK3 MUT (R169H	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
FGFR2	G503A	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	G503A	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
BRCA2	Q73*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	Q73*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q73*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	Q73*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	Q73*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	Q73*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	Q73*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	Q73*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q73*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q73*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q73*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q73*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	Q73*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q73*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
RET	P218L	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	P218L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	P218L	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	P218L	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	P218L	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	P218L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	P218L	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	P218L	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	P218L	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
BRCA2	Y600*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	Y600*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Y600*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	Y600*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	Y600*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	Y600*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	Y600*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	Y600*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Y600*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Y600*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Y600*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Y600*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	Y600*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Y600*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
BRAF	G466V	Complete Match	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	G466V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	G466V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	NCCN guidelines
BRAF	G466V	Different Mutation	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G466V	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G466V	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	G466V	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	G466V	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	G466V	Different Mutation	ERK inhibitor	Responsive	HNSC, BT	Case report
BRAF	G466V	Different Mutation	EGFR TK inhibitor	Resistant	LUAD	Case report
BRAF	G466V	Different Mutation	MEK inhibitor	Responsive	CM	Case report
BRAF	G466V	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	G466V	Different Mutation	BRAF inhibitor	Responsive	CM	Case report
BRAF	G466V	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	G466V	Different Mutation	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	G466V	Different Mutation	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	G466V	Different Mutation	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	G466V	Different Mutation	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	G466V	Different Mutation	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	G466V	Different Mutation	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	G466V	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	G466V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	G466V	Different Mutation	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	G466V	Different Mutation	BRAF inhibitor;HSP90 inhibitor	Responsive	CM	Pre-clinical
BRAF	G466V	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	G466V	Different Mutation	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	G466V	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	G466V	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	G466V	Different Mutation	MEK inhibitor	Responsive	TH	Early trials
BRAF	G466V	Different Mutation	BRAF inhibitor;PI3K pathway inhibitor	Responsive	CM	Pre-clinical
BRAF	G466V	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	G466V	Different Mutation	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	G466V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	G466V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	G466V	Different Mutation	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	G466V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	G466V	Different Mutation	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	G466V	Different Mutation	BRAF inhibitor;CDK2/4 inhibitor	Responsive	CM	Pre-clinical
BRAF	G466V	Different Mutation	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	G466V	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	G466V	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	G466V	Different Mutation	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	G466V	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	G466V	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	G466V	Different Mutation	BRAF inhibitor	Responsive	OV	Case report
BRAF	G466V	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	G466V	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	G466V	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	G466V	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	G466V	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	G466V	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	G466V	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
CTNNB1	S37A	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	S37A	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
RAF1	M469I	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	M469I	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	M469I	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
KMT2A	S1685Y	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S1685Y	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S1685Y	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S1685Y	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S1685Y	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S1685Y	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
TMPRSS2	G362E	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	G362E	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
KMT2D	R4319*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
RET	R355W	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R355W	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R355W	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R355W	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R355W	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R355W	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R355W	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R355W	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R355W	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
TP53	Y205C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y205C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y205C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y205C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y205C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y205C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y205C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y205C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y205C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y205C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y205C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y205C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y205C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y205C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y205C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	D281Y	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	D281Y	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	D281Y	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	D281Y	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	D281Y	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	D281Y	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	D281Y	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D281Y	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D281Y	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	D281Y	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	D281Y	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	D281Y	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D281Y	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	D281Y	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D281Y	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	C2081*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	C2081*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	C2081*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	C2081*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
FBXW7	G419*	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	G419*	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	G419*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	G419*	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
ROS1	E1518D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	E1518D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	E1518D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	E1518D	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	E1518D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
TP53	R158P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R158P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R158P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R158P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R158P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R158P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R158P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R158P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R158P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R158P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R158P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R158P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R158P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R158P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R158P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	L802V	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	L802V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	L802V	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	L802V	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	L802V	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	L802V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	L802V	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	L802V	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	L802V	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ABL1	N368S	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	N368S	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	N368S	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	N368S	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	N368S	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	N368S	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
RNF43	W194*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
ARID1A	Q1131*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1131*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1131*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q1131*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
BRAF	R389H	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	R389H	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	R389H	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	R389H	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
BRCA2	R3052W	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	R3052W	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	R3052W	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	R3052W	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	R3052W	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	R3052W	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	R3052W	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	R3052W	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	R3052W	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	R3052W	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	R3052W	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	R3052W	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	R3052W	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	R3052W	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
SETD2	Q1422*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	Q1422*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C242*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C242*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C242*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C242*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C242*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C242*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C242*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C242*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C242*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C242*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C242*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C242*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C242*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C242*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C242*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	R525W	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R525W	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R525W	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R525W	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R525W	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R525W	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R525W	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R525W	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R525W	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
RNF43	E131*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
AKT3	R220H	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
RB1	Y606*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	Y606*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	Y606*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	Y606*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	Y606*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	Y606*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	Y606*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
ERBB4	Q1181E	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ARID1A	R376Gfs*15	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R376Gfs*15	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R376Gfs*15	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	R376Gfs*15	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
RET	R694Q	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R694Q	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R694Q	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R694Q	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R694Q	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R694Q	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R694Q	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R694Q	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R694Q	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
TMPRSS2	S270L	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	S270L	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
APC	R2237*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
PTPRD	W1038*	Complete Match	IGF1R inhibitor	Responsive	S	Case report
TP53	L252P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L252P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L252P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L252P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L252P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L252P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L252P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L252P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L252P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L252P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L252P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L252P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L252P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L252P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L252P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R283P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R283P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R283P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R283P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R283P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R283P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R283P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R283P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R283P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R283P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R283P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R283P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R283P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R283P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R283P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BCOR	Q596*	Complete Match	Enzastaurin (PKCb inhibitor)	Responsive	ST	Pre-clinical
TP53	A83Ffs*66	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	A83Ffs*66	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	A83Ffs*66	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	A83Ffs*66	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	A83Ffs*66	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	A83Ffs*66	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	A83Ffs*66	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A83Ffs*66	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A83Ffs*66	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	A83Ffs*66	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	A83Ffs*66	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	A83Ffs*66	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A83Ffs*66	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	A83Ffs*66	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A83Ffs*66	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ESR1	Q502*	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
ARID1A	Q844*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q844*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q844*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q844*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
FBXW7	E110*	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	E110*	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	E110*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	E110*	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
ERBB4	R524H	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ARID1A	Q482*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q482*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q482*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q482*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	E286V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E286V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E286V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E286V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E286V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E286V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E286V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E286V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E286V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E286V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E286V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E286V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E286V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E286V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E286V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TSC2	G1172Ffs*61	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	G1172Ffs*61	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	G1172Ffs*61	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	G1172Ffs*61	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	G1172Ffs*61	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	G1172Ffs*61	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	G1172Ffs*61	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	S1514*	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	S1514*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	S1514*	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	S1514*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	S1514*	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	S1514*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	S1514*	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
BRD4	A1189V	Different Alteration	BET inhibitor	Responsive	NMC	Case report
TP53	I254N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I254N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I254N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I254N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I254N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I254N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I254N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I254N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I254N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I254N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I254N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I254N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I254N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I254N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I254N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I255N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I255N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I255N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I255N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I255N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I255N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I255N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I255N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I255N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I255N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I255N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I255N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I255N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I255N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I255N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2A	K1219N	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	K1219N	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	K1219N	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	K1219N	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	K1219N	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	K1219N	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
PTEN	D92H	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	D92H	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	D92H	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	D92H	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	D92H	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	D92H	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	D92H	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	D92H	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	D92H	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	D92H	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	D92H	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	D92H	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	D92H	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	D92H	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	D92H	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	D92H	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	D92H	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	D92H	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	D92H	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	D92H	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	D92H	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	D92H	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	D92H	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	D92H	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	D92H	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
RET	Y483*	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	Y483*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	Y483*	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	Y483*	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	Y483*	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	Y483*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	Y483*	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	Y483*	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	Y483*	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
AKT3	D299Y), AKT3 MUT* (L344I	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
ESR1	M427I	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
RB1	E166*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	E166*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	E166*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	E166*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	E166*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	E166*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	E166*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
ATR	E275*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATR	E275*	Complete Match	Olaparib (PARP inhibitor)	Responsive	CANCER, OV	Pre-clinical
ATR	E275*	Different Alteration	Olaparib (PARP inhibitor)	Responsive	OV, CANCER	Pre-clinical
APC	P1584Hfs*2	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
JAK2	R1063C	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
ROS1	D513Y	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	D513Y	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	D513Y	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	D513Y	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	D513Y	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ERBB4	R525H	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
SMARCA4	E579*	Complete Match	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	E579*	Complete Match	AURKA inhibitor	Responsive	NSCLC	Pre-clinical
SMARCA4	E579*	Complete Match	EZH2 inhibitor	Responsive	OV	Case report
SMARCA4	E579*	Different Alteration	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	E579*	Different Alteration	EZH2 inhibitor	Responsive	OV	Case report
NF1	K2169*	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NF1	K2169*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	HNC	Case report
NF1	K2169*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	K2169*	Complete Match	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	K2169*	Complete Match	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NF1	K2169*	Complete Match	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	K2169*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	K2169*	Complete Match	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	K2169*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	NF	Late trials
NF1	K2169*	Complete Match	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	K2169*	Complete Match	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	K2169*	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	MPN, PLEN	Pre-clinical
NF1	K2169*	Complete Match	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	K2169*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	HNC, SG	Case report
NF1	K2169*	Complete Match	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	K2169*	Complete Match	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	K2169*	Complete Match	MEK inhibitor	Responsive	LK, G	Pre-clinical
NF1	K2169*	Complete Match	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	K2169*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	K2169*	Complete Match	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	K2169*	Complete Match	MTOR inhibitor	Responsive	LK, G, MPN	Pre-clinical
NF1	K2169*	Complete Match	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	K2169*	Complete Match	Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor)	Responsive	HC	Case report
NF1	K2169*	Complete Match	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	K2169*	Complete Match	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	K2169*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	K2169*	Complete Match	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	K2169*	Complete Match	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	K2169*	Complete Match	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	K2169*	Complete Match	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	K2169*	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	K2169*	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	K2169*	Complete Match	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	K2169*	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	K2169*	Complete Match	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	K2169*	Complete Match	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	K2169*	Different Alteration	MTOR inhibitor	Responsive	MPN, G, LK	Pre-clinical
NF1	K2169*	Different Alteration	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	K2169*	Different Alteration	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	K2169*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	K2169*	Different Alteration	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	K2169*	Different Alteration	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	K2169*	Different Alteration	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	K2169*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	K2169*	Different Alteration	MEK inhibitor	Responsive	G, LK	Pre-clinical
NF1	K2169*	Different Alteration	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	K2169*	Different Alteration	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	K2169*	Different Alteration	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	K2169*	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	K2169*	Different Alteration	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	K2169*	Different Alteration	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	K2169*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	K2169*	Different Alteration	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	K2169*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SG, HNC	Case report
NF1	K2169*	Different Alteration	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	K2169*	Different Alteration	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	K2169*	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	K2169*	Different Alteration	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	K2169*	Different Alteration	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	K2169*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	K2169*	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	PLEN, MPN	Pre-clinical
NF1	K2169*	Different Alteration	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	K2169*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	K2169*	Different Alteration	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	K2169*	Different Alteration	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	K2169*	Different Alteration	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	K2169*	Different Alteration	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	K2169*	Different Alteration	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
MAP2K1	Q56_E62delinsRK	Different Mutation	MEK inhibitor	Resistant	CANCER	Pre-clinical
MAP2K1	Q56_E62delinsRK	Different Mutation	novel MEK inhibitor	Responsive	CM	Pre-clinical
MAP2K1	Q56_E62delinsRK	Different Mutation	MEK inhibitor	Resistant	CM	Case report
MAP2K1	Q56_E62delinsRK	Different Mutation	ERK inhibitor	Responsive	CANCER	Pre-clinical
MAP2K1	Q56_E62delinsRK	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Case report
MAP2K1	Q56_E62delinsRK	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
MAP2K1	Q56_E62delinsRK	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CANCER	Pre-clinical
MAP2K1	Q56_E62delinsRK	Different Mutation	Panitumumab;Trametinib (EGFR mAb inhibitor;MEK inhibitor)	Responsive	COREAD	Case report
MAP2K1	Q56_E62delinsRK	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
MAP2K1	Q56_E62delinsRK	Different Mutation	BRAF inhibitor	Resistant	CM	Early trials
MAP2K1	Q56_E62delinsRK	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
MAP2K1	Q56_E62delinsRK	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Case report
SMARCA4	splice_donor_variant	Complete Match	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	splice_donor_variant	Complete Match	AURKA inhibitor	Responsive	NSCLC	Pre-clinical
SMARCA4	splice_donor_variant	Complete Match	EZH2 inhibitor	Responsive	OV	Case report
SMARCA4	splice_donor_variant	Different Alteration	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	splice_donor_variant	Different Alteration	EZH2 inhibitor	Responsive	OV	Case report
ERBB4	R927*	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	CM	Pre-clinical
ERBB4	R927*	Different Mutation	ERBB2 inhibitor	Resistant	BRCA	Case report
ERBB4	R927*	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ALK	P835L	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	P835L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	P835L	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	P835L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	P835L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	P835L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P835L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	P835L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P835L	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P835L	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	P835L	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	P835L	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	P835L	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	P835L	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	P835L	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	P835L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	P835L	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	P835L	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P835L	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
SETD2	G675*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	G675*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SMARCA4	Y187*	Complete Match	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	Y187*	Complete Match	AURKA inhibitor	Responsive	NSCLC	Pre-clinical
SMARCA4	Y187*	Complete Match	EZH2 inhibitor	Responsive	OV	Case report
SMARCA4	Y187*	Different Alteration	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	Y187*	Different Alteration	EZH2 inhibitor	Responsive	OV	Case report
KRAS	G12H	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12H	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12H	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12H	Complete Match	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12H	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12H	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12H	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12H	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12H	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12H	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12H	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12H	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12H	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12H	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12H	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12H	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12H	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12H	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12H	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12H	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12H	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12H	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12H	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12H	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12H	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12H	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12H	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12H	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12H	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12H	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12H	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12H	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12H	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12H	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12H	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12H	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12H	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12H	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12H	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12H	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12H	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
KDR	R961W	Different Mutation	VEGFR2 inhibitor	Resistant	COREAD	Case report
KDR	R961W	Different Mutation	Cabozantinib (Pan-kinase inhibitor)	Responsive	COREAD	Pre-clinical
KDR	R961W	Complete Match	Pazopanib (VEGFR inhibitor)	Responsive	BCC	Case report
KDR	R961W	Different Mutation	VEGFR inhibitor	Responsive	CANCER	Pre-clinical
BRD4	S1204R	Different Alteration	BET inhibitor	Responsive	NMC	Case report
RNF43	Q22*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
ALK	K721N	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	K721N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	K721N	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	K721N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	K721N	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	K721N	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	K721N	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	K721N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	K721N	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	K721N	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	K721N	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	K721N	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	K721N	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	K721N	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	K721N	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	K721N	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	K721N	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	K721N	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	K721N	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
PIK3CA	Y1021C	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	Y1021C	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	Y1021C	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	Y1021C	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	Y1021C	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	Y1021C	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	Y1021C	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	Y1021C	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	Y1021C	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	Y1021C	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	Y1021C	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	Y1021C	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	Y1021C	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	Y1021C	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
MET	R191W	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
STK11	Q399*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	Q399*	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	Q399*	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	Q399*	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	Q399*	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	Q399*	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Q399*	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Q399*	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	Q399*	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	Q399*	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	Q399*	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Q399*	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
PIK3CA	G106R	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	G106R	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	G106R	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	G106R	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	G106R	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	G106R	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	G106R	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	G106R	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	G106R	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	G106R	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	G106R	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	G106R	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	G106R	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	G106R	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
BRCA2	E254*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	E254*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	E254*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	E254*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	E254*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	E254*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	E254*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	E254*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	E254*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	E254*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	E254*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	E254*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	E254*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	E254*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
APC	R405*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
ERBB4	A1219T	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
EGFR	L62F	Different Alteration	Cetuximab (EGFR mAb inhibitor)	Responsive	COREAD	FDA guidelines
EGFR	L62F	Different Alteration	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
EGFR	L62F	Different Mutation	Rindopepimut (Vaccine)	Responsive	GB	Late trials
EGFR	L62F	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	L62F	Different Mutation	Gefitinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	L62F	Different Mutation	HSP90 inhibitor	Responsive	L	Early trials
EGFR	L62F	Different Mutation	Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	L62F	Different Mutation	MEK inhibitor	Responsive	L	Pre-clinical
EGFR	L62F	Different Mutation	EGFR TK inhibitor	Responsive	L	Late trials
EGFR	L62F	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	NCCN guidelines
EGFR	L62F	Different Mutation	Osimertinib (EGFR inhibitor)	Resistant	L	Early trials
EGFR	L62F	Different Mutation	EGFR-TKI's (EGFR inhibitor)	Resistant	L	Late trials
EGFR	L62F	Different Mutation	HSP90 inhibitor	Responsive	L	Case report
EGFR	L62F	Different Mutation	EGFR inhibitor	Resistant	L	Late trials
EGFR	L62F	Different Mutation	Poziotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	L62F	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Pre-clinical
EGFR	L62F	Different Mutation	HSP90 inhibitor (HSP90 inhibitor)	Responsive	L	Early trials
EGFR	L62F	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	G	Pre-clinical
EGFR	L62F	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	L62F	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	L62F	Different Mutation	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
EGFR	L62F	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Responsive	COREAD	Case report
EGFR	L62F	Different Mutation	novel EGFR mAb inhibitor	Responsive	COREAD	Early trials
EGFR	L62F	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	L62F	Different Mutation	Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor)	Responsive	HNC	Case report
EGFR	L62F	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	L62F	Different Mutation	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Case report
EGFR	L62F	Different Mutation	EGFR inhibitor	Responsive	L	Early trials
EGFR	L62F	Different Mutation	Erlotinib (EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	L62F	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	L62F	Different Mutation	EGFR inhibitor	Responsive	NSCLC	Late trials
EGFR	L62F	Different Mutation	Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	L62F	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	L62F	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	L62F	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	L	Late trials
EGFR	L62F	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Pre-clinical
EGFR	L62F	Different Mutation	Erlotinib (EGFR inhibitor)	No Responsive	L	Case report
EGFR	L62F	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	ED	Case report
EGFR	L62F	Different Mutation	EGFR inhibitor	No Responsive	G	Early trials
EGFR	L62F	Different Mutation	EGFR inhibitor	Resistant	NSCLC	Case report
EGFR	L62F	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	L62F	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant;Resistant	COREAD	Pre-clinical;Case report
EGFR	L62F	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Responsive	HNC	Case report
EGFR	L62F	Different Alteration	Gefitinib (EGFR inhibitor)	Responsive	ED	Late trials
EGFR	L62F	Different Alteration	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Early trials
EGFR	L62F	Different Alteration	EGFR inhibitor	Responsive	HNSC	Case report
EGFR	L62F	Different Alteration	EGFR inhibitor	No Responsive	G	Early trials
EGFR	L62F	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	L	Early trials
EGFR	L62F	Different Alteration	EGFR mAb inhibitor	Responsive	COREAD	Late trials
EGFR	L62F	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	L62F	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
FBXW7	G654S	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	G654S	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	G654S	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	G654S	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
RET	P560L	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	P560L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	P560L	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	P560L	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	P560L	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	P560L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	P560L	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	P560L	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	P560L	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
MET	H1339Y	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
NOTCH1	splice_acceptor_variant	Different Mutation	Gamma secretase inhibitor	Responsive	CANCER	Early trials
NOTCH1	splice_acceptor_variant	Different Mutation	Gamma secretase inhibitor;CDK4 inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	splice_acceptor_variant	Different Mutation	Gamma secretase inhibitor;MTOR inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	splice_acceptor_variant	Different Mutation	Gamma secretase inhibitor	Responsive;Responsive	ALL	Early trials;Pre-clinical
NOTCH1	splice_acceptor_variant	Different Mutation	NOTCH1 inhibitor	Responsive	ADCC	Case report
NOTCH1	splice_acceptor_variant	Different Mutation	OMP-52M51 (NOTCH1 inhibitor)	Responsive	CANCER	Early trials
NOTCH1	splice_acceptor_variant	Different Mutation	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	splice_acceptor_variant	Complete Match	Gamma secretase inhibitor	Responsive	MCL	Pre-clinical
NOTCH1	splice_acceptor_variant	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	splice_acceptor_variant	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRAF	G265R	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	G265R	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	G265R	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	G265R	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TP53	C141R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C141R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C141R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C141R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C141R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C141R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C141R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C141R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C141R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C141R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C141R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	Q503*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q503*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q503*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q503*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	L137Q	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L137Q	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L137Q	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L137Q	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L137Q	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L137Q	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L137Q	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L137Q	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L137Q	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L137Q	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L137Q	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L137Q	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L137Q	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L137Q	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L137Q	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TMPRSS2	G242E	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	G242E	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
NTRK3	R130H	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R130H	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R130H	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
RB1	S618*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	S618*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	S618*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	S618*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	S618*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	S618*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	S618*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
EGFR	S227F	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	S227F	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
AKT3	R95M	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
RET	S696L	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	S696L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	S696L	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	S696L	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	S696L	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	S696L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	S696L	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	S696L	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	S696L	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ARID1A	E1802*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1802*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1802*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E1802*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ROS1	R1617M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	R1617M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	R1617M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	R1617M	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	R1617M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
TP53	C275F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C275F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C275F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C275F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C275F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C275F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C275F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C275F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C275F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C275F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C275F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C275F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C275F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C275F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C275F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RB1	K265*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	K265*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	K265*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	K265*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	K265*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	K265*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	K265*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
TP53	T155P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T155P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T155P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T155P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T155P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T155P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T155P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T155P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T155P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T155P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T155P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T155P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T155P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T155P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T155P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	G122Pfs*108	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	G122Pfs*108	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	G122Pfs*108	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	G122Pfs*108	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
SETD2	E397*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	E397*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
ROS1	W1289*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	W1289*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	W1289*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	W1289*	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	W1289*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
PIK3CA	N1044S	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	N1044S	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	N1044S	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	N1044S	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	N1044S	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	N1044S	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	N1044S	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	N1044S	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	N1044S	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	N1044S	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	N1044S	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	N1044S	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	N1044S	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	N1044S	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
RET	R817C	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R817C	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R817C	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R817C	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R817C	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R817C	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R817C	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R817C	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R817C	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
NTRK3	R791Q	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R791Q	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R791Q	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
ATM	S1056*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	S1056*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	S1056*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	S1056*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	S1056*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	S1056*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	S1056*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	S1056*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	S1056*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	S1056*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	S1056*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	S1056*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	S1056*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
TP53	R175H), TP53 MUT (R337C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R175H), TP53 MUT (R337C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R175H), TP53 MUT (R337C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R175H), TP53 MUT (R337C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R175H), TP53 MUT (R337C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R175H), TP53 MUT (R337C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (R337C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (R337C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R175H), TP53 MUT (R337C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R175H), TP53 MUT (R337C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (R337C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H), TP53 MUT (R337C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R175H), TP53 MUT (R337C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H), TP53 MUT (R337C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CRLF2	T223M	Different Alteration	MTOR inhibitor	Responsive	ALL	Pre-clinical
CRLF2	T223M	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2D	R5027*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
KMT2A	E1690K	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	E1690K	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	E1690K	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	E1690K	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	E1690K	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	E1690K	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ATM	E2039*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	E2039*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	E2039*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	E2039*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	E2039*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	E2039*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E2039*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	E2039*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E2039*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	E2039*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	E2039*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	E2039*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	E2039*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
TP53	L194V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L194V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L194V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L194V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L194V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L194V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L194V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L194V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L194V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L194V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L194V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L194V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L194V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L194V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L194V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FANCA	splice_acceptor_variant	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Case report
FANCA	splice_acceptor_variant	Different Alteration	Olaparib (PARP inhibitor)	Responsive	PRAD	Case report
NOTCH1	R1946H	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1946H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	C238S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C238S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C238S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C238S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C238S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C238S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C238S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C238S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C238S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C238S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C238S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C238S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C238S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C238S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C238S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	S645*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S645*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S645*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	S645*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
SMARCA4	Q1472*	Complete Match	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	Q1472*	Complete Match	AURKA inhibitor	Responsive	NSCLC	Pre-clinical
SMARCA4	Q1472*	Complete Match	EZH2 inhibitor	Responsive	OV	Case report
SMARCA4	Q1472*	Different Alteration	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	Q1472*	Different Alteration	EZH2 inhibitor	Responsive	OV	Case report
RNF43	E334), RNF43 MUT (S468	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
ARID1A	E2058*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E2058*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E2058*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E2058*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
RB1	R455*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	R455*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R455*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R455*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	R455*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R455*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R455*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
NTRK3	D75N	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	D75N	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	D75N	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	R678W	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	R678W	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	R678W	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	ST, BRCA, GEJA	FDA guidelines
ERBB2	R678W	Different Alteration	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	R678W	Different Alteration	MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor)	Responsive	SOLID	Early trials
ERBB2	R678W	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	R678W	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	R678W	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER, BRCA	Pre-clinical
ERBB2	R678W	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	CANCER	Early trials
ERBB2	R678W	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Case report
ERBB2	R678W	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA, LUAD	Case report
ERBB2	R678W	Different Mutation	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	L	Early trials
ERBB2	R678W	Different Mutation	Neratinib (ERBB2 inhibitor)	Resistant	BRCA	Case report
ERBB2	R678W	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	R678W	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	LUAD	Case report
ERBB2	R678W	Different Mutation	Lapatinib (ERBB2 inhibitor)	Resistant	BRCA	Pre-clinical
ERBB2	R678W	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB2	R678W	Complete Match	Temsirolimus (MTOR inhibitor)	Responsive	LUAD	Early trials
ERBB2	R678W	Complete Match	Dacomitinib (Pan ERBB inhibitor)	Responsive	NSCLC	Early trials
ERBB2	R678W	Complete Match	Neratinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	R678W	Different Mutation	ERBB2 inhibitor	Responsive	LUAD	Early trials
ERBB2	R678W	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Early trials
ERBB2	R678W	Different Mutation	ERBB2 mAb inhibitor	Responsive	LUAD	Early trials
ERBB2	R678W	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	R678W	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	R678W	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	LUAD	Early trials
ERBB2	R678W	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BRCA	Late trials
ERBB2	R678W	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	BT	Early trials
ERBB2	R678W	Different Alteration	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Responsive	COREAD	Late trials
ERBB2	R678W	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	OV	Early trials
ERBB2	R678W	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BLCA	Case report
ERBB2	R678W	Different Alteration	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	COREAD	Case report
ERBB2	R678W	Different Alteration	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
ERBB2	R678W	Different Alteration	Osimertinib (EGFR inhibitor)	Resistant	LUAD	Case report
ERBB2	R678W	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	BT	Early trials
ERBB2	R678W	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Early trials
ERBB2	R678W	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	BT	Early trials
ERBB2	R678W	Different Alteration	Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor)	Responsive	BRCA	Early trials
ERBB2	R678W	Different Alteration	HER2 inhibitor;CDK4/6 inhibitor	Responsive	BRCA	Pre-clinical
ERBB2	R678W	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	R678W	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	ST	Early trials
ERBB2	R678W	Different Alteration	Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
ERBB2	R678W	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	ST, GEJA	FDA guidelines
ERBB2	R678W	Different Alteration	ERBB2 inhibitor;CDK4/6 inhibitor	Responsive	BRCA	Pre-clinical
ERBB2	R678W	Different Alteration	Ado-Trastuzumab Emtansine (EGFR mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	R678W	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	HNC	Case report
ERBB2	R678W	Different Alteration	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Late trials
ERBB2	R678W	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	No Responsive	ED	Early trials
ERBB2	R678W	Different Alteration	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Responsive	ED	Pre-clinical
ERBB2	R678W	Different Alteration	Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy)	Responsive	ST	Early trials
ERBB2	R678W	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	ST	Case report
ERBB2	R678W	Different Alteration	EGFR inhibitor	Resistant	LUAD	Pre-clinical
KMT2A	P3818S	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P3818S	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P3818S	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P3818S	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P3818S	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P3818S	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
GATA3	R306*	Complete Match	Aromatase ihibitor	Responsive	BRCA	Pre-clinical
NOTCH2	E494Q	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
RET	L790F	Different Mutation	Vandetanib (Pan-TK inhibitor)	Responsive	THCA, TH	FDA guidelines
RET	L790F	Different Mutation	Cabozantinib (Pan-kinase inhibitor)	Responsive	TH	Pre-clinical
RET	L790F	Different Mutation	RET inhibitor	Responsive	TH	Early trials
RET	L790F	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	TH	Pre-clinical
RET	L790F	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Resistant	LUAD	Pre-clinical
RET	L790F	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	L790F	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	L790F	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	L790F	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	L790F	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	L790F	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	L790F	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	L790F	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	L790F	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
TP53	H178P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H178P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H178P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H178P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H178P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H178P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H178P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H178P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H178P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H178P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H178P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H178P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H178P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H178P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H178P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	D609H	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12S	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12S	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12S	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12S	Complete Match	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12S	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12S	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12S	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12S	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12S	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12S	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12S	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12S	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12S	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12S	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12S	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12S	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12S	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12S	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12S	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12S	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12S	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12S	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12S	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12S	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12S	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12S	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12S	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12S	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12S	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12S	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12S	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12S	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12S	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12S	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12S	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12S	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12S	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12S	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12S	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12S	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12S	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
NOTCH1	A495T	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	A495T	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ALK	A730S	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	A730S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	A730S	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	A730S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	A730S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	A730S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A730S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	A730S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A730S	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A730S	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	A730S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	A730S	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	A730S	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	A730S	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	A730S	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	A730S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	A730S	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	A730S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A730S	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
TP53	P190R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P190R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P190R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P190R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P190R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P190R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P190R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P190R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P190R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P190R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P190R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P190R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P190R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P190R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P190R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRCA2	L1740fs1	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	L1740fs1	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	L1740fs1	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	L1740fs1	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	L1740fs1	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	L1740fs1	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	L1740fs1	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	L1740fs1	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	L1740fs1	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	L1740fs1	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	L1740fs1	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	L1740fs1	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	L1740fs1	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	L1740fs1	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
TP53	L145R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L145R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L145R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L145R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L145R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L145R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L145R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L145R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L145R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L145R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L145R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L145R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L145R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L145R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L145R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2A	S577G	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S577G	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S577G	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S577G	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S577G	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S577G	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
RB1	Y805*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	Y805*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	Y805*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	Y805*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	Y805*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	Y805*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	Y805*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
CDKN1B	E75*	Complete Match	CDK2/4 inhibitor	Responsive	CANCER	Pre-clinical
CDKN1B	E75*	Different Alteration	CDK2/4 inhibitor	Responsive	CANCER	Pre-clinical
ERBB4	G223R	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	N236T	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	N236T	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	N236T	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	N236T	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
ROS1	T722M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	T722M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	T722M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	T722M	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	T722M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
TP53	S240R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	S240R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	S240R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	S240R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	S240R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	S240R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	S240R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S240R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	S240R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	S240R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	S240R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	S240R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S240R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	S240R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	S240R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	V412A	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	V412A	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	V412A	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	V412A	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	V412A	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	V412A	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	V412A	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	V412A	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	V412A	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ABL1	V1031M), ABL1 MUT* (R1009*	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	V1031M), ABL1 MUT* (R1009*	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	V1031M), ABL1 MUT* (R1009*	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	V1031M), ABL1 MUT* (R1009*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	V1031M), ABL1 MUT* (R1009*	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	V1031M), ABL1 MUT* (R1009*	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
FGFR2	P444L	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	P444L	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
MET	R739C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
NOTCH1	L2419I	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	L2419I	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRD4	P297T), BRD4 MUT* (R1121H	Different Alteration	BET inhibitor	Responsive	NMC	Case report
BRD4	I403V	Different Alteration	BET inhibitor	Responsive	NMC	Case report
FBXW7	R658*	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	R658*	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	R658*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	R658*	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
TP53	C238W	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C238W	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C238W	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C238W	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C238W	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C238W	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C238W	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C238W	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C238W	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C238W	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C238W	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C238W	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C238W	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C238W	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C238W	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	R46K	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R46K	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R46K	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	R46K	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R46K	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R46K	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R46K	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R46K	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
ALK	D1141N	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	D1141N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	D1141N	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	D1141N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	D1141N	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	D1141N	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	D1141N	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	D1141N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	D1141N	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	D1141N	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	D1141N	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	D1141N	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	D1141N	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	D1141N	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	D1141N	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	D1141N	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	D1141N	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	D1141N	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	D1141N	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ESR1	D218N	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
STAG2	splice_acceptor_variant	Complete Match	PARP inhibitor	Responsive	G	Pre-clinical
ALK	G756S	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	G756S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	G756S	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	G756S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	G756S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	G756S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G756S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	G756S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G756S	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G756S	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	G756S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	G756S	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	G756S	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	G756S	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	G756S	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	G756S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	G756S	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	G756S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G756S	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
PIK3CA	E453K	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	E453K	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	E453K	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	E453K	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	E453K	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	E453K	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	E453K	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	E453K	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	E453K	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	E453K	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	E453K	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	E453K	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	E453K	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	E453K	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
CDK12	E1177*	Complete Match	PARP inhibitor	Responsive	OV	Pre-clinical
CDK12	E1177*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
ERBB4	Q900*	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	CM	Pre-clinical
ERBB4	Q900*	Different Mutation	ERBB2 inhibitor	Resistant	BRCA	Case report
ERBB4	Q900*	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
NOTCH1	N268K	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	N268K	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	N310Pfs*35	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	N310Pfs*35	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	N310Pfs*35	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	N310Pfs*35	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	N310Pfs*35	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	N310Pfs*35	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	N310Pfs*35	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N310Pfs*35	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N310Pfs*35	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	N310Pfs*35	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	N310Pfs*35	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	N310Pfs*35	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N310Pfs*35	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	N310Pfs*35	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N310Pfs*35	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FGFR2	Y376C), FGFR2 MUT (Y376C), FGFR2 MUT* (I379V	Different Alteration	FGFR inhibitor	Resistant	CH	Early trials
FGFR2	Y376C	Different Mutation	FGFR inhibitor	Responsive	LUSC	Pre-clinical
FGFR2	Y376C	Different Mutation	Dovitinib (FGFR inhibitor)	Resistant	ED	Pre-clinical
FGFR2	Y376C	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	ED	Pre-clinical
FGFR2	Y376C	Different Mutation	FGFR inhibitor	Responsive	ED	Pre-clinical
FGFR2	Y376C	Different Mutation	FGFR inhibitor	Responsive	L	Pre-clinical
FGFR2	Y376C	Different Mutation	FGFR inhibitor	Responsive	BT	Case report
FGFR2	Y376C	Different Alteration	FGFR inhibitor	Responsive	ST	Early trials
FGFR2	Y376C	Different Alteration	FGFR inhibitor	Responsive	BRCA	Case report
FGFR2	Y376C), FGFR2 MUT* (I379V	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	Y376C), FGFR2 MUT* (I379V	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
ALK	P97S	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	P97S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	P97S	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	P97S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	P97S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	P97S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P97S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	P97S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P97S	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P97S	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	P97S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	P97S	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	P97S	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	P97S	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	P97S	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	P97S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	P97S	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	P97S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P97S	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
NOTCH2	R2051Q	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
PTEN	Y27S	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y27S	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y27S	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	Y27S	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	Y27S	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	Y27S	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y27S	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y27S	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	Y27S	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	Y27S	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y27S	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y27S	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	Y27S	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y27S	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	Y27S	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y27S	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	Y27S	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y27S	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y27S	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	Y27S	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y27S	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y27S	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y27S	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	Y27S	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y27S	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
NOTCH1	R1234Q	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1234Q	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	C1045Y	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	C1045Y	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NF1	L252*	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NF1	L252*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	HNC	Case report
NF1	L252*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	L252*	Complete Match	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	L252*	Complete Match	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NF1	L252*	Complete Match	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	L252*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	L252*	Complete Match	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	L252*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	NF	Late trials
NF1	L252*	Complete Match	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	L252*	Complete Match	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	L252*	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	MPN, PLEN	Pre-clinical
NF1	L252*	Complete Match	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	L252*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	HNC, SG	Case report
NF1	L252*	Complete Match	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	L252*	Complete Match	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	L252*	Complete Match	MEK inhibitor	Responsive	LK, G	Pre-clinical
NF1	L252*	Complete Match	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	L252*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	L252*	Complete Match	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	L252*	Complete Match	MTOR inhibitor	Responsive	LK, G, MPN	Pre-clinical
NF1	L252*	Complete Match	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	L252*	Complete Match	Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor)	Responsive	HC	Case report
NF1	L252*	Complete Match	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	L252*	Complete Match	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	L252*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	L252*	Complete Match	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	L252*	Complete Match	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	L252*	Complete Match	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	L252*	Complete Match	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	L252*	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	L252*	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	L252*	Complete Match	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	L252*	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	L252*	Complete Match	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	L252*	Complete Match	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	L252*	Different Alteration	MTOR inhibitor	Responsive	MPN, G, LK	Pre-clinical
NF1	L252*	Different Alteration	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	L252*	Different Alteration	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	L252*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	L252*	Different Alteration	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	L252*	Different Alteration	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	L252*	Different Alteration	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	L252*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	L252*	Different Alteration	MEK inhibitor	Responsive	G, LK	Pre-clinical
NF1	L252*	Different Alteration	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	L252*	Different Alteration	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	L252*	Different Alteration	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	L252*	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	L252*	Different Alteration	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	L252*	Different Alteration	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	L252*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	L252*	Different Alteration	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	L252*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SG, HNC	Case report
NF1	L252*	Different Alteration	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	L252*	Different Alteration	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	L252*	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	L252*	Different Alteration	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	L252*	Different Alteration	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	L252*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	L252*	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	PLEN, MPN	Pre-clinical
NF1	L252*	Different Alteration	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	L252*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	L252*	Different Alteration	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	L252*	Different Alteration	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	L252*	Different Alteration	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	L252*	Different Alteration	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	L252*	Different Alteration	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
ROS1	Y2342C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	Y2342C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	Y2342C	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	Y2342C	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	Y2342C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
BRD4	F698V	Different Alteration	BET inhibitor	Responsive	NMC	Case report
MET	R469Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
FGFR2	E466K	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	E466K	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
APC	splice_acceptor_variant	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
SMARCA4	E1612*	Complete Match	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	E1612*	Complete Match	AURKA inhibitor	Responsive	NSCLC	Pre-clinical
SMARCA4	E1612*	Complete Match	EZH2 inhibitor	Responsive	OV	Case report
SMARCA4	E1612*	Different Alteration	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	E1612*	Different Alteration	EZH2 inhibitor	Responsive	OV	Case report
PDGFRA	T276M	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
ARID1A	E1490Kfs*11	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1490Kfs*11	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1490Kfs*11	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E1490Kfs*11	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ESR1	R37W	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
ERBB4	K722E	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ESR1	G204S	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
ERBB4	P790S	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ALK	A1289V	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	A1289V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	A1289V	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	A1289V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	A1289V	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	A1289V	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A1289V	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	A1289V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A1289V	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A1289V	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	A1289V	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	A1289V	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	A1289V	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	A1289V	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	A1289V	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	A1289V	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	A1289V	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	A1289V	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A1289V	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
MET	E1017K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
KMT2A	T2180I), MLL MUT* (G47D	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	T2180I), MLL MUT* (G47D	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	T2180I), MLL MUT* (G47D	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	T2180I), MLL MUT* (G47D	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	T2180I), MLL MUT* (G47D	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	T2180I), MLL MUT* (G47D	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NTRK3	G393D	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	G393D	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	G393D	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NTRK1	A631V), NTRK1 MUT* (P392S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	A631V), NTRK1 MUT* (P392S	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	A631V), NTRK1 MUT* (P392S	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	A631V), NTRK1 MUT* (P392S	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
NOTCH1	P743L	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	P743L	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRD4	A277V	Different Alteration	BET inhibitor	Responsive	NMC	Case report
BRAF	D40N	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	D40N	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	D40N	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	D40N	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
NTRK3	R326H	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R326H	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R326H	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
ERBB4	R1304Q	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
TSC1	K168*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC1	K168*	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC1	K168*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA	FDA guidelines
TSC1	K168*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	ST, S	Case report
TSC1	K168*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	R	Case report
TSC1	K168*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	GCA	FDA guidelines
TSC1	K168*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Case report
RNF43	S216*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
BRD4	P1137L	Different Alteration	BET inhibitor	Responsive	NMC	Case report
ARID1A	Q412*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q412*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q412*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q412*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ERBB2	V777L	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	V777L	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	V777L	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	ST, BRCA, GEJA	FDA guidelines
ERBB2	V777L	Different Alteration	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	V777L	Different Alteration	MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor)	Responsive	SOLID	Early trials
ERBB2	V777L	Complete Match	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	V777L	Complete Match	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	V777L	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER, BRCA	Pre-clinical
ERBB2	V777L	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	CANCER	Early trials
ERBB2	V777L	Complete Match	Neratinib (ERBB2 inhibitor)	Responsive	CANCER	Early trials
ERBB2	V777L	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Case report
ERBB2	V777L	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA, LUAD	Case report
ERBB2	V777L	Different Mutation	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	L	Early trials
ERBB2	V777L	Different Mutation	Neratinib (ERBB2 inhibitor)	Resistant	BRCA	Case report
ERBB2	V777L	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	V777L	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	LUAD	Case report
ERBB2	V777L	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	V777L	Different Mutation	Lapatinib (ERBB2 inhibitor)	Resistant	BRCA	Pre-clinical
ERBB2	V777L	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB2	V777L	Complete Match	Temsirolimus (MTOR inhibitor)	Responsive	LUAD	Early trials
ERBB2	V777L	Complete Match	Dacomitinib (Pan ERBB inhibitor)	Responsive	NSCLC	Early trials
ERBB2	V777L	Complete Match	Neratinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	V777L	Different Mutation	ERBB2 inhibitor	Responsive	LUAD	Early trials
ERBB2	V777L	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Early trials
ERBB2	V777L	Different Mutation	ERBB2 mAb inhibitor	Responsive	LUAD	Early trials
ERBB2	V777L	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	V777L	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	V777L	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	LUAD	Early trials
ERBB2	V777L	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BRCA	Late trials
ERBB2	V777L	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	BT	Early trials
ERBB2	V777L	Different Alteration	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Responsive	COREAD	Late trials
ERBB2	V777L	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	OV	Early trials
ERBB2	V777L	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BLCA	Case report
ERBB2	V777L	Different Alteration	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	COREAD	Case report
ERBB2	V777L	Different Alteration	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
ERBB2	V777L	Different Alteration	Osimertinib (EGFR inhibitor)	Resistant	LUAD	Case report
ERBB2	V777L	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	BT	Early trials
ERBB2	V777L	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Early trials
ERBB2	V777L	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	BT	Early trials
ERBB2	V777L	Different Alteration	Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor)	Responsive	BRCA	Early trials
ERBB2	V777L	Different Alteration	HER2 inhibitor;CDK4/6 inhibitor	Responsive	BRCA	Pre-clinical
ERBB2	V777L	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	V777L	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	ST	Early trials
ERBB2	V777L	Different Alteration	Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
ERBB2	V777L	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	ST, GEJA	FDA guidelines
ERBB2	V777L	Different Alteration	ERBB2 inhibitor;CDK4/6 inhibitor	Responsive	BRCA	Pre-clinical
ERBB2	V777L	Different Alteration	Ado-Trastuzumab Emtansine (EGFR mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	V777L	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	HNC	Case report
ERBB2	V777L	Different Alteration	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Late trials
ERBB2	V777L	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	No Responsive	ED	Early trials
ERBB2	V777L	Different Alteration	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Responsive	ED	Pre-clinical
ERBB2	V777L	Different Alteration	Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy)	Responsive	ST	Early trials
ERBB2	V777L	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	ST	Case report
ERBB2	V777L	Different Alteration	EGFR inhibitor	Resistant	LUAD	Pre-clinical
KMT2D	splice_acceptor_variant	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
NTRK1	R748Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R748Q	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R748Q	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R748Q	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
RET	E459K	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	E459K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	E459K	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	E459K	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E459K	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E459K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	E459K	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E459K	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E459K	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ERBB4	R976S	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
KMT2A	E2442Q	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	E2442Q	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	E2442Q	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	E2442Q	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	E2442Q	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	E2442Q	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
APC	R332*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
FGFR2	V12L	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	V12L	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
SF3B1	K741N	Different Mutation	Spliceosome inhibitor	Responsive	CANCER	Pre-clinical
RET	R144H	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R144H	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R144H	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R144H	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R144H	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R144H	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R144H	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R144H	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R144H	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
GNAS	Q227L	Different Mutation	JAK inhibitor	Responsive	CANCER	Pre-clinical
PTEN	L112P	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	L112P	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	L112P	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	L112P	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	L112P	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	L112P	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	L112P	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	L112P	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	L112P	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	L112P	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	L112P	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	L112P	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	L112P	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	L112P	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	L112P	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	L112P	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	L112P	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	L112P	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	L112P	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	L112P	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	L112P	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	L112P	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	L112P	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	L112P	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	L112P	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PDGFRA	M642T	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
RNF43	E278*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
ARID1A	Q515*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q515*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q515*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q515*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	R273G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R273G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R273G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R273G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R273G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R273G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R273G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R273G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R273G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R273G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R273G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R273G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R273G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R273G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R273G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R213Q	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R213Q	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R213Q	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R213Q	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R213Q	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R213Q	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R213Q	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R213Q	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R213Q	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R213Q	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R213Q	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R213Q	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R213Q	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R213Q	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R213Q	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2D	Q3364*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
PBRM1	E991*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	E991*	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	E991*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	E991*	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	E991*	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R267Q	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R267Q	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R267Q	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R267Q	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R267Q	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R267Q	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R267Q	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R267Q	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R267Q	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R267Q	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R267Q	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R267Q	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R267Q	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R267Q	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R267Q	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	N106Tfs*4	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	N106Tfs*4	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	N106Tfs*4	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	N106Tfs*4	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
MET	S1356L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
NTRK3	R735C	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R735C	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R735C	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
RET	K603I	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	K603I	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	K603I	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	K603I	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	K603I	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	K603I	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	K603I	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	K603I	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	K603I	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ERBB4	N822K	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
KMT2A	S1554L	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S1554L	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S1554L	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S1554L	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S1554L	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S1554L	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NOTCH1	G2130R	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	G2130R	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NTRK1	A636V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	A636V	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	A636V	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	A636V	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
SETD2	R1459*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	R1459*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
FLT3	W603*	Different Mutation	Quizartinib (Pan-TK inhibitor)	Resistant	AML	Pre-clinical
FLT3	W603*	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Resistant	AML	Pre-clinical
FLT3	W603*	Different Mutation	Venetoclax (BCL2 inhibitor)	Resistant	AML	Early trials
FLT3	W603*	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	AML	Early trials
FLT3	W603*	Different Mutation	Quizartinib (Pan-TK inhibitor)	Responsive	AML	Early trials
FLT3	W603*	Different Mutation	Sorafenib;Azacytidine (Pan-TK inhibitor;Chemotherapy)	Responsive	AML	Early trials
FLT3	W603*	Different Mutation	FLT3 inhibitor	Responsive	AML	Early trials
FLT3	W603*	Different Mutation	Crenolanib (FLT3 inhibitor)	Responsive	AML	Pre-clinical
FLT3	W603*	Different Mutation	Midostaurin (Pan-TK inhibitor)	Responsive	AML	Pre-clinical
FLT3	W603*	Different Mutation	novel FLT3 inhibitor	Responsive	AML	Pre-clinical
FLT3	W603*	Different Mutation	Midostaurin (Pan-TK inhibitor)	Responsive	AML	Case report
FLT3	W603*	Different Mutation	Lestaurtinib (Pan-TK inhibitor)	Responsive	AML	Case report
TP53	L114Cfs*34	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	L114Cfs*34	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	L114Cfs*34	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	L114Cfs*34	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	L114Cfs*34	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	L114Cfs*34	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	L114Cfs*34	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L114Cfs*34	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	L114Cfs*34	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	L114Cfs*34	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	L114Cfs*34	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	L114Cfs*34	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L114Cfs*34	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	L114Cfs*34	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	L114Cfs*34	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	I1900M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	I1900M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	I1900M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	I1900M	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	I1900M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
STK11	splice_acceptor_variant), KRAS MUT (G12D	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	splice_acceptor_variant), KRAS MUT (G12D	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	splice_acceptor_variant), KRAS MUT (G12D	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	splice_acceptor_variant), KRAS MUT (G12D	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
RB1	E748Afs*36	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	E748Afs*36	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	E748Afs*36	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	E748Afs*36	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	E748Afs*36	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	E748Afs*36	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	E748Afs*36	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
ERBB4	Q446K	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ARID1A	Q1411*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1411*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1411*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q1411*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
PIK3CA	M1043I	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	M1043I	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	M1043I	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	M1043I	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	M1043I	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	M1043I	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	M1043I	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	M1043I	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	M1043I	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	M1043I	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	M1043I	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	M1043I	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	M1043I	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	M1043I	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
PBRM1	H899Lfs*12	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	H899Lfs*12	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	H899Lfs*12	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	H899Lfs*12	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	H899Lfs*12	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
NOTCH1	L14Q	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	L14Q	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
EGFR	R255Q	Different Alteration	Cetuximab (EGFR mAb inhibitor)	Responsive	COREAD	FDA guidelines
EGFR	R255Q	Different Alteration	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
EGFR	R255Q	Different Mutation	Rindopepimut (Vaccine)	Responsive	GB	Late trials
EGFR	R255Q	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	R255Q	Different Mutation	Gefitinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	R255Q	Different Mutation	HSP90 inhibitor	Responsive	L	Early trials
EGFR	R255Q	Different Mutation	Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	R255Q	Different Mutation	MEK inhibitor	Responsive	L	Pre-clinical
EGFR	R255Q	Different Mutation	EGFR TK inhibitor	Responsive	L	Late trials
EGFR	R255Q	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	NCCN guidelines
EGFR	R255Q	Different Mutation	Osimertinib (EGFR inhibitor)	Resistant	L	Early trials
EGFR	R255Q	Different Mutation	EGFR-TKI's (EGFR inhibitor)	Resistant	L	Late trials
EGFR	R255Q	Different Mutation	HSP90 inhibitor	Responsive	L	Case report
EGFR	R255Q	Different Mutation	EGFR inhibitor	Resistant	L	Late trials
EGFR	R255Q	Different Mutation	Poziotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	R255Q	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Pre-clinical
EGFR	R255Q	Different Mutation	HSP90 inhibitor (HSP90 inhibitor)	Responsive	L	Early trials
EGFR	R255Q	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	G	Pre-clinical
EGFR	R255Q	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	R255Q	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	R255Q	Different Mutation	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
EGFR	R255Q	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Responsive	COREAD	Case report
EGFR	R255Q	Different Mutation	novel EGFR mAb inhibitor	Responsive	COREAD	Early trials
EGFR	R255Q	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	R255Q	Different Mutation	Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor)	Responsive	HNC	Case report
EGFR	R255Q	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	R255Q	Different Mutation	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Case report
EGFR	R255Q	Different Mutation	EGFR inhibitor	Responsive	L	Early trials
EGFR	R255Q	Different Mutation	Erlotinib (EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	R255Q	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	R255Q	Different Mutation	EGFR inhibitor	Responsive	NSCLC	Late trials
EGFR	R255Q	Different Mutation	Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	R255Q	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	R255Q	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	R255Q	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	L	Late trials
EGFR	R255Q	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Pre-clinical
EGFR	R255Q	Different Mutation	Erlotinib (EGFR inhibitor)	No Responsive	L	Case report
EGFR	R255Q	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	ED	Case report
EGFR	R255Q	Different Mutation	EGFR inhibitor	No Responsive	G	Early trials
EGFR	R255Q	Different Mutation	EGFR inhibitor	Resistant	NSCLC	Case report
EGFR	R255Q	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	R255Q	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant;Resistant	COREAD	Pre-clinical;Case report
EGFR	R255Q	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Responsive	HNC	Case report
EGFR	R255Q	Different Alteration	Gefitinib (EGFR inhibitor)	Responsive	ED	Late trials
EGFR	R255Q	Different Alteration	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Early trials
EGFR	R255Q	Different Alteration	EGFR inhibitor	Responsive	HNSC	Case report
EGFR	R255Q	Different Alteration	EGFR inhibitor	No Responsive	G	Early trials
EGFR	R255Q	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	L	Early trials
EGFR	R255Q	Different Alteration	EGFR mAb inhibitor	Responsive	COREAD	Late trials
EGFR	R255Q	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	R255Q	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
KRAS	G13P	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G13P	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G13P	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G13P	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G13P	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G13P	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G13P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G13P	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13P	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G13P	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G13P	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G13P	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G13P	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G13P	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G13P	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G13P	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G13P	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G13P	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G13P	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G13P	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13P	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G13P	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13P	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G13P	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G13P	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G13P	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G13P	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G13P	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G13P	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G13P	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G13P	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G13P	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G13P	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G13P	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13P	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G13P	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13P	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G13P	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G13P	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G13P	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G13P	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G13P	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	H179P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	H179P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	H179P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	H179P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	H179P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	H179P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	H179P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H179P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	H179P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	H179P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	H179P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	H179P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H179P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	H179P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	H179P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	P48Q	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	P48Q	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	P48Q	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	P48Q	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	P48Q	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	P48Q	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	P48Q	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	P48Q	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
BRAF	N580D	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	N580D	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	N580D	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	N580D	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
SETD2	Q1932*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	Q1932*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
RNF43	W15*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
ARID1A	N1951Kfs*9	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	N1951Kfs*9	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	N1951Kfs*9	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	N1951Kfs*9	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
SETD2	Q1931*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	Q1931*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
PTEN	D24H	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	D24H	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	D24H	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	D24H	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	D24H	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	D24H	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	D24H	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	D24H	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	D24H	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	D24H	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	D24H	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	D24H	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	D24H	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	D24H	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	D24H	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	D24H	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	D24H	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	D24H	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	D24H	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	D24H	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	D24H	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	D24H	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	D24H	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	D24H	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	D24H	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
FLT3	V592I	Different Mutation	Quizartinib (Pan-TK inhibitor)	Resistant	AML	Pre-clinical
FLT3	V592I	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Resistant	AML	Pre-clinical
FLT3	V592I	Different Mutation	Venetoclax (BCL2 inhibitor)	Resistant	AML	Early trials
FLT3	V592I	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	AML	Early trials
FLT3	V592I	Different Mutation	Quizartinib (Pan-TK inhibitor)	Responsive	AML	Early trials
FLT3	V592I	Different Mutation	Sorafenib;Azacytidine (Pan-TK inhibitor;Chemotherapy)	Responsive	AML	Early trials
FLT3	V592I	Different Mutation	FLT3 inhibitor	Responsive	AML	Early trials
FLT3	V592I	Different Mutation	Crenolanib (FLT3 inhibitor)	Responsive	AML	Pre-clinical
FLT3	V592I	Different Mutation	Midostaurin (Pan-TK inhibitor)	Responsive	AML	Pre-clinical
FLT3	V592I	Different Mutation	novel FLT3 inhibitor	Responsive	AML	Pre-clinical
FLT3	V592I	Different Mutation	Midostaurin (Pan-TK inhibitor)	Responsive	AML	Case report
FLT3	V592I	Different Mutation	Lestaurtinib (Pan-TK inhibitor)	Responsive	AML	Case report
TP53	K120R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	K120R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	K120R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	K120R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	K120R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	K120R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	K120R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K120R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K120R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	K120R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	K120R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	K120R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K120R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	K120R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K120R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
SETD2	Q1750), SETD2 MUT (Q2139	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	Q1750), SETD2 MUT (Q2139	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
KMT2A	R1811Q	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	R1811Q	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	R1811Q	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	R1811Q	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	R1811Q	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	R1811Q	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ERBB4	P170T	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ROS1	V2089M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	V2089M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	V2089M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	V2089M	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	V2089M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
CDKN2A	L94Rfs*16	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	L94Rfs*16	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	L94Rfs*16	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	L94Rfs*16	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	L94Rfs*16	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	L94Rfs*16	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	L94Rfs*16	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	L94Rfs*16	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
FGFR2	C492Y	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	C492Y	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
SETD2	E1636*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	E1636*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
RB1	E465*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	E465*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	E465*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	E465*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	E465*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	E465*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	E465*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
AKT3	K68T	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
RET	Q857*	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	Q857*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	Q857*	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	Q857*	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	Q857*	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	Q857*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	Q857*	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	Q857*	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	Q857*	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
KMT2D	Q4045*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
SETD2	Q1619*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	Q1619*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
RB1	S634*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	S634*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	S634*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	S634*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	S634*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	S634*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	S634*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
ARID1A	P1621Cfs*26	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	P1621Cfs*26	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	P1621Cfs*26	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	P1621Cfs*26	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
EZH2	E636*	Different Mutation	EZH2 inhibitor	Responsive	LY	Pre-clinical
EZH2	E636*	Different Mutation	EZH2 inhibitor	Responsive	LY	Early trials
KIT	D52N	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	AML	Pre-clinical
KIT	D52N	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	HES, ALL, MDS, SM, ECL, MDPS, CML	FDA guidelines
KIT	D52N	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	D52N	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Pre-clinical
KIT	D52N	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Case report
KIT	D52N	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CANCER	Pre-clinical
KIT	D52N	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	SM	Early trials
KIT	D52N	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Case report
KIT	D52N	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	D52N	Different Mutation	HSP90 inhibitor	Responsive	GIST	Early trials
KIT	D52N	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Early trials
KIT	D52N	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	D52N	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	GIST	FDA guidelines
KIT	D52N	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	D52N	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Responsive	CM	Late trials;NCCN guidelines
KIT	D52N	Different Mutation	Regorafenib (Pan-kinase inhibitor)	Responsive	GIST	FDA guidelines
KIT	D52N	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	D52N	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	CM	Late trials
KIT	D52N	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	D52N	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	FDA guidelines
KIT	D52N	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	CM	Early trials
KIT	D52N	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	THYM	Case report
KIT	D52N	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	D52N	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	D52N	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KIT	D52N	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	D52N	Different Mutation	HSP90 inhibitor	Responsive	GIST	Pre-clinical
KIT	D52N	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Pre-clinical
KIT	D52N	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Pre-clinical
KIT	D52N	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	Late trials
KIT	D52N	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	GIST	Pre-clinical
KIT	D52N	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Late trials
KIT	D52N	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	D52N	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	GIST	Early trials
KIT	D52N	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	D52N	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	D52N	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	D52N	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	CM	Case report
KIT	D52N	Different Alteration	Sunitinib (Pan-TK inhibitor)	No Responsive	CM	Early trials
KIT	D52N	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	No Responsive	CM	Early trials
TP53	E56*), TP53 MUT (V157I	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E56*), TP53 MUT (V157I	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E56*), TP53 MUT (V157I	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E56*), TP53 MUT (V157I	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E56*), TP53 MUT (V157I	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E56*), TP53 MUT (V157I	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E56*), TP53 MUT (V157I	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E56*), TP53 MUT (V157I	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E56*), TP53 MUT (V157I	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E56*), TP53 MUT (V157I	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E56*), TP53 MUT (V157I	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E56*), TP53 MUT (V157I	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E56*), TP53 MUT (V157I	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E56*), TP53 MUT (V157I	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E56*), TP53 MUT (V157I	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RNF43	Q488*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
TP53	D259F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	D259F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	D259F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	D259F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	D259F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	D259F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	D259F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D259F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D259F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	D259F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	D259F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	D259F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D259F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	D259F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D259F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	C633*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	C633*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	C633*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	C633*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	C633*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	C633*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	C633*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	C633*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	C633*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	C633*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	C633*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	C633*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	C633*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RET	R189H	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R189H	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R189H	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R189H	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R189H	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R189H	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R189H	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R189H	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R189H	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
CRLF2	R153W	Different Alteration	MTOR inhibitor	Responsive	ALL	Pre-clinical
CRLF2	R153W	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
ATM	R2598*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R2598*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R2598*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R2598*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R2598*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R2598*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R2598*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R2598*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R2598*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R2598*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R2598*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R2598*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R2598*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
KRAS	G12R), KRAS MUT (G12C	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12R), KRAS MUT (G12C	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12R), KRAS MUT (G12C	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12R), KRAS MUT (G12C	Complete Match	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12R), KRAS MUT (G12C	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12R), KRAS MUT (G12C	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12R), KRAS MUT (G12C	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12R), KRAS MUT (G12C	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12R), KRAS MUT (G12C	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12R), KRAS MUT (G12C	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12R), KRAS MUT (G12C	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12R), KRAS MUT (G12C	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12R), KRAS MUT (G12C	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12R), KRAS MUT (G12C	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12R), KRAS MUT (G12C	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12R), KRAS MUT (G12C	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12R), KRAS MUT (G12C	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12R), KRAS MUT (G12C	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12R), KRAS MUT (G12C	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12R), KRAS MUT (G12C	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12R), KRAS MUT (G12C	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12R), KRAS MUT (G12C	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12R), KRAS MUT (G12C	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
NTRK3	V451I	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	V451I	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	V451I	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
ROS1	F992L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	F992L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	F992L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	F992L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	F992L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
CDKN2A	N42K	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	N42K	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	N42K	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	N42K	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	N42K	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	N42K	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	N42K	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	N42K	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
TP53	R273H), TP53 MUT (L264V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R273H), TP53 MUT (L264V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R273H), TP53 MUT (L264V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R273H), TP53 MUT (L264V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R273H), TP53 MUT (L264V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R273H), TP53 MUT (L264V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R273H), TP53 MUT (L264V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R273H), TP53 MUT (L264V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R273H), TP53 MUT (L264V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R273H), TP53 MUT (L264V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R273H), TP53 MUT (L264V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R273H), TP53 MUT (L264V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R273H), TP53 MUT (L264V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R273H), TP53 MUT (L264V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R273H), TP53 MUT (L264V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C176L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C176L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C176L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C176L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C176L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C176L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C176L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C176L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C176L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C176L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C176L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C176L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C176L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M246K	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	M246K	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	M246K	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	M246K	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	M246K	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	M246K	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M246K	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M246K	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M246K	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	M246K	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	M246K	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	M246K	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M246K	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	M246K	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M246K	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ESR1	A505T	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
TP53	M133T), TP53 MUT (R175H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	M133T), TP53 MUT (R175H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	M133T), TP53 MUT (R175H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	M133T), TP53 MUT (R175H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	M133T), TP53 MUT (R175H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M133T), TP53 MUT (R175H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M133T), TP53 MUT (R175H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M133T), TP53 MUT (R175H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	M133T), TP53 MUT (R175H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	M133T), TP53 MUT (R175H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	M133T), TP53 MUT (R175H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M133T), TP53 MUT (R175H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	M133T), TP53 MUT (R175H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M133T), TP53 MUT (R175H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R174W	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R174W	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R174W	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R174W	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R174W	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R174W	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R174W	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R174W	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R174W	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R174W	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R174W	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R174W	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R174W	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R174W	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R174W	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FANCC	Q366*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
FANCC	Q366*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
KRAS	G12V), KRAS MUT (L19F	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12V), KRAS MUT (L19F	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12V), KRAS MUT (L19F	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12V), KRAS MUT (L19F	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12V), KRAS MUT (L19F	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12V), KRAS MUT (L19F	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12V), KRAS MUT (L19F	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12V), KRAS MUT (L19F	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12V), KRAS MUT (L19F	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12V), KRAS MUT (L19F	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12V), KRAS MUT (L19F	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12V), KRAS MUT (L19F	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12V), KRAS MUT (L19F	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12V), KRAS MUT (L19F	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12V), KRAS MUT (L19F	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12V), KRAS MUT (L19F	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12V), KRAS MUT (L19F	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12V), KRAS MUT (L19F	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12V), KRAS MUT (L19F	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12V), KRAS MUT (L19F	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
PIK3CA	E542Q	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	E542Q	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	E542Q	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	E542Q	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	E542Q	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	E542Q	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	E542Q	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	E542Q	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	E542Q	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	E542Q	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	E542Q	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	E542Q	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	E542Q	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	E542Q	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
ARID1A	Q497*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q497*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q497*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q497*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ERBB4	R1275W	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ATM	R2034*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R2034*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R2034*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R2034*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R2034*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R2034*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R2034*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R2034*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R2034*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R2034*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R2034*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R2034*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R2034*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ARID1A	Q172*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q172*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q172*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q172*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
AKT3	H351Q	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12D), KRAS MUT (A146V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12D), KRAS MUT (A146V	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (A146V	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12D), KRAS MUT (A146V	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12D), KRAS MUT (A146V	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12D), KRAS MUT (A146V	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12D), KRAS MUT (A146V	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12D), KRAS MUT (A146V	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12D), KRAS MUT (A146V	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (A146V	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12D), KRAS MUT (A146V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (A146V	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12D), KRAS MUT (A146V	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (A146V	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12D), KRAS MUT (A146V	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12D), KRAS MUT (A146V	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12D), KRAS MUT (A146V	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12D), KRAS MUT (A146V	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12D), KRAS MUT (A146V	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12D), KRAS MUT (A146V	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
AKT1	L52R	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
AKT1	L52R	Different Mutation	allosteric AKT inhibitor	Responsive	CANCER	Early trials
AKT1	L52R	Different Mutation	non-allosteric AKT inhibitor	Responsive	CANCER	Early trials
AKT1	L52R	Different Mutation	PI3K pathway inhibitor	Responsive	HNSC	Case report
AKT1	L52R	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Early trials
AKT1	L52R	Different Mutation	AKT inhibitor	Responsive	CANCER	Pre-clinical
AKT1	L52R	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	FH	Case report
ROS1	R1910Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	R1910Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	R1910Q	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	R1910Q	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	R1910Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
VHL	R64P	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
ARID1A	C1105*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	C1105*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	C1105*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	C1105*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
RNF43	Q518*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
CDKN2A	L65Hfs*50	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	L65Hfs*50	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	L65Hfs*50	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	L65Hfs*50	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	L65Hfs*50	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	L65Hfs*50	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	L65Hfs*50	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	L65Hfs*50	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
NF2	W74*	Complete Match	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	W74*	Complete Match	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	W74*	Complete Match	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	W74*	Complete Match	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	W74*	Complete Match	MTOR inhibitor	Responsive	MEN	Pre-clinical
NF2	W74*	Complete Match	Lapatinib (ERBB2 inhibitor)	Responsive	NF, SCHW	Early trials
NF2	W74*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	W74*	Complete Match	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	W74*	Complete Match	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	W74*	Complete Match	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	W74*	Complete Match	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	W74*	Complete Match	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	W74*	Complete Match	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	W74*	Complete Match	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	W74*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	W74*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	W74*	Different Alteration	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	W74*	Different Alteration	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	W74*	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	W74*	Different Alteration	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	W74*	Different Alteration	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	W74*	Different Alteration	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	W74*	Different Alteration	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	W74*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	W74*	Different Alteration	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	W74*	Different Alteration	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	W74*	Different Alteration	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	W74*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	W74*	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	SCHW, NF	Early trials
NF2	W74*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	W74*	Different Alteration	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	W74*	Different Alteration	MTOR inhibitor	Responsive	MEN	Pre-clinical
VHL	S65A	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
RNF43	Q84*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
PBRM1	Q478*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	Q478*	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	Q478*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	Q478*	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	Q478*	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
JAK2	V617F	Complete Match	JAK inhibitor	Responsive	AML	Pre-clinical
JAK2	V617F	Complete Match	Ruxolitinib (JAK inhibitor)	Responsive	AML	Early trials
JAK2	V617F	Complete Match	Ruxolitinib (JAK inhibitor)	Responsive	MY	FDA guidelines
JAK2	V617F	Complete Match	PD1 inhibitor	Resistant	CM	Case report
JAK2	V617F	Different Alteration	JAK inhibitor	Responsive	BRCA	Pre-clinical
JAK2	V617F	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
ARID1A	Q492*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q492*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q492*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q492*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	G655*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	G655*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	G655*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	G655*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ABL1	A602T	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	A602T	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	A602T	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	A602T	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	A602T	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	A602T	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
PALB2	C828*	Complete Match	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	C828*	Complete Match	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	C828*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
PALB2	C828*	Complete Match	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	C828*	Different Alteration	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	C828*	Different Alteration	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	C828*	Different Alteration	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	C828*	Different Alteration	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
TP53	R175H), TP53 MUT (R181H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R175H), TP53 MUT (R181H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R175H), TP53 MUT (R181H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R175H), TP53 MUT (R181H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R175H), TP53 MUT (R181H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R175H), TP53 MUT (R181H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (R181H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (R181H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R175H), TP53 MUT (R181H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R175H), TP53 MUT (R181H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (R181H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H), TP53 MUT (R181H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R175H), TP53 MUT (R181H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H), TP53 MUT (R181H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NTRK3	H532Y	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	H532Y	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	H532Y	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
ABL1	G924V	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	G924V	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G924V	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	G924V	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G924V	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	G924V	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
RET	C585*	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	C585*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	C585*	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	C585*	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	C585*	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	C585*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	C585*	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	C585*	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	C585*	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
B2M	splice_donor_variant	Complete Match	PD1 Ab inhibitor	Resistant	CM	Case report
ALK	R753Q	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	R753Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	R753Q	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	R753Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	R753Q	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	R753Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R753Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	R753Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R753Q	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R753Q	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	R753Q	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	R753Q	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	R753Q	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	R753Q	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	R753Q	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	R753Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	R753Q	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	R753Q	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R753Q	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ARID1A	Q581*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q581*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q581*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q581*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	C124R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C124R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C124R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C124R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C124R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C124R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C124R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C124R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C124R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C124R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C124R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C124R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C124R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C124R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C124R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R181P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R181P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R181P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R181P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R181P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R181P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R181P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R181P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R181P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R181P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R181P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R181P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R181P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R181P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R181P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
AKT3	R249C	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
NRAS	G13D	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
NRAS	G13D	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
NRAS	G13D	Different Mutation	MEK inhibitor	Responsive	CM	Late trials
NRAS	G13D	Different Mutation	BRAF inhibitor	Resistant	CM	Early trials
NRAS	G13D	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CM	Early trials
NRAS	G13D	Complete Match	HSP90 inhibitor	Responsive	CM	Pre-clinical
NRAS	G13D	Complete Match	MEK inhibitor	Responsive	AML, LUAD, ALL	Pre-clinical
NRAS	G13D	Complete Match	Pan-RAF inhibitor	Responsive	CM	Case report
NRAS	G13D	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
NRAS	G13D	Complete Match	ERK inhibitor	Responsive	CM	Case report
NRAS	G13D	Complete Match	MEK inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
NRAS	G13D	Complete Match	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NRAS	G13D	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	MYMA	Pre-clinical
NRAS	G13D	Different Mutation	ERK inhibitor	Responsive	CANCER	Pre-clinical
BRAF	D594N	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	D594N	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	D594N	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	NCCN guidelines
BRAF	D594N	Different Mutation	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	D594N	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	D594N	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	D594N	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	D594N	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	D594N	Different Mutation	ERK inhibitor	Responsive	HNSC, BT	Case report
BRAF	D594N	Different Mutation	EGFR TK inhibitor	Resistant	LUAD	Case report
BRAF	D594N	Different Mutation	MEK inhibitor	Responsive	CM	Case report
BRAF	D594N	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	D594N	Different Mutation	BRAF inhibitor	Responsive	CM	Case report
BRAF	D594N	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	D594N	Different Mutation	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	D594N	Different Mutation	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	D594N	Different Mutation	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	D594N	Different Mutation	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	D594N	Different Mutation	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	D594N	Different Mutation	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	D594N	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	D594N	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	D594N	Different Mutation	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	D594N	Different Mutation	BRAF inhibitor;HSP90 inhibitor	Responsive	CM	Pre-clinical
BRAF	D594N	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	D594N	Different Mutation	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	D594N	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	D594N	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	D594N	Different Mutation	MEK inhibitor	Responsive	TH	Early trials
BRAF	D594N	Different Mutation	BRAF inhibitor;PI3K pathway inhibitor	Responsive	CM	Pre-clinical
BRAF	D594N	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	D594N	Different Mutation	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	D594N	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	D594N	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	D594N	Different Mutation	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	D594N	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	D594N	Different Mutation	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	D594N	Different Mutation	BRAF inhibitor;CDK2/4 inhibitor	Responsive	CM	Pre-clinical
BRAF	D594N	Different Mutation	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	D594N	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	D594N	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	D594N	Different Mutation	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	D594N	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	D594N	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	D594N	Different Mutation	BRAF inhibitor	Responsive	OV	Case report
BRAF	D594N	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	D594N	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	D594N	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	D594N	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	D594N	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	D594N	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	D594N	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
NF1	splice_acceptor_variant	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NF1	splice_acceptor_variant	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	HNC	Case report
NF1	splice_acceptor_variant	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	splice_acceptor_variant	Complete Match	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	splice_acceptor_variant	Complete Match	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	splice_acceptor_variant	Complete Match	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	NF	Late trials
NF1	splice_acceptor_variant	Complete Match	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	splice_acceptor_variant	Complete Match	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	MPN, PLEN	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	HNC, SG	Case report
NF1	splice_acceptor_variant	Complete Match	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	splice_acceptor_variant	Complete Match	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	MEK inhibitor	Responsive	LK, G	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	splice_acceptor_variant	Complete Match	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	MTOR inhibitor	Responsive	LK, G, MPN	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor)	Responsive	HC	Case report
NF1	splice_acceptor_variant	Complete Match	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	splice_acceptor_variant	Complete Match	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	splice_acceptor_variant	Complete Match	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	splice_acceptor_variant	Complete Match	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	splice_acceptor_variant	Complete Match	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	splice_acceptor_variant	Complete Match	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	splice_acceptor_variant	Complete Match	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	splice_acceptor_variant	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	splice_acceptor_variant	Complete Match	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	splice_acceptor_variant	Complete Match	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	splice_acceptor_variant	Different Alteration	MTOR inhibitor	Responsive	MPN, G, LK	Pre-clinical
NF1	splice_acceptor_variant	Different Alteration	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	splice_acceptor_variant	Different Alteration	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	splice_acceptor_variant	Different Alteration	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	splice_acceptor_variant	Different Alteration	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_acceptor_variant	Different Alteration	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	splice_acceptor_variant	Different Alteration	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	splice_acceptor_variant	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	splice_acceptor_variant	Different Alteration	MEK inhibitor	Responsive	G, LK	Pre-clinical
NF1	splice_acceptor_variant	Different Alteration	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	splice_acceptor_variant	Different Alteration	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	splice_acceptor_variant	Different Alteration	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	splice_acceptor_variant	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	splice_acceptor_variant	Different Alteration	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_acceptor_variant	Different Alteration	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	splice_acceptor_variant	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	splice_acceptor_variant	Different Alteration	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	splice_acceptor_variant	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SG, HNC	Case report
NF1	splice_acceptor_variant	Different Alteration	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	splice_acceptor_variant	Different Alteration	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	splice_acceptor_variant	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	splice_acceptor_variant	Different Alteration	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	splice_acceptor_variant	Different Alteration	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	splice_acceptor_variant	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	splice_acceptor_variant	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	PLEN, MPN	Pre-clinical
NF1	splice_acceptor_variant	Different Alteration	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	splice_acceptor_variant	Different Alteration	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	splice_acceptor_variant	Different Alteration	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_acceptor_variant	Different Alteration	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	splice_acceptor_variant	Different Alteration	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	splice_acceptor_variant	Different Alteration	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	splice_acceptor_variant	Different Alteration	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
TP53	K164*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	K164*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	K164*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	K164*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	K164*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	K164*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	K164*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K164*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K164*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	K164*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	K164*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	K164*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K164*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	K164*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K164*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FBXW7	Y545H	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	Y545H	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	Y545H	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	Y545H	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
TP53	Y220D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y220D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y220D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y220D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y220D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y220D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y220D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y220D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y220D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y220D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y220D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y220D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y220D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y220D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y220D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R805*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R805*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R805*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R805*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R805*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R805*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R805*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R805*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R805*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R805*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R805*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R805*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R805*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
PIK3R1	E52*	Complete Match	AKT inhibitor	Responsive	G	Pre-clinical
PIK3R1	E52*	Complete Match	PI3K pathway inhibitor	Responsive	ED	Case report
MET	H748Y	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
PDGFRA	P553L	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
PBRM1	R921*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Pre-clinical
PBRM1	R921*	Complete Match	anti-PD1 inhibitor	Responsive	RCCC	Early trials
PBRM1	R921*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RCC	Early trials
PBRM1	R921*	Complete Match	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
PBRM1	R921*	Different Alteration	EZH2 inhibitor	Responsive	CANCER	Pre-clinical
NF1	R304*	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NF1	R304*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	HNC	Case report
NF1	R304*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	R304*	Complete Match	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	R304*	Complete Match	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NF1	R304*	Complete Match	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	R304*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	R304*	Complete Match	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	R304*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	NF	Late trials
NF1	R304*	Complete Match	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	R304*	Complete Match	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	R304*	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	MPN, PLEN	Pre-clinical
NF1	R304*	Complete Match	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	R304*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	HNC, SG	Case report
NF1	R304*	Complete Match	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	R304*	Complete Match	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	R304*	Complete Match	MEK inhibitor	Responsive	LK, G	Pre-clinical
NF1	R304*	Complete Match	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	R304*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	R304*	Complete Match	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	R304*	Complete Match	MTOR inhibitor	Responsive	LK, G, MPN	Pre-clinical
NF1	R304*	Complete Match	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	R304*	Complete Match	Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor)	Responsive	HC	Case report
NF1	R304*	Complete Match	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	R304*	Complete Match	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	R304*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	R304*	Complete Match	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	R304*	Complete Match	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	R304*	Complete Match	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	R304*	Complete Match	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	R304*	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	R304*	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	R304*	Complete Match	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	R304*	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	R304*	Complete Match	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	R304*	Complete Match	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	R304*	Different Alteration	MTOR inhibitor	Responsive	MPN, G, LK	Pre-clinical
NF1	R304*	Different Alteration	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	R304*	Different Alteration	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	R304*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	R304*	Different Alteration	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	R304*	Different Alteration	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	R304*	Different Alteration	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	R304*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	R304*	Different Alteration	MEK inhibitor	Responsive	G, LK	Pre-clinical
NF1	R304*	Different Alteration	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	R304*	Different Alteration	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	R304*	Different Alteration	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	R304*	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	R304*	Different Alteration	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	R304*	Different Alteration	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	R304*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	R304*	Different Alteration	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	R304*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SG, HNC	Case report
NF1	R304*	Different Alteration	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	R304*	Different Alteration	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	R304*	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	R304*	Different Alteration	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	R304*	Different Alteration	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	R304*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	R304*	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	PLEN, MPN	Pre-clinical
NF1	R304*	Different Alteration	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	R304*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	R304*	Different Alteration	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	R304*	Different Alteration	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	R304*	Different Alteration	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	R304*	Different Alteration	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	R304*	Different Alteration	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
CDKN2A	splice_acceptor_variant), CDKN2A MUT (H83Y	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	splice_acceptor_variant), CDKN2A MUT (H83Y	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	splice_acceptor_variant), CDKN2A MUT (H83Y	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	splice_acceptor_variant), CDKN2A MUT (H83Y	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	splice_acceptor_variant), CDKN2A MUT (H83Y	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	splice_acceptor_variant), CDKN2A MUT (H83Y	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	splice_acceptor_variant), CDKN2A MUT (H83Y	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	splice_acceptor_variant), CDKN2A MUT (H83Y	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
RNF43	Y357*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
RB1	S565*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	S565*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	S565*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	S565*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	S565*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	S565*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	S565*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
BRD4	T573M	Different Alteration	BET inhibitor	Responsive	NMC	Case report
NOTCH2	D1189H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
CDKN2A	V25Gfs*17	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	V25Gfs*17	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	V25Gfs*17	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	V25Gfs*17	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	V25Gfs*17	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	V25Gfs*17	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	V25Gfs*17	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	V25Gfs*17	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
RNF43	W259*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
CDKN2A	L104R	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	L104R	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	L104R	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	L104R	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	L104R	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	L104R	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	L104R	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	L104R	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
RET	P684T	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	P684T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	P684T	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	P684T	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	P684T	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	P684T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	P684T	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	P684T	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	P684T	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
KMT2D	Q2380*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
NTRK1	R104C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R104C	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R104C	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R104C	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
NTRK3	E322Q	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	E322Q	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	E322Q	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NTRK1	M239I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	M239I	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	M239I	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	M239I	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
NOTCH2	P2322H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	V1575L	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	V1575L	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	G1250S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	G1250S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ESR1	P325L	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
TP53	E343*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E343*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E343*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E343*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E343*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E343*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E343*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E343*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E343*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E343*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E343*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E343*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E343*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E343*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E343*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ALK	G899S), ALK MUT* (G903E	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	G899S), ALK MUT* (G903E	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	G899S), ALK MUT* (G903E	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	G899S), ALK MUT* (G903E	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	G899S), ALK MUT* (G903E	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	G899S), ALK MUT* (G903E	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G899S), ALK MUT* (G903E	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	G899S), ALK MUT* (G903E	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G899S), ALK MUT* (G903E	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G899S), ALK MUT* (G903E	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	G899S), ALK MUT* (G903E	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	G899S), ALK MUT* (G903E	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	G899S), ALK MUT* (G903E	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	G899S), ALK MUT* (G903E	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	G899S), ALK MUT* (G903E	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	G899S), ALK MUT* (G903E	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	G899S), ALK MUT* (G903E	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	G899S), ALK MUT* (G903E	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G899S), ALK MUT* (G903E	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
FBXW7	G391D	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	G391D	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	G391D	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	G391D	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
TSC2	S487*	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	S487*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	S487*	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	S487*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	S487*	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	S487*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	S487*	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
NOTCH1	P2340S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	P2340S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	E286A	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E286A	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E286A	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E286A	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E286A	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E286A	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E286A	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E286A	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E286A	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E286A	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E286A	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E286A	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E286A	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E286A	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E286A	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NF1	K200*	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NF1	K200*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	HNC	Case report
NF1	K200*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	K200*	Complete Match	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	K200*	Complete Match	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NF1	K200*	Complete Match	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	K200*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	K200*	Complete Match	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	K200*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	NF	Late trials
NF1	K200*	Complete Match	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	K200*	Complete Match	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	K200*	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	MPN, PLEN	Pre-clinical
NF1	K200*	Complete Match	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	K200*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	HNC, SG	Case report
NF1	K200*	Complete Match	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	K200*	Complete Match	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	K200*	Complete Match	MEK inhibitor	Responsive	LK, G	Pre-clinical
NF1	K200*	Complete Match	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	K200*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	K200*	Complete Match	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	K200*	Complete Match	MTOR inhibitor	Responsive	LK, G, MPN	Pre-clinical
NF1	K200*	Complete Match	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	K200*	Complete Match	Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor)	Responsive	HC	Case report
NF1	K200*	Complete Match	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	K200*	Complete Match	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	K200*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	K200*	Complete Match	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	K200*	Complete Match	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	K200*	Complete Match	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	K200*	Complete Match	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	K200*	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	K200*	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	K200*	Complete Match	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	K200*	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	K200*	Complete Match	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	K200*	Complete Match	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	K200*	Different Alteration	MTOR inhibitor	Responsive	MPN, G, LK	Pre-clinical
NF1	K200*	Different Alteration	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	K200*	Different Alteration	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	K200*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	K200*	Different Alteration	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	K200*	Different Alteration	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	K200*	Different Alteration	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	K200*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	K200*	Different Alteration	MEK inhibitor	Responsive	G, LK	Pre-clinical
NF1	K200*	Different Alteration	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	K200*	Different Alteration	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	K200*	Different Alteration	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	K200*	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	K200*	Different Alteration	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	K200*	Different Alteration	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	K200*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	K200*	Different Alteration	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	K200*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SG, HNC	Case report
NF1	K200*	Different Alteration	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	K200*	Different Alteration	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	K200*	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	K200*	Different Alteration	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	K200*	Different Alteration	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	K200*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	K200*	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	PLEN, MPN	Pre-clinical
NF1	K200*	Different Alteration	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	K200*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	K200*	Different Alteration	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	K200*	Different Alteration	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	K200*	Different Alteration	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	K200*	Different Alteration	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	K200*	Different Alteration	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NOTCH1	V2024I	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	V2024I	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ERBB4	R1250W	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
RB1	R358*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	R358*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R358*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R358*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	R358*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	R358*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	R358*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
ERBB4	D300H	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
AKT3	E232K	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
ABL1	S1119C	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	S1119C	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	S1119C	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	S1119C	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	S1119C	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	S1119C	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
FGFR3	R223H	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	R223H	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	R223H	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
NOTCH1	A1931T	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	A1931T	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
SETD2	E1959*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	E1959*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
NTRK3	R306H	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R306H	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R306H	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
SETD2	splice_donor_variant	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	splice_donor_variant	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
KMT2D	Q3651*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
ESR1	R269H	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
NTRK3	R518C	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R518C	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R518C	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
RET	R1050*	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R1050*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R1050*	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R1050*	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R1050*	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R1050*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R1050*	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R1050*	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R1050*	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
KRAS	K117N	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	K117N	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	K117N	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	K117N	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	K117N	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	K117N	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	K117N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	K117N	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	K117N	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	K117N	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	K117N	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	K117N	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	K117N	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	K117N	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	K117N	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	K117N	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	K117N	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	K117N	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	K117N	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	K117N	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	K117N	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	K117N	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	K117N	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	K117N	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	K117N	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	K117N	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	K117N	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	K117N	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	K117N	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	K117N	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	K117N	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	K117N	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	K117N	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	K117N	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	K117N	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	K117N	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	K117N	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	K117N	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	K117N	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	K117N	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	K117N	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	K117N	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
NOTCH2	D1042H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ATM	Y2371*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	Y2371*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	Y2371*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	Y2371*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	Y2371*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	Y2371*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Y2371*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	Y2371*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Y2371*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Y2371*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Y2371*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	Y2371*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	Y2371*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ROS1	D2108N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	D2108N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	D2108N	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	D2108N	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	D2108N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
NTRK3	T578N	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	T578N	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	T578N	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
TP53	V203M	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V203M	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V203M	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V203M	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V203M	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V203M	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V203M	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V203M	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V203M	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V203M	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V203M	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V203M	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V203M	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V203M	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V203M	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P316Afs*29	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P316Afs*29	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P316Afs*29	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P316Afs*29	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P316Afs*29	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P316Afs*29	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P316Afs*29	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P316Afs*29	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P316Afs*29	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P316Afs*29	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P316Afs*29	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P316Afs*29	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P316Afs*29	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P316Afs*29	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P316Afs*29	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB3	M60R	Different Mutation	PI3K pathway inhibitor;MEK inhibitor	Responsive	CANCER	Pre-clinical
ERBB3	M60R	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	CANCER	Pre-clinical
ERBB3	M60R	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB3	M60R	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BLCA	Case report
ERBB3	M60R	Different Mutation	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB3	M60R	Different Mutation	ERBB3 mAb inhibitor	Responsive	CANCER	Pre-clinical
ERBB3	M60R	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Early trials
MAP2K1	P124L	Complete Match	MEK inhibitor	Resistant	CANCER	Pre-clinical
MAP2K1	P124L	Different Mutation	MEK inhibitor	Resistant	CM	Case report
MAP2K1	P124L	Complete Match	ERK inhibitor	Responsive	CANCER	Pre-clinical
MAP2K1	P124L	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Case report
MAP2K1	P124L	Complete Match	BRAF inhibitor	Resistant	CM	Case report
MAP2K1	P124L	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CANCER	Pre-clinical
MAP2K1	P124L	Complete Match	MEK inhibitor	Resistant	CM	Case report
MAP2K1	P124L	Different Mutation	Panitumumab;Trametinib (EGFR mAb inhibitor;MEK inhibitor)	Responsive	COREAD	Case report
MAP2K1	P124L	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
MAP2K1	P124L	Complete Match	BRAF inhibitor	Resistant	CM	Early trials
MAP2K1	P124L	Complete Match	ERK inhibitor	Responsive	CM	Pre-clinical
MAP2K1	P124L	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Case report
ERBB4	R837T	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	V600_W604delinsE	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	V600_W604delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	V600_W604delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	NCCN guidelines
BRAF	V600_W604delinsE	Different Mutation	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600_W604delinsE	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600_W604delinsE	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600_W604delinsE	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	V600_W604delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	V600_W604delinsE	Different Mutation	ERK inhibitor	Responsive	HNSC, BT	Case report
BRAF	V600_W604delinsE	Different Mutation	EGFR TK inhibitor	Resistant	LUAD	Case report
BRAF	V600_W604delinsE	Different Mutation	MEK inhibitor	Responsive	CM	Case report
BRAF	V600_W604delinsE	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	V600_W604delinsE	Different Mutation	BRAF inhibitor	Responsive	CM	Case report
BRAF	V600_W604delinsE	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	V600_W604delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	V600_W604delinsE	Different Mutation	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	V600_W604delinsE	Different Mutation	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	V600_W604delinsE	Different Mutation	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	V600_W604delinsE	Different Mutation	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	V600_W604delinsE	Different Mutation	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	V600_W604delinsE	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	V600_W604delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	V600_W604delinsE	Different Mutation	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	V600_W604delinsE	Different Mutation	BRAF inhibitor;HSP90 inhibitor	Responsive	CM	Pre-clinical
BRAF	V600_W604delinsE	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	V600_W604delinsE	Different Mutation	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	V600_W604delinsE	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	V600_W604delinsE	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	V600_W604delinsE	Different Mutation	MEK inhibitor	Responsive	TH	Early trials
BRAF	V600_W604delinsE	Different Mutation	BRAF inhibitor;PI3K pathway inhibitor	Responsive	CM	Pre-clinical
BRAF	V600_W604delinsE	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	V600_W604delinsE	Different Mutation	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	V600_W604delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600_W604delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	V600_W604delinsE	Different Mutation	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	V600_W604delinsE	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	V600_W604delinsE	Different Mutation	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	V600_W604delinsE	Different Mutation	BRAF inhibitor;CDK2/4 inhibitor	Responsive	CM	Pre-clinical
BRAF	V600_W604delinsE	Different Mutation	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	V600_W604delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	V600_W604delinsE	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	V600_W604delinsE	Different Mutation	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	V600_W604delinsE	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	V600_W604delinsE	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	V600_W604delinsE	Different Mutation	BRAF inhibitor	Responsive	OV	Case report
BRAF	V600_W604delinsE	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	V600_W604delinsE	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600_W604delinsE	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	V600_W604delinsE	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	V600_W604delinsE	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	V600_W604delinsE	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	V600_W604delinsE	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TP53	D281G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	D281G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	D281G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	D281G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	D281G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	D281G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	D281G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D281G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D281G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	D281G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	D281G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	D281G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D281G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	D281G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D281G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	E424K	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	E424K	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	F134C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	F134C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	F134C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	F134C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	F134C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	F134C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	F134C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F134C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	F134C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	F134C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	F134C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	F134C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F134C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	F134C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	F134C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RNF43	R330*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
STK11	K84*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	K84*	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	K84*	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	K84*	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	K84*	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	K84*	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	K84*	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	K84*	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	K84*	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	K84*	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	K84*	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	K84*	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	K84*), KRAS MUT (G12R	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	K84*), KRAS MUT (G12R	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	K84*), KRAS MUT (G12R	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	K84*), KRAS MUT (G12R	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	A76Qfs*20	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	A76Qfs*20	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	A76Qfs*20	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	A76Qfs*20	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	A76Qfs*20	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	A76Qfs*20	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	A76Qfs*20	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	A76Qfs*20	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	A76Qfs*20	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	A76Qfs*20	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	A76Qfs*20	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	A76Qfs*20	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	A76Qfs*20), KRAS MUT (G12D	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	A76Qfs*20), KRAS MUT (G12D	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	A76Qfs*20), KRAS MUT (G12D	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	A76Qfs*20), KRAS MUT (G12D	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
FGFR3	L542M	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	L542M	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	L542M	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TP53	R174_R175delinsSG	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R174_R175delinsSG	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R174_R175delinsSG	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R174_R175delinsSG	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R174_R175delinsSG	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R174_R175delinsSG	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R174_R175delinsSG	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R174_R175delinsSG	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R174_R175delinsSG	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R174_R175delinsSG	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R174_R175delinsSG	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R174_R175delinsSG	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R174_R175delinsSG	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R174_R175delinsSG	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R174_R175delinsSG	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I195A	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I195A	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I195A	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I195A	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I195A	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I195A	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I195A	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I195A	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I195A	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I195A	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I195A	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I195A	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I195A	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I195A	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I195A	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RB1	T116fs1	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	T116fs1	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	T116fs1	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	T116fs1	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	T116fs1	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	T116fs1	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	T116fs1	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
ERBB4	M832I	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
AKT3	D271E	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
TP53	P72Afs*51	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	P72Afs*51	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	P72Afs*51	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	P72Afs*51	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	P72Afs*51	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	P72Afs*51	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	P72Afs*51	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P72Afs*51	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	P72Afs*51	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	P72Afs*51	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	P72Afs*51	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	P72Afs*51	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P72Afs*51	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	P72Afs*51	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	P72Afs*51	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	R1461*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1461*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1461*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	R1461*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ATR	E1360*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATR	E1360*	Complete Match	Olaparib (PARP inhibitor)	Responsive	CANCER, OV	Pre-clinical
ATR	E1360*	Different Alteration	Olaparib (PARP inhibitor)	Responsive	OV, CANCER	Pre-clinical
ERBB3	D297Y	Different Mutation	PI3K pathway inhibitor;MEK inhibitor	Responsive	CANCER	Pre-clinical
ERBB3	D297Y	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	CANCER	Pre-clinical
ERBB3	D297Y	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB3	D297Y	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BLCA	Case report
ERBB3	D297Y	Different Mutation	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB3	D297Y	Different Mutation	ERBB3 mAb inhibitor	Responsive	CANCER	Pre-clinical
ERBB3	D297Y	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Early trials
FANCA	R591*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Case report
FANCA	R591*	Different Alteration	Olaparib (PARP inhibitor)	Responsive	PRAD	Case report
RAF1	P271L	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	P271L	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	P271L	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
NTRK3	T149K	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	T149K	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	T149K	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
ARID1A	Q185*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q185*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q185*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q185*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
BRAF	V600_K601delinsE	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	V600_K601delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	V600_K601delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	NCCN guidelines
BRAF	V600_K601delinsE	Different Mutation	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600_K601delinsE	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600_K601delinsE	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600_K601delinsE	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	V600_K601delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	V600_K601delinsE	Different Mutation	ERK inhibitor	Responsive	HNSC, BT	Case report
BRAF	V600_K601delinsE	Different Mutation	EGFR TK inhibitor	Resistant	LUAD	Case report
BRAF	V600_K601delinsE	Different Mutation	MEK inhibitor	Responsive	CM	Case report
BRAF	V600_K601delinsE	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	V600_K601delinsE	Different Mutation	BRAF inhibitor	Responsive	CM	Case report
BRAF	V600_K601delinsE	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	V600_K601delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	V600_K601delinsE	Different Mutation	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	V600_K601delinsE	Different Mutation	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	V600_K601delinsE	Different Mutation	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	V600_K601delinsE	Different Mutation	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	V600_K601delinsE	Different Mutation	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	V600_K601delinsE	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	V600_K601delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	V600_K601delinsE	Different Mutation	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	V600_K601delinsE	Different Mutation	BRAF inhibitor;HSP90 inhibitor	Responsive	CM	Pre-clinical
BRAF	V600_K601delinsE	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	V600_K601delinsE	Different Mutation	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	V600_K601delinsE	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	V600_K601delinsE	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	V600_K601delinsE	Different Mutation	MEK inhibitor	Responsive	TH	Early trials
BRAF	V600_K601delinsE	Different Mutation	BRAF inhibitor;PI3K pathway inhibitor	Responsive	CM	Pre-clinical
BRAF	V600_K601delinsE	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	V600_K601delinsE	Different Mutation	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	V600_K601delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600_K601delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	V600_K601delinsE	Different Mutation	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	V600_K601delinsE	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	V600_K601delinsE	Different Mutation	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	V600_K601delinsE	Different Mutation	BRAF inhibitor;CDK2/4 inhibitor	Responsive	CM	Pre-clinical
BRAF	V600_K601delinsE	Different Mutation	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	V600_K601delinsE	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	V600_K601delinsE	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	V600_K601delinsE	Different Mutation	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	V600_K601delinsE	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	V600_K601delinsE	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	V600_K601delinsE	Different Mutation	BRAF inhibitor	Responsive	OV	Case report
BRAF	V600_K601delinsE	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	V600_K601delinsE	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	V600_K601delinsE	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	V600_K601delinsE	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	V600_K601delinsE	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	V600_K601delinsE	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	V600_K601delinsE	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
TSC2	E1692*	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	E1692*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	E1692*	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	E1692*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	E1692*	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	E1692*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	E1692*	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
TP53	Y163H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y163H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y163H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y163H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y163H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y163H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y163H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y163H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y163H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y163H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y163H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y163H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y163H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y163H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y163H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CDKN2A	R22Lfs*4	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R22Lfs*4	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R22Lfs*4	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	R22Lfs*4	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R22Lfs*4	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R22Lfs*4	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R22Lfs*4	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R22Lfs*4	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
PDGFRA	D846Y	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	R	Pre-clinical
PDGFRA	D846Y	Complete Match	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	NCCN guidelines
PDGFRA	D846Y	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	GIST	NCCN guidelines
PDGFRA	D846Y	Complete Match	Regorafenib (Pan-kinase inhibitor)	Responsive	GIST	NCCN guidelines
PDGFRA	D846Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	CM	Pre-clinical
PDGFRA	D846Y	Different Mutation	Crenolanib (FLT3 inhibitor)	Responsive	CM	Pre-clinical
PDGFRA	D846Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	HES	Case report
PDGFRA	D846Y	Different Mutation	Crenolanib (FLT3 inhibitor)	Responsive	GIST	Early trials
PDGFRA	D846Y	Different Mutation	HSP90 inhibitor	Responsive	GIST	Pre-clinical
PDGFRA	D846Y	Different Mutation	HSP90 inhibitor (HSP90 inhibitor)	Responsive	GIST	Pre-clinical
PDGFRA	D846Y	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	GIST	Pre-clinical
PDGFRA	D846Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Late trials
PDGFRA	D846Y	Different Mutation	PDGFR inhibitor	Responsive	GIST	Early trials
PDGFRA	D846Y	Different Mutation	Sunitinib (Pan-TK inhibitor)	Resistant	GIST	Late trials
PDGFRA	D846Y	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Early trials
PDGFRA	D846Y	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	Late trials
PDGFRA	D846Y	Different Alteration	PDGFR inhibitor	No Responsive	G	Pre-clinical
PDGFRA	D846Y	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
CRLF2	P119H	Different Alteration	MTOR inhibitor	Responsive	ALL	Pre-clinical
CRLF2	P119H	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
JAK2	R803*	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
CBL	Y371H	Complete Match	JAK inhibitor	Responsive	MDPS	Pre-clinical
CBL	Y371H	Complete Match	Dasatinib (BCR-ABL inhibitor)	Responsive	MDPS	Pre-clinical
U2AF1	N38I	Complete Match	FLT3 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R290Lfs*15	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R290Lfs*15	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R290Lfs*15	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R290Lfs*15	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R290Lfs*15	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R290Lfs*15	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R290Lfs*15	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R290Lfs*15	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R290Lfs*15	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R290Lfs*15	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R290Lfs*15	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R290Lfs*15	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R290Lfs*15	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R290Lfs*15	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R290Lfs*15	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	S1085*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S1085*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S1085*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	S1085*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E1786*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1786*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1786*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E1786*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ESR1	R256*	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
TP53	R65*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R65*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R65*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R65*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R65*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R65*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R65*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R65*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R65*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R65*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R65*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R65*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R65*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R65*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R65*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	R1287Hfs*11	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1287Hfs*11	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R1287Hfs*11	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	R1287Hfs*11	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	D148Ifs*32	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	D148Ifs*32	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	D148Ifs*32	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	D148Ifs*32	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	D148Ifs*32	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	D148Ifs*32	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	D148Ifs*32	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D148Ifs*32	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D148Ifs*32	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	D148Ifs*32	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	D148Ifs*32	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	D148Ifs*32	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D148Ifs*32	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	D148Ifs*32	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D148Ifs*32	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PDGFRA	P28A	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
CDKN2A	G6Afs*20	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	G6Afs*20	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	G6Afs*20	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	G6Afs*20	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	G6Afs*20	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	G6Afs*20	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	G6Afs*20	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	G6Afs*20	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
KRAS	A146P	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	A146P	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	A146P	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	A146P	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	A146P	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	A146P	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	A146P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	A146P	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	A146P	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	A146P	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	A146P	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	A146P	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	A146P	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	A146P	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	A146P	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	A146P	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	A146P	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	A146P	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	A146P	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	A146P	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	A146P	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	A146P	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	A146P	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	A146P	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	A146P	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	A146P	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	A146P	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	A146P	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	A146P	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	A146P	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	A146P	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	A146P	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	A146P	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	A146P	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	A146P	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	A146P	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	A146P	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	A146P	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	A146P	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	A146P	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	A146P	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	A146P	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
MAP2K1	C121S	Different Mutation	MEK inhibitor	Resistant	CANCER	Pre-clinical
MAP2K1	C121S	Complete Match	MEK inhibitor	Resistant	CM	Case report
MAP2K1	C121S	Different Mutation	ERK inhibitor	Responsive	CANCER	Pre-clinical
MAP2K1	C121S	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Case report
MAP2K1	C121S	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
MAP2K1	C121S	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CANCER	Pre-clinical
MAP2K1	C121S	Different Mutation	MEK inhibitor	Resistant	CM	Case report
MAP2K1	C121S	Different Mutation	Panitumumab;Trametinib (EGFR mAb inhibitor;MEK inhibitor)	Responsive	COREAD	Case report
MAP2K1	C121S	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
MAP2K1	C121S	Different Mutation	BRAF inhibitor	Resistant	CM	Early trials
MAP2K1	C121S	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
MAP2K1	C121S	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Case report
KMT2A	R1064*	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	R1064*	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	R1064*	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	R1064*	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	R1064*	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	R1064*	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ERBB4	S1173Y	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
BRCA2	E335*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	E335*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	E335*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	E335*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	E335*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	E335*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	E335*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	E335*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	E335*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	E335*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	E335*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	E335*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	E335*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	E335*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
CDKN2A	V59Afs*56	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	V59Afs*56	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	V59Afs*56	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	V59Afs*56	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	V59Afs*56	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	V59Afs*56	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	V59Afs*56	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	V59Afs*56	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
KMT2A	Q805*	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	Q805*	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	Q805*	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	Q805*	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	Q805*	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	Q805*	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
PIK3R2	E5*	Different Mutation	MTOR inhibitor	Responsive	ED	Pre-clinical
ARID1A	G85Afs*14	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	G85Afs*14	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	G85Afs*14	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	G85Afs*14	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	C275W	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C275W	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C275W	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C275W	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C275W	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C275W	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C275W	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C275W	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C275W	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C275W	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C275W	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C275W	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C275W	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C275W	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C275W	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	Q456*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q456*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q456*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q456*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
STK11	M51Ifs*110	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	M51Ifs*110	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	M51Ifs*110	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	M51Ifs*110	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	M51Ifs*110	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	M51Ifs*110	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	M51Ifs*110	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	M51Ifs*110	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	M51Ifs*110	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	M51Ifs*110	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	M51Ifs*110	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	M51Ifs*110	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	M51Ifs*110), KRAS MUT (Q61H	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	M51Ifs*110), KRAS MUT (Q61H	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	M51Ifs*110), KRAS MUT (Q61H	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	M51Ifs*110), KRAS MUT (Q61H	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
TP53	K120N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	K120N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	K120N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	K120N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	K120N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	K120N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	K120N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K120N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K120N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	K120N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	K120N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	K120N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K120N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	K120N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K120N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RAF1	V379G	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	V379G	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	V379G	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
KMT2A	P3115R	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P3115R	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P3115R	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P3115R	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P3115R	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P3115R	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
PIK3CA	P104A	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	P104A	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	P104A	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	P104A	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	P104A	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	P104A	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	P104A	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	P104A	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	P104A	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	P104A	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	P104A	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	P104A	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	P104A	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	P104A	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
CDKN2A	A5Rfs*24	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	A5Rfs*24	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	A5Rfs*24	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	A5Rfs*24	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	A5Rfs*24	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	A5Rfs*24	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	A5Rfs*24	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	A5Rfs*24	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
BCOR	Q156*	Complete Match	Enzastaurin (PKCb inhibitor)	Responsive	ST	Pre-clinical
FGFR2	F7V	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	F7V	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
ALK	G156R	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	G156R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	G156R	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	G156R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	G156R	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	G156R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G156R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	G156R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G156R	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G156R	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	G156R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	G156R	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	G156R	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	G156R	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	G156R	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	G156R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	G156R	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	G156R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G156R	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
STK11	K146*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	K146*	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	K146*	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	K146*	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	K146*	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	K146*	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	K146*	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	K146*	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	K146*	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	K146*	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	K146*	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	K146*	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
PIK3CA	Q546H	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	Q546H	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	Q546H	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	Q546H	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	Q546H	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	Q546H	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	Q546H	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	Q546H	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	Q546H	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	Q546H	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	Q546H	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	Q546H	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	Q546H	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	Q546H	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
EGFR	splice_acceptor_variant	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	splice_acceptor_variant	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
FGFR2	R255G	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	R255G	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
RNF43	C451*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
BRD4	R1331W	Different Alteration	BET inhibitor	Responsive	NMC	Case report
RET	R813Q	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R813Q	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R813Q	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R813Q	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R813Q	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R813Q	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R813Q	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R813Q	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R813Q	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ERBB4	R106H	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
TP53	M160Ifs*6	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	M160Ifs*6	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	M160Ifs*6	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	M160Ifs*6	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	M160Ifs*6	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	M160Ifs*6	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M160Ifs*6	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M160Ifs*6	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M160Ifs*6	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	M160Ifs*6	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	M160Ifs*6	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	M160Ifs*6	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M160Ifs*6	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	M160Ifs*6	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M160Ifs*6	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T155_R156delinsNC	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T155_R156delinsNC	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T155_R156delinsNC	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T155_R156delinsNC	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T155_R156delinsNC	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T155_R156delinsNC	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T155_R156delinsNC	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T155_R156delinsNC	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T155_R156delinsNC	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T155_R156delinsNC	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T155_R156delinsNC	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T155_R156delinsNC	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T155_R156delinsNC	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T155_R156delinsNC	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T155_R156delinsNC	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	R189C	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	R189C	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	R189C	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	R189C	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R189C	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	R189C	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	R189C	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R189C	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	R189C	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
BRCA2	Y1672*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	Y1672*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Y1672*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	Y1672*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	Y1672*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	Y1672*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	Y1672*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	Y1672*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Y1672*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Y1672*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Y1672*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Y1672*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	Y1672*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Y1672*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
RAF1	F240V	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	F240V	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	F240V	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
ALK	D70E	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	D70E	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	D70E	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	D70E	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	D70E	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	D70E	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	D70E	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	D70E	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	D70E	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	D70E	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	D70E	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	D70E	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	D70E	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	D70E	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	D70E	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	D70E	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	D70E	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	D70E	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	D70E	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
BRD4	A1268V	Different Alteration	BET inhibitor	Responsive	NMC	Case report
ALK	Q778K	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q778K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	Q778K	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	Q778K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	Q778K	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	Q778K	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	Q778K	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	Q778K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	Q778K	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	Q778K	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	Q778K	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	Q778K	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	Q778K	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q778K	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q778K	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	Q778K	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	Q778K	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	Q778K	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	Q778K	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
SMARCA4	Q555*	Complete Match	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	Q555*	Complete Match	AURKA inhibitor	Responsive	NSCLC	Pre-clinical
SMARCA4	Q555*	Complete Match	EZH2 inhibitor	Responsive	OV	Case report
SMARCA4	Q555*	Different Alteration	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	Q555*	Different Alteration	EZH2 inhibitor	Responsive	OV	Case report
MET	N635S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
TP53	I255S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I255S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I255S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I255S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I255S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I255S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I255S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I255S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I255S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I255S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I255S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I255S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I255S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I255S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I255S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PIK3CA	Q546P	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	Q546P	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	Q546P	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	Q546P	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	Q546P	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	Q546P	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	Q546P	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	Q546P	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	Q546P	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	Q546P	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	Q546P	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	Q546P	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	Q546P	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	Q546P	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
ROS1	W215G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	W215G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	W215G	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	W215G	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	W215G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ERBB4	V226I	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
APC	S104*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
KMT2D	Q1717*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
FBXW7	R479*	Complete Match	Steroid	Responsive	ALL	Late trials
FBXW7	R479*	Complete Match	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
FBXW7	R479*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	COREAD	Pre-clinical
FBXW7	R479*	Different Alteration	Tubulin inhibitor	Resistant	CANCER	Pre-clinical
NF1	R440*	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NF1	R440*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	HNC	Case report
NF1	R440*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	R440*	Complete Match	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	R440*	Complete Match	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NF1	R440*	Complete Match	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	R440*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	R440*	Complete Match	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	R440*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	NF	Late trials
NF1	R440*	Complete Match	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	R440*	Complete Match	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	R440*	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	MPN, PLEN	Pre-clinical
NF1	R440*	Complete Match	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	R440*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	HNC, SG	Case report
NF1	R440*	Complete Match	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	R440*	Complete Match	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	R440*	Complete Match	MEK inhibitor	Responsive	LK, G	Pre-clinical
NF1	R440*	Complete Match	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	R440*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	R440*	Complete Match	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	R440*	Complete Match	MTOR inhibitor	Responsive	LK, G, MPN	Pre-clinical
NF1	R440*	Complete Match	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	R440*	Complete Match	Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor)	Responsive	HC	Case report
NF1	R440*	Complete Match	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	R440*	Complete Match	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	R440*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	R440*	Complete Match	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	R440*	Complete Match	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	R440*	Complete Match	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	R440*	Complete Match	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	R440*	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	R440*	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	R440*	Complete Match	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	R440*	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	R440*	Complete Match	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	R440*	Complete Match	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	R440*	Different Alteration	MTOR inhibitor	Responsive	MPN, G, LK	Pre-clinical
NF1	R440*	Different Alteration	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	R440*	Different Alteration	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	R440*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	R440*	Different Alteration	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	R440*	Different Alteration	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	R440*	Different Alteration	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	R440*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	R440*	Different Alteration	MEK inhibitor	Responsive	G, LK	Pre-clinical
NF1	R440*	Different Alteration	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	R440*	Different Alteration	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	R440*	Different Alteration	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	R440*	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	R440*	Different Alteration	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	R440*	Different Alteration	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	R440*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	R440*	Different Alteration	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	R440*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SG, HNC	Case report
NF1	R440*	Different Alteration	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	R440*	Different Alteration	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	R440*	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	R440*	Different Alteration	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	R440*	Different Alteration	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	R440*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	R440*	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	PLEN, MPN	Pre-clinical
NF1	R440*	Different Alteration	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	R440*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	R440*	Different Alteration	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	R440*	Different Alteration	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	R440*	Different Alteration	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	R440*	Different Alteration	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	R440*	Different Alteration	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NOTCH1	S2471L	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	S2471L	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ALK	D305N	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	D305N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	D305N	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	D305N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	D305N	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	D305N	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	D305N	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	D305N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	D305N	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	D305N	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	D305N	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	D305N	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	D305N	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	D305N	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	D305N	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	D305N	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	D305N	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	D305N	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	D305N	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
MET	A837V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
KMT2A	K1000I	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	K1000I	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	K1000I	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	K1000I	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	K1000I	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	K1000I	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
BAP1	Q483*	Complete Match	EZH2 inhibitor	Responsive	MESO	Pre-clinical
BAP1	Q483*	Complete Match	PARP inhibitor	Responsive	R, CANCER	Pre-clinical
BAP1	Q483*	Complete Match	HDAC inhibitor	Responsive	CM	Pre-clinical
BAP1	Q483*	Different Alteration	PARP inhibitor	Responsive	CANCER, R	Pre-clinical
BAP1	Q483*	Different Alteration	EZH2 inhibitor	Responsive	MESO	Pre-clinical
BAP1	Q483*	Different Alteration	HDAC inhibitor	Responsive	CM	Pre-clinical
ATR	E1861*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATR	E1861*	Complete Match	Olaparib (PARP inhibitor)	Responsive	CANCER, OV	Pre-clinical
ATR	E1861*	Different Alteration	Olaparib (PARP inhibitor)	Responsive	OV, CANCER	Pre-clinical
RNF43	E66*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
ARID1A	Q507*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q507*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q507*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q507*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
RAF1	E286K	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	E286K	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	E286K	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
NTRK1	R686C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R686C	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R686C	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R686C	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
ABL1	L69V	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	L69V	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	L69V	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	L69V	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	L69V	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	L69V	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
TP53	I232T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I232T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I232T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I232T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I232T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I232T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I232T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I232T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I232T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I232T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I232T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I232T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I232T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I232T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I232T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	E1853*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1853*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1853*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E1853*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ERBB4	V986F	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
TP53	R267G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R267G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R267G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R267G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R267G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R267G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R267G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R267G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R267G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R267G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R267G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R267G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R267G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R267G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R267G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ESR1	D170E	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
NOTCH2	N1629K	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ARID1A	Q481*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q481*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q481*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q481*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
STK11	E256*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	E256*	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	E256*	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	E256*	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	E256*	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	E256*	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	E256*	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	E256*	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	E256*	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	E256*	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	E256*	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	E256*	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	E256*), KRAS MUT (Q61R	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	E256*), KRAS MUT (Q61R	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	E256*), KRAS MUT (Q61R	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	E256*), KRAS MUT (Q61R	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
ARID1A	R693), ARID1A MUT (G414	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R693), ARID1A MUT (G414	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	R693), ARID1A MUT (G414	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	R693), ARID1A MUT (G414	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
PIK3CA	Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
FAT1	C3738*	Complete Match	BET inhibitor	Responsive	HNSC	Pre-clinical
ALK	A120P	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	A120P	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	A120P	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	A120P	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	A120P	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	A120P	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A120P	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	A120P	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A120P	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A120P	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	A120P	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	A120P	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	A120P	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	A120P	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	A120P	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	A120P	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	A120P	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	A120P	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A120P	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
NTRK1	G643V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	G643V	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	G643V	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	G643V	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
PIK3CA	E545K), PIK3CA MUT (R108H	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	E545K), PIK3CA MUT (R108H	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	E545K), PIK3CA MUT (R108H	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	E545K), PIK3CA MUT (R108H	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	E545K), PIK3CA MUT (R108H	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	E545K), PIK3CA MUT (R108H	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	E545K), PIK3CA MUT (R108H	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	E545K), PIK3CA MUT (R108H	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	E545K), PIK3CA MUT (R108H	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	E545K), PIK3CA MUT (R108H	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	E545K), PIK3CA MUT (R108H	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	E545K), PIK3CA MUT (R108H	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	E545K), PIK3CA MUT (R108H	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	E545K), PIK3CA MUT (R108H	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
EGFR	R836C	Different Alteration	Cetuximab (EGFR mAb inhibitor)	Responsive	COREAD	FDA guidelines
EGFR	R836C	Different Alteration	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
EGFR	R836C	Different Mutation	Rindopepimut (Vaccine)	Responsive	GB	Late trials
EGFR	R836C	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	R836C	Different Mutation	Gefitinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	R836C	Different Mutation	HSP90 inhibitor	Responsive	L	Early trials
EGFR	R836C	Different Mutation	Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	R836C	Different Mutation	MEK inhibitor	Responsive	L	Pre-clinical
EGFR	R836C	Different Mutation	EGFR TK inhibitor	Responsive	L	Late trials
EGFR	R836C	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	NCCN guidelines
EGFR	R836C	Different Mutation	Osimertinib (EGFR inhibitor)	Resistant	L	Early trials
EGFR	R836C	Different Mutation	EGFR-TKI's (EGFR inhibitor)	Resistant	L	Late trials
EGFR	R836C	Different Mutation	HSP90 inhibitor	Responsive	L	Case report
EGFR	R836C	Different Mutation	EGFR inhibitor	Resistant	L	Late trials
EGFR	R836C	Different Mutation	Poziotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	R836C	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Pre-clinical
EGFR	R836C	Different Mutation	HSP90 inhibitor (HSP90 inhibitor)	Responsive	L	Early trials
EGFR	R836C	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	G	Pre-clinical
EGFR	R836C	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	R836C	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	R836C	Different Mutation	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
EGFR	R836C	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Responsive	COREAD	Case report
EGFR	R836C	Different Mutation	novel EGFR mAb inhibitor	Responsive	COREAD	Early trials
EGFR	R836C	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	R836C	Different Mutation	Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor)	Responsive	HNC	Case report
EGFR	R836C	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	R836C	Different Mutation	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Case report
EGFR	R836C	Different Mutation	EGFR inhibitor	Responsive	L	Early trials
EGFR	R836C	Different Mutation	Erlotinib (EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	R836C	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	R836C	Different Mutation	EGFR inhibitor	Responsive	NSCLC	Late trials
EGFR	R836C	Different Mutation	Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	R836C	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	R836C	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	R836C	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	L	Late trials
EGFR	R836C	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Pre-clinical
EGFR	R836C	Different Mutation	Erlotinib (EGFR inhibitor)	No Responsive	L	Case report
EGFR	R836C	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	ED	Case report
EGFR	R836C	Different Mutation	EGFR inhibitor	No Responsive	G	Early trials
EGFR	R836C	Different Mutation	EGFR inhibitor	Resistant	NSCLC	Case report
EGFR	R836C	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	R836C	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant;Resistant	COREAD	Pre-clinical;Case report
EGFR	R836C	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Responsive	HNC	Case report
EGFR	R836C	Different Alteration	Gefitinib (EGFR inhibitor)	Responsive	ED	Late trials
EGFR	R836C	Different Alteration	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Early trials
EGFR	R836C	Different Alteration	EGFR inhibitor	Responsive	HNSC	Case report
EGFR	R836C	Different Alteration	EGFR inhibitor	No Responsive	G	Early trials
EGFR	R836C	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	L	Early trials
EGFR	R836C	Different Alteration	EGFR mAb inhibitor	Responsive	COREAD	Late trials
EGFR	R836C	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	R836C	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
JAK2	I973S	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
SMARCB1	R201*	Complete Match	HDAC inhibitor	Responsive	MRT	Pre-clinical
SMARCB1	R201*	Complete Match	EZH2 inhibitor	Responsive	MRT	Case report
SMARCB1	R201*	Different Alteration	EZH2 inhibitor	Responsive	MRT	Case report
PIK3CA	V344A	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	V344A	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	V344A	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	V344A	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	V344A	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	V344A	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	V344A	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	V344A	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	V344A	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	V344A	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	V344A	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	V344A	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	V344A	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	V344A	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
RET	splice_donor_variant), RET MUT* (T244A	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	splice_donor_variant), RET MUT* (T244A	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	splice_donor_variant), RET MUT* (T244A	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	splice_donor_variant), RET MUT* (T244A	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	splice_donor_variant), RET MUT* (T244A	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	splice_donor_variant), RET MUT* (T244A	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	splice_donor_variant), RET MUT* (T244A	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	splice_donor_variant), RET MUT* (T244A	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	splice_donor_variant), RET MUT* (T244A	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
MSH2	R621*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
MSH2	R621*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
APC	R283*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
TP53	K351*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	K351*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	K351*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	K351*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	K351*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	K351*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	K351*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K351*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K351*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	K351*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	K351*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	K351*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K351*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	K351*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K351*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	N1800D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	N1800D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	N1800D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	N1800D	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	N1800D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
KMT2A	G3318D	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	G3318D	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	G3318D	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	G3318D	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	G3318D	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	G3318D	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
AKT3	D188D	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61_E62delinsRK	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61_E62delinsRK	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	Q61_E62delinsRK	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	Q61_E62delinsRK	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	Q61_E62delinsRK	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	Q61_E62delinsRK	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61_E62delinsRK	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	Q61_E62delinsRK	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	Q61_E62delinsRK	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	Q61_E62delinsRK	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	Q61_E62delinsRK	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	Q61_E62delinsRK	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61_E62delinsRK	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	Q61_E62delinsRK	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61_E62delinsRK	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	Q61_E62delinsRK	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	Q61_E62delinsRK	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	Q61_E62delinsRK	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	Q61_E62delinsRK	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	Q61_E62delinsRK	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61_E62delinsRK	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	Q61_E62delinsRK	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	Q61_E62delinsRK	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	Q61_E62delinsRK	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
ALK	A29T	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	A29T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	A29T	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	A29T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	A29T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	A29T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A29T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	A29T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	A29T	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A29T	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	A29T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	A29T	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	A29T	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	A29T	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	A29T	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	A29T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	A29T	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	A29T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	A29T	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
FGFR2	R251*	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	R251*	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
TP53	R337C), TP53 MUT (R181C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R337C), TP53 MUT (R181C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R337C), TP53 MUT (R181C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R337C), TP53 MUT (R181C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R337C), TP53 MUT (R181C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R337C), TP53 MUT (R181C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R337C), TP53 MUT (R181C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R337C), TP53 MUT (R181C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R337C), TP53 MUT (R181C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R337C), TP53 MUT (R181C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R337C), TP53 MUT (R181C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R337C), TP53 MUT (R181C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R337C), TP53 MUT (R181C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R337C), TP53 MUT (R181C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R337C), TP53 MUT (R181C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2D	R4904*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12D), KRAS MUT (K117R	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12D), KRAS MUT (K117R	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (K117R	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12D), KRAS MUT (K117R	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12D), KRAS MUT (K117R	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12D), KRAS MUT (K117R	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12D), KRAS MUT (K117R	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12D), KRAS MUT (K117R	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12D), KRAS MUT (K117R	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (K117R	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12D), KRAS MUT (K117R	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (K117R	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12D), KRAS MUT (K117R	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (K117R	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12D), KRAS MUT (K117R	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12D), KRAS MUT (K117R	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12D), KRAS MUT (K117R	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12D), KRAS MUT (K117R	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12D), KRAS MUT (K117R	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12D), KRAS MUT (K117R	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
JAK2	V63A	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
PTEN	Q298E	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Q298E	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Q298E	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	Q298E	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	Q298E	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	Q298E	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Q298E	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Q298E	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	Q298E	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	Q298E	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Q298E	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Q298E	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	Q298E	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Q298E	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	Q298E	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Q298E	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	Q298E	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Q298E	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Q298E	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	Q298E	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Q298E	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Q298E	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Q298E	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	Q298E	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Q298E	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PIK3CA	R93Q	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	R93Q	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	R93Q	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	R93Q	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	R93Q	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	R93Q	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	R93Q	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	R93Q	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	R93Q	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	R93Q	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	R93Q	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	R93Q	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	R93Q	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	R93Q	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
ROS1	D2055G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	D2055G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	D2055G	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	D2055G	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	D2055G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
NOTCH1	R1211Q	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1211Q	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
RET	I788M	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	I788M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	I788M	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	I788M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	I788M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	I788M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	I788M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	I788M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	I788M	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
NOTCH2	S2162F	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
KMT2A	K895R	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	K895R	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	K895R	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	K895R	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	K895R	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	K895R	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NOTCH2	V1759A	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
JAK2	E965G	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
PDGFRA	R822C	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	R	Pre-clinical
PDGFRA	R822C	Complete Match	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	NCCN guidelines
PDGFRA	R822C	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	GIST	NCCN guidelines
PDGFRA	R822C	Complete Match	Regorafenib (Pan-kinase inhibitor)	Responsive	GIST	NCCN guidelines
PDGFRA	R822C	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	CM	Pre-clinical
PDGFRA	R822C	Different Mutation	Crenolanib (FLT3 inhibitor)	Responsive	CM	Pre-clinical
PDGFRA	R822C	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	HES	Case report
PDGFRA	R822C	Different Mutation	Crenolanib (FLT3 inhibitor)	Responsive	GIST	Early trials
PDGFRA	R822C	Different Mutation	HSP90 inhibitor	Responsive	GIST	Pre-clinical
PDGFRA	R822C	Different Mutation	HSP90 inhibitor (HSP90 inhibitor)	Responsive	GIST	Pre-clinical
PDGFRA	R822C	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	GIST	Pre-clinical
PDGFRA	R822C	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Late trials
PDGFRA	R822C	Different Mutation	PDGFR inhibitor	Responsive	GIST	Early trials
PDGFRA	R822C	Different Mutation	Sunitinib (Pan-TK inhibitor)	Resistant	GIST	Late trials
PDGFRA	R822C	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Early trials
PDGFRA	R822C	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	Late trials
PDGFRA	R822C	Different Alteration	PDGFR inhibitor	No Responsive	G	Pre-clinical
PDGFRA	R822C	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
FGFR3	Y770N), FGFR3 MUT* (Y337N), FGFR3 MUT* (G295D	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	Y770N), FGFR3 MUT* (Y337N), FGFR3 MUT* (G295D	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	Y770N), FGFR3 MUT* (Y337N), FGFR3 MUT* (G295D	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
NOTCH1	Q1037E), NOTCH1 MUT* (P1367L	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	Q1037E), NOTCH1 MUT* (P1367L	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BCR	A226V	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
BCR	A226V	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
BCR	A226V	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	A226V	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	A226V	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
BCR	A226V	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
BRCA2	R2659K	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	R2659K	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	R2659K	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	R2659K	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	R2659K	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	R2659K	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	R2659K	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	R2659K	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	R2659K	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	R2659K	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	R2659K	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	R2659K	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	R2659K	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	R2659K	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
NOTCH1	D528Y	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	D528Y	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
TP53	C141Pfs*4	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C141Pfs*4	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C141Pfs*4	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C141Pfs*4	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C141Pfs*4	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C141Pfs*4	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C141Pfs*4	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141Pfs*4	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141Pfs*4	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C141Pfs*4	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C141Pfs*4	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C141Pfs*4	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141Pfs*4	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C141Pfs*4	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141Pfs*4	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	H582Q	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ROS1	R560H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	R560H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	R560H	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	R560H	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	R560H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ALK	R188C	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	R188C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	R188C	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	R188C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	R188C	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	R188C	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R188C	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	R188C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R188C	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R188C	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	R188C	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	R188C	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	R188C	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	R188C	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	R188C	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	R188C	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	R188C	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	R188C	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R188C	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ESR1	T76S	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
ARID1A	S1828*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S1828*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S1828*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	S1828*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
EGFR	L25P	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	L25P	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
BRCA1	R71G	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA1	R71G	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA1	R71G	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA1	R71G	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	R71G	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	R71G	Complete Match	WEE1 inhibitor	Responsive	CANCER	Case report
BRCA1	R71G	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA1	R71G	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA1	R71G	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	R71G	Complete Match	PARP inhibitor	Responsive	PA	Case report
BRCA1	R71G	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	R71G	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
ROS1	T1735M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	T1735M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	T1735M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	T1735M	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	T1735M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ARID1A	Q1145*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1145*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q1145*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q1145*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y234D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Y234D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Y234D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Y234D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Y234D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Y234D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Y234D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y234D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Y234D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Y234D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Y234D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Y234D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y234D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Y234D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Y234D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
AKT3	A300T	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
KMT2A	I1870T	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	I1870T	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	I1870T	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	I1870T	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	I1870T	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	I1870T	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ERBB4	R393W	Complete Match	Lapatinib (ERBB2 inhibitor)	Responsive	CM	Pre-clinical
ERBB4	R393W	Different Mutation	ERBB2 inhibitor	Resistant	BRCA	Case report
ERBB4	R393W	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
NOTCH1	P2377L	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	P2377L	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
KMT2A	G28W	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	G28W	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	G28W	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	G28W	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	G28W	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	G28W	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
TP53	G279R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G279R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G279R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G279R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G279R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G279R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G279R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G279R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G279R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G279R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G279R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G279R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G279R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G279R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G279R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ESR1	H216R	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
NOTCH1	N1489S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	N1489S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH2	D333Y	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	C2308W	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	C2308W	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NRG1	splice_acceptor_variant	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	splice_acceptor_variant	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
FGFR3	P460L	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	P460L	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	P460L	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
PALB2	splice_donor_variant	Complete Match	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	splice_donor_variant	Complete Match	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	splice_donor_variant	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
PALB2	splice_donor_variant	Complete Match	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	splice_donor_variant	Different Alteration	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	splice_donor_variant	Different Alteration	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	splice_donor_variant	Different Alteration	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	splice_donor_variant	Different Alteration	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
NOTCH1	S2491Y	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	S2491Y	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRCA2	K3019*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	K3019*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	K3019*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	K3019*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	K3019*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	K3019*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	K3019*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	K3019*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	K3019*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	K3019*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	K3019*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	K3019*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	K3019*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	K3019*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
EGFR	S1130G	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	S1130G	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
ABL1	D748V	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	D748V	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	D748V	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	D748V	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	D748V	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	D748V	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
STK11	Q159*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	Q159*	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	Q159*	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	Q159*	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	Q159*	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	Q159*	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Q159*	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Q159*	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	Q159*	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	Q159*	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	Q159*	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Q159*	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Q159*), KRAS MUT (G12V	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	Q159*), KRAS MUT (G12V	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	Q159*), KRAS MUT (G12V	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	Q159*), KRAS MUT (G12V	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
NOTCH1	V1829M	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	V1829M	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
RET	L1018F	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	L1018F	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	L1018F	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	L1018F	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	L1018F	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	L1018F	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	L1018F	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	L1018F	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	L1018F	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
BCR	D936E	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
BCR	D936E	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
BCR	D936E	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	D936E	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	D936E	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
BCR	D936E	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
TP53	R282W), TP53 MUT (K164E	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R282W), TP53 MUT (K164E	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R282W), TP53 MUT (K164E	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R282W), TP53 MUT (K164E	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R282W), TP53 MUT (K164E	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R282W), TP53 MUT (K164E	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R282W), TP53 MUT (K164E	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R282W), TP53 MUT (K164E	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R282W), TP53 MUT (K164E	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R282W), TP53 MUT (K164E	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R282W), TP53 MUT (K164E	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R282W), TP53 MUT (K164E	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R282W), TP53 MUT (K164E	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R282W), TP53 MUT (K164E	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R282W), TP53 MUT (K164E	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
RET	G938D	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	G938D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	G938D	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	G938D	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	G938D	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	G938D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	G938D	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	G938D	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	G938D	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
TP53	K101*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	K101*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	K101*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	K101*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	K101*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	K101*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	K101*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K101*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K101*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	K101*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	K101*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	K101*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K101*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	K101*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K101*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2A	S2315N	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S2315N	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S2315N	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S2315N	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S2315N	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S2315N	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
SETD2	K1587*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	K1587*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
DNMT3A	S663*	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
MPL	W515R	Different Mutation	JAK inhibitor	Responsive	MDPS	Pre-clinical
TMPRSS2	3-UTRSNV	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	3-UTRSNV	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
BRAF	T212A	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	T212A	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	T212A	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	T212A	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
ROS1	P1558T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	P1558T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	P1558T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	P1558T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	P1558T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
EGFR	Y891C	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	Y891C	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
BRCA1	E1380*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA1	E1380*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA1	E1380*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA1	E1380*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	E1380*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	E1380*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Case report
BRCA1	E1380*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA1	E1380*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA1	E1380*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	E1380*	Complete Match	PARP inhibitor	Responsive	PA	Case report
BRCA1	E1380*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	E1380*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
NOTCH1	V413M	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	V413M	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ROS1	Y419H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	Y419H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	Y419H	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	Y419H	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	Y419H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ALK	R1214C	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1214C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	R1214C	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	R1214C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	R1214C	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	R1214C	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R1214C	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	R1214C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R1214C	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R1214C	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	R1214C	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	R1214C	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	R1214C	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1214C	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1214C	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	R1214C	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	R1214C	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	R1214C	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R1214C	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
BRD4	V1155M	Different Alteration	BET inhibitor	Responsive	NMC	Case report
NOTCH1	V874I	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	V874I	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
SMARCB1	splice_donor_variant	Complete Match	HDAC inhibitor	Responsive	MRT	Pre-clinical
SMARCB1	splice_donor_variant	Complete Match	EZH2 inhibitor	Responsive	MRT	Case report
SMARCB1	splice_donor_variant	Different Alteration	EZH2 inhibitor	Responsive	MRT	Case report
STK11	Y246), STK11 MUT (S240	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	PA	Case report
STK11	Y246), STK11 MUT (S240	Complete Match	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	Y246), STK11 MUT (S240	Complete Match	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	Y246), STK11 MUT (S240	Complete Match	BET inhibitor	Resistant	L	Pre-clinical
STK11	Y246), STK11 MUT (S240	Complete Match	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	Y246), STK11 MUT (S240	Complete Match	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y246), STK11 MUT (S240	Complete Match	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y246), STK11 MUT (S240	Different Alteration	MTOR inhibitor	Responsive	CANCER	Pre-clinical
STK11	Y246), STK11 MUT (S240	Different Alteration	PD1 inhibitor	Resistant	CANCER	Early trials
STK11	Y246), STK11 MUT (S240	Different Alteration	Phenformin (Anti-diabetic)	Responsive	LUAD	Pre-clinical
STK11	Y246), STK11 MUT (S240	Different Alteration	MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y246), STK11 MUT (S240	Different Alteration	SRC inhibitor;PI3K/MEK inhibitor	Responsive	LUAD	Pre-clinical
STK11	Y246), STK11 MUT (S240), KRAS MUT (G12R	Complete Match	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
STK11	Y246), STK11 MUT (S240), KRAS MUT (G12R	Complete Match	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	Y246), STK11 MUT (S240), KRAS MUT (G12R	Different Alteration	PD1 Ab inhibitor	Resistant	LUAD	Early trials
STK11	Y246), STK11 MUT (S240), KRAS MUT (G12R	Different Alteration	MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy)	Resistant	LUAD	Pre-clinical
NTRK1	R347H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R347H	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R347H	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R347H	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
FGFR3	V423L	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	V423L	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	V423L	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
ALK	P671T	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	P671T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	P671T	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	P671T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	P671T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	P671T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P671T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	P671T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	P671T	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P671T	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	P671T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	P671T	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	P671T	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	P671T	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	P671T	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	P671T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	P671T	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	P671T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	P671T	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
RET	G748D	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	G748D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	G748D	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	G748D	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	G748D	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	G748D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	G748D	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	G748D	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	G748D	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
RAF1	R318Q	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	R318Q	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	R318Q	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
NOTCH2	P2274S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
MAP2K1	D67N	Complete Match	MEK inhibitor	Resistant	CANCER	Pre-clinical
MAP2K1	D67N	Different Mutation	MEK inhibitor	Resistant	CM	Case report
MAP2K1	D67N	Different Mutation	ERK inhibitor	Responsive	CANCER	Pre-clinical
MAP2K1	D67N	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Case report
MAP2K1	D67N	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
MAP2K1	D67N	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CANCER	Pre-clinical
MAP2K1	D67N	Different Mutation	Panitumumab;Trametinib (EGFR mAb inhibitor;MEK inhibitor)	Responsive	COREAD	Case report
MAP2K1	D67N	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
MAP2K1	D67N	Different Mutation	BRAF inhibitor	Resistant	CM	Early trials
MAP2K1	D67N	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
MAP2K1	D67N	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Case report
KMT2A	R160*	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	R160*	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	R160*	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	R160*	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	R160*	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	R160*	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NOTCH1	C182Y	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	C182Y	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRAF	K601E	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	K601E	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	K601E	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	NCCN guidelines
BRAF	K601E	Different Mutation	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	K601E	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	K601E	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	K601E	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	K601E	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	K601E	Different Mutation	ERK inhibitor	Responsive	HNSC, BT	Case report
BRAF	K601E	Different Mutation	EGFR TK inhibitor	Resistant	LUAD	Case report
BRAF	K601E	Different Mutation	MEK inhibitor	Responsive	CM	Case report
BRAF	K601E	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	K601E	Different Mutation	BRAF inhibitor	Responsive	CM	Case report
BRAF	K601E	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	K601E	Different Mutation	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	K601E	Different Mutation	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	K601E	Different Mutation	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	K601E	Different Mutation	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	K601E	Different Mutation	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	K601E	Different Mutation	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	K601E	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	K601E	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	K601E	Different Mutation	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	K601E	Different Mutation	BRAF inhibitor;HSP90 inhibitor	Responsive	CM	Pre-clinical
BRAF	K601E	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	K601E	Different Mutation	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	K601E	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	K601E	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	K601E	Different Mutation	MEK inhibitor	Responsive	TH	Early trials
BRAF	K601E	Different Mutation	BRAF inhibitor;PI3K pathway inhibitor	Responsive	CM	Pre-clinical
BRAF	K601E	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	K601E	Different Mutation	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	K601E	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	K601E	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	K601E	Different Mutation	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	K601E	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	K601E	Different Mutation	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	K601E	Different Mutation	BRAF inhibitor;CDK2/4 inhibitor	Responsive	CM	Pre-clinical
BRAF	K601E	Different Mutation	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	K601E	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	K601E	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	K601E	Different Mutation	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	K601E	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	K601E	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	K601E	Different Mutation	BRAF inhibitor	Responsive	OV	Case report
BRAF	K601E	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	K601E	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	K601E	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	K601E	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	K601E	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	K601E	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	K601E	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
MAP2K1	D67N), BRAF MUT (K601E	Different Mutation	BRAF inhibitor	Responsive	CM	Case report
ABL1	G829S	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	G829S	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G829S	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	G829S	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	G829S	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	G829S	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
APC	S89*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
PDGFRA	H966R	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
KMT2A	S2256G	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S2256G	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S2256G	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S2256G	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S2256G	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S2256G	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
RET	A325T	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	A325T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	A325T	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	A325T	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	A325T	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	A325T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	A325T	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	A325T	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	A325T	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ROS1	H62N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	H62N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	H62N	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	H62N	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	H62N	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
KMT2A	S1277L	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S1277L	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S1277L	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S1277L	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S1277L	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S1277L	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
LRP1B	R1632*	Complete Match	Liposomal Doxorubicin (Chemotherapy)	Resistant	OV	Early trials
LRP1B	R1632*	Different Alteration	Liposomal Doxorubicin (Chemotherapy)	Resistant	OV	Early trials
TP53	R213P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R213P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R213P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R213P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R213P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R213P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R213P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R213P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R213P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R213P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R213P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R213P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R213P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R213P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R213P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ARID1A	Q479*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q479*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q479*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q479*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ABL1	R1084Q	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	R1084Q	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R1084Q	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	R1084Q	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R1084Q	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	R1084Q	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ROS1	F1807L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	F1807L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	F1807L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	F1807L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	F1807L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
NOTCH2	R2047G	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
KMT2A	Y1622S	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	Y1622S	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	Y1622S	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	Y1622S	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	Y1622S	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	Y1622S	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
TP53	G279E	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G279E	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G279E	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G279E	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G279E	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G279E	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G279E	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G279E	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G279E	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G279E	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G279E	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G279E	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G279E	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G279E	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G279E	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	K658E	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	K658E	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BCR	M1083T	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
BCR	M1083T	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
BCR	M1083T	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	M1083T	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	M1083T	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
BCR	M1083T	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
JAK2	P97S	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
RAF1	I32V	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	I32V	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	I32V	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
PDGFRA	R585G	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
PALB2	E159*	Complete Match	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	E159*	Complete Match	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	E159*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
PALB2	E159*	Complete Match	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	E159*	Different Alteration	PARP inhibitor	Responsive	PRAD	Early trials
PALB2	E159*	Different Alteration	PARP inhibitor	Responsive	PA	Pre-clinical
PALB2	E159*	Different Alteration	Mytomycin C (Chemotherapy)	Responsive	PA	Case report
PALB2	E159*	Different Alteration	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRAF	L597R	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	L597R	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	L597R	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	NCCN guidelines
BRAF	L597R	Different Mutation	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	L597R	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	L597R	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	L597R	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	L597R	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	L597R	Different Mutation	ERK inhibitor	Responsive	HNSC, BT	Case report
BRAF	L597R	Different Mutation	EGFR TK inhibitor	Resistant	LUAD	Case report
BRAF	L597R	Complete Match	MEK inhibitor	Responsive	CM	Case report
BRAF	L597R	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	L597R	Complete Match	BRAF inhibitor	Responsive	CM	Case report
BRAF	L597R	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	L597R	Different Mutation	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	L597R	Different Mutation	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	L597R	Different Mutation	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	L597R	Different Mutation	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	L597R	Different Mutation	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	L597R	Different Mutation	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	L597R	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	L597R	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	L597R	Different Mutation	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	L597R	Different Mutation	BRAF inhibitor;HSP90 inhibitor	Responsive	CM	Pre-clinical
BRAF	L597R	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	L597R	Different Mutation	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	L597R	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	L597R	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	L597R	Different Mutation	MEK inhibitor	Responsive	TH	Early trials
BRAF	L597R	Different Mutation	BRAF inhibitor;PI3K pathway inhibitor	Responsive	CM	Pre-clinical
BRAF	L597R	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	L597R	Different Mutation	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	L597R	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	L597R	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	L597R	Different Mutation	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	L597R	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	L597R	Different Mutation	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	L597R	Different Mutation	BRAF inhibitor;CDK2/4 inhibitor	Responsive	CM	Pre-clinical
BRAF	L597R	Different Mutation	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	L597R	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	L597R	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	L597R	Different Mutation	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	L597R	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	L597R	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	L597R	Different Mutation	BRAF inhibitor	Responsive	OV	Case report
BRAF	L597R	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	L597R	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	L597R	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	L597R	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	L597R	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	L597R	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	L597R	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
ALK	Q1429R	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q1429R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	Q1429R	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	Q1429R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	Q1429R	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	Q1429R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	Q1429R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	Q1429R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	Q1429R	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	Q1429R	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	Q1429R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	Q1429R	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	Q1429R	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q1429R	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q1429R	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	Q1429R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	Q1429R	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	Q1429R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	Q1429R	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
PIK3CA	E545D	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	E545D	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	E545D	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	E545D	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	E545D	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	E545D	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	E545D	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	E545D	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	E545D	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	E545D	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	E545D	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	E545D	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	E545D	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	E545D	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
KMT2D	W1973*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
EGFR	A822T	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	A822T	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
NOTCH2	R1675H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
KMT2A	H2777R	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	H2777R	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	H2777R	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	H2777R	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	H2777R	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	H2777R	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
RET	L398V	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	L398V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	L398V	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	L398V	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	L398V	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	L398V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	L398V	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	L398V	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	L398V	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
NRG1	S514R	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	S514R	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
PDGFRA	Q323E	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
RNF43	Q305*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
ROS1	A320D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	A320D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	A320D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	A320D	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	A320D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
BRCA2	Y1655*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	Y1655*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Y1655*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	Y1655*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	Y1655*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	Y1655*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	Y1655*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	Y1655*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Y1655*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Y1655*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Y1655*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Y1655*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	Y1655*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Y1655*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
ERBB4	G660E	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
NTRK3	L378V	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	L378V	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	L378V	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
KRAS	G13R	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G13R	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G13R	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G13R	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G13R	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G13R	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G13R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G13R	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13R	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G13R	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G13R	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G13R	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G13R	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G13R	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G13R	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G13R	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G13R	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G13R	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G13R	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G13R	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13R	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G13R	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13R	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G13R	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G13R	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G13R	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G13R	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G13R	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G13R	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G13R	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G13R	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G13R	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G13R	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G13R	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13R	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G13R	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G13R	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G13R	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G13R	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G13R	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G13R	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G13R	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
IDH1	R132G	Complete Match	Venetoclax (BCL2 inhibitor)	Responsive	AML	Early trials
IDH1	R132G	Complete Match	IDH1 inhibitor	Responsive	AML	Early trials
IDH1	R132G	Complete Match	AG-120 (IDH1 inhibitor)	Responsive	G	Early trials
IDH1	R132G	Complete Match	Dasatinib (BCR-ABL inhibitor)	Responsive	CH	Early trials
IDH1	R132G	Complete Match	Ivosidenib (IDH1 inhibitor)	Responsive	AML	Early trials
IDH1	R132G	Complete Match	BCL2 inhibitor	Responsive	AML	Pre-clinical
IDH1	R132G	Complete Match	BCL2 inhibitor (BCL2 inhibitor)	Responsive	AML	Pre-clinical
IDH1	R132G	Complete Match	Dasatinib (BCR-ABL inhibitor)	Responsive	BT	Pre-clinical
IDH1	R132G	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ERBB4	Q216K	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
NOTCH1	R1598H	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1598H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ERBB4	N34S	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ALK	R860I	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	R860I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	R860I	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	R860I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	R860I	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	R860I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R860I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	R860I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R860I	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R860I	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	R860I	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	R860I	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	R860I	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	R860I	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	R860I	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	R860I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	R860I	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	R860I	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R860I	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ARID1A	Q761*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q761*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q761*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q761*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12V), KRAS MUT (G13D	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12V), KRAS MUT (G13D	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12V), KRAS MUT (G13D	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12V), KRAS MUT (G13D	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12V), KRAS MUT (G13D	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12V), KRAS MUT (G13D	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12V), KRAS MUT (G13D	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12V), KRAS MUT (G13D	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12V), KRAS MUT (G13D	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12V), KRAS MUT (G13D	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12V), KRAS MUT (G13D	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12V), KRAS MUT (G13D	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12V), KRAS MUT (G13D	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12V), KRAS MUT (G13D	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12V), KRAS MUT (G13D	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12V), KRAS MUT (G13D	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12V), KRAS MUT (G13D	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12V), KRAS MUT (G13D	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12V), KRAS MUT (G13D	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12V), KRAS MUT (G13D	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
NTRK3	T404K	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	T404K	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	T404K	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
TP53	A159V), TP53 MUT (N235S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	A159V), TP53 MUT (N235S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	A159V), TP53 MUT (N235S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	A159V), TP53 MUT (N235S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	A159V), TP53 MUT (N235S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	A159V), TP53 MUT (N235S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	A159V), TP53 MUT (N235S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A159V), TP53 MUT (N235S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A159V), TP53 MUT (N235S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	A159V), TP53 MUT (N235S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	A159V), TP53 MUT (N235S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	A159V), TP53 MUT (N235S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A159V), TP53 MUT (N235S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	A159V), TP53 MUT (N235S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A159V), TP53 MUT (N235S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH2	E1147K	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
RET	E511K	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	E511K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	E511K	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	E511K	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E511K	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E511K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	E511K	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E511K	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E511K	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
KMT2A	S3662G	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S3662G	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S3662G	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S3662G	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S3662G	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S3662G	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NOTCH2	T942A	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
PDGFRA	D423N	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
BAP1	E647*	Complete Match	EZH2 inhibitor	Responsive	MESO	Pre-clinical
BAP1	E647*	Complete Match	PARP inhibitor	Responsive	R, CANCER	Pre-clinical
BAP1	E647*	Complete Match	HDAC inhibitor	Responsive	CM	Pre-clinical
BAP1	E647*	Different Alteration	PARP inhibitor	Responsive	CANCER, R	Pre-clinical
BAP1	E647*	Different Alteration	EZH2 inhibitor	Responsive	MESO	Pre-clinical
BAP1	E647*	Different Alteration	HDAC inhibitor	Responsive	CM	Pre-clinical
SMO	A235T	Different Mutation	Vismodegib (SHH inhibitor)	Resistant	BCC	Case report
SMO	A235T	Different Mutation	Vismodegib (SHH inhibitor)	Responsive	L	Case report
SMO	A235T	Different Mutation	Vismodegib (SHH inhibitor)	Resistant	MB	Case report
KMT2A	S809F	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S809F	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S809F	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S809F	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S809F	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S809F	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
KMT2D	Q3944*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
ROS1	D1853A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	D1853A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	D1853A	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	D1853A	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	D1853A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
NOTCH1	A1742S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	A1742S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ERBB4	G1061E	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
EGFR	N528I	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	N528I	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
TP53	E285*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	E285*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	E285*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	E285*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	E285*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	E285*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	E285*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E285*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	E285*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	E285*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	E285*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	E285*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E285*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	E285*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	E285*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ALK	R806H	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	R806H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	R806H	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	R806H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	R806H	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	R806H	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R806H	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	R806H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R806H	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R806H	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	R806H	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	R806H	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	R806H	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	R806H	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	R806H	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	R806H	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	R806H	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	R806H	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R806H	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
NTRK1	L79Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	L79Q	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	L79Q	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	L79Q	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
BRAF	V487G	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	V487G	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	V487G	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	V487G	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
ATM	R2138*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R2138*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R2138*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R2138*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R2138*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R2138*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R2138*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R2138*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R2138*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R2138*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R2138*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R2138*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R2138*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
BRD4	R1290C	Different Alteration	BET inhibitor	Responsive	NMC	Case report
TP53	G266E), TP53 MUT (R306*	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G266E), TP53 MUT (R306*	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G266E), TP53 MUT (R306*	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G266E), TP53 MUT (R306*	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G266E), TP53 MUT (R306*	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G266E), TP53 MUT (R306*	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G266E), TP53 MUT (R306*	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G266E), TP53 MUT (R306*	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G266E), TP53 MUT (R306*	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G266E), TP53 MUT (R306*	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G266E), TP53 MUT (R306*	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G266E), TP53 MUT (R306*	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G266E), TP53 MUT (R306*	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G266E), TP53 MUT (R306*	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G266E), TP53 MUT (R306*	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	E2265*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	E2265*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	E2265*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	E2265*	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	E2265*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ESR1	G90D	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
ATM	R2763*), ATM MUT (CdsStartSNV	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	R2763*), ATM MUT (CdsStartSNV	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	R2763*), ATM MUT (CdsStartSNV	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	R2763*), ATM MUT (CdsStartSNV	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	R2763*), ATM MUT (CdsStartSNV	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	R2763*), ATM MUT (CdsStartSNV	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R2763*), ATM MUT (CdsStartSNV	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	R2763*), ATM MUT (CdsStartSNV	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R2763*), ATM MUT (CdsStartSNV	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	R2763*), ATM MUT (CdsStartSNV	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	R2763*), ATM MUT (CdsStartSNV	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	R2763*), ATM MUT (CdsStartSNV	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	R2763*), ATM MUT (CdsStartSNV	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
MET	A1372T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
FGFR3	R110Q	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	R110Q	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	R110Q	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
BRCA2	S2835*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	S2835*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	S2835*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	S2835*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	S2835*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	S2835*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	S2835*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	S2835*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	S2835*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	S2835*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	S2835*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	S2835*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	S2835*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	S2835*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
CDKN2A	I49S	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	I49S	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	I49S	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	I49S	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	I49S	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	I49S	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	I49S	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	I49S	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
ROS1	K689R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	K689R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	K689R	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	K689R	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	K689R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
KMT2A	K609R	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	K609R	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	K609R	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	K609R	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	K609R	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	K609R	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NTRK3	T500I	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	T500I	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	T500I	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NOTCH2	S688F	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NTRK1	P695L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	P695L	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	P695L	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	P695L	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
NOTCH1	L2081P	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	L2081P	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NTRK1	T292K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	T292K	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	T292K	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	T292K	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
CTNNB1	D32A	Different Mutation	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	D32A	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
RET	D850Y	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	D850Y	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	D850Y	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	D850Y	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	D850Y	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	D850Y	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	D850Y	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	D850Y	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	D850Y	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
BRAF	Q94K	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	Q94K	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	Q94K	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	Q94K	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
PIK3CA	N345Y	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	N345Y	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	N345Y	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	N345Y	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	N345Y	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	N345Y	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	N345Y	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	N345Y	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	N345Y	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	N345Y	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	N345Y	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	N345Y	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	N345Y	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	N345Y	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
RNF43	Q414*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
KMT2A	I2562V	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	I2562V	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	I2562V	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	I2562V	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	I2562V	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	I2562V	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ATM	Q2881*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	Q2881*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	Q2881*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	Q2881*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	Q2881*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q2881*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q2881*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	Q2881*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q2881*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	Q2881*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	Q2881*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	Q2881*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	Q2881*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
PDGFRA	P975R	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
ROS1	E1541K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	E1541K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	E1541K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	E1541K	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	E1541K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
KMT2D	Q4473*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
ALK	G1121D	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	G1121D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	G1121D	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	G1121D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	G1121D	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	G1121D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G1121D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	G1121D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G1121D	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G1121D	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	G1121D	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	G1121D	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	G1121D	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	G1121D	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	G1121D	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	G1121D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	G1121D	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	G1121D	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G1121D	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
NOTCH1	R1413H	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1413H	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ESR1	L544V	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
KMT2D	Q4262*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
KMT2A	S1910L	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	S1910L	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	S1910L	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	S1910L	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	S1910L	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	S1910L	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ATM	W156*	Different Mutation	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ATM	W156*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ATM	W156*	Complete Match	Olaparib (PARP inhibitor)	Responsive	ST, PRAD	Early trials
ATM	W156*	Complete Match	PARP inhibitor	Responsive	ST	Early trials
ATM	W156*	Complete Match	ATR inhibitor	Responsive	COREAD	Case report
ATM	W156*	Complete Match	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	W156*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATM	W156*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	W156*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
ATM	W156*	Different Alteration	DNA-PKc inhibitor	Responsive	LY	Pre-clinical
ATM	W156*	Different Alteration	PARP inhibitor	Responsive	ST	Early trials
ATM	W156*	Different Alteration	ATR inhibitor	Responsive	COREAD	Case report
ATM	W156*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
ALK	R1120R	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1120R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	R1120R	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	R1120R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	R1120R	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	R1120R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R1120R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	R1120R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R1120R	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R1120R	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	R1120R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	R1120R	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	R1120R	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1120R	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1120R	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	R1120R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	R1120R	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	R1120R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R1120R	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
MET	N796T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
ERBB4	R168Q	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
KIT	H697Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	AML	Pre-clinical
KIT	H697Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	HES, ALL, MDS, SM, ECL, MDPS, CML	FDA guidelines
KIT	H697Y	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Pre-clinical
KIT	H697Y	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Case report
KIT	H697Y	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CANCER	Pre-clinical
KIT	H697Y	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	SM	Early trials
KIT	H697Y	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Case report
KIT	H697Y	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	H697Y	Different Mutation	HSP90 inhibitor	Responsive	GIST	Early trials
KIT	H697Y	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Early trials
KIT	H697Y	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Late trials
KIT	H697Y	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	H697Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive;Responsive	CM	Late trials;NCCN guidelines
KIT	H697Y	Complete Match	Regorafenib (Pan-kinase inhibitor)	Responsive	GIST	FDA guidelines
KIT	H697Y	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Early trials
KIT	H697Y	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	CM	Late trials
KIT	H697Y	Complete Match	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	FDA guidelines
KIT	H697Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	CM	Early trials
KIT	H697Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	THYM	Case report
KIT	H697Y	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	H697Y	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	H697Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KIT	H697Y	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	THYM	Case report
KIT	H697Y	Different Mutation	HSP90 inhibitor	Responsive	GIST	Pre-clinical
KIT	H697Y	Complete Match	Sunitinib (Pan-TK inhibitor)	Responsive	THYM	Pre-clinical
KIT	H697Y	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	AML	Pre-clinical
KIT	H697Y	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	GIST	Late trials
KIT	H697Y	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	GIST	Pre-clinical
KIT	H697Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Late trials
KIT	H697Y	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive;Resistant	GIST	FDA guidelines;Pre-clinical
KIT	H697Y	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	GIST	Early trials
KIT	H697Y	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	GIST	Pre-clinical
KIT	H697Y	Different Mutation	Nilotinib (BCR-ABL inhibitor)	Responsive	CM	Case report
KIT	H697Y	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	CM	Case report
KIT	H697Y	Different Alteration	Sunitinib (Pan-TK inhibitor)	No Responsive	CM	Early trials
KIT	H697Y	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	No Responsive	CM	Early trials
ARID1A	E72*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E72*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E72*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E72*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
NOTCH2	V2221L	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12D), KRAS MUT (V14G	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (V14G	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12D), KRAS MUT (V14G	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12D), KRAS MUT (V14G	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12D), KRAS MUT (V14G	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12D), KRAS MUT (V14G	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12D), KRAS MUT (V14G	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12D), KRAS MUT (V14G	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (V14G	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12D), KRAS MUT (V14G	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (V14G	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12D), KRAS MUT (V14G	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12D), KRAS MUT (V14G	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12D), KRAS MUT (V14G	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12D), KRAS MUT (V14G	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12D), KRAS MUT (V14G	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12D), KRAS MUT (V14G	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12D), KRAS MUT (V14G	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12D), KRAS MUT (V14G	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	K164E	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	K164E	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	K164E	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	K164E	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	K164E	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	K164E	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	K164E	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K164E	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	K164E	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	K164E	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	K164E	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	K164E	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K164E	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	K164E	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	K164E	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
APC	R1687*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
ESR1	A571V	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
FAT1	splice_acceptor_variant	Complete Match	BET inhibitor	Responsive	HNSC	Pre-clinical
TP53	R158C	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R158C	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R158C	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R158C	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R158C	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R158C	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R158C	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R158C	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R158C	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R158C	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R158C	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R158C	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R158C	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R158C	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R158C	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
MET	K783E	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
HRAS	Q61R	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	CER	Pre-clinical
HRAS	Q61R	Complete Match	MEK inhibitor +/- MTOR inhibitor	Responsive	AML	Pre-clinical
HRAS	Q61R	Complete Match	MTOR inhibitor	Responsive	CESC	Pre-clinical
HRAS	Q61R	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	Responsive	CANCER	Early trials
TSC1	splice_donor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC1	splice_donor_variant	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC1	splice_donor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA	FDA guidelines
TSC1	splice_donor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	ST, S	Case report
TSC1	splice_donor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	R	Case report
TSC1	splice_donor_variant	Complete Match	Everolimus (MTOR inhibitor)	Responsive	GCA	FDA guidelines
TSC1	splice_donor_variant	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Case report
BCR	R1262G	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
BCR	R1262G	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
BCR	R1262G	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	R1262G	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	R1262G	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
BCR	R1262G	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ROS1	A1750P	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	A1750P	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	A1750P	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	A1750P	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	A1750P	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
BCR	E1079K	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
BCR	E1079K	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
BCR	E1079K	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	E1079K	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	E1079K	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
BCR	E1079K	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
NOTCH1	S1941C	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	S1941C	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
KMT2A	P3248L	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P3248L	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P3248L	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P3248L	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P3248L	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P3248L	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
FGFR3	S610Y	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	S610Y	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	S610Y	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
RAF1	S77I	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	S77I	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	S77I	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
NOTCH1	H709R), NOTCH1 MUT* (G995S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	H709R), NOTCH1 MUT* (G995S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ALK	V1023M	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	V1023M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	V1023M	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	V1023M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	V1023M	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	V1023M	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	V1023M	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	V1023M	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	V1023M	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	V1023M	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	V1023M	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	V1023M	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	V1023M	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	V1023M	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	V1023M	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	V1023M	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	V1023M	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	V1023M	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	V1023M	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ARID1A	Q920*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q920*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q920*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q920*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ALK	E1000G	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	E1000G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	E1000G	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	E1000G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	E1000G	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	E1000G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	E1000G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	E1000G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	E1000G	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	E1000G	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	E1000G	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	E1000G	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	E1000G	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	E1000G	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	E1000G	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	E1000G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	E1000G	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	E1000G	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	E1000G	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
NOTCH1	P1386L	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	P1386L	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
RAF1	R218*	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	R218*	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	R218*	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
ROS1	R863Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	R863Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	R863Q	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	R863Q	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	R863Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
FGFR2	D273D	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	D273D	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
TP53	C141F	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C141F	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C141F	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C141F	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C141F	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C141F	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C141F	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141F	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C141F	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C141F	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C141F	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C141F	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141F	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C141F	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C141F	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
DNMT3A	R771*	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
TP53	R175H), TP53 MUT (R283S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R175H), TP53 MUT (R283S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R175H), TP53 MUT (R283S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R175H), TP53 MUT (R283S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R175H), TP53 MUT (R283S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R175H), TP53 MUT (R283S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (R283S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (R283S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R175H), TP53 MUT (R283S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R175H), TP53 MUT (R283S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R175H), TP53 MUT (R283S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H), TP53 MUT (R283S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R175H), TP53 MUT (R283S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175H), TP53 MUT (R283S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NOTCH1	S225L	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	S225L	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRD4	S490S	Different Alteration	BET inhibitor	Responsive	NMC	Case report
FGFR3	R238L	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	R238L	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	R238L	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
PIK3CA	N345K	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	N345K	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	N345K	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	N345K	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	N345K	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	N345K	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	N345K	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	N345K	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	N345K	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	N345K	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	N345K	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	N345K	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	N345K	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	N345K	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
ARID1A	Q297*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q297*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q297*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q297*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
NOTCH1	N325N	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	N325N	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
AKT3	R465P	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
KMT2A	P3306T	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P3306T	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P3306T	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P3306T	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P3306T	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P3306T	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
VHL	R113P	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
AKT3	5-UTRSNV	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
ERBB2	S310Y	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	S310Y	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	S310Y	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	ST, BRCA, GEJA	FDA guidelines
ERBB2	S310Y	Different Alteration	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	S310Y	Different Alteration	MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor)	Responsive	SOLID	Early trials
ERBB2	S310Y	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	S310Y	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	S310Y	Complete Match	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER, BRCA	Pre-clinical
ERBB2	S310Y	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	CANCER	Early trials
ERBB2	S310Y	Complete Match	Neratinib (ERBB2 inhibitor)	Responsive	CANCER	Early trials
ERBB2	S310Y	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Case report
ERBB2	S310Y	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	BRCA, LUAD	Case report
ERBB2	S310Y	Different Mutation	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	L	Early trials
ERBB2	S310Y	Different Mutation	Neratinib (ERBB2 inhibitor)	Resistant	BRCA	Case report
ERBB2	S310Y	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BRCA	Pre-clinical
ERBB2	S310Y	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	LUAD	Case report
ERBB2	S310Y	Different Mutation	Lapatinib (ERBB2 inhibitor)	Resistant	BRCA	Pre-clinical
ERBB2	S310Y	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	CANCER	Pre-clinical
ERBB2	S310Y	Complete Match	Temsirolimus (MTOR inhibitor)	Responsive	LUAD	Early trials
ERBB2	S310Y	Complete Match	Dacomitinib (Pan ERBB inhibitor)	Responsive	NSCLC	Early trials
ERBB2	S310Y	Complete Match	Neratinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	S310Y	Different Mutation	ERBB2 inhibitor	Responsive	LUAD	Early trials
ERBB2	S310Y	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Early trials
ERBB2	S310Y	Different Mutation	ERBB2 mAb inhibitor	Responsive	LUAD	Early trials
ERBB2	S310Y	Different Mutation	Neratinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	S310Y	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Early trials
ERBB2	S310Y	Different Mutation	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	LUAD	Early trials
ERBB2	S310Y	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BRCA	Late trials
ERBB2	S310Y	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	BT	Early trials
ERBB2	S310Y	Different Alteration	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Responsive	COREAD	Late trials
ERBB2	S310Y	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	OV	Early trials
ERBB2	S310Y	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	BLCA	Case report
ERBB2	S310Y	Different Alteration	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Responsive	COREAD	Case report
ERBB2	S310Y	Different Alteration	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
ERBB2	S310Y	Different Alteration	Osimertinib (EGFR inhibitor)	Resistant	LUAD	Case report
ERBB2	S310Y	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	BT	Early trials
ERBB2	S310Y	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Early trials
ERBB2	S310Y	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	BT	Early trials
ERBB2	S310Y	Different Alteration	Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor)	Responsive	BRCA	Early trials
ERBB2	S310Y	Different Alteration	HER2 inhibitor;CDK4/6 inhibitor	Responsive	BRCA	Pre-clinical
ERBB2	S310Y	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	S310Y	Different Alteration	Pertuzumab (ERBB2 mAb inhibitor)	Responsive	ST	Early trials
ERBB2	S310Y	Different Alteration	Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
ERBB2	S310Y	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	ST, GEJA	FDA guidelines
ERBB2	S310Y	Different Alteration	ERBB2 inhibitor;CDK4/6 inhibitor	Responsive	BRCA	Pre-clinical
ERBB2	S310Y	Different Alteration	Ado-Trastuzumab Emtansine (EGFR mAb inhibitor)	Responsive	BRCA	FDA guidelines
ERBB2	S310Y	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	Responsive	HNC	Case report
ERBB2	S310Y	Different Alteration	Neratinib (ERBB2 inhibitor)	Responsive	BRCA	Late trials
ERBB2	S310Y	Different Alteration	Trastuzumab (ERBB2 mAb inhibitor)	No Responsive	ED	Early trials
ERBB2	S310Y	Different Alteration	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Responsive	ED	Pre-clinical
ERBB2	S310Y	Different Alteration	Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy)	Responsive	ST	Early trials
ERBB2	S310Y	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	ST	Case report
ERBB2	S310Y	Different Alteration	EGFR inhibitor	Resistant	LUAD	Pre-clinical
RNF43	E401*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
FGFR3	D758N	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	D758N	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	D758N	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
ALK	S737S	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	S737S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	S737S	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	S737S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	S737S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	S737S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	S737S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	S737S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	S737S	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	S737S	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	S737S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	S737S	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	S737S	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	S737S	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	S737S	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	S737S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	S737S	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	S737S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	S737S	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
RET	T75A	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	T75A	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	T75A	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	T75A	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	T75A	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	T75A	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	T75A	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	T75A	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	T75A	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
CDKN2A	R24P	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R24P	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R24P	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	R24P	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R24P	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R24P	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R24P	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R24P	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
VHL	R108H	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
EPHA2	splice_donor_variant	Different Mutation	MTOR inhibitor	Responsive	LUSC	Pre-clinical
EPHA2	splice_donor_variant	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUSC	Pre-clinical
EPHA2	splice_donor_variant	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	CANCER	Pre-clinical
NTRK1	R750H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R750H	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R750H	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R750H	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
ROS1	T280T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	T280T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	T280T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	T280T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	T280T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ARID1A	E1767*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1767*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	E1767*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	E1767*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
RET	N763N	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	N763N	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	N763N	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	N763N	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	N763N	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	N763N	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	N763N	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	N763N	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	N763N	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
RAF1	C637Y	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	C637Y	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	C637Y	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
MET	V1173L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
APC	E201*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
ALK	E296Q	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	E296Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	E296Q	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	E296Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	E296Q	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	E296Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	E296Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	E296Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	E296Q	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	E296Q	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	E296Q	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	E296Q	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	E296Q	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	E296Q	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	E296Q	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	E296Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	E296Q	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	E296Q	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	E296Q	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
PTEN	L25*	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	L25*	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	L25*	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	L25*	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	L25*	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	L25*	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	L25*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	L25*	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	L25*	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	L25*	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	L25*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	L25*	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	L25*	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	L25*	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	L25*	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	L25*	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	L25*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	L25*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	L25*	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	L25*	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	L25*	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	L25*	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	L25*	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	L25*	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	L25*	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
KMT2D	Q4228*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
NOTCH2	S2090T	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ROS1	G2248G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	G2248G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	G2248G	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	G2248G	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	G2248G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
FGFR3	R116H	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	R116H	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	R116H	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
MSH3	M518Ifs*18	Complete Match	DNA-PKc inhibitor	Responsive	CANCER	Pre-clinical
NTRK3	L657I	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	L657I	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	L657I	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
ALK	G1125G	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	G1125G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	G1125G	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	G1125G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	G1125G	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	G1125G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G1125G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	G1125G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G1125G	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G1125G	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	G1125G	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	G1125G	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	G1125G	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	G1125G	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	G1125G	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	G1125G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	G1125G	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	G1125G	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G1125G	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
EGFR	I1050T	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	I1050T	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
ATR	splice_donor_variant	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATR	splice_donor_variant	Complete Match	Olaparib (PARP inhibitor)	Responsive	CANCER, OV	Pre-clinical
ATR	splice_donor_variant	Different Alteration	Olaparib (PARP inhibitor)	Responsive	OV, CANCER	Pre-clinical
FGFR2	A516T	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	A516T	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
KMT2D	R5448*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
KMT2A	3-UTRSNV	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	3-UTRSNV	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	3-UTRSNV	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	3-UTRSNV	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	3-UTRSNV	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	3-UTRSNV	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
TMPRSS2	V133M	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	V133M	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
NOTCH1	T692A	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	T692A	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NRG1	S30R	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	S30R	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
RB1	S567*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	S567*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	S567*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	S567*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	S567*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	S567*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	S567*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
EGFR	A419S), EGFR MUT* (V85V	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	A419S), EGFR MUT* (V85V	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
APC	G2597*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G578G), ALK MUT* (Q1134K	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ARID1A	G660*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	G660*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	G660*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	G660*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ABL1	P684P	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	P684P	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	P684P	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	P684P	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	P684P	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	P684P	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
FAT1	G2130*	Complete Match	BET inhibitor	Responsive	HNSC	Pre-clinical
DNMT3A	E94*	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
RB1	S780*	Different Alteration	Palbociclib (CDK4/6 inhibitor)	Responsive	PRAD	Pre-clinical
RB1	S780*	Complete Match	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	S780*	Complete Match	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	S780*	Complete Match	HDAC inhibitor	Responsive	RB	Pre-clinical
RB1	S780*	Different Alteration	MDM2/MDMX inhibitor	Responsive	RB	Pre-clinical
RB1	S780*	Different Alteration	Cisplatin (Chemotherapy)	Responsive	BLCA	Early trials
RB1	S780*	Different Alteration	HDAC inhibitor	Responsive	RB	Pre-clinical
KMT2A	G2161C), MLL MUT* (A1670S), MLL MUT* (V1414V	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	G2161C), MLL MUT* (A1670S), MLL MUT* (V1414V	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	G2161C), MLL MUT* (A1670S), MLL MUT* (V1414V	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	G2161C), MLL MUT* (A1670S), MLL MUT* (V1414V	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	G2161C), MLL MUT* (A1670S), MLL MUT* (V1414V	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	G2161C), MLL MUT* (A1670S), MLL MUT* (V1414V	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NOTCH1	Q462K), NOTCH1 MUT* (Q619K), NOTCH1 MUT* (C826F), NOTCH1 MUT* (L2276L	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	Q462K), NOTCH1 MUT* (Q619K), NOTCH1 MUT* (C826F), NOTCH1 MUT* (L2276L	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRD4	A1203A	Different Alteration	BET inhibitor	Responsive	NMC	Case report
EGFR	Q581Q	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	Q581Q	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
ALK	D954H	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	D954H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	D954H	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	D954H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	D954H	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	D954H	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	D954H	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	D954H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	D954H	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	D954H	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	D954H	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	D954H	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	D954H	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	D954H	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	D954H	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	D954H	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	D954H	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	D954H	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	D954H	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
TMPRSS2	CdsStartSNV	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	CdsStartSNV	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
MAP2K1	E203K	Different Mutation	MEK inhibitor	Resistant	CANCER	Pre-clinical
MAP2K1	E203K	Different Mutation	novel MEK inhibitor	Responsive	CM	Pre-clinical
MAP2K1	E203K	Different Mutation	MEK inhibitor	Resistant	CM	Case report
MAP2K1	E203K	Different Mutation	ERK inhibitor	Responsive	CANCER	Pre-clinical
MAP2K1	E203K	Complete Match	Vemurafenib (BRAF inhibitor)	Resistant	CM	Case report
MAP2K1	E203K	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
MAP2K1	E203K	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CANCER	Pre-clinical
MAP2K1	E203K	Different Mutation	Panitumumab;Trametinib (EGFR mAb inhibitor;MEK inhibitor)	Responsive	COREAD	Case report
MAP2K1	E203K	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
MAP2K1	E203K	Different Mutation	BRAF inhibitor	Resistant	CM	Early trials
MAP2K1	E203K	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
MAP2K1	E203K	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Case report
NRG1	S157L	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	S157L	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
BRD4	P1022L	Different Alteration	BET inhibitor	Responsive	NMC	Case report
BRAF	A311T	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	A311T	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	A311T	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	A311T	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
PIK3CA	P104S	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	P104S	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	P104S	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	P104S	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	P104S	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	P104S	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	P104S	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	P104S	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	P104S	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	P104S	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	P104S	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	P104S	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	P104S	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	P104S	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
ABL1	R134H	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	R134H	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R134H	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	R134H	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	R134H	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	R134H	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
KMT2A	A1669A	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	A1669A	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	A1669A	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	A1669A	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	A1669A	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	A1669A	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ROS1	S1581S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	S1581S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	S1581S	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	S1581S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	S1581S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
MET	T440P	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
ARID1A	Y1279*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y1279*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Y1279*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Y1279*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
ROS1	R1609*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	R1609*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	R1609*	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	R1609*	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	R1609*	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
TSC2	R905Q	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	R905Q	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	R905Q	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	R905Q	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	R905Q	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	R905Q	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	R905Q	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
ROS1	E698K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	E698K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	E698K	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	E698K	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	E698K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
NOTCH1	L2242V	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	L2242V	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	P284L	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	P284L	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
LRP1B	Q2396*	Complete Match	Liposomal Doxorubicin (Chemotherapy)	Resistant	OV	Early trials
LRP1B	Q2396*	Different Alteration	Liposomal Doxorubicin (Chemotherapy)	Resistant	OV	Early trials
AKT3	L272L	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
KMT2A	H801Y	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	H801Y	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	H801Y	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	H801Y	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	H801Y	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	H801Y	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
FGFR3	A334T	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	A334T	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	A334T	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
NOTCH1	R1663R	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1663R	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BAP1	splice_acceptor_variant	Complete Match	EZH2 inhibitor	Responsive	MESO	Pre-clinical
BAP1	splice_acceptor_variant	Complete Match	PARP inhibitor	Responsive	R, CANCER	Pre-clinical
BAP1	splice_acceptor_variant	Complete Match	HDAC inhibitor	Responsive	CM	Pre-clinical
BAP1	splice_acceptor_variant	Different Alteration	PARP inhibitor	Responsive	CANCER, R	Pre-clinical
BAP1	splice_acceptor_variant	Different Alteration	EZH2 inhibitor	Responsive	MESO	Pre-clinical
BAP1	splice_acceptor_variant	Different Alteration	HDAC inhibitor	Responsive	CM	Pre-clinical
MAP2K1	F53L	Different Mutation	MEK inhibitor	Resistant	CANCER	Pre-clinical
MAP2K1	F53L	Different Mutation	novel MEK inhibitor	Responsive	CM	Pre-clinical
MAP2K1	F53L	Different Mutation	MEK inhibitor	Resistant	CM	Case report
MAP2K1	F53L	Different Mutation	ERK inhibitor	Responsive	CANCER	Pre-clinical
MAP2K1	F53L	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Case report
MAP2K1	F53L	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
MAP2K1	F53L	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CANCER	Pre-clinical
MAP2K1	F53L	Different Mutation	Panitumumab;Trametinib (EGFR mAb inhibitor;MEK inhibitor)	Responsive	COREAD	Case report
MAP2K1	F53L	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
MAP2K1	F53L	Different Mutation	BRAF inhibitor	Resistant	CM	Early trials
MAP2K1	F53L	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
MAP2K1	F53L	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Case report
BRD4	L1327L), BRD4 MUT* (A1328Pfs*20	Different Alteration	BET inhibitor	Responsive	NMC	Case report
PDGFRA	Q412E	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
NOTCH1	I2547I	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	I2547I	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
EGFR	E534K), EGFR MUT* (L267F	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	E534K), EGFR MUT* (L267F	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ABL1	F621F), ABL1 MUT* (S157N	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	F621F), ABL1 MUT* (S157N	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	F621F), ABL1 MUT* (S157N	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	F621F), ABL1 MUT* (S157N	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	F621F), ABL1 MUT* (S157N	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	F621F), ABL1 MUT* (S157N	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
JAK2	S593F), JAK2 MUT* (G2R	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
PDGFRA	D902N), PDGFRA MUT* (splice_donor_variant), PDGFRA MUT* (V594M), PDGFRA MUT* (P344S	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
POLE	splice_donor_variant	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
POLE	splice_donor_variant	Complete Match	PD1 Ab inhibitor	Responsive	COREAD	Case report
POLE	splice_donor_variant	Different Mutation	PD1 Ab inhibitor	Responsive	G, ED	Case report
POLE	splice_donor_variant	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
FGFR3	T338I), FGFR3 MUT* (E336K	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	T338I), FGFR3 MUT* (E336K	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	T338I), FGFR3 MUT* (E336K	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
RET	E991K), RET MUT* (Q857Q	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	E991K), RET MUT* (Q857Q	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	E991K), RET MUT* (Q857Q	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	E991K), RET MUT* (Q857Q	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E991K), RET MUT* (Q857Q	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	E991K), RET MUT* (Q857Q	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	E991K), RET MUT* (Q857Q	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E991K), RET MUT* (Q857Q	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	E991K), RET MUT* (Q857Q	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ROS1	E563E), ROS1 MUT* (V614I), ROS1 MUT* (L1995L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	E563E), ROS1 MUT* (V614I), ROS1 MUT* (L1995L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	E563E), ROS1 MUT* (V614I), ROS1 MUT* (L1995L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	E563E), ROS1 MUT* (V614I), ROS1 MUT* (L1995L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	E563E), ROS1 MUT* (V614I), ROS1 MUT* (L1995L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
KMT2A	P3362S), MLL MUT* (intron_variant	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P3362S), MLL MUT* (intron_variant	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P3362S), MLL MUT* (intron_variant	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P3362S), MLL MUT* (intron_variant	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P3362S), MLL MUT* (intron_variant	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P3362S), MLL MUT* (intron_variant	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NTRK3	A124V	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	A124V	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	A124V	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NOTCH1	splice_donor_variant), NOTCH1 MUT* (C788C), NOTCH1 MUT* (E843E), NOTCH1 MUT* (G925S), NOTCH1 MUT* (P1417L), NOTCH1 MUT* (R1438H), NOTCH1 MUT* (intron_variant), NOTCH1 MUT* (G1917G), NOTCH1 MUT* (T2063T	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	splice_donor_variant), NOTCH1 MUT* (C788C), NOTCH1 MUT* (E843E), NOTCH1 MUT* (G925S), NOTCH1 MUT* (P1417L), NOTCH1 MUT* (R1438H), NOTCH1 MUT* (intron_variant), NOTCH1 MUT* (G1917G), NOTCH1 MUT* (T2063T	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRD4	P1033L	Different Alteration	BET inhibitor	Responsive	NMC	Case report
NOTCH1	V1232M	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	V1232M	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
AKT3	A135A	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	R1758C	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	R1758C	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ROS1	L1508L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	L1508L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	L1508L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	L1508L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	L1508L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
NOTCH1	A1869S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	A1869S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRD4	P996T	Different Alteration	BET inhibitor	Responsive	NMC	Case report
CRLF2	A177A	Different Alteration	MTOR inhibitor	Responsive	ALL	Pre-clinical
CRLF2	A177A	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
ALK	G1123G	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	G1123G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	G1123G	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	G1123G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	G1123G	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	G1123G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G1123G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	G1123G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G1123G	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G1123G	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	G1123G	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	G1123G	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	G1123G	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	G1123G	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	G1123G	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	G1123G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	G1123G	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	G1123G	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G1123G	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
MET	N704D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
NTRK3	T93M	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	T93M	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	T93M	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
NOTCH1	V485M), NOTCH1 MUT* (T1379T	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	V485M), NOTCH1 MUT* (T1379T	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ALK	T1506T	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	T1506T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	T1506T	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	T1506T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	T1506T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	T1506T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	T1506T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	T1506T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	T1506T	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	T1506T	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	T1506T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	T1506T	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	T1506T	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	T1506T	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	T1506T	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	T1506T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	T1506T	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	T1506T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	T1506T	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
BRD4	P723A	Different Alteration	BET inhibitor	Responsive	NMC	Case report
JAK2	S797C), JAK2 MUT* (L453L	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
ERBB4	R50R	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ARID1A	S1138*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S1138*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	S1138*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	S1138*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
NRAS	Q61L	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
NRAS	Q61L	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
NRAS	Q61L	Complete Match	MEK inhibitor	Responsive	CM	Late trials
NRAS	Q61L	Complete Match	BRAF inhibitor	Resistant	CM	Early trials
NRAS	Q61L	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CM	Early trials
NRAS	Q61L	Complete Match	HSP90 inhibitor	Responsive	CM	Pre-clinical
NRAS	Q61L	Complete Match	MEK inhibitor	Responsive	AML, LUAD, ALL	Pre-clinical
NRAS	Q61L	Complete Match	Pan-RAF inhibitor	Responsive	CM	Case report
NRAS	Q61L	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
NRAS	Q61L	Complete Match	ERK inhibitor	Responsive	CM	Case report
NRAS	Q61L	Complete Match	MEK inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
NRAS	Q61L	Complete Match	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NRAS	Q61L	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	MYMA	Pre-clinical
NRAS	Q61L	Different Mutation	ERK inhibitor	Responsive	CANCER	Pre-clinical
RAF1	T303A	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	T303A	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	T303A	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
BRD4	P759P	Different Alteration	BET inhibitor	Responsive	NMC	Case report
ESR1	T594M	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
ROS1	F542L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	F542L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	F542L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	F542L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	F542L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
CDKN2A	D153Y	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	D153Y	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	D153Y	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	D153Y	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	D153Y	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	D153Y	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	D153Y	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	D153Y	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
ROS1	A99S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	A99S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	A99S	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	A99S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	A99S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
BRCA1	E848*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA1	E848*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA1	E848*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA1	E848*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	E848*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	E848*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Case report
BRCA1	E848*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA1	E848*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA1	E848*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	E848*	Complete Match	PARP inhibitor	Responsive	PA	Case report
BRCA1	E848*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	E848*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
TP53	A74Vfs*45	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	A74Vfs*45	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	A74Vfs*45	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	A74Vfs*45	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	A74Vfs*45	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	A74Vfs*45	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	A74Vfs*45	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A74Vfs*45	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	A74Vfs*45	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	A74Vfs*45	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	A74Vfs*45	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	A74Vfs*45	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A74Vfs*45	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	A74Vfs*45	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	A74Vfs*45	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
LRP1B	R3064*	Complete Match	Liposomal Doxorubicin (Chemotherapy)	Resistant	OV	Early trials
LRP1B	R3064*	Different Alteration	Liposomal Doxorubicin (Chemotherapy)	Resistant	OV	Early trials
RAF1	K375N	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	K375N	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	K375N	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
PTEN	Y346*	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y346*	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y346*	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	Y346*	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	Y346*	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	Y346*	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y346*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y346*	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	Y346*	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	Y346*	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y346*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y346*	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	Y346*	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y346*	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	Y346*	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y346*	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	Y346*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y346*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y346*	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	Y346*	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y346*	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y346*	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y346*	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	Y346*	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y346*	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
LRP1B	K3039*	Complete Match	Liposomal Doxorubicin (Chemotherapy)	Resistant	OV	Early trials
LRP1B	K3039*	Different Alteration	Liposomal Doxorubicin (Chemotherapy)	Resistant	OV	Early trials
NF1	R1968*	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NF1	R1968*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	HNC	Case report
NF1	R1968*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	R1968*	Complete Match	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	R1968*	Complete Match	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NF1	R1968*	Complete Match	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	R1968*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	R1968*	Complete Match	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	R1968*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	NF	Late trials
NF1	R1968*	Complete Match	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	R1968*	Complete Match	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	R1968*	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	MPN, PLEN	Pre-clinical
NF1	R1968*	Complete Match	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	R1968*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	HNC, SG	Case report
NF1	R1968*	Complete Match	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	R1968*	Complete Match	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	R1968*	Complete Match	MEK inhibitor	Responsive	LK, G	Pre-clinical
NF1	R1968*	Complete Match	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	R1968*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	R1968*	Complete Match	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	R1968*	Complete Match	MTOR inhibitor	Responsive	LK, G, MPN	Pre-clinical
NF1	R1968*	Complete Match	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	R1968*	Complete Match	Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor)	Responsive	HC	Case report
NF1	R1968*	Complete Match	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	R1968*	Complete Match	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	R1968*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	R1968*	Complete Match	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	R1968*	Complete Match	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	R1968*	Complete Match	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	R1968*	Complete Match	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	R1968*	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	R1968*	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	R1968*	Complete Match	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	R1968*	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	R1968*	Complete Match	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	R1968*	Complete Match	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	R1968*	Different Alteration	MTOR inhibitor	Responsive	MPN, G, LK	Pre-clinical
NF1	R1968*	Different Alteration	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	R1968*	Different Alteration	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	R1968*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	R1968*	Different Alteration	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	R1968*	Different Alteration	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	R1968*	Different Alteration	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	R1968*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	R1968*	Different Alteration	MEK inhibitor	Responsive	G, LK	Pre-clinical
NF1	R1968*	Different Alteration	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	R1968*	Different Alteration	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	R1968*	Different Alteration	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	R1968*	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	R1968*	Different Alteration	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	R1968*	Different Alteration	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	R1968*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	R1968*	Different Alteration	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	R1968*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SG, HNC	Case report
NF1	R1968*	Different Alteration	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	R1968*	Different Alteration	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	R1968*	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	R1968*	Different Alteration	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	R1968*	Different Alteration	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	R1968*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	R1968*	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	PLEN, MPN	Pre-clinical
NF1	R1968*	Different Alteration	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	R1968*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	R1968*	Different Alteration	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	R1968*	Different Alteration	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	R1968*	Different Alteration	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	R1968*	Different Alteration	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	R1968*	Different Alteration	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
FGFR3	P300S	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	P300S	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	P300S	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
EGFR	R108K	Different Alteration	Cetuximab (EGFR mAb inhibitor)	Responsive	COREAD	FDA guidelines
EGFR	R108K	Different Alteration	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
EGFR	R108K	Different Mutation	Rindopepimut (Vaccine)	Responsive	GB	Late trials
EGFR	R108K	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	R108K	Different Mutation	Gefitinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	R108K	Different Mutation	HSP90 inhibitor	Responsive	L	Early trials
EGFR	R108K	Different Mutation	Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	R108K	Different Mutation	MEK inhibitor	Responsive	L	Pre-clinical
EGFR	R108K	Different Mutation	EGFR TK inhibitor	Responsive	L	Late trials
EGFR	R108K	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	NCCN guidelines
EGFR	R108K	Different Mutation	Osimertinib (EGFR inhibitor)	Resistant	L	Early trials
EGFR	R108K	Different Mutation	EGFR-TKI's (EGFR inhibitor)	Resistant	L	Late trials
EGFR	R108K	Different Mutation	HSP90 inhibitor	Responsive	L	Case report
EGFR	R108K	Different Mutation	EGFR inhibitor	Resistant	L	Late trials
EGFR	R108K	Different Mutation	Poziotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	R108K	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Pre-clinical
EGFR	R108K	Different Mutation	HSP90 inhibitor (HSP90 inhibitor)	Responsive	L	Early trials
EGFR	R108K	Complete Match	Erlotinib (EGFR inhibitor)	Responsive	G	Pre-clinical
EGFR	R108K	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	R108K	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	R108K	Different Mutation	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
EGFR	R108K	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Responsive	COREAD	Case report
EGFR	R108K	Different Mutation	novel EGFR mAb inhibitor	Responsive	COREAD	Early trials
EGFR	R108K	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	R108K	Different Mutation	Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor)	Responsive	HNC	Case report
EGFR	R108K	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	R108K	Different Mutation	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Case report
EGFR	R108K	Different Mutation	EGFR inhibitor	Responsive	L	Early trials
EGFR	R108K	Different Mutation	Erlotinib (EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	R108K	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	R108K	Different Mutation	EGFR inhibitor	Responsive	NSCLC	Late trials
EGFR	R108K	Different Mutation	Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	R108K	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	R108K	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	R108K	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	L	Late trials
EGFR	R108K	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Pre-clinical
EGFR	R108K	Different Mutation	Erlotinib (EGFR inhibitor)	No Responsive	L	Case report
EGFR	R108K	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	ED	Case report
EGFR	R108K	Different Mutation	EGFR inhibitor	No Responsive	G	Early trials
EGFR	R108K	Different Mutation	EGFR inhibitor	Resistant	NSCLC	Case report
EGFR	R108K	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	R108K	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant;Resistant	COREAD	Pre-clinical;Case report
EGFR	R108K	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Responsive	HNC	Case report
EGFR	R108K	Different Alteration	Gefitinib (EGFR inhibitor)	Responsive	ED	Late trials
EGFR	R108K	Different Alteration	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Early trials
EGFR	R108K	Different Alteration	EGFR inhibitor	Responsive	HNSC	Case report
EGFR	R108K	Different Alteration	EGFR inhibitor	No Responsive	G	Early trials
EGFR	R108K	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	L	Early trials
EGFR	R108K	Different Alteration	EGFR mAb inhibitor	Responsive	COREAD	Late trials
EGFR	R108K), EGFR MUT* (R324L	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	R108K), EGFR MUT* (R324L	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
TSC2	T993Nfs*12	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	T993Nfs*12	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	T993Nfs*12	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	T993Nfs*12	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	T993Nfs*12	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	T993Nfs*12	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	T993Nfs*12	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
TP53	R158C), TP53 MUT (P177S	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R158C), TP53 MUT (P177S	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R158C), TP53 MUT (P177S	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R158C), TP53 MUT (P177S	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R158C), TP53 MUT (P177S	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R158C), TP53 MUT (P177S	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R158C), TP53 MUT (P177S	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R158C), TP53 MUT (P177S	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R158C), TP53 MUT (P177S	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R158C), TP53 MUT (P177S	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R158C), TP53 MUT (P177S	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R158C), TP53 MUT (P177S	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R158C), TP53 MUT (P177S	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R158C), TP53 MUT (P177S	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R158C), TP53 MUT (P177S	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
PDGFRA	L521L	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
GNAQ	Q209P	Complete Match	Selumetinib (MEK inhibitor)	Responsive	CM	Early trials
GNAQ	Q209P	Complete Match	HDAC inhibitor	Responsive	CM	Pre-clinical
GNAQ	Q209P	Complete Match	PKC inhibitor	Responsive	CM	Pre-clinical
GNAQ	Q209P	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
APC	S2054*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
BCOR	E1518*	Complete Match	Enzastaurin (PKCb inhibitor)	Responsive	ST	Pre-clinical
CTNNB1	D32V	Complete Match	Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy)	Responsive	ED	Early trials
CTNNB1	D32V	Complete Match	Tankyrase inhibitor	Resistant	COREAD	Pre-clinical
ESR1	G262E), ESR1 MUT* (intron_variant	Different Alteration	ESR1 inhibitor	Resistant	BRCA	Pre-clinical
ERBB4	L110F	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
EGFR	K294K	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	K294K	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	intron_variant), ALK MUT* (E974K	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ABL1	E925K), ABL1 MUT* (D444D), ABL1 MUT* (K356K	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	E925K), ABL1 MUT* (D444D), ABL1 MUT* (K356K	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	E925K), ABL1 MUT* (D444D), ABL1 MUT* (K356K	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	E925K), ABL1 MUT* (D444D), ABL1 MUT* (K356K	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	E925K), ABL1 MUT* (D444D), ABL1 MUT* (K356K	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	E925K), ABL1 MUT* (D444D), ABL1 MUT* (K356K	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
SETD2	W1460*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	W1460*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
PTEN	S170N), PTEN MUT (L108F	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	S170N), PTEN MUT (L108F	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	S170N), PTEN MUT (L108F	Complete Match	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	S170N), PTEN MUT (L108F	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	S170N), PTEN MUT (L108F	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	S170N), PTEN MUT (L108F	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	S170N), PTEN MUT (L108F	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	S170N), PTEN MUT (L108F	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	S170N), PTEN MUT (L108F	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	S170N), PTEN MUT (L108F	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	S170N), PTEN MUT (L108F	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	S170N), PTEN MUT (L108F	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	S170N), PTEN MUT (L108F	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	S170N), PTEN MUT (L108F	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	S170N), PTEN MUT (L108F	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	S170N), PTEN MUT (L108F	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	S170N), PTEN MUT (L108F	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	S170N), PTEN MUT (L108F	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	S170N), PTEN MUT (L108F	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	S170N), PTEN MUT (L108F	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	S170N), PTEN MUT (L108F	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	S170N), PTEN MUT (L108F	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	S170N), PTEN MUT (L108F	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	S170N), PTEN MUT (L108F	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	S170N), PTEN MUT (L108F	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PDGFRA	V598I), PDGFRA MUT* (R554R), PDGFRA MUT* (T364I	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
LRP1B	W4421*	Complete Match	Liposomal Doxorubicin (Chemotherapy)	Resistant	OV	Early trials
LRP1B	W4421*	Different Alteration	Liposomal Doxorubicin (Chemotherapy)	Resistant	OV	Early trials
FANCA	W386*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Case report
FANCA	W386*	Different Alteration	Olaparib (PARP inhibitor)	Responsive	PRAD	Case report
FGFR3	P550S), FGFR3 MUT* (E231K), FGFR3 MUT* (P220P	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	P550S), FGFR3 MUT* (E231K), FGFR3 MUT* (P220P	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	P550S), FGFR3 MUT* (E231K), FGFR3 MUT* (P220P	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
TMPRSS2	S419S	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	S419S	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
DNMT3A	R736C	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
ROS1	L426L), ROS1 MUT* (V1260M), ROS1 MUT* (R2096R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	L426L), ROS1 MUT* (V1260M), ROS1 MUT* (R2096R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	L426L), ROS1 MUT* (V1260M), ROS1 MUT* (R2096R	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	L426L), ROS1 MUT* (V1260M), ROS1 MUT* (R2096R	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	L426L), ROS1 MUT* (V1260M), ROS1 MUT* (R2096R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
MET	splice_donor_variant), MET MUT* (C561Y), MET MUT* (E240E	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
KMT2A	G967E	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	G967E	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	G967E	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	G967E	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	G967E	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	G967E	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
NF1	E2749*	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NF1	E2749*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	HNC	Case report
NF1	E2749*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	E2749*	Complete Match	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	E2749*	Complete Match	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NF1	E2749*	Complete Match	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	E2749*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	E2749*	Complete Match	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	E2749*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	NF	Late trials
NF1	E2749*	Complete Match	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	E2749*	Complete Match	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	E2749*	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	MPN, PLEN	Pre-clinical
NF1	E2749*	Complete Match	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	E2749*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	HNC, SG	Case report
NF1	E2749*	Complete Match	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	E2749*	Complete Match	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	E2749*	Complete Match	MEK inhibitor	Responsive	LK, G	Pre-clinical
NF1	E2749*	Complete Match	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	E2749*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	E2749*	Complete Match	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	E2749*	Complete Match	MTOR inhibitor	Responsive	LK, G, MPN	Pre-clinical
NF1	E2749*	Complete Match	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	E2749*	Complete Match	Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor)	Responsive	HC	Case report
NF1	E2749*	Complete Match	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	E2749*	Complete Match	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	E2749*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	E2749*	Complete Match	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	E2749*	Complete Match	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	E2749*	Complete Match	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	E2749*	Complete Match	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	E2749*	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	E2749*	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	E2749*	Complete Match	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	E2749*	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	E2749*	Complete Match	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	E2749*	Complete Match	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	E2749*	Different Alteration	MTOR inhibitor	Responsive	MPN, G, LK	Pre-clinical
NF1	E2749*	Different Alteration	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	E2749*	Different Alteration	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	E2749*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	E2749*	Different Alteration	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	E2749*	Different Alteration	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	E2749*	Different Alteration	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	E2749*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	E2749*	Different Alteration	MEK inhibitor	Responsive	G, LK	Pre-clinical
NF1	E2749*	Different Alteration	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	E2749*	Different Alteration	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	E2749*	Different Alteration	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	E2749*	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	E2749*	Different Alteration	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	E2749*	Different Alteration	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	E2749*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	E2749*	Different Alteration	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	E2749*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SG, HNC	Case report
NF1	E2749*	Different Alteration	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	E2749*	Different Alteration	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	E2749*	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	E2749*	Different Alteration	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	E2749*	Different Alteration	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	E2749*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	E2749*	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	PLEN, MPN	Pre-clinical
NF1	E2749*	Different Alteration	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	E2749*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	E2749*	Different Alteration	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	E2749*	Different Alteration	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	E2749*	Different Alteration	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	E2749*	Different Alteration	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	E2749*	Different Alteration	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NTRK1	R583H), NTRK1 MUT* (T580I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R583H), NTRK1 MUT* (T580I	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R583H), NTRK1 MUT* (T580I	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R583H), NTRK1 MUT* (T580I	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
NOTCH1	W133*	Different Mutation	Gamma secretase inhibitor	Responsive	CANCER	Early trials
NOTCH1	W133*	Different Mutation	Gamma secretase inhibitor;CDK4 inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	W133*	Different Mutation	Gamma secretase inhibitor;MTOR inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	W133*	Different Mutation	Gamma secretase inhibitor	Responsive;Responsive	ALL	Early trials;Pre-clinical
NOTCH1	W133*	Different Mutation	NOTCH1 inhibitor	Responsive	ADCC	Case report
NOTCH1	W133*	Different Mutation	OMP-52M51 (NOTCH1 inhibitor)	Responsive	CANCER	Early trials
NOTCH1	W133*	Different Mutation	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	W133*	Complete Match	Gamma secretase inhibitor	Responsive	MCL	Pre-clinical
NOTCH1	W133), NOTCH1 MUT (V322M), NOTCH1 MUT* (D1348D), NOTCH1 MUT* (G1366D	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	W133), NOTCH1 MUT (V322M), NOTCH1 MUT* (D1348D), NOTCH1 MUT* (G1366D	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
BRD4	G187G), BRD4 MUT* (P310H), BRD4 MUT* (A481V), BRD4 MUT* (intron_variant	Different Alteration	BET inhibitor	Responsive	NMC	Case report
BRAF	S602F	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Pre-clinical
BRAF	S602F	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HISEC, HISLC, NSCLC	NCCN guidelines
BRAF	S602F	Different Mutation	Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	S602F	Different Mutation	Trametinib (MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	S602F	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	CM	FDA guidelines
BRAF	S602F	Different Mutation	Pan-RAF inhibitor	Responsive	CANCER	Pre-clinical
BRAF	S602F	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CANCER	Pre-clinical
BRAF	S602F	Different Mutation	ERK inhibitor	Responsive	HNSC, BT	Case report
BRAF	S602F	Different Mutation	EGFR TK inhibitor	Resistant	LUAD	Case report
BRAF	S602F	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	Early trials
BRAF	S602F	Different Mutation	Sorafenib (Pan-TK inhibitor)	Responsive	CM	Pre-clinical
BRAF	S602F	Different Mutation	Vemurafenib (BRAF inhibitor)	No Responsive	COREAD	Early trials
BRAF	S602F	Different Mutation	MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor)	Responsive	COREAD	Early trials
BRAF	S602F	Different Mutation	Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor)	Responsive	COREAD	NCCN guidelines
BRAF	S602F	Different Mutation	Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor)	Responsive	COREAD	Early trials
BRAF	S602F	Different Mutation	BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Early trials
BRAF	S602F	Different Mutation	BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor	Responsive	COREAD	Early trials
BRAF	S602F	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	S602F	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	MA	Early trials
BRAF	S602F	Different Mutation	BRAF inhibitor;MEK inhibitor	Responsive	TH	Early trials
BRAF	S602F	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	S602F	Different Mutation	Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor)	Responsive	COREAD	Early trials
BRAF	S602F	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	LUAD	FDA guidelines
BRAF	S602F	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	NSCLC	NCCN guidelines
BRAF	S602F	Different Mutation	MEK inhibitor	Responsive	TH	Early trials
BRAF	S602F	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	LUAD, TH	Early trials
BRAF	S602F	Different Mutation	MEK inhibitor	Responsive	OV	Pre-clinical
BRAF	S602F	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	HCL, LUAD, MYMA	Case report
BRAF	S602F	Different Mutation	Pan-RAF inhibitor	Responsive	CM	Early trials
BRAF	S602F	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
BRAF	S602F	Different Mutation	BRAF inhibitor	Responsive	G	Pre-clinical
BRAF	S602F	Different Mutation	PLX4720 (BRAF inhibitor)	Responsive	MA	Pre-clinical
BRAF	S602F	Different Mutation	Vemurafenib (BRAF inhibitor)	Responsive	THCA	Early trials
BRAF	S602F	Different Mutation	Selumetinib (MEK inhibitor)	Responsive	PG	Early trials
BRAF	S602F	Different Mutation	ERK inhibitor	Responsive	LUAD	Early trials
BRAF	S602F	Different Mutation	ERK inhibitor	Responsive	CM	Pre-clinical
BRAF	S602F	Different Mutation	Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor)	Responsive	NEU	Case report
BRAF	S602F	Different Mutation	BRAF inhibitor	Responsive	OV	Case report
BRAF	S602F	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	GIST	Case report
BRAF	S602F	Different Mutation	Dabrafenib (BRAF inhibitor)	Responsive	CM	FDA guidelines
BRAF	S602F	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	LUAD	Case report
BRAF	S602F), BRAF MUT* (G758G	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	G758G	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	S602F), BRAF MUT* (G758G	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	S602F), BRAF MUT* (G758G	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
PTEN	S170N), PTEN MUT (L108F), BRAF MUT (S602F	Complete Match	MEK inhibitor	Resistant	CM	Pre-clinical
PTEN	S170N), PTEN MUT (L108F), BRAF MUT (S602F	Complete Match	BRAF inhibitor	Resistant	CM	Early trials
PTEN	S170N), PTEN MUT (L108F), BRAF MUT (S602F	Different Alteration	BRAF inhibitor	Resistant	CM	Early trials
PTEN	S170N), PTEN MUT (L108F), BRAF MUT (S602F	Different Alteration	MEK inhibitor	Resistant	CM	Pre-clinical
NF1	E2749*), BRAF MUT (S602F	Complete Match	Vemurafenib (BRAF inhibitor)	Resistant	CM	Case report
NF1	E2749*), BRAF MUT (S602F	Complete Match	Selumetinib (MEK inhibitor)	Resistant	CM	Case report
NF1	E2749*), BRAF MUT (S602F	Different Alteration	Selumetinib (MEK inhibitor)	Resistant	CM	Case report
NF1	E2749*), BRAF MUT (S602F	Different Alteration	Vemurafenib (BRAF inhibitor)	Resistant	CM	Case report
VHL	S65L	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
TP53	I254T	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	I254T	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	I254T	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	I254T	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	I254T	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	I254T	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	I254T	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I254T	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	I254T	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	I254T	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	I254T	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	I254T	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I254T	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	I254T	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	I254T	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KRAS	Q61R), KRAS MUT (E62A	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61R), KRAS MUT (E62A	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	Q61R), KRAS MUT (E62A	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	Q61R), KRAS MUT (E62A	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	Q61R), KRAS MUT (E62A	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61R), KRAS MUT (E62A	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	Q61R), KRAS MUT (E62A	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	Q61R), KRAS MUT (E62A	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	Q61R), KRAS MUT (E62A	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	Q61R), KRAS MUT (E62A	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	Q61R), KRAS MUT (E62A	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61R), KRAS MUT (E62A	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	Q61R), KRAS MUT (E62A	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61R), KRAS MUT (E62A	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	Q61R), KRAS MUT (E62A	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	Q61R), KRAS MUT (E62A	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	Q61R), KRAS MUT (E62A	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	Q61R), KRAS MUT (E62A	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	Q61R), KRAS MUT (E62A	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61R), KRAS MUT (E62A	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	Q61R), KRAS MUT (E62A	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	Q61R), KRAS MUT (E62A	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
FGFR3	H721H	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	H721H	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	H721H	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
FGFR2	E275Q	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	E275Q	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
ABL1	A287V), ABL1 MUT* (V280M), ABL1 MUT* (T277T	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	A287V), ABL1 MUT* (V280M), ABL1 MUT* (T277T	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	A287V), ABL1 MUT* (V280M), ABL1 MUT* (T277T	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	A287V), ABL1 MUT* (V280M), ABL1 MUT* (T277T	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	A287V), ABL1 MUT* (V280M), ABL1 MUT* (T277T	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	A287V), ABL1 MUT* (V280M), ABL1 MUT* (T277T	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
PTEN	C250Y	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	C250Y	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	C250Y	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	C250Y	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	C250Y	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	C250Y	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	C250Y	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	C250Y	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	C250Y	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	C250Y	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	C250Y	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	C250Y	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	C250Y	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	C250Y	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	C250Y	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	C250Y	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	C250Y	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	C250Y	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	C250Y	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	C250Y	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	C250Y	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	C250Y	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	C250Y	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	C250Y	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	C250Y	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
FGFR3	K705E), FGFR3 MUT* (P401T	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	K705E), FGFR3 MUT* (P401T	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	K705E), FGFR3 MUT* (P401T	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
NOTCH1	intron_variant), NOTCH1 MUT* (intron_variant	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	intron_variant), NOTCH1 MUT* (intron_variant	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ABL1	L298L	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	L298L	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	L298L	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	L298L	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	L298L	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	L298L	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
NRAS	E63K	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
NRAS	E63K	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
NRAS	E63K	Different Mutation	MEK inhibitor	Responsive	CM	Late trials
NRAS	E63K	Different Mutation	BRAF inhibitor	Resistant	CM	Early trials
NRAS	E63K	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CM	Early trials
NRAS	E63K	Complete Match	HSP90 inhibitor	Responsive	CM	Pre-clinical
NRAS	E63K	Complete Match	MEK inhibitor	Responsive	AML, LUAD, ALL	Pre-clinical
NRAS	E63K	Complete Match	Pan-RAF inhibitor	Responsive	CM	Case report
NRAS	E63K	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
NRAS	E63K	Complete Match	ERK inhibitor	Responsive	CM	Case report
NRAS	E63K	Complete Match	MEK inhibitor +/- PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
NRAS	E63K	Complete Match	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NRAS	E63K	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	MYMA	Pre-clinical
NRAS	E63K	Different Mutation	ERK inhibitor	Responsive	CANCER	Pre-clinical
TP53	G334V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G334V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G334V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G334V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G334V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G334V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G334V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G334V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G334V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G334V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G334V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G334V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G334V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G334V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G334V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
VHL	A149S	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
FGFR3	P694L	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	P694L	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	P694L	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
BRAF	K630E	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	K630E	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	K630E	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	K630E	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
ABL1	S749L	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
ABL1	S749L	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	S749L	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
ABL1	S749L	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
ABL1	S749L	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
ABL1	S749L	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
RET	T754T), RET MUT* (L362I	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	T754T), RET MUT* (L362I	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	T754T), RET MUT* (L362I	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	T754T), RET MUT* (L362I	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	T754T), RET MUT* (L362I	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	T754T), RET MUT* (L362I	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	T754T), RET MUT* (L362I	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	T754T), RET MUT* (L362I	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	T754T), RET MUT* (L362I	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
KMT2A	V46G	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	V46G	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	V46G	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	V46G	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	V46G	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	V46G	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ATR	Y628*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATR	Y628*	Complete Match	Olaparib (PARP inhibitor)	Responsive	CANCER, OV	Pre-clinical
ATR	Y628*	Different Alteration	Olaparib (PARP inhibitor)	Responsive	OV, CANCER	Pre-clinical
BCR	R1090R	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
BCR	R1090R	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
BCR	R1090R	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	R1090R	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	R1090R	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
BCR	R1090R	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
TP53	C242R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	C242R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	C242R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	C242R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	C242R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	C242R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	C242R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C242R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	C242R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	C242R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	C242R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	C242R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C242R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	C242R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	C242R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	R95H	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ROS1	D2135V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	D2135V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	D2135V	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	D2135V	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	D2135V	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
ALK	E119D	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	E119D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	E119D	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	E119D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	E119D	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	E119D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	E119D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	E119D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	E119D	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	E119D	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	E119D	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	E119D	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	E119D	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	E119D	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	E119D	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	E119D	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	E119D	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	E119D	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	E119D	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
NOTCH1	A40G	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	A40G	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
KMT2A	G48G	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	G48G	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	G48G	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	G48G	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	G48G	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	G48G	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
PIK3CA	G106V	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	G106V	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	G106V	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	G106V	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	G106V	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	G106V	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	G106V	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	G106V	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	G106V	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	G106V	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	G106V	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	G106V	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	G106V	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	G106V	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
KMT2A	K2502R	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	K2502R	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	K2502R	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	K2502R	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	K2502R	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	K2502R	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ALK	L1425L	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	L1425L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	L1425L	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	L1425L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	L1425L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	L1425L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	L1425L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	L1425L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	L1425L	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	L1425L	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	L1425L	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	L1425L	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	L1425L	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	L1425L	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	L1425L	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	L1425L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	L1425L	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	L1425L	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	L1425L	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
NTRK3	C362F	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	C362F	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	C362F	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
BRCA2	N3124I	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	N3124I	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	N3124I	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	N3124I	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	N3124I	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	N3124I	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	N3124I	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	N3124I	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	N3124I	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	N3124I	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	N3124I	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	N3124I	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	N3124I	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	N3124I	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
TP53	R158G	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R158G	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R158G	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R158G	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R158G	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R158G	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R158G	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R158G	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R158G	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R158G	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R158G	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R158G	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R158G	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R158G	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R158G	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
FANCA	splice_donor_variant	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Case report
FANCA	splice_donor_variant	Different Alteration	Olaparib (PARP inhibitor)	Responsive	PRAD	Case report
BRCA2	Q1037*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	Q1037*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q1037*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	Q1037*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	Q1037*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	Q1037*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	Q1037*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	Q1037*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	Q1037*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q1037*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q1037*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	Q1037*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	Q1037*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	Q1037*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
BRCA1	R1495M	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA1	R1495M	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA1	R1495M	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA1	R1495M	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	R1495M	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	R1495M	Complete Match	WEE1 inhibitor	Responsive	CANCER	Case report
BRCA1	R1495M	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA1	R1495M	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA1	R1495M	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA1	R1495M	Complete Match	PARP inhibitor	Responsive	PA	Case report
BRCA1	R1495M	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA1	R1495M	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
ALK	S15Y), ALK MUT* (A17T	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	S15Y), ALK MUT* (A17T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	S15Y), ALK MUT* (A17T	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	S15Y), ALK MUT* (A17T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	S15Y), ALK MUT* (A17T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	S15Y), ALK MUT* (A17T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	S15Y), ALK MUT* (A17T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	S15Y), ALK MUT* (A17T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	S15Y), ALK MUT* (A17T	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	S15Y), ALK MUT* (A17T	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	S15Y), ALK MUT* (A17T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	S15Y), ALK MUT* (A17T	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	S15Y), ALK MUT* (A17T	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	S15Y), ALK MUT* (A17T	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	S15Y), ALK MUT* (A17T	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	S15Y), ALK MUT* (A17T	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	S15Y), ALK MUT* (A17T	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	S15Y), ALK MUT* (A17T	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	S15Y), ALK MUT* (A17T	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
PTEN	Y68H	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y68H	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Y68H	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	Y68H	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	Y68H	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	Y68H	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y68H	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y68H	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	Y68H	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	Y68H	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y68H	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y68H	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	Y68H	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y68H	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	Y68H	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y68H	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	Y68H	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Y68H	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Y68H	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	Y68H	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Y68H	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Y68H	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Y68H	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	Y68H	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Y68H	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
ARID1A	W1498*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	W1498*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	W1498*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	W1498*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
NOTCH2	T197I	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ATR	R1653*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATR	R1653*	Complete Match	Olaparib (PARP inhibitor)	Responsive	CANCER, OV	Pre-clinical
ATR	R1653*	Different Alteration	Olaparib (PARP inhibitor)	Responsive	OV, CANCER	Pre-clinical
RET	D842N	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	D842N	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	D842N	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	D842N	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	D842N	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	D842N	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	D842N	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	D842N	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	D842N	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
KMT2A	G48G), MLL MUT* (V46G), MLL MUT* (G43R	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	G48G), MLL MUT* (V46G), MLL MUT* (G43R	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	G48G), MLL MUT* (V46G), MLL MUT* (G43R	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	G48G), MLL MUT* (V46G), MLL MUT* (G43R	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	G48G), MLL MUT* (V46G), MLL MUT* (G43R	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	G48G), MLL MUT* (V46G), MLL MUT* (G43R	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
TP53	D208V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	D208V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	D208V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	D208V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	D208V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	D208V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	D208V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D208V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	D208V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	D208V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	D208V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	D208V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D208V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	D208V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	D208V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
MET	V378I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
TP53	M133I), TP53 MUT (F134V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	M133I), TP53 MUT (F134V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	M133I), TP53 MUT (F134V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	M133I), TP53 MUT (F134V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	M133I), TP53 MUT (F134V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	M133I), TP53 MUT (F134V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M133I), TP53 MUT (F134V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M133I), TP53 MUT (F134V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M133I), TP53 MUT (F134V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	M133I), TP53 MUT (F134V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	M133I), TP53 MUT (F134V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	M133I), TP53 MUT (F134V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M133I), TP53 MUT (F134V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	M133I), TP53 MUT (F134V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M133I), TP53 MUT (F134V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRCA2	C2473*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Case report
BRCA2	C2473*	Complete Match	Olaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	C2473*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	OV	Late trials
BRCA2	C2473*	Complete Match	Chemotherapy (PARP inhibitor;Chemotherapy)	Responsive	OV	Early trials
BRCA2	C2473*	Complete Match	PARP inhibitor;Chemotherapy	Responsive	OV	Early trials
BRCA2	C2473*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	PA	Case report
BRCA2	C2473*	Complete Match	Olaparib (PARP inhibitor)	Responsive	PRAD	Early trials
BRCA2	C2473*	Complete Match	Rucaparib (PARP inhibitor)	Responsive	OV	FDA guidelines
BRCA2	C2473*	Complete Match	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	C2473*	Complete Match	Veliparib;Cisplatin (PARP inhibitor;Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	C2473*	Complete Match	Platinum Agent (Chemotherapy)	Responsive	BRCA	Early trials
BRCA2	C2473*	Complete Match	PARP inhibitor	Responsive	BRCA	Early trials
BRCA2	C2473*	Different Alteration	PD1/PDL1 inhibitor	Responsive	UTH	Early trials
BRCA2	C2473*	Different Alteration	PARP inhibitor	Responsive	OV	Pre-clinical
TP53	M237V	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	M237V	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	M237V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	M237V	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	M237V	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	M237V	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	M237V	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M237V	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	M237V	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	M237V	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	M237V	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	M237V	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M237V	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	M237V	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	M237V	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
VHL	P81S	Complete Match	VEGFR inhibitor	Responsive	R	Pre-clinical
FGFR3	3-UTRBlockSubstitution	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	3-UTRBlockSubstitution	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	3-UTRBlockSubstitution	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
NOTCH2	V1925V	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NRG1	E76G	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	LUAD	Pre-clinical
NRG1	E76G	Different Alteration	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	LUAD	Case report
MTOR	L1460P	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Pre-clinical
MTOR	L1460P	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	R	Case report
MTOR	L1460P	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	AS, R, ST, AG	Case report
MTOR	L1460P	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	BLCA	Case report
MTOR	L1460P	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	ST	Case report
MTOR	L1460P	Different Mutation	Everolimus (MTOR inhibitor)	Resistant	THCA	Case report
MTOR	L1460P	Different Mutation	MTOR kinase inhibitor	Responsive	CANCER	Pre-clinical
PDGFRA	D452Y	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
PIK3CA	V344M	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	V344M	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	V344M	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	V344M	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	V344M	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	V344M	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	V344M	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	V344M	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	V344M	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	V344M	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	V344M	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	V344M	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	V344M	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	V344M	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
PTEN	Q245*	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Q245*	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
PTEN	Q245*	Different Mutation	BYL719 (PIK3CA inhibitor)	Resistant	BRCA	Case report
PTEN	Q245*	Complete Match	ATM inhibitor	Responsive	BRCA	Pre-clinical
PTEN	Q245*	Complete Match	PI3K pathway inhibitor	Responsive	BRCA, ED, TH, CANCER, L, G, OV	Pre-clinical
PTEN	Q245*	Complete Match	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Q245*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Q245*	Complete Match	PARP inhibitor	Responsive	ED	Case report
PTEN	Q245*	Complete Match	PD1 Ab inhibitor	Resistant	CM	Early trials
PTEN	Q245*	Complete Match	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Q245*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Q245*	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
PTEN	Q245*	Complete Match	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Q245*	Complete Match	AKT inhibitor	Responsive	PA	Case report
PTEN	Q245*	Complete Match	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Q245*	Different Alteration	PI3K pathway inhibitor	Responsive	L, BRCA, CANCER, G, ED, TH, OV	Pre-clinical
PTEN	Q245*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	PRAD	Early trials
PTEN	Q245*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	CANCER	Early trials
PTEN	Q245*	Different Alteration	PARP inhibitor	Responsive	ED	Case report
PTEN	Q245*	Different Alteration	PIK3CB inhibitor	Responsive	PRAD	Case report
PTEN	Q245*	Different Alteration	EGFR mAb inhibitor	Resistant	COREAD	Late trials
PTEN	Q245*	Different Alteration	MTOR inhibitor	No Responsive	ED	Early trials
PTEN	Q245*	Different Alteration	AKT inhibitor	Responsive	PA	Case report
PTEN	Q245*	Different Alteration	PI3K pathway inhibitor;AR antagonist	Responsive	PRAD	Pre-clinical
PTEN	Q245*	Different Alteration	PI3K pathway inhibitor;MEK inhibitor	Responsive	OV	Pre-clinical
DNMT3A	E491*	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
NTRK3	K627N	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	K627N	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	K627N	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
BRD4	H990Q	Different Alteration	BET inhibitor	Responsive	NMC	Case report
TP53	Q100Rfs*23	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q100Rfs*23	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q100Rfs*23	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q100Rfs*23	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q100Rfs*23	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q100Rfs*23	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q100Rfs*23	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q100Rfs*23	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q100Rfs*23	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q100Rfs*23	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q100Rfs*23	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q100Rfs*23	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q100Rfs*23	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q100Rfs*23	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q100Rfs*23	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
CBL	G415R	Different Mutation	JAK inhibitor	Responsive	MDPS	Pre-clinical
CBL	G415R	Different Mutation	Dasatinib (BCR-ABL inhibitor)	Responsive	MDPS	Pre-clinical
NOTCH2	P6S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ALK	G1585S	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	G1585S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	G1585S	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	G1585S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	G1585S	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	G1585S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G1585S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	G1585S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	G1585S	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G1585S	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	G1585S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	G1585S	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	G1585S	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	G1585S	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	G1585S	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	G1585S	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	G1585S	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	G1585S	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	G1585S	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ROS1	A860D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	A860D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	A860D	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	A860D	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	A860D	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
EGFR	V536M	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	V536M	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
PDGFRA	R500Q	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
RAF1	L541P	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	PRAD	Pre-clinical
RAF1	L541P	Different Alteration	Pan-RAF inhibitor	Responsive	PRAD	Pre-clinical
RAF1	L541P	Different Alteration	U0126 (MEK inhibitor)	Responsive	PRAD	Pre-clinical
ALK	I4I	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	I4I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	I4I	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	I4I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	I4I	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	I4I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	I4I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	I4I	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	I4I	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	I4I	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	I4I	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	I4I	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	I4I	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	I4I	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	I4I	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	I4I	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	I4I	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	I4I	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	I4I	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
FGFR3	G654S	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	G654S	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	G654S	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
NTRK3	intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
BCR	intron_variant), BCR MUT* (intron_variant	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
BCR	intron_variant), BCR MUT* (intron_variant	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
BCR	intron_variant), BCR MUT* (intron_variant	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	intron_variant), BCR MUT* (intron_variant	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	intron_variant), BCR MUT* (intron_variant	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
BCR	intron_variant), BCR MUT* (intron_variant	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
KMT2A	D525G	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	D525G	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	D525G	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	D525G	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	D525G	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	D525G	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
KMT2A	P3403L	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P3403L	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P3403L	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P3403L	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P3403L	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P3403L	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
EGFR	R427C), EGFR MUT* (R224H	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	R427C), EGFR MUT* (R224H	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
KRAS	G12_G13delinsVD	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12_G13delinsVD	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	G12_G13delinsVD	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	G12_G13delinsVD	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	G12_G13delinsVD	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	G12_G13delinsVD	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	G12_G13delinsVD	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12_G13delinsVD	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	G12_G13delinsVD	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	G12_G13delinsVD	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	G12_G13delinsVD	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	G12_G13delinsVD	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	G12_G13delinsVD	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12_G13delinsVD	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	G12_G13delinsVD	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	G12_G13delinsVD	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	G12_G13delinsVD	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	G12_G13delinsVD	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	G12_G13delinsVD	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	G12_G13delinsVD	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	G12_G13delinsVD	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	G12_G13delinsVD	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	G12_G13delinsVD	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	G12_G13delinsVD	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	G12_G13delinsVD	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
NTRK3	R116L	Different Alteration	IGF1R inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R116L	Different Alteration	PI3K pathway inhibitor	Responsive	BRCA	Pre-clinical
NTRK3	R116L	Different Alteration	Midostaurin (Pan-TK inhibitor)	Responsive	BRCA	Pre-clinical
TP53	Q331H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q331H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q331H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q331H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q331H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q331H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q331H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q331H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q331H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q331H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q331H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q331H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q331H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q331H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q331H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ROS1	I1507T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	I1507T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	I1507T	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	I1507T	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	I1507T	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
KMT2D	Q3601*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
ALK	L1609P	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	L1609P	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	L1609P	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	L1609P	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	L1609P	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	L1609P	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	L1609P	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	L1609P	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	L1609P	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	L1609P	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	L1609P	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	L1609P	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	L1609P	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	L1609P	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	L1609P	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	L1609P	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	L1609P	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	L1609P	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	L1609P	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
PIK3CA	E39K	Different Mutation	BRAF inhibitor	Resistant	CM	Case report
PIK3CA	E39K	Complete Match	PI3K pathway inhibitor	Responsive	BLCA, HNC	Case report
PIK3CA	E39K	Complete Match	PI3K pathway inhibitor	Responsive	HNSC	Case report
PIK3CA	E39K	Complete Match	PI3K pathway inhibitor	Responsive	G, THCA	Pre-clinical
PIK3CA	E39K	Complete Match	Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy)	Responsive	BRCA	Late trials
PIK3CA	E39K	Complete Match	PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
PIK3CA	E39K	Complete Match	PI3K pathway inhibitor	Responsive	ED, OV, CESC	Early trials
PIK3CA	E39K	Complete Match	PI3K pathway inhibitor	Responsive	BRCA	Late trials
PIK3CA	E39K	Complete Match	PIK3CA inhibitor	Responsive	BRCA	Early trials
PIK3CA	E39K	Complete Match	PIK3CA inhibitor	Responsive	ST	Case report
PIK3CA	E39K	Complete Match	AKT inhibitor	Responsive	BRCA	Early trials
PIK3CA	E39K	Complete Match	PI3K pathway inhibitor	Responsive;Responsive	L	Pre-clinical;Case report
PIK3CA	E39K	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Late trials
PIK3CA	E39K	Different Alteration	PI3K pathway inhibitor	Resistant	BRCA	Pre-clinical
RET	V804M	Different Mutation	Vandetanib (Pan-TK inhibitor)	Responsive	THCA, TH	FDA guidelines
RET	V804M	Different Mutation	Cabozantinib (Pan-kinase inhibitor)	Responsive	TH	Pre-clinical
RET	V804M	Different Mutation	RET inhibitor	Responsive	TH	Early trials
RET	V804M	Different Mutation	Sunitinib (Pan-TK inhibitor)	Responsive	TH	Pre-clinical
RET	V804M	Different Mutation	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Resistant	LUAD	Pre-clinical
RET	V804M	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	V804M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	V804M	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	V804M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	V804M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	V804M	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	V804M	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	V804M	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	V804M	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
FGFR3	3-UTRBlockSubstitution), FGFR3 MUT* (3-UTRBlockSubstitution), FGFR3 MUT* (intron_variant	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	3-UTRBlockSubstitution), FGFR3 MUT* (3-UTRBlockSubstitution), FGFR3 MUT* (intron_variant	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	3-UTRBlockSubstitution), FGFR3 MUT* (3-UTRBlockSubstitution), FGFR3 MUT* (intron_variant	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
MET	intron_variant), MET MUT* (IntronicBlockSubstitution	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	G	Case report
EGFR	S229T	Different Alteration	Cetuximab (EGFR mAb inhibitor)	Responsive	COREAD	FDA guidelines
EGFR	S229T	Different Alteration	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
EGFR	S229T	Different Mutation	Rindopepimut (Vaccine)	Responsive	GB	Late trials
EGFR	S229T	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	S229T	Different Mutation	Gefitinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	S229T	Different Mutation	HSP90 inhibitor	Responsive	L	Early trials
EGFR	S229T	Different Mutation	Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	S229T	Different Mutation	MEK inhibitor	Responsive	L	Pre-clinical
EGFR	S229T	Different Mutation	EGFR TK inhibitor	Responsive	L	Late trials
EGFR	S229T	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	NCCN guidelines
EGFR	S229T	Different Mutation	Osimertinib (EGFR inhibitor)	Resistant	L	Early trials
EGFR	S229T	Different Mutation	EGFR-TKI's (EGFR inhibitor)	Resistant	L	Late trials
EGFR	S229T	Different Mutation	HSP90 inhibitor	Responsive	L	Case report
EGFR	S229T	Different Mutation	EGFR inhibitor	Resistant	L	Late trials
EGFR	S229T	Different Mutation	Poziotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	S229T	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Pre-clinical
EGFR	S229T	Different Mutation	HSP90 inhibitor (HSP90 inhibitor)	Responsive	L	Early trials
EGFR	S229T	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	G	Pre-clinical
EGFR	S229T	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	S229T	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	S229T	Different Mutation	Rociletinib (EGFR inhibitor)	Resistant	LUAD	Case report
EGFR	S229T	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Responsive	COREAD	Case report
EGFR	S229T	Different Mutation	novel EGFR mAb inhibitor	Responsive	COREAD	Early trials
EGFR	S229T	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	S229T	Different Mutation	Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor)	Responsive	HNC	Case report
EGFR	S229T	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	S229T	Different Mutation	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Case report
EGFR	S229T	Different Mutation	EGFR inhibitor	Responsive	L	Early trials
EGFR	S229T	Different Mutation	Erlotinib (EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	S229T	Different Mutation	Osimertinib (EGFR inhibitor)	Responsive	NSCLC	FDA guidelines
EGFR	S229T	Different Mutation	EGFR inhibitor	Responsive	NSCLC	Late trials
EGFR	S229T	Different Mutation	Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor)	Responsive	L	Early trials
EGFR	S229T	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Resistant	L	NCCN/CAP guidelines
EGFR	S229T	Different Mutation	Erlotinib (EGFR inhibitor)	Responsive	L	Early trials
EGFR	S229T	Different Mutation	Afatinib (ERBB2 & EGFR inhibitor)	Responsive	L	Late trials
EGFR	S229T	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	Pre-clinical
EGFR	S229T	Different Mutation	Erlotinib (EGFR inhibitor)	No Responsive	L	Case report
EGFR	S229T	Different Mutation	Lapatinib (ERBB2 inhibitor)	Responsive	ED	Case report
EGFR	S229T	Different Mutation	EGFR inhibitor	No Responsive	G	Early trials
EGFR	S229T	Different Mutation	EGFR inhibitor	Resistant	NSCLC	Case report
EGFR	S229T	Different Mutation	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	Case report
EGFR	S229T	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant;Resistant	COREAD	Pre-clinical;Case report
EGFR	S229T	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Responsive	HNC	Case report
EGFR	S229T	Different Alteration	Gefitinib (EGFR inhibitor)	Responsive	ED	Late trials
EGFR	S229T	Different Alteration	Gefitinib (EGFR inhibitor)	No Responsive	HNC	Early trials
EGFR	S229T	Different Alteration	EGFR inhibitor	Responsive	HNSC	Case report
EGFR	S229T	Different Alteration	EGFR inhibitor	No Responsive	G	Early trials
EGFR	S229T	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	L	Early trials
EGFR	S229T	Different Alteration	EGFR mAb inhibitor	Responsive	COREAD	Late trials
EGFR	S229T	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	S229T	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
DNMT3A	Y528*	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2D	Q3965*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
RNF43	W200*	Complete Match	Porcupine inhibitor	Responsive	COREAD	Case report
CDKN2A	R80*), CDKN2A MUT (H83Y	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R80*), CDKN2A MUT (H83Y	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R80*), CDKN2A MUT (H83Y	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	R80*), CDKN2A MUT (H83Y	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R80*), CDKN2A MUT (H83Y	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	R80*), CDKN2A MUT (H83Y	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	R80*), CDKN2A MUT (H83Y	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	R80*), CDKN2A MUT (H83Y	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
BCR	intron_variant	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
BCR	intron_variant	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
BCR	intron_variant	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	intron_variant	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	intron_variant	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
BCR	intron_variant	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
TP53	Q16Wfs*28	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	Q16Wfs*28	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	Q16Wfs*28	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	Q16Wfs*28	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	Q16Wfs*28	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	Q16Wfs*28	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	Q16Wfs*28	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q16Wfs*28	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	Q16Wfs*28	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	Q16Wfs*28	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	Q16Wfs*28	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	Q16Wfs*28	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q16Wfs*28	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	Q16Wfs*28	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	Q16Wfs*28	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
NTRK1	IntronicBlockSubstitution	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	IntronicBlockSubstitution	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	IntronicBlockSubstitution	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	IntronicBlockSubstitution	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
AKT3	Q442*	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	G1258S	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	G1258S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
DNMT3A	R598*	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
NOTCH1	A1570A	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	A1570A	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
NTRK1	E581K	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	E581K	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	E581K	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	E581K	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
KMT2D	S1223*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
KMT2A	P1354S	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P1354S	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P1354S	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P1354S	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P1354S	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P1354S	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
ALK	D460G	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	D460G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	D460G	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	D460G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	D460G	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	D460G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	D460G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	D460G	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	D460G	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	D460G	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	D460G	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	D460G	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	D460G	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	D460G	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	D460G	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	D460G	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	D460G	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	D460G	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	D460G	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
KMT2A	D2681G	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	D2681G	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	D2681G	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	D2681G	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	D2681G	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	D2681G	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
FGFR2	G647A	Different Alteration	FGFR inhibitor	Responsive	COREAD	Early trials
FGFR2	G647A	Different Alteration	FGFR inhibitor	Responsive	BT	Early trials
ALK	R136Q	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	R136Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	R136Q	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	R136Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	R136Q	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	R136Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R136Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	R136Q	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R136Q	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R136Q	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	R136Q	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	R136Q	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	R136Q	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	R136Q	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	R136Q	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	R136Q	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	R136Q	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	R136Q	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R136Q	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
EGFR	D1168Y	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	L	Case report
EGFR	D1168Y	Different Alteration	Erlotinib (EGFR inhibitor)	Responsive	NSCLC	Case report
SETD2	Q1344*	Complete Match	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
SETD2	Q1344*	Different Alteration	WEE1 inhibitor	Responsive	CANCER	Pre-clinical
TSC2	W1610), TSC2 MUT (Q572	Different Mutation	Temsirolimus (MTOR inhibitor)	Responsive	ED	Case report
TSC2	W1610), TSC2 MUT (Q572	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA, GCA	FDA guidelines
TSC2	W1610), TSC2 MUT (Q572	Complete Match	SRC inhibitor	Responsive	LAM	Pre-clinical
TSC2	W1610), TSC2 MUT (Q572	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC2	W1610), TSC2 MUT (Q572	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC2	W1610), TSC2 MUT (Q572	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	THCA	Case report
TSC2	W1610), TSC2 MUT (Q572	Different Alteration	SRC inhibitor	Responsive	LAM	Pre-clinical
NF1	Q2228*	Different Mutation	Vemurafenib (BRAF inhibitor)	Resistant	CM	Pre-clinical
NF1	Q2228*	Different Mutation	Everolimus (MTOR inhibitor)	Responsive	HNC	Case report
NF1	Q2228*	Complete Match	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	Q2228*	Complete Match	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	Q2228*	Complete Match	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NF1	Q2228*	Complete Match	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	Q2228*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	Q2228*	Complete Match	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	Q2228*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	NF	Late trials
NF1	Q2228*	Complete Match	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	Q2228*	Complete Match	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	Q2228*	Complete Match	Nilotinib (BCR-ABL inhibitor)	Responsive	MPN, PLEN	Pre-clinical
NF1	Q2228*	Complete Match	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	Q2228*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	HNC, SG	Case report
NF1	Q2228*	Complete Match	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	Q2228*	Complete Match	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	Q2228*	Complete Match	MEK inhibitor	Responsive	LK, G	Pre-clinical
NF1	Q2228*	Complete Match	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	Q2228*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	Q2228*	Complete Match	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	Q2228*	Complete Match	MTOR inhibitor	Responsive	LK, G, MPN	Pre-clinical
NF1	Q2228*	Complete Match	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	Q2228*	Complete Match	Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor)	Responsive	HC	Case report
NF1	Q2228*	Complete Match	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	Q2228*	Complete Match	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	Q2228*	Complete Match	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	Q2228*	Complete Match	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	Q2228*	Complete Match	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	Q2228*	Complete Match	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	Q2228*	Complete Match	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	Q2228*	Complete Match	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	Q2228*	Complete Match	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	Q2228*	Complete Match	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	Q2228*	Complete Match	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	Q2228*	Complete Match	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	Q2228*	Complete Match	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	Q2228*	Different Alteration	MTOR inhibitor	Responsive	MPN, G, LK	Pre-clinical
NF1	Q2228*	Different Alteration	PLX3397 (Pan-TK inhibitor)	Responsive	PLEN	Pre-clinical
NF1	Q2228*	Different Alteration	Erlotinib (EGFR inhibitor)	Resistant	L	Pre-clinical
NF1	Q2228*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	G	Case report
NF1	Q2228*	Different Alteration	BRD4 inhibitor	Responsive	MPN	Pre-clinical
NF1	Q2228*	Different Alteration	Trametinib (MEK inhibitor)	No Responsive	OS	Case report
NF1	Q2228*	Different Alteration	Cediranib (ALK inhibitor)	No Responsive	PLEN	Early trials
NF1	Q2228*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	G	Case report
NF1	Q2228*	Different Alteration	MEK inhibitor	Responsive	G, LK	Pre-clinical
NF1	Q2228*	Different Alteration	Vinblastine (Chemotherapy)	Responsive	G	Early trials
NF1	Q2228*	Different Alteration	Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor)	Responsive	MPN	Pre-clinical
NF1	Q2228*	Different Alteration	Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor)	No Responsive	MPN	Early trials
NF1	Q2228*	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Resistant	L	Pre-clinical
NF1	Q2228*	Different Alteration	MTOR inhibitor;HSP90 inhibitor	Responsive	MPN	Pre-clinical
NF1	Q2228*	Different Alteration	Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	Responsive	G	Case report
NF1	Q2228*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	PLEN	Early trials
NF1	Q2228*	Different Alteration	Tamoxifen (Hormonal therapy)	Responsive	MPN	Pre-clinical
NF1	Q2228*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SG, HNC	Case report
NF1	Q2228*	Different Alteration	Pan-RAF inhibitor;MEK inhibitor	Responsive	CM	Pre-clinical
NF1	Q2228*	Different Alteration	Tipifarnib (Farnesyltransferase inhibitor)	No Responsive	PLEN	Early trials
NF1	Q2228*	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	PLEN	Early trials
NF1	Q2228*	Different Alteration	Retinoic Acid	Resistant	NB	Pre-clinical
NF1	Q2228*	Different Alteration	Everolimus (MTOR inhibitor)	No Responsive	MPN	Early trials
NF1	Q2228*	Different Alteration	Sirolimus (MTOR inhibitor)	Responsive	PLEN	Early trials
NF1	Q2228*	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	PLEN, MPN	Pre-clinical
NF1	Q2228*	Different Alteration	Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor)	Responsive	G	Case report
NF1	Q2228*	Different Alteration	Trametinib (MEK inhibitor)	Responsive	CM	Pre-clinical
NF1	Q2228*	Different Alteration	AURK inhibitor	Responsive	MPN	Pre-clinical
NF1	Q2228*	Different Alteration	Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor)	No Responsive	G	Case report
NF1	Q2228*	Different Alteration	PD1 Ab inhibitor	Responsive	CM	Early trials
NF1	Q2228*	Different Alteration	MEK inhibitor	Responsive	MPN	Pre-clinical
NF1	Q2228*	Different Alteration	KIT inhibitor;MTOR inhibitor	Responsive	MPN	Pre-clinical
NTRK1	T403S	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	T403S	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	T403S	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	T403S	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
JAK2	Y570*	Different Alteration	Ruxolitinib (JAK inhibitor)	Responsive	ALL	Pre-clinical
ALK	L143R	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	L143R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	L143R	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	L143R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	L143R	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	L143R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	L143R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	L143R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	L143R	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	L143R	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	L143R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	L143R	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	L143R	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	L143R	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	L143R	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	L143R	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	L143R	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	L143R	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	L143R	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
RET	I1028F	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	I1028F	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	I1028F	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	I1028F	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	I1028F	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	I1028F	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	I1028F	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	I1028F	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	I1028F	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
BRAF	IntronicBlockSubstitution	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	IntronicBlockSubstitution	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	IntronicBlockSubstitution	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	IntronicBlockSubstitution	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
FGFR3	3-UTRBlockSubstitution), FGFR3 MUT* (3-UTRBlockSubstitution	Different Alteration	FGFR inhibitor	Responsive	BLCA	Case report
FGFR3	3-UTRBlockSubstitution), FGFR3 MUT* (3-UTRBlockSubstitution	Different Alteration	FGFR inhibitor	Responsive	G	Early trials
FGFR3	3-UTRBlockSubstitution), FGFR3 MUT* (3-UTRBlockSubstitution	Different Alteration	FGFR inhibitor	Responsive	NSCLC	Pre-clinical
BCR	I200I	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
BCR	I200I	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
BCR	I200I	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	I200I	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	I200I	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
BCR	I200I	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
ERBB4	L521V	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
ROS1	T859R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	T859R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	T859R	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	T859R	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	T859R	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
PDGFRA	R383H	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	MDPS, MDS, ECL, HES	FDA guidelines
ARID1A	N106Afs*5	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	N106Afs*5	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	N106Afs*5	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	N106Afs*5	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
PIK3R2	E210*	Different Mutation	MTOR inhibitor	Responsive	ED	Pre-clinical
ALK	R1113W	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1113W	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	R1113W	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	R1113W	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	R1113W	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	R1113W	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R1113W	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	R1113W	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	R1113W	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R1113W	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	R1113W	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	R1113W	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	R1113W	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1113W	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	R1113W	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	R1113W	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	R1113W	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	R1113W	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	R1113W	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
AKT3	R66Q	Different Alteration	ATP competitive AKT inhibitor	Responsive	BRCA	Pre-clinical
NOTCH1	A2256V	Different Alteration	Gamma secretase inhibitor	Responsive	ALL	Pre-clinical
NOTCH1	A2256V	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
ROS1	P696A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	P696A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	P696A	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	P696A	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	P696A	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
NTRK1	R452C	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Case report
NTRK1	R452C	Different Alteration	Pan-TKR inhibitor	Responsive	CANCER	Early trials
NTRK1	R452C	Different Alteration	Pan-TK inhibitor	Responsive	LUAD	Pre-clinical
NTRK1	R452C	Different Alteration	Pan-TK inhibitor	Responsive	COREAD	Case report
TMPRSS2	C157C	Different Alteration	DNA-PKc inhibitor	Responsive	PRAD	Pre-clinical
TMPRSS2	C157C	Different Alteration	PARP inhibitor	Responsive	PRAD	Pre-clinical
BCR	F77S	Different Alteration	Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	CML, ALL	FDA guidelines
BCR	F77S	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	ALL, CML	FDA guidelines
BCR	F77S	Different Alteration	Nilotinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	F77S	Different Alteration	Bosutinib (BCR-ABL inhibitor)	Responsive	CML	FDA guidelines
BCR	F77S	Different Alteration	Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor)	Responsive	ALL	Pre-clinical
BCR	F77S	Different Alteration	Dasatinib (BCR-ABL inhibitor)	Responsive	ALL, CML	FDA guidelines
BRD4	M926K	Different Alteration	BET inhibitor	Responsive	NMC	Case report
TP53	V143E	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	V143E	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	V143E	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	V143E	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	V143E	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	V143E	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	V143E	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V143E	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	V143E	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	V143E	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	V143E	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	V143E	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V143E	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	V143E	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	V143E	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ALK	M1223L	Different Alteration	ALK inhibitor;SRC inhibitor	Responsive	LUAD	Pre-clinical
ALK	M1223L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	GB, LY	Early trials
ALK	M1223L	Different Alteration	Lorlatinib (ALK&ROS1 inhibitor)	Responsive	NSCLC	Early trials
ALK	M1223L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	THCA, IM	Case report
ALK	M1223L	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Early trials
ALK	M1223L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	M1223L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	IM, COREAD	Case report
ALK	M1223L	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD, NSCLC	FDA guidelines
ALK	M1223L	Different Alteration	Brigatinib (Pan-TK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	M1223L	Different Alteration	Entrictinib (Pan-TK inhibitor)	Responsive	COREAD	Case report
ALK	M1223L	Different Alteration	Alectinib (ALK inhibitor)	Responsive	LUAD	FDA guidelines
ALK	M1223L	Different Alteration	HSP90 inhibitor (HSP90 inhibitor)	Responsive	LUAD	Early trials
ALK	M1223L	Different Alteration	ALK inhibitor;IGF1R inhibitor	Responsive	LUAD	Pre-clinical
ALK	M1223L	Different Alteration	ALK inhibitor;MEK inhibitor	Responsive	LUAD	Pre-clinical
ALK	M1223L	Different Alteration	novel ALK inhibitor	Responsive	LUAD	Early trials
ALK	M1223L	Different Alteration	Ceritinib (ALK inhibitor)	Responsive	HEMATO	Early trials
ALK	M1223L	Different Alteration	ALK inhibitor	Responsive	COREAD	Case report
ALK	M1223L	Different Alteration	Alectinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ALK	M1223L	Different Alteration	MEK inhibitor (ALK inhibitor;MEK inhibitor)	Responsive	LUAD	Pre-clinical
ROS1	R1948H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	IM	Case report
ROS1	R1948H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	NSCLC	FDA guidelines
ROS1	R1948H	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Case report
ROS1	R1948H	Different Alteration	HSP90 inhibitor	Responsive	LUAD	Pre-clinical
ROS1	R1948H	Different Alteration	Crizotinib (ALK inhibitor)	Responsive	LUAD	Early trials
KMT2D	Q3845*	Complete Match	Bicalutamide (AR inhibitor)	Responsive	LUSC	Pre-clinical
NPM1	splice_donor_variant	Complete Match	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
NPM1	splice_donor_variant	Complete Match	DOT1L inhibitor;MLL1 inhibitor	Responsive	AML	Pre-clinical
RET	S365L	Different Alteration	Nintedanib (Pan-TK inhibitor)	Responsive	LUAD	Case report
RET	S365L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	LUAD	Early trials
RET	S365L	Different Alteration	RET inhibitor	Responsive	LUAD	Pre-clinical
RET	S365L	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	S365L	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	LUAD	Early trials
RET	S365L	Different Alteration	Cabozantinib (Pan-kinase inhibitor)	Responsive	THCA	Pre-clinical
RET	S365L	Different Alteration	Vandetanib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	S365L	Different Alteration	Sunitinib (Pan-TK inhibitor)	Responsive	THCA	Pre-clinical
RET	S365L	Different Alteration	RET inhibitor	Responsive	TH	Pre-clinical
ARID1A	Q2026*	Complete Match	EZH2 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q2026*	Complete Match	PD1 inhibitor	Responsive	OV	Pre-clinical
ARID1A	Q2026*	Complete Match	PARP inhibitor	Responsive	CANCER	Pre-clinical
ARID1A	Q2026*	Complete Match	ATR inhibitor	Responsive	CANCER	Pre-clinical
TP53	R337P	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R337P	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R337P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R337P	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R337P	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R337P	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R337P	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R337P	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R337P	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R337P	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R337P	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R337P	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R337P	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R337P	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R337P	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KMT2A	P3493S	Different Alteration	EPZ-5676 (DOT1L inhibitor)	Responsive	ALL, MDS, AML	Early trials
KMT2A	P3493S	Different Alteration	BET inhibitor	Responsive	ALL	Pre-clinical
KMT2A	P3493S	Different Alteration	BET inhibitor	Responsive	AML	Pre-clinical
KMT2A	P3493S	Different Alteration	Daunorubicin (Chemotherapy)	Responsive	AML	FDA guidelines
KMT2A	P3493S	Different Alteration	Belinostat (HDAC inhibitor)	Responsive	AML	Early trials
KMT2A	P3493S	Different Alteration	DOT1L inhibitor	Responsive	AML	Early trials
TP53	G154D	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G154D	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G154D	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G154D	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G154D	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G154D	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G154D	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G154D	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G154D	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G154D	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G154D	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G154D	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G154D	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G154D	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G154D	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
KRAS	Q61P	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61P	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61P	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	Q61P	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	Q61P	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	Q61P	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	Q61P	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	Q61P	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61P	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61P	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	Q61P	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	Q61P	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61P	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	Q61P	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	Q61P	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	Q61P	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	Q61P	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	Q61P	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	Q61P	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	Q61P	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61P	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	Q61P	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61P	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	Q61P	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	Q61P	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61P	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	Q61P	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61P	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	Q61P	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	Q61P	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	Q61P	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	Q61P	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	Q61P	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61P	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61P	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	Q61P	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61P	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	Q61P	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61P	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	Q61P	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	Q61P	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	Q61P	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
TP53	R175L	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	R175L	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	R175L	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	R175L	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	R175L	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	R175L	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	R175L	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175L	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	R175L	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	R175L	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	R175L	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	R175L	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175L	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	R175L	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	R175L	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	N239H	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	N239H	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	N239H	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	N239H	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	N239H	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	N239H	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	N239H	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N239H	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	N239H	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	N239H	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	N239H	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	N239H	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N239H	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	N239H	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	N239H	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T211N	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	T211N	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	T211N	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	T211N	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	T211N	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	T211N	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	T211N	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T211N	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	T211N	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	T211N	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	T211N	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	T211N	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T211N	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	T211N	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	T211N	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
ERBB4	R1112L	Different Alteration	Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor)	Responsive	LUAD	Pre-clinical
APC	Q412), APC MUT (E1408	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
APC	Y1027*	Complete Match	Tankyrase inhibitor	Responsive	COREAD	Pre-clinical
TSC1	S1084*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	BLCA	Early trials
TSC1	S1084*	Complete Match	MTOR inhibitor	Responsive	RA	Early trials
TSC1	S1084*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	RA	FDA guidelines
TSC1	S1084*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	ST, S	Case report
TSC1	S1084*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	R	Case report
TSC1	S1084*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	GCA	FDA guidelines
TSC1	S1084*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	R	Case report
TP53	G244R	Different Mutation	HSP90 inhibitor	Responsive	CANCER	Pre-clinical
TP53	G244R	Complete Match	Decitabine (Chemotherapy)	Responsive	AML, MDPS	Early trials
TP53	G244R	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Resistant	BRCA	Early trials
TP53	G244R	Different Mutation	HDM2 inhibitor	Responsive	AML	Early trials
TP53	G244R	Complete Match	Cisplatin (Chemotherapy)	Resistant	FGCT, MGCT	Early trials
TP53	G244R	Complete Match	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
TP53	G244R	Complete Match	Gemcitabine (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G244R	Complete Match	Mitomycin C (Chemotherapy)	Responsive	BLCA	Pre-clinical
TP53	G244R	Complete Match	WEE1 inhibitor	Responsive	HNC	Pre-clinical
TP53	G244R	Complete Match	MDM2 inhibitor	Resistant	LIP	Early trials
TP53	G244R	Complete Match	Doxorubicin (Anthracycline antitumor antibiotic)	Responsive	BLCA	Pre-clinical
TP53	G244R	Complete Match	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G244R	Complete Match	WEE1 inhibitor	Responsive	OV	Early trials
TP53	G244R	Different Alteration	Pramlintide (Amylin analogue)	Responsive	THYM	Pre-clinical
TP53	G244R	Different Alteration	AZD6738 (ATR inhibitor)	Responsive	BCL	Early trials
BRAF	G503E	Different Alteration	Sorafenib (Pan-TK inhibitor)	Responsive	CM, LUAD, PRAD	Pre-clinical
BRAF	G503E	Different Alteration	MEK inhibitor	Responsive	LUAD, CM, PRAD	Pre-clinical
BRAF	G503E	Different Alteration	Selumetinib (MEK inhibitor)	Responsive	OV	Case report
BRAF	G503E	Different Alteration	BRAF inhibitor;MEK inhibitor	Responsive	LUAD	Case report
NOTCH2	N1723S	Different Alteration	Gamma secretase inhibitor	Responsive	BRCA	Pre-clinical
CDKN2A	A36Cfs17), CDKN2A MUT (L37Afs6	Complete Match	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	A36Cfs17), CDKN2A MUT (L37Afs6	Complete Match	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	A36Cfs17), CDKN2A MUT (L37Afs6	Complete Match	CDK4/6 inhibitor	Responsive	CM	Case report
CDKN2A	A36Cfs17), CDKN2A MUT (L37Afs6	Complete Match	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	A36Cfs17), CDKN2A MUT (L37Afs6	Different Alteration	CDK4/6 inhibitor	Responsive	CANCER, G	Pre-clinical
CDKN2A	A36Cfs17), CDKN2A MUT (L37Afs6	Different Alteration	Ilorasertib (AURKA-VEGF inhibitor)	Responsive	CANCER	Early trials
CDKN2A	A36Cfs17), CDKN2A MUT (L37Afs6	Different Alteration	PD1 inhibitor	Resistant	CM	Early trials
CDKN2A	A36Cfs17), CDKN2A MUT (L37Afs6	Different Alteration	CDK4/6 inhibitor	Responsive	CM	Case report
KRAS	Q61R), KRAS MUT (E62V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	FDA guidelines
KRAS	Q61R), KRAS MUT (E62V	Different Mutation	Cetuximab (EGFR mAb inhibitor)	No Responsive	COREAD	Late trials
KRAS	Q61R), KRAS MUT (E62V	Different Mutation	MEK inhibitor	Responsive	ALL	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Different Mutation	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Resistant	GIST	Case report
KRAS	Q61R), KRAS MUT (E62V	Complete Match	MEK inhibitor	Responsive	OV, CER, AML	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	Abemaciclib (CDK4/6 inhibitor)	Responsive	L	Early trials
KRAS	Q61R), KRAS MUT (E62V	Complete Match	MEK inhibitor;PI3K pathway inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	Cetuximab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61R), KRAS MUT (E62V	Complete Match	Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor)	Responsive	HC	Early trials
KRAS	Q61R), KRAS MUT (E62V	Complete Match	EGFR inhibitor	Resistant	L	NCCN guidelines
KRAS	Q61R), KRAS MUT (E62V	Complete Match	CDK4 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	Selumetinib (MEK inhibitor)	Responsive	NSCLC	Early trials
KRAS	Q61R), KRAS MUT (E62V	Complete Match	BET inhibitor	Responsive	L	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor)	Responsive	OV	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	FAK inhibitor	Responsive	L	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	EGFR inhibitor	Resistant	NSCLC	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	EZH2 inhibitor	Resistant	CANCER	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	MEK inhibitor	Responsive	BT, L	Early trials
KRAS	Q61R), KRAS MUT (E62V	Complete Match	MEK inhibitor;IGF1R inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	MTOR inhibitor;BH3 mimetics	Responsive	COREAD	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	EGFR mAb inhibitor;MEK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	pan-RAF inhibitor	Responsive	ED	Case report
KRAS	Q61R), KRAS MUT (E62V	Complete Match	EGFR mAb inhibitor	Resistant	ST	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61R), KRAS MUT (E62V	Complete Match	Selumetinib (MEK inhibitor)	No Responsive	L	Early trials
KRAS	Q61R), KRAS MUT (E62V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	L	Early trials
KRAS	Q61R), KRAS MUT (E62V	Complete Match	Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor)	Responsive	LUAD	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor)	Resistant	COREAD	Late trials
KRAS	Q61R), KRAS MUT (E62V	Complete Match	pan-RAF inhibitor	Responsive	L	Early trials
KRAS	Q61R), KRAS MUT (E62V	Complete Match	JAK/TBK1/IKKε inhibitor	Responsive	L	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	FAS inhibitor	Responsive	L	Case report
KRAS	Q61R), KRAS MUT (E62V	Complete Match	HSP90 inhibitor	Responsive	L	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	ERK inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	PI3K pathway inhibitor;MEK inhibitor	No Responsive	PA	Early trials
KRAS	Q61R), KRAS MUT (E62V	Complete Match	MEK inhibitor;BCL-XL inhibitor	Responsive	COREAD	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor)	Responsive	PA	Early trials
KRAS	Q61R), KRAS MUT (E62V	Complete Match	Panitumumab (EGFR mAb inhibitor)	Resistant	COREAD	NCCN guidelines
KRAS	Q61R), KRAS MUT (E62V	Complete Match	PI3K pathway inhibitor	Resistant	ED	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Complete Match	CDK4/6 inhibitor;MEK inhibitor	Responsive	CESC	Pre-clinical
KRAS	Q61R), KRAS MUT (E62V	Different Alteration	BRAF inhibitor;MEK inhibitor	Resistant	COREAD	Case report
KRAS	Q61R), KRAS MUT (E62V	Different Alteration	BRAF inhibitor;EGFR mAb inhibitor	Resistant	COREAD	Case report
JAK3	R657Q	Complete Match	JAK inhibitor	Responsive	MKB	Pre-clinical
JAK3	R657Q	Different Mutation	JAK inhibitor	Responsive	LY	Pre-clinical
NF2	K99*	Complete Match	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	K99*	Complete Match	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	K99*	Complete Match	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	K99*	Complete Match	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	K99*	Complete Match	MTOR inhibitor	Responsive	MEN	Pre-clinical
NF2	K99*	Complete Match	Lapatinib (ERBB2 inhibitor)	Responsive	NF, SCHW	Early trials
NF2	K99*	Complete Match	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	K99*	Complete Match	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	K99*	Complete Match	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	K99*	Complete Match	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	K99*	Complete Match	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	K99*	Complete Match	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	K99*	Complete Match	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	K99*	Complete Match	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	K99*	Complete Match	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	K99*	Complete Match	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	K99*	Different Alteration	FAK inhibitor	Responsive	OV	Pre-clinical
NF2	K99*	Different Alteration	MEK inhibitor	Responsive	TH	Pre-clinical
NF2	K99*	Different Alteration	Erlotinib (EGFR inhibitor)	No Responsive	SCHW	Early trials
NF2	K99*	Different Alteration	Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog)	Responsive	MEN	Pre-clinical
NF2	K99*	Different Alteration	PDK1 inhibitor	Responsive	SCHW	Pre-clinical
NF2	K99*	Different Alteration	PAK inhibitor	Responsive	SCHW, MEN	Pre-clinical
NF2	K99*	Different Alteration	AR42 (HDAC inhibitor)	Responsive	SCHW	Pre-clinical
NF2	K99*	Different Alteration	Imatinib (BCR-ABL inhibitor & KIT inhibitor)	Responsive	SCHW	Pre-clinical
NF2	K99*	Different Alteration	Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy)	Responsive	BRCA	Case report
NF2	K99*	Different Alteration	AR42 (HDAC inhibitor)	Responsive	MEN	Early trials
NF2	K99*	Different Alteration	FAK inhibitor	Responsive;Responsive	MESO	Early trials;Pre-clinical
NF2	K99*	Different Alteration	Bevacizumab (VEGFR mAb inhibitor)	Responsive	SCHW	Early trials
NF2	K99*	Different Alteration	Lapatinib (ERBB2 inhibitor)	Responsive	SCHW, NF	Early trials
NF2	K99*	Different Alteration	Everolimus (MTOR inhibitor)	Responsive	SCHW	Early trials
NF2	K99*	Different Alteration	HSP90 inhibitor	Responsive	MEN	Pre-clinical
NF2	K99*	Different Alteration	MTOR inhibitor	Responsive	MEN	Pre-clinical
SMARCA4	Y834Sfs*24	Complete Match	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	Y834Sfs*24	Complete Match	AURKA inhibitor	Responsive	NSCLC	Pre-clinical
SMARCA4	Y834Sfs*24	Complete Match	EZH2 inhibitor	Responsive	OV	Case report
SMARCA4	Y834Sfs*24	Different Alteration	EZH2 inhibitor	Responsive	OVRT	Case report
SMARCA4	Y834Sfs*24	Different Alteration	EZH2 inhibitor	Responsive	OV	Case report
ATR	L1907*	Complete Match	Temozolomide (Chemotherapy)	Responsive	G	Pre-clinical
ATR	L1907*	Complete Match	Olaparib (PARP inhibitor)	Responsive	CANCER, OV	Pre-clinical
ATR	L1907*	Different Alteration	Olaparib (PARP inhibitor)	Responsive	OV, CANCER	Pre-clinical

Variation	Gene	Transcript	Protein Alteration	Consequence	Tumour Driver	Oncogenic Classification

Drug-Gene Interactions help

Druggable categories in the cohort

Focus the search to a gene of interest:

Select a gene (Top 250):

Gene	Interaction Source	Interaction Types	Drug Claim Primary Name	Drug Name	ChEMBL ID
KRAS	CKB		lenalidomide	LENALIDOMIDE	CHEMBL848
KRAS	CKB		GA201	IMGATUZUMAB	CHEMBL2109389
KRAS	CKB		3144
KRAS	OncoKB		Selumetinib	SELUMETINIB	CHEMBL1614701
KRAS	CKB		BKM120	BUPARLISIB	CHEMBL2017974
KRAS	CKB		Gefitinib	GEFITINIB	CHEMBL939
KRAS	CKB		CGM097
KRAS	CKB		IRX4204	IRX-4204	CHEMBL75133
KRAS	CKB		MK2206	MK-2206	CHEMBL1079175
KRAS	CKB		Radiotherapy
KRAS	CGI		Sorafenib	SORAFENIB	CHEMBL1336
KRAS	CIViC		SCH772984
KRAS	CIViC		CISPLATIN
KRAS	CIViC		ERLOTINIB	ERLOTINIB	CHEMBL553
KRAS	CIViC		CHEMOTHERAPY
KRAS	CKB		APS-2-79
KRAS	CKB		GDC0879	CHEMBL525191	CHEMBL525191
KRAS	CKB		KO-947
KRAS	CIViC		AZD8186	AZD-8186	CHEMBL3545424
KRAS	CKB		Vemurafenib	VEMURAFENIB	CHEMBL1229517
KRAS	CIViC		PEMBROLIZUMAB	PEMBROLIZUMAB	CHEMBL3137343
KRAS	CKB		Ipatasertib	IPATASERTIB	CHEMBL2177390
KRAS	OncoKB		Cabozantinib	CABOZANTINIB	CHEMBL2105717
KRAS	CKB		Trametinib	TRAMETINIB	CHEMBL2103875
KRAS	CKB		GI-4000
KRAS	ClearityFoundationBiomarkers		PANITUMUMAB	PANITUMUMAB	CHEMBL1201827
KRAS	CKB		AZD5363	AZD-5363	CHEMBL2178577
KRAS	CKB		LY3009120	LY-3009120	CHEMBL3545195
KRAS	CGI		Lapatinib	LAPATINIB	CHEMBL554
KRAS	ClearityFoundationBiomarkers		RAFAMETINIB
KRAS	OncoKB		KO-947
KRAS	DoCM		CETUXIMAB	CETUXIMAB	CHEMBL1201577
KRAS	CKB		GDC-0068	IPATASERTIB	CHEMBL2177390
KRAS	CKB		Cetuximab	CETUXIMAB	CHEMBL1201577
KRAS	CKB		DEL-22379
KRAS	CGI		Cetuximab	CETUXIMAB	CHEMBL1201577
KRAS	CKB		NS1
KRAS	CGI		BCL2 inhibitor
KRAS	CIViC		GDC-0623
KRAS	DoCM		PANITUMUMAB	PANITUMUMAB	CHEMBL1201827
KRAS	CKB		Selumetinib	SELUMETINIB	CHEMBL1614701
KRAS	CKB		AZD4785
KRAS	CKB		PKI-402	CHEMBL589258	CHEMBL589258
KRAS	CIViC		R1507	TEPROTUMUMAB	CHEMBL1743079
KRAS	OncoKB		Trametinib	TRAMETINIB	CHEMBL2103875
KRAS	CIViC		DOCETAXEL	DOCETAXEL	CHEMBL92
KRAS	CGI		MEK inhibitor
KRAS	CKB		SAR245409	VOXTALISIB	CHEMBL3545366
KRAS	CKB		Romidepsin	ROMIDEPSIN	CHEMBL1213490
KRAS	CKB		FOLFOX
KRAS	CKB		AUY922	NVP-AUY922	CHEMBL252164
KRAS	CKB		BGJ398	INFIGRATINIB	CHEMBL1852688
KRAS	CKB		ARS-853
KRAS	CKB		Panitumumab	PANITUMUMAB	CHEMBL1201827
KRAS	CIViC		BEZ235	DACTOLISIB	CHEMBL1879463
KRAS	CKB		VX-11e
KRAS	ClearityFoundationBiomarkers		TRAMETINIB	TRAMETINIB	CHEMBL2103875
KRAS	CKB		UC-857993
KRAS	CIViC		BEZ235 (NVP-BEZ235, DACTOLISIB)	DACTOLISIB	CHEMBL1879463
KRAS	CGI		Regorafenib	REGORAFENIB	CHEMBL1946170
KRAS	CIViC		GEMCITABINE	GEMCITABINE	CHEMBL888
KRAS	CKB		Reolysin
KRAS	CIViC		CETUXIMAB	CETUXIMAB	CHEMBL1201577
KRAS	CKB		Saracatinib	SARACATINIB	CHEMBL217092
KRAS	CIViC		PD0325901	PD-0325901	CHEMBL507361
KRAS	CKB		Dinaciclib	DINACICLIB	CHEMBL2103840
KRAS	OncoKB		Binimetinib	BINIMETINIB	CHEMBL3187723
KRAS	CKB		AMG 232
KRAS	MyCancerGenomeClinicalTrial	inhibitor	REGORAFENIB	REGORAFENIB	CHEMBL1946170
KRAS	CKB		Osimertinib	OSIMERTINIB	CHEMBL3353410
KRAS	CKB		bortezomib	BORTEZOMIB	CHEMBL325041
KRAS	OncoKB		LY3214996
KRAS	CIViC		ADOPTIVE T-CELL TRANSFER
KRAS	CKB		Afatinib	AFATINIB	CHEMBL1173655
KRAS	CKB		Capecitabine	CAPECITABINE	CHEMBL1773
KRAS	CKB		DHM25
KRAS	CKB		PI-3065
KRAS	TALC	vaccine	RAS PEPTIDE CANCER VACCINE
KRAS	OncoKB		Abemaciclib	ABEMACICLIB	CHEMBL3301610
KRAS	CKB		Sunitinib	SUNITINIB	CHEMBL535
KRAS	CKB		AT-7867	CHEMBL428462	CHEMBL428462
KRAS	CKB		Abemaciclib	ABEMACICLIB	CHEMBL3301610
KRAS	CKB		Olaparib	OLAPARIB	CHEMBL521686
KRAS	CKB		Ponatinib	PONATINIB	CHEMBL1171837
KRAS	CIViC		AZD5438	AZD-5438	CHEMBL488436
KRAS	CIViC		BEVACIZUMAB	BEVACIZUMAB	CHEMBL1201583
KRAS	CKB		GDC-0980	APITOLISIB	CHEMBL1922094
KRAS	CKB		Alpelisib	ALPELISIB	CHEMBL2396661
KRAS	CKB		Copanlisib	COPANLISIB	CHEMBL3218576
KRAS	CKB		Venetoclax	VENETOCLAX	CHEMBL3137309
KRAS	CKB		Pemetrexed	PEMETREXED (CHEMBL1201258)	CHEMBL1201258
KRAS	CKB		AZ-TAK1
KRAS	CIViC		PACLITAXEL	PACLITAXEL	CHEMBL428647
KRAS	CKB		MLN2480	MLN-2480	CHEMBL3348923
KRAS	CKB		AZD4547	AZD-4547	CHEMBL3184679
KRAS	CKB		AMG 337	AMG-337	CHEMBL3545212
KRAS	ClearityFoundationBiomarkers		TEMSIROLIMUS	TEMSIROLIMUS	CHEMBL1201182
KRAS	OncoKB		Atezolizumab	ATEZOLIZUMAB	CHEMBL3707227
KRAS	CKB		Panobinostat	PANOBINOSTAT	CHEMBL483254
KRAS	OncoKB		Docetaxel	DOCETAXEL	CHEMBL92
KRAS	CKB		LY411575	CHEMBL392068	CHEMBL392068
KRAS	CKB		Necitumumab	NECITUMUMAB	CHEMBL1743047
KRAS	CKB		Phenformin	PHENFORMIN	CHEMBL170988
KRAS	CGI		Trametinib	TRAMETINIB	CHEMBL2103875
KRAS	CKB		Oxaliplatin	OXALIPLATIN	CHEMBL414804
KRAS	CKB		Vistusertib	BENZONATATE	CHEMBL1374379
KRAS	CKB		LY294002	LY-294002	CHEMBL98350
KRAS	CKB		7RH
KRAS	ClearityFoundationBiomarkers		EVEROLIMUS	EVEROLIMUS	CHEMBL1908360
KRAS	CKB		PD98509
KRAS	CKB		Trastuzumab	TRASTUZUMAB	CHEMBL1201585
KRAS	CKB		AZD9291	OSIMERTINIB	CHEMBL3353410
KRAS	CKB		Neratinib	NERATINIB	CHEMBL180022
KRAS	CKB		Ridaforolimus	RIDAFOROLIMUS	CHEMBL2103839
KRAS	CKB		A-443654	A-443654	CHEMBL379300
KRAS	CKB		UC-773587
KRAS	CKB		Gemcitabine	GEMCITABINE	CHEMBL888
KRAS	CKB		SAR125844	SAR-125844	CHEMBL3545325
KRAS	CKB		Navitoclax	NAVITOCLAX	CHEMBL443684
KRAS	CKB		DT-061
KRAS	CKB		GSK343
KRAS	CKB		GDC-0032	TASELISIB	CHEMBL2387080
KRAS	CKB		Binimetinib	BINIMETINIB	CHEMBL3187723
KRAS	CIViC		GEFITINIB	GEFITINIB	CHEMBL939
KRAS	CKB		KRAS mutant-specific TIL
KRAS	CGI		MEK
KRAS	CKB		DZNep
KRAS	CKB		AT13148	AT-13148	CHEMBL3544960
KRAS	CKB		Aurora Kinase Inhibitor II	ANILINOQUINAZOLINE1	CHEMBL382590
KRAS	CIViC		DECITABINE	DECITABINE	CHEMBL1201129
KRAS	CKB		Ixabepilone	IXABEPILONE	CHEMBL1201752
KRAS	CKB		AZD8835	CANDICIDIN	CHEMBL1200647
KRAS	CGI		Selumetinib	SELUMETINIB	CHEMBL1614701
KRAS	CIViC		PEMETREXED	PEMETREXED (CHEMBL1201258)	CHEMBL1201258
KRAS	CKB		Ralimetinib	RALIMETINIB	CHEMBL2364626
KRAS	CKB		Pimasertib	PIMASERTIB	CHEMBL2107832
KRAS	CKB		AG490	CHEMBL56543	CHEMBL56543
KRAS	CKB		Carboplatin	CARBOPLATIN	CHEMBL1351
KRAS	CKB		CI-1040	CI-1040	CHEMBL105442
KRAS	CKB		PF3644022	CHEMBL1231206	CHEMBL1231206
KRAS	CKB		Paclitaxel	PACLITAXEL	CHEMBL428647
KRAS	CKB		AZD8186	AZD-8186	CHEMBL3545424
KRAS	CIViC		NIVOLUMAB	NIVOLUMAB	CHEMBL2108738
KRAS	CKB		Salirasib	SALIRASIB	CHEMBL23293
KRAS	CKB		Atezolizumab	ATEZOLIZUMAB	CHEMBL3707227
KRAS	CIViC		ABEMACICLIB	ABEMACICLIB	CHEMBL3301610
KRAS	CKB		BI2536	BI-2536	CHEMBL513909
KRAS	GuideToPharmacologyInteractions	inhibitor	LONAFARNIB	LONAFARNIB	CHEMBL298734
KRAS	CKB		CC-223	CC-223	CHEMBL3545151
KRAS	CKB		SCH772984
KRAS	CKB		Pazopanib	PAZOPANIB	CHEMBL477772
KRAS	CKB		PF-04691502	PF-04691502	CHEMBL1234354
KRAS	CKB		Cobimetinib	COBIMETINIB	CHEMBL2146883
KRAS	CKB		CID1067700
KRAS	CGI		Panitumumab	PANITUMUMAB	CHEMBL1201827
KRAS	CIViC		FOLFOX4
KRAS	CKB		rigosertib	RIGOSERTIB	CHEMBL1241855
KRAS	OncoKB		Regorafenib	REGORAFENIB	CHEMBL1946170
KRAS	CKB		AZD8055	AZD-8055	CHEMBL1801204
KRAS	CGI		Ponatinib	PONATINIB	CHEMBL1171837
KRAS	CKB		Rilotumumab	RILOTUMUMAB	CHEMBL1743063
KRAS	OncoKB		Cobimetinib	COBIMETINIB	CHEMBL2146883
KRAS	CKB		Midostaurin	MIDOSTAURIN	CHEMBL608533
KRAS	CKB		GDC-0941	PICTILISIB	CHEMBL521851
KRAS	CIViC		G-573
KRAS	CKB		Lapatinib	LAPATINIB	CHEMBL554
KRAS	CKB		BEZ235	DACTOLISIB	CHEMBL1879463
KRAS	CKB		cabozantinib	CABOZANTINIB	CHEMBL2105717
KRAS	CKB		Cisplatin
KRAS	CKB		PHT-427
KRAS	CGI		BCL2
KRAS	CKB		KPT-185
KRAS	CIViC		TRAMETINIB	TRAMETINIB	CHEMBL2103875
KRAS	OncoKB		GDC-0994	GDC-0994	CHEMBL3544964
KRAS	ClearityFoundationBiomarkers		GEFITINIB	GEFITINIB	CHEMBL939
KRAS	CKB		OSI-027	OSI-027	CHEMBL3120215
KRAS	OncoKB		Palbociclib	PALBOCICLIB	CHEMBL189963
KRAS	CKB		cobimetinib	COBIMETINIB	CHEMBL2146883
KRAS	MyCancerGenomeClinicalTrial	inhibitor	SELUMETINIB	SELUMETINIB	CHEMBL1614701
KRAS	ClearityFoundationBiomarkers		PD-325901	PD-0325901	CHEMBL507361
KRAS	OncoKB		Panitumumab	PANITUMUMAB	CHEMBL1201827
KRAS	OncoKB		Ribociclib	Ribociclib	CHEMBL3545110
KRAS	CKB		PF-477736	PF-00477736	CHEMBL3545137
KRAS	CIViC		EGFR INHIBITOR	CHEMBL387187	CHEMBL387187
KRAS	CKB		Demcizumab	DEMCIZUMAB	CHEMBL2109384
KRAS	CKB		Volasertib	VOLASERTIB	CHEMBL1233528
KRAS	CKB		Pembrolizumab	PEMBROLIZUMAB	CHEMBL3137343
KRAS	CGI		inhibitor
KRAS	CKB		SH-1242
KRAS	CKB		DS-7423	DS-7423	CHEMBL3545248
KRAS	CKB		BGB-283	BGB-283	CHEMBL3545246
KRAS	CKB		AZ628
KRAS	CKB		SHP099
KRAS	CKB		GDC-0623
KRAS	CKB
KRAS	CKB		Sirolimus	SIROLIMUS	CHEMBL413
KRAS	CKB		Erlotinib	ERLOTINIB	CHEMBL553
KRAS	CKB		BAY1082439	BAY-1082439	CHEMBL3545245
KRAS	CIViC		ATEZOLIZUMAB	ATEZOLIZUMAB	CHEMBL3707227
KRAS	CKB		Tazemetostat
KRAS	CIViC		BINIMETINIB	BINIMETINIB	CHEMBL3187723
KRAS	CKB		JNJ-42756493	JNJ-42756493	CHEMBL3545376
KRAS	CKB		Regorafenib	REGORAFENIB	CHEMBL1946170
KRAS	CKB		BYL719	ALPELISIB	CHEMBL2396661
KRAS	CKB		Refametinib	Refametinib	CHEMBL2138601
KRAS	CKB		RO5126766
KRAS	CKB		PX-866	SONOLISIB	CHEMBL411907
KRAS	CKB		TAE226	CHEMBL458997	CHEMBL458997
KRAS	CKB		Nilotinib	NILOTINIB	CHEMBL255863
KRAS	CKB		Palbociclib	PALBOCICLIB	CHEMBL189963
KRAS	CKB		Camptothecin	CAMPTOTHECIN	CHEMBL65
KRAS	CKB		P7170	Panulisib	CHEMBL3545322
KRAS	CKB		Sapanisertib	INK-128	CHEMBL3545056
KRAS	CKB		XL147	PILARALISIB (CHEMBL3218575)	CHEMBL3218575
KRAS	CKB		Metformin	METFORMIN	CHEMBL1431
KRAS	CKB		MLN0128	INK-128	CHEMBL3545056
KRAS	OncoKB		Erlotinib	ERLOTINIB	CHEMBL553
KRAS	CKB		Docetaxel	DOCETAXEL	CHEMBL92
KRAS	ClearityFoundationBiomarkers		MEK162	BINIMETINIB	CHEMBL3187723
KRAS	CIViC		RAF265	CHIR-265	CHEMBL558752
KRAS	CKB		RO4987655	Ro-4987655	CHEMBL1614766
KRAS	CKB		TVB-2640
KRAS	CKB		Encorafenib	ENCORAFENIB	CHEMBL3301612
KRAS	CKB		Danusertib	DANUSERTIB	CHEMBL402548
KRAS	CKB		MLN1117	INK-1117	CHEMBL3545055
KRAS	CKB		Linsitinib	LINSITINIB	CHEMBL1091644
KRAS	CIViC		DASATINIB	DASATINIB	CHEMBL1421
KRAS	CKB		BAY1125976	BAY-1125976	CHEMBL3545049
KRAS	CKB		TW-37	CHEMBL217354	CHEMBL217354
KRAS	CKB		ABT-737	CHEMBL376408	CHEMBL376408
KRAS	MyCancerGenomeClinicalTrial	inhibitor	SIMVASTIN
KRAS	TdgClinicalTrial		GI-4000
KRAS	ClearityFoundationBiomarkers		VANDETANIB	VANDETANIB	CHEMBL24828
KRAS	CKB		Fluorouracil	FLUOROURACIL	CHEMBL185
KRAS	CKB		BBI608	2-ACETYL FURANONAPTHOQUINONE	CHEMBL64130
KRAS	CKB		BVD-523	Ulixertinib	CHEMBL3545022
KRAS	CKB		Rigosertib	RIGOSERTIB	CHEMBL1241855
KRAS	CKB		LGX818	ENCORAFENIB	CHEMBL3301612
KRAS	ClearityFoundationBiomarkers		GDC-0973	COBIMETINIB	CHEMBL2146883
KRAS	CIViC		SELUMETINIB (AZD6244)	SELUMETINIB	CHEMBL1614701
KRAS	CKB		OPB-111077
KRAS	CKB		Dasatinib	DASATINIB	CHEMBL1421
KRAS	CKB		WEHI-539
KRAS	CIViC		PANITUMUMAB	PANITUMUMAB	CHEMBL1201827
KRAS	CKB		Doxil
KRAS	CIViC		AFATINIB	AFATINIB	CHEMBL1173655
KRAS	CKB		BI-847325
KRAS	CIViC		CARBOPLATIN	CARBOPLATIN	CHEMBL1351
KRAS	ClearityFoundationBiomarkers		CETUXIMAB	CETUXIMAB	CHEMBL1201577
KRAS	CKB		PD-0325901	PD-0325901	CHEMBL507361
KRAS	CGI		Decitabine	DECITABINE	CHEMBL1201129
KRAS	CKB		BMS-754807	BMS-754807	CHEMBL575448
KRAS	CKB		Deguelin	DEGUELIN	CHEMBL393417
KRAS	CKB		PF-05212384	GEDATOLISIB	CHEMBL592445
KRAS	CKB		fasudil	FASUDIL	CHEMBL38380
KRAS	CKB		poziotinib	Poziotinib	CHEMBL3545154
KRAS	CKB		VX-970	VX-970	CHEMBL3545202
KRAS	CGI		Imatinib	IMATINIB	CHEMBL941
KRAS	CKB		Everolimus	EVEROLIMUS	CHEMBL1908360
KRAS	CancerCommons	inhibitor	REOLYSIN
KRAS	CKB		CUDC-907	CUDC-907	CHEMBL3545052
KRAS	ClearityFoundationBiomarkers		ERLOTINIB	ERLOTINIB	CHEMBL553
KRAS	CKB		MK-1775	AZD-1775	CHEMBL1976040
KRAS	CKB		Aphanin
KRAS	ClearityFoundationBiomarkers		PIMASERTIB	PIMASERTIB	CHEMBL2107832
KRAS	ClearityFoundationBiomarkers		SELUMETINIB	SELUMETINIB	CHEMBL1614701
KRAS	CKB		Irinotecan	IRINOTECAN	CHEMBL481
KRAS	CGI		Trastuzumab	TRASTUZUMAB	CHEMBL1201585
KRAS	CIViC		ARRY-142886	SELUMETINIB	CHEMBL1614701
KRAS	CKB		Ramucirumab	RAMUCIRUMAB	CHEMBL1743062
KRAS	CKB		SML-10-70-1
KRAS	CKB		MEK162	BINIMETINIB	CHEMBL3187723
KRAS	CKB		FOLFIRI	CETUXIMAB	CHEMBL1201577
KRAS	CIViC		ARS-853
KRAS	CKB		ER2
KRAS	CKB		Temsirolimus	TEMSIROLIMUS	CHEMBL1201182
KRAS	CKB		Sorafenib	SORAFENIB	CHEMBL1336
KRAS	CGI		Docetaxel	DOCETAXEL	CHEMBL92
KRAS	OncoKB		Cetuximab	CETUXIMAB	CHEMBL1201577
KRAS	CGI		Palbociclib	PALBOCICLIB	CHEMBL189963
KRAS	CIViC		ENCORAFENIB	ENCORAFENIB	CHEMBL3301612
KRAS	CKB		Crizotinib	CRIZOTINIB	CHEMBL601719
KRAS	CKB		Dabrafenib	DABRAFENIB	CHEMBL2028663
KRAS	CKB		GSK1120212	TRAMETINIB	CHEMBL2103875
KRAS	CIViC		PALBOCICLIB	PALBOCICLIB	CHEMBL189963
KRAS	CGI		Abemaciclib	ABEMACICLIB	CHEMBL3301610
KRAS	CKB		SRA737
KRAS	CKB		Bevacizumab	BEVACIZUMAB	CHEMBL1201583
KRAS	CKB		CC-90003
KRAS	CKB		TAK-733	TAK-733	CHEMBL1615025
KRAS	CKB		Gedatolisib	GEDATOLISIB	CHEMBL592445
KRAS	CKB		XMT-1536
KRAS	CGI		Gemcitabine	GEMCITABINE	CHEMBL888
KRAS	CKB		ABT-263	NAVITOCLAX	CHEMBL443684
KRAS	CKB		CH5132799	PA-799	CHEMBL1684984

Interactions & Pathways

Oncogenic Pathways help

Select a Pathway:

Interaction Networks help

Select protein-coding gene (Top 250):

Include interactions: Protein-Protein Protein-Phenotype Protein-Drug

Legend:

Phenotype
Protein
Drug

Loading...

Reactome Pathways help

All significant pathways (p<0.05) in the selected cohort are presented in the Voronoi interactive plot, with colour intensity representing the number of patients affected
Click here to show visualisation below or here to open the visualisation in a new window

There are Blood (Plasma, Serum, Buffy coat), FFPE tissue, Fresh frozen tissue samples from unique donors available at PCRFTB, based on the selected clinical filters (Age, Sex, Race, Diagnosis). Researchers can request for samples by submitting an Expression of Interest to PCRFTB.

Overview

Sex

Race

Diagnosis

Tumor stage

Age at Diagnosis

Clinical filters

Molecular filters